FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Moayyedi, P Quigley, EMM Lacy, BE Lembo, AJ Saito, YA Schiller, LR Soffer, EE Spiegel, BMR Ford, AC AF Moayyedi, Paul Quigley, Eamonn M. M. Lacy, Brian E. Lembo, Anthony J. Saito, Yuri A. Schiller, Lawrence R. Soffer, Edy E. Spiegel, Brennan M. R. Ford, Alexander C. TI The Effect of Fiber Supplementation on Irritable Bowel Syndrome: A Systematic Review and Meta-analysis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Review ID RANDOMIZED-CONTROLLED-TRIAL; DOUBLE-BLIND TRIAL; PRIMARY-CARE; HUMAN-COLON; ISPAGHULA; SYMPTOMS; PLACEBO; MANAGEMENT; PSYLLIUM; THERAPY AB OBJECTIVES: Fiber has been used for many years to treat irritable bowel syndrome (IBS). This approach had fallen out of favor until a recent resurgence, which was based on new randomized controlled trial (RCT) data that suggested it might be effective. We have previously conducted a systematic review of fiber in IBS, but new RCT data for fiber therapy necessitate a new analysis; thus, we have conducted a systematic review of this intervention. METHODS: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched up to December 2013. Trials recruiting adults with IBS, which compared fiber supplements with placebo, control therapy, or "usual management", were eligible. Dichotomous symptom data were pooled to obtain a relative risk (RR) of remaining symptomatic after therapy as well as number needed to treat (NNT) with a 95% confidence interval (CI). RESULTS: We identified 14 RCTs involving 906 patients that had evaluated fiber in IBS. There was a significant benefit of fiber in IBS (RR = 0.86; 95% CI 0.80-0.94 with an NNT = 10; 95% CI = 6-33). There was no significant heterogeneity between results (I 2 = 0%, Cochran Q = 13.85 (d.f. = 14), P = 0.46). The benefit was only seen in RCTs on soluble fiber (RR = 0.83; 95% CI 0.73-0.94 with an NNT = 7; 95% CI 4-25) with no effect seen with bran (RR = 0.90; 95% CI 0.79-1.03). CONCLUSIONS: Soluble fiber is effective in treating IBS. Bran did not appear to be of benefit, although we did not uncover any evidence of harm from this intervention, as others have speculated from uncontrolled data. C1 [Moayyedi, Paul] McMaster Univ, Hlth Sci Ctr, Farncombe Family Digest Hlth Res Inst, Hamilton, ON L8N 3Z5, Canada. [Quigley, Eamonn M. M.] Houston Methodist Hosp, Dept Med, Div Gastroenterol & Hepatol, Houston, TX USA. [Lacy, Brian E.] Dartmouth Hitchcock Med Ctr, Div Gastroenterol & Hepatol, Lebanon, NH 03766 USA. [Lembo, Anthony J.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Saito, Yuri A.] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA. [Schiller, Lawrence R.] Baylor Univ, Med Ctr, Digest Hlth Associates Texas, Dallas, TX USA. [Soffer, Edy E.] Univ So Calif, Div Gastroenterol Cedars Sinai, Los Angeles, CA USA. [Spiegel, Brennan M. R.] VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol, Los Angeles, CA USA. [Ford, Alexander C.] St James Univ Hosp, Leeds Gastroenterol Inst, Leeds LS9 7TF, W Yorkshire, England. [Ford, Alexander C.] Univ Leeds, Leeds Inst Biomed & Clin Sci, Leeds, W Yorkshire, England. RP Moayyedi, P (reprint author), McMaster Univ, Hlth Sci Ctr, Farncombe Family Digest Hlth Res Inst, Hamilton, ON L8N 3Z5, Canada. EM moayyep@mcmaster.ca RI Ford, Alexander/K-5491-2012; Moayyedi, Paul/M-6178-2014 OI Ford, Alexander/0000-0001-6371-4359; Moayyedi, Paul/0000-0002-3616-9292 FU American College of Gastroenterology FX This study was supported by the American College of Gastroenterology. NR 33 TC 33 Z9 35 U1 5 U2 17 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2014 VL 109 IS 9 BP 1367 EP 1374 DI 10.1038/ajg.2014.195 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS7UJ UT WOS:000344459800007 PM 25070054 ER PT J AU Kedrin, D Masia, R Nazarian, RM Garber, JJ AF Kedrin, Dmitriy Masia, Ricard Nazarian, Rosalynn M. Garber, John J. TI Mycobacterium chelonae Bacteremia After First Dose of Infliximab for Ulcerative Colitis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Letter ID CUTANEOUS INFECTIONS; TUBERCULOSIS C1 [Kedrin, Dmitriy; Garber, John J.] Massachusetts Gen Hosp, Crohns & Colitis Ctr, Gastrointestinal Unit, Boston, MA 02114 USA. [Masia, Ricard; Nazarian, Rosalynn M.] Massachusetts Gen Hosp, Dept Pathol, Lab Med, Boston, MA 02114 USA. RP Garber, JJ (reprint author), Massachusetts Gen Hosp, Crohns & Colitis Ctr, Gastrointestinal Unit, Boston, MA 02114 USA. EM jjgarber@mgh.harvard.edu OI Kedrin, Dmitriy/0000-0001-6093-7282 FU NIDDK NIH HHS [K08 DK094966, T32 DK007191] NR 11 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2014 VL 109 IS 9 BP 1501 EP 1502 DI 10.1038/ajg.2014.209 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS7UJ UT WOS:000344459800032 PM 25196883 ER PT J AU Abujudeh, HH Aran, S Besheli, LD Miguel, K Halpern, E Thrall, JH AF Abujudeh, Hani H. Aran, Shima Besheli, Laleh Daftari Miguel, Karen Halpern, Elkan Thrall, James H. TI Outpatient Falls Prevention Program Outcome: An Increase, a Plateau, and a Decrease in Incident Reports SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article DE falls; incident reports; process quality improvement; quality; quality improvement program; risk reduction ID HOSPITALIZED-PATIENTS; RISK-FACTORS; RANDOMIZED-TRIAL; ADVERSE EVENTS; OLDER-PEOPLE; STRATEGIES; INTERVENTIONS; ASSOCIATION; ADULTS; CARE AB OBJECTIVE. We implemented an outpatient falls guideline in 2008 in the department of radiology. Here, we describe our multiyear experience. MATERIALS AND METHODS. This was a retrospective study conducted between April 2006 and September 2013 to investigate outpatient falls. The span of the study was divided into eight periods. The incident reporting system was searched for the falls and the fall-related variables. RESULTS. A total of 327 falls occurred during 5,080,512 radiology examinations (rate, 0.64/10,000 total examinations). The highest rate was in period 6 (0.83/10,000 examinations). The average for periods 1 and 2 is 0.39/10,000 examinations (37 falls/945,427 examinations), and the average for periods 3-6 is 0.77/10,000 examinations (204 falls/2,656,805 examinations). The average rate for periods 7 and 8 is 0.58/10,000 examinations (86 falls/1,478,280 examinations). There was a statistically significant increase in the total number of falls reported between period 2 and period 3 (p = 0.02). There was a statistically significant decrease in outpatient falls between period 6 and period 7 (p = 0.01). The number of falls among patients 60 years old or older was 177 falls/2,180,093 examinations (rate, 0.81/10,000 examinations), and that among patients younger than 60 years was 150 falls/2,900,419 examinations (rate, 0.52/10,000 examinations), with a statistically significant difference (p = 0.007). Although the rate of falls was higher among female patients, there was no statistically significant difference between the sexes (p = 0.18). CONCLUSION. The outcome of the outpatient falls guideline was characterized by an increase, a plateau, and a decrease in incident reports. The initial increase may be due to the Hawthorne effect. The plateau may represent the value closest to the true incidence. The decrease may represent the effect of the program. C1 [Abujudeh, Hani H.; Aran, Shima; Besheli, Laleh Daftari; Miguel, Karen; Halpern, Elkan; Thrall, James H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA. RP Abujudeh, HH (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, 55 Fruit St,Founders Bldg,210, Boston, MA 02114 USA. EM Abujudeh.Hani@mgh.harvard.edu NR 45 TC 7 Z9 7 U1 3 U2 5 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD SEP PY 2014 VL 203 IS 3 BP 620 EP 626 DI 10.2214/AJR.13.11982 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AS9HE UT WOS:000344553100037 PM 25148166 ER PT J AU Deipolyi, AR Kalva, SP Oklu, R Walker, TG Wicky, S Ganguli, S AF Deipolyi, Amy R. Kalva, Sanjeeva P. Oklu, Rahmi Walker, T. Gregory Wicky, Stephan Ganguli, Suvranu TI Reduction in Portal Venous Pressure by Transjugular Intrahepatic Portosystemic Shunt for Treatment of Hemorrhagic Stomal Varices SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article DE embolization; portal hypertension; stomal varices; TIPS; transjugular intrahepatic portosystemic shunt ID BLEEDING ECTOPIC VARICES; PERISTOMAL VARICES; GASTRIC VARICES; SYSTEMIC SHUNT; EMBOLIZATION; MANAGEMENT; HYPERTENSION; SCLEROTHERAPY; PREVENTION; TRIAL AB OBJECTIVE. Stomal varices can cause life-threatening gastrointestinal hemorrhage in patients with portal hypertension. Optimal therapy is not well defined. The purpose of this study was to determine the safety and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) creation for the treatment of hemorrhagic stomal varices. MATERIALS AND METHODS. All patients who underwent TIPS creation for hemorrhagic stomal varices refractory to medical or endoscopic therapy over a 20-year period (1992-2012) were included. Ten patients (mean age, 63 +/- 12 years) were identified. Retrospective chart review was used to document demographic characteristics, procedure details, technical and clinical success, complications, recurrent hemorrhage, and need for repeat interventions. Patients underwent follow-up for an average of 2 years (range, 22 days-9.6 years). RESULTS. All patients had cirrhosis and portal hypertension. Average corrected sinusoidal pressures were 11 +/- 2.4 mm Hg (range, 6-15 mm Hg) before TIPS placement and 4.3 +/- 1.8 mm Hg (range, 2-8 mm Hg) after TIPS placement. Five patients (50%) underwent adjunctive embolization of stomal varices through the TIPS, which did not affect outcome. Complications included one patient each with a contrast allergy and renal failure. Six patients experienced complete resolution of bleeding without further intervention (60%). Four patients had recurrent stomal hemorrhage. Two of the four needed TIPS revision for occlusion; one underwent oversewing of the ostomy; and in one the hemorrhage resolved with conservative measures after confirmation of TIPS patency. CONCLUSION. TIPS creation, with or without adjunctive variceal embolization, is a safe and effective treatment of refractory hemorrhagic stomal varices. Reintervention for recurrent bleeding may be required and appears effective. C1 [Deipolyi, Amy R.] NYU, Med Ctr, Dept Radiol, Div Vasc & Intervent Radiol, New York, NY 10016 USA. [Kalva, Sanjeeva P.] Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA. [Oklu, Rahmi; Walker, T. Gregory; Wicky, Stephan; Ganguli, Suvranu] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Sect Intervent Radiol, Boston, MA USA. RP Deipolyi, AR (reprint author), NYU, Med Ctr, Dept Radiol, Div Vasc & Intervent Radiol, 660 First Ave,7th F1, New York, NY 10016 USA. EM Amy.Deipolyi@nyumc.org OI Deipolyi, Amy/0000-0003-3144-386X NR 22 TC 4 Z9 5 U1 0 U2 1 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD SEP PY 2014 VL 203 IS 3 BP 668 EP 673 DI 10.2214/AJR.13.12211 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AS9HE UT WOS:000344553100045 PM 25148174 ER PT J AU Wilson, AC Wilhelm, S Hartmann, AS AF Wilson, Anne C. Wilhelm, Sabine Hartmann, Andrea S. TI Experiential avoidance in body dysmorphic disorder SO BODY IMAGE LA English DT Article DE Body dysmorphic disorder; Experiential avoidance; OC spectrum disorder; Body image ID RELIABILITY; VALIDITY; SCALE AB Experiential avoidance (i.e., the attempt to avoid certain internal experiences including bodily sensations, thoughts, emotions, memories, and urges) has been studied in various psychological disorders. However, research examining experiential avoidance in individuals with body dysmorphic disorder (BDD) is limited and inconsistent. The present study compared experiential avoidance in individuals with primary BDD (n =23) to healthy controls (n = 22). Standardized measures were used to assess baseline clinical characteristics as well as experiential avoidance. Compared to healthy controls, individuals with BDD presented with significantly greater experiential avoidance (p <.001, d= -2.51). In BDD, experiential avoidance was positively correlated with depressive symptoms (p <.01) and avoidant coping strategies (p <.01). Clinician sensitivity to experiential avoidance may serve to improve the course of treatment for BDD. (C) 2014 Elsevier Ltd. All rights reserved. C1 Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Wilson, AC (reprint author), Ohio State Univ, Dept Psychol, 1835 Neil Ave, Columbus, OH 43210 USA. EM wilson.2796@osu.edu NR 20 TC 1 Z9 1 U1 3 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1740-1445 EI 1873-6807 J9 BODY IMAGE JI Body Image PD SEP PY 2014 VL 11 IS 4 BP 380 EP 383 DI 10.1016/j.bodyim.2014.06.006 PG 4 WC Psychology, Clinical; Psychiatry; Psychology, Multidisciplinary SC Psychology; Psychiatry GA AT3GJ UT WOS:000344823600008 PM 25010929 ER PT J AU Colombo, F D'ascenzo, F Moretti, C Omede, P Fox, KAA Rumsfeld, JS Tarantini, G Biondi-Zoccai, G Gaita, F AF Colombo, F. D'ascenzo, F. Moretti, C. Omede, P. Fox, K. A. A. Rumsfeld, J. S. Tarantini, G. Biondi-Zoccai, G. Gaita, F. TI Discontinuation of dual antiplatelet therapy over 12 months after acute coronary syndromes increases risk for adverse events in patients treated with pci: systematic review and meta-analysis SO EUROPEAN HEART JOURNAL LA English DT Meeting Abstract CT Congress of the European-Society-of-Cardiology (ESC) CY AUG 30-SEP 03, 2014 CL Barcelona, SPAIN SP European Soc Cardiol C1 [Colombo, F.; D'ascenzo, F.; Moretti, C.; Omede, P.; Gaita, F.] Univ Hosp S Giovanni Battista, Dept Cardiol, Hosp Molinette, Turin, Italy. [Fox, K. A. A.] Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland. [Rumsfeld, J. S.] Denver VA Med Ctr, Denver, CO USA. [Tarantini, G.] Univ Padua, Div Cardiol, Dept Cardiac Thorac & Vasc Sci, Padua, Italy. [Biondi-Zoccai, G.] Univ Roma La Sapienza, Dept Medicosurg Sci & Biotechnol, I-00185 Rome, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD SEP 1 PY 2014 VL 35 SU 1 MA P150 BP 25 EP 26 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AQ7MG UT WOS:000343001300088 ER PT J AU Chanyavanich, P Januzzi, J Katekao, W Ninwaranon, S Yamwong, S Sritara, P AF Chanyavanich, P. Januzzi, J. Katekao, W. Ninwaranon, S. Yamwong, S. Sritara, P. TI A comparison of soluble ST2 and high sensitivity C-reactive protein for prediction of cardiovascular mortality in the Electricity Generating Authority of Thailand cohort study SO EUROPEAN HEART JOURNAL LA English DT Meeting Abstract CT Congress of the European-Society-of-Cardiology (ESC) CY AUG 30-SEP 03, 2014 CL Barcelona, SPAIN SP European Soc Cardiol C1 [Chanyavanich, P.; Katekao, W.; Ninwaranon, S.; Yamwong, S.; Sritara, P.] Mahidol Univ, Ramathibodi Hosp, Bangkok, Thailand. [Januzzi, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD SEP 1 PY 2014 VL 35 SU 1 MA P1285 BP 221 EP 221 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AQ7MG UT WOS:000343001301174 ER PT J AU Katekao, W See, O Bayes-Genis, A Januzzi, J Vathesatogkit, P Chanyavanich, P Suwannaphong, S Yamwong, S Sritara, P AF Katekao, W. See, O. Bayes-Genis, A. Januzzi, J. Vathesatogkit, P. Chanyavanich, P. Suwannaphong, S. Yamwong, S. Sritara, P. TI Long-term predictive value of soluble ST2 concentrations and left ventricular remodeling: the EGAT study SO EUROPEAN HEART JOURNAL LA English DT Meeting Abstract CT Congress of the European-Society-of-Cardiology (ESC) CY AUG 30-SEP 03, 2014 CL Barcelona, SPAIN SP European Soc Cardiol C1 [Katekao, W.; See, O.; Vathesatogkit, P.; Chanyavanich, P.; Suwannaphong, S.; Yamwong, S.; Sritara, P.] Mahidol Univ, Ramathibodi Hosp, Dept Cardiol, Bangkok 10700, Thailand. [Bayes-Genis, A.] Hosp Badalona Germans Trias & Pujol, Dept Cardiol, Badalona, Barcelona, Spain. [Januzzi, J.] Massachusetts Gen Hosp, Dept Cardiol, Boston, MA 02114 USA. RI Bayes-Genis, Antoni/C-4002-2015 OI Bayes-Genis, Antoni/0000-0002-3044-197X NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD SEP 1 PY 2014 VL 35 SU 1 MA P1287 BP 221 EP 221 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AQ7MG UT WOS:000343001301176 ER PT J AU Afilalo, J Grapsa, J Nihoyannopoulos, P Beaudoin, J Gibbs, JSR Channick, RN Langleben, D Rudski, LG Picard, MH Levine, RA AF Afilalo, J. Grapsa, J. Nihoyannopoulos, P. Beaudoin, J. Gibbs, J. S. R. Channick, R. N. Langleben, D. Rudski, L. G. Picard, M. H. Levine, R. A. TI Leaflet adaptation as a determinant of tricuspid regurgitation severity in patients with pulmonary hypertension SO EUROPEAN HEART JOURNAL LA English DT Meeting Abstract CT Congress of the European-Society-of-Cardiology (ESC) CY AUG 30-SEP 03, 2014 CL Barcelona, SPAIN SP European Soc Cardiol C1 [Afilalo, J.; Beaudoin, J.; Channick, R. N.; Picard, M. H.; Levine, R. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Grapsa, J.; Nihoyannopoulos, P.; Gibbs, J. S. R.] Hammersmith Hosp, London, England. [Langleben, D.; Rudski, L. G.] McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD SEP 1 PY 2014 VL 35 SU 1 MA P1388 BP 245 EP 245 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AQ7MG UT WOS:000343001301267 ER PT J AU Vergallo, R Papafaklis, M Wang, Z Fujimoto, J Biasucci, L Crea, F Feldman, C Michalis, L Stone, P Jang, IK AF Vergallo, R. Papafaklis, M. Wang, Z. Fujimoto, J. Biasucci, L. Crea, F. Feldman, C. Michalis, L. Stone, P. Jang, I. K. TI Low endothelial shear stress is associated with high-risk coronary plaque characteristics in humans: a combined frequency-domain optical coherence tomography and computational flow dynamics study SO EUROPEAN HEART JOURNAL LA English DT Meeting Abstract CT Congress of the European-Society-of-Cardiology (ESC) CY AUG 30-SEP 03, 2014 CL Barcelona, SPAIN SP European Soc Cardiol C1 [Vergallo, R.; Jang, I. K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Vergallo, R.; Papafaklis, M.; Feldman, C.; Stone, P.; Jang, I. K.] Harvard Univ, Sch Med, Boston, MA USA. [Papafaklis, M.; Feldman, C.; Stone, P.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Wang, Z.; Fujimoto, J.] MIT, Cambridge, MA 02139 USA. [Biasucci, L.; Crea, F.] Univ Cattolica Sacro Cuore, I-00168 Rome, Italy. [Michalis, L.] Univ Ioannina, GR-45110 Ioannina, Greece. RI Wang, Zhao/E-3515-2015 OI Wang, Zhao/0000-0002-3628-5699 NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD SEP 1 PY 2014 VL 35 SU 1 MA 1789 BP 343 EP 343 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AQ7MG UT WOS:000343001302067 ER PT J AU Vegh, EM Kandala, J Januszkiewicz, L Miller, A Orencole, M Blendea, D Merkely, B Singh, JP AF Vegh, E. M. Kandala, J. Januszkiewicz, L. Miller, A. Orencole, M. Blendea, D. Merkely, B. Singh, J. P. TI Post-CRT implant electrocardiographic score as a predictor of clinical outcome SO EUROPEAN HEART JOURNAL LA English DT Meeting Abstract CT Congress of the European-Society-of-Cardiology (ESC) CY AUG 30-SEP 03, 2014 CL Barcelona, SPAIN SP European Soc Cardiol C1 [Vegh, E. M.; Merkely, B.] Semmelweis Univ, Ctr Heart, H-1085 Budapest, Hungary. [Kandala, J.; Januszkiewicz, L.; Miller, A.; Orencole, M.; Blendea, D.; Singh, J. P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Resynchronizat Therapy Program, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD SEP 1 PY 2014 VL 35 SU 1 MA 2049 BP 356 EP 356 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AQ7MG UT WOS:000343001302115 ER PT J AU Bondermann, D Ghio, S Felix, SB Ghofrani, HA Michelakis, E Mitrovic, V Oudiz, RJ Boateng, F Roessig, L Semigran, MJ AF Bondermann, D. Ghio, S. Felix, S. B. Ghofrani, H. A. Michelakis, E. Mitrovic, V. Oudiz, R. J. Boateng, F. Roessig, L. Semigran, M. J. CA LEft Ventricular Systolic TI Riociguat for heart failure with secondary pulmonary hypertension: post-hoc analysis of the LEPHT study SO EUROPEAN HEART JOURNAL LA English DT Meeting Abstract CT Congress of the European-Society-of-Cardiology (ESC) CY AUG 30-SEP 03, 2014 CL Barcelona, SPAIN SP European Soc Cardiol C1 [Bondermann, D.] Med Univ Vienna, Vienna, Austria. [Ghio, S.] Univ Hosp, Dept Cardiol, Fdn IRCCS Policlin San Matteo, Pavia, Italy. [Felix, S. B.] Univ Med Greifswald, Greifswald, Germany. [Felix, S. B.] DZHK German Ctr Cardiovasc Res, Dept Cardiol & Internal Med B, Greifswald, Germany. [Ghofrani, H. A.] UGMLC, Giessen, Germany. [Michelakis, E.] Univ Alberta, Dept Med, Edmonton, AB, Canada. [Mitrovic, V.] Kerckhoff Klin Forsch Gesell GmbH, Bad Nauheim, Germany. [Oudiz, R. J.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA. [Boateng, F.] Bayer HealthCare Pharmaceut, New York, NY USA. [Roessig, L.] Bayer Pharma AG, Berlin, Germany. [Semigran, M. J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD SEP 1 PY 2014 VL 35 SU 1 MA 2221 BP 385 EP 385 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AQ7MG UT WOS:000343001302222 ER PT J AU Gold, MR Singh, JP Ellenbogen, KA Yu, Y Wold, ND Meyer, TE Birgersdotter-Green, U AF Gold, M. R. Singh, J. P. Ellenbogen, K. A. Yu, Y. Wold, N. D. Meyer, T. E. Birgersdotter-Green, U. CA SMART AV Investigators TI The relationship between RV-LV delay and left ventricular reverse remodeling with Cardiac Resynchronization Therapy SO EUROPEAN HEART JOURNAL LA English DT Meeting Abstract CT Congress of the European-Society-of-Cardiology (ESC) CY AUG 30-SEP 03, 2014 CL Barcelona, SPAIN SP European Soc Cardiol C1 [Gold, M. R.] Med Univ S Carolina, Charleston, SC 29425 USA. [Singh, J. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Ellenbogen, K. A.] Virginia Commonwealth Univ, Richmond, VA 23284 USA. [Yu, Y.; Wold, N. D.; Meyer, T. E.] Boston Sci Corp, St Paul, MN USA. [Birgersdotter-Green, U.] Univ Calif San Diego, San Diego, CA 92103 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD SEP 1 PY 2014 VL 35 SU 1 MA P2962 BP 532 EP 533 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AQ7MG UT WOS:000343001303069 ER PT J AU Steinberg, BA Hellkamp, AS Lokhnygina, Y Patel, MR Breithardt, G Singer, DE Mahaffey, KW Fox, KAA Califf, RM Piccini, JP AF Steinberg, B. A. Hellkamp, A. S. Lokhnygina, Y. Patel, M. R. Breithardt, G. Singer, D. E. Mahaffey, K. W. Fox, K. A. A. Califf, R. M. Piccini, J. P. CA ROCKET AF Steering Comm TI Higher risk of death and stroke in patients with persistent versus paroxysmal atrial fibrillation: results from the ROCKET AF trial SO EUROPEAN HEART JOURNAL LA English DT Meeting Abstract CT Congress of the European-Society-of-Cardiology (ESC) CY AUG 30-SEP 03, 2014 CL Barcelona, SPAIN SP European Soc Cardiol C1 [Steinberg, B. A.; Hellkamp, A. S.; Lokhnygina, Y.; Patel, M. R.; Piccini, J. P.] Duke Univ, Duke Clin Res Inst, Med Ctr, Durham, NC USA. [Breithardt, G.] Univ Hosp Munster, Munster, Germany. [Singer, D. E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Mahaffey, K. W.] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. [Fox, K. A. A.] Univ Edinburgh, Royal Infirm Edinburgh, Edinburgh, Midlothian, Scotland. [Califf, R. M.] Duke Univ, Duke Translat Med Inst, Med Ctr, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD SEP 1 PY 2014 VL 35 SU 1 MA 4871 BP 866 EP 866 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AQ7MG UT WOS:000343001305056 ER PT J AU Giugliano, RP Giugliano, RP Ruff, CT Wiviott, SD Murphy, SA Kappelhof, JAN Shi, M Mercuri, M Braunwald, E Antman, EM AF Giugliano, R. P. Giugliano, R. P. Ruff, C. T. Wiviott, S. D. Murphy, S. A. Kappelhof, J. A. N. Shi, M. Mercuri, M. Braunwald, E. Antman, E. M. CA ENGAGE AF-TIMI 48 Investigators TI Reduction in bleeding with edoxaban vs warfarin linked to lower all-cause mortality in 21,105 pateints randomized in the ENGAGE AF-TIMI 48 trial SO EUROPEAN HEART JOURNAL LA English DT Meeting Abstract CT Congress of the European-Society-of-Cardiology (ESC) CY AUG 30-SEP 03, 2014 CL Barcelona, SPAIN SP European Soc Cardiol C1 [Giugliano, R. P.; Giugliano, R. P.; Ruff, C. T.; Wiviott, S. D.; Murphy, S. A.; Braunwald, E.; Antman, E. M.] Brigham & Womens Hosp, Dept Med, Cardiovasc Div, TIMI Study Grp, Boston, MA 02115 USA. [Kappelhof, J. A. N.; Shi, M.; Mercuri, M.] Daiichi Sankyo, Pharma Dev, Edison, NJ USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD SEP 1 PY 2014 VL 35 SU 1 MA 4874 BP 867 EP 867 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AQ7MG UT WOS:000343001305059 ER PT J AU Washam, JB Stevens, SR Lokhnygina, Y Halperin, JL Breithardt, G Singer, DE Fox, KAA Califf, RM Piccini, JP Patel, MR AF Washam, J. B. Stevens, S. R. Lokhnygina, Y. Halperin, J. L. Breithardt, G. Singer, D. E. Fox, K. A. A. Califf, R. M. Piccini, J. P. Patel, M. R. CA ROCKET AF Steering Comm TI Digoxin use in patients with atrial fibrillation is associated with adverse cardiac outcomes: results from the ROCKET AF trial SO EUROPEAN HEART JOURNAL LA English DT Meeting Abstract CT Congress of the European-Society-of-Cardiology (ESC) CY AUG 30-SEP 03, 2014 CL Barcelona, SPAIN SP European Soc Cardiol C1 [Washam, J. B.; Stevens, S. R.; Lokhnygina, Y.; Piccini, J. P.; Patel, M. R.] Duke Univ, Duke Clin Res Inst, Med Ctr, Durham, NC USA. [Halperin, J. L.] Mt Sinai Med Ctr, New York, NY 10029 USA. [Breithardt, G.] Univ Hosp Munster, Munster, Germany. [Singer, D. E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Fox, K. A. A.] Univ Edinburgh, Royal Infirm Edinburgh, Edinburgh, Midlothian, Scotland. [Califf, R. M.] Duke Univ, Duke Translat Med Inst, Med Ctr, Durham, NC USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD SEP 1 PY 2014 VL 35 SU 1 MA 4873 BP 867 EP 867 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AQ7MG UT WOS:000343001305058 ER PT J AU Conrotto, F Scacciatella, P Meliga, E Chieffo, A Kim, YH Onuma, Y Margey, R Capranzano, P Jegere, S Marra, S AF Conrotto, F. Scacciatella, P. Meliga, E. Chieffo, A. Kim, Y. H. Onuma, Y. Margey, R. Capranzano, P. Jegere, S. Marra, S. TI Long term outcomes of percutaneous coronary interventions or bypass grafting surgery for left main coronary artery disease in octogenarians: a DELTA registry sub-study SO EUROPEAN HEART JOURNAL LA English DT Meeting Abstract CT Congress of the European-Society-of-Cardiology (ESC) CY AUG 30-SEP 03, 2014 CL Barcelona, SPAIN SP European Soc Cardiol C1 [Conrotto, F.; Scacciatella, P.; Marra, S.] Citta Salute & Sci Hosp, Turin, Italy. [Meliga, E.] AO Ordine Mauriziano Umberto I, Turin, Italy. [Chieffo, A.] San Raffaele Hosp Milan IRCCS, Milan, Italy. [Kim, Y. H.] Asan Med Ctr, Seoul, South Korea. [Onuma, Y.] Erasmus MC, Rotterdam, Netherlands. [Margey, R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Capranzano, P.] Ferrarotto Hosp, Catania, Italy. [Jegere, S.] Paul Stradins Clin Univ Hosp, Riga, Latvia. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD SEP 1 PY 2014 VL 35 SU 1 MA P5427 BP 970 EP 970 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AQ7MG UT WOS:000343001305453 ER PT J AU Van den Ham, HA Klungel, OH Singer, DE Leufkens, HGM Van Staa, TP AF Van den Ham, H. A. Klungel, O. H. Singer, D. E. Leufkens, H. G. M. Van Staa, T. P. CA Protect, I TI Comparison of ATRIA and CHA2DS2-VASc risk stratification schemes for the prediction of stroke in the individual patient with atrial fibrillation and the impact on treatment decisions SO EUROPEAN HEART JOURNAL LA English DT Meeting Abstract CT Congress of the European-Society-of-Cardiology (ESC) CY AUG 30-SEP 03, 2014 CL Barcelona, SPAIN SP European Soc Cardiol C1 [Van den Ham, H. A.; Klungel, O. H.; Leufkens, H. G. M.] Utrecht Inst Pharmaceut Sci Pharmacoepidemiol & P, Utrecht, Netherlands. [Singer, D. E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Van Staa, T. P.] London Sch Hyg & Trop Med, London WC1, England. RI Klungel, Olaf/I-9563-2016 NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD SEP 1 PY 2014 VL 35 SU 1 MA 5833 BP 1032 EP 1032 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AQ7MG UT WOS:000343001306234 ER PT J AU Musuku, J Chipili, J Long, A Tadmor, B Spector, J AF Musuku, J. Chipili, J. Long, A. Tadmor, B. Spector, J. TI Teachers' knowledge and attitudes related to rheumatic heart disease SO EUROPEAN HEART JOURNAL LA English DT Meeting Abstract CT Congress of the European-Society-of-Cardiology (ESC) CY AUG 30-SEP 03, 2014 CL Barcelona, SPAIN SP European Soc Cardiol C1 [Musuku, J.; Chipili, J.] Univ Teaching Hosp, Dept Paediat & Child Hlth, Lusaka, Zambia. [Long, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Tadmor, B.; Spector, J.] Novartis Inst BioMed Res, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD SEP 1 PY 2014 VL 35 SU 1 MA P6078 BP 1069 EP 1069 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AQ7MG UT WOS:000343001306373 ER PT J AU Brunner-La Rocca, HP Eurlings, L Karlstrom, P Erntell, H Berger, R Pfisterer, ME Gaggin, HK Januzzi, JL Richards, AM Troughton, RW AF Brunner-La Rocca, H. P. Eurlings, L. Karlstrom, P. Erntell, H. Berger, R. Pfisterer, M. E. Gaggin, H. K. Januzzi, J. L. Richards, A. M. Troughton, R. W. TI Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomised trials SO EUROPEAN HEART JOURNAL LA English DT Meeting Abstract CT Congress of the European-Society-of-Cardiology (ESC) CY AUG 30-SEP 03, 2014 CL Barcelona, SPAIN SP European Soc Cardiol C1 [Brunner-La Rocca, H. P.; Eurlings, L.] Maastricht Univ Med Ctr, Maastricht, Netherlands. [Karlstrom, P.] Ryhov Cty Hosp, Jonkoping, Sweden. [Erntell, H.] Karolinska Inst, Stockholm, Sweden. [Berger, R.] Med Univ Vienna, Vienna, Austria. [Pfisterer, M. E.] Univ Basel Hosp, CH-4031 Basel, Switzerland. [Gaggin, H. K.; Januzzi, J. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Richards, A. M.; Troughton, R. W.] Univ Otago Christchurch, Christchurch, New Zealand. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD SEP 1 PY 2014 VL 35 SU 1 MA P6546 BP 1180 EP 1180 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AQ7MG UT WOS:000343001306798 ER PT J AU Karmon, AE Cardozo, ER Rueda, BR Styer, AK AF Karmon, Anatte E. Cardozo, Eden R. Rueda, Bo R. Styer, Aaron K. TI MicroRNAs in the development and pathobiology of uterine leiomyomata: does evidence support future strategies for clinical intervention? SO HUMAN REPRODUCTION UPDATE LA English DT Article DE leiomyoma; microRNA; fibroid; biomarker; myometrium ID ESTROGEN-RECEPTOR-ALPHA; SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR-BETA; GONADOTROPIN-RELEASING-HORMONE; CHRONIC LYMPHOCYTIC-LEUKEMIA; FEMALE REPRODUCTIVE-TRACT; GENE-EXPRESSION; BREAST-CANCER; MATCHED MYOMETRIUM; UP-REGULATION AB BACKGROUND: Human leiomyomata (fibroids) are benign tumors of the uterus, represent the most common neoplasms of reproductive-aged women and have a prevalence of similar to 70% in the general population. This disorder conveys a significant degree of morbidity and remains the leading indication for hysterectomy in the USA. Prior investigations of aberrant microRNA (miRNA) expression in various malignancies have provided invaluable insight into the role of this class of small non-coding RNAs in tumor growth. Evidence of irregular miRNA expression in uterine fibroids has garnered recent interest for diagnostic and therapeutic applications. SincemiRNA gene targets modulate several processes implicated in the genesis of uterine fibroids, more focused investigation has the potential to elucidate the functional significance of miRNA in the genesis and pathology of the disease. METHODS: Comprehensive electronic searches of peer reviewed published literature in PubMed (US National Library of Medicine, National Institute of Health; http://www.ncbi.nlm.nih.gov/pubmed/) were performed for content related to the biologic functions of miRNA, the roles of miRNA in human disease and studies investigating miRNA in the context of uterine leiomyomata. Herein, this article will review the current evidence supporting the use of miRNA expression profiling as an investigative tool to assess the pathobiology of uterine fibroids and will discuss potential future applications of miRNAs as biomarkers and therapeutic targets. RESULTS: Mounting evidence supports a functional role for miRNA as either indirect or direct regulators of gene expression which impacts the pathobiology of uterine fibroids. Specifically, miRNAs let-7, 200a, 200c, 93, 106b and 21 have been implicated in cellular proliferation, apoptosis, extracellular matrix turnover, angiogenesis and inflammation. Preliminary data provide evidence to suggest that respective in vitro miRNA expression in leiomyomata and myometrium is regulated by sex steroids. CONCLUSIONS: Collectively, the identification of aberrantly expressed miRNAs in uterine leiomyomata and accumulating data derived from mining of gene target prediction models and recent functional studies support the concept that miRNAs might impact the genesis and progression of disease. However, the specific biologic functions of differential miRNA expression have yet to be confirmed in vivo. Further functional studies and developing miRNA technology may provide the basis for future applications of miRNAs in clinical medicine as biomarkers and therapeutic targets. C1 [Karmon, Anatte E.; Cardozo, Eden R.; Rueda, Bo R.; Styer, Aaron K.] Massachusetts Gen Hosp, Vincent Dept Obstet & Gynecol, Vincent Ctr Reprod Biol, Boston, MA 02114 USA. [Karmon, Anatte E.; Cardozo, Eden R.; Rueda, Bo R.; Styer, Aaron K.] Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA. RP Styer, AK (reprint author), Massachusetts Gen Hosp, Vincent Dept Obstet & Gynecol, Vincent Ctr Reprod Biol, Their 904,55 Fruit St, Boston, MA 02114 USA. EM astyer@partners.org FU Vincent Department of Obstetrics and Gynecology at Massachusetts General Hospital; Vincent Club; Office of Diversity Inclusion and Community Partnership/Harvard Catalyst at Harvard Medical School FX This work was supported by Vincent Department of Obstetrics and Gynecology at Massachusetts General Hospital, The Vincent Club, and The Office of Diversity Inclusion and Community Partnership/Harvard Catalyst at Harvard Medical School. NR 168 TC 9 Z9 10 U1 1 U2 8 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1355-4786 EI 1460-2369 J9 HUM REPROD UPDATE JI Hum. Reprod. Update PD SEP-OCT PY 2014 VL 20 IS 5 BP 670 EP 687 DI 10.1093/humupd/dmu017 PG 18 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA AT1FG UT WOS:000344678100005 PM 24706045 ER PT J AU Choi, NC Chun, TT Ancukiewicz, M Niemierko, A Fischman, AJ AF Choi, Noah C. Chun, Tristen T. Ancukiewicz, Marek Niemierko, Andrzej Fischman, Alan J. TI CORRELATIONS BETWEEN THE SIMPLIFIED KINETIC METHOD (SKM) AND STANDARD UPTAKE VALUES (SUVS) OF 18F-FDG PET IN LUNG CANCER SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE 18F-FDG PET; Response-monitoring; Simplified-kinetic-method; Standard-uptake-value C1 [Choi, Noah C.; Chun, Tristen T.; Ancukiewicz, Marek; Niemierko, Andrzej; Fischman, Alan J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD SEP PY 2014 VL 9 IS 9 SU 3 MA P1.19 BP S165 EP S165 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AT0LH UT WOS:000344627100030 ER PT J AU Gandhi, L Lubiniecki, G Balmanoukian, A Hui, R Hamid, O Rizvi, NA Leighl, N Gubens, M Goldman, JW Emancipator, K Dolled-Filhart, M Lunceford, JK Niewood, M Gergich, K Garon, EB AF Gandhi, Leena Lubiniecki, Gregory Balmanoukian, Ani Hui, Rina Hamid, Omid Rizvi, Naiyer A. Leighl, Natasha Gubens, Matthew Goldman, Jonathan W. Emancipator, Kenneth Dolled-Filhart, Marisa Lunceford, Jared K. Niewood, Michelle Gergich, Kevin Garon, Edward B. TI MK-3475 (ANTI-PD-1 MONOCLONAL ANTIBODY) FOR NON-SMALL CELL LUNG CANCER (NSCLC): ANTITUMOR ACTIVITY AND ASSOCIATION WITH TUMOR PD-L1 EXPRESSION SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE MK-3475; immunotherapy; PD-1; PD-L1 C1 [Gandhi, Leena] Dana Farber Canc Inst, Boston, MA 02115 USA. [Lubiniecki, Gregory; Niewood, Michelle; Gergich, Kevin] Merck & Co Inc, N Wales, PA USA. [Balmanoukian, Ani; Hamid, Omid] Angeles Clin & Res Inst, Los Angeles, CA USA. [Hui, Rina] Westmead Hosp, Sydney, NSW, Australia. [Rizvi, Naiyer A.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Leighl, Natasha] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [Gubens, Matthew] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Goldman, Jonathan W.] Univ Calif Los Angeles, Santa Monica, CA USA. [Emancipator, Kenneth; Dolled-Filhart, Marisa; Lunceford, Jared K.] Merck & Co Inc, Rahway, NJ 07065 USA. [Garon, Edward B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 1 Z9 1 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD SEP PY 2014 VL 9 IS 9 SU 3 MA PD.1 BP S154 EP S154 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AT0LH UT WOS:000344627100005 ER PT J AU Rizvi, NA Gettinger, SN Horn, L Gandhi, L Spigel, DR Powderly, JD Heist, RS Carvajal, RD Jackman, DM Sequist, LV Smith, DC Leming, PD Topalian, SL Hodi, FS Sznol, M Harbison, CT Kollia, GD Brahmer, JR Antonia, SJ AF Rizvi, Naiyer A. Gettinger, Scott N. Horn, Leora Gandhi, Leena Spigel, David R. Powderly, John D. Heist, Rebecca S. Carvajal, Richard D. Jackman, David M. Sequist, Lecia V. Smith, David C. Leming, Philip D. Topalian, Suzanne L. Hodi, F. Stephen Sznol, Mario Harbison, Christopher T. Kollia, Georgia D. Brahmer, Julie R. Antonia, Scott J. TI NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): SURVIVAL AND CLINICAL ACTIVITY BY SUBGROUP ANALYSIS SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE nivolumab; immunotherapy; erlotinib; chemotherapy C1 [Rizvi, Naiyer A.; Carvajal, Richard D.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Gettinger, Scott N.] Yale Univ, Ctr Canc, New Haven, CT USA. [Horn, Leora] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Gandhi, Leena; Smith, David C.; Hodi, F. Stephen] Dana Farber Canc Inst, Boston, MA 02115 USA. [Spigel, David R.] Tennessee Oncol Pllc, Sarah Cannon Res Inst, Nashville, TN USA. [Powderly, John D.] Carolina Biooncol Inst, Huntersville, NC USA. [Heist, Rebecca S.; Sequist, Lecia V.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Smith, David C.] Univ Michigan, Ann Arbor, MI 48109 USA. [Leming, Philip D.] Christ Hosp Ctr, Cincinnati, OH USA. [Topalian, Suzanne L.; Brahmer, Julie R.] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Sznol, Mario] Yale Univ, Ctr Comprehens Canc, New Haven, CT USA. [Harbison, Christopher T.; Kollia, Georgia D.] Bristol Myers Squibb Co, Princeton, NJ USA. [Antonia, Scott J.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. NR 0 TC 0 Z9 0 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD SEP PY 2014 VL 9 IS 9 SU 3 MA O.1 BP S152 EP S152 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AT0LH UT WOS:000344627100002 ER PT J AU Uchida, M Davis, J Wozniak, J AF Uchida, Mai Davis, Jacqueline Wozniak, Janet TI Familiality and Indicators of Risk for Bipolar Disorder in Youth with Attention-Deficit/Hyperactivity Disorder SO PSYCHIATRIC ANNALS LA English DT Article ID CHILD-BEHAVIOR CHECKLIST; MAJOR DEPRESSIVE DISORDER; CLINICAL CHARACTERISTICS; I DISORDER; FOLLOW-UP; DYSREGULATION PROFILE; ADOLESCENTS; MANIA; METAANALYSIS; FAMILY AB Our literature review aims to identify risks for pediatric bipolar disorder in youth in the presence of symptoms of attention-deficit/hyperactivity disorder (ADHD). This issue is of clinical and scientific significance as these two disorders share multiple characteristics, as well as high rates of comorbidity with disruptive behavior disorders. Family studies validate that these disorders often co-exist and suggest that a family history heightens the risk for the development of bipolar disorder. Elevated emotional dysregulation scores on the Child Behavioral Check List present another risk factor that is associated with the diagnosis of bipolar disorder in youth. In addition, ADHD children initially presenting with depression are at an increased risk for manic switches; a switch can be predicted by the presence of a family history of mood disorders, emotional and behavioral dysregulation, subthreshold manic symptoms, and psychosis. Taken together, these risk factors can aid clinicians in making an accurate diagnosis of mania in youth with ADHD. C1 [Uchida, Mai; Wozniak, Janet] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA. [Uchida, Mai; Davis, Jacqueline; Wozniak, Janet] Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol, Boston, MA 02114 USA. RP Wozniak, J (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Warren 705, Boston, MA 02114 USA. EM jwozniak@partners.org NR 30 TC 2 Z9 2 U1 0 U2 2 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0048-5713 EI 1938-2456 J9 PSYCHIAT ANN JI Psychiatr. Ann. PD SEP PY 2014 VL 44 IS 9 BP 423 EP 427 DI 10.3928/00485713-20140908-06 PG 5 WC Psychiatry SC Psychiatry GA AT5GY UT WOS:000344973200006 ER PT J AU Gamma, F Goldstein, JM Seidman, LJ Fitzmaurice, GM Tsuang, MT Buka, SL AF Gamma, Franziska Goldstein, Jill M. Seidman, Larry J. Fitzmaurice, Garrett M. Tsuang, Ming T. Buka, Stephen L. TI Early Intermodal Integration in Offspring of Parents With Psychosis SO SCHIZOPHRENIA BULLETIN LA English DT Article DE schizophrenia; high-risk study; developmental psychology ID MOTHER-INFANT INTERACTION; NEW-ENGLAND FAMILY; BIPOLAR DISORDER; ADOPTIVE PARENTS; HIGH-RISK; MATERNAL PSYCHOPATHOLOGY; COMMUNICATION DEVIANCE; FACIAL EXPRESSIONS; SCHIZOPHRENIA; PERCEPTION AB Identifying early developmental indicators of risk for schizophrenia is important for prediction and possibly illness prevention. Disturbed intermodality has been proposed as one important neurodevelopmental risk for schizophrenia. Early intermodal integration (EII) is the infant's ability to link motility and perception and to relate perception across modalities. We hypothesized that infants of parents with schizophrenia would have more EII abnormalities than infants of healthy parents and that infants of parents with affective psychosis would be intermediate in severity. The New England Family Study high-risk sample, ascertained from community populations, was utilized. Eight-month-old infants of parents with schizophrenia (n = 58), affective psychoses (n = 128), and healthy controls (n = 174) were prospectively assessed. Diagnoses of parents were determined 30 years later blind to offspring data. EII measures were grouped into 3 domains characterizing different aspects of infant development: (1) one's own body, (2) objects, and (3) social interactions. Results demonstrated that body-and object-related EII abnormalities were significantly increased for infants of parents with schizophrenia compared with control infants and not significantly increased for infants of parents with affective psychoses. EII abnormalities in relation to social interactions were significantly increased in infants of parents with schizophrenia and affective psychoses. Thus, body-and object-related EII abnormalities were most severe in infants of parents with schizophrenia, supporting the importance of intermodality dysfunction as an early indicator of the vulnerability to schizophrenia. Future research should evaluate how this dysfunction evolves with development and its associations with other psychopathological and neurodevelopmental deficits in youth at risk for psychosis. C1 [Gamma, Franziska; Buka, Stephen L.] Les Toises, Ctr Psychiat & Psychotherapy, CH-1005 Lausanne, Switzerland. [Goldstein, Jill M.; Tsuang, Ming T.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Psychiat,Div Womens Hlth,Connors Ctr Womens, Boston, MA 02115 USA. [Goldstein, Jill M.; Tsuang, Ming T.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Womens Hlth,Connors Ctr Womens, Boston, MA 02115 USA. [Seidman, Larry J.; Tsuang, Ming T.] Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr, Dept Psychiat, Publ Psychiat Div, Boston, MA USA. [Seidman, Larry J.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Fitzmaurice, Garrett M.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Tsuang, Ming T.] Univ Calif San Diego, Dept Psychiat, Ctr Behav Genom, Inst Genom Med, San Diego, CA 92103 USA. [Tsuang, Ming T.] Harvard Univ, Sch Med, Harvard Inst Psychiat Epidemiol & Genet, Boston, MA USA. [Buka, Stephen L.] Brown Univ, Dept Community Hlth, Providence, RI 02912 USA. [Buka, Stephen L.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. [Buka, Stephen L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. RP Buka, SL (reprint author), Les Toises, Ctr Psychiat & Psychotherapy, Ave Mousquines 4, CH-1005 Lausanne, Switzerland. EM franziska.gamma@lestoises.ch FU National Institute of Mental Health [RO1 MH50647, RO1 MH63951, RO1 MH56956]; Stanley Medical Research Institute; National Association for Research on Schizophrenia and Depression; Swiss National Science Foundation; Department of Psychiatry-Centre hospitalier universitaire vaudois (CHUV); Societe Academique Vaudoise in Lausanne, Switzerland FX National Institute of Mental Health (RO1 MH50647 to M. T. T, J.M.G., S. L. B., and L.J.S.) (1994-2003, to M. T. T., P. I.; 2003-2006, to J.M.G., P. I.); Stanley Medical Research Institute (to L.J.S. and S. L. B.); National Association for Research on Schizophrenia and Depression (to L.J.S.), National Institute of Mental Health (RO1 MH63951 to L.J.S., RO1 MH56956 to J.M.G.); Swiss National Science Foundation, the Department of Psychiatry-Centre hospitalier universitaire vaudois (CHUV); Societe Academique Vaudoise in Lausanne, Switzerland (to F.G.) NR 48 TC 7 Z9 7 U1 1 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD SEP PY 2014 VL 40 IS 5 BP 992 EP 1000 DI 10.1093/schbul/sbt111 PG 9 WC Psychiatry SC Psychiatry GA AT0ET UT WOS:000344610800009 PM 23986303 ER PT J AU Canales, BK Schafer, AL Shoback, DM Carpenter, TO AF Canales, Benjamin K. Schafer, Anne L. Shoback, Dolores M. Carpenter, Thomas O. TI Gastric bypass in obese rats causes bone loss, vitamin D deficiency, metabolic acidosis, and elevated peptide YY SO SURGERY FOR OBESITY AND RELATED DISEASES LA English DT Article DE Morbid obesity; Gastric bypass surgery; Bone turnover markers; Bone resorption; Metabolic bone disease; Metabolic acidosis; Peptide YY ID BARIATRIC SURGERY; MINERAL DENSITY; WEIGHT-LOSS; PREMENOPAUSAL WOMEN; PARATHYROID-HORMONE; BODY-COMPOSITION; MORBID-OBESITY; TURNOVER; MARKERS; MASS AB Background: Metabolic bone disease and bariatric surgery have long been interconnected. The objective of this study is to better understand the mechanisms of bone mass loss after Roux-en-Y gastric bypass (RYGB) surgery. We evaluated mineral homeostasis and bone mass in diet-induced obese (DIO) rats after RYGB or sham surgery. Methods: Twelve DIO male Sprague Dawley rats underwent RYGB (n = 8) or sham (n = 4) surgery at 21 weeks of age. Postoperatively, animals ate an ad libitum 40% fat, normal calcium diet and were euthanized 22 weeks later. Serum and urine chemistries, insulin, leptin, bone turnover markers (BTM), and calciotropic and gut hormones were measured before and 22 weeks after surgery. Femurs were analyzed using microcomputed tomography (mu CT). Results: Compared to sham, RYGB animals had lower serum bicarbonate, calcium, 25-hydroxyvitamin D, insulin, and leptin levels with higher serum parathyroid hormone, peptide YY, and urinary calcium at 43 weeks of age Sham control rats gained weight and had coupled decreases in formation (P1NP and OC) and unchanged resorption (CTX) BTMs. Comparatively, RYGB animals had higher serum CTX and OC but even lower P1NP levels than controls. mu CT revealed lower trabecular bone volume, number, and thickness and lower cortical bone volume, thickness, and moment of inertia relative to controls. Conclusion: In rats with DIO, long-term RYGB-associated bone resorption appears to be driven in part by vitamin D malabsorption and secondary hyperparathyroidism. Other mechanisms, such as chronic acidosis, changes in fat-secreted hormones, and persistently elevated gut-derived hormone peptide YY, may also contribute to observed bone mass differences. Further investigation of these potential contributors to bone loss may lead to new targets for skeletal maintenance after RYGB. (C) 2014 American Society for Metabolic and Bariatric Surgery. All rights reserved. C1 [Canales, Benjamin K.] North Florida South Georgia Vet Affairs Med Ctr, Dept Urol, Gainesville, FL USA. [Canales, Benjamin K.] Univ Florida, Gainesville, FL 32610 USA. [Schafer, Anne L.; Shoback, Dolores M.] San Francisco VA Med Ctr, Endocrine Res Unit, San Francisco, CA USA. [Schafer, Anne L.; Shoback, Dolores M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Carpenter, Thomas O.] Yale Univ, Sch Med, Dept Pediat Endocrinol, New Haven, CT USA. RP Canales, BK (reprint author), Univ Florida, Dept Urol, 1600 SW Archer Rd,POB 100247, Gainesville, FL 32610 USA. EM benjamin.canales@urology.ufl.edu FU NIH [K08 DK089000-04, P30-AR46032, R03 DK100732-01]; AUA Foundation Rising Star in Urology Research Award; Veterans Affairs Grant [IK2 CX000549-03]; Ethicon Endo-Surgery; Astellas Global Development, Inc. FX This study was funded by NIH K08 DK089000-04, P30-AR46032, R03 DK100732-01, AUA Foundation Rising Star in Urology Research Award in conjunction with Astellas Global Development, Inc., Veterans Affairs Grant IK2 CX000549-03, and Ethicon Endo-Surgery. NR 33 TC 4 Z9 5 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1550-7289 EI 1878-7533 J9 SURG OBES RELAT DIS JI Surg. Obes. Relat. Dis. PD SEP-OCT PY 2014 VL 10 IS 5 BP 878 EP 884 DI 10.1016/j.soard.2014.01.021 PG 7 WC Surgery SC Surgery GA AT1UL UT WOS:000344719200026 PM 24969093 ER PT J AU Brethauer, SA Kothari, S Sudan, R Williams, B English, WJ Brengman, M Kurian, M Hutter, M Stegemann, L Kallies, K Nguyen, NT Ponce, J Morton, JM AF Brethauer, Stacy A. Kothari, Shanu Sudan, Ranjan Williams, Brandon English, Wayne J. Brengman, Matthew Kurian, Marina Hutter, Matthew Stegemann, Lloyd Kallies, Kara Nguyen, Ninh T. Ponce, Jaime Morton, John M. TI Systematic review on reoperative bariatric surgery American Society for Metabolic and Bariatric Surgery Revision Task Force SO SURGERY FOR OBESITY AND RELATED DISEASES LA English DT Review DE Reoperative; Revisional; Bariatric; Weight regain; Complications ID Y GASTRIC BYPASS; VERTICAL BANDED GASTROPLASTY; LAPAROSCOPIC SLEEVE GASTRECTOMY; TOTAL HIP-REPLACEMENT; SUPER-OBESE-PATIENT; WEIGHT-LOSS SURGERY; MORBID-OBESITY; DUODENAL SWITCH; BILIOPANCREATIC DIVERSION; FOLLOW-UP AB Background: Reoperative bariatric surgery has become a common practice in many bariatric surgery programs. There is currently little evidence-based guidance regarding specific indications and outcomes for reoperative bariatric surgery. A task force was convened to review the current evidence regarding reoperative bariatric surgery. The aim of the review was to identify procedure-specific indications and outcomes for reoperative procedures. Methods: Literature search was conducted to identify studies reporting indications for and outcomes after reoperative bariatric surgery. Specifically, operations to treat complications, failed weight loss, and weight regain were evaluated. Abstract and manuscript reviews were completed by the task force members to identify, grade, and categorize relevant studies. Results: A total of 819 articles were identified in the initial search. After review for inclusion criteria and data quality, 175 articles were included in the systematic review and analysis. The majority of published studies are single center retrospective reviews. The evidence supporting reoperative surgery for acute and chronic complications is described. The evidence regarding reoperative surgery for failed weight loss and weight regain generally demonstrates improved weight loss and co-morbidity reduction after reintervention. Procedure-specific outcomes are described. Complication rates are generally reported to be higher after reoperative surgery compared to primary surgery. Conclusion: The indications and outcomes for reoperative bariatric surgery are procedure-specific but the current evidence does support additional treatment for persistent obesity, co-morbid disease, and complications. (C) 2014 American Society for Metabolic and Bariatric Surgery. All rights reserved. C1 [Brethauer, Stacy A.] Cleveland Clin, Bariatr & Metab Inst, Cleveland, OH 44195 USA. [Kothari, Shanu; Kallies, Kara] Gunderson Hlth Syst, Dept Surg, La Crosse, WI USA. [Sudan, Ranjan] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA. [Williams, Brandon] Vanderbilt Ctr Surg Weight Loss, Nashville, TN USA. [English, Wayne J.] Marquette Gen Hosp, Dept Surg, Marquette, MI USA. [Brengman, Matthew] Adv Surg Partners Virginia, Richmond, VA USA. [Kurian, Marina] NYU, Dept Surg, Bariatr Surg Associates, New York, NY 10016 USA. [Hutter, Matthew] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Stegemann, Lloyd] Better Weigh Ctr, Corpus Christi, TX USA. [Nguyen, Ninh T.] Univ Calif Irvine, Med Ctr, Dept Surg, Orange, CA 92668 USA. [Ponce, Jaime] Dalton Surg Grp, Dalton, GA USA. [Morton, John M.] Stanford Univ, Dept Surg, Palo Alto, CA 94304 USA. RP Brethauer, SA (reprint author), Cleveland Clin, Bariatr & Metab Inst, 9500 Euclid Ave,M61, Cleveland, OH 44195 USA. EM brethas@ccf.org FU Covidien FX This project was supported by an unrestricted educational grant by Covidien. NR 179 TC 41 Z9 41 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1550-7289 EI 1878-7533 J9 SURG OBES RELAT DIS JI Surg. Obes. Relat. Dis. PD SEP-OCT PY 2014 VL 10 IS 5 BP 952 EP 972 DI 10.1016/j.soard.2014.02.014 PG 21 WC Surgery SC Surgery GA AT1UL UT WOS:000344719200040 PM 24776071 ER PT J AU Dabelea, D Ma, Y Knowler, WC Marcovina, S Saudek, CD Arakaki, R White, NH Kahn, SE Orchard, TJ Goldberg, R Palmer, J Hamman, RF AF Dabelea, D. Ma, Y. Knowler, W. C. Marcovina, S. Saudek, C. D. Arakaki, R. White, N. H. Kahn, S. E. Orchard, T. J. Goldberg, R. Palmer, J. Hamman, R. F. CA Diabet Prevention Program Res Grp TI Diabetes autoantibodies do not predict progression to diabetes in adults: the Diabetes Prevention Program SO DIABETIC MEDICINE LA English DT Article ID GLUTAMIC-ACID DECARBOXYLASE; IMPAIRED GLUCOSE-TOLERANCE; ISLET-CELL AUTOIMMUNITY; LIFE-STYLE; LOW-PREVALENCE; ANTIBODIES; POPULATION; MELLITUS; INSULIN; GAD65 AB Aims To determine if the presence of diabetes autoantibodies predicts the development of diabetes among participants in the Diabetes Prevention Program. Methods A total of 3050 participants were randomized into three treatment groups: intensive lifestyle intervention, metformin and placebo. Glutamic acid decarboxylase (GAD) 65 autoantibodies and insulinoma-associated-2 autoantibodies were measured at baseline and participants were followed for 3.2 years for the development of diabetes. Results The overall prevalence of GAD autoantibodies was 4.0%, and it varied across racial/ethnic groups from 2.4% among Asian-Pacific Islanders to 7.0% among non-Hispanic black people. There were no significant differences in BMI or metabolic variables (glucose, insulin, HbA(1c), estimated insulin resistance, corrected insulin response) stratified by baseline GAD antibody status. GAD autoantibody positivity did not predict diabetes overall (adjusted hazard ratio 0.98; 95% CI 0.56-1.73) or in any of the three treatment groups. Insulinoma-associated-2 autoantibodies were positive in only one participant (0.033%). Conclusions These data suggest that 'diabetes autoimmunity', as reflected by GAD antibodies and insulinoma-associated-2 autoantibodies, in middle-aged individuals at risk for diabetes is not a clinically relevant risk factor for progression to diabetes. C1 [Dabelea, D.; Hamman, R. F.] Univ Colorado Denver, Dept Epidemiol, Colorado Sch Publ Hlth, Aurora, CO 80045 USA. [Ma, Y.] George Washington Univ, Ctr Biostat, Rockville, MD USA. [Knowler, W. C.] NIDDKD, Phoenix, AZ USA. [Marcovina, S.] Northwest Lipid Res Labs, Seattle, WA USA. [Saudek, C. D.] Johns Hopkins Univ, Sch Med, Dept Med, Div Endocrinol & Metab, Baltimore, MD 21205 USA. [Arakaki, R.] Univ Hawaii Manoa, John A Burns Sch Med, Dept Med, Honolulu, HI 96822 USA. [White, N. H.] Washington Univ, St Louis Childrens Hosp, Sch Med, Dept Pediat & Med,Pediat Patient Oriented Res Uni, St Louis, MO 63110 USA. [Kahn, S. E.; Palmer, J.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Kahn, S. E.; Palmer, J.] Univ Washington, Seattle, WA 98195 USA. [Orchard, T. J.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Goldberg, R.] Univ Miami, Sch Med, Diabet Res Inst, Miami, FL USA. RP Dabelea, D (reprint author), Univ Colorado Denver, Dept Epidemiol, Colorado Sch Publ Hlth, Aurora, CO 80045 USA. EM dppmail@bsc.gwu.edu RI Uwaifo, Gabriel/M-2361-2016; OI Uwaifo, Gabriel/0000-0002-6962-9304; orchard, trevor/0000-0001-9552-3215; Franks, Paul/0000-0002-0520-7604; Kahn, Steven/0000-0001-7307-9002 FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health [U01 DK048489]; NIDDK; Indian Health Service; Office of Research on Minority Health; National Institute of Child Health and Human Development; National Institute on Aging; Centers for Disease Control and Prevention; Office of Research on Women's Health; Department of Veterans Affairs; American Diabetes Association FX The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health provided funding to the clinical centres and the coordinating centre for the design and conduct of the study, and collection, management, analysis and interpretation of the data (U01 DK048489). The Southwestern American Indian Centers were supported directly by the NIDDK and by the Indian Health Service. The General Clinical Research Center Program, National Center for Research Resources supported data collection at many of the clinical centres. Funding for data collection and participant support was also provided by the Office of Research on Minority Health, the National Institute of Child Health and Human Development, the National Institute on Aging, the Centers for Disease Control and Prevention, the Office of Research on Women's Health, the Department of Veterans Affairs, and the American Diabetes Association. Bristol-Myers Squibb and Parke-Davis provided medication. This research was also supported, in part, by the intramural research program of the NIDDK. Lipha (Merck-Sante) provided medicines, and LifeScan Inc., Health O Meter, Hoechst Marion Roussel, Inc., Merck-Medco Managed Care, Inc., Merck and Co., Nike Sports Marketing, Slim Fast Foods Co., and Quaker Oats Co. donated materials, equipment or medicines for concomitant conditions. The opinions expressed are those of the investigators and do not necessarily reflect the views of the funding agencies. A complete list of centres, investigators, and staff can be found in Appendix S1. NR 30 TC 5 Z9 5 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0742-3071 EI 1464-5491 J9 DIABETIC MED JI Diabetic Med. PD SEP PY 2014 VL 31 IS 9 BP 1064 EP 1068 DI 10.1111/dme.12437 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AS1AN UT WOS:000344008700008 PM 24646311 ER PT J AU Sadeghian, H Gorji, A AF Sadeghian, H. Gorji, A. TI Neuronal Death and Damage by Repetitive Cortical Spreading Depression in Cortical and Subcortical Regions of Brain: an Electrophysiology Study in Juvenile Rat Brain SO HEADACHE LA English DT Meeting Abstract CT 56th Annual Scientific Meeting of the American-Headache-Society CY JUN 26-29, 2014 CL Los Angeles, CA SP Amer Headache Soc C1 [Gorji, A.] Univ Munster, D-48149 Munster, Germany. [Sadeghian, H.] Massachusetts Gen Hosp, Neurovasc Res Lab, Charlestown, MA USA. RI Mousapour Gorji, Ahmad/D-3670-2017 NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-8748 EI 1526-4610 J9 HEADACHE JI Headache PD SEP PY 2014 VL 54 IS 8 MA LBP24 BP 1428 EP 1428 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA AR9XQ UT WOS:000343930900041 ER PT J AU Sadeghian, H Motiei-Langroudi, R AF Sadeghian, H. Motiei-Langroudi, R. TI Does Severity of Headaches after Mild Traumatic Brain Injury Associates with a Higher Frequency of Headaches Late after Trauma? SO HEADACHE LA English DT Meeting Abstract CT 56th Annual Scientific Meeting of the American-Headache-Society CY JUN 26-29, 2014 CL Los Angeles, CA SP Amer Headache Soc C1 [Sadeghian, H.] Massachusetts Gen Hosp, Neurovasc Res Lab, Charlestown, MA USA. [Motiei-Langroudi, R.] Shohada Tajrish Hosp, Tehran, Iran. NR 0 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-8748 EI 1526-4610 J9 HEADACHE JI Headache PD SEP PY 2014 VL 54 IS 8 MA LBP26 BP 1429 EP 1429 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA AR9XQ UT WOS:000343930900043 ER PT J AU Sadeghian, H Motiei-Langroudi, R Ghabaee, M AF Sadeghian, H. Motiei-Langroudi, R. Ghabaee, M. TI Comparison of Levetiracetam and Sodium Valproate in Migraine Prophylaxis: a Randomized Placebo-controlled Study SO HEADACHE LA English DT Meeting Abstract CT 56th Annual Scientific Meeting of the American-Headache-Society CY JUN 26-29, 2014 CL Los Angeles, CA SP Amer Headache Soc C1 [Ghabaee, M.] Univ Tehran Med Sci, Iranian Ctr Neurol Res, Tehran, Iran. [Sadeghian, H.] Massachusetts Gen Hosp, Neurovasc Res Lab, Charlestown, MA USA. [Motiei-Langroudi, R.] Shohada Tajrish Hosp, Tehran, Iran. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-8748 EI 1526-4610 J9 HEADACHE JI Headache PD SEP PY 2014 VL 54 IS 8 MA LBP30 BP 1431 EP 1431 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA AR9XQ UT WOS:000343930900047 ER PT J AU Ackman, JB Verzosa, S Kovach, AE Louissaint, A Lanuti, M Wright, CD Halpern, EF AF Ackman, Jeanne B. Verzosa, Stacey Kovach, Alexandra E. Louissaint, Abner, Jr. Lanuti, Michael Wright, Cameron D. Halpern, Elkan F. TI THE BENIGN THYMECTOMY RATE AT A QUATERNARY REFERRAL HOSPITAL: DOES MRI HAVE POTENTIAL TO REDUCE IT? SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE MRI; thymic hyperplasia; thymic cyst; Thymectomy C1 [Ackman, Jeanne B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Thorac Imaging & Intervent, Boston, MA USA. [Verzosa, Stacey] Massachusetts Gen Hosp, Div Thorac Imaging & Intervent, Boston, MA 02114 USA. [Kovach, Alexandra E.; Louissaint, Abner, Jr.; Lanuti, Michael; Wright, Cameron D.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Halpern, Elkan F.] Mgh Inst Technol Assessment, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD SEP PY 2014 VL 9 IS 10 SU 4 MA O4.02 BP S222 EP S223 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AT0LL UT WOS:000344627500015 ER PT J AU Cahill, DP Loebel, F Bogner, W Marjanska, M Gerstner, E Batchelor, T Rosen, BR Chi, A Andronesi, OC AF Cahill, D. P. Loebel, F. Bogner, W. Marjanska, M. Gerstner, E. Batchelor, T. Rosen, B. R. Chi, A. Andronesi, O. C. TI MONITORING OF TREATMENT RESPONSE IN IDH-MUTANT GLIOMAS WITH IN-VIVO 3D MAGNETIC RESONANCE SPECTROSCOPY SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 11th Congress of the European-Association-of-Neuro-Oncology CY OCT 09-12, 2014 CL Turin, ITALY SP European Assoc Neuro Oncol C1 [Cahill, D. P.; Loebel, F.; Gerstner, E.; Batchelor, T.; Rosen, B. R.; Chi, A.; Andronesi, O. C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bogner, W.] Med Univ Vienna, Dept Radiol, MR Ctr Excellence, Vienna, Austria. [Marjanska, M.] Univ Minnesota, Ctr Magnet Resonance Res, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD SEP PY 2014 VL 16 SU 2 MA O8.02 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA AS4HT UT WOS:000344235700064 ER PT J AU Reardon, DA Nayak, L DeAngelis, LM Wen, PY Brandes, AA Soffietti, R Peerboom, DM Lin, NU Chamberlain, M Macdonald, D AF Reardon, D. A. Nayak, L. DeAngelis, L. M. Wen, P. Y. Brandes, A. A. Soffietti, R. Peerboom, D. M. Lin, N. U. Chamberlain, M. Macdonald, D. TI THE NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE: A TOOL TO ASSESS NEUROLOGIC FUNCTION FOR INTEGRATION IN THE RADIOLOGIC ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 11th Congress of the European-Association-of-Neuro-Oncology CY OCT 09-12, 2014 CL Turin, ITALY SP European Assoc Neuro Oncol C1 [Reardon, D. A.; Nayak, L.; Wen, P. Y.; Lin, N. U.] Dana Farber Canc Inst, Boston, MA 02115 USA. [DeAngelis, L. M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Brandes, A. A.] Bellaria Maggiore Hosp, Bologna, Italy. [Soffietti, R.] Univ Turin, San Giovanni Battista Hosp, Turin, Italy. [Peerboom, D. M.] Cleveland Clin, Cleveland, OH 44106 USA. [Chamberlain, M.] Univ Washington, Seattle, WA 98195 USA. [Macdonald, D.] London Reg Canc Program, London, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD SEP PY 2014 VL 16 SU 2 MA P15.13 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA AS4HT UT WOS:000344235700293 ER PT J AU Wen, PY Lee, EQ Van den Bent, M Soffieti, R Bendszus, M Mehta, M Baumert, B Vogelbaum, M Chang, SM Lin, NU AF Wen, P. Y. Lee, E. Q. Van den Bent, M. Soffieti, R. Bendszus, M. Mehta, M. Baumert, B. Vogelbaum, M. Chang, S. M. Lin, N. U. TI RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR BRAIN METASTASES SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 11th Congress of the European-Association-of-Neuro-Oncology CY OCT 09-12, 2014 CL Turin, ITALY SP European Assoc Neuro Oncol C1 [Wen, P. Y.; Lee, E. Q.; Lin, N. U.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Van den Bent, M.] Erasmus Univ Hosp, Daniel den Hoed Canc Ctr, Rotterdam, Netherlands. [Soffieti, R.] Univ Turin, Turin, Italy. [Bendszus, M.] Heidelberg Univ, Heidelberg, Germany. [Mehta, M.] Univ Maryland, Baltimore, MD 21201 USA. [Baumert, B.] Univ Bonn, Bonn, Germany. [Vogelbaum, M.] Cleveland Clin, Cleveland, OH 44106 USA. [Chang, S. M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD SEP PY 2014 VL 16 SU 2 MA O7.01 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA AS4HT UT WOS:000344235700053 ER PT J AU Haddock, LJ Ramsey, DJ Young, LH AF Haddock, Luis J. Ramsey, David J. Young, Lucy H. TI Complications of Subspecialty Ophthalmic Care: Endophthalmitis after Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Medications SO SEMINARS IN OPHTHALMOLOGY LA English DT Review DE Age-related macular degeneration (AMD); endophthalmitis; intravitreal injection; post-injection complications; vascular endothelial growth factor (VEGF) ID CONTROLLED CLINICAL-TRIALS; MACULAR DEGENERATION; TOPICAL ANTIBIOTICS; POVIDONE-IODINE; FACTOR AGENTS; PROPHYLAXIS; VITRECTOMY; METAANALYSIS; PREVENTION; MANAGEMENT AB The use of medications directed against vascular endothelial growth factor (VEGF) signaling has revolutionized the treatment of age-related macular degeneration (AMD) and many other retinal diseases in the last decade. However, the rapidly increasing use of these agents has led to a rise in treatment-associated complications. One of the most feared by patients and ophthalmologists is post-injection endophthalmitis, which can result in severe vision loss and, in rare cases, loss of the eye. The aim of this article is to review the incidence, clinical findings, risk factors, management, and visual outcomes in cases of endophthalmitis following intravitreal injections of anti-VEGF medications. C1 [Haddock, Luis J.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02114 USA. Mass Gen Hosp, Boston, MA 02114 USA. RP Haddock, LJ (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, 243 Charles St, Boston, MA 02114 USA. EM ljhaddock@med.miami.edu NR 33 TC 2 Z9 2 U1 0 U2 5 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0882-0538 EI 1744-5205 J9 SEMIN OPHTHALMOL JI Semin. Ophthalmol. PD SEP-NOV PY 2014 VL 29 IS 5-6 SI SI BP 257 EP 262 DI 10.3109/08820538.2014.959616 PG 6 WC Ophthalmology SC Ophthalmology GA AS0ZW UT WOS:000344006400001 PM 25325851 ER PT J AU Ramsey, DJ Haddock, LJ Young, LH Eliott, D AF Ramsey, David J. Haddock, Luis J. Young, Lucy H. Eliott, Dean TI Complications of Subspecialty Ophthalmic Care: Systemic Complications from the Intravitreal Administration of Agents that Target the Vascular Endothelial Growth Factor Pathway SO SEMINARS IN OPHTHALMOLOGY LA English DT Review DE Angiogenesis; choroidal neovascularization; intravitreal injection; systemic side effects; vascular endothelial growth factor ID DIABETIC MACULAR EDEMA; ANTI-VEGF AGENTS; PACLITAXEL PLUS BEVACIZUMAB; OCULAR NEOVASCULAR DISEASE; CHOROIDAL NEOVASCULARIZATION; INTRAOCULAR PHARMACOKINETICS; THROMBOTIC MICROANGIOPATHY; PEGAPTANIB SODIUM; FACTOR INHIBITORS; ADVERSE EVENTS AB The treatment of neovascular age-related macular degeneration (AMD) and other pathologic ocular conditions that overexpress the vascular endothelial growth factor (VEGF) has been revolutionized in the last decade by the introduction of intravitreal agents that target the VEGF pathway. Since treatment trials are designed primarily to assess the prevention of vision loss caused by ocular conditions, they are inadequate for detecting rare, but potentially serious, systemic side effects. The aim of this article is to present what the ophthalmologist needs to know about systemic complications from anti-VEGF therapy and review the likelihood that these side effects occur in the context of small, but often-repeated, intravitreal doses of these potent biological medications. Preferred practice patterns need to be developed that weigh the ability of these medications to mitigate potentially blinding conditions, while at the same time minimizing the risk of adverse outcomes in specific patient populations that possess multiple and often interrelated medical comorbidities. C1 [Eliott, Dean] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Eliott, D (reprint author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM Dean_Eliott@meei.harvard.edu NR 145 TC 3 Z9 3 U1 1 U2 4 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0882-0538 EI 1744-5205 J9 SEMIN OPHTHALMOL JI Semin. Ophthalmol. PD SEP-NOV PY 2014 VL 29 IS 5-6 SI SI BP 263 EP 275 DI 10.3109/08820538.2014.959195 PG 13 WC Ophthalmology SC Ophthalmology GA AS0ZW UT WOS:000344006400002 PM 25325852 ER PT J AU Shikari, H Silva, PS Sun, JK AF Shikari, Hasanain Silva, Paolo S. Sun, Jennifer K. TI Complications of Intravitreal Injections in Patients with Diabetes SO SEMINARS IN OPHTHALMOLOGY LA English DT Review DE Aflibercept; bevacizumab; complications; diabetes; diabetic macula edema; diabetic retinopathy; intravitreal injections; ranibizumab ID RANDOMIZED CLINICAL-TRIAL; TRIAMCINOLONE ACETONIDE INJECTION; LIDOCAINE GEL ANESTHESIA; RANIBIZUMAB PLUS PROMPT; ANTI-VEGF AGENTS; MACULAR EDEMA; INTRAOCULAR-PRESSURE; BEVACIZUMAB AVASTIN; POVIDONE-IODINE; CATARACT-SURGERY AB Intravitreal injections for the treatment of retinal disorders and intraocular infection have become a common ophthalmic procedure, and injections of anti-vascular endothelial growth factor agents or steroids are frequently performed for the treatment of diabetic macular edema or other diabetic vascular pathology. Diabetic patients may be at higher risk of adverse events than non-diabetic individuals given frequent systemic comorbidities, such as cardiovascular and renal disease, susceptibility to infection, and unique ocular pathology that includes fibrovascular proliferation. Fortunately, many associated complications, including endophthalmitis, are related to the injection procedure and can therefore be circumvented by careful attention to injection techniques. This review highlights the safety profile of intravitreal injections in patients with diabetes. Although diabetic patients may theoretically be at higher risk than non-diabetic patients for complications, a comprehensive review of the literature does not demonstrate substantial increased risk of intravitreal injections in patients with diabetes. C1 [Shikari, Hasanain; Silva, Paolo S.; Sun, Jennifer K.] Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA. [Shikari, Hasanain; Silva, Paolo S.; Sun, Jennifer K.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. RP Sun, JK (reprint author), Joslin Diabet Ctr, Beetham Eye Inst, 1 Joslin Pl, Boston, MA 02215 USA. EM Jennifer.Sun@joslin.harvard.edu NR 125 TC 9 Z9 10 U1 0 U2 6 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0882-0538 EI 1744-5205 J9 SEMIN OPHTHALMOL JI Semin. Ophthalmol. PD SEP-NOV PY 2014 VL 29 IS 5-6 SI SI BP 276 EP 289 DI 10.3109/08820538.2014.962167 PG 14 WC Ophthalmology SC Ophthalmology GA AS0ZW UT WOS:000344006400003 PM 25325853 ER PT J AU Deschler, EK Sun, JK Silva, PS AF Deschler, Emily K. Sun, Jennifer K. Silva, Paolo S. TI Side-Effects and Complications of Laser Treatment in Diabetic Retinal Disease SO SEMINARS IN OPHTHALMOLOGY LA English DT Review DE Genetic testing; inherited retinal degeneration; lysosomal disorder; mitochondrial disorder; peroxisomal disorder; primary ciliopathy; syndromic disease ID ENDOTHELIAL GROWTH-FACTOR; PANRETINAL PHOTO-COAGULATION; FOCAL ARGON-LASER; MACULAR EDEMA; DIODE-LASER; CHOROIDAL NEOVASCULARIZATION; CONTRAST SENSITIVITY; SUBRETINAL NEOVASCULARIZATION; SCATTER PHOTOCOAGULATION; PIGMENT EPITHELIUM AB Laser treatment for diabetic retinopathy was the first intraocular treatment to provide a highly effective means for preventing visual loss in patients with diabetes. Although inherently destructive, laser treatment is remarkably effective in preventing visual loss and preserving vision long-term. This review will describe briefly the current techniques and discuss in detail the reported side-effects and potential complications of laser treatment of diabetic retinal disease. C1 [Deschler, Emily K.; Sun, Jennifer K.; Silva, Paolo S.] Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA. [Sun, Jennifer K.; Silva, Paolo S.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. RP Deschler, EK (reprint author), Joslin Diabet Ctr, Beetham Eye Inst, 1 Joslin Pl, Boston, MA 02215 USA. EM emily.deschler@gmail.com; paoloantonio.silva@joslin.harvard.edu NR 73 TC 0 Z9 2 U1 0 U2 6 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0882-0538 EI 1744-5205 J9 SEMIN OPHTHALMOL JI Semin. Ophthalmol. PD SEP-NOV PY 2014 VL 29 IS 5-6 SI SI BP 290 EP 300 DI 10.3109/08820538.2014.959198 PG 11 WC Ophthalmology SC Ophthalmology GA AS0ZW UT WOS:000344006400004 PM 25325854 ER PT J AU Qian, CX Young, LH AF Qian, Cynthia X. Young, Lucy H. TI The Impact of Cataract Surgery on AMD Development and Progression SO SEMINARS IN OPHTHALMOLOGY LA English DT Review DE Age-related macular degeneration; blue-blocking intraocular lens; cataract; cataract surgery; pseudophakia ID AGE-RELATED MACULOPATHY; FILTERING INTRAOCULAR LENSES; BLUE MOUNTAINS EYE; QUALITY-OF-LIFE; BEAVER DAM EYE; MACULAR DEGENERATION; RISK-FACTORS; INTRAVITREAL BEVACIZUMAB; 10-YEAR INCIDENCE; VISUAL-ACUITY AB Age-related macular degeneration (AMD) and cataract are two leading causes of visual impairment worldwide which often occur concurrently in the same patient. With more than 1.6 million cataract operations performed per year in the United States, many of which occur in the nearly 1.75 million individuals diagnosed with AMD, there is ample incentive to further explore the interaction between these two conditions. Notably, the role of cataract surgery on AMD development and progression is of particular interest. This review summarizes the major findings from literature focusing on the effect of cataract surgery on AMD. C1 [Qian, Cynthia X.; Young, Lucy H.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Retina Serv,Dept Ophthalmol, Boston, MA 02114 USA. RP Young, LH (reprint author), Harvard Univ, Sch Med, Retina Serv, Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM lucy_young@meei.harvard.edu NR 59 TC 3 Z9 3 U1 2 U2 6 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0882-0538 EI 1744-5205 J9 SEMIN OPHTHALMOL JI Semin. Ophthalmol. PD SEP-NOV PY 2014 VL 29 IS 5-6 SI SI BP 301 EP 311 DI 10.3109/08820538.2014.962166 PG 11 WC Ophthalmology SC Ophthalmology GA AS0ZW UT WOS:000344006400005 PM 25325855 ER PT J AU Miller, JB Papakostas, TD Vavvas, DG AF Miller, John B. Papakostas, Thanos D. Vavvas, Demetrios G. TI Complications of Emulsified Silicone Oil after Retinal Detachment Repair SO SEMINARS IN OPHTHALMOLOGY LA English DT Review DE Emulsification; glaucoma; keratopathy; retinal detachment; silicone oil ID ELEVATED INTRAOCULAR-PRESSURE; PARS-PLANA VITRECTOMY; LIQUID SILICONE; PENETRATING KERATOPLASTY; INTRAVENTRICULAR SILICONE; SECONDARY GLAUCOMA; OPTIC-NERVE; RISK-FACTOR; INJECTION; SURGERY AB Intraocular silicone oil has several important indications in vitreoretinal surgery, particularly the repair of complicated retinal detachments. Emulsification is a clinically significant complication of using silicone oil tamponade. There are several factors that can promote or prevent silicone oil emulsification after retinal detachment repair, including protein surfactants, contaminants, and shear forces. However, the duration of tamponade remains the most significant one. After emulsification has occurred, keratopathy and glaucoma are the most common complications. However, recent work has shown that emulsification can also affect the retina, optic nerve, and even extraocular structures. Limiting the amount of time the silicone oil remains in the eye is the most important factor in reducing its complications. C1 [Miller, John B.; Papakostas, Thanos D.; Vavvas, Demetrios G.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02114 USA. RP Miller, JB (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv, 243 Charles St, Boston, MA 02114 USA. EM John_Miller@meei.harvard.edu OI Vavvas, Demetrios/0000-0002-8622-6478 NR 61 TC 3 Z9 3 U1 0 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0882-0538 EI 1744-5205 J9 SEMIN OPHTHALMOL JI Semin. Ophthalmol. PD SEP-NOV PY 2014 VL 29 IS 5-6 SI SI BP 312 EP 318 DI 10.3109/08820538.2014.962181 PG 7 WC Ophthalmology SC Ophthalmology GA AS0ZW UT WOS:000344006400006 PM 25325856 ER PT J AU Werdich, XQ Place, EM Pierce, EA AF Werdich, Xiang Q. Place, Emily M. Pierce, Eric A. TI Systemic Diseases Associated with Retinal Dystrophies SO SEMINARS IN OPHTHALMOLOGY LA English DT Review DE Genetic testing; inherited retinal degeneration; lysosomal disorder; mitochondrial disorder; peroxisomal disorder; primary ciliopathy; syndromic disease ID BARDET-BIEDL-SYNDROME; HEREDOPATHIA-ATACTICA-POLYNEURITIFORMIS; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; FAMILIAL JUVENILE NEPHRONOPHTHISIS; NEURONAL CEROID-LIPOFUSCINOSES; PHYTANOYL-COA HYDROXYLASE; KEARNS-SAYRE SYNDROME; ACID STORAGE DISEASE; REFSUMS-DISEASE; MITOCHONDRIAL-DNA AB Inherited retinal degeneration (IRD) may occur in isolation or as part of a multi-systemic condition. Ocular manifestations may be the presenting symptom of a syndromic disease and can include retinitis pigmentosa, cone-rod dystrophy, or maculopathy. Alternatively, patients affected with syndromic disease may already have other systemic manifestations at the time retinal disease is diagnosed. Some of these systemic diseases can cause significant morbidity. Here, we review several of these syndromic IRDs and their underlying genetic causes. Early recognition and referral for systemic evaluation and surveillance may lead to early intervention and an improved outcome. Obtaining a molecular diagnosis can be beneficial in securing a definitive diagnosis, especially in cases with atypical presentations. A genetic diagnosis may also be informative with regard to prognosis and potential therapies. Effective management and rehabilitation for patients with syndromic retinal dystrophy requires a comprehensive genetic-based team approach involving patients, family members, ophthalmologists, primary care physicians, and geneticists. C1 [Werdich, Xiang Q.; Place, Emily M.; Pierce, Eric A.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA. RP Werdich, XQ (reprint author), Massachusetts Eye & Ear Infirm, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA. EM xawerdich@hotmail.com OI Pierce, Eric/0000-0002-2354-4102 NR 84 TC 4 Z9 5 U1 0 U2 10 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0882-0538 EI 1744-5205 J9 SEMIN OPHTHALMOL JI Semin. Ophthalmol. PD SEP-NOV PY 2014 VL 29 IS 5-6 SI SI BP 319 EP 328 DI 10.3109/08820538.2014.959202 PG 10 WC Ophthalmology SC Ophthalmology GA AS0ZW UT WOS:000344006400007 PM 25325857 ER PT J AU Haddad, NMN Sun, JK Abujaber, S Schlossman, DK Silva, PS AF Haddad, Nour Maya N. Sun, Jennifer K. Abujaber, Samer Schlossman, Deborah K. Silva, Paolo S. TI Cataract Surgery and its Complications in Diabetic Patients SO SEMINARS IN OPHTHALMOLOGY LA English DT Review DE Cataract; complications; diabetes; diabetic macula edema; diabetic retinopathy ID INTRAVITREAL BEVACIZUMAB INJECTION; POSTERIOR CAPSULE OPACIFICATION; OPTICAL COHERENCE TOMOGRAPHY; INTRAOCULAR-LENS IMPLANTATION; CYSTOID MACULAR EDEMA; RISK-FACTORS; TRIAMCINOLONE ACETONIDE; PROGNOSTIC-FACTORS; MAILLARD REACTION; NATURAL-HISTORY AB Diabetic patients are known to have an increased risk of cataract development and cataract surgery is a common surgical procedure for diabetic individuals. Cataract extraction (CE) in diabetic patients as compared to non-diabetic patients is associated with higher risks of reported complications such as capsular contraction and opacification as well as post-surgical worsening of macular edema (ME) and diabetic retinopathy (DR). In this paper, we review the pathogenesis of diabetic cataract, the risk factors contributing to cataract complications as well as DR progression, and assess preventive measures and treatment options for DR and ME following CE. C1 [Haddad, Nour Maya N.; Sun, Jennifer K.; Schlossman, Deborah K.; Silva, Paolo S.] Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA. [Sun, Jennifer K.; Silva, Paolo S.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. [Abujaber, Samer] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA. RP Haddad, NMN (reprint author), Joslin Diabet Ctr, Beetham Eye Inst, 1 Joslin Pl, Boston, MA 02215 USA. EM nour.haddad@joslin.harvard.edu NR 82 TC 8 Z9 8 U1 1 U2 6 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0882-0538 EI 1744-5205 J9 SEMIN OPHTHALMOL JI Semin. Ophthalmol. PD SEP-NOV PY 2014 VL 29 IS 5-6 SI SI BP 329 EP 337 DI 10.3109/08820538.2014.959197 PG 9 WC Ophthalmology SC Ophthalmology GA AS0ZW UT WOS:000344006400008 PM 25325858 ER PT J AU Modjtahedi, BS Eliott, D AF Modjtahedi, Bobeck S. Eliott, Dean TI Vitreoretinal Complications of the Boston Keratoprosthesis SO SEMINARS IN OPHTHALMOLOGY LA English DT Review DE Choroidal detachment; endophthalmitis; retinal detachment; retroprosthetic membrane; vitreous hemorrhage; vitritis ID UNIVERSITY-OF-CALIFORNIA; TYPE-1 KERATOPROSTHESIS; I KERATOPROSTHESIS; POSTOPERATIVE ENDOPHTHALMITIS; PERMANENT KERATOPROSTHESIS; INFECTIOUS ENDOPHTHALMITIS; PEDIATRIC KERATOPROSTHESIS; BACTERIAL ENDOPHTHALMITIS; RISK-FACTORS; EXPERIENCE AB The Boston Keratoprosthesis has allowed for visual restoration in patients with corneal blindness; however, vitreoretinal complications remain a significant cause of ocular morbidity. Retroprosthetic membranes, infectious endophthalmitis, sterile vitritis, vitreous hemorrhage, vitreous opacities, retinal detachment, cystoid macular edema, choroidal detachments, retinal vascular occlusion, and epiretinal membrane have all been described, may require the intervention of a vitreoretinal specialist, and are reviewed herein. A strong familiarity with associated posterior segment complications is important to maximizing patient outcomes. C1 [Modjtahedi, Bobeck S.; Eliott, Dean] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Retina Serv,Dept Ophthalmol, Boston, MA 02114 USA. RP Eliott, D (reprint author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Retina Serv, 243 Charles St, Boston, MA 02114 USA. EM Dean_Eliott@meei.harvard.edu FU Heed Ophthalmic Foundation FX Dr. Modjtahedi receives research support from the Heed Ophthalmic Foundation. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. NR 42 TC 4 Z9 4 U1 1 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0882-0538 EI 1744-5205 J9 SEMIN OPHTHALMOL JI Semin. Ophthalmol. PD SEP-NOV PY 2014 VL 29 IS 5-6 SI SI BP 338 EP 348 DI 10.3109/08820538.2014.959204 PG 11 WC Ophthalmology SC Ophthalmology GA AS0ZW UT WOS:000344006400009 PM 25325859 ER PT J AU Robert, MC Dohlman, CH AF Robert, Marie-Claude Dohlman, Claes H. TI A Review of Corneal Melting after Boston Keratoprosthesis SO SEMINARS IN OPHTHALMOLOGY LA English DT Review DE Matrix metalloproteinases; mucous membrane pemphigoid; retroprosthetic membrane; sterile keratolysis; Stevens-Johnson syndrome ID PERIPHERAL ULCERATIVE KERATITIS; UNIVERSITY-OF-CALIFORNIA; STEVENS-JOHNSON-SYNDROME; MATRIX METALLOPROTEINASES; TYPE-1 KERATOPROSTHESIS; I KERATOPROSTHESIS; EPITHELIAL-CELLS; RABBIT CORNEA; MEDROXYPROGESTERONE; OUTCOMES AB Use of the Boston Keratoprosthesis (B-KPro) has grown significantly, both in the United States and overseas over the course of the last decade. It is the most frequently employed keratoprosthesis for the management of complex corneal blindness. Improving outcomes and reductions in devastating complications such as corneal melting and infection have motivated this increase in use. We review the epidemiology and pathophysiology of corneal melting following B-KPro as well as the advances in B-KPro design and postoperative care that have halted the occurrence of melting. Eyes with autoimmune diseases such as Stevens-Johnson syndrome, toxic epidermal necrolysis syndrome, and mucous membrane pemphigoid remain particularly vulnerable to corneal melt, leak, and extrusion. The development of new strategies to prevent melting in eyes with autoimmune disease is crucial to improve the outcomes of this group of patients, as they are often those with the most desperate need for visual rehabilitation with a B-KPro. C1 [Robert, Marie-Claude; Dohlman, Claes H.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02144 USA. RP Robert, MC (reprint author), Massachusetts Eye & Ear Infirm, Dept Ophthalmol, 243 Charles St, Boston, MA 02144 USA. EM Marie-Claude_Robert@MEEI.harvard.edu NR 73 TC 13 Z9 13 U1 1 U2 9 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0882-0538 EI 1744-5205 J9 SEMIN OPHTHALMOL JI Semin. Ophthalmol. PD SEP-NOV PY 2014 VL 29 IS 5-6 SI SI BP 349 EP 357 DI 10.3109/08820538.2014.959186 PG 9 WC Ophthalmology SC Ophthalmology GA AS0ZW UT WOS:000344006400010 PM 25325860 ER PT J AU Raoof, D Pineda, R AF Raoof, Duna Pineda, Roberto TI Dry Eye after Laser In-Situ Keratomileusis SO SEMINARS IN OPHTHALMOLOGY LA English DT Review DE Artificial tears; corneal nerves; dry eye disease; dry eye syndrome; keratitis sicca; laser in-situ keratomileusis; punctual plugs ID MEIBOMIAN GLAND DYSFUNCTION; OCULAR SURFACE; FEMTOSECOND-LASER; REFRACTIVE SURGERY; CORNEAL SENSATION; MECHANICAL-MICROKERATOME; HINGE POSITION; RISK-FACTORS; LASIK; MANAGEMENT AB Laser-assisted in-situ keratomileusis (LASIK) is one of the most commonly performed refractive procedures with excellent visual outcomes. Dry eye syndrome is one of the most frequently seen complications after LASIK, with most patients developing at least some mild dry eye symptoms postoperatively. To achieve improved visual outcomes and greater patient satisfaction, it is essential to identify patients prone to dry eyes preoperatively, and initiate treatment early in the course. Enhanced understanding of the pathophysiology of post-LASIK dry eye will help advance our approach to its management. C1 [Raoof, Duna; Pineda, Roberto] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA USA. RP Raoof, D (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM duna_raoof@meei.harvard.edu FU Heed Ophthalmic Foundation FX The authors acknowledge funding from the Heed Ophthalmic Foundation. NR 42 TC 5 Z9 5 U1 2 U2 15 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0882-0538 EI 1744-5205 J9 SEMIN OPHTHALMOL JI Semin. Ophthalmol. PD SEP-NOV PY 2014 VL 29 IS 5-6 SI SI BP 358 EP 362 DI 10.3109/08820538.2014.962663 PG 5 WC Ophthalmology SC Ophthalmology GA AS0ZW UT WOS:000344006400011 PM 25325861 ER PT J AU Shah, DN Melki, S AF Shah, Deepika N. Melki, Samir TI Complications of Femtosecond-Assisted Laser In-Situ Keratomileusis Flaps SO SEMINARS IN OPHTHALMOLOGY LA English DT Review DE Femtosecond; flap complications; LASIK; management; refractive ID TRANSIENT LIGHT-SENSITIVITY; MORIA M2 MICROKERATOME; EPITHELIAL INGROWTH; DRY EYE; MECHANICAL-MICROKERATOME; REFRACTIVE SURGERY; CORNEAL SENSATION; RAINBOW GLARE; PHOTOREFRACTIVE KERATECTOMY; RADIAL KERATOTOMY AB Femtosecond-assisted laser in-situ keratomileusis flaps have revolutionized refractive surgery since their introduction. Although these lasers are exceedingly safe, complications still do occur. This review focuses specifically on examining the literature and evidence for flap complications during femtosecond-assisted laser in-situ keratomileusis as well as their management. C1 [Shah, Deepika N.; Melki, Samir] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA USA. RP Melki, S (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM Samir_melki@meei.harvard.edu NR 67 TC 5 Z9 5 U1 2 U2 10 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0882-0538 EI 1744-5205 J9 SEMIN OPHTHALMOL JI Semin. Ophthalmol. PD SEP-NOV PY 2014 VL 29 IS 5-6 SI SI BP 363 EP 375 DI 10.3109/08820538.2014.959194 PG 13 WC Ophthalmology SC Ophthalmology GA AS0ZW UT WOS:000344006400012 PM 25325862 ER PT J AU Bozorg, S Pineda, R AF Bozorg, Sara Pineda, Roberto TI Cataract and Keratoconus: Minimizing Complications in Intraocular Lens Calculations SO SEMINARS IN OPHTHALMOLOGY LA English DT Review DE Biometry; degeneration; ectasia; intraocular lens exchange; myopia ID POWER CALCULATIONS; EYES; IMPLANTATION; OUTCOMES AB Patients with both cataract and keratoconus present unique challenges for the surgeon. Accurate keratometry (K) and axial length (AL) readings may be impossible, and uncertainty is introduced when estimating the corneal power for intraocular lens (IOL) selection. Different options on how to choose an IOL and how to manage irregular astigmatism of a keratoconic patient with cataract have been proposed and are reviewed. The stage of keratoconus and the history of the patient are both critical in determining the strategy used in treatment of cataracts. C1 [Bozorg, Sara; Pineda, Roberto] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02144 USA. RP Bozorg, S (reprint author), Massachusetts Eye & Ear Infirm, Dept Ophthalmol, 243 Charles St, Boston, MA 02144 USA. EM sara.bozorg@gmail.com NR 15 TC 1 Z9 1 U1 0 U2 4 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0882-0538 EI 1744-5205 J9 SEMIN OPHTHALMOL JI Semin. Ophthalmol. PD SEP-NOV PY 2014 VL 29 IS 5-6 SI SI BP 376 EP 379 DI 10.3109/08820538.2014.959193 PG 4 WC Ophthalmology SC Ophthalmology GA AS0ZW UT WOS:000344006400013 PM 25325863 ER PT J AU Haddadin, RI Chodosh, J AF Haddadin, Ramez I. Chodosh, James TI Corneal Transplantation and Glaucoma SO SEMINARS IN OPHTHALMOLOGY LA English DT Review DE DALK; DMEK; DSEK; keratoplasty; keratoprosthesis; ocular hypertension ID STRIPPING ENDOTHELIAL KERATOPLASTY; INTRAOCULAR-PRESSURE ELEVATION; ANTERIOR LAMELLAR KERATOPLASTY; POST-PENETRATING-KERATOPLASTY; BOSTON TYPE-1 KERATOPROSTHESIS; OSTEO-ODONTO-KERATOPROSTHESIS; OPTICAL COHERENCE TOMOGRAPHY; TUBE SHUNT IMPLANTATION; INTRA-OCULAR PRESSURE; LASER TRANSSCLERAL CYCLOPHOTOCOAGULATION AB Glaucoma is the leading cause of irreversible vision loss post-keratoplasty and an important cause of graft failure. With newer techniques, such as lamellar, endothelial, and laser-assisted keratoplasty as well as keratoprosthesis gaining popularity, clinicians will need to consider the incidence, risks, evaluation, and management of glaucoma for each type of keratoplasty when determining which type of transplant may be most appropriate. A comprehensive literature search of glaucoma in the setting of corneal transplantation was performed and serves as the basis for this review. Preexisting glaucoma and aphakia are notable risk factors. Patients that are candidates for deep anterior lamellar keratoplasty may benefit from reduced rates of post-keratoplasty glaucoma. Although glaucoma also complicates eyes with Descemet stripping endothelial keratoplasty, the severity is less and the intraocular pressure is more easily controlled when compared to penetrating keratoplasty. Endothelial keratoplasty creates unique perioperative issues mostly related to management of anterior chamber air bubbles. C1 [Haddadin, Ramez I.; Chodosh, James] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Ophthalmol Cornea & Refract Surg Serv, Boston, MA 02114 USA. RP Haddadin, RI (reprint author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Ophthalmol Cornea & Refract Surg Serv, 243 Charles St, Boston, MA 02114 USA. EM ramez@post.harvard.edu NR 216 TC 3 Z9 3 U1 0 U2 6 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0882-0538 EI 1744-5205 J9 SEMIN OPHTHALMOL JI Semin. Ophthalmol. PD SEP-NOV PY 2014 VL 29 IS 5-6 SI SI BP 380 EP 396 DI 10.3109/08820538.2014.959201 PG 17 WC Ophthalmology SC Ophthalmology GA AS0ZW UT WOS:000344006400014 PM 25325864 ER PT J AU Giovingo, M AF Giovingo, Michael TI Complications of Glaucoma Drainage Device Surgery: A Review SO SEMINARS IN OPHTHALMOLOGY LA English DT Review DE Complications; glaucoma; glaucoma drainage device; seton; trabeculectomy ID PENETRATING KERATOPLASTY; OCULAR MASSAGE; VALVE IMPLANT; FOLLOW-UP; BAERVELDT; ENDOPHTHALMITIS; SILICONE; OUTCOMES; TUBE AB Purpose: To review current literature on the complications of the use of glaucoma drainage device surgery. Summary: The use of glaucoma drainage devices has increased significantly in recent years for both primary treatment of glaucoma and refractory glaucoma. The efficacy and safety of glaucoma drainage devices has been well established, so they are a viable surgical option in patients who fail medical therapy. With the increased use of these devices, understanding their complications is essential in managing these patients. The prevention and management of complications associated with glaucoma drainage device insertion has some similarities to that of a trabeculectomy. The glaucoma drainage devices have additional complications associated with the fact that hardware is left within the eye. There have been no definitive answers as to the perfect surgical technique to prevent complications but careful surgical performance, tube placement and use of a double-layered graft over the tube are likely to lead to a better outcome. The rate of complications also dictates careful follow up to identify these complications early in their process as early intervention will likely lead to better outcomes. C1 Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. RP Giovingo, M (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM mcgiovingo@gmail.com NR 31 TC 2 Z9 2 U1 1 U2 7 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0882-0538 EI 1744-5205 J9 SEMIN OPHTHALMOL JI Semin. Ophthalmol. PD SEP-NOV PY 2014 VL 29 IS 5-6 SI SI BP 397 EP 402 DI 10.3109/08820538.2014.959199 PG 6 WC Ophthalmology SC Ophthalmology GA AS0ZW UT WOS:000344006400015 PM 25325865 ER PT J AU Sangal, N Chen, TC AF Sangal, Neha Chen, Teresa C. TI Cataract Surgery in Pseudoexfoliation Syndrome SO SEMINARS IN OPHTHALMOLOGY LA English DT Review DE Glaucoma; phacoemulsification; surgical complications ID INTRAOCULAR-LENS IMPLANTATION; CAPSULAR TENSION RING; EXFOLIATION SYNDROME; INTRAOPERATIVE COMPLICATIONS; IOL IMPLANTATION; RISK-FACTORS; PHACOEMULSIFICATION; EYES; DISLOCATION; ASSOCIATION AB Pseudoexfoliation (PXF) syndrome is characterized by the deposition of distinctive fibrillar material in the anterior segment of the eye. It is an age-related process that is associated with open and narrow angle glaucomas and the formation of cataracts. Not only is PXF associated with the formation of dense nuclear cataracts, it is also well known that those presenting with PXF are at a higher risk of developing complications during, and even after, cataract surgery. Complications associated with cataract surgery in PXF can occur from poor pupillary dilation, zonular weakness leading to intraoperative or postoperative lens dislocation and vitreous loss, postoperative intraocular pressure (IOP) spikes potentiating glaucomatous damage, capsular phimosis, prolonged inflammation, and postoperative corneal decompensation. The surgeon should be prepared to encounter the various potential intraoperative and postoperative complications in eyes with pseudoexfoliation syndrome during cataract surgery. In this way, the surgeon can plan his/her surgical technique to help avoid surprises during cataract surgery and be prepared to manage the potential postoperative complications that can occur in pseudoexfoliation eyes. C1 [Sangal, Neha; Chen, Teresa C.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA USA. RP Sangal, N (reprint author), 243 Charles St, Boston, MA 02114 USA. EM nsangal84@gmail.com NR 49 TC 3 Z9 3 U1 0 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0882-0538 EI 1744-5205 J9 SEMIN OPHTHALMOL JI Semin. Ophthalmol. PD SEP-NOV PY 2014 VL 29 IS 5-6 SI SI BP 403 EP 408 DI 10.3109/08820538.2014.959189 PG 6 WC Ophthalmology SC Ophthalmology GA AS0ZW UT WOS:000344006400016 PM 25325866 ER PT J AU Bakir, B Pasquale, LR AF Bakir, Belal Pasquale, Louis R. TI Causes and Treatment of Choroidal Effusion after Glaucoma Surgery SO SEMINARS IN OPHTHALMOLOGY LA English DT Review DE Anatomy; differential diagnosis; etiology; physiology; prevalence; prophylaxis ID ANGLE-CLOSURE GLAUCOMA; UVEOSCLERAL OUTFLOW; UVEAL EFFUSION; PRESSURE AB Choroidal effusion is a prevalent and potentially vision-threatening complication following glaucoma surgery. This review article will introduce readers to the anatomy and physiology of choroidal effusion. Evidence from the literature will be reviewed to discuss the prevalence of choroidal effusion after glaucoma surgery. Etiology, clinical presentation, and differential diagnosis of choroidal effusion will be detailed in this review article. Finally, readers will gain insight into methods to prevent and treat choroidal effusion after glaucoma surgery. C1 [Bakir, Belal; Pasquale, Louis R.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. RP Pasquale, LR (reprint author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA. EM Louis_Pasquale@meei.harvard.edu NR 20 TC 4 Z9 4 U1 0 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0882-0538 EI 1744-5205 J9 SEMIN OPHTHALMOL JI Semin. Ophthalmol. PD SEP-NOV PY 2014 VL 29 IS 5-6 SI SI BP 409 EP 413 DI 10.3109/08820538.2014.959200 PG 5 WC Ophthalmology SC Ophthalmology GA AS0ZW UT WOS:000344006400017 PM 25325867 ER PT J AU Massoud, VA Fay, A Yoon, MK AF Massoud, Vicky A. Fay, Aaron Yoon, Michael K. TI Cerebrospinal Fluid Leak as a Complication of Oculoplastic Surgery SO SEMINARS IN OPHTHALMOLOGY LA English DT Review DE CSF; dacryocystorhinostomy; decompression; exenteration; orbit ID ORBITAL DECOMPRESSION; GRAVES ORBITOPATHY; CSF LEAKS; BONE WAX; DACRYOCYSTORHINOSTOMY; EXENTERATION; FISTULA; OPHTHALMOPATHY; MANAGEMENT; REPAIR AB Purpose: Cerebrospinal fluid leak is a rare, but potentially morbid complication of orbital surgery. In this review, we analyze the reported cases of CSF leak in such surgeries, determine their causes, clinical presentations and sequellae, and highlight the different methods to detect and manage them. Methods: A comprehensive literature review was conducted in PubMed. Results: Twenty-one cases of CSF leak occurred with orbital exenteration, 34 with orbital decompression, four with DCR, two with enucleation, and four cases with other skull base surgery. Operating in high-risk areas increased the risk of dural injury. Once detected, CSF leak was either controlled by bed rest and head elevation or required a surgical repair. The various techniques of surgical management are discussed. Conclusion: The number of reported surgical CSF leaks in the orbit is relatively low. To prevent this complication, it is essential to have intimate knowledge of orbital anatomy, especially in the setting of pre-existing abnormalities. If CSF leak occurs, it should be rapidly recognized and adequately managed to prevent further morbidity. C1 [Massoud, Vicky A.; Fay, Aaron; Yoon, Michael K.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. [Massoud, Vicky A.; Fay, Aaron; Yoon, Michael K.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. RP Yoon, MK (reprint author), 243 Charles St, Boston, MA 02114 USA. EM michael_yoon@meei.harvard.edu NR 70 TC 2 Z9 2 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0882-0538 EI 1744-5205 J9 SEMIN OPHTHALMOL JI Semin. Ophthalmol. PD SEP-NOV PY 2014 VL 29 IS 5-6 SI SI BP 440 EP 449 DI 10.3109/08820538.2014.959187 PG 10 WC Ophthalmology SC Ophthalmology GA AS0ZW UT WOS:000344006400022 PM 25325872 ER PT J AU MacIntosh, PW Yoon, MK Fay, A AF MacIntosh, Peter W. Yoon, Michael K. Fay, Aaron TI Complications of Intralesional Bleomycin in the Treatment of Orbital Lymphatic Malformations SO SEMINARS IN OPHTHALMOLOGY LA English DT Review DE Cystic hygroma; lymphangioma; lymphatics; orbital compartment syndrome; pulmonary fibrosis ID VASCULAR MALFORMATIONS; ENDOTHELIAL-CELLS; CYSTIC HYGROMA; LYMPHANGIOMA; NECK; HEAD; INJECTION; SCLEROTHERAPY; CHILDREN; THERAPY AB Purpose: Lymphatic malformations (LM) are associated with significant morbidity, and in the orbit, can lead to vision loss. Treatment of these lesions is complicated by their infiltrative nature, making surgical excision challenging. Bleomycin has been used since the 1970s for sclerosis of LM to reduce the need for or improve the success of surgical excision. This paper reviews the complications associated with intralesional bleomycin in the treatment of orbital LM. Methods: A comprehensive literature search was performed on PubMed. Thirty full-length English articles were reviewed. Results: The pathophysiology and imaging characteristic of LM were first reviewed. The head and neck literature was heavily cited given the dearth of specific orbital data. This review highlights the common techniques and dosages for injection, the overall success rate of this treatment, and its common side effects. The orbital data were then reviewed, and differentiated from the head and neck literature. Conclusion: Sclerotherapy of most LM with bleomycin appears to be safe and effective, but the lack of specific orbital data means we must extrapolate LM data from other fields to orbital LM with caution. Additional research is warranted, though the risk-benefit ratio remains unknown. C1 [MacIntosh, Peter W.; Yoon, Michael K.; Fay, Aaron] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02138 USA. [MacIntosh, Peter W.; Yoon, Michael K.; Fay, Aaron] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. RP MacIntosh, PW (reprint author), Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02138 USA. EM pwmacintosh@gmail.com NR 30 TC 1 Z9 2 U1 0 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0882-0538 EI 1744-5205 J9 SEMIN OPHTHALMOL JI Semin. Ophthalmol. PD SEP-NOV PY 2014 VL 29 IS 5-6 SI SI BP 450 EP 455 DI 10.3109/08820538.2014.959617 PG 6 WC Ophthalmology SC Ophthalmology GA AS0ZW UT WOS:000344006400023 PM 25325873 ER PT J AU Uchiyama, E Papaliodis, GN Lobo, AM Sobrin, L AF Uchiyama, Eduardo Papaliodis, George N. Lobo, Ann-Marie Sobrin, Lucia TI Side-Effects of Anti-Inflammatory Therapy in Uveitis SO SEMINARS IN OPHTHALMOLOGY LA English DT Review DE Eye; immunomodulation; immunomodulatory therapy; immunosuppression; inflammation ID DEXAMETHASONE INTRAVITREAL IMPLANT; CORTICOSTEROID-SPARING THERAPY; OCULAR INFLAMMATORY DISORDERS; SIGHT-THREATENING UVEITIS; NECROSIS FACTOR THERAPY; RHEUMATOID-ARTHRITIS; POSTERIOR UVEITIS; LONG-TERM; IMMUNOSUPPRESSIVE DRUGS; MYCOPHENOLATE-MOFETIL AB Uveitis is a group of inflammatory ocular conditions that cause significant visual morbidity around the world. Many of the cases of blindness secondary to uveitis can be avoided with adequate and aggressive management of the intraocular inflammation. Steroids have been utilized in the treatment of noninfectious uveitis for more than 60 years, but their chronic use is associated with severe ocular and systemic side-effects. Ophthalmologists are often not familiar with the systemic steroid-sparing agents available for the management of ocular inflammation and depend primarily on the use of corticosteroids. In this article, we review the most common agents utilized in the treatment of uveitis and their side-effect profiles. C1 [Uchiyama, Eduardo; Papaliodis, George N.; Lobo, Ann-Marie; Sobrin, Lucia] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA. [Uchiyama, Eduardo; Papaliodis, George N.; Lobo, Ann-Marie; Sobrin, Lucia] Harvard Univ, Sch Med, Boston, MA USA. RP Sobrin, L (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM Lucia_Sobrin@meei.harvard.edu NR 105 TC 5 Z9 5 U1 1 U2 9 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0882-0538 EI 1744-5205 J9 SEMIN OPHTHALMOL JI Semin. Ophthalmol. PD SEP-NOV PY 2014 VL 29 IS 5-6 SI SI BP 456 EP 467 DI 10.3109/08820538.2014.959203 PG 12 WC Ophthalmology SC Ophthalmology GA AS0ZW UT WOS:000344006400024 PM 25325874 ER PT J AU Rashid, A Jakobiec, FA AF Rashid, Alia Jakobiec, Frederick A. TI Avoiding the Major Complication of Ophthalmic Pathology: Misdiagnosis. A Review of Three Common Diagnostic Challenges SO SEMINARS IN OPHTHALMOLOGY LA English DT Review DE Adenoid cystic carcinoma; androgen receptor; adipophilin; histopathology; immunohistochemistry; lymphoid tumors; MyB; PLAG1 gene; pleomorphic adenoma; sebaceous carcinoma ID COMPUTED TOMOGRAPHIC DIAGNOSIS; OCULAR ADNEXAL LYMPHOMA; SEBACEOUS-CARCINOMA; SURGICAL PATHOLOGY; FOLLICULAR LYMPHOMA; ANATOMIC PATHOLOGY; PATIENT SAFETY; CELL CARCINOMA; FEATURES; ERRORS AB Diagnostic errors in ophthalmic pathology are not uncommon. Pathology is a very subjective specialty with several biases dependent on such factors as training, experience, practice patterns, personal anecdotes, and inevitable human error. In addition to these factors, there are many cases where difficulty in diagnosis lies in differentiating between two very closely related, or similar appearing, entities that may have vastly different prognostic consequences. In this paper, we review three challenging areas wherein diagnostic dilemmas may occur. We outline some of the lessons we have learned in arriving at a correct diagnosis, which includes an admission of one's own limitations requiring consultation with other pathology subspecialists, and the use of immunohistochemistry. C1 [Rashid, Alia; Jakobiec, Frederick A.] Massachusetts Eye & Ear Infirm, David G Cogan Ophthalm Pathol Lab, Boston, MA 02114 USA. [Rashid, Alia; Jakobiec, Frederick A.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. RP Jakobiec, FA (reprint author), Massachusetts Eye & Ear Infirm, David G Cogan Ophthalm Pathol Lab, 243 Charles St,Suite 328, Boston, MA 02114 USA. EM fred_jakobiec@meei.harvard.edu NR 37 TC 0 Z9 0 U1 0 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0882-0538 EI 1744-5205 J9 SEMIN OPHTHALMOL JI Semin. Ophthalmol. PD SEP-NOV PY 2014 VL 29 IS 5-6 SI SI BP 468 EP 474 DI 10.3109/08820538.2014.959196 PG 7 WC Ophthalmology SC Ophthalmology GA AS0ZW UT WOS:000344006400025 PM 25325875 ER PT J AU Harley, AE Yang, M Stoddard, AM Adamkiewicz, G Walker, R Tucker-Seeley, RD Allen, JD Sorensen, G AF Harley, Amy E. Yang, May Stoddard, Anne M. Adamkiewicz, Gary Walker, Renee Tucker-Seeley, Reginald D. Allen, Jennifer D. Sorensen, Glorian TI Patterns and Predictors of Health Behaviors Among Racially/ Ethnically Diverse Residents of Low-Income Housing Developments SO AMERICAN JOURNAL OF HEALTH PROMOTION LA English DT Article DE Health Promotion; Health Behavior; Low-Income Population; African Americans; Immigrants; Public Housing; Prevention Research; Manuscript format: research; Research purpose: modeling/relationship testing; Study design: nonexperimental; Outcome measure: behavioral; Setting: local community; Health focus: fitness/physical activity nutrition, and smoking control; Target population age: adults; Target population circumstances: education/income level, geographic location and race/ethnicity ID PHYSICAL-ACTIVITY; UNITED-STATES; VEGETABLE CONSUMPTION; BUILT ENVIRONMENT; FINANCIAL STRESS; RANDOMIZED-TRIAL; AMERICAN WOMEN; OLDER-ADULTS; FAT INTAKE; RISK AB Purpose. Purpose. To examine behavioral patterns and sociodemographic predictors of diet, inactivity, and tobacco use among a diverse sample of residents from low-income housing developments. Design. In this cross-sectional survey study, households and residents were randomly selected using multistage cluster sampling. Setting. The study was conducted in 20 low-income housing developments in the Boston, Massachusetts, metropolitan area. Subjects. Subjects were 828 residents who completed the survey (response rate = 49.3%). Forty-one percent of participants were Hispanic and 38% were non-Hispanic Black Measures. Outcomes measured were diet, inactivity, and tobacco use. Predictors measured were age, race/ethnicity, gender, education, country in which the subject was born, language spoken, and financial hardship. Analysis. Logistic regression analyses were conducted to examine the association of three health behaviors with sociodemographic factors. Results. Age, gender, language spoken, and financial hardship showed significant relationships with all three behaviors. For example, those who reported less financial hardship (odds ratio [OR] = 1.75) were more likely to eat healthier Residents who spoke no English, or at least one language in addition to English, were significantly more likely to report healthier eating (OR= 2.78 and 3.30, respectively) than those who spoke English only. Men were significantly more likely to report less healthy eating (OR= 0.65) than were women. Similar trends emerged for inactivity and tobacco use. Conclusion. Effective health promotion interventions in low-income housing developments that leverage protective factors while addressing risk factors have the potential to reduce income-related health disparities in these concentrated resource-deprived neighborhoods. (Am J Health Promot 2014;29[1]:59-67.) C1 [Harley, Amy E.; Walker, Renee] Univ Wisconsin, Joseph J Zilber Sch Publ Hlth, Milwaukee, WI 53201 USA. [Yang, May; Stoddard, Anne M.] New England Res Inst Inc, Watertown, MA USA. [Adamkiewicz, Gary; Tucker-Seeley, Reginald D.; Sorensen, Glorian] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Tucker-Seeley, Reginald D.; Allen, Jennifer D.; Sorensen, Glorian] Dana Farber Canc Inst, Boston, MA USA. RP Harley, AE (reprint author), Univ Wisconsin, Joseph J Zilber Sch Publ Hlth, POB 413, Milwaukee, WI 53201 USA. EM harley@uwm.edu RI Allen, Jennifer/M-2113-2015 FU NCI NIH HHS [R25 CA057711, R01 CA111310, R01 CA111310-01A1, K01 CA169041, R25 CA057713] NR 49 TC 6 Z9 6 U1 0 U2 14 PU AMER JOURNAL HEALTH PROMOTION INC PI TROY PA PO BOX 1254, TROY, MI 48099-1254 USA SN 0890-1171 EI 2168-6602 J9 AM J HEALTH PROMOT JI Am. J. Health Promot. PD SEP-OCT PY 2014 VL 29 IS 1 BP 59 EP 67 DI 10.4278/ajhp.121009-QUAN-492 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR8XZ UT WOS:000343855900012 PM 24359221 ER PT J AU Louis, DN Perry, A Burger, P Ellison, DW Reifenberger, G von Deimling, A Aldape, K Brat, D Collins, VP Eberhart, C Figarella-Branger, D Fuller, GN Giangaspero, F Giannini, C Hawkins, C Kleihues, P Korshunov, A Kros, JM Lopes, MB Ng, HK Ohgaki, H Paulus, W Pietsch, T Rosenblum, M Rushing, E Soylemezoglu, F Wiestler, O Wesseling, P AF Louis, David N. Perry, Arie Burger, Peter Ellison, David W. Reifenberger, Guido von Deimling, Andreas Aldape, Kenneth Brat, Daniel Collins, V. Peter Eberhart, Charles Figarella-Branger, Dominique Fuller, Gregory N. Giangaspero, Felice Giannini, Caterina Hawkins, Cynthia Kleihues, Paul Korshunov, Andrey Kros, Johan M. Lopes, M. Beatriz Ng, Ho-Keung Ohgaki, Hiroko Paulus, Werner Pietsch, Torsten Rosenblum, Marc Rushing, Elisabeth Soylemezoglu, Figen Wiestler, Otmar Wesseling, Pieter TI International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading SO BRAIN PATHOLOGY LA English DT Article DE Astrocytoma; atypical teratoid rhabdoid tumor; brain tumors; classification; glioblastoma; glioma; grading; medulloblastoma; oligodendroglioma; World Health Organization AB Major discoveries in the biology of nervous system tumors have raised the question of how non-histological data such as molecular information can be incorporated into the next World Health Organization (WHO) classification of central nervous system tumors. To address this question, a meeting of neuropathologists with expertise in molecular diagnosis was held in Haarlem, the Netherlands, under the sponsorship of the International Society of Neuropathology (ISN). Prior to the meeting, participants solicited input from clinical colleagues in diverse neuro-oncological specialties. The present white paper catalogs the recommendations of the meeting, at which a consensus was reached that incorporation of molecular information into the next WHO classification should follow a set of provided ISN-Haarlem guidelines. Salient recommendations include that (i) diagnostic entities should be defined as narrowly as possible to optimize interobserver reproducibility, clinicopathological predictions and therapeutic planning; (ii) diagnoses should be layered with histologic classification, WHO grade and molecular information listed below an integrated diagnosis; (iii) determinations should be made for each tumor entity as to whether molecular information is required, suggested or not needed for its definition; (iv) some pediatric entities should be separated from their adult counterparts; (v) input for guiding decisions regarding tumor classification should be solicited from experts in complementary disciplines of neuro-oncology; and (iv) entity-specific molecular testing and reporting formats should be followed in diagnostic reports. It is hoped that these guidelines will facilitate the forthcoming update of the fourth edition of the WHO classification of central nervous system tumors. C1 [Louis, David N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA USA. [Perry, Arie] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA. [Burger, Peter; Eberhart, Charles] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA. [Ellison, David W.] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA. [Reifenberger, Guido] Univ Dusseldorf, Dept Neuropathol, Dusseldorf, Germany. [Reifenberger, Guido; von Deimling, Andreas; Korshunov, Andrey] German Canc Res Ctr, Clin Cooperat Unit Neuropathol, German Canc Consortium DKTK, Heidelberg, Germany. [von Deimling, Andreas] Heidelberg Univ, Inst Pathol, Dept Neuropathol, Heidelberg, Germany. [Aldape, Kenneth] Princess Margaret Hosp, Dept Pathol, Toronto, ON M4X 1K9, Canada. [Brat, Daniel] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. [Collins, V. Peter] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England. [Figarella-Branger, Dominique] Aix Marseille Univ, La Timone Hosp, Dept Pathol & Neuropathol, Marseille, France. [Fuller, Gregory N.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX USA. [Giangaspero, Felice] Univ Roma La Sapienza, Dept Radiol Oncol & Anatomopathol Sci, Rome, Italy. [Giangaspero, Felice] IRCCS Neuromed, Pozzilli, Italy. [Giannini, Caterina] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA. [Hawkins, Cynthia] Univ Toronto, Hosp Sick Children, Dept Paediat Lab Med, Toronto, ON M5G 1X8, Canada. [Kleihues, Paul] Univ Zurich, Fac Med, CH-8006 Zurich, Switzerland. [Korshunov, Andrey] Univ Heidelberg Hosp, Dept Neuropathol, Heidelberg, Germany. [Kros, Johan M.] Erasmus MC, Dept Pathol, Rotterdam, Netherlands. [Lopes, M. Beatriz] Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA. [Ng, Ho-Keung] Chinese Univ Hong Kong, Dept Anat Pathol & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China. [Ohgaki, Hiroko] IARC, Lyon, France. [Paulus, Werner] Univ Hosp Munster, Inst Neuropathol, Munster, Germany. [Pietsch, Torsten] Univ Bonn, Brain Tumor Reference Ctr, Inst Neuropathol, Bonn, Germany. [Rosenblum, Marc] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA. [Rushing, Elisabeth] Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland. [Soylemezoglu, Figen] Hacettepe Univ, Dept Pathol, Ankara, Turkey. [Wiestler, Otmar] German Canc Res Ctr, Heidelberg, Germany. [Wesseling, Pieter] Vrije Univ Amsterdam, Dept Pathol, Med Ctr, NL-1081 HV Amsterdam, Netherlands. [Wesseling, Pieter] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NL-6525 ED Nijmegen, Netherlands. RP Louis, DN (reprint author), Massachusetts Gen Hosp, Pathol Serv, WRN225,55 Fruit St, Boston, MA 02114 USA. EM dlouis@mgh.harvard.edu; Arie.Perry@ucsf.edu; p.wesseling@vumc.nl RI von Deimling, Andreas/F-7774-2013; Ng, Ho Keung/I-3952-2015; Wesseling, P./H-8114-2014; OI von Deimling, Andreas/0000-0002-5863-540X; Wesseling, P./0000-0001-5453-5201; Fuller, Gregory/0000-0001-9447-2647 FU STOPbraintumors Foundation in The Netherlands; International Society of Neuropathology FX The meeting was made possible through generous support from the STOPbraintumors Foundation in The Netherlands and was sponsored by the International Society of Neuropathology. We thank the many neuro-oncologists, neurosurgeons, neuropathologists, neuroradiologists, radiation oncologists and medical oncologists who provided input on the subquestions prior to the meeting and on the recommendations of the meeting afterwards. We also thank Dr. Roger McLendon of the Department of Pathology, Duke University Medical Center, Durham, NC, USA, who was unable to attend the meeting but who provided input from the Duke neuro-oncology group prior to the meeting. NR 2 TC 161 Z9 165 U1 4 U2 21 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1015-6305 EI 1750-3639 J9 BRAIN PATHOL JI Brain Pathol. PD SEP PY 2014 VL 24 IS 5 BP 429 EP 435 DI 10.1111/bpa.12171 PG 7 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA AR9UT UT WOS:000343925000001 PM 24990071 ER PT J AU Harris, B Ross, J Sanchez-Reilly, S AF Harris, Brande Ross, Jeanette Sanchez-Reilly, Sandra TI Sleeping in the Arms of Cancer A Review of Sleeping Disorders Among Patients With Cancer SO CANCER JOURNAL LA English DT Review DE Cancer patients; cancer-related fatigue; insomnia; research ID COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; CHRONIC PRIMARY INSOMNIA; BREAST-CANCER; PSYCHOTROPIC-DRUGS; PRESCRIPTION PATTERNS; RADIATION-THERAPY; PROSTATE-CANCER; DISTURBANCE; FATIGUE AB It is well known that cancer patients experience lack of sleep, which affects their symptoms and decrease their much needed energy, particularly while undergoing treatment. Insomnia, which is defined as a predominant complaint of dissatisfaction with sleep quantity or quality during different phases of the sleep cycle, could easily affect patients' quality of life and even cancer treatment outcomes. In this article, we review the current research on and treatments for insomnia, as well as explore cancer-related fatigue and its connections to sleep disorders. C1 [Harris, Brande; Ross, Jeanette; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, Div Geriatr Gerontol & Palliat Med, Dept Med, San Antonio, TX 78229 USA. [Harris, Brande; Ross, Jeanette; Sanchez-Reilly, Sandra] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Geriatr Educ Ctr, San Antonio, TX USA. [Harris, Brande] Air Force Inst Technol, Wright Patterson AFB, OH USA. RP Harris, B (reprint author), 7703 Floyd Curl Dr MC 7875, San Antonio, TX 78229 USA. EM harrisbm@uthscsa.edu NR 35 TC 1 Z9 1 U1 2 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1528-9117 EI 1540-336X J9 CANCER J JI Cancer J. PD SEP-OCT PY 2014 VL 20 IS 5 BP 299 EP 305 DI 10.1097/PPO.0000000000000067 PG 7 WC Oncology SC Oncology GA AR9IA UT WOS:000343885700002 PM 25299138 ER PT J AU Daskalopoulou, SS Cooke, AB Gomez, YH Mutter, AF Filippaios, A Mesfum, ET Mantzoros, CS AF Daskalopoulou, Stella S. Cooke, Alexandra B. Gomez, Yessica-Haydee Mutter, Andrew F. Filippaios, Andreas Mesfum, Ertirea T. Mantzoros, Christos S. TI Plasma irisin levels progressively increase in response to increasing exercise workloads in young, healthy, active subjects SO EUROPEAN JOURNAL OF ENDOCRINOLOGY LA English DT Article ID FNDC5 GENE-EXPRESSION; SKELETAL-MUSCLE; ADIPOSE-TISSUE; HUMANS; METABOLISM; OBESITY; MASS; RELEASE; DISEASE; SERUM AB Background: Irisin, a recently discovered myokine, has been shown to induce browning of white adipose tissue, enhancing energy expenditure and mediating some of the beneficial effects of exercise. We aimed to estimate the time frame of changes in irisin levels after acute exercise and the effect of different exercise workloads and intensities on circulating irisin levels immediately post-exercise. Methods: In a pilot study, four healthy subjects (22.5 +/- 1.7 years) underwent maximal workload exercise (maximal oxygen consumption, VO2 (max)) and blood was drawn at prespecified intervals to define the time frame of pre- and post-exercise irisin changes over a 24-h period. In the main study, 35 healthy, non-smoking (23.0 +/- 3.3 years) men and women (n=20/15) underwent three exercise protocols >= 48-h apart, in random order: i) maximal workload (VO2 max); ii) relative workload (70% of VO2 (max)/10 min); and iii) absolute workload (75 W/10 min). Blood was drawn immediately pre- exercise and 3 min post-exercise. Results: In the pilot study, irisin levels increased by 35% 3 min post-exercise, then dropped and remained relatively constant. In the main study, irisin levels post-exercise were significantly higher than those of pre- exercise after all workloads (all, P<0.001). Post-to-pre-exercise differences in irisin levels were significantly different between workloads (P=0.001), with the greatest increase by 34% following maximal workload (P=0.004 vs relative and absolute). Conclusions: Circulating irisin levels were acutely elevated in response to exercise, with a greater increase after maximal workload. These findings suggest that irisin release could be a function of muscle energy demand. Future studies need to determine the underlying mechanisms of irisin release and explore irisin's therapeutic potential. C1 [Daskalopoulou, Stella S.; Cooke, Alexandra B.; Mutter, Andrew F.] McGill Univ, Fac Med, Dept Med, Div Expt Med, Montreal, PQ, Canada. [Daskalopoulou, Stella S.; Gomez, Yessica-Haydee] McGill Univ, Ctr Hlth, Res Inst, Div Internal Med,Dept Med,Fac Med, Montreal, PQ, Canada. [Mesfum, Ertirea T.; Mantzoros, Christos S.] VA Boston Healthcare Syst, Endocrinol Sect, Boston, MA USA. [Filippaios, Andreas; Mantzoros, Christos S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA. RP Daskalopoulou, SS (reprint author), Montreal Gen Hosp, 1650 Cedar Ave,C2-101-4, Montreal, PQ H3G 1A4, Canada. EM stella.daskalopoulou@mcgill.ca FU Canadian Institutes of Health Research (MOP) [102626] FX This study was funded by a grant from the Canadian Institutes of Health Research (MOP#102626) to S S Daskalopoulou. NR 31 TC 27 Z9 28 U1 1 U2 11 PU BIOSCIENTIFICA LTD PI BRISTOL PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND SN 0804-4643 EI 1479-683X J9 EUR J ENDOCRINOL JI Eur. J. Endocrinol. PD SEP PY 2014 VL 171 IS 3 BP 343 EP 352 DI 10.1530/EJE-14-0204 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AR6CO UT WOS:000343670900012 PM 24920292 ER PT J AU Greenstein, RJ Su, LY Shahidi, A Brown, WD Clifford, A Brown, ST AF Greenstein, Robert J. Su, Liya Shahidi, Azra Brown, William D. Clifford, Anya Brown, Sheldon T. TI Unanticipated Mycobacterium tuberculosis complex culture inhibition by immune modulators, immune suppressants, a growth enhancer, and vitamins A and D: clinical implications SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Vitamin A; Vitamin D; Mycobacterium avium subspecies; paratuberculosis; Tuberculosis; Thioguanine; Clofazimine ID AVIUM SUBSPECIES PARATUBERCULOSIS; DRUG-RESISTANT TUBERCULOSIS; MULTICENTER LABORATORY VALIDATION; IN-VITRO ACTIVITIES; CROHNS-DISEASE; INTRACELLULAR ACTIVITIES; PULMONARY TUBERCULOSIS; ANTIMICROBIAL DRUGS; CLASSICAL 2ND-LINE; MONENSIN SODIUM AB Background: The development of novel antibiotics to treat multidrug-resistant (MDR) tuberculosis is time-consuming and expensive. Multiple immune modulators, immune suppressants, anti-inflammatories, and growth enhancers, and vitamins A and D, inhibit Mycobacterium avium subspecies paratuberculosis (MAP) in culture. We studied the culture inhibition of Mycobacterium tuberculosis complex by these agents. Methods: Biosafety level two M. tuberculosis complex (ATCC 19015 and ATCC 25177) was studied in radiometric Bactec or MGIT culture. Agents evaluated included clofazimine, methotrexate, 6-mercaptopurine, cyclosporine A, rapamycin, tacrolimus, monensin, and vitamins A and D. Results: All the agents mentioned above caused dose-dependent inhibition of the M. tuberculosis complex. There was no inhibition by the anti-inflammatory 5-aminosalicylic acid, which causes bacteriostatic inhibition of MAP. Conclusions: We conclude that, at a minimum, studies with virulent M. tuberculosis are indicated with the agents mentioned above, as well as with the thioamide 5-propothiouricil, which has previously been shown to inhibit the M. tuberculosis complex in culture. Our data additionally emphasize the importance of vitamins A and D in treating mycobacterial diseases. (C) 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license. C1 [Greenstein, Robert J.] James J Peters Vet Affairs Med Ctr, Dept Surg, Bronx, NY 10468 USA. [Greenstein, Robert J.; Su, Liya; Brown, William D.; Clifford, Anya] James J Peters Vet Affairs Med Ctr, Lab Mol Surg Res, Bronx, NY USA. [Shahidi, Azra] James J Peters Vet Affairs Med Ctr, Dept Pathol, Bronx, NY USA. [Brown, Sheldon T.] James J Peters Vet Affairs Med Ctr, Infect Dis Sect, Bronx, NY USA. [Brown, Sheldon T.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. RP Greenstein, RJ (reprint author), James J Peters Vet Affairs Med Ctr, Dept Surg, Bronx, NY 10468 USA. EM BGAxis@aol.com FU Bronx Veterans Research Fund Inc. FX The project was funded intramurally by the Bronx Veterans Research Fund Inc. The Bronx Veterans Research Fund Inc. had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. No other funding was obtained. NR 82 TC 2 Z9 2 U1 2 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 EI 1878-3511 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD SEP PY 2014 VL 26 BP 37 EP 43 DI 10.1016/j.ijid.2014.01.026 PG 7 WC Infectious Diseases SC Infectious Diseases GA AR8IH UT WOS:000343818300008 PM 24998461 ER PT J AU Dobrev, I Furlong, C Cheng, JT Rosowski, JJ AF Dobrev, Ivo Furlong, Cosme Cheng, Jeffrey T. Rosowski, John J. TI Full-field transient vibrometry of the human tympanic membrane by local phase correlation and high-speed holography SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE acoustic-solid interaction; high-speed holography; local phase correlation; otology; transient response; tympanic membrane; high-speed cameras ID MIDDLE-EAR; VIBRATION; MOTION; INTERFEROMETRY; EMISSIONS; SURFACE; MODEL AB Understanding the human hearing process would be helped by quantification of the transient mechanical response of the human ear, including the human tympanic membrane (TM or eardrum). We propose a new hybrid high-speed holographic system (HHS) for acquisition and quantification of the full-field nanometer transient (i.e., >10 kHz) displacement of the human TM. We have optimized and implemented a 2 + 1 frame local correlation (LC) based phase sampling method in combination with a high-speed (i.e., >40 K fps) camera acquisition system. To our knowledge, there is currently no existing system that provides such capabilities for the study of the human TM. The LC sampling method has a displacement difference of <11 nm relative to measurements obtained by a four-phase step algorithm. Comparisons between our high-speed acquisition system and a laser Doppler vibrometer indicate differences of <10 mu s. The high temporal (i.e., >40 kHz) and spatial (i.e., >100 k data points) resolution of our HHS enables parallel measurements of all points on the surface of the TM, which allows quantification of spatially dependent motion parameters, such as modal frequencies and acoustic delays. Such capabilities could allow inferring local material properties across the surface of the TM. c The Authors. Published by SPIE under a Creative Commons Attribution 3.0 Unported License. C1 [Dobrev, Ivo; Furlong, Cosme] Worcester Polytech Inst, Ctr Holog Studies & Laser MicromechaTron, Dept Mech Engn, Worcester, MA 01609 USA. [Furlong, Cosme; Cheng, Jeffrey T.; Rosowski, John J.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. [Furlong, Cosme; Cheng, Jeffrey T.; Rosowski, John J.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA. RP Dobrev, I (reprint author), Worcester Polytech Inst, Ctr Holog Studies & Laser MicromechaTron, Dept Mech Engn, Worcester, MA 01609 USA. EM ivo_d@wpi.edu FU National Institute on Deafness and Other Communication Disorders; National Institute of Health; MEEI; Mittal Fund; NanoEngineering, Science, and Technology program at the Worcester Polytechnic Institute; Mechanical Engineering Department FX The authors would like to acknowledge the help of Michael Ravicz at the Eaton-Peabody Laboratory of the Massachusetts Eye and Ear Infirmary (MEEI) and Ellery Harrington and Morteza Khaleghi at the Center for Holographic Studies and Laser Micro-MechaTronics at Worcester Polytechnic Institute. This work has been funded by the National Institute on Deafness and Other Communication Disorders, the National Institute of Health, MEEI, and the Mittal Fund. The authors also gratefully acknowledge the support of the NanoEngineering, Science, and Technology program at the Worcester Polytechnic Institute, Mechanical Engineering Department. NR 29 TC 6 Z9 6 U1 0 U2 7 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 EI 1560-2281 J9 J BIOMED OPT JI J. Biomed. Opt. PD SEP PY 2014 VL 19 IS 9 AR 096001 DI 10.1117/1.JBO.19.9.096001 PG 12 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA AR9EK UT WOS:000343874900011 PM 25191832 ER PT J AU Wirth, D Snuderl, M Curry, W Yaroslavskya, A AF Wirth, Dennis Snuderl, Matija Curry, William Yaroslavskya, Anna TI Comparative evaluation of methylene blue and demeclocycline for enhancing optical contrast of gliomas in optical images SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE glioblastoma; methylene blue; demeclocycline; reflectance; fluorescence; confocal imaging ID TETRACYCLINE AB Contrast agents have shown to be useful in the detection of cancers. The goal of this study was to compare enhancement of brain cancer contrast using reflectance and fluorescence confocal imaging of two fluorophores, methylene blue (MB) and demeclocycline (DMN). MB absorbs light in the red spectral range and fluoresces in the near-infrared. It is safe for in vivo staining of human skin and breast tissue. However, its safety for staining human brain is questionable. Thus, DMN, which absorbs light in the violet spectral range and fluoresces between 470 and 570 nm, could provide a safer alternative to MB. Fresh human gliomas, obtained from surgeries, were cut in half and stained with aqueous solutions of MB and DMN, respectively. Stained tissues were imaged using multimodal confocal microscopy. Resulting reflectance and fluorescence optical images were compared with hematoxylin and eosin histopathology, processed from each imaged tissue. Results indicate that images of tissues stained with either stain exhibit comparable contrast and resolution of morphological detail. Further studies are required to establish the safety and efficacy of these contrast agents for use in human brain. (C) The Authors. Published by SPIE under a Creative Commons Attribution 3.0 Unported License. C1 [Wirth, Dennis; Yaroslavskya, Anna] Univ Massachusetts, Dept Phys & Appl Phys, Lowell, MA 01854 USA. [Snuderl, Matija] NYU, Langone Med Ctr, New York, NY 10016 USA. [Snuderl, Matija] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA. [Curry, William] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. RP Yaroslavskya, A (reprint author), Univ Massachusetts, Dept Phys & Appl Phys, One Univ Ave, Lowell, MA 01854 USA. EM Anna_Yaroslavsky@uml.edu OI Snuderl, Matija/0000-0003-0752-0917 FU MGH Cancer Center; UML seed grant FX We acknowledge I. Tabatadze for processing histopathology and C. Kwon for sample transportations. Funding was provided by MGH Cancer Center and UML seed grant. NR 11 TC 1 Z9 1 U1 0 U2 3 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 EI 1560-2281 J9 J BIOMED OPT JI J. Biomed. Opt. PD SEP PY 2014 VL 19 IS 9 AR 090504 DI 10.1117/1.JBO.19.9.090504 PG 3 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA AR9EK UT WOS:000343874900004 PM 25239672 ER PT J AU Cho, TA AF Cho, Tracey A. TI Neurorheumatology Preface SO SEMINARS IN NEUROLOGY LA English DT Editorial Material C1 Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Cho, TA (reprint author), Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St, Boston, MA 02114 USA. EM tcho@partners.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0271-8235 EI 1098-9021 J9 SEMIN NEUROL JI Semin. Neurol. PD SEP PY 2014 VL 34 IS 4 BP 369 EP 370 DI 10.1055/s-0034-1390384 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA AR7UB UT WOS:000343784100002 PM 25369431 ER PT J AU Miloslavsky, EM Cho, TA AF Miloslavsky, Eli M. Cho, Tracey A. TI Clinical Approach to Neurorheumatology SO SEMINARS IN NEUROLOGY LA English DT Article DE rheumatology; autoimmune condition; clinical approach; vasculitis; lupus; sarcoidosis; Behcet disease ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; CONNECTIVE-TISSUE DISEASE; GIANT-CELL ARTERITIS; OF-THE-LITERATURE; CLASSIFICATION CRITERIA; WEGENER GRANULOMATOSIS; OCULAR MANIFESTATIONS; RAYNAUDS-PHENOMENON; BEHCETS-SYNDROME; VASCULITIS AB Rheumatologic conditions are an important cause of both central and peripheral nervous system pathology. A thorough evaluation for an underlying rheumatologic process is an important component of a patient presenting with neurologic symptoms. In this review, the authors present an approach to evaluating rheumatologic conditions, focusing primarily on the history and physical examination. They focus on the most specific signs and symptoms that may help the neurologist assess whether an underlying rheumatologic process is present. In addition, they discuss the interpretation of such findings with an eye toward narrowing the differential diagnosis and directing further testing. C1 [Miloslavsky, Eli M.; Cho, Tracey A.] Harvard Univ, Sch Med, Boston, MA USA. [Miloslavsky, Eli M.] Massachusetts Gen Hosp, Dept Med, Rheumatol Unit, Boston, MA 02114 USA. [Cho, Tracey A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Miloslavsky, EM (reprint author), Massachusetts Gen Hosp, Dept Med, Rheumatol Unit, Boston, MA 02114 USA. EM emiloslavsky@mgh.harvard.edu NR 45 TC 0 Z9 0 U1 1 U2 1 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0271-8235 EI 1098-9021 J9 SEMIN NEUROL JI Semin. Neurol. PD SEP PY 2014 VL 34 IS 4 BP 371 EP 377 DI 10.1055/s-0034-1390385 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA AR7UB UT WOS:000343784100003 PM 25369432 ER PT J AU Hickey, MK Murali, M AF Hickey, Meghan K. Murali, Mandakolathur TI Laboratory Testing in Neurorheumatology SO SEMINARS IN NEUROLOGY LA English DT Article DE antinuclear antibodies; extractable nuclear antigen; rheumatoid factor; erythrocyte sedimentation rate; C-Reactive protein anti-SSA; anti-SSB; cryoglobulins; antineutrophilic cytoplasmic antibody; HLA-B51 ID C-REACTIVE PROTEIN; ERYTHROCYTE SEDIMENTATION-RATE; SYSTEMIC-LUPUS-ERYTHEMATOSUS; GIANT-CELL ARTERITIS; EXTRACTABLE NUCLEAR ANTIGENS; CONNECTIVE-TISSUE DISEASE; ANTINUCLEAR ANTIBODY-TEST; STIFF-PERSON SYNDROME; RHEUMATOID-ARTHRITIS; MICROSCOPIC POLYANGIITIS AB Laboratory testing in cases of neuro-rheumatologic disease can be daunting, and the results can be difficult to interpret if not placed in the correct clinical context. To best help our patients and also to practice in a cost-effective environment, laboratory testing must be performed in a logical manner, guided by symptoms and clinical judgment. The authors discuss the different laboratory tests used in the diagnosis and evaluation of rheumatologic diseases often encountered in the practice of neurology. It is important to understand how the tests are performed and which methods are used at your own institution. Testing should be ordered with a specific diagnosis in mind so as not to confuse the clinical picture with possible false-positive results. Through discussion of the various testing options, the authors advocate a step-wise approach to investigation. C1 [Hickey, Meghan K.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Murali, Mandakolathur] Massachusetts Gen Hosp, Dept Med, Clin Immunol Lab, Boston, MA 02114 USA. [Murali, Mandakolathur] Massachusetts Gen Hosp, Dept Pathol, Clin Immunol Lab, Boston, MA 02114 USA. RP Hickey, MK (reprint author), Massachusetts Gen Hosp, Dept Neurol, 15 Parkman Ave, Boston, MA 02114 USA. EM meghankhickey@gmail.com NR 76 TC 0 Z9 0 U1 1 U2 4 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0271-8235 EI 1098-9021 J9 SEMIN NEUROL JI Semin. Neurol. PD SEP PY 2014 VL 34 IS 4 BP 378 EP 385 DI 10.1055/s-0034-1390386 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA AR7UB UT WOS:000343784100004 PM 25369433 ER PT J AU Agnihotri, SP Singhal, T Stern, BJ Cho, TA AF Agnihotri, Shruti P. Singhal, Tarun Stern, Barney J. Cho, Tracey A. TI Neurosarcoidosis SO SEMINARS IN NEUROLOGY LA English DT Article DE sarcoidosis; neurologic complications; neurosarcoidosis; cranial neuropathy; aseptic meningitis; granuloma; myelitis ID CENTRAL-NERVOUS-SYSTEM; REFRACTORY NEUROSARCOIDOSIS; CNS SARCOIDOSIS; MANIFESTATIONS; MANAGEMENT; DIAGNOSIS; PRESENTATIONS; INVOLVEMENT; INFLIXIMAB; NEUROPATHY AB Sarcoidosis is an idiopathic multisystem granulomatous disorder. Neurologic manifestations in sarcoidosis are varied and making a diagnosis of neurosarcoidosis can be difficult as it mimics various other neurologic diseases. Knowledge of the syndromes associated with neurosarcoidosis can help guide the diagnostic evaluation. Definitive diagnosis requires neurologic tissue evidence of noncaseating granuloma, but in practice probable diagnosis is often made through nonneurologic biopsy and a characteristic syndrome and imaging. Treatment remains empiric, but new advances in immunologic therapy hold promise for effective and less-toxic regimens. C1 [Agnihotri, Shruti P.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA. [Singhal, Tarun; Cho, Tracey A.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA. [Singhal, Tarun] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA. [Stern, Barney J.] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA. [Cho, Tracey A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Cho, TA (reprint author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. EM tcho@partners.org NR 55 TC 5 Z9 5 U1 0 U2 4 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0271-8235 EI 1098-9021 J9 SEMIN NEUROL JI Semin. Neurol. PD SEP PY 2014 VL 34 IS 4 BP 386 EP 394 DI 10.1055/s-0034-1390387 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA AR7UB UT WOS:000343784100005 PM 25369434 ER PT J AU Carruthers, R Carruthers, M Della-Torre, E AF Carruthers, Robert Carruthers, Mollie Della-Torre, Emanuel TI IgG4-Related Disease and Other Causes of Inflammatory Meningeal Disease SO SEMINARS IN NEUROLOGY LA English DT Article DE pachymeningitis; IgG4-related disease; inflammatory meningeal disease ID CEREBROSPINAL-FLUID ANALYSIS; G4-RELATED HYPERTROPHIC PACHYMENINGITIS; SERUM IGG4 CONCENTRATIONS; KOYANAGI-HARADA SYNDROME; OF-THE-LITERATURE; LYMPHOMATOID GRANULOMATOSIS; RHEUMATOID MENINGITIS; BEHCETS-DISEASE; CRANIAL PACHYMENINGITIS; WEGENERS-GRANULOMATOSIS AB Immunoglobulin-4 (IgG4-) related disease is a newly described treatable condition that has recently expanded the differential diagnosis of inflammatory meningeal disorders. This review will discuss the main clinical and pathophysiological features of IgG4-related meningeal disease in the context of meningeal inflammatory disorders in general. Particular attention will be dedicated to the differential diagnosis and the different therapeutic approaches. C1 [Carruthers, Robert] Brigham & Womens Hosp, Dept Neurol, Brookline, MA 02446 USA. [Carruthers, Mollie] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Della-Torre, Emanuel] IRCCS San Raffaele Sci, Dept Med & Clin Immunol, Milan, Italy. RP Carruthers, R (reprint author), Brigham & Womens Hosp, Dept Neurol, 1 Brookline Pl Suite 225, Brookline, MA 02446 USA. EM drrobertcarruthers@gmail.com OI Della Torre, Emanuel/0000-0002-9192-4270 NR 77 TC 3 Z9 4 U1 1 U2 7 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0271-8235 EI 1098-9021 J9 SEMIN NEUROL JI Semin. Neurol. PD SEP PY 2014 VL 34 IS 4 BP 395 EP 404 DI 10.1055/s-0034-1390388 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA AR7UB UT WOS:000343784100006 PM 25369435 ER PT J AU Reda, H Chin, RL AF Reda, Haatem Chin, Russell L. TI Peripheral Neuropathies of Rheumatologic Disease and Gluten-Related Disorders SO SEMINARS IN NEUROLOGY LA English DT Article DE vasculitis; rheumatologic; neuropathy; celiac; fibromyalgia ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; GIANT-CELL ARTERITIS; ANTINEUTROPHIL CYTOPLASMIC ANTIBODY; ANCA-ASSOCIATED VASCULITIS; CHURG-STRAUSS-SYNDROME; ADULT CELIAC-DISEASE; TERM-FOLLOW-UP; FIBER POLYNEUROPATHY UNDERLIES; DAILY ORAL CYCLOPHOSPHAMIDE; MICROSCOPIC POLYANGIITIS AB Peripheral nervous system disease is a common and often debilitating feature of many systemic rheumatologic disorders. Such involvement takes many forms, reflecting the variety of underlying pathophysiology, though most patients present with painful multifocal neuropathy (usually vasculitic) or a distal sensory more than motor peripheral neuropathy (sometimes vasculitic and nearly always axonal). The presence of peripheral nervous system involvement is often an early signal of the generalization of inflammatory disease in blood vessels or extravascular tissues, though peripheral neuropathy is not itself an independent predictor of mortality. Nonetheless, progressive multifocal neuropathy, motor neuropathy, small fiber neuropathy, and sensory neuronopathy should be treated early and aggressively with immunosuppression (or the gluten-free diet in appropriate situations) to limit morbidity. Given the rapidly evolving therapeutic landscape, partnership with a rheumatologist is essential. Treatment is usually sustained for 1 to 2 years, and remission is possible in many cases within 6 to 12 months, with variable rates of relapse and treatment resistance. Patients should be meticulously monitored for relapse with serial laboratory testing, electrodiagnostic studies, and clinical examination. Functional rating scores, such as the neuropathy impairment scale and the total neuropathy score are useful for longitudinal assessment. C1 [Reda, Haatem] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Chin, Russell L.] Weill Cornell Med Coll, Dept Neurol, New York, NY USA. RP Reda, H (reprint author), Massachusetts Gen Hosp, Dept Neurol, 15 Parkman St,WACC 835, Boston, MA 02114 USA. EM hreda@partners.org NR 165 TC 0 Z9 0 U1 1 U2 7 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0271-8235 EI 1098-9021 J9 SEMIN NEUROL JI Semin. Neurol. PD SEP PY 2014 VL 34 IS 4 BP 413 EP 424 DI 10.1055/s-0034-1390390 PG 12 WC Clinical Neurology SC Neurosciences & Neurology GA AR7UB UT WOS:000343784100008 PM 25369437 ER PT J AU Bhattacharyya, S Helfgott, SM AF Bhattacharyya, Shamik Helfgott, Simon M. TI Neurologic Complications of Systemic Lupus Erythematosus, Sjogren Syndrome, and Rheumatoid Arthritis SO SEMINARS IN NEUROLOGY LA English DT Article DE systemic lupus erythematosus; Sjogren syndrome; rheumatoid arthritis; cervical spine subluxation; antiphospholipid syndrome; neuromyelitis optica; myelitis; peripheral neuropathy ID CENTRAL-NERVOUS-SYSTEM; ANTIPHOSPHOLIPID-ANTIBODY-SYNDROME; CEREBRAL VASCULITIS; NEUROPSYCHIATRIC SYNDROMES; CLINICAL-MANIFESTATIONS; PERIPHERAL NEUROPATHY; AMERICAN-COLLEGE; CLASSIFICATION CRITERIA; PATHOGENETIC MECHANISMS; COGNITIVE IMPAIRMENT AB Neurologic complications are frequent and often morbid in systemic lupus erythematosus, Sjogren syndrome, and rheumatoid arthritis. Although all are systemic inflammatory syndromes, each disease affects the nervous system distinctly, such as peripheral neuropathy in Sjogren syndrome, cerebrovascular disease in lupus, and cervical spine subluxation in rheumatoid arthritis. Some neurologic complications share convergent pathophysiology across diseases, such as neuromyelitis optica spectrum disorders in both Sjogren syndrome and lupus. Ill-defined cognitive complaints are especially common in lupus and Sjogren syndrome. For the majority of the complications, evidence for treatment efficacy is limited and requires further investigation. C1 [Bhattacharyya, Shamik] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Bhattacharyya, Shamik] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA. [Bhattacharyya, Shamik] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA. [Helfgott, Simon M.] Brigham & Womens Hosp, Dept Rheumatol, Boston, MA 02115 USA. [Helfgott, Simon M.] Harvard Univ, Sch Med, Dept Rheumatol, Boston, MA USA. RP Bhattacharyya, S (reprint author), Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St, Boston, MA 02114 USA. EM sbhattacharyya3@partners.org OI Bhattacharyya, Shamik/0000-0001-8047-3622 NR 104 TC 3 Z9 3 U1 0 U2 4 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0271-8235 EI 1098-9021 J9 SEMIN NEUROL JI Semin. Neurol. PD SEP PY 2014 VL 34 IS 4 BP 425 EP 436 DI 10.1055/s-0034-1390391 PG 12 WC Clinical Neurology SC Neurosciences & Neurology GA AR7UB UT WOS:000343784100009 PM 25369438 ER PT J AU Miller, JJ Venna, N Siva, A AF Miller, Julie J. Venna, Nagagopal Siva, Aksel TI Neuro-Behcet Disease and Autoinflammatory Disorders SO SEMINARS IN NEUROLOGY LA English DT Article DE neuro-Behcet; autoinflammatory syndromes; neurologic disease; cerebral venous thrombosis; vasculitis ID MANIFESTATIONS; INVOLVEMENT; DIAGNOSIS; SUSCEPTIBILITY; METAANALYSIS; INFLIXIMAB; MANAGEMENT; SPECTRUM; CRITERIA; SYSTEM AB Misregulation of innate Immunity leads to autoinflammation. Behcet disease is an autoinflammatory condition involving recurrent attacks of inflammation in skin, eyes, joints, and even the nervous system. The etiology may involve vascular inflammation. Central nervous system involvement in neuro-Behcet disease (NBD) comes in the form of parenchymal NBD or nonparenchymal NBD. The parenchymal form has a predilection for the brainstem, diencephalon and cerebral hemispheres, and represents a meningoencephalitis thought to be related to small vessel vasculitis. Cerebral venous sinus thrombosis, arising from a vasculitic process of large veins, comprises the majority of vascular NBD cases. The rarer monogenetic autoinflammatory syndromes are characterized by periodic fever, and typically present in the pediatric population. Neurologic involvement in these syndromes typically presents in the form of an aseptic meningitis. Treatment of autoinflammatory disorders involves immune modulation with corticosteroids, disease-modifying antirheumatic medications, and increasingly antibodies targeting cytokines like tumor necrosis factor alpha and interleukin 1. C1 [Miller, Julie J.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA. [Miller, Julie J.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Venna, Nagagopal] Massachusetts Gen Hosp, Neurol Associates, Neurol Clin, Boston, MA 02115 USA. [Venna, Nagagopal] Massachusetts Gen Hosp, Neurol Associates, Neuroinfect Dis Clin, Boston, MA 02115 USA. [Siva, Aksel] Istanbul Univ, Cerrahpasa Med Sch, Dept Neurol, Istanbul, Turkey. RP Miller, JJ (reprint author), Massachusetts Gen Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA. EM jmiller30@partners.org RI Siva, Aksel/A-7727-2017 NR 49 TC 0 Z9 0 U1 0 U2 3 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0271-8235 EI 1098-9021 J9 SEMIN NEUROL JI Semin. Neurol. PD SEP PY 2014 VL 34 IS 4 BP 437 EP 443 DI 10.1055/s-0034-1390392 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA AR7UB UT WOS:000343784100010 PM 25369439 ER PT J AU Vodopivec, I Lobo, AM Prasad, S AF Vodopivec, Ivana Lobo, Ann-Marie Prasad, Sashank TI Ocular Inflammation in Neurorheumatic Disease SO SEMINARS IN NEUROLOGY LA English DT Article DE nervous system; neuroimmunology; neuroinflammation; ocular inflammation; uveomeningeal syndromes ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; PLACOID PIGMENT EPITHELIOPATHY; GIANT-CELL ARTERITIS; KOYANAGI-HARADA-DISEASE; OF-THE-LITERATURE; WEGENERS-GRANULOMATOSIS; NEUROMYELITIS-OPTICA; POLYARTERITIS-NODOSA; IGG4-RELATED DISEASE; CLINICAL-FEATURES AB Neuroimmunologic and systemic rheumatic diseases are frequently accompanied by inflammation of the eye, ocular adnexa, and orbital tissues. An understanding of the diverse forms of ophthalmic pathology in these conditions aids the clinician in making appropriate preventative, diagnostic, therapeutic, and prognostic decisions. In this review, the authors address ocular inflammation in neurorheumatic disease in three sections: first, they highlight current perspectives on immune mechanisms in the development of these disorders; next, they provide a framework for the recognition and evaluation of ophthalmologic inflammatory entities; finally, they discuss in detail several inflammatory conditions that affect the nervous system and the eye, emphasizing the features that should alert neurologists to initiate ophthalmologic evaluation. The conditions discussed include multiple sclerosis, neuromyelitis optica, chronic relapsing inflammatory optic neuropathy, Susac syndrome, Cogan syndrome, acute posterior multifocal placoid pigment epitheliopathy, Vogt-Koyanagi-Harada disease, Behcet disease, sarcoidosis, systemic lupus erythematosus, granulomatosis with polyangiitis (Wegener granulomatosis), polyarteritis nodosa, giant cell arteritis, IgG4-related disease, and Sjogren syndrome. C1 [Vodopivec, Ivana; Prasad, Sashank] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA. [Vodopivec, Ivana] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Lobo, Ann-Marie] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. [Lobo, Ann-Marie] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Prasad, Sashank] Brigham & Womens Hosp, Dept Neurol, Div Neuroophthalmol, Boston, MA 02115 USA. RP Vodopivec, I (reprint author), Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St, Boston, MA 02114 USA. EM ivodopivec@partners.org NR 79 TC 3 Z9 3 U1 1 U2 6 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0271-8235 EI 1098-9021 J9 SEMIN NEUROL JI Semin. Neurol. PD SEP PY 2014 VL 34 IS 4 BP 444 EP 457 DI 10.1055/s-0034-1390393 PG 14 WC Clinical Neurology SC Neurosciences & Neurology GA AR7UB UT WOS:000343784100011 PM 25369440 ER PT J AU Linnoila, JJ Rosenfeld, MR Dalmau, J AF Linnoila, Jenny J. Rosenfeld, Myrna R. Dalmau, Josep TI Neuronal Surface Antibody-Mediated Autoimmune Encephalitis SO SEMINARS IN NEUROLOGY LA English DT Article DE autoimmune; limbic; encephalitis; neuronal antibodies ID D-ASPARTATE RECEPTOR; HERPES-SIMPLEX ENCEPHALITIS; PARANEOPLASTIC NEUROLOGICAL SYNDROMES; RAPID-EYE-MOVEMENT; LIMBIC ENCEPHALITIS; GLUTAMATE-RECEPTOR; GLYCINE RECEPTOR; STATUS EPILEPTICUS; AMPA RECEPTOR; CASE SERIES AB In the past few years, many autoimmune encephalitides have been identified, with specific clinical syndromes and associated antibodies against neuronal surface antigens. There is compelling evidence that many of these antibodies are pathogenic and most of these encephalitides are highly responsive to immunotherapies. The clinical spectra of some of these antibody-mediated syndromes, especially those reported in only a few patients, are evolving. Others, such as anti-N-methyl-D-aspartate (NMDA) receptor encephalitis, are well characterized. Diagnosis involves recognizing the specific syndromes and identifying the antibody in a patient's cerebrospinal fluid (CSF) and/or serum. These syndromes are associated with variable abnormalities in CSF, magnetic resonance imaging, and electroencephalography. Treatment is often multidisciplinary and should be focused upon neutralizing the effects of antibodies and eliminating their source. Overlapping disorders have been noted, with some patients having more than one neurologic autoimmune disease. In other patients, viral infections such as herpes simplex virus encephalitis trigger robust antineuronal autoimmune responses. C1 [Linnoila, Jenny J.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Rosenfeld, Myrna R.] Hosp Clin Barcelona, IDIBAPS, Dept Neurol, Barcelona, Spain. [Rosenfeld, Myrna R.; Dalmau, Josep] Ctr Recerca Biomed CELLEX, Lab Neuroimmonol P3A, Barcelona, Spain. [Rosenfeld, Myrna R.; Dalmau, Josep] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Dalmau, Josep] IDIBAPS, ICREA, Barcelona 08036, Spain. RP Dalmau, J (reprint author), IDIBAPS, ICREA, Barcelona 08036, Spain. EM jdalmau@clinic.ub.es OI Rosenfeld, Myrna/0000-0001-5095-2534; Dalmau, Josep/0000-0001-5856-2813 FU National Institute of Neurologic Disorders and Stroke at the National Institutes of Health, USA (JL) [R25NS065743]; National Institutes of Health, USA (JD) [R01NS077851]; Fondo Investigaciones Sanitarias, Spain (JD) [11/01780]; Fundacio la Marato, Spain (JD) [TV3] FX Supported in part by grant R25NS065743 from the National Institute of Neurologic Disorders and Stroke at the National Institutes of Health, USA (JL); grant R01NS077851 from the National Institutes of Health, USA (JD); grant 11/01780 from the Fondo Investigaciones Sanitarias, Spain (JD); and grant TV3 from Fundacio la Marato, Spain (JD). NR 86 TC 15 Z9 16 U1 3 U2 14 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0271-8235 EI 1098-9021 J9 SEMIN NEUROL JI Semin. Neurol. PD SEP PY 2014 VL 34 IS 4 BP 458 EP 466 DI 10.1055/s-0034-1390394 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA AR7UB UT WOS:000343784100012 PM 25369441 ER PT J AU Vodopivec, I Miloslavsky, EM Kotton, CN Cho, TA AF Vodopivec, Ivana Miloslavsky, Eli M. Kotton, Camille N. Cho, Tracey A. TI A Neurologist's Guide to Safe Use of Immunomodulatory Therapies SO SEMINARS IN NEUROLOGY LA English DT Article DE immunosuppressive drugs; intravenous immunoglobulin; safety; infection; vaccination; glucocorticoid-induced osteoporosis; infertility; malignancy ID PNEUMOCYSTIS-CARINII-PNEUMONIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; HEPATITIS-B-VIRUS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; GLUCOCORTICOID-INDUCED OSTEOPOROSIS; MODIFYING ANTIRHEUMATIC DRUGS; NECROSIS FACTOR AGENTS; RHEUMATOID-ARTHRITIS; AUTOIMMUNE-DISEASES; HERPES-ZOSTER AB Increased understanding of the pathogenesis of immune-mediated neurologic conditions with concomitant development of new therapeutic agents modulating various aspects of the immune system has resulted in the use of innovative therapies in the treatment of these diseases. These novel immunomodulatory therapeutic regimens also augment the potential for complications, including severe adverse effects. In this review, the authors address practical issues regarding management of patients with neuroimmunological conditions treated with immunomodulatory therapies, including glucocorticoids, methotrexate, azathioprine, mycophenolate, cyclophosphamide, rituximab, tumor necrosis factor-a inhibitors, and intravenous immunoglobulins. Particular focus is placed on their infectious and noninfectious adverse effects, contra-indications, safety monitoring, risk surveillance, and preventive strategies in clinical practice. C1 [Vodopivec, Ivana; Miloslavsky, Eli M.; Kotton, Camille N.; Cho, Tracey A.] Harvard Univ, Sch Med, Boston, MA USA. [Vodopivec, Ivana; Cho, Tracey A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Miloslavsky, Eli M.] Massachusetts Gen Hosp, Dept Med, Rheumatol Unit, Boston, MA 02114 USA. [Kotton, Camille N.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA. RP Vodopivec, I (reprint author), Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St, Boston, MA 02114 USA. EM ivodopivec@partners.org NR 116 TC 2 Z9 2 U1 1 U2 4 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0271-8235 EI 1098-9021 J9 SEMIN NEUROL JI Semin. Neurol. PD SEP PY 2014 VL 34 IS 4 BP 467 EP 478 DI 10.1055/s-0034-1390395 PG 12 WC Clinical Neurology SC Neurosciences & Neurology GA AR7UB UT WOS:000343784100013 PM 25369442 ER PT J AU Borsari, B Peterson, C Zamboanga, BL Correia, CJ Olthuis, JV Ham, LS Grossbard, J AF Borsari, Brian Peterson, Colleen Zamboanga, Byron L. Correia, Christopher J. Olthuis, Janine V. Ham, Lindsay S. Grossbard, Joel TI The Hazardous Drinking Games Measure (HDGM): A multi-site implementation SO AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE LA English DT Article DE Alcohol-related problems; assessment; college students; drinking games ID DISORDERS IDENTIFICATION TEST; BLOOD-ALCOHOL CONCENTRATIONS; MANDATED COLLEGE-STUDENTS; HIGH-SCHOOL; HEAVY DRINKING; INTERVENTIONS; CONSUMPTION; CONSEQUENCES; PARTICIPATION; BEHAVIORS AB Background: Drinking game participation has been associated with increased frequency and quantity of alcohol use, as well as alcohol-related problems, in college students. To date, the assessment of drinking games typically entails the use of self-developed measures of frequency of participation and amount of alcohol consumed while playing. Objectives: The Hazardous Drinking Games Measure (HDGM) is the first effort to create a comprehensive yet concise method of assessing drinking game participation. The HDGM assesses drinking during games, the specific types of drinking games played, and negative consequences experienced as a result of playing drinking games. Method: Data from three samples of college students (n = 1002) who completed the HDGM and other self-report questionnaires of drinking behaviors were used for exploratory analyses. Results: Exploratory analyses suggest that the HDGM adequately captures the nuances of drinking game participation in this population and demonstrates initial evidence of good content and criterion-related validity and test-retest reliability. However, the HDGM did not predict risky drinking above and beyond standard measures of drinks per week and alcohol-related problems in any samples. Conclusion: The HDGM may be useful for campuswide assessment of drinking games and as a source of game-specific feedback when integrated into campus prevention and intervention efforts. C1 [Borsari, Brian] Providence VA Med Ctr, Mental Hlth & Behav Sci Serv, Providence, RI 02912 USA. [Borsari, Brian; Peterson, Colleen] Brown Sch Publ Hlth, Ctr Alcohol & Addict Studies, Providence, RI 02906 USA. [Zamboanga, Byron L.] Smith Coll, Dept Psychol, Northampton, MA 01063 USA. [Correia, Christopher J.] Auburn Univ, Dept Psychol, Auburn, AL 36849 USA. [Olthuis, Janine V.] Dalhousie Univ, Dept Psychol & Neurosci, Halifax, NS, Canada. [Ham, Lindsay S.] Univ Arkansas, Dept Psychol Sci, Fayetteville, AR 72701 USA. [Grossbard, Joel] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Borsari, B (reprint author), Brown Sch Publ Hlth, Ctr Alcohol & Addict Studies, Box G-S121-5, Providence, RI 02906 USA. EM Brian_Borsari@brown.edu FU National Institute on Alcohol Abuse and Alcoholism [R01 AA017427, R01 AA015518, VISN1 CDA2012-18]; Canadian Institutes of Health Research Vanier Canada Graduate Scholarship FX Brian Borsari's contribution to this paper was supported by National Institute on Alcohol Abuse and Alcoholism grants R01 AA017427 and R01 AA015518 and VISN1 CDA2012-18 to B. Borsari. Janine V. Olthuis' contribution to this paper was supported by a Canadian Institutes of Health Research Vanier Canada Graduate Scholarship. The authors would like to thank Elise Clerkin for her early efforts on organizing the data. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Canadian Institutes of Health Research, National Institute on Alcohol Abuse and Alcoholism or the National Institutes of Health, the Department of Veterans Affairs or the United States Government. NR 50 TC 3 Z9 3 U1 1 U2 4 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0095-2990 EI 1097-9891 J9 AM J DRUG ALCOHOL AB JI Am. J. Drug Alcohol Abuse PD SEP PY 2014 VL 40 IS 5 SI SI BP 395 EP 402 DI 10.3109/00952990.2014.924522 PG 8 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA AR5MS UT WOS:000343629300008 PM 25192208 ER PT J AU Sri-On, J Chang, YC Curley, DP Camargo, CA Weissman, JS Singer, SJ Liu, SW AF Sri-On, Jiraporn Chang, Yuchiao Curley, David P. Camargo, Carlos A., Jr. Weissman, Joel S. Singer, Sara J. Liu, Shan W. TI Boarding is associated with higher rates of medication delays and adverse events but fewer laboratory-related delays SO AMERICAN JOURNAL OF EMERGENCY MEDICINE LA English DT Article ID LENGTH-OF-STAY; EMERGENCY-DEPARTMENT; CARE; PNEUMONIA; PATIENT; SAFETY; UNIT; PAIN AB Background: Hospital crowding and emergency department (ED) boarding are large and growing problems. To date, there has been a paucity of information regarding the quality of care received by patients boarding in the ED compared with the care received by patients on an inpatient unit. We compared the rate of delays and adverse events at the event level that occur while boarding in the ED vs while on an inpatient unit. Methods: This study was a secondary analysis of data from medical record review and administrative databases at 2 urban academic teaching hospitals from August 1, 2004, through January 31, 2005. We measured delayed repeat cardiac enzymes, delayed partial thromboplastin time level checks, delayed antibiotic administration, delayed administration of home medications, and adverse events. We compared the incidence of events during ED boarding vs while on an inpatient unit. Results: Among 1431 patient medical records, we identified 1016 events. Emergency department boarding was associated with an increased risk of home medication delays (risk ratio [RR], 1.54; 95% confidence interval [CI], 1.26-1.88), delayed antibiotic administration (RR, 2.49; 95% CI, 1.72-3.52), and adverse events (RR, 2.36; 95% CI, 1.15-4.72). On the contrary, ED boarding was associated with fewer delays in repeat cardiac enzymes (RR, 0.17; 95% CI, 0.09-0.27) and delayed partial thromboplastin time checks (RR, 0.54; 95% CI, 0.27-0.96). Conclusion: Compared with inpatient units, ED boarding was associated with more medication-related delays and adverse events but fewer laboratory-related delays. Until we can eliminate ED boarding, it is critical to identify areas for improvement. (C) 2014 Elsevier Inc. All rights reserved. C1 [Sri-On, Jiraporn; Chang, Yuchiao; Curley, David P.; Camargo, Carlos A., Jr.; Liu, Shan W.] Massachusetts Gen Hosp, Emergency Dept, Boston, MA 02114 USA. [Weissman, Joel S.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Singer, Sara J.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. RP Liu, SW (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Zero Emerson,Suite 346, Boston, MA 02114 USA. EM sliu1@partners.org OI Sri-on, Jiraporn/0000-0002-8853-2567 NR 25 TC 4 Z9 4 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0735-6757 EI 1532-8171 J9 AM J EMERG MED JI Am. J. Emerg. Med. PD SEP PY 2014 VL 32 IS 9 BP 1033 EP 1036 DI 10.1016/j.ajem.2014.06.001 PG 4 WC Emergency Medicine SC Emergency Medicine GA AR1AY UT WOS:000343312600016 PM 25027202 ER PT J AU Louis, DN Gerber, GK Baron, JM Bry, L Dighe, AS Getz, G Higgins, JM Kuo, FC Lane, WJ Michaelson, JS Le, LP Mermel, CH Gilbertson, JR Golden, JA AF Louis, David N. Gerber, Georg K. Baron, Jason M. Bry, Lyn Dighe, Anand S. Getz, Gad Higgins, John M. Kuo, Frank C. Lane, William J. Michaelson, James S. Le, Long P. Mermel, Craig H. Gilbertson, John R. Golden, Jeffrey A. TI Computational Pathology An Emerging Definition SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Editorial Material C1 [Louis, David N.; Baron, Jason M.; Dighe, Anand S.; Getz, Gad; Higgins, John M.; Michaelson, James S.; Le, Long P.; Mermel, Craig H.; Gilbertson, John R.] Massachusetts Gen Hosp, Partners Program Computat Pathol, Boston, MA 02114 USA. [Louis, David N.; Baron, Jason M.; Dighe, Anand S.; Getz, Gad; Higgins, John M.; Michaelson, James S.; Le, Long P.; Mermel, Craig H.; Gilbertson, John R.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Gerber, Georg K.; Bry, Lyn; Kuo, Frank C.; Lane, William J.; Golden, Jeffrey A.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Louis, David N.; Gerber, Georg K.; Baron, Jason M.; Bry, Lyn; Dighe, Anand S.; Getz, Gad; Kuo, Frank C.; Lane, William J.; Michaelson, James S.; Le, Long P.; Mermel, Craig H.; Gilbertson, John R.; Golden, Jeffrey A.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Higgins, John M.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA. [Getz, Gad; Le, Long P.; Mermel, Craig H.] Broad Inst, Cambridge, MA USA. RP Golden, JA (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA. EM jagolden@partners.org NR 0 TC 12 Z9 12 U1 0 U2 2 PU COLL AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 EI 1543-2165 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD SEP PY 2014 VL 138 IS 9 BP 1133 EP 1138 DI 10.5858/arpa.2014-0034-ED PG 6 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA AR5PI UT WOS:000343635800002 PM 25171694 ER PT J AU Fischer, AH Schwartz, MR Moriarty, AT Wilbur, DC Souers, R Fatheree, L Booth, CN Clayton, AC Kurtyz, DFI Padmanabhan, V Crothers, BA AF Fischer, Andrew H. Schwartz, Mary R. Moriarty, Ann T. Wilbur, David C. Souers, Rhona Fatheree, Lisa Booth, Christine N. Clayton, Amy C. Kurtyz, Daniel F. I. Padmanabhan, Vijayalakshmi Crothers, Barbara A. TI Immunohistochemistry Practices of Cytopathology Laboratories A Survey of Participants in the College of American Pathologists Nongynecologic Cytopathology Education Program SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article ID TRANSFERRED CYTOLOGIC SPECIMENS; COMMONLY USED IMMUNOSTAINS; AUTOMATED CELL BLOCK; BREAST-CANCER; CLINICAL-ONCOLOGY/COLLEGE; GUIDELINE RECOMMENDATIONS; IMMUNOCYTOCHEMISTRY; VALIDATION; PROGESTERONE; ESTROGEN AB Context.-Immunohistochemistry (IHC) is important for cytology but poses special challenges because preanalytic conditions may differ from the conditions of IHC-positive controls. Objectives.-To broadly survey cytology laboratories to quantify preanalytic platforms for cytology IHC and identify problems with particular platforms or antigens. To discover how validation guidelines for HER2 testing have affected cytology. Design.-A voluntary survey of cytology IHC practices was sent to 1899 cytology laboratories participating in the College of American Pathologists Nongynecologic Cytopathology Education Program in the fall of 2009. Results.-A total of 818 laboratories (43%) responded to the survey by April 2010. Three hundred fourty-five of 791 respondents (44%) performed IHC on cytology specimens. Seventeen different fixation and processing platforms prior to antibody reaction were reported. A total of 59.2% of laboratories reported differences between the platforms for cytology specimens and positive controls, but most (155 of 184; 84%) did not alter antibody dilutions or antigen retrieval for cytology IHC. When asked to name 2 antibodies for which staining conditions differed between cytology and surgical samples, there were 18 responses listing 14 antibodies. A total of 30.6% of laboratories performing IHC offered HER2 testing before publication of the 2007 College of American Pathologists/American Society of Clinical Oncologists guidelines, compared with 33.6% afterward, with increased performance of testing by reference laboratories. Three laboratories validated a nonformalin HER2 platform. Conclusions.-The platforms for cytology IHC and positive controls differ for most laboratories, yet conditions are uncommonly adjusted for cytology specimens. Except for the unsuitability of air-dried smears for HER2 testing, the survey did not reveal evidence of systematic problems with any antibody or platform. C1 [Fischer, Andrew H.] Univ Massachusetts Mem Hlth Care, Dept Pathol, Worcester, MA 01605 USA. [Schwartz, Mary R.] Methodist Hosp, Dept Pathol & Genom Med, Houston, TX 77030 USA. [Moriarty, Ann T.] AmeriPath Indiana, Dept Pathol, Indianapolis, IN USA. [Wilbur, David C.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Souers, Rhona] Coll Amer Pathologists, Dept Stat Biostat, Northfield, IL USA. [Fatheree, Lisa] Coll Amer Pathologists, Dept Cytol Surveys, Northfield, IL USA. [Booth, Christine N.] Cleveland Clin Fdn, Dept Anat Pathol, Cleveland, OH 44195 USA. [Clayton, Amy C.] Mayo Clin, Dept Anat Pathol, Rochester, MN USA. [Kurtyz, Daniel F. I.] Wisconsin State Lab Hyg, Dept Cytol, Madison, WI USA. [Padmanabhan, Vijayalakshmi] Dartmouth Hitchcock Med Ctr, Dept Pathol, Lebanon, NH 03766 USA. [Crothers, Barbara A.] Walter Reed Army Med Ctr, Dept Pathol, Washington, DC 20307 USA. [Crothers, Barbara A.] Walter Reed Army Med Ctr, Area Lab Serv, Washington, DC 20307 USA. RP Fischer, AH (reprint author), Univ Massachusetts Mem Hlth Care, Dept Pathol, 1 Innovat Dr, Worcester, MA 01605 USA. EM Fischa01@ummhc.org OI Fischer, Andrew/0000-0002-5944-4621 FU Hologic, Inc FX Dr Fischer is an inventor of the Cellient Automated Cell Block System, licensed to Hologic, Inc, and he receives royalties for sales of this technology. The other authors have no relevant financial interest in the products or companies described in this article. NR 27 TC 5 Z9 6 U1 1 U2 3 PU COLL AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 EI 1543-2165 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD SEP PY 2014 VL 138 IS 9 BP 1167 EP 1172 DI 10.5858/arpa.2013-0259-CP PG 6 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA AR5PI UT WOS:000343635800007 PM 24840035 ER PT J AU Dummer, R Flaherty, K Kefford, R Ascierto, PA Moutouh-de Parseval, L Wasserman, E Schadendorf, D AF Dummer, R. Flaherty, K. Kefford, R. Ascierto, P. A. Moutouh-de Parseval, L. Wasserman, E. Schadendorf, D. TI The development of the BRAF inhibitor encorafenib (LGX818) and mitogen-activated protein kinase kinase inhibitor binimetinib (MEK162) in patients with metastatic melanoma SO BRITISH JOURNAL OF DERMATOLOGY LA English DT Meeting Abstract CT 15th World Congress on Cancers of the Skin CY SEP 03-06, 2014 CL Edinburgh, SCOTLAND C1 [Dummer, R.] Univ Zurich Hosp, CH-8091 Zurich, Switzerland. [Flaherty, K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kefford, R.] Univ Sydney, Melanoma Inst Australia, Westmead Inst Canc Res, Sydney, NSW 2006, Australia. [Kefford, R.] Univ Sydney, Westmead Hosp, Sydney, NSW 2006, Australia. [Ascierto, P. A.] Natl Canc Inst, Naples, Italy. [Moutouh-de Parseval, L.] Novartis Pharma AG, Basel, Switzerland. [Wasserman, E.] Novartis Pharmaceut, E Hanover, NJ USA. [Schadendorf, D.] Univ Hosp Essen, Essen, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-0963 EI 1365-2133 J9 BRIT J DERMATOL JI Br. J. Dermatol. PD SEP PY 2014 VL 171 IS 3 MA 150 BP E80 EP E80 PG 1 WC Dermatology SC Dermatology GA AS1AA UT WOS:000344006900151 ER PT J AU Kefford, R Hamid, O Robert, C Ribas, A Wolchock, JD Hodi, FS Joshua, AM Hwu, WJ Gangadhar, TC Patnaik, A Hersey, P Weber, J Joseph, R Gergich, K Li, X Chun, P Ebbinghaus, S Kang, SP Daud, A AF Kefford, R. Hamid, O. Robert, C. Ribas, A. Wolchock, J. D. Hodi, F. S. Joshua, A. M. Hwu, W. -J. Gangadhar, T. C. Patnaik, A. Hersey, P. Weber, J. Joseph, R. Gergich, K. Li, X. Chun, P. Ebbinghaus, S. Kang, S. P. Daud, A. TI Randomized comparison of two doses of the anti-programmed death-1 monoclonal antibody MK-3475 for ipilimumab (IPI)-refractory and IPI-naive melanoma SO BRITISH JOURNAL OF DERMATOLOGY LA English DT Meeting Abstract CT 15th World Congress on Cancers of the Skin CY SEP 03-06, 2014 CL Edinburgh, SCOTLAND C1 [Kefford, R.] Westmead Hosp, Sydney, NSW, Australia. [Kefford, R.] Melanoma Inst, Sydney, NSW, Australia. [Hamid, O.] Angeles Clin & Res Inst, Los Angeles, CA USA. [Robert, C.] Inst Gustave Roussy, Paris, France. [Ribas, A.] David Geffen UCLA Sch Med, Los Angeles, CA USA. [Wolchock, J. D.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Hodi, F. S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Joshua, A. M.] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada. [Hwu, W. -J.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Gangadhar, T. C.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Patnaik, A.] START, San Antonio, TX USA. [Hersey, P.] Univ Sydney, Sydney, NSW 2006, Australia. [Weber, J.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [Joseph, R.] Mayo Clin, Ctr Canc, Jacksonville, FL 32224 USA. [Gergich, K.; Li, X.; Chun, P.; Ebbinghaus, S.; Kang, S. P.] Merck Sharp & Dohme Corp, Whitehouse Stn, NJ USA. [Daud, A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-0963 EI 1365-2133 J9 BRIT J DERMATOL JI Br. J. Dermatol. PD SEP PY 2014 VL 171 IS 3 MA 097 BP E56 EP E56 PG 1 WC Dermatology SC Dermatology GA AS1AA UT WOS:000344006900098 ER PT J AU Holbrook, EH Iwema, CL Peluso, CE Schwob, JE AF Holbrook, Eric H. Iwema, Carrie L. Peluso, Carolyn E. Schwob, James E. TI The Regeneration of P2 Olfactory Sensory Neurons Is Selectively Impaired Following Methyl Bromide Lesion SO CHEMICAL SENSES LA English DT Article DE axonal regeneration; olfactory bulb; olfactory epithelium; olfactory receptor; olfactory sensory neuron; olfactotoxin ID ODORANT RECEPTOR EXPRESSION; GLOBOSE BASAL-CELLS; SYNAPSE FORMATION; TOPOGRAPHIC MAP; RE-INNERVATION; BULB; EPITHELIUM; MOUSE; SYSTEM; MICE AB The capacity of the peripheral olfactory system to recover after injury has not been thoroughly explored. P2-IRES-tauLacZ mice were exposed to methyl bromide, which causes epithelial damage and kills 90% of the P2 neurons. With subsequent neuronal regeneration, P2 neurons recover within their usual territory to equal control numbers by 1 month but then decline sharply to roughly 40% of control by 3 months. At this time, the P2 projection onto the olfactory bulb is erroneous in several respects. Instead of converging onto 1 or 2 glomeruli per surface, small collections of P2 axons innervate multiple glomeruli at roughly the same position in the bulb as in controls. Within these glomeruli, the P2 axons are aggregated near the edge, whereas the remainder of the glomerulus contains olfactory marker protein (+), non-P2 axons, violating the one receptor one glomerulus rule normally observed. The aggregates are denser than found in control P2-innervated glomeruli, suggesting that the P2 axons may not be synaptically connected. Based on published literature and other data, we hypothesize that P2 neurons lose out in an activity-based competition for synaptic territory within the glomeruli and are not maintained at control numbers due to a lack of trophic support from the bulb. C1 [Holbrook, Eric H.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA. [Holbrook, Eric H.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Holbrook, Eric H.; Schwob, James E.] Tufts Univ, Sch Med, Dept Dev Mol & Chem Biol, Boston, MA 02111 USA. [Iwema, Carrie L.; Schwob, James E.] SUNY Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA. [Iwema, Carrie L.; Schwob, James E.] SUNY Upstate Med Univ, Program Neurosci, Syracuse, NY 13210 USA. [Peluso, Carolyn E.] Tufts Univ, Sackler Sch Grad Biomed Sci, Program Cell Mol & Dev Biol, Boston, MA 02111 USA. RP Schwob, JE (reprint author), Tufts Univ, Sch Med, Dept Dev Mol & Chem Biol, 136 Harrison Ave, Boston, MA 02111 USA. EM jim.schwob@tufts.edu OI Iwema, Carrie/0000-0002-2750-305X FU National Institutes of Health [R01 DC000467, K08 DC008109] FX This work was supported by the National Institutes of Health [R01 DC000467 to J.E.S. and K08 DC008109 to E.H.H.]. NR 59 TC 3 Z9 3 U1 0 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0379-864X EI 1464-3553 J9 CHEM SENSES JI Chem. Senses PD SEP PY 2014 VL 39 IS 7 BP 601 EP 616 DI 10.1093/chemse/bju033 PG 16 WC Behavioral Sciences; Food Science & Technology; Neurosciences; Physiology SC Behavioral Sciences; Food Science & Technology; Neurosciences & Neurology; Physiology GA AR2JF UT WOS:000343409600005 PM 25056730 ER PT J AU Vina, ER Utset, TO Hannon, MJ Masi, CM Roberts, N Kwoh, CK AF Vina, E. R. Utset, T. O. Hannon, M. J. Masi, C. M. Roberts, N. Kwoh, C. K. TI Racial differences in treatment preferences among lupus patients: a two-site study SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY LA English DT Article DE systemic lupus erythematosus; cyclophosphamide; clinical trial; treatment preferences ID RANDOMIZED CONTROLLED-TRIALS; INVASIVE CARDIAC PROCEDURES; 3 ETHNIC-GROUPS; JOINT REPLACEMENT; AFRICAN-AMERICAN; DISEASE-ACTIVITY; ERYTHEMATOSUS; NEPHRITIS; HEALTH; RACE AB Objective To identify the demographic, clinical and psychosocial characteristics associated with racial differences in willingness to receive cyclophosphamide (CYC) or participate in a research clinical trial (RCT) among patients with systemic lupus erythematosus (SLE). Methods Data from 163 African-American (AA) and 180 white (WH) SLE patients were evaluated. Structured interviews and chart reviews were conducted to determine treatment preferences in hypothetical situations and identify variables that may affect preferences. Logistic regression models were performed to evaluate the relationship between patient preferences and race, adjusted for patient characteristics. Results Among patients who had never received CYC (n=293), 62.9% AAs compared to 87.6% WHs were willing to receive the medication (p<0.001). This difference persisted (OR 0.37 [95% CI, 0.16-0.87]) after adjusting for socio-demographics, clinical characteristics, and perceptions about CYC and physicians. Income and higher perception of CYC effectiveness, were other determinants of willingness to receive CYC. Among patients who had never participated in an RCT (n=326), 64.9% AAs compared to 84.3% WHs were willing to do so (p<0.001). This difference persisted (OR 0.41 [95% CI, 0.20-0.83]) after adjusting for socio-demographics, clinical context and patients' perceptions of physicians. SLE damage score, number of immunosuppressive medications and higher trust in physicians were also independently associated with willingness to participate in an RCT. Conclusion Race remains an independent determinant of treatment preferences after adjustment for income, medications, medication efficacy expectations and trust in physicians. While some factors related to racial differences in preferences are relatively fixed, others that may alleviate these differences also exist, including medication beliefs and provider trust. C1 [Vina, E. R.; Hannon, M. J.; Roberts, N.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Vina, E. R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Utset, T. O.; Masi, C. M.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA. [Masi, C. M.] North Shore Univ Hlth Syst, Evanston, IL USA. [Kwoh, C. K.] Univ Arizona, Sch Med, Tucson, AZ USA. RP Vina, ER (reprint author), Arthrit Res Ctr, 3347 Forbes Ave,Ste 220, Pittsburgh, PA 15213 USA. EM evina1@pitt.edu NR 39 TC 6 Z9 6 U1 1 U2 2 PU CLINICAL & EXPER RHEUMATOLOGY PI PISA PA VIA SANTA MARIA 31, 56126 PISA, ITALY SN 0392-856X J9 CLIN EXP RHEUMATOL JI Clin. Exp. Rheumatol. PD SEP-OCT PY 2014 VL 32 IS 5 BP 680 EP 688 PG 9 WC Rheumatology SC Rheumatology GA AR5OH UT WOS:000343633200010 PM 25084365 ER PT J AU Ghahramanlou-Holloway, M Brown, GK Currier, GW Brenner, L Knox, KL Grammer, G Carreno-Ponce, JT Stanley, B AF Ghahramanlou-Holloway, Marjan Brown, Gregory K. Currier, Glenn W. Brenner, Lisa Knox, Kerry L. Grammer, Geoffrey Carreno-Ponce, Jaime T. Stanley, Barbara TI Safety Planning for Military (SAFE MIL): Rationale, design, and safety considerations of a randomized controlled trial to reduce suicide risk among psychiatric inpatients SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Suicide; Prevention; Safety Planning Intervention; Military; Inpatient psychiatry; Randomized controlled trial ID NEUROPSYCHIATRIC INTERVIEW MINI; PREVENTION; VALIDITY; SCALE; INDEX; HELP AB Mental health related hospitalizations and suicide are both significant public health problems within the United States Department of Defense (DoD). To date, few evidence-based suicide prevention programs have been developed for delivery to military personnel and family members admitted for psychiatric inpatient care due to suicidal self-directed violence. This paper describes the rationale and detailed methodology for a study called Safety Planning for Military (SAFE MIL) which involves a randomized controlled trial (RCT) at the largest military treatment facility in the United States. The purpose of this study is to test the efficacy of a brief, readily accessible, and personalized treatment called the Safety Planning Intervention (Stanley and Brown, 2012). Primary outcomes, measured by blinded assessors at one and six months following psychiatric discharge, include suicide ideation, suicide-related coping, and attitudes toward help seeking. Additionally, given the study's focus on a highly vulnerable patient population, a description of safety considerations for human subjects' participation is provided. Based on this research team's experience, the implementation of an infrastructure in support of RCT research within DoD settings and the processing of regulatory approvals for a clinical trial with high risk suicidal patients are expected to take up to 18-24 months. Recommendations for expediting the advancement of clinical trials research within the DoD are provided in order to maximize cost efficacy and minimize the research to practice gap. Published by Elsevier Inc. C1 [Ghahramanlou-Holloway, Marjan; Carreno-Ponce, Jaime T.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Med & Clin Psychol, Bethesda, MD 20814 USA. [Ghahramanlou-Holloway, Marjan; Carreno-Ponce, Jaime T.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Psychiat, Bethesda, MD 20814 USA. [Brown, Gregory K.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Brown, Gregory K.] Philadelphia VA Med Ctr, MIRECC, VISN 4, Philadelphia, PA USA. [Brown, Gregory K.] Dept Vet Affairs, Philadelphia, PA USA. [Currier, Glenn W.; Knox, Kerry L.] VA Ctr Excellence, Canandaigua, NY USA. [Currier, Glenn W.; Knox, Kerry L.] Univ Rochester, Rochester, NY 14627 USA. [Brenner, Lisa] Denver VA Med Ctr, MIRECC, VISN 19, Dept Vet Affairs, Denver, CO USA. [Grammer, Geoffrey] Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, Bethesda, MD USA. [Stanley, Barbara] Columbia Univ, Dept Psychiat, New York, NY USA. [Stanley, Barbara] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. RP Ghahramanlou-Holloway, M (reprint author), Uniformed Serv Univ Hlth Sci, Dept Med & Clin Psychol, 4301 Jones Bridge Rd,Room 3050, Bethesda, MD 20814 USA. EM marjan.holloway@usuhs.edu FU WRNMMC Department of Psychiatry; Colonel both of the United States Army FX We would like to acknowledge the contributions of the research staff who have contributed to the implementation of this study: Kacie Armstrong, Dr. Elisabeth Carlin, Dr. John Dennis, Kathryn DeYoung, Kristen Kochanski, Kari Koss, Dr. Laura Neely, Kyna Pak, Kanchana Perera, Lauren Pierce, Graham Sterling, Christina Yang, and Marcus VanSicIde. In particular, Robert Wheeler's assistance as the study IRB Coordinator and Katheryn Ryan's persistence as a follow-up assessor have been invaluable. The support offered by various members of the MOMRP (in particular Dr. Katharine Nassaeur) and the leadership of Carl Castro, Ph.D., United States Army Colonel (Retired) have been instrumental. The guidance provided by the members of the USUHS and WRNMMC IRBs and the HRPO (in particular by Dr. Karen Eaton, Mary Kelleher, Denise Neath, and LTC Molly Klote) has maximized the safety of human subjects in this research and minimized lengthy IRB reviews. Finally, we would also like to acknowledge the institutional support received from the WRNMMC Department of Psychiatry through the leadership of John Bradley, M.D., Colonel (Retired) and Brett Schneider, M.D., Colonel both of the United States Army. NR 29 TC 3 Z9 4 U1 1 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 EI 1559-2030 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD SEP PY 2014 VL 39 IS 1 BP 113 EP 123 DI 10.1016/j.cct.2014.07.003 PG 11 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA AR5JB UT WOS:000343620100014 PM 25020008 ER PT J AU Laurance, J Henderson, S Howitt, PJ Matar, M Al Kuwari, H Edgman-Levitan, S Darzi, A AF Laurance, Jeremy Henderson, Sarah Howitt, Peter J. Matar, Mariam Al Kuwari, Hanan Edgman-Levitan, Susan Darzi, Ara TI Patient Engagement: Four Case Studies That Highlight The Potential For Improved Health Outcomes And Reduced Costs SO HEALTH AFFAIRS LA English DT Article ID SAFETY AB The energy of patients and members of the public worldwide who care about improving health is a huge, but still largely unrecognized and untapped, resource. The aim of patient engagement is to shift the clinical paradigm from determining "what is the matter?" to discovering "what matters to you?" This article presents four case studies from around the world that highlight the proven and potential abilities of increased patient engagement to improve health outcomes and reduce costs, while extending the reach of treatment and diagnostic programs into the community. The cases are an online mental health community in the United Kingdom, a genetic screening program in the United Arab Emirates, a World Health Organization checklist for new mothers, and a hospital-based patient engagement initiative in the United States. Evidence from these and similar endeavors suggests that closer collaboration on the part of patients, families, health care providers, health care systems, and policy makers at multiple levels could help diverse nations provide more effective and population-appropriate health care with fewer resources. C1 [Laurance, Jeremy; Henderson, Sarah; Howitt, Peter J.] Univ London Imperial Coll Sci Technol & Med, Ctr Hlth Policy, Inst Global Hlth Innovat, London SW7 2AZ, England. [Henderson, Sarah; Howitt, Peter J.; Edgman-Levitan, Susan; Darzi, Ara] Qatar Fdn, World Innovat Summit Hlth, Doha, Qatar. [Matar, Mariam] United Arab Emirates Genet Dis Assoc, Dubai, U Arab Emirates. [Al Kuwari, Hanan] Hamad Med Corp, Doha, Qatar. [Edgman-Levitan, Susan] Massachusetts Gen Hosp, John D Stoeckle Ctr Primary Care Innovat, Boston, MA 02114 USA. [Darzi, Ara] Univ London Imperial Coll Sci Technol & Med, Inst Global Hlth Innovat, London SW7 2AZ, England. RP Laurance, J (reprint author), Univ London Imperial Coll Sci Technol & Med, Ctr Hlth Policy, Inst Global Hlth Innovat, London SW7 2AZ, England. EM j.laurance@imperial.ac.uk FU Qatar Foundation FX Some of the material in this article was previously presented at the World Innovation Summit for Health, an initiative of Qatar Foundation, in Doha, Qatar, December 11, 2013. The authors acknowledge Qatar Foundation for funding the research in this article. Mariam Matar is the founder and chairperson of the United Arab Emirates Genetic Diseases Association. The authors thank Nicky Runeckles (Big White Wall), Shams Syed (World Health Organization), and Kathleen Murray (Beth Israel Deaconess Medical Center). NR 27 TC 14 Z9 14 U1 0 U2 12 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD SEP PY 2014 VL 33 IS 9 BP 1627 EP 1634 DI 10.1377/hlthaff.2014.0375 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA AR2GK UT WOS:000343401600017 PM 25201668 ER PT J AU Hebert, PL Liu, CF Conrad, DA AF Hebert, Paul L. Liu, Chuan-Fen Conrad, Douglas A. TI Cost Savings: The Authors Reply SO HEALTH AFFAIRS LA English DT Letter C1 [Hebert, Paul L.; Liu, Chuan-Fen] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Conrad, Douglas A.] Univ Washington, Seattle, WA 98195 USA. RP Hebert, PL (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. NR 1 TC 0 Z9 0 U1 0 U2 2 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD SEP PY 2014 VL 33 IS 9 DI 10.1377/hlthaff.2014.0807 PG 1 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA AR2GK UT WOS:000343401600030 PM 25201677 ER PT J AU Ross, E Tanser, F Pei, P Newell, ML Losina, E Thiebaut, R Weinstein, M Freedberg, K Anglaret, X Scott, C Dabis, F Walensky, R AF Ross, Eric Tanser, Frank Pei, Pamela Newell, Marie-Louise Losina, Elena Thiebaut, Rodolphe Weinstein, Milton Freedberg, Kenneth Anglaret, Xavier Scott, Callie Dabis, Francois Walensky, Rochelle TI The Impact of the 2013 WHO Antiretroviral Therapy Guidelines on the Feasibility of HIV Population Prevention Trials SO HIV CLINICAL TRIALS LA English DT Article DE highly active antiretro viral therapy; HIV; prevention; randomized controlled trials ID SOUTH-AFRICA; COTE-DIVOIRE; COST-EFFECTIVENESS; RANDOMIZED-TRIAL; SCALE-UP; INFECTION; TRANSMISSION; PROGRAM; DECLINE; COHORT AB Background: Several cluster-randomized HIV prevention trials aim to demonstrate the population-level preventive impact of antiretroviral therapy (ART). 2013 World Health Organization (WHO) guidelines raising the ART initiation threshold to CD4 <500/mu L could attenuate these trials' effect size by increasing ART usage in control clusters. Methods: We used a computational model to simulate strategies from a hypothetical cluster-randomized HIV prevention trial. The primary model outcome was the relative reduction in 24-month HIV incidence between control (ART offered with CD4 below threshold) and intervention (ART offered to all) strategies. We assessed this incidence reduction using the revised (CD4 <500/mu L) and prior (CD4 <350/mu L) control ART initiation thresholds. Additionally, we evaluated changes to trial characteristics that could bolster the incidence reduction. Results: With a control ART initiation threshold of CD4 <350/mu L, 24-month HIV incidence under control and intervention strategies was 2.46/100 person-years (PY) and 1.96/100 PY, a 21% reduction. Raising the threshold to CD4 <500/mu L decreased the incidence reduction by more than one-third, to 12%. Using this higher threshold, moving to a 36-month horizon (vs 24-month), yearly control-strategy HIV screening (vs biannual), and intervention-strategy screening every 2 months (vs biannual), resulted in a 31% incidence reduction that was similar to effect size projections for ongoing trials. Alternate assumptions regarding cross-cluster contamination had the greatest influence on the incidence reduction. Conclusions: Implementing the 2013 WHO HIV treatment threshold could substantially diminish the incidence reduction in HIV population prevention trials. Alternative HIV testing frequencies and trial horizons can bolster this incidence reduction, but they could be logistically and ethically challenging. The feasibility of HIV population prevention trials should be reassessed as the implementation of treatment guidelines evolves. C1 [Ross, Eric; Pei, Pamela; Losina, Elena; Freedberg, Kenneth; Scott, Callie; Walensky, Rochelle] Massachusetts Gen Hosp, Dept Gen Med, Med Practice Evaluat Ctr, Boston, MA 02114 USA. [Tanser, Frank] Univ KwaZulu Natal, Africa Ctr Hlth & Populat Studies, Durban, South Africa. [Newell, Marie-Louise] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England. [Newell, Marie-Louise] Univ Southampton, Fac Social & Human Sci, Southampton, Hants, England. [Losina, Elena] Brigham & Womens Hosp, Dept Orthoped, Boston, MA 02115 USA. [Losina, Elena; Freedberg, Kenneth; Walensky, Rochelle] Harvard Univ, Ctr AIDS Res, Cambridge, MA 02138 USA. [Losina, Elena; Freedberg, Kenneth; Walensky, Rochelle] Harvard Univ, Sch Med, Boston, MA USA. [Thiebaut, Rodolphe; Anglaret, Xavier; Dabis, Francois] Ctr INSERM U897 Epidemiol & Biostat, Bordeaux, France. [Thiebaut, Rodolphe; Anglaret, Xavier; Dabis, Francois] Univ Bordeaux 2, ISPED, F-33076 Bordeaux, France. [Weinstein, Milton; Freedberg, Kenneth] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Weinstein, Milton] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Freedberg, Kenneth; Walensky, Rochelle] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Anglaret, Xavier; Dabis, Francois] Programme PAC CI ANRS, Abidjan, Cote Ivoire. [Dabis, Francois] Univ Bordeaux 2, INSERM, F-33076 Bordeaux, France. RP Walensky, R (reprint author), Massachusetts Gen Hosp, Div Infect Dis, 50 Staniford St,9th Floor, Boston, MA 02114 USA. EM rwalensky@mgh.harvard.edu RI Anglaret, Xavier/F-7333-2013; OI Newell, Marie-Louise/0000-0002-1074-7699 FU Agence Nationale de Recherches sur le SIDA et les hepatites virales [ANRS 12136, ANRS 12212]; National Institute of Allergy and Infectious Diseases (NIAID) [R01 AI058736, R01 AI093269, R01 HD058482, UM1 AI068636] FX This research was supported by Agence Nationale de Recherches sur le SIDA et les hepatites virales (ANRS 12136, ANRS 12212) and National Institute of Allergy and Infectious Diseases (NIAID, R01 AI058736, R01 AI093269, R01 HD058482, and UM1 AI068636). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Dr. Pei reports personal fees from United BioSource Corporation, outside the submitted work. Dr. Weinstein reports personal fees from OptumInsight, outside the submitted work. NR 60 TC 1 Z9 1 U1 1 U2 7 PU THOMAS LAND PUBLISHERS, INC PI ST LOUIS PA 255 JEFFERSON RD, ST LOUIS, MO 63119-3627 USA SN 1528-4336 EI 1945-5771 J9 HIV CLIN TRIALS JI HIV Clin. Trials PD SEP-OCT PY 2014 VL 15 IS 5 BP 185 EP 198 DI 10.1310/hct1505-185 PG 14 WC Infectious Diseases; Pharmacology & Pharmacy SC Infectious Diseases; Pharmacology & Pharmacy GA AR5NC UT WOS:000343630200001 PM 25350957 ER PT J AU Changela, A Changela, K Javaiya, H Changela, D Lee, S Guevara, E AF Changela, Avani Changela, Kinesh Javaiya, Hemangkumar Changela, Dipali Lee, Sarah Guevara, Elizabeth TI Acute Cholecystitis in Thrombotic Thrombocytopenic Purpura SO INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION LA English DT Article C1 [Changela, Avani; Changela, Kinesh; Changela, Dipali; Lee, Sarah; Guevara, Elizabeth] Brooklyn Hosp Ctr, Brooklyn, NY 11201 USA. [Javaiya, Hemangkumar] James J Peters VA Med Ctr, New York, NY USA. RP Changela, K (reprint author), Brooklyn Hosp Ctr, 121 Dekalb Ave, Brooklyn, NY 11201 USA. EM kinooo2002@gmail.com NR 5 TC 0 Z9 0 U1 0 U2 3 PU SPRINGER INDIA PI NEW DELHI PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA SN 0971-4502 EI 0974-0449 J9 INDIAN J HEMATOL BLO JI Indian J. Hematol. Blood Transfus. PD SEP PY 2014 VL 30 SU 1 BP S286 EP S287 DI 10.1007/s12288-014-0361-9 PG 2 WC Hematology SC Hematology GA AR6XL UT WOS:000343724300081 ER PT J AU Greene, MC Kelly, JF AF Greene, M. Claire Kelly, John F. TI The Prevalence of Cannabis Withdrawal and Its Influence on Adolescents' Treatment Response and Outcomes: A 12-Month Prospective Investigation SO JOURNAL OF ADDICTION MEDICINE LA English DT Article DE addiction; adolescent; cannabis; marijuana; substance use disorder; withdrawal ID DIAGNOSTIC INTERVIEW SCHEDULE; MARIJUANA WITHDRAWAL; DEPENDENCE SYMPTOMS; ABUSE; VALIDITY; ALCOHOL; SENSITIVITY; INVOLVEMENT; INVENTORY; SEVERITY AB Background: Withdrawal, a diagnostic indicator of cannabis use disorder, is often minimized or ignored as a consequence of cannabis use, particularly among adolescents. This study aims to characterize cannabis withdrawal among adolescents in outpatient treatment for substance use disorder and evaluate the clinical significance of withdrawal as a predictor of substance-related outcomes. Methods: Adolescent outpatients (N = 127) reporting cannabis as their drug of choice (n = 90) were stratified by the presence of withdrawal and compared on demographic and clinical variables at treatment intake. Hierarchical linear models compared the effect of withdrawal on percentage days abstinent (PDA) and related outcomes over a 1-year follow-up period. Results: Adolescents reporting withdrawal (40%) were more likely to meet criteria for cannabis dependence, have higher levels of substance use severity, report more substance-related consequences, and have a mood disorder. Withdrawal was not associated with PDA over the follow-up period; however, this relationship was moderated by problem recognition such that adolescents reporting withdrawal and a drug problem improved at a greater rate with respect to PDA than those who did not recognize a problem with drugs and did not report withdrawal. Discussion: Withdrawal is common among adolescent outpatients and is associated with a more clinically severe profile. In this sample, all adolescents reporting withdrawal met criteria for cannabis dependence, suggesting that withdrawal is a highly specific indicator of cannabis use disorder. Although withdrawal does not seem to be independently associated with substance use outcomes posttreatment, moderating factors such as drug problem recognition should be taken into account when formulating treatment and continuing care plans. C1 [Greene, M. Claire; Kelly, John F.] Massachusetts Gen Hosp, Dept Psychiat, Ctr Addict Med, Boston, MA 02114 USA. [Greene, M. Claire] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Greene, MC (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Ctr Addict Med, 60 Staniford St, Boston, MA 02114 USA. EM mgree116@jhu.edu FU National Institute of Alcohol Abuse and Alcoholism (NIAAA) [R01AA015526] FX This research was funded by the National Institute of Alcohol Abuse and Alcoholism (NIAAA; R01AA015526). NR 40 TC 5 Z9 5 U1 2 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD SEP-OCT PY 2014 VL 8 IS 5 BP 359 EP 367 DI 10.1097/ADM.0000000000000064 PG 9 WC Substance Abuse SC Substance Abuse GA AR2MI UT WOS:000343421100009 PM 25100311 ER PT J AU Ahmed, M Bursztajn, HJ Abramson, R Nisenbaum, S AF Ahmed, Mohiuddin Bursztajn, Harold J. Abramson, Ronald Nisenbaum, Steven TI An alternative name for schizophrenia SO LANCET PSYCHIATRY LA English DT Letter C1 [Ahmed, Mohiuddin] NRI Community Serv, Woonsocket, RI 02895 USA. [Ahmed, Mohiuddin] Rhode Isl Coll, Providence, RI 02908 USA. [Bursztajn, Harold J.] Harvard Univ, Sch Med, BIDMC MMHC, Cambridge, MA 02138 USA. [Abramson, Ronald] New England Chapter Int Soc Psychol & Social Appr, Wayland, MA USA. [Nisenbaum, Steven] Harvard Univ, Med Sch Psychiat, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. RP Ahmed, M (reprint author), NRI Community Serv, Woonsocket, RI 02895 USA. EM ahmedmohiuddin1@live.com NR 1 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2215-0374 J9 LANCET PSYCHIAT JI Lancet Psychiatry PD SEP PY 2014 VL 1 IS 4 BP E5 EP E5 PG 1 WC Psychiatry SC Psychiatry GA AR6OW UT WOS:000343703800003 PM 26360867 ER PT J AU Deckersbach, T Das, SK Urban, LE Salinardi, T Batra, P Rodman, AM Arulpragasam, AR Dougherty, DD Roberts, SB AF Deckersbach, T. Das, S. K. Urban, L. E. Salinardi, T. Batra, P. Rodman, A. M. Arulpragasam, A. R. Dougherty, D. D. Roberts, S. B. TI Pilot randomized trial demonstrating reversal of obesity-related abnormalities in reward system responsivity to food cues with a behavioral intervention SO NUTRITION & DIABETES LA English DT Article ID WEIGHT-LOSS; BRAIN; ACTIVATION; ADDICTION; DOPAMINE; CRAVINGS; HUNGER AB OBJECTIVES: Obesity is associated with hyperactivation of the reward system for high-calorie (HC) versus low-calorie (LC) food cues, which encourages unhealthy food selection and overeating. However, the extent to which this hyperactivation can be reversed is uncertain, and to date there has been no demonstration of changes by behavioral intervention. SUBJECTS AND METHODS: We used functional magnetic resonance imaging to measure changes in activation of the striatum for food images at baseline and 6 months in a pilot study of 13 overweight or obese adults randomized to a control group or a novel weight-loss intervention. RESULTS: Compared to controls, intervention participants achieved significant weight loss (-6.3 +/- 1.0 kg versus +2.1 +/- 1.1 kg, P < 0.001) and had increased activation for LC food images with a composition consistent with that recommended in the behavioral intervention at 6 months versus baseline in the right ventral putamen (P = 0.04), decreased activation for HC images of typically consumed foods in the left dorsal putamen (P = 0.01). There was also a large significant shift in relative activation favoring LC versus HC foods in both regions (P < 0.04). CONCLUSIONS: This study provides the first demonstration of a positive shift in activation of the reward system toward healthy versus unhealthy food cues in a behavioral intervention, suggesting new avenues to enhance behavioral treatments of obesity. C1 [Deckersbach, T.; Rodman, A. M.; Arulpragasam, A. R.; Dougherty, D. D.] Harvard Univ, Sch Med, Dept Psychiat, Div Neurotherapeut, Boston, MA 02115 USA. [Das, S. K.; Urban, L. E.; Salinardi, T.; Batra, P.; Roberts, S. B.] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Energy Metab & Obes Lab, Boston, MA 02111 USA. RP Deckersbach, T (reprint author), Massachusetts Gen Hosp, Div Neurotherapeut, Dept Psychiat, 73 High St Charlestown, Boston, MA 02129 USA. EM Deckersbach.Thilo@mgh.harvard.edu; Susan.Roberts@tufts.edu FU US Department of Agriculture [58-1950-0-0014]; Tufts University; pilot grant from the Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University FX We thank Lesley Fisher, Madeline Gould and Molly Schleicher for help in preparing MRIs, Jennifer Felsted for commenting on the manuscript, and Joan Guilfoyle and J Phillip Karl for assisting with subjects. This work was supported by the US Department of Agriculture agreement no. 58-1950-0-0014 with Tufts University and a pilot grant from the Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University. NR 32 TC 9 Z9 9 U1 1 U2 10 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2044-4052 J9 NUTR DIABETES JI Nutr. Diabetes PD SEP PY 2014 VL 4 AR e129 DI 10.1038/nutd.2014.26 PG 7 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA AR3YR UT WOS:000343525700001 PM 25177910 ER PT J AU Sabini, RC Nutini, DN Nutini, M AF Sabini, Rosanna C. Nutini, Dennis N. Nutini, Marykatharine TI Return-to-Play Guidelines in Concussion: Revisiting the Literature SO PHYSICIAN AND SPORTSMEDICINE LA English DT Article DE baseline functional status; concussion; concussion management; return-to-play guidelines ID SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC MIGRAINE CHARACTERISTICS; SCHOOL FOOTBALL PLAYERS; BASE-LINE; NEUROCOGNITIVE PERFORMANCE; RECURRENT CONCUSSION; SEX-DIFFERENCES; INTERNATIONAL-CONFERENCE; PROFESSIONAL FOOTBALL AB Return-to-play (RTP) guidelines in concussion management and treatment continue to challenge clinicians, despite recent updates to the protocols and the ongoing media attention. The current guidelines address individualized treatment planning but are difficult to apply to athletes who experience prolonged symptoms, are younger, or have sustained multiple concussions. Recent literature findings have contributed to an improved understanding and applicability of the guidelines while emphasizing a multidisciplinary paradigm in formulating an individualized RTP decision. Successful implementation of the RTP guidelines will ensure that athletes are protected from further injury and return to their baseline functional status. C1 [Sabini, Rosanna C.] Southside Hosp North Shore LIJ, Dept Phys Med & Rehabil, Bay Shore, NY 11706 USA. [Nutini, Dennis N.; Nutini, Marykatharine] Spaulding Rehabil Hosp, Boston, MA USA. [Nutini, Dennis N.; Nutini, Marykatharine] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nutini, Dennis N.; Nutini, Marykatharine] Harvard Univ, Sch Med, Boston, MA USA. RP Sabini, RC (reprint author), Southside Hosp North Shore LIJ, 301 East Main St, Bay Shore, NY 11706 USA. EM drsabini@gmail.com NR 93 TC 0 Z9 0 U1 2 U2 14 PU JTE MULTIMEDIA PI WEST CONSHOHOCKEN PA 18 ELIZABETH ST, STE 110, WEST CONSHOHOCKEN, PA 19428 USA SN 0091-3847 J9 PHYSICIAN SPORTSMED JI Physician Sportsmed. PD SEP PY 2014 VL 42 IS 3 BP 10 EP 19 DI 10.3810/psm.2014.09.2070 PG 10 WC Primary Health Care; Orthopedics; Sport Sciences SC General & Internal Medicine; Orthopedics; Sport Sciences GA AR2FQ UT WOS:000343399400001 PM 25295761 ER PT J AU Provencher, MT Frank, RM Scuderi, MG Solomon, DJ Ghodadra, NS Bach, BR McCarty, E Romeo, AA AF Provencher, Matthew T. Frank, Rachel M. Scuderi, Matthew G. Solomon, Daniel J. Ghodadra, Neil S. Bach, Bernard R., Jr. McCarty, Eric Romeo, Anthony A. TI General and Disease-Specific Use of Outcomes Scores for the Shoulder: A Survey of AOSSM, AANA, and ISAKOS Members SO PHYSICIAN AND SPORTSMEDICINE LA English DT Article DE shoulder; outcomes scores; ASES; UCLA; Constant score ID ROTATOR CUFF DISEASE; CROSS-CULTURAL ADAPTATION; LIFE MEASUREMENT TOOL; 36-ITEM SHORT-FORM; AMERICAN-SHOULDER; SCORING SYSTEMS; FUNCTIONAL ASSESSMENT; RESPONSE RATES; HEALTH-STATUS; E-MAIL AB Objective: To report on the knowledge and use of both general and disease-specific shoulder outcomes scores among orthopedic surgeons. Methods: A 22-question Internet survey was administered to members of the American Orthopaedic Society for Sports Medicine, the Arthroscopy Association of North American, and the International Society of Arthroscopy, Knee Surgery, and Orthopedic Sports Medicine via voluntary e-mail participation. Questions targeted demographic information, preferred surgical management of shoulder conditions, and the preferred use of shoulder outcomes instruments in clinical practice. Results: Excluding defunct and duplicate e-mails among membership societies, a total of 3892 unique e-mails were sent, from which 1129 surveys were returned and were fully completed (29%). The largest number of respondents were in private practice (52%); 21% were in academia; and 26% were in a mix of settings. As for location, 74% practiced in the United States, 10% in Europe, 8% in Mexico/South America, and 6% in Asia. A total of 31% total respondents used scores all or most of the time, and 30% used scores at least some of the time. Respondents felt that the 3 most commonly utilized shoulder scores were the American Shoulder and Elbow Surgeons (ASES) score, the University of California at Los Angeles (UCLA) score, and the Constant score. The majority of respondents (76%) performed all-arthroscopic instability repairs. The ASES and Western Ontario Shoulder Instability Index (WOSI) scores were the most preferred measures to monitor instability patients, whether or not the scores were actually implemented in their practice. Most perform between 10 and 25 superior labrum anterior-posterior repairs per year and preferred the ASES, UCLA, and Constant scores for these repairs; rotator cuff repair preferred outcomes instruments were similar. When asked to choose 1 score for all shoulder conditions, the ASES was the clear favorite. Conclusions: This study reports the knowledge and utilization of shoulder scores for both general and disease-specific conditions. Most respondents preferred the ASES score for most shoulder conditions; however, other scores, such as the WOSI, the Constant, and the Short-Form (SF)-36/12, were popular. This information offers insight into the current and future use of shoulder outcomes both for general and disease-specific use. C1 [Provencher, Matthew T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg,Sports Med Serv, Boston, MA USA. [Frank, Rachel M.; Ghodadra, Neil S.; Bach, Bernard R., Jr.; Romeo, Anthony A.] Rush Univ, Med Ctr, Dept Orthopaed Surg, Chicago, IL 60612 USA. [Scuderi, Matthew G.] Upstate Univ, Med Ctr, Dept Orthopaed Surg, East Syracuse, NY USA. [Solomon, Daniel J.] Naval Med Ctr, Dept Orthopaed Surg, San Diego, CA USA. [McCarty, Eric] Univ Colorado, Dept Orthopaed Surg, Denver, CO 80202 USA. RP Provencher, MT (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, 175 Cambridge St,4th Floor, Boston, MA 02114 USA. OI Romeo, Anthony/0000-0003-4848-3411 NR 61 TC 2 Z9 2 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0091-3847 EI 2326-3660 J9 PHYSICIAN SPORTSMED JI Physician Sportsmed. PD SEP PY 2014 VL 42 IS 3 BP 120 EP 130 DI 10.3810/psm.2014.09.2083 PG 11 WC Primary Health Care; Orthopedics; Sport Sciences SC General & Internal Medicine; Orthopedics; Sport Sciences GA AR2FQ UT WOS:000343399400014 PM 25295774 ER PT J AU Bernstein, EJ Isakova, T Sullivan, ME Chibnik, LB Wolf, M Kay, J AF Bernstein, Elana J. Isakova, Tamara Sullivan, Mary E. Chibnik, Lori B. Wolf, Myles Kay, Jonathan TI Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study SO RHEUMATOLOGY LA English DT Article DE nephrogenic systemic fibrosis; gadolinium; phosphorus; fibroblast growth factor 23; magnetic resonance imaging; chronic kidney disease; dialysis ID GADOLINIUM; HEMODIALYSIS; DISEASE; FGF-23 AB Objective. Nephrogenic systemic fibrosis (NSF) is an iatrogenic fibrosing disorder that primarily affects individuals with chronic kidney disease (CKD) following exposure to gadolinium-based contrast agents (GBCAs). Derangements of calcium and phosphorus have been reported in patients with NSF. The aim of this study was to investigate potential factors in addition to GBCA exposure that may be involved in the pathogenesis of NSF. We hypothesized that patients with stage 5 CKD and NSF would manifest greater alterations in calcium, phosphorus and fibroblast growth factor 23 (FGF23) levels than those who do not have NSF. Methods. Levels of phosphorus, calcium, FGF23 and 25-hydroxy-vitamin D were measured in 10 patients with stage 5 CKD and biopsy-proven NSF and in 19 patients with stage 5 CKD without NSF. Statistical analyses were performed using Fisher's exact test for categorical variables and the Kruskal-Wallis test for continuous variables. Results. Patients with NSF had significantly lower phosphorus levels compared with controls (P = 0.01). There were no significant differences between NSF patients and controls in calcium, 25-hydroxy-vitamin D, intact parathyroid hormone or FGF23 levels. Conclusion. Differences in phosphorus metabolism may exist between patients with stage 5 CKD and NSF compared with patients with stage 5 CKD without NSF. C1 [Bernstein, Elana J.] Columbia Univ Coll Phys & Surg, Dept Med, Div Rheumatol, New York, NY 10032 USA. [Isakova, Tamara; Wolf, Myles] Northwestern Univ, Div Nephrol, Feinberg Sch Med, Chicago, IL 60611 USA. [Sullivan, Mary E.] Massachusetts Gen Hosp, MGH Clin Res Ctr, Boston, MA 02114 USA. [Chibnik, Lori B.] Harvard Univ, Sch Med, Dept Neurol, Program Neuropsychiat Genom,Brigham & Womens Hosp, Boston, MA 02115 USA. [Kay, Jonathan] Univ Massachusetts, Sch Med, Dept Med, Div Rheumatol, Worcester, MA USA. [Kay, Jonathan] UMass Mem Med Ctr, Worcester, MA USA. RP Bernstein, EJ (reprint author), Columbia Univ Coll Phys & Surg, Dept Med, Div Rheumatol, 630 West 168th St,Suite 10-445, New York, NY 10032 USA. EM ejb2153@columbia.edu FU Harvard Clinical and Translational Science Center (National Center for Research Resources, National Institutes of Health) [1UL1RR025758-04]; Arthritis Foundation Clinical to Research Transition Award; National Institutes of Health [KL2TR000458] FX This work was supported by the Harvard Clinical and Translational Science Center (National Center for Research Resources, National Institutes of Health Award 1UL1RR025758-04). The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University and its affiliated academic health care centres or the National Institutes of Health. E.J.B.'s work was supported by an Arthritis Foundation Clinical to Research Transition Award and the National Institutes of Health (grant KL2TR000458). NR 13 TC 4 Z9 4 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-0324 EI 1462-0332 J9 RHEUMATOLOGY JI RHEUMATOLOGY PD SEP PY 2014 VL 53 IS 9 BP 1613 EP 1617 DI 10.1093/rheumatology/keu151 PG 5 WC Rheumatology SC Rheumatology GA AR2MS UT WOS:000343422200012 PM 24706993 ER PT J AU Cardoso, SW Luz, PM Velasque, L Torres, T Coelho, L Freedberg, KA Veloso, VG Walensky, RP Grinsztejn, B AF Cardoso, Sandra W. Luz, Paula M. Velasque, Luciane Torres, Thiago Coelho, Lara Freedberg, Kenneth A. Veloso, Valdilea G. Walensky, Rochelle P. Grinsztejn, Beatriz TI Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil SO AIDS RESEARCH AND THERAPY LA English DT Article DE HIV/AIDS; Antiretroviral treatment; Effectiveness; Cohort study; Rio de Janeiro; Brazil ID HIV-INFECTED PATIENTS; AIDS PATIENTS; SOUTH-AFRICA; HIV-1-INFECTED PATIENTS; CLINICAL-RESPONSE; INITIAL TREATMENT; HAART REGIMEN; OUTCOMES; EFFICACY; PREDICTORS AB Background: While Brazil has had a long-standing policy of free access to antiretroviral therapy (ART) for all in need, the epidemiological impact of ART on human immunodeficiency virus (HIV) RNA suppression in this middle-income country has not been well evaluated. We estimate first-line ART effectiveness in a large Brazilian cohort and examine the socio-demographic, behavioral, clinical and structural factors associated with virologic suppression. Methods: Virologic suppression on first-line ART at 6, 12, and 24 months from start of ART was defined as having a viral load measurement <= 400 copies/mL without drug class modification and/or discontinuation. Drug class modification and/or discontinuation were defined based on the class of a particular drug. Quasi-Poisson regression was used to quantify the association of factors with virologic suppression. Results: From January 2000 through June 2010, 1311 patients started first-line ART; 987 (75%) patients used NNRTI-based regimens. Virologic suppression was achieved by 77%, 76% and 68% of patients at 6, 12 and 24 months, respectively. Factors associated with virologic suppression at 12 months were: >8 years of formal education (compared to <4 years, risk ratio (RR) 1.13, 95% confidence interval (95% CI) 1.03-1.24), starting ART in 2005-2010 (compared to 2000-2004, RR 1.25 95% CI 1.15-1.35), and clinical trial participation (compared to no participation, RR 1.08 95% CI 1.01-1.16). Also at 12 months, women showed less virologic suppression compared to heterosexual men (RR 0.90 95% CI 0.82-0.99). For the 24-month endpoint, in addition to higher education, starting ART in the later period, and clinical trial participation, older age and an NNRTI-based regimen were also independently associated with virologic suppression. Conclusions: Our results show that in Brazil, a middle-income country with free access to treatment, over three-quarters of patients receiving routine care reached virologic suppression on first-line ART by the end of the first year. Higher education, more recent ART initiation and clinical trial participation were associated with improved outcomes both for the 12-month and the 24-month endpoints, suggesting that further studies are needed to understand what aspects relating to these factors lead to higher virologic suppression. C1 [Cardoso, Sandra W.; Luz, Paula M.; Velasque, Luciane; Torres, Thiago; Coelho, Lara; Veloso, Valdilea G.; Grinsztejn, Beatriz] FundaCao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil. [Velasque, Luciane] Univ Fed Estado Rio de Janeiro, Dept Matemat & Estat, Rio De Janeiro, Brazil. [Freedberg, Kenneth A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Freedberg, Kenneth A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. [Freedberg, Kenneth A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Dept Med, Boston, MA 02114 USA. [Freedberg, Kenneth A.; Walensky, Rochelle P.] Harvard Univ, Sch Med, Ctr AIDS Res, Boston, MA USA. RP Luz, PM (reprint author), FundaCao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil. EM paula.luz@ipec.fiocruz.br FU National Council of Technological and Scientific Development (CNPq); Research Funding Agency of the State of Rio de Janeiro (FAPERJ); National Institute of Allergy and Infectious Diseases (NIAID) [R01 AI058736, R01 AI093269] FX BG acknowledges funding from the National Council of Technological and Scientific Development (CNPq) and the Research Funding Agency of the State of Rio de Janeiro (FAPERJ). PML acknowledges funding from the National Council of Technological and Scientific Development (CNPq) and the Research Funding Agency of the State of Rio de Janeiro (FAPERJ). KAF and RPW acknowledge funding from National Institute of Allergy and Infectious Diseases (NIAID, R01 AI058736, R01 AI093269). NR 41 TC 7 Z9 7 U1 1 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-6405 J9 AIDS RES THER JI Aids Res. Ther. PD SEP 1 PY 2014 VL 11 AR 29 DI 10.1186/1742-6405-11-29 PG 10 WC Infectious Diseases SC Infectious Diseases GA AQ9LC UT WOS:000343174000001 PM 25206924 ER PT J AU Ljungman, PL Wilker, EH Rice, MB Schwartz, J Gold, DR Koutrakis, P Vita, JA Mitchell, GF Vasan, RS Benjamin, EJ Mittleman, MA Hamburg, NM AF Ljungman, Petter L. Wilker, Elissa H. Rice, Mary B. Schwartz, Joel Gold, Diane R. Koutrakis, Petros Vita, Joseph A. Mitchell, Gary F. Vasan, Ramachandran S. Benjamin, Emelia J. Mittleman, Murray A. Hamburg, Naomi M. TI Short-Term Exposure to Air Pollution and Digital Vascular Function SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE air pollutants; endothelium, vascular; particulate matter; vascular diseases ID ACUTE ARTERIAL VASOCONSTRICTION; CROSS-SECTIONAL RELATIONS; PARTICULATE MATTER; ENDOTHELIAL FUNCTION; AMBIENT CONCENTRATIONS; MYOCARDIAL-INFARCTION; HEALTHY-ADULTS; HEART-DISEASE; INHALATION; ATHEROSCLEROSIS AB We investigated associations between ambient air pollution and microvessel function measured by peripheral arterial tonometry between 2003 and 2008 in the Framingham Heart Study Offspring and Third Generation Cohorts. We measured particulate matter with aerodynamic diameter <= 2.5 mu m (PM2.5), black carbon, sulfates, particle number, nitrogen oxides, and ozone by using fixed monitors, and we determined moving averages for 1-7 days preceding vascular testing. We examined associations between these exposures and hyperemic response to ischemia and baseline pulse amplitude, a measure of arterial tone (n = 2,369). Higher short-term exposure to air pollutants, including PM2.5, black carbon, and particle number was associated with higher baseline pulse amplitude. For example, higher 3-day average PM2.5 exposure was associated with 6.3% higher baseline pulse amplitude (95% confidence interval: 2.0, 10.9). However, there were no consistent associations between the air pollution exposures assessed and hyperemic response. Our findings in a community-based sample exposed to relatively low pollution levels suggest that short-term exposure to ambient particulate pollution is not associated with vasodilator response, but that particulate air pollution is associated with baseline pulse amplitude, suggesting potentially adverse alterations in baseline vascular tone or compliance. C1 [Ljungman, Petter L.; Wilker, Elissa H.; Rice, Mary B.; Mittleman, Murray A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Cardiovasc Epidemiol Res Unit,Dept Cardiol, Boston, MA 02215 USA. [Ljungman, Petter L.] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden. [Schwartz, Joel; Gold, Diane R.; Koutrakis, Petros] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Rice, Mary B.] Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA. [Vita, Joseph A.; Vasan, Ramachandran S.; Benjamin, Emelia J.; Hamburg, Naomi M.] NHLBI, Bethesda, MD 20892 USA. [Vita, Joseph A.; Vasan, Ramachandran S.; Benjamin, Emelia J.; Hamburg, Naomi M.] Boston Univ Framingham Heart Study, Framingham, MA USA. [Vita, Joseph A.; Vasan, Ramachandran S.; Benjamin, Emelia J.; Hamburg, Naomi M.] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA. [Mitchell, Gary F.] Cardiovasc Engn Inc, Norwood, MA USA. RP Ljungman, PL (reprint author), Beth Israel Deaconess Med Ctr, Cardiovasc Epidemiol Res Unit, Cardiovasc Div, 375 Longwood Ave,Suite 440, Boston, MA 02215 USA. EM petter.ljungman@ki.se RI Ljungman, Petter/C-6371-2014; OI Ljungman, Petter/0000-0002-7815-2632; Ramachandran, Vasan/0000-0001-7357-5970; Benjamin, Emelia/0000-0003-4076-2336 FU National Heart, Lung, and Blood Institute [N01HC 25195, 1R01HL60040, 1RO1HL70100]; US Environmental Protection Agency [R832416, RD83479801]; National Institute of Environmental Health Sciences [ES009825, K99E S022243, 1F32ES023352-01, P30ES000002]; Swedish Council for Working Life and Social Research; Swedish Heart-Lung Foundation; Swedish Society of Cardiology; Swedish Society for Medical Research FX This work was supported by the National Heart, Lung, and Blood Institute (grants N01HC 25195, 1R01HL60040, and 1RO1HL70100), the US Environmental Protection Agency (grants R832416 and RD83479801), the National Institute of Environmental Health Sciences (grants ES009825, K99E S022243, 1F32ES023352-01, and P30ES000002), the Swedish Council for Working Life and Social Research Marie Curie International Postdoctoral Fellowship Programme, the Swedish Heart-Lung Foundation, the Swedish Society of Cardiology, and the Swedish Society for Medical Research. NR 38 TC 4 Z9 5 U1 0 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD SEP 1 PY 2014 VL 180 IS 5 BP 482 EP 489 DI 10.1093/aje/kwu161 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ7XG UT WOS:000343032600005 PM 25100647 ER PT J AU Greiner, AL Albutt, K Rouhani, SA Scott, J Dombrowski, K VanRooyen, MJ Bartels, SA AF Greiner, Ashley L. Albutt, Katherine Rouhani, Shada A. Scott, Jennifer Dombrowski, Kirk VanRooyen, Michael J. Bartels, Susan A. TI Respondent-Driven Sampling to Assess Outcomes of Sexual Violence: A Methodological Assessment SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE Democratic Republic of Congo; respondent-driven sampling; sexual violence; sexual violence-related pregnancy ID HIDDEN POPULATIONS; HIV PREVALENCE; RISK BEHAVIORS; MENTAL-HEALTH; BISEXUAL MEN; DRUG-USERS; WORKERS; INFECTION; SYMPTOMS; KAMPALA AB Sexual violence is pervasive in eastern Democratic Republic of Congo (DRC). Survivors of sexual violence encounter numerous challenges, and women with a sexual violence-related pregnancy (SVRP) face even more complex sequelae. Because of the stigma associated with SVRP, there is no conventional sampling frame and, therefore, a paucity of research on SVRP outcomes. Respondent-driven sampling (RDS), used to study this "hidden" population, uses a peer recruitment sampling system that maintains strict participant privacy and controls and tracks recruitment. If RDS assumptions are met and the sample attains equilibrium, sample weights to correct for biases associated with traditional chain referral sampling can be calculated. Questionnaires were administered to female participants who were raising a child from a SVRP and/or who terminated a SVRP. A total of 852 participants were recruited from October 9, 2012, to November 7, 2012. There was rapid recruitment, and there were long referral chains. The majority of the variables reached equilibrium; thus, trends established in the sample population reflected the target population's trends. To our knowledge, this is the first study to use RDS to study outcomes of sexual violence. RDS was successfully applied to this population and context and should be considered as a sampling methodology in future sexual violence research. C1 [Greiner, Ashley L.; Albutt, Katherine; Rouhani, Shada A.; Scott, Jennifer; VanRooyen, Michael J.; Bartels, Susan A.] Harvard Humanitarian Initiat, Cambridge, MA USA. [Greiner, Ashley L.; Rouhani, Shada A.; Scott, Jennifer; VanRooyen, Michael J.; Bartels, Susan A.] Harvard Univ, Sch Med, Boston, MA USA. [Greiner, Ashley L.; Bartels, Susan A.] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA. [Rouhani, Shada A.; VanRooyen, Michael J.] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA. [Albutt, Katherine] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Scott, Jennifer] Beth Israel Deaconess Med Ctr, Dept Obstet & Gynecol, Boston, MA 02215 USA. [Scott, Jennifer] Brigham & Womens Hosp, Dept Med, Div Womens Hlth, Boston, MA 02115 USA. [Dombrowski, Kirk] Univ Nebraska, Dept Sociol, Lincoln, NE 68588 USA. [VanRooyen, Michael J.] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA. RP Greiner, AL (reprint author), Beth Israel Deaconess Med Ctr, Dept Emergency Med, 1 Deaconess Rd,WCC 2, Boston, MA 02215 USA. EM agreinermd@gmail.com FU Eleanor Miles Shore Foundation [01025283] FX This work was supported by the Eleanor Miles Shore Foundation (grant 01025283); and by generous donations to the Harvard Humanitarian Initiative. NR 38 TC 2 Z9 2 U1 1 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD SEP 1 PY 2014 VL 180 IS 5 BP 536 EP 544 DI 10.1093/aje/kwu149 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ7XG UT WOS:000343032600011 PM 25073471 ER PT J AU Strle, K Stupica, D Drouin, EE Steere, AC Strle, F AF Strle, Klemen Stupica, Dasa Drouin, Elise E. Steere, Allen C. Strle, Franc TI Pathogenesis of Post-Lyme Disease Symptoms Reply SO CLINICAL INFECTIOUS DISEASES LA English DT Letter C1 [Strle, Klemen; Drouin, Elise E.; Steere, Allen C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol Allergy & Immunol,Ctr Immunol & Inf, Boston, MA USA. [Stupica, Dasa; Strle, Franc] Univ Med Ctr Ljubljana, Dept Infect Dis, Ljubljana, Slovenia. RP Strle, K (reprint author), Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, 55 Fruit St,CNY149-8301, Boston, MA 02114 USA. EM kstrle@partners.org NR 4 TC 0 Z9 0 U1 1 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 1 PY 2014 VL 59 IS 5 DI 10.1093/cid/ciu343 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AQ6KQ UT WOS:000342921100028 PM 24812297 ER PT J AU Miller, MW Wolf, EJ Keane, TM AF Miller, Mark W. Wolf, Erika J. Keane, Terence M. TI Posttraumatic Stress Disorder in DSM-5: New Criteria and Controversies SO CLINICAL PSYCHOLOGY-SCIENCE AND PRACTICE LA English DT Article DE dissociative subtype; DSM-5; ICD-11; posttraumatic stress disorder ID ET-AL. 2012; VIETNAM COMBAT VETERANS; CONFIRMATORY FACTOR-ANALYSES; MOTOR-VEHICLE ACCIDENTS; LATENT CLASS ANALYSIS; COMPLEX PTSD; DISSOCIATIVE-SUBTYPE; MENTAL-DISORDERS; PSYCHOPHYSIOLOGICAL ASSESSMENT; INTERNATIONAL CLASSIFICATION AB The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5; American Psychiatric Association, 2013) featured extensive changes to the posttraumatic stress disorder (PTSD) diagnosis. PTSD was moved out of the anxiety disorders into a new class of "trauma-and stressor-related disorders," and the definition of what constitutes a traumatic experience was revised. Three new symptoms were added, existing ones were modified, and a new four-cluster organization and diagnostic algorithm were introduced. Finally, a new dissociative subtype was added to the diagnosis. We review these changes, discuss some of the controversies surrounding them, and then introduce a new debate involving a radically different conceptualization of PTSD proposed for International Classification of Diseases, 11th edition. C1 [Miller, Mark W.; Wolf, Erika J.; Keane, Terence M.] Boston Univ, Sch Med, VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02215 USA. RP Miller, MW (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD 116B 2, 150 South Huntington Ave, Boston, MA 02130 USA. EM mark.miller5@va.gov; terry.keane@va.gov OI Wolf, Erika/0000-0003-2666-2435 FU Department of Veterans Affairs (VA) Merit Review Grant [5I01CX000431-02]; VA Career Development Award; VA-Department of Defense Award for the Consortium FX This work was supported in part by Department of Veterans Affairs (VA) Merit Review Grant 5I01CX000431-02 awarded to Mark Miller, a VA Career Development Award to Erika Wolf, and VA-Department of Defense Award for the Consortium to Alleviate PTSD (CAP) to Terence M. Keane. NR 83 TC 8 Z9 8 U1 5 U2 50 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0969-5893 EI 1468-2850 J9 CLIN PSYCHOL-SCI PR JI Clin. Psychol.-Sci. Pract. PD SEP PY 2014 VL 21 IS 3 BP 208 EP 220 DI 10.1111/cpsp.12070 PG 13 WC Psychology, Clinical SC Psychology GA AQ7PG UT WOS:000343010700002 ER PT J AU Reddy, LF Horan, WP Green, MF AF Reddy, L. Felice Horan, William P. Green, Michael F. TI Revisions and Refinements of the Diagnosis of Schizophrenia in DSM-5 SO CLINICAL PSYCHOLOGY-SCIENCE AND PRACTICE LA English DT Article DE diagnosis; DSM-5; schizophrenia ID ATTENUATED PSYCHOSIS SYNDROME; NEGATIVE SYMPTOMS; 1ST-RANK SYMPTOMS; SCHIZOAFFECTIVE DISORDER; COGNITION; CLASSIFICATION; FUTURE; NEUROSCIENCE; IMPAIRMENTS; PREDICTION AB The DSM-5 changes to the diagnostic criteria for schizophrenia reflect modest incremental changes. The two most substantial changes, the elimination of subtypes and de-emphasis of Schneiderian First-Rank Symptoms, are a significant departure from long-standing approaches to conceptualizing and defining schizophrenia, but are unlikely to have an appreciable impact on caseness or clinical management. Several minor modifications to the diagnosis are generally useful additions that will likely enhance diagnostic precision. The two most controversial changes that were considered, the addition of dimensional ratings and attenuated psychosis syndrome, were ultimately placed in the third section of DSM-5 for further research and consideration. In sum, the changes demonstrate increased precision of diagnosis, with minimal changes in caseness. C1 [Reddy, L. Felice] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat, Los Angeles, CA 90024 USA. RP Reddy, LF (reprint author), VA Greater Los Angeles Healthcare Syst, MIRECC 210A,11301 Wilshire Blvd,Bldg 210,Room 117, Los Angeles, CA 90073 USA. EM lenafelice@ucla.edu NR 54 TC 1 Z9 1 U1 4 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0969-5893 EI 1468-2850 J9 CLIN PSYCHOL-SCI PR JI Clin. Psychol.-Sci. Pract. PD SEP PY 2014 VL 21 IS 3 BP 236 EP 244 DI 10.1111/cpsp.12071 PG 9 WC Psychology, Clinical SC Psychology GA AQ7PG UT WOS:000343010700004 ER PT J AU Yonekawa, Y Kim, IK Gragoudas, ES Njauw, CNJ Tsao, HS Jakobiec, FA Stacy, RC AF Yonekawa, Yoshihiro Kim, Ivana K. Gragoudas, Evangelos S. Njauw, Ching-Ni J. Tsao, Hensin Jakobiec, Frederick A. Stacy, Rebecca C. TI Aggressive skull base metastasis from uveal melanoma: a clinicopathologic study SO EUROPEAN JOURNAL OF OPHTHALMOLOGY LA English DT Article DE Choroidal melanoma; Intraocular tumor; Metastasis; Uveal melanoma AB Purpose: We present the clinical, pathologic, and genetic findings of the first reported case of choroidal melanoma that developed a late recurrence and aggressive metastasis to the skull base without evidence of hepatic involvement. Methods: Retrospective chart review and clinicopathologic correlation of ocular and brain tissue, including sequencing of BAP1 for mutations. Results: A 55-year-old woman was diagnosed with choroidal melanoma and treated with proton radiotherapy Six years later, she developed a rapidly growing local recurrence involving the ciliary body and iris. Upon enucleation, histopathology revealed an iris and ciliary body epithelioid melanoma that was contiguous with the previously treated, regressed spindle cell choroidal melanoma. Imaging was initially negative for brain involvement. Two months later, she developed cranial neuropathies and was found to have a large skull base lesion that required surgical debulking for pain palliation. Histopathology confirmed the lesion to be metastatic melanoma. Both ocular and brain tumor specimens were wild-type for BAP1. Throughout her course, she developed no hepatic metastases. Conclusions: Uveal melanoma may metastasize to the skull base. The present case was characterized by delayed onset and unusual aggressiveness of the metastatic disease, and lack of BAP1 mutation. The unusual course highlights a unique phenotype that may reflect an alternate molecular mechanism for metastatic disease. C1 [Yonekawa, Yoshihiro; Kim, Ivana K.; Gragoudas, Evangelos S.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv,Dept Ophthalmol, Boston, MA USA. [Njauw, Ching-Ni J.; Tsao, Hensin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. [Tsao, Hensin] Harvard Univ, Sch Med, Dept Dermatol, Melanoma & Pigmented Lesion Ctr,Massachusetts Gen, Boston, MA 02115 USA. [Jakobiec, Frederick A.; Stacy, Rebecca C.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, David G Cogan Lab Ophthalm Pathol,Dept Ophthalmol, Boston, MA USA. RP Stacy, RC (reprint author), Massachusetts Eye & Ear Infirm, David G Cogan Lab Ophthalm Pathol, 243 Charles St, Boston, MA 02114 USA. EM rebecca_stacy@meei.harvard.edu NR 4 TC 1 Z9 1 U1 0 U2 1 PU WICHTIG EDITORE PI MILAN PA 72/74 VIA FRIULI, 20135 MILAN, ITALY SN 1120-6721 EI 1724-6016 J9 EUR J OPHTHALMOL JI Eur. J. Ophthalmol. PD SEP-OCT PY 2014 VL 24 IS 5 BP 811 EP 813 DI 10.5301/ejo.5000468 PG 3 WC Ophthalmology SC Ophthalmology GA AR0OH UT WOS:000343270700028 PM 24729140 ER PT J AU Liu, CL Chen, YM Kochevar, IE Jurkunas, UV AF Liu, Cailing Chen, Yuming Kochevar, Irene E. Jurkunas, Ula V. TI Decreased DJ-1 Leads to Impaired Nrf2-Regulated Antioxidant Defense and Increased UV-A-Induced Apoptosis in Corneal Endothelial Cells SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE corneal endothelial cells; DJ-1; Nrf2; oxidative stress; ultraviolet A light ID NF-E2-RELATED FACTOR-2 NRF2; EARLY-ONSET PARKINSONISM; OXIDATIVE DAMAGE; FUCHS DYSTROPHY; NUCLEAR TRANSLOCATION; SINGLET OXYGEN; IN-VITRO; GENE; EXPRESSION; RADIATION AB PURPOSE. To investigate the role of DJ-1 in Nrf2-regulated antioxidant defense in corneal endothelial cells (CECs) at baseline and in response to ultraviolet A (UV-A)-induced oxidative stress. METHODS. DJ-1-deficient CECs were obtained by transfection of an immortalized normal human corneal endothelial cell line (HCECi) with DJ-1 small interfering RNA (siRNA) or by isolation of CECs from ex vivo corneas of DJ-1 knockout mice. Levels of reactive oxygen species (ROS), protein carbonyls, Nrf2 subcellular localization, Nrf2 target genes, and protein interaction between Keap1/Nrf2 and Cul3/Nrf2 were compared between normal and DJ-1-deficient CECs. Oxidative stress was induced by irradiating HCECi cells with UV-A, and cell death and levels of activated caspase3 and phospho-p53 were determined. RESULTS. DJ-1 siRNA-treated cells exhibited increased levels of ROS production and protein carbonyls as well as a 2.2-fold decrease in nuclear Nrf2 protein when compared to controls. DJ-1 downregulation led to attenuated gene expression of Nrf2 and its target genes HO-1 and NQO1. Similar levels of Nrf2 inhibitor, Keap1, and Cul3/Nrf2 and Keap1/Nrf2 were observed in DJ-1 siRNA-treated cells as compared to controls. Ultraviolet A irradiation resulted in a 3.0-fold increase in cell death and elevated levels of activated caspase3 and phospho-p53 in DJ-1 siRNA-treated cells compared to controls. CONCLUSIONS. Downregulation of DJ-1 impairs nuclear translocation of Nrf2, causing decreased antioxidant gene expression and increased oxidative damage. The decline in DJ-1 levels leads to heightened CEC susceptibility to UV-A light by activating p53-dependent apoptosis. Targeting the DJ-1-Nrf2 axis may provide a potential therapeutic approach for enhancing antioxidant defense in corneal endothelial disorders. C1 [Liu, Cailing; Chen, Yuming; Jurkunas, Ula V.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst,Dept Ophthalmol, Boston, MA USA. [Kochevar, Irene E.] Harvard Univ, Massachusetts Gen Hosp, Wellman Ctr Photomed, Sch Med, Boston, MA USA. RP Jurkunas, UV (reprint author), Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA. EM ula_jurkunas@meei.harvard.edu FU National Institutes of Health/National Eye Institute [R01 EY20581]; Research to Prevent Blindness Award FX Supported by National Institutes of Health/National Eye Institute Grant R01 EY20581 and a Research to Prevent Blindness Award (UVJ). NR 51 TC 10 Z9 10 U1 0 U2 13 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD SEP PY 2014 VL 55 IS 9 BP 5551 EP 5560 DI 10.1167/iovs.14-14580 PG 10 WC Ophthalmology SC Ophthalmology GA AQ9DX UT WOS:000343146900010 PM 25082883 ER PT J AU Kodati, S Chauhan, SK Chen, YH Dohlman, TH Karimian, P Saban, D Dana, R AF Kodati, Shilpa Chauhan, Sunil K. Chen, Yihe Dohlman, Thomas H. Karimian, Parisa Saban, Daniel Dana, Reza TI CCR7 Is Critical for the Induction and Maintenance of Th17 Immunity in Dry Eye Disease SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE CCR7; dry eye; cornea; Th17 ID RISK CORNEAL TRANSPLANTATION; OCULAR SURFACE; DESICCATING STRESS; DENDRITIC CELLS; LACRIMAL KERATOCONJUNCTIVITIS; EXPRESSION; TRAFFICKING; POPULATION; PREVALENCE; CHEMOKINES AB PURPOSE. We characterized antigen-presenting cell (APC)-relevant chemokine receptor expression in dry eye disease (DED), and investigated the effect of topical CC chemokine receptor (CCR)-7 blockade specifically on Th17 cell immunity and dry eye disease severity. METHODS. We induced DED in female C57BL/6 mice. Chemokine receptor expression by corneal APCs was characterized using immunohistochemistry. To determine the functional role of CCR7 in DED, mice were treated topically with either anti-CCR7, a control isotype antibody, or left untreated, and clinical disease severity, Th17 responses, and molecular markers of DED were quantified. RESULTS. Frequencies of CD11b(+) cells and their chemokine expression were increased in the cornea of DED mice. Mice treated topically with anti-CCR7 antibody displayed a significant reduction in clinical disease severity and Th17 response compared to the isotype and untreated groups. Topical CCR7 blockade was effective in ameliorating DED in its acute and chronic stages. CONCLUSIONS. Our findings suggest that CCR7-mediated trafficking of APCs drives the induction and maintenance of Th17 immunity in DED and that CCR7 blockade is effective in suppressing the immunopathogenic mechanisms in DED. C1 Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA USA. Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA. RP Dana, R (reprint author), Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA. EM Reza_Dana@meei.harvard.edu FU National Eye Institute/National Institutes of Health Grant [EY 020889] FX Supported by the National Eye Institute/National Institutes of Health Grant EY 020889. The authors alone are responsible for the content and writing of the paper. NR 33 TC 9 Z9 10 U1 0 U2 5 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD SEP PY 2014 VL 55 IS 9 BP 5871 EP 5877 DI 10.1167/iovs.14-14481 PG 7 WC Ophthalmology SC Ophthalmology GA AQ9DX UT WOS:000343146900053 PM 25139737 ER PT J AU Hua, J Jin, YP Chen, YH Inomata, T Lee, H Chauhan, SK Petasis, NA Serhan, CN Dana, R AF Hua, Jing Jin, Yiping Chen, Yihe Inomata, Takenori Lee, HyunSoo Chauhan, Sunil K. Petasis, Nicos A. Serhan, Charles N. Dana, Reza TI The Resolvin D1 Analogue Controls Maturation of Dendritic Cells and Suppresses Alloimmunity in Corneal Transplantation SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE transplant rejection; resolvin; dendritic cell ID POLYUNSATURATED FATTY-ACIDS; DRAINING LYMPH-NODES; DOCOSAHEXAENOIC ACID; T-CELLS; ANTIINFLAMMATORY PROPERTIES; ALLOGRAFT-REJECTION; HUMAN PHAGOCYTES; LIPID MEDIATORS; BONE-MARROW; RECEPTOR AB PURPOSE. To analyze the effect of a resolvin D1 (RvD1) analogue (RvD1a) on dendritic cell maturation, T-cell sensitization, and allograft rejection in corneal allotransplantation. METHODS. The receptor expression of RvD1 (ALX/FPR2) on bone marrow-derived dendritic cells (BMDC) was measured using quantitative real-time PCR. We determined BMDC maturation after treatment with RvD1a using ELISA to measure interleukin (IL)-12 protein expression and flow cytometry to assess the expression of CD40, major histocompatibility complex (MHC) II, CD80, and CD86. After corneal transplantation in BALB/c mice, we analyzed T-cell infiltration in the cornea and the draining lymph nodes using flow cytometry. The enzyme-linked immunospot (ELISPOT) assay was used to measure T-cell sensitization via the direct and indirect pathway. Angiogenesis and lymphangiogenesis in the cornea after transplantation were measured using immunohistochemistry. Graft opacity and survival were evaluated by slit lamp biomicroscopy. RESULTS. The receptor for RvD1, lipoxin A4/formyl peptide receptor 2 (ALX/FPR2), was expressed at a significantly lower level on immature than mature dendritic cells (DCs), and RvD1a reduced DC expression of MHC II, CD40, and IL-12 following lipopolysaccharide (LPS) stimulation. Using a murine model of corneal transplantation, RvD1a-treated hosts exhibited significantly reduced allosensitization as demonstrated by decreased frequencies of interferon-gamma-secreting T cells in the draining lymph nodes, and reduced T-cell infiltration into the grafts. Graft survival was significantly enhanced and angiogenesis at the graft site was suppressed in RvD1a-treated hosts compared with vehicle-treated hosts. CONCLUSIONS. These results suggest that RvD1 inhibits DC maturation and reduces alloimmune sensitization following transplantation, thereby establishing a novel connection between resolvin D1 and the regulation of DC-mediated, antigen-specific immunity. C1 [Hua, Jing; Jin, Yiping; Chen, Yihe; Inomata, Takenori; Lee, HyunSoo; Chauhan, Sunil K.; Dana, Reza] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA USA. [Hua, Jing; Jin, Yiping; Chen, Yihe; Inomata, Takenori; Lee, HyunSoo; Chauhan, Sunil K.; Dana, Reza] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA. [Petasis, Nicos A.] Univ So Calif, Dept Chem, Los Angeles, CA 90089 USA. [Petasis, Nicos A.] Univ So Calif, Loker Hydrocarbon Res Inst, Los Angeles, CA 90089 USA. [Serhan, Charles N.] Harvard Univ, Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Sch Med,Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA. RP Dana, R (reprint author), Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA. EM reza_dana@meei.harvard.edu OI Inomata, Takenori/0000-0003-3435-1055 FU National Institutes of Health, National Eye Institute [R01 EY 12963]; Richard Lindstrom/EBAA Research Fund; National Institute of General Medical Sciences [GM095467, GM038765] FX Supported by the National Institutes of Health, National Eye Institute (R01 EY 12963 [RD]), Richard Lindstrom/EBAA Research Fund (YJ, RD), and the National Institute of General Medical Sciences (GM095467 and GM038765 [CNS]). NR 59 TC 6 Z9 6 U1 1 U2 6 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD SEP PY 2014 VL 55 IS 9 BP 5944 EP 5951 DI 10.1167/iovs.14-14356 PG 8 WC Ophthalmology SC Ophthalmology GA AQ9DX UT WOS:000343146900062 PM 25146982 ER PT J AU Basch, E Reeve, BB Mitchell, SA Clauser, SB Minasian, LM Dueck, AC Mendoza, TR Hay, J Atkinson, TM Abernethy, AP Bruner, DW Cleeland, CS Sloan, JA Chilukuri, R Baumgartner, P Denicoff, A St Germain, D O'Mara, AM Chen, A Kelaghan, J Bennett, AV Sit, L Rogak, L Barz, A Paul, DB Schrag, D AF Basch, Ethan Reeve, Bryce B. Mitchell, Sandra A. Clauser, Steven B. Minasian, Lori M. Dueck, Amylou C. Mendoza, Tito R. Hay, Jennifer Atkinson, Thomas M. Abernethy, Amy P. Bruner, Deborah W. Cleeland, Charles S. Sloan, Jeff A. Chilukuri, Ram Baumgartner, Paul Denicoff, Andrea St Germain, Diane O'Mara, Ann M. Chen, Alice Kelaghan, Joseph Bennett, Antonia V. Sit, Laura Rogak, Lauren Barz, Allison Paul, Diane B. Schrag, Deborah TI Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Editorial Material ID CLINICIAN; SYMPTOMS; CHEMOTHERAPY; TRIALS; ONCOLOGY; CHALLENGES; ACCURACY; PERIODS; RECALL; VOICE AB The standard approach for documenting symptomatic adverse events (AEs) in cancer clinical trials involves investigator reporting using the National Cancer Institute's (NCI's) Common Terminology Criteria for Adverse Events (CTCAE). Because this approach underdetects symptomatic AEs, the NCI issued two contracts to create a patient-reported outcome (PRO) measurement system as a companion to the CTCAE, called the PRO-CTCAE. This Commentary describes development of the PRO-CTCAE by a group of multidisciplinary investigators and patient representatives and provides an overview of qualitative and quantitative studies of its measurement properties. A systematic evaluation of all 790 AEs listed in the CTCAE identified 78 appropriate for patient self-reporting. For each of these, a PRO-CTCAE plain language term in English and one to three items characterizing the frequency, severity, and/or activity interference of the AE were created, rendering a library of 124 PRO-CTCAE items. These items were refined in a cognitive interviewing study among patients on active cancer treatment with diverse educational, racial, and geographic backgrounds. Favorable measurement properties of the items, including construct validity, reliability, responsiveness, and between-mode equivalence, were determined prospectively in a demographically diverse population of patients receiving treatments for many different tumor types. A software platform was built to administer PRO-CTCAE items to clinical trial participants via the internet or telephone interactive voice response and was refined through usability testing. Work is ongoing to translate the PRO-CTCAE into multiple languages and to determine the optimal approach for integrating the PRO-CTCAE into clinical trial workflow and AE analyses. It is envisioned that the PRO-CTCAE will enhance the precision and patient-centeredness of adverse event reporting in cancer clinical research. C1 [Basch, Ethan; Reeve, Bryce B.; Bennett, Antonia V.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27514 USA. [Basch, Ethan; Reeve, Bryce B.; Bennett, Antonia V.] Univ N Carolina, Gillings Sch Publ Hlth, Dept Hlth Policy & Management, Chapel Hill, NC 27514 USA. [Basch, Ethan; Sit, Laura; Rogak, Lauren] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, Hlth Outcomes Res Grp, New York, NY 10021 USA. [Hay, Jennifer; Atkinson, Thomas M.] Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, New York, NY 10021 USA. [Mitchell, Sandra A.; Clauser, Steven B.] NCI, Outcomes Res Branch, Appl Res Program, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Minasian, Lori M.] NCI, Canc Prevent Div, Bethesda, MD 20892 USA. [Denicoff, Andrea] NCI, NCTN Clin Trials Operat, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA. [St Germain, Diane; O'Mara, Ann M.; Kelaghan, Joseph] NCI, Community Oncol & Prevent Trials Res Grp, Canc Prevent Div, Bethesda, MD 20892 USA. [Chen, Alice] NCI, Invest Drug Branch, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA. [Dueck, Amylou C.] Mayo Clin Arizona, Coll Med, Div Hlth Sci Res, Scottsdale, AZ USA. [Mendoza, Tito R.; Cleeland, Charles S.] Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Div Internal Med, Houston, TX 77030 USA. [Paul, Diane B.] Patient Advocate, New York, NY USA. [Abernethy, Amy P.] Duke Univ, Dept Med, Duke Ctr Learning HealthCare, Duke Canc Res Program, Durham, NC USA. [Bruner, Deborah W.] Emory Univ, Nell Hodgson Woodruff Sch Nursing, Winship Canc Inst, Atlanta, GA 30322 USA. [Sloan, Jeff A.] Mayo Clin Rochester, Rochester, MN USA. [Chilukuri, Ram; Baumgartner, Paul] SemanticBits LLC, Herndon, VA USA. [Barz, Allison] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA. [Schrag, Deborah] Dana Farber Canc Inst, Div Populat Sci, Dept Med Oncol, Boston, MA 02115 USA. RP Basch, E (reprint author), Univ N Carolina, Ctr Comprehens Canc, Canc Outcomes Res Program Lineberger, 170 Manning Dr, Chapel Hill, NC 27514 USA. EM ebasch@med.unc.edu NR 42 TC 47 Z9 47 U1 0 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-J. Natl. Cancer Inst. PD SEP PY 2014 VL 106 IS 9 AR dju244 DI 10.1093/jnci/dju244 PG 11 WC Oncology SC Oncology GA AQ7XU UT WOS:000343034600018 ER PT J AU Carey, LA Barry, W AF Carey, Lisa A. Barry, William TI Making Sense of Dual HER2-Targeting in Early Breast Cancer? SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Editorial Material ID OPEN-LABEL; PHASE-3 TRIAL; TRASTUZUMAB; LAPATINIB; MULTICENTER; PERTUZUMAB C1 [Carey, Lisa A.] Univ N Carolina, Div Hematol Oncol, Chapel Hill, NC 27599 USA. [Barry, William] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. RP Carey, LA (reprint author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB7305,3009 Old Clin Bldg, Chapel Hill, NC 27599 USA. EM lisa_carey@med.unc.edu NR 14 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-J. Natl. Cancer Inst. PD SEP PY 2014 VL 106 IS 9 AR dju259 DI 10.1093/jnci/dju259 PG 2 WC Oncology SC Oncology GA AQ7XU UT WOS:000343034600024 ER PT J AU Inamura, K Yamauchi, M Nishihara, R Lochhead, P Qian, ZR Kuchiba, A Kim, SA Mima, K Sukawa, Y Jung, SY Zhang, XZ Wu, K Cho, E Chan, AT Meyerhardt, JA Harris, CC Fuchs, CS Ogino, S AF Inamura, Kentaro Yamauchi, Mai Nishihara, Reiko Lochhead, Paul Qian, Zhi Rong Kuchiba, Aya Kim, Sun A. Mima, Kosuke Sukawa, Yasutaka Jung, Seungyoun Zhang, Xuehong Wu, Kana Cho, Eunyoung Chan, Andrew T. Meyerhardt, Jeffrey A. Harris, Curtis C. Fuchs, Charles S. Ogino, Shuji TI Tumor LINE-1 Methylation Level and Microsatellite Instability in Relation to Colorectal Cancer Prognosis SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID DNA MISMATCH REPAIR; MOLECULAR PATHOLOGICAL EPIDEMIOLOGY; III COLON-CANCER; MICRORNA EXPRESSION; BRAF MUTATION; ADJUVANT CHEMOTHERAPY; RECTAL-CANCER; ASPIRIN USE; STAGE-II; HYPOMETHYLATION AB Background Hypomethylation in long interspersed nucleotide element-1 (LINE-1) and high-degree microsatellite instability (MSI-high) in colorectal cancer (CRC) have been associated with inferior and superior survival, respectively; however, it remains uncertain whether the prognostic association of LINE-1 hypomethylation differs by MSI status. We hypothesized that the adverse prognostic association of LINE-1 hypomethylation might be stronger in MSI-high CRCs than in microsatellite stable (MSS) CRCs. Methods Utilizing 1211 CRCs in the Nurses' Health Study and the Health Professionals Follow-up Study, we examined patient survival according to LINE-1 hypomethylation status in strata of MSI status. A Cox proportional hazards model was used to compute multivariable CRC-specific mortality hazard ratios (HRs) for a 10% decrease in LINE-1 methylation level (range = 23.1-93.1%), adjusting for potential confounders, including CpG island methylator phenotype, and KRAS, BRAF, and PIK3CA mutations. Statistical tests (log-rank test, chi-square test, and likelihood ratio test) were two-sided. Results In MSI-high cancers, the association of LINE-1 hypomethylation with higher mortality (HR = 2.45, 95% confidence interval [CI] = 1.64 to 3.66, P < .001) was stronger than that in MSS cancers (HR = 1.10, 95% CI = 0.98 to 1.24, P = .11) (Pinteraction < .001, between LINE-1 and MSI statuses). In MSI-high cases with CRC family history, the association of LINE-1 hypomethylation with higher mortality (HR = 5.13, 95% CI = 1.99 to 13.2; P < .001) was stronger than that in MSI-high cases without CRC family history (HR = 1.62, 95% CI = 0.89 to 2.94, P = .11) (Pinteraction = .02, between LINE-1 and CRC family history statuses). Conclusions The association of LINE-1 hypomethylation with inferior survival is stronger in MSI-high CRCs than in MSS CRCs. Tumor LINE-1 methylation level may be a useful prognostic biomarker to identify aggressive carcinomas among MSI-high CRCs. C1 [Inamura, Kentaro; Yamauchi, Mai; Nishihara, Reiko; Lochhead, Paul; Qian, Zhi Rong; Kuchiba, Aya; Kim, Sun A.; Mima, Kosuke; Sukawa, Yasutaka; Meyerhardt, Jeffrey A.; Fuchs, Charles S.; Ogino, Shuji] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Inamura, Kentaro; Yamauchi, Mai; Nishihara, Reiko; Lochhead, Paul; Qian, Zhi Rong; Kuchiba, Aya; Kim, Sun A.; Mima, Kosuke; Sukawa, Yasutaka; Jung, Seungyoun; Zhang, Xuehong; Cho, Eunyoung; Chan, Andrew T.; Meyerhardt, Jeffrey A.; Harris, Curtis C.; Fuchs, Charles S.; Ogino, Shuji] Harvard Univ, Sch Med, Boston, MA 02215 USA. [Inamura, Kentaro; Harris, Curtis C.] NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA. [Nishihara, Reiko; Kuchiba, Aya; Wu, Kana] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Lochhead, Paul] Univ Aberdeen, Inst Med Sci, Gastrointestinal Res Grp, Aberdeen, Scotland. [Jung, Seungyoun; Zhang, Xuehong; Cho, Eunyoung; Chan, Andrew T.; Fuchs, Charles S.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA. [Cho, Eunyoung] Brown Univ, Warren Alpert Med Sch, Dept Dermatol, Providence, RI USA. [Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA. [Ogino, Shuji] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. RP Ogino, S (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Room M422, Boston, MA 02215 USA. EM shuji_ogino@dfci.harvard.edu FU US National Institutes of Health (NIH) [P01 CA87969, P01 CA55075, UM1 CA167552, P50 CA127003, R01 CA136950, R01 CA137178, K24 DK098311, R01 CA151993]; Bennett Family Fund; Entertainment Industry Foundation through the National Colorectal Cancer Research Alliance; Japan Society for the Promotion of Science Postdoctoral Fellowship for Research Abroad; Takashi Tsuruo Memorial Fund; Harvard University Frank Knox Memorial Fellowship; Asan Medical Center; Uehara Memorial Foundation FX This work was supported by US National Institutes of Health (NIH) grants (P01 CA87969 to S. E. Hankinson, P01 CA55075 to W. C. Willett, UM1 CA167552 to W. C. Willett, P50 CA127003 to CSF, R01 CA136950 to EC, R01 CA137178 and K24 DK098311 to ATC, and R01 CA151993 to SO) and by grants from the Bennett Family Fund and the Entertainment Industry Foundation through the National Colorectal Cancer Research Alliance. KI is supported by the Japan Society for the Promotion of Science Postdoctoral Fellowship for Research Abroad and by the Takashi Tsuruo Memorial Fund. PL is a Scottish Government Clinical Academic Fellow and was supported by a Harvard University Frank Knox Memorial Fellowship. SAK is supported by an early exchange postdoctoral fellowship grant from Asan Medical Center. KM is supported by a fellowship grant from the Uehara Memorial Foundation. ATC is a Damon Runyon Clinical Investigator. NR 61 TC 5 Z9 5 U1 1 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-J. Natl. Cancer Inst. PD SEP PY 2014 VL 106 IS 9 AR dju195 DI 10.1093/jnci/dju195 PG 10 WC Oncology SC Oncology GA AQ7XU UT WOS:000343034600002 ER PT J AU Wivagg, CN Bhattacharyya, RP Hung, DT AF Wivagg, Carl N. Bhattacharyya, Roby P. Hung, Deborah T. TI Mechanisms of beta-lactam killing and resistance in the context of Mycobacterium tuberculosis SO JOURNAL OF ANTIBIOTICS LA English DT Review ID PENICILLIN-BINDING-PROTEINS; INFECTIOUS-DISEASES-SOCIETY; RESUSCITATION-PROMOTING FACTORS; CLINICAL-PRACTICE GUIDELINES; ESCHERICHIA-COLI; CELL-WALL; STAPHYLOCOCCUS-AUREUS; ENTEROCOCCUS-FAECIUM; OUTER-MEMBRANE; BACTERICIDAL ANTIBIOTICS AB beta-Lactams are one of the most useful classes of antibiotics against many common bacterial pathogens. One exception is Mycobacterium tuberculosis. However, with increasing incidence of multidrug-resistant tuberculosis and a need for new agents to treat it, the use of beta-lactams, specifically the combination of carbapenem and clavulanate, is now being revisited. With this attention, comes the need to better understand both the mechanisms of action of beta-lactams against M. tuberculosis as well as possible mechanisms of resistance, within the context of what is known about the beta-lactam action in other bacteria. M. tuberculosis has two major mechanisms of intrinsic resistance: a highly active beta-lactamase and a poorly permeable outer membrane. Within the cell wall, beta-lactams bind several enzymes with differing peptidoglycan-synthetic and -lytic functions. The inhibition of these enzymes may lead to cell death through several mechanisms, involving disruption of the balance of synthetic and lethal activities. Currently, all known means of resistance to the beta-lactams rely on diminishing the proportion of peptidoglycan-synthetic proteins bound and inhibited by beta-lactams, through either exclusion or destruction of the antibiotic, or through replacement or supplementation of target enzymes. In this review, we discuss possible mechanisms for beta-lactam activity in M. tuberculosis and the means by which it may acquire resistance, within the context of what is known in other bacterial species. C1 [Wivagg, Carl N.; Hung, Deborah T.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA. [Wivagg, Carl N.; Bhattacharyya, Roby P.; Hung, Deborah T.] Broad Inst, Cambridge, MA 02114 USA. [Bhattacharyya, Roby P.] Massachusetts Gen Hosp, Div Infect Dis, Dept Med, Boston, MA 02114 USA. [Hung, Deborah T.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. RP Hung, DT (reprint author), Broad Inst, Cambridge, MA 02114 USA. EM hung@molbio.mgh.harvard.edu NR 131 TC 13 Z9 13 U1 7 U2 47 PU JAPAN ANTIBIOTICS RESEARCH ASSOC PI TOKYO PA 2 20 8 KAMIOSAKI SHINAGAWA KU, TOKYO, 141, JAPAN SN 0021-8820 J9 J ANTIBIOT JI J. Antibiot. PD SEP PY 2014 VL 67 IS 9 SI SI BP 645 EP 654 DI 10.1038/ja.2014.94 PG 10 WC Biotechnology & Applied Microbiology; Immunology; Microbiology; Pharmacology & Pharmacy SC Biotechnology & Applied Microbiology; Immunology; Microbiology; Pharmacology & Pharmacy GA AQ8VE UT WOS:000343113000006 PM 25052484 ER PT J AU Yogo, N Shapiro, L Erlandson, KM AF Yogo, Norihiro Shapiro, Leland Erlandson, Kristine M. TI Sepedonium intra-abdominal infection: a case report and review of an emerging fungal infection SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Letter DE peritonitis; peritoneal dialysis; diabetes mellitus; environmental fungus C1 [Yogo, Norihiro; Shapiro, Leland; Erlandson, Kristine M.] Univ Colorado, Dept Med, Div Infect Dis, Aurora, CO 80045 USA. [Shapiro, Leland] Denver Vet Affairs Med Ctr, Div Infect Dis, Dept Med, Denver, CO USA. RP Yogo, N (reprint author), Univ Colorado, Dept Med, Div Infect Dis, Anschutz Med Campus, Aurora, CO 80045 USA. EM norihiro.yogo@ucdenver.edu NR 7 TC 0 Z9 0 U1 1 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 EI 1460-2091 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD SEP PY 2014 VL 69 IS 9 BP 2583 EP 2585 DI 10.1093/jac/dku138 PG 4 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA AR1DL UT WOS:000343322200043 PM 24788660 ER PT J AU Cha, JH Wee, HJ Seo, JH Ahn, BJ Park, JH Yang, JM Lee, SW Lee, OH Lee, HJ Gelman, IH Arai, K Lo, EH Kim, KW AF Cha, Jong-Ho Wee, Hee-Jun Seo, Ji Hae Ahn, Bum Ju Park, Ji-Hyeon Yang, Jun-Mo Lee, Sae-Won Lee, Ok-Hee Lee, Hyo-Jong Gelman, Irwin H. Arai, Ken Lo, Eng H. Kim, Kyu-Won TI Prompt meningeal reconstruction mediated by oxygen-sensitive AKAP12 scaffolding protein after central nervous system injury SO NATURE COMMUNICATIONS LA English DT Article ID EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH-FACTOR-BETA; RETINOIC ACID; TGF-BETA; DOWN-REGULATION; E-CADHERIN; BRAIN ANGIOGENESIS; BREAST-CANCER; SNAIL; BARRIER AB The meninges forms a critical epithelial barrier, which protects the central nervous system (CNS), and therefore its prompt reconstruction after CNS injury is essential for reducing neuronal damage. Meningeal cells migrate into the lesion site after undergoing an epithelial-mesenchymal transition (EMT) and repair the impaired meninges. However, the molecular mechanisms of meningeal EMT remain largely undefined. Here we show that TGF-beta 1 and retinoic acid (RA) released from the meninges, together with oxygen tension, could constitute the mechanism for rapid meningeal reconstruction. AKAP12 is an effector of this mechanism, and its expression in meningeal cells is regulated by integrated upstream signals composed of TGF-beta 1, RA and oxygen tension. Functionally, AKAP12 modulates meningeal EMT by regulating the TGF-beta 1-non-Smad-SNAI1 signalling pathway. Collectively, TGF-beta 1, RA and oxygen tension can modulate the dynamic change in AKAP12 expression, causing prompt meningeal reconstruction after CNS injury by regulating the transition between the epithelial and mesenchymal states of meningeal cells. C1 [Cha, Jong-Ho; Wee, Hee-Jun; Seo, Ji Hae; Ahn, Bum Ju; Park, Ji-Hyeon; Yang, Jun-Mo; Kim, Kyu-Won] Seoul Natl Univ, SNU Harvard NeuroVasc Protect Res Ctr, Coll Pharm, Seoul 151742, South Korea. [Cha, Jong-Ho; Wee, Hee-Jun; Seo, Ji Hae; Ahn, Bum Ju; Park, Ji-Hyeon; Yang, Jun-Mo; Kim, Kyu-Won] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 151742, South Korea. [Kim, Kyu-Won] Seoul Natl Univ, Dept Mol Med & Biopharmaceut Sci, Grad Sch Convergence Sci & Technol, Seoul 151742, South Korea. [Kim, Kyu-Won] Seoul Natl Univ, Coll Med, Seoul 151742, South Korea. [Kim, Kyu-Won] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea. [Lee, Sae-Won] Seoul Natl Univ Hosp, Dept Internal Med, Innovat Res Inst Cell Therapy, Seoul 110799, South Korea. [Lee, Ok-Hee] CHA Univ, Dept Biomed Sci, Seoul 135081, South Korea. [Lee, Hyo-Jong] Inje Univ, Coll Pharm, Gimhae 621749, South Korea. [Gelman, Irwin H.] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA. [Arai, Ken; Lo, Eng H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neuroprotect Res Lab,Dept Radiol, Boston, MA 02129 USA. [Arai, Ken; Lo, Eng H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neuroprotect Res Lab,Dept Neurol, Boston, MA 02129 USA. RP Kim, KW (reprint author), Seoul Natl Univ, SNU Harvard NeuroVasc Protect Res Ctr, Coll Pharm, Seoul 151742, South Korea. EM qwonkim@snu.ac.kr FU Global Research Laboratory Program [2011-0021874]; Brain Korea 21 Program; Global Core Research Center (GCRC) Program [2011-0030001]; National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning (MSIP) [2013-036038]; NRF of Korea - Ministry of Education [2013R1A1A2058956]; NIH [R37-NS37074, R01-76694, P01-NS55104] FX This work was supported by the Global Research Laboratory Program (2011-0021874), Brain Korea 21 Program, the Global Core Research Center (GCRC) Program (2011-0030001), 2013-036038 through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (MSIP), and Basic Science Research Program (2013R1A1A2058956 to J.-H.S.) through the NRF of Korea funded by the Ministry of Education. E. H. L. is the recipient of NIH grants (R37-NS37074, R01-76694 and P01-NS55104). We thank the Aging Tissue Bank for providing research information. NR 69 TC 4 Z9 4 U1 2 U2 11 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD SEP PY 2014 VL 5 AR 4952 DI 10.1038/ncomms5952 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AQ7HZ UT WOS:000342984800008 PM 25229625 ER PT J AU Springelkamp, H Hohn, R Mishra, A Hysi, PG Khor, CC Loomis, SJ Bailey, JNC Gibson, J Thorleifsson, G Janssen, SF Luo, XY Ramdas, WD Vithana, E Nongpiur, ME Montgomery, G Xu, L Mountain, JE Gharahkhani, P Lu, Y Amin, N Karssen, LC Sim, KS van Leeuwen, EM Iglesias, AI Verhoeven, VJM Hauser, MA Loon, SC Despriet, DDG Nag, A Venturini, C Sanfilippo, PG Schillert, A Kang, JH Landers, J Jonasson, F Cree, AJ van Koolwijk, LME Rivadeneira, F Souzeau, E Jonsson, V Menon, G Weinreb, RN de Jong, PTVM Oostra, BA Uitterlinden, AG Hofman, A Ennis, S Thorsteinsdottir, U Burdon, KP Spector, TD Mirshahi, A Saw, SM Vingerling, JR Teo, YY Haines, JL Wolfs, RCW Lemij, HG Tai, ES Jansonius, NM Jonas, JB Cheng, CY Aung, T Viswanathan, AC Klaver, CCW Craig, JE Macgregor, S Mackey, DA Lotery, AJ Stefansson, K Bergen, AAB Young, TL Wiggs, JL Pfeiffer, N Wong, TY Pasquale, LR Hewitt, AW van Duijn, CM Hammond, CJ AF Springelkamp, Henriet Hoehn, Rene Mishra, Aniket Hysi, Pirro G. Khor, Chiea-Chuen Loomis, Stephanie J. Bailey, Jessica N. Cooke Gibson, Jane Thorleifsson, Gudmar Janssen, Sarah F. Luo, Xiaoyan Ramdas, Wishal D. Vithana, Eranga Nongpiur, Monisha E. Montgomery, GrantW. Xu, Liang Mountain, Jenny E. Gharahkhani, Puya Lu, Yi Amin, Najaf Karssen, Lennart C. Sim, Kar-Seng van Leeuwen, Elisabeth M. Iglesias, Adriana I. Verhoeven, Virginie J. M. Hauser, Michael A. Loon, Seng-Chee Despriet, Dominiek D. G. Nag, Abhishek Venturini, Cristina Sanfilippo, Paul G. Schillert, Arne Kang, Jae H. Landers, John Jonasson, Fridbert Cree, Angela J. van Koolwijk, Leonieke M. E. Rivadeneira, Fernando Souzeau, Emmanuelle Jonsson, Vesteinn Menon, Geeta Weinreb, Robert N. de Jong, Paulus T. V. M. Oostra, Ben A. Uitterlinden, Andre G. Hofman, Albert Ennis, Sarah Thorsteinsdottir, Unnur Burdon, Kathryn P. Spector, Timothy D. Mirshahi, Alireza Saw, Seang-Mei Vingerling, Johannes R. Teo, Yik-Ying Haines, Jonathan L. Wolfs, Roger C. W. Lemij, Hans G. Tai, E-Shyong Jansonius, Nomdo M. Jonas, Jost B. Cheng, Ching-Yu Aung, Tin Viswanathan, Ananth C. Klaver, Caroline C. W. Craig, Jamie E. Macgregor, Stuart Mackey, David A. Lotery, Andrew J. Stefansson, Kari Bergen, Arthur A. B. Young, Terri L. Wiggs, Janey L. Pfeiffer, Norbert Wong, Tien-Yin Pasquale, Louis R. Hewitt, Alex W. van Duijn, Cornelia M. Hammond, Christopher J. CA Blue Mt Eye Study GWAS Grp NEIGHBORHOOD Consortium Wellcome Trust Case Control Consor TI Meta-analysis of genome-wide association studies identifies novel loci that influence cupping and the glaucomatous process SO NATURE COMMUNICATIONS LA English DT Article ID OPEN-ANGLE GLAUCOMA; CENTRAL CORNEAL THICKNESS; TO-DISC RATIO; INTRAOCULAR-PRESSURE; SUSCEPTIBILITY LOCI; HERITABILITY; POPULATION; ABNORMALITIES; DISRUPTION; PARAMETERS AB Glaucoma is characterized by irreversible optic nerve degeneration and is the most frequent cause of irreversible blindness worldwide. Here, the International Glaucoma Genetics Consortium conducts a meta-analysis of genome-wide association studies of vertical cup-disc ratio (VCDR), an important disease-related optic nerve parameter. In 21,094 individuals of European ancestry and 6,784 individuals of Asian ancestry, we identify 10 new loci associated with variation in VCDR. In a separate risk-score analysis of five case-control studies, Caucasians in the highest quintile have a 2.5-fold increased risk of primary open-angle glaucoma as compared with those in the lowest quintile. This study has more than doubled the known loci associated with optic disc cupping and will allow greater understanding of mechanisms involved in this common blinding condition. C1 [Springelkamp, Henriet; Ramdas, Wishal D.; Despriet, Dominiek D. G.; Vingerling, Johannes R.; Wolfs, Roger C. W.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, NL-3000 CA Rotterdam, Netherlands. [Springelkamp, Henriet; Amin, Najaf; Karssen, Lennart C.; van Leeuwen, Elisabeth M.; Iglesias, Adriana I.; van Koolwijk, Leonieke M. E.; Rivadeneira, Fernando; de Jong, Paulus T. V. M.; Uitterlinden, Andre G.; Hofman, Albert; Vingerling, Johannes R.; Klaver, Caroline C. W.; van Duijn, Cornelia M.] Erasmus MC, Dept Epidemiol, NL-3000 CA Rotterdam, Netherlands. [Hoehn, Rene; Mirshahi, Alireza; Pfeiffer, Norbert] Univ Med Ctr Mainz, Dept Ophthalmol, D-55131 Mainz, Germany. [Mishra, Aniket; Gharahkhani, Puya; Macgregor, Stuart; Young, Terri L.] Royal Brisbane Hosp, QIMR Berghofer Med Res Inst, Dept Genet & Computat Biol, Brisbane, Qld 4006, Australia. [Hysi, Pirro G.; Nag, Abhishek; Venturini, Cristina; Spector, Timothy D.; Hammond, Christopher J.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London WC2R 2LS, England. [Khor, Chiea-Chuen; Vithana, Eranga; Nongpiur, Monisha E.; Loon, Seng-Chee; Saw, Seang-Mei; Cheng, Ching-Yu; Wong, Tien-Yin] Natl Univ Singapore, Dept Ophthalmol, Singapore 119077, Singapore. [Khor, Chiea-Chuen; Vithana, Eranga; Nongpiur, Monisha E.; Loon, Seng-Chee; Saw, Seang-Mei; Cheng, Ching-Yu; Wong, Tien-Yin] Natl Univ Hlth Syst, Singapore 119077, Singapore. [Khor, Chiea-Chuen; Sim, Kar-Seng] Genome Inst Singapore, Div Human Genet, Singapore 138672, Singapore. [Loomis, Stephanie J.; Wiggs, Janey L.; Pasquale, Louis R.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA. [Loomis, Stephanie J.; Haines, Jonathan L.; Wiggs, Janey L.; Pasquale, Louis R.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Bailey, Jessica N. Cooke; Haines, Jonathan L.] Vanderbilt Univ, Sch Med, Ctr Human Genet, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA. [Bailey, Jessica N. Cooke; Haines, Jonathan L.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA. [Gibson, Jane] Univ Southampton, Fac Nat & Environm Sci, Ctr Biol Sci, Southampton SO17 1BJ, Hants, England. [Thorleifsson, Gudmar; Verhoeven, Virginie J. M.; Thorsteinsdottir, Unnur; Stefansson, Kari] deCODE Amgen, IS-101 Reykjavik, Iceland. [Janssen, Sarah F.; Bergen, Arthur A. B.] Royal Netherlands Acad Arts & Sci KNAW, NIN, Dept Clin & Mol Ophthalmogenet, NL-1105 BA Amsterdam, Netherlands. [Luo, Xiaoyan; Young, Terri L.] Duke Univ, Ctr Eye, Dept Ophthalmol, Durham, NC 27710 USA. [Vithana, Eranga; Nongpiur, Monisha E.; Saw, Seang-Mei; Cheng, Ching-Yu; Wong, Tien-Yin] Singapore Eye Res Inst, Singapore Natl Eye Ctr, Singapore 168751, Singapore. [Vithana, Eranga; Saw, Seang-Mei; Cheng, Ching-Yu; Wong, Tien-Yin] Duke Natl Univ Singapore, Grad Sch Med, Singapore 169857, Singapore. [Montgomery, GrantW.] Royal Brisbane Hosp, QIMR Berghofer Med Res Inst, Dept Genet & Computat Biol, Mol Epidemiol Lab, Brisbane, Qld 4006, Australia. [Xu, Liang; Jonas, Jost B.] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Inst Ophthalmol, Beijing 100730, Peoples R China. [Xu, Liang] Beijing Ophthalmol & Visual Sci Key Lab, Beijing 100730, Peoples R China. [Mountain, Jenny E.] Telethon Inst Child Hlth Res, Subiaco, WA 6008, Australia. [Hauser, Michael A.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Hauser, Michael A.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA. [Venturini, Cristina] UCL Inst Ophthalmol, London EC1V 9EL, England. [Sanfilippo, Paul G.; Mackey, David A.; Hewitt, Alex W.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, CERA, Melbourne, Vic 3002, Australia. [Schillert, Arne] Med Univ Lubeck, Inst Med Biometry & Stat, D-23562 Lubeck, Germany. [Kang, Jae H.; Pasquale, Louis R.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA. [Landers, John; Souzeau, Emmanuelle; Burdon, Kathryn P.; Craig, Jamie E.] Flinders Univ S Australia, Dept Ophthalmol, Adelaide, SA 5042, Australia. [Jonasson, Fridbert; Thorsteinsdottir, Unnur] Univ Iceland, Fac Med, IS-101 Reykjavik, Iceland. [Jonasson, Fridbert; Jonsson, Vesteinn] Landspitali Natl Univ Hosp, Dept Ophthalmol, IS-101 Reykjavik, Iceland. [Cree, Angela J.; Lotery, Andrew J.] Univ Southampton, Fac Med, Southampton SO17 1BJ, Hants, England. [Rivadeneira, Fernando; Uitterlinden, Andre G.] Erasmus MC, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands. [Rivadeneira, Fernando; Uitterlinden, Andre G.] Netherlands Consortium Hlth Ageing, NL-2593 CE The Hague, Netherlands. [Menon, Geeta] Frimley Pk Hosp NHS Fdn Trust, Dept Ophthalmol, Frimley GU16 7UJ, Surrey, England. [Weinreb, Robert N.] Univ Calif San Diego, Dept Ophthalmol, San Diego, CA 92093 USA. [Weinreb, Robert N.] Univ Calif San Diego, Hamilton Glaucoma Ctr, San Diego, CA 92093 USA. [de Jong, Paulus T. V. M.] Netherlands Inst Neurosci, Dept Retinal Signal Proc, NL-1105 BA Amsterdam, Netherlands. [de Jong, Paulus T. V. M.; Bergen, Arthur A. B.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands. [de Jong, Paulus T. V. M.] Leiden Univ, Med Ctr, Dept Ophthalmol, NL-2333 ZA Leiden, Netherlands. [Oostra, Ben A.] Erasmus MC, Dept Clin Genet, NL-3000 CA Rotterdam, Netherlands. [Ennis, Sarah] Univ Southampton, Fac Med, Southampton SO17 1BJ, Hants, England. [Saw, Seang-Mei; Teo, Yik-Ying; Tai, E-Shyong] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117597, Singapore. [Saw, Seang-Mei; Teo, Yik-Ying; Tai, E-Shyong] Natl Univ Hlth Syst, Singapore 117597, Singapore. [Teo, Yik-Ying] Natl Univ Singapore, Dept Stat & Appl Probabil, Singapore 119077, Singapore. [Lemij, Hans G.] Rotterdam Eye Hosp, Glaucoma Serv, NL-3011 BH Rotterdam, Netherlands. [Tai, E-Shyong] Natl Univ Singapore, Dept Med, Singapore 119077, Singapore. [Tai, E-Shyong] Natl Univ Hlth Syst, Singapore 119077, Singapore. [Jansonius, Nomdo M.] Univ Groningen, Univ Med Ctr Groningen, Dept Ophthalmol, NL-9700 RB Groningen, Netherlands. Heidelberg Univ, Seegartenklin Heidelberg, Med Fac Mannheim, Dept Ophthalmol, D-69117 Heidelberg, Germany. [Viswanathan, Ananth C.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London EC1V 2PD, England. [Viswanathan, Ananth C.] UCL Inst Ophthalmol, London EC1V 2PD, England. [Mackey, David A.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, Perth, WA 6009, Australia. [Bergen, Arthur A. B.] Univ Amsterdam, Acad Med Ctr, Dept Clin Genet, NL-1105 AZ Amsterdam, Netherlands. RP van Duijn, CM (reprint author), Erasmus MC, Dept Epidemiol, NL-3000 CA Rotterdam, Netherlands. EM c.vanduijn@erasmusmc.nl RI Macgregor, Stuart/C-6442-2009; Blackwell, Jenefer/H-3015-2015; Jankowski, Janusz/H-2706-2012; Deloukas, Panos/B-2922-2013; Rivadeneira, Fernando/O-5385-2015; Mathew, Christopher/G-3434-2015; Hewitt, Alex/D-1936-2013; Mackey, David/H-5340-2014; Palmer, Colin/C-7053-2008; OI Gillman, Matthew/0000-0002-2340-6930; Plomin, Robert/0000-0002-0756-3629; Gharahkhani, Puya/0000-0002-4203-5952; Hohn, Rene /0000-0003-2870-1469; Khor, Chiea Chuen/0000-0002-1128-4729; Hammond, Christopher/0000-0002-3227-2620; Wood, Nicholas/0000-0002-9500-3348; Tai, E Shyong/0000-0003-2929-8966; Karssen, Lennart C./0000-0002-1959-342X; Macgregor, Stuart/0000-0001-6731-8142; Sim, Kar Seng/0000-0002-3822-7759; Jankowski, Janusz/0000-0003-2130-9181; Deloukas, Panos/0000-0001-9251-070X; Rivadeneira, Fernando/0000-0001-9435-9441; Mathew, Christopher/0000-0003-4178-1838; Hewitt, Alex/0000-0002-5123-5999; Mackey, David/0000-0001-7914-4709; Palmer, Colin/0000-0002-6415-6560; Corvin, Aiden/0000-0001-6717-4089; Baird, Paul/0000-0002-1305-3502; Pirinen, Matti/0000-0002-1664-1350 FU British Heart Foundation [PG/13/66/30442]; Department of Health [SRF/01/010]; NCI NIH HHS [CA49449, CA55075, CA87969]; NCRR NIH HHS [RR015574]; NEI NIH HHS [3R01EY015872-05S1, 3R01EY019126-02S1, EY006827, EY008208, EY009149, EY009847, EY010886, EY011008, EY011671, EY012118, EY013178, EY015473, EY015543, EY015682, EY015872, EY09580, EY13315, EY144428, EY144448, EY18660, P30 EY014104, P30EY014104, R01 EY011405, R01 EY014685, R01 EY015473, R01 EY022305, R01 EY023512, R01EY022305, T32 EY007157, T32 EY021453, T32 EY21453-2]; NHGRI NIH HHS [HG005259-01, HG004608, HG004728, U01 HG004446, U01 HG004728, U01-HG004424]; NHLBI NIH HHS [HL073389, HL73042]; PHS HHS [HHSN268200782096C]; Wellcome Trust [076113, 085475/B/08/Z, 085475/Z/08/Z] NR 43 TC 22 Z9 22 U1 2 U2 13 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD SEP PY 2014 VL 5 AR 4883 DI 10.1038/ncomms5883 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AQ7HM UT WOS:000342983300010 PM 25241763 ER PT J AU Pascali, G Matesic, L Collier, TL Wyatt, N Fraser, BH Pham, TQ Salvadori, PA Greguric, I AF Pascali, Giancarlo Matesic, Lidia Collier, Thomas L. Wyatt, Naomi Fraser, Benjamin H. Pham, Tien Q. Salvadori, Piero A. Greguric, Ivan TI Optimization of nucleophilic F-18 radiofluorinations using a microfluidic reaction approach SO NATURE PROTOCOLS LA English DT Article ID POSITRON-EMISSION-TOMOGRAPHY; DOSE-ON-DEMAND; DEVICE; RADIOPHARMACEUTICALS; RADIOCHEMISTRY; RADIOSYNTHESIS; TECHNOLOGY; CHEMISTRY AB Microfluidic techniques are increasingly being used to synthesize positron-emitting radiopharmaceuticals. Several reports demonstrate higher incorporation yields, with shorter reaction times and reduced amounts of reagents compared with traditional vessel-based techniques. Microfluidic techniques, therefore, have tremendous potential for allowing rapid and cost-effective optimization of new radiotracers. This protocol describes the implementation of a suitable microfluidic process to optimize classical F-18 radiofluorination reactions by rationalizing the time and reagents used. Reaction optimization varies depending on the systems used, and it typically involves 5-10 experimental days of up to 4 h of sample collection and analysis. In particular, the protocol allows optimization of the key fluidic parameters in the first tier of experiments: reaction temperature, residence time and reagent ratio. Other parameters, such as solvent, activating agent and precursor concentration need to be stated before the experimental runs. Once the optimal set of parameters is found, repeatability and scalability are also tested in the second tier of experiments. This protocol allows the standardization of a microfluidic methodology that could be applied in any radiochemistry laboratory, in order to enable rapid and efficient radiosynthesis of new and existing [F-18]-radiotracers. Here we show how this method can be applied to the radiofluorination optimization of [F-18]-MEL050, a melanoma tumor imaging agent. This approach, if integrated into a good manufacturing practice (GMP) framework, could result in the reduction of materials and the time required to bring new radiotracers toward preclinical and clinical applications. C1 [Pascali, Giancarlo; Matesic, Lidia; Wyatt, Naomi; Fraser, Benjamin H.; Pham, Tien Q.; Greguric, Ivan] Australian Nucl Sci & Technol Org, LifeSci Div, Lucas Heights, NSW, Australia. [Collier, Thomas L.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Salvadori, Piero A.] CNR, Inst Clin Physiol, I-56100 Pisa, Italy. RP Pascali, G (reprint author), Australian Nucl Sci & Technol Org, LifeSci Div, Lucas Heights, NSW, Australia. EM giancarlo.pascali@ansto.gov.au RI Salvadori, Piero/B-2342-2012; OI Salvadori, Piero/0000-0001-6114-1059; Pascali, Giancarlo/0000-0001-7919-8416 NR 27 TC 9 Z9 9 U1 0 U2 19 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1754-2189 EI 1750-2799 J9 NAT PROTOC JI Nat. Protoc. PD SEP PY 2014 VL 9 IS 9 BP 2017 EP 2029 DI 10.1038/nprot.2014.137 PG 13 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA AR0BD UT WOS:000343227100002 PM 25079426 ER PT J AU Bi, WL Beroukhim, R AF Bi, Wenya Linda Beroukhim, Rameen TI Beating the odds: extreme long-term survival with glioblastoma SO NEURO-ONCOLOGY LA English DT Editorial Material ID NEWLY-DIAGNOSED GLIOBLASTOMA; POPULATION-BASED ANALYSIS; TEMOZOLOMIDE; BEVACIZUMAB; RADIOTHERAPY; GLIOMAS; TRIAL; IDH1 C1 [Bi, Wenya Linda] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA. [Bi, Wenya Linda; Beroukhim, Rameen] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. [Beroukhim, Rameen] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Beroukhim, Rameen] Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA. RP Beroukhim, R (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,SM1022C, Boston, MA 02215 USA. EM rameen_beroukhim@dfci.harvard.edu NR 20 TC 3 Z9 3 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD SEP PY 2014 VL 16 IS 9 BP 1159 EP 1160 DI 10.1093/neuonc/nou166 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA AQ7LJ UT WOS:000342998100001 PM 25096192 ER PT J AU Chamberlain, M Soffietti, R Raizer, J Ruda, R Brandsma, D Boogerd, W Taillibert, S Groves, MD Le Rhun, E Junck, L van den Bent, M Wen, PY Jaeckle, KA AF Chamberlain, Marc Soffietti, Riccardo Raizer, Jeffrey Ruda, Roberta Brandsma, Dieta Boogerd, Willem Taillibert, Sophie Groves, Morris D. Le Rhun, Emilie Junck, Larry van den Bent, Martin Wen, Patrick Y. Jaeckle, Kurt A. TI Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials SO NEURO-ONCOLOGY LA English DT Review ID PHASE-II TRIAL; DOSE INTRAVENOUS METHOTREXATE; CEREBROSPINAL-FLUID CYTOLOGY; NERVOUS-SYSTEM METASTASES; NEOPLASTIC MENINGITIS; BREAST-CANCER; SOLID TUMORS; INTRATHECAL CHEMOTHERAPY; LYMPHOMATOUS MENINGITIS; PROGNOSTIC-SIGNIFICANCE AB Purpose. To date, response criteria and optimal methods for assessment of outcome have not been standardized in patients with leptomeningeal metastasis (LM). Methods. A Response Assessment in Neuro-Oncology working group of experts in LM critically reviewed published literature regarding randomized clinical trials (RCTs) and trial design in patients with LM. Results. A literature review determined that 6 RCTs regarding the treatment of LM have been published, all of which assessed the response to intra-CSF based chemotherapy. Amongst these RCTs, only a single trial attempted to determine whether intra-CSF chemotherapy was of benefit compared with systemic therapy. Otherwise, this pragmatic question has not been formally addressed in patients with solid cancers and LM. The methodology of the 6 RCTs varied widely with respect to pretreatment evaluation, type of treatment, and response to treatment. Additionally there was little uniformity in reporting of treatment-related toxicity. One RCT suggests no advantage of combined versus single-agent intra-CSF chemotherapy in patients with LM. No specific intra-CSF regimen has shown superior efficacy in the treatment of LM, with the exception of liposomal cytarabine in patients with lymphomatous meningitis. Problematic with all RCTs is the lack of standardization with respect to response criteria. There was considerable variation in definitions of response by clinical examination, neuroimaging, and CSF analysis. Conclusion. Based upon a review of published RCTs in LM, there exists a significant unmet need for guidelines for evaluating patients with LM in clinical practice as well as for response assessment in clinical trials. C1 [Chamberlain, Marc] Univ Washington, Dept Neurol, Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. [Soffietti, Riccardo; Ruda, Roberta] Univ Hosp, Dept Neurosci, Div Neurooncol, Turin, Italy. [Raizer, Jeffrey] Northwestern Univ, Dept Neurol, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. [Brandsma, Dieta; Boogerd, Willem] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Neurooncol, Amsterdam, Netherlands. [Taillibert, Sophie] Grp Hosp Pitie Salpetriere, Dept Neurooncol Mazarin, F-75634 Paris, France. [Taillibert, Sophie] Grp Hosp Pitie Salpetriere, Dept Radiat Oncol, F-75634 Paris, France. [Taillibert, Sophie] Univ Paris 06, Paris, France. [Groves, Morris D.] Texas Oncol US Oncol Res, Austin Brain Tumor Ctr, Austin, TX USA. [Le Rhun, Emilie] Univ Hosp, Dept Neurooncol, Lille, France. [Le Rhun, Emilie] Ctr Oscar Lambret, Dept Neurol, F-59020 Lille, France. [Junck, Larry] Univ Michigan, Dept Neurol, Ann Arbor, MI USA. [van den Bent, Martin] Erasmus MC Daniel den Hoed Canc Ctr, Dept Neurooncol, Rotterdam, Netherlands. [Wen, Patrick Y.] Massachusetts Gen Hosp, Dept Neurol, Dana Farber Canc Inst, Boston, MA 02114 USA. [Jaeckle, Kurt A.] Mayo Clin Florida, Dept Neurol & Oncol, Jacksonville, FL USA. RP Chamberlain, M (reprint author), Univ Washington, Dept Neurol & Neurol Surg, Div Neurooncol, Fred Hutchinson Res Canc Ctr,Seattle Canc Care Al, 825 Eastlake Ave,POB 19023,MS G4940, Seattle, WA 98109 USA. EM chammbemc@u.washington.edu NR 51 TC 29 Z9 30 U1 1 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD SEP PY 2014 VL 16 IS 9 BP 1176 EP 1185 DI 10.1093/neuonc/nou089 PG 10 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA AQ7LJ UT WOS:000342998100008 PM 24867803 ER PT J AU Tarnoki, AD Tarnoki, DL Baffy, G AF Tarnoki, Adam D. Tarnoki, David L. Baffy, Gyorgy TI Response to the letter entitled "Bioimpedance analysis-The shortcomings" SO OBESITY RESEARCH & CLINICAL PRACTICE LA English DT Letter DE Genetics; Body composition parameters; Bioelectrical impedance analysis; Twin study ID X-RAY ABSORPTIOMETRY; BIOELECTRICAL-IMPEDANCE; WEIGHT C1 [Tarnoki, Adam D.; Tarnoki, David L.] Semmelweis Univ, Dept Radiol & Oncotherapy, H-1082 Budapest, Hungary. [Baffy, Gyorgy] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Dept Med, Boston, MA 02130 USA. RP Tarnoki, AD (reprint author), Semmelweis Univ, Dept Radiol & Oncotherapy, 78-A Ulloi St, H-1082 Budapest, Hungary. EM tarnoki4@gmail.com NR 8 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1871-403X EI 1878-0318 J9 OBES RES CLIN PRACT JI Obes. Res. Clin. Pract. PD SEP-OCT PY 2014 VL 8 IS 5 BP E511 EP E512 DI 10.1016/j.orcp.2014.06.005 PG 2 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA AQ8SS UT WOS:000343102900012 PM 25081810 ER PT J AU Meylan, S Moskowitz, SM Kim, SH Collins, J AF Meylan, Sylvain Moskowitz, Samuel M. Kim, Sun Ho Collins, James TI A NOVEL THERAPEUTIC APPROACH THAT TARGETS PERSISTER CELLS SO PEDIATRIC PULMONOLOGY LA English DT Meeting Abstract ID CYSTIC-FIBROSIS; PSEUDOMONAS-AERUGINOSA C1 [Moskowitz, Samuel M.; Kim, Sun Ho] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA. [Meylan, Sylvain; Collins, James] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA. NR 6 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 8755-6863 EI 1099-0496 J9 PEDIATR PULM JI Pediatr. Pulmonol. PD SEP PY 2014 VL 49 SU 38 MA S4.4 BP 132 EP 132 PG 1 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA AQ6MD UT WOS:000342926000016 ER PT J AU Solomon, GM Frances, R Chu, KK Gabriel, G Birket, SE Lemke, K Klena, N Mojahed, D Tearney, G Lo, C Rowe, SM AF Solomon, G. M. Frances, R. Chu, K. K. Gabriel, G. Birket, S. E. Lemke, K. Klena, N. Mojahed, D. Tearney, G. Lo, C. Rowe, S. M. TI MICRO-OCT TO INTERROGATE MECHANISMS OF ALTERED CILIARY DYNAMICS AND MUCUS TRANSPORT SO PEDIATRIC PULMONOLOGY LA English DT Meeting Abstract C1 [Solomon, G. M.; Birket, S. E.; Rowe, S. M.] UAB, Dept Internal Med, Birmingham, AL USA. [Frances, R.; Gabriel, G.; Lemke, K.; Klena, N.; Lo, C.] Univ Pittsburgh, Pittsburgh, PA USA. [Chu, K. K.; Mojahed, D.; Tearney, G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 8755-6863 EI 1099-0496 J9 PEDIATR PULM JI Pediatr. Pulmonol. PD SEP PY 2014 VL 49 SU 38 MA 83 BP 244 EP 244 PG 1 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA AQ6MD UT WOS:000342926000167 ER PT J AU Birket, SE Tuggle, KL Chu, KK Tearney, GJ Fanucchi, MV Sorscher, EJ Rowe, SM AF Birket, S. E. Tuggle, K. L. Chu, K. K. Tearney, G. J. Fanucchi, M., V Sorscher, E. J. Rowe, S. M. TI CFTR-/- RAT EXHIBITS DELAYED MUCOCILIARY CLEARANCE CHARACTERISTIC OF CYSTIC FIBROSIS AIRWAY DISEASE SO PEDIATRIC PULMONOLOGY LA English DT Meeting Abstract C1 [Birket, S. E.; Tuggle, K. L.; Fanucchi, M., V; Sorscher, E. J.; Rowe, S. M.] Univ Alabama Birmingham, Birmingham, AL USA. [Chu, K. K.; Tearney, G. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 8755-6863 EI 1099-0496 J9 PEDIATR PULM JI Pediatr. Pulmonol. PD SEP PY 2014 VL 49 SU 38 MA 87 BP 246 EP 246 PG 1 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA AQ6MD UT WOS:000342926000171 ER PT J AU Ford, TN Chu, KK Birket, SE Solomon, GM Mazur, M Rowe, SM Tearney, GJ AF Ford, T. N. Chu, K. K. Birket, S. E. Solomon, G. M. Mazur, M. Rowe, S. M. Tearney, G. J. TI DUAL-MODALITY FLUORESCENCE/MICRO-OPTICAL COHERENCE TOMOGRAPHY SO PEDIATRIC PULMONOLOGY LA English DT Meeting Abstract C1 [Birket, S. E.; Solomon, G. M.; Mazur, M.; Rowe, S. M.] Univ Alabama Birmingham, Birmingham, AL USA. [Ford, T. N.; Chu, K. K.; Tearney, G. J.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 8755-6863 EI 1099-0496 J9 PEDIATR PULM JI Pediatr. Pulmonol. PD SEP PY 2014 VL 49 SU 38 MA 94 BP 248 EP 248 PG 1 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA AQ6MD UT WOS:000342926000178 ER PT J AU Wells, JM Farris, RF Dransfield, MT Rowe, SM AF Wells, J. M. Farris, R. F. Dransfield, M. T. Rowe, S. M. TI CT-DETECTED PULMONARY ARTERY ENLARGEMENT PREDICTS PULMONARY EXACERBATIONS IN CYSTIC FIBROSIS SO PEDIATRIC PULMONOLOGY LA English DT Meeting Abstract C1 [Wells, J. M.; Farris, R. F.; Dransfield, M. T.; Rowe, S. M.] UAB, Birmingham, AL USA. [Wells, J. M.; Dransfield, M. T.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 8755-6863 EI 1099-0496 J9 PEDIATR PULM JI Pediatr. Pulmonol. PD SEP PY 2014 VL 49 SU 38 MA 213 BP 291 EP 291 PG 1 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA AQ6MD UT WOS:000342926000297 ER PT J AU Fernandez, CM Watson, JD Bowers, H Chu, KK Li, Y Birket, SE Mazur, M Raju, S Tearney, GJ Baker, S Rowe, SM AF Fernandez, C. M. Watson, J. D. Bowers, H. Chu, K. K. Li, Y. Birket, S. E. Mazur, M. Raju, S. Tearney, G. J. Baker, S. Rowe, S. M. TI PAAG DECREASES VISCOSITY AND IMPROVES TRANSPORTABILITY OF CYSTIC FIBROSIS MUCUS IN SITU SO PEDIATRIC PULMONOLOGY LA English DT Meeting Abstract C1 [Fernandez, C. M.; Watson, J. D.; Bowers, H.; Li, Y.; Birket, S. E.; Mazur, M.; Raju, S.; Rowe, S. M.] Univ Alabama Birmingham, Birmingham, AL USA. [Chu, K. K.; Tearney, G. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Baker, S.] Synedgen Inc, Claremont, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 8755-6863 EI 1099-0496 J9 PEDIATR PULM JI Pediatr. Pulmonol. PD SEP PY 2014 VL 49 SU 38 MA 253 BP 306 EP 306 PG 1 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA AQ6MD UT WOS:000342926000337 ER PT J AU Chu, KK Unglert, C Carruth, RW Ford, TN Singh, K Birket, SE Solomon, GM Rowe, SM Tearney, GJ AF Chu, K. K. Unglert, C. Carruth, R. W. Ford, T. N. Singh, K. Birket, S. E. Solomon, G. M. Rowe, S. M. Tearney, G. J. TI IN VIVO FUNCTIONAL IMAGING OF CILIA AND MUCOCILIARY TRANSPORT WITH HIGH RESOLUTION mu OCT SO PEDIATRIC PULMONOLOGY LA English DT Meeting Abstract C1 [Birket, S. E.; Solomon, G. M.; Rowe, S. M.] Univ Alabama Birmingham, Birmingham, AL USA. [Chu, K. K.; Unglert, C.; Carruth, R. W.; Ford, T. N.; Singh, K.; Tearney, G. J.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 8755-6863 EI 1099-0496 J9 PEDIATR PULM JI Pediatr. Pulmonol. PD SEP PY 2014 VL 49 SU 38 MA 278 BP 315 EP 315 PG 1 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA AQ6MD UT WOS:000342926000362 ER PT J AU Linnemann, RW Buxton, D O'Malley, PJ Friedman, D Georgiopoulos, AM Sicilian, L Sawicki, GS Moskowitz, SM AF Linnemann, R. W. Buxton, D. O'Malley, P. J. Friedman, D. Georgiopoulos, A. M. Sicilian, L. Sawicki, G. S. Moskowitz, S. M. TI DEVELOPMENT OF A CF-SPECIFIC PALLIATIVE CARE CURRICULUM AND ASSESSMENT OF CF PROVIDER COMFORT WITH PALLIATIVE CARE SKILLS SO PEDIATRIC PULMONOLOGY LA English DT Meeting Abstract C1 [Linnemann, R. W.; Buxton, D.; O'Malley, P. J.; Friedman, D.; Georgiopoulos, A. M.; Sicilian, L.; Moskowitz, S. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Sawicki, G. S.] Boston Childrens Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 8755-6863 EI 1099-0496 J9 PEDIATR PULM JI Pediatr. Pulmonol. PD SEP PY 2014 VL 49 SU 38 MA 576 BP 428 EP 429 PG 2 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA AQ6MD UT WOS:000342926000660 ER PT J AU Andreano, JM Dickerson, BC Barrett, LF AF Andreano, Joseph M. Dickerson, Bradford C. Barrett, Lisa Feldman TI Sex differences in the persistence of the amygdala response to negative material SO SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE LA English DT Article DE amygdala; sex; habituation ID POSTTRAUMATIC-STRESS-DISORDER; NATIONAL-COMORBIDITY-SURVEY; EVENT-RELATED FMRI; GENDER-DIFFERENCES; FUNCTIONAL MRI; NEUTRAL FACES; PSYCHIATRIC-DISORDERS; FACIAL EXPRESSIONS; EMOTIONAL MEMORY; HORMONAL CYCLE AB Previous studies have indicated that men and women have different amygdala responses to novel (vs familiar) and valenced (positive vs negative) material. It is not known, however, whether these affective sex differences are related. In this study, we tested whether women have more persistent amygdala responses to familiar, negative material than men do. During fMRI, male and female participants viewed evocative images that varied in novelty and valence. Women and men showed equivalent responses to novel negative material, but women showed a sustained amygdala response to familiar negative material relative to men, indicating that women's amygdala responses were more persistent over multiple repetitions of negative material. Individuals with more persistent amygdala responses also reported greater levels of negative effect. These findings have implications for sex differences in the incidence of affective disorders. C1 [Andreano, Joseph M.; Barrett, Lisa Feldman] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02129 USA. [Dickerson, Bradford C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02129 USA. [Barrett, Lisa Feldman] Northeastern Univ, Dept Psychol, Boston, MA 02115 USA. RP Andreano, JM (reprint author), 149 13th St, Boston, MA 02129 USA. EM andreano@nmr.mgh.harvard.edu FU National Institute on Aging [R01AG030311] FX This research and the preparation of this manuscript were funded by National Institute on Aging; grant #R01AG030311. NR 62 TC 6 Z9 6 U1 2 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1749-5016 EI 1749-5024 J9 SOC COGN AFFECT NEUR JI Soc. Cogn. Affect. Neurosci. PD SEP PY 2014 VL 9 IS 9 BP 1388 EP 1394 DI 10.1093/scan/nst127 PG 7 WC Neurosciences; Psychology; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA AQ7IH UT WOS:000342985600019 PM 24036962 ER PT J AU Takayesu, JK Ramoska, EA Clark, TR Hansoti, B Dougherty, J Freeman, W Weaver, KR Chang, YC Gross, E AF Takayesu, James Kimo Ramoska, Edward A. Clark, Ted R. Hansoti, Bhakti Dougherty, Joseph Freeman, Will Weaver, Kevin R. Chang, Yuchiao Gross, Eric TI Factors Associated With Burnout During Emergency Medicine Residency SO ACADEMIC EMERGENCY MEDICINE LA English DT Article ID AMERICAN-SURGEONS; PATIENT-CARE; JOB BURNOUT; PHYSICIANS; SATISFACTION; VALIDITY; WELLNESS; QUALITY; STRESS AB Objectives: While the prevalence of burnout in practicing emergency physicians has been studied, little is known of the prevalence and risk factors in emergency medicine (EM) residents. The aim of this study was to assess the prevalence of burnout among EM residents and the individual-level factors associated with burnout. Methods: Eight EM residency programs were surveyed using the Maslach Burnout Inventory (MBI). Demographic data and data on job satisfaction and tolerance of uncertainty in clinical decision-making were collected using validated instruments. Results: Of 289 eligible residents, 218 completed the MBI (response rate = 75%). A total of 142 residents (65%) met the criteria for burnout. Complete data sets of the other instruments were obtained from 193 (response rate = 67%), and this group comprised our study population. Subjects having a significant other or spouse had a higher prevalence of burnout compared to single residents (60% vs. 40%, p = 0.002). Poor global job satisfaction (p < 0.0001), lack of administrative autonomy (p = 0.021), and lack of clinical autonomy (p = 0.031) correlated with burnout, as did intolerance of uncertainty (p = 0.015). Conclusions: Burnout is highly prevalent in EM residents. Interventions should be targeted at 1) improving resident autonomy in the emergency department where possible, 2) supervision and instruction on medical decision-making that may affect or teach individuals to cope with risk tolerance, and 3) social supports to reduce work-home conflicts during training. (C) 2014 by the Society for Academic Emergency Medicine C1 [Takayesu, James Kimo; Chang, Yuchiao] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Ramoska, Edward A.] Drexel Univ Coll Med, Dept Emergency Med, Philadelphia, PA 19104 USA. [Clark, Ted R.] So Illinois Univ, Div Emergency Med, Carbondale, IL 62901 USA. [Hansoti, Bhakti] Johns Hopkins Univ, Dept Emergency Med, Baltimore, MD USA. [Dougherty, Joseph] Ohio Valley Med Ctr, Dept Emergency Med, Wheeling, WV USA. [Freeman, Will] Louisiana State Univ Heath Baton Rouge Emergency, Dept Emergency Med, Baton Rouge, LA USA. [Weaver, Kevin R.] Lehigh Valley Hlth Network, Dept Emergency Med, Bethlehem, PA USA. [Gross, Eric] Hennepin Cty Med Ctr, Dept Emergency Med, Minneapolis, MN 55415 USA. RP Ramoska, EA (reprint author), Drexel Univ Coll Med, Dept Emergency Med, Philadelphia, PA 19104 USA. EM edward.ramoska@drexelmed.edu OI Hansoti, Bhakti/0000-0003-0188-9764 NR 27 TC 9 Z9 9 U1 1 U2 17 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1069-6563 EI 1553-2712 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD SEP PY 2014 VL 21 IS 9 BP 1031 EP 1035 DI 10.1111/acem.12464 PG 5 WC Emergency Medicine SC Emergency Medicine GA AQ4ZL UT WOS:000342810800011 ER PT J AU Tanev, KS Vento, JA AF Tanev, Kaloyan S. Vento, John A. TI Ms L: A Case of a Reversible Phenotypic and Brain Function Equivalent of Frontotemporal Dementia SO AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS LA English DT Article DE frontotemporal dementia; pick disease of the brain; pseudodementia; single-photon emission computerized tomography; magnetic resonance imaging ID SPECIAL TOPIC PAPERS; PICKS-DISEASE; VARIANT AB Frontotemporal dementia (FTD) is second only to Alzheimer's disease in individuals younger than 65 years of age. Behavioral variant FTD (bvFTD) presents with nonspecific symptoms such as disinhibition, apathy, or emotional blunting. Although neuropsychological testing and structural neuroimaging are not very helpful in diagnosing bvFTD in its initial stages, newer quantitative structural methods and functional neuroimaging have better sensitivity and specificity. Ms L presented with blunted affect, disinhibition, impairments in insight, planning ability and social comportment, changed dietary habits, and episodes of mutism. Her brain magnetic resonance imaging was normal whereas her single-photon emission computed tomography (SPECT) pattern was consistent with FTD. Her clinical presentation was consistent with bvFTD yet both the symptoms and SPECT findings reversed after 2 years of follow-up. We suggest that Ms L had a reversible phenotypic and brain function equivalent of bvFTD. The case highlights the limitations of our diagnostic tools and the complex relationship between clinical symptoms, neuroimaging, and etiology. C1 [Tanev, Kaloyan S.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Vento, John A.] Univ Connecticut, Ctr Hlth, Dept Radiol, Farmington, CT USA. RP Tanev, KS (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Warren 1220, Boston, MA 02114 USA. EM ktanev@partners.org NR 12 TC 0 Z9 0 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1533-3175 EI 1938-2731 J9 AM J ALZHEIMERS DIS JI Am. J. Alzheimers Dis. Other Dement. PD SEP PY 2014 VL 29 IS 6 BP 513 EP 520 DI 10.1177/1533317514522851 PG 8 WC Geriatrics & Gerontology; Clinical Neurology SC Geriatrics & Gerontology; Neurosciences & Neurology GA AQ4XX UT WOS:000342805900005 PM 24550543 ER PT J AU Silberbogen, AK Busby, AK Ulloa, EW AF Silberbogen, Amy K. Busby, Andrea K. Ulloa, Erin W. TI Impact of Psychological Distress on Prostate Cancer Screening in U.S. Military Veterans SO AMERICAN JOURNAL OF MENS HEALTH LA English DT Article DE prostate cancer; screening; PTSD; depression; barriers ID POSTTRAUMATIC-STRESS-DISORDER; AFRICAN-AMERICAN WOMEN; AGENT-ORANGE EXPOSURE; PSYCHOMETRIC PROPERTIES; RADICAL PROSTATECTOMY; HEALTH BEHAVIORS; PTSD CHECKLIST; FAMILY-HISTORY; PERCEIVED RISK; MENTAL-HEALTH AB The benefit of routine prostate cancer screening is currently under debate; however, many experts recommend that men with elevated risk for the disease discuss the potential risks and benefits of screening with their health care team. Psychological factors have been negatively associated with preventive health behaviors such as cancer screenings. The purpose of this study was to investigate the impact of depressive and trauma-related symptoms on prostate cancer screening behaviors and relevant health care perceptions among a sample of U. S. military veterans, as veterans are at higher risk for prostate cancer, depression, and posttraumatic stress disorder than the general population. Participants (n = 350) were a national sample of predominantly Caucasian (84.6%) male U.S. military veterans (60.5 years +/- 8.9) who completed an online questionnaire regarding past prostate cancer screening engagement, as well as validated measures of depression, posttraumatic stress disorder, and perceived barriers and benefits to prostate cancer screening. Results indicate that greater depressive symptoms, trauma-related symptoms, and perceived barriers were associated with lower rates of past prostate cancer screening among this veteran sample and that greater depressive and trauma-related symptoms were associated with greater perceived barriers to prostate cancer screening. As prostate cancer screening recommendations continue to evolve, it is important for health care providers not only to discuss pros and cons of screening with high risk men but also to consider the impact of psychological distress on the decision-making process. C1 [Silberbogen, Amy K.; Busby, Andrea K.; Ulloa, Erin W.] VA Boston Healthcare Syst, Boston, MA 02130 USA. [Silberbogen, Amy K.] Boston Univ, Sch Med, Boston, MA 02118 USA. RP Silberbogen, AK (reprint author), VA Boston Healthcare Syst, Mail Stop 116-B,150 S Huntington Ave, Boston, MA 02130 USA. EM Amy.Silberbogen@va.gov FU Veterans Health Administration Rehabilitation, Research, and Development Service [F4120] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Preparation of this article was supported by a grant from the Veterans Health Administration Rehabilitation, Research, and Development Service (F4120). NR 53 TC 1 Z9 1 U1 4 U2 9 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1557-9883 EI 1557-9891 J9 AM J MENS HEALTH JI Am. J. Mens Health PD SEP PY 2014 VL 8 IS 5 BP 399 EP 408 DI 10.1177/1557988313516357 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ7GU UT WOS:000342981400005 PM 24362494 ER PT J AU Scalea, JR Okumi, M Villani, V Shimizu, A Nishimura, H Gillon, BC Torabi, R Cormack, T Moran, S LeGuern, C Sachs, DH Yamada, K AF Scalea, J. R. Okumi, M. Villani, V. Shimizu, A. Nishimura, H. Gillon, B. C. Torabi, R. Cormack, T. Moran, S. LeGuern, C. Sachs, D. H. Yamada, K. TI Abrogation of Renal Allograft Tolerance in MGH Miniature Swine: The Role of Intra-Graft and Peripheral Factors in Long-Term Tolerance SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article ID CLASS-I; TRANSPLANTATION TOLERANCE; KIDNEY ALLOGRAFTS; BLOOD LYMPHOCYTES; INDUCTION; CYCLOSPORINE; MAINTENANCE; ANTIGEN; CELLS; MODEL AB We have previously demonstrated that long-term tolerance (LTT) of an MHC class-I mismatched renal allograft can be achieved with a short course of cyclosporine. In order to examine regulatory mechanisms underlying tolerance in this model, we assessed the contributions of factors within the graft and in the peripheral blood for their relative roles in the maintenance of stable tolerance. Twelve LTT recipients of MHC class-I mismatched primary kidneys were subjected to a treatment consisting of donor-specific transfusion followed by leukapheresis, in order to remove peripheral leukocytes, including putative regulatory T cells (Tregs). Following treatment, 2 controls were followed clinically and 10 animals had the primary graft removed and received a second, donor-MHC-matched kidney. Neither control animal showed evidence of rejection, while 8 of 10 retransplanted animals developed either rejection crisis or full rejection of the second transplant. In vitro assays confirmed that the removed leukocytes were suppressive and that CD4(+)Foxp3(+) Treg reconstitution in blood and kidney grafts correlated with return to normal renal function in animals experiencing transient rejection crises. These data indicate that components of accepted kidney grafts as well as peripheral regulatory components both contribute to the tolerogenic environment required for tolerance of MHC class-I mismatched allotransplants. C1 [Scalea, J. R.; Okumi, M.; Villani, V.; Shimizu, A.; Nishimura, H.; Gillon, B. C.; Torabi, R.; Cormack, T.; Moran, S.; LeGuern, C.; Sachs, D. H.; Yamada, K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA 02114 USA. RP Yamada, K (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA 02114 USA. EM kaz.yamada@tbrc.mgh.harvard.edu OI Villani, Vincenzo/0000-0002-6078-9766 FU American Society of Transplantation grant; Massachusetts General Hospital Swine Facility grant [1C06RR20135-01]; MGH Swine Facility grant [C06 RR020135-01]; NIH/NIAID [4R37AI031046-21] FX This work was supported in part by an American Society of Transplantation grant awarded to JRS, Massachusetts General Hospital Swine Facility grant 1C06RR20135-01, the MGH Swine Facility grant #C06 RR020135-01 and NIH/NIAID 4R37AI031046-21. The authors gratefully acknowledge Novartis for cyclopsorine, Drs. David Leonard and Joren Madsen for critical review of the manuscript and Rebecca A. Brophy for expert editorial assistance. NR 27 TC 6 Z9 6 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD SEP PY 2014 VL 14 IS 9 BP 2001 EP 2010 DI 10.1111/ajt.12816 PG 10 WC Surgery; Transplantation SC Surgery; Transplantation GA AQ3BP UT WOS:000342664000011 PM 25100613 ER PT J AU Adam, B Randhawa, P Chan, S Zeng, G Regele, H Kushner, YB Colvin, RB Reeve, J Mengel, M AF Adam, B. Randhawa, P. Chan, S. Zeng, G. Regele, H. Kushner, Y. B. Colvin, R. B. Reeve, J. Mengel, M. TI Banff Initiative for Quality Assurance in Transplantation (BIFQUIT): Reproducibility of Polyomavirus Immunohistochemistry in Kidney Allografts SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article ID ANTIBODY-MEDIATED REJECTION; LARGE MULTICENTER TRIAL; INTEROBSERVER REPRODUCIBILITY; WORKING PROPOSAL; BK VIRUS; NEPHROPATHY; AGREEMENT; DIAGNOSIS; PATHOLOGY; BIOPSY AB Immunohistochemistry (IHC) is the gold standard for diagnosing (positive vs. negative) polyomavirus BK (BKV) nephropathy and has the potential for disease staging based on staining intensity and quantification of infected cells. This multicenter trial evaluated the reproducibility of BKV IHC among 81 pathologists at 60 institutions. Participants stained tissuemicroarray slides and scored themfor staining intensity and percentage of positive nuclei. Staining protocol details and evaluation scores were collected online. Slides were returned for centralized panel re-evaluation and kappa statisticswere calculated. Individual assessment of staining intensity and percentage was more reproducible than combined scoring. Inter-institutional reproducibility was moderate for staining intensity (k = 0.49) and percentage (k = 0.42), fair for combined (k = 0.25) and best for simple positive/negative scoring (k = 0.78). Inter-observer reproducibility was substantial for intensity (k = 0.74), percentage (k = 0.66), positive/negative (k = 0.78) and moderate for combined scoring (k = 0.43). Inter-laboratory reproducibility was fair for intensity (k = 0.37), percentage (k = 0.40) and combined (k = 0.24), but substantial for positive/negative scoring (k = 0.67). BKV RNA copies/cell correlated with staining intensity (r = 0.56) and percentage (r = 0.62). These results indicate that BKV IHC is reproducible between observers but scoring should be simplified to a single-feature schema. Standardization of tissue processing and staining protocols would further improve inter-laboratory reproducibility. C1 [Adam, B.; Chan, S.; Reeve, J.; Mengel, M.] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB, Canada. [Randhawa, P.; Zeng, G.] Univ Pittsburgh, Dept Pathol, Div Transplantat Pathol, Pittsburgh, PA USA. [Chan, S.; Reeve, J.] Univ Alberta, Alberta Transplant Appl Genom Ctr, Edmonton, AB, Canada. [Regele, H.] Med Univ Vienna, Vienna Gen Hosp, Dept Pathol, Vienna, Austria. [Kushner, Y. B.; Colvin, R. B.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Kushner, Y. B.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Colvin, R. B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Mengel, M (reprint author), Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB, Canada. EM mmengel@ualberta.ca FU NIAID NIH HHS [R01 AI 51227, R01 AI051227] NR 24 TC 9 Z9 9 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD SEP PY 2014 VL 14 IS 9 BP 2137 EP 2147 DI 10.1111/ajt.12794 PG 11 WC Surgery; Transplantation SC Surgery; Transplantation GA AQ3BP UT WOS:000342664000025 PM 25091177 ER PT J AU Pesanova, D Nemcova, L Vodickova-Kepkova, K Vodicka, P Jeseta, M Machatkova, M Kanka, J AF Pesanova, D. Nemcova, L. Vodickova-Kepkova, K. Vodicka, P. Jeseta, M. Machatkova, M. Kanka, J. TI Detection of genes associated with developmental competence of bovine oocytes, quantification of transcript levels before and after oocyte maturation SO ANIMAL REPRODUCTION SCIENCE LA English DT Meeting Abstract CT 4th Mammalian Embryo Genomics Meeting CY OCT 09-11, 2013 CL Quebec, CANADA SP EmbryoGENE Network C1 [Pesanova, D.; Nemcova, L.; Vodickova-Kepkova, K.; Vodicka, P.; Kanka, J.] Acad Sci Czech Republic, Inst Anim Physiol & Genet, Libechov, Czech Republic. [Jeseta, M.; Machatkova, M.] Vet Res Inst, CS-62132 Brno, Czech Republic. [Vodicka, P.] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA USA. [Vodicka, P.] Harvard Univ, Sch Med, Charlestown, MA USA. RI Jeseta, Michal/A-3159-2013 OI Jeseta, Michal/0000-0003-1778-3454 NR 0 TC 0 Z9 0 U1 4 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-4320 EI 1873-2232 J9 ANIM REPROD SCI JI Anim. Reprod. Sci. PD SEP PY 2014 VL 149 IS 1-2 SI SI BP 99 EP 100 DI 10.1016/j.anireprosci.2014.06.014 PG 2 WC Agriculture, Dairy & Animal Science; Reproductive Biology SC Agriculture; Reproductive Biology GA AQ5WH UT WOS:000342878800016 ER PT J AU Mattfeld, AT Gabrieli, JDE Biederman, J Spencer, T Brown, A Kotte, A Kagan, E Whitfield-Gabrieli, S AF Mattfeld, Aaron T. Gabrieli, John D. E. Biederman, Joseph Spencer, Thomas Brown, Ariel Kotte, Amelia Kagan, Elana Whitfield-Gabrieli, Susan TI Brain differences between persistent and remitted attention deficit hyperactivity disorder SO BRAIN LA English DT Article DE ADHD; default-mode network; fMRI; posterior cingulate cortex; longitudinal ID EXECUTIVE FUNCTION DEFICITS; DEFICIT/HYPERACTIVITY DISORDER; FUNCTIONAL CONNECTIVITY; DEFAULT NETWORK; ADHD; METAANALYSIS; NEUROSCIENCE; DYSFUNCTION; GIRLS; FMRI AB Previous resting state studies examining the brain basis of attention deficit hyperactivity disorder have not distinguished between patients who persist versus those who remit from the diagnosis as adults. To characterize the neurobiological differences and similarities of persistence and remittance, we performed resting state functional magnetic resonance imaging in individuals who had been longitudinally and uniformly characterized as having or not having attention deficit hyperactivity disorder in childhood and again in adulthood (16 years after baseline assessment). Intrinsic functional brain organization was measured in patients who had a persistent diagnosis in childhood and adulthood (n = 13), in patients who met diagnosis in childhood but not in adulthood (n = 22), and in control participants who never had attention deficit hyperactivity disorder (n = 17). A positive functional correlation between posterior cingulate and medial prefrontal cortices, major components of the default-mode network, was reduced only in patients whose diagnosis persisted into adulthood. A negative functional correlation between medial and dorsolateral prefrontal cortices was reduced in both persistent and remitted patients. The neurobiological dissociation between the persistence and remittance of attention deficit hyperactivity disorder may provide a framework for the relation between the clinical diagnosis, which indicates the need for treatment, and additional deficits that are common, such as executive dysfunctions. C1 [Mattfeld, Aaron T.; Gabrieli, John D. E.; Whitfield-Gabrieli, Susan] MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA. [Mattfeld, Aaron T.; Gabrieli, John D. E.; Whitfield-Gabrieli, Susan] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA. [Biederman, Joseph; Spencer, Thomas; Brown, Ariel; Kotte, Amelia; Kagan, Elana] Massachusetts Gen Hosp, Clin & Res Program Paediat Psychopharmacol, Boston, MA 02114 USA. [Biederman, Joseph; Spencer, Thomas; Brown, Ariel; Kotte, Amelia; Kagan, Elana] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Kotte, Amelia] Univ Hawaii Manoa, Dept Psychol, Honolulu, HI 96822 USA. RP Mattfeld, AT (reprint author), MIT, McGovern Inst Brain Res, Dept Brain & Cognit Sci, 43 Vassar St,46-4033F,Bldg 46, Cambridge, MA 02139 USA. EM amattfel@mit.edu OI Kotte, Amelia/0000-0002-0198-7914 FU Poitras Centre for Affective Disorders Research at the McGovern Institute for Brain Research at MIT; Paediatric Psychopharmacology Council Fund at the Massachusetts General Hospital FX The Poitras Centre for Affective Disorders Research at the McGovern Institute for Brain Research at MIT supported this work. Additional support derived from the Paediatric Psychopharmacology Council Fund at the Massachusetts General Hospital. NR 30 TC 18 Z9 18 U1 4 U2 11 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 EI 1460-2156 J9 BRAIN JI Brain PD SEP PY 2014 VL 137 BP 2423 EP 2428 DI 10.1093/brain/awu137 PN 9 PG 6 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AQ7LD UT WOS:000342996000012 PM 24916335 ER PT J AU Chonghaile, TN Roderick, JE Glenfield, C Ryan, J Sallan, SE Silverman, LB Loh, ML Hunger, SP Wood, B DeAngelo, DJ Stone, R Harris, M Gutierrez, A Kelliher, MA Letai, A AF Chonghaile, Triona Ni Roderick, Justine E. Glenfield, Cian Ryan, Jeremy Sallan, Stephen E. Silverman, Lewis B. Loh, Mignon L. Hunger, Stephen P. Wood, Brent DeAngelo, Daniel J. Stone, Richard Harris, Marian Gutierrez, Alejandro Kelliher, Michelle A. Letai, Anthony TI Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199 SO CANCER DISCOVERY LA English DT Article ID CHRONIC LYMPHOCYTIC-LEUKEMIA; BH3 DOMAINS; ANTIAPOPTOTIC BCL-2; DEATH; BAX; EXPRESSION; INHIBITOR; MUTATIONS; APOPTOSIS; PROTEINS AB Acute lymphoblastic leukemia (ALL) is a hematopoietic malignancy derived from immature B-lymphoid and T-lymphoid cells (T-ALL). In T-ALL, there is an early T-cell progenitor (ETP) subgroup that has a very high risk for relapse. In this study, we used mitochondrial BH3 profiling to determine antiapoptotic protein dependencies in T-ALL. We found that T-ALL cell lines and primary patient samples are dependent upon BCL-XL, except when the cancer bears an ETP phenotype, in which case it is BCL-2 dependent. These distinctions directly relate to differential sensitivity to the BH3 mimetics ABT-263 and ABT-199, both in vitro and in vivo. We thus describe for the first time a change of antiapoptotic protein dependence that is related to the differentiation stage of the leukemic clone. Our findings demonstrate that BCL-2 is a clinically relevant target for therapeutic intervention with ABT-199 in ETP-ALL. SIGNIFICANCE: ETP T-ALL is a treatment-resistant subtype of T-ALL for which novel targeted therapies are urgently needed. We have discovered, through BH3 profiling, that ETP-ALL is BCL-2 dependent and is very sensitive to in vitro and in vivo treatment with ABT-199, a drug well tolerated in clinical trials. (C) 2014 AACR. C1 [Chonghaile, Triona Ni; Ryan, Jeremy; DeAngelo, Daniel J.; Stone, Richard; Letai, Anthony] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. [Roderick, Justine E.; Kelliher, Michelle A.] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA USA. [Glenfield, Cian] Trinity Coll Dublin, Smurfit Inst, Dept Genet, Dublin, Ireland. [Sallan, Stephen E.; Silverman, Lewis B.; Gutierrez, Alejandro] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA. [Loh, Mignon L.] Univ Calif San Francisco, Dept Pediat, Benioff Childrens Hosp, San Francisco, CA USA. [Hunger, Stephen P.] Univ Colorado, Sch Med, Pediat Hematol Oncol BMT, Aurora, CO USA. [Hunger, Stephen P.] Childrens Hosp Colorado, Aurora, CO USA. [Wood, Brent] Univ Washington, Dept Med, Seattle, WA USA. [Harris, Marian] Boston Childrens Hosp, Dept Pathol, Boston, MA USA. [Gutierrez, Alejandro] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA. RP Letai, A (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA. EM michelle.kelliher@umassmed.edu; anthony_letai@dfci.harvard.edu RI Ni Chonghaile, Triona/L-9418-2015 OI Ni Chonghaile, Triona/0000-0002-3041-4031 FU NIH/National Cancer Institute [CA167124]; NCI [U10 CA98543, U10 CA98413, U24 CA114766]; American Cancer Society Post-Doctoral Fellowship [125087-PF-13-247-01-LIB]; NIH/NCI [CA096899, R01 CA129974]; William Lawrence and Blanche Hughes Foundation; Linde Family Foundation FX This work was supported by a grant (CA167124 to A. Gutierrez) from the NIH/National Cancer Institute. A. Gutierrez is a Research Fellow of the Gabrielle's Angel Foundation for Cancer Research. T. Ni Chonghaile is a Multiple Myeloma Research Fellow. This work was supported by grants from the NCI to the Children's Oncology Group, including U10 CA98543 (COG Chair's grant), U10 CA98413 (COG Statistical Center), and U24 CA114766 (COG Specimen Banking). S.P. Hunger is the Ergen Family Chair in Pediatric Cancer. J.E. Roderick was supported by the American Cancer Society Post-Doctoral Fellowship (125087-PF-13-247-01-LIB). This work was also supported by a grant from the NIH/NCI awarded to M.A. Kelliher (CA096899). A. Letai gratefully acknowledges support from the William Lawrence and Blanche Hughes Foundation, the Linde Family Foundation, and from the NIH/NCI (R01 CA129974). NR 49 TC 32 Z9 32 U1 0 U2 14 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 2159-8274 EI 2159-8290 J9 CANCER DISCOV JI Cancer Discov. PD SEP PY 2014 VL 4 IS 9 BP 1074 EP 1087 DI 10.1158/2159-8290.CD-14-0353 PG 14 WC Oncology SC Oncology GA AQ8XE UT WOS:000343121400029 PM 24994123 ER PT J AU Costa, MD Henriques, T Munshi, MN Segal, AR Goldberger, AL AF Costa, Madalena D. Henriques, Teresa Munshi, Medha N. Segal, Alissa R. Goldberger, Ary L. TI Dynamical glucometry: Use of multiscale entropy analysis in diabetes SO CHAOS LA English DT Article ID DETRENDED FLUCTUATION ANALYSIS; GLUCOSE COMPLEXITY; TIME-SERIES; GLYCEMIC VARIABILITY; BLOOD GLUCOSE; MELLITUS AB Diabetes mellitus (DM) is one of the world's most prevalent medical conditions. Contemporary management focuses on lowering mean blood glucose values toward a normal range, but largely ignores the dynamics of glucose fluctuations. We probed analyte time series obtained from continuous glucose monitor (CGM) sensors. We show that the fluctuations in CGM values sampled every 5 min are not uncorrelated noise. Next, using multiscale entropy analysis, we quantified the complexity of the temporal structure of the CGM time series from a group of elderly subjects with type 2 DM and age-matched controls. We further probed the structure of these CGM time series using detrended fluctuation analysis. Our findings indicate that the dynamics of glucose fluctuations from control subjects are more complex than those of subjects with type 2 DM over time scales ranging from about 5 min to 5 h. These findings support consideration of a new framework, dynamical glucometry, to guide mechanistic research and to help assess and compare therapeutic interventions, which should enhance complexity of glucose fluctuations and not just lower mean and variance of blood glucose levels. (C) 2014 AIP Publishing LLC. C1 [Costa, Madalena D.; Henriques, Teresa; Goldberger, Ary L.] Harvard Univ, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA. [Costa, Madalena D.; Munshi, Medha N.; Goldberger, Ary L.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Henriques, Teresa] Ctr Res Hlth Technol & Informat Syst CINTESIS, Oporto, Portugal. [Henriques, Teresa] Inst Telecomunicacoes, Oporto, Portugal. [Munshi, Medha N.; Segal, Alissa R.] Joslin Diabet Ctr, Boston, MA 02215 USA. [Segal, Alissa R.] MCPHS Univ, Boston, MA 02215 USA. RP Costa, MD (reprint author), Harvard Univ, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA. RI FMUP, CINTESIS/C-6631-2014; Henriques, Teresa/B-3919-2016 OI FMUP, CINTESIS/0000-0001-7248-2086; Henriques, Teresa/0000-0002-4032-9594 FU National Institutes of Health [K99/R00 AG030677, R01GM104987]; G. Harold and Leila Y. Mathers Charitable Foundation; James S. McDonnell Foundation; Portuguese National Science Foundation [SFRH/BD/70858/2010]; Graetz Foundation FX This work was supported by the National Institutes of Health Grants Nos. K99/R00 AG030677 (M. D. C.) and R01GM104987 (A. L. G.); the G. Harold and Leila Y. Mathers Charitable Foundation (A. L. G), the James S. McDonnell Foundation (M. D. C.); the Portuguese National Science Foundation through the Ph.D. Grant No. SFRH/BD/70858/2010 and the Graetz Foundation (M.M.). NR 22 TC 14 Z9 14 U1 0 U2 6 PU AMER INST PHYSICS PI MELVILLE PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1, MELVILLE, NY 11747-4501 USA SN 1054-1500 EI 1089-7682 J9 CHAOS JI Chaos PD SEP PY 2014 VL 24 IS 3 AR 033139 DI 10.1063/1.4894537 PG 5 WC Mathematics, Applied; Physics, Mathematical SC Mathematics; Physics GA AQ5BB UT WOS:000342816300041 PM 25273219 ER PT J AU Ramakrishnan, M Kinsey, BM Singh, RA Kosten, TR Orson, FM AF Ramakrishnan, Muthu Kinsey, Berma M. Singh, Rana A. Kosten, Thomas R. Orson, Frank M. TI Hapten Optimization for Cocaine Vaccine with Improved Cocaine Recognition SO CHEMICAL BIOLOGY & DRUG DESIGN LA English DT Article DE addiction; antibody; benzoylecgonine; carrier protein; cocaine; hapten; mice; outer membrane protein complex; specificity; substance abuse; TA-CD vaccine; vaccine ID COMPLEX CONJUGATE VACCINE; DOUBLE-BLIND; DEPENDENCE; IMMUNOGENICITY; IMMUNIZATION; EFFICACY; ABUSE; TRIAL; BUTYRYLCHOLINESTERASE; ADDICTION AB In the absence of any effective pharmacotherapy for cocaine addiction, immunotherapy is being actively pursued as a therapeutic intervention. While several different cocaine haptens have been explored to develop anticocaine antibodies, none of the hapten was successfully designed, which had a protonated tropane nitrogen as is found in native cocaine under physiological conditions, including the succinyl norcocaine (SNC) hapten that has been tested in phase II clinical trials. Herein, we discuss three different cocaine haptens: hexyl norcocaine (HNC), bromoacetamido butyl norcocaine (BNC), and succinyl butyl norcocaine (SBNC), each with a tertiary nitrogen structure mimicking that of native cocaine which could optimize the specificity of anticocaine antibodies for better cocaine recognition. Mice immunized with these haptens conjugated to immunogenic proteins produced high titre anticocaine antibodies. However, during chemical conjugation of HNC and BNC haptens to carrier proteins, the 2b methyl ester group is hydrolyzed, and immunizing mice with these conjugate vaccines in mice produced antibodies that bound both cocaine and the inactive benzoylecgonine metabolite. While in the case of the SBNC conjugate, vaccine hydrolysis of the methyl ester did not appear to occur, leading to antibodies with high specificity to cocaine over BE. Although we observed similar specificity with a SNC hapten, the striking difference is that SBNC carries a positive charge on the tropane nitrogen atom, and therefore, it is expected to have better binding of cocaine. The 50% cocaine inhibitory concentration (IC50) value for SBNC antibodies (2.8 mu M) was significantly better than the SNC antibodies (9.4 mu M) when respective hapten-BSA was used as a substrate. In addition, antibodies from both sera had no inhibitory effect from BE. In contrast to BNC and HNC, the SBNC conjugate was also found to be highly stable without any noticeable hydrolysis for several months at 4 degrees C and 2-3 days in pH 10 buffer at 37 degrees C. C1 [Ramakrishnan, Muthu; Kinsey, Berma M.; Singh, Rana A.; Kosten, Thomas R.; Orson, Frank M.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Ramakrishnan, Muthu; Kinsey, Berma M.; Singh, Rana A.; Orson, Frank M.] Baylor Coll Med, Dept Med & Clin Immunol, Houston, TX 77030 USA. [Kosten, Thomas R.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Orson, Frank M.] Baylor Coll Med, Ctr Translat Res Inflammatory Dis, Houston, TX 77030 USA. [Orson, Frank M.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA. RP Orson, FM (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. EM forson@bcm.edu FU National Institute on Drug Abuse (NIDA) [R21 DA035591, R01 DA030338]; Michael E. DeBakey Veterans Affairs Medical Center Research Program; Department of Veterans Affairs Merit Review Program FX We would like to thank Yan Wu and Bangyi Mao for expert technical assistance. This work was supported by the National Institute on Drug Abuse (NIDA) Grants R21 DA035591 and R01 DA030338, the Michael E. DeBakey Veterans Affairs Medical Center Research Program, and the Department of Veterans Affairs Merit Review Program. Materials for this work were provided by the NIDA Drug Supply Program and OMPC from Merck Research Laboratories (West Point, PA). NR 29 TC 3 Z9 3 U1 1 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1747-0277 EI 1747-0285 J9 CHEM BIOL DRUG DES JI Chem. Biol. Drug Des. PD SEP PY 2014 VL 84 IS 3 BP 354 EP 363 DI 10.1111/cbdd.12326 PG 10 WC Biochemistry & Molecular Biology; Chemistry, Medicinal SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy GA AQ7FN UT WOS:000342978100012 PM 24803171 ER PT J AU Fishman, JA AF Fishman, J. A. TI From the classic concepts to modern practice SO CLINICAL MICROBIOLOGY AND INFECTION LA English DT Review DE organ transplantation; donor-derived infection; viral infection; immunosuppressive therapies; microbiome; nucleic acid test; opportunistic infections; prophylaxis; solid organ transplantation; tolerance ID ORGAN-TRANSPLANT RECIPIENTS; INFECTION; TRANSMISSION; DONOR; VIRUS; MICROBIOTA; ALLOGRAFT; UPDATE AB Transplant infectious disease is a field in evolution. For most allograft recipients, immunosuppressive therapies are more potent and have reduced the incidence of acute allograft rejection. At the same time, these therapies have increased susceptibility to many opportunistic infections and virally-mediated malignancies. Immunological tolerance has been achieved in only small numbers of patients who avoid drug toxicities and infection for as long as tolerance persists. The traditional timeline of post-transplant infections remains useful in the development of a differential diagnosis for patients with infectious syndromes. However, patterns of infection in the post-transplant period have changed over the past decade. Recipients are derived from a broader range of socioeconomic and geographical backgrounds. Infections are diagnosed more often, with improved microbiological assays (e.g. nucleic acid testing, NAT) used routinely in the diagnosis and management of common infections and increasingly in the screening of organ donors. Patterns of opportunistic infection have been altered by the increased identification of organisms demonstrating antimicrobial resistance and by the broader use of strategies to prevent viral, bacterial and fungal (including Pneumocystis) infections. Newer techniques are being applied (e.g. HLA-linked tetramer binding, intracellular cytokine staining) to assess pathogen-specific immunity. These are being integrated into clinical practice to assess individual susceptibility to specific infections. Infection, inflammation and the human microbiome are recognized as playing a central role in shaping innate and adaptive immune responses, graft rejection and autoimmunity. The full impact of infection on transplantation is only beginning to be appreciated. C1 [Fishman, J. A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Transplant Infect Dis & Compromised Host Ctr, Boston, MA 02114 USA. RP Fishman, JA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp,MGH Transplant Ctr, Transplant Infect Dis & Compromised Host Program, 55 Fruit St,WH510A, Boston, MA 02114 USA. EM jfishman@partners.org NR 24 TC 6 Z9 6 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1198-743X EI 1469-0691 J9 CLIN MICROBIOL INFEC JI Clin. Microbiol. Infect. PD SEP PY 2014 VL 20 SU 7 SI SI BP 4 EP 9 DI 10.1111/1469-0691.12593 PG 6 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA AQ5LA UT WOS:000342849100002 PM 24528498 ER PT J AU Price, M Yuen, EK Goetter, EM Herbert, JD Forman, EM Acierno, R Ruggiero, KJ AF Price, Matthew Yuen, Erica K. Goetter, Elizabeth M. Herbert, James D. Forman, Evan M. Acierno, Ron Ruggiero, Kenneth J. TI mHealth: A Mechanism to Deliver More Accessible, More Effective Mental Health Care SO CLINICAL PSYCHOLOGY & PSYCHOTHERAPY LA English DT Article DE mHealth; mobile phone; technology-based care; access to care ID COGNITIVE-BEHAVIORAL THERAPY; POSTTRAUMATIC-STRESS-DISORDER; VIRTUAL-REALITY; EXPOSURE THERAPY; IN-VIVO; DEPRESSION; ANXIETY; PSYCHOTHERAPY; INTERVENTION; TECHNOLOGY AB The increased popularity and functionality of mobile devices has a number of implications for the delivery of mental health services. Effective use of mobile applications has the potential to (a) increase access to evidence-based care; (b) better inform consumers of care and more actively engage them in treatment; (c) increase the use of evidence-based practices; and (d) enhance care after formal treatment has concluded. The current paper presents an overview of the many potential uses of mobile applications as a means to facilitate ongoing care at various stages of treatment. Examples of current mobile applications in behavioural treatment and research are described, and the implications of such uses are discussed. Finally, we provide recommendations for methods to include mobile applications into current treatment and outline future directions for evaluation. Copyright (c) 2013 John Wiley & Sons, Ltd. C1 [Price, Matthew] Univ Vermont, Burlington, VT 05405 USA. [Yuen, Erica K.] Univ Tampa, Tampa, FL 33606 USA. [Goetter, Elizabeth M.; Herbert, James D.; Forman, Evan M.] Drexel Univ, Philadelphia, PA 19104 USA. [Goetter, Elizabeth M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Acierno, Ron; Ruggiero, Kenneth J.] Med Univ S Carolina, Charleston, SC 29425 USA. [Acierno, Ron; Ruggiero, Kenneth J.] Ralph H Johnson VAMC, Charleston, SC USA. RP Price, M (reprint author), Univ Vermont, Dept Psychol, Burlington, VT 05405 USA. EM Matthew.price@uvm.edu FU NIDDK NIH HHS [R21 DK080430, R21 DK08043]; NIMH NIH HHS [R34 MH096907, R01 MH081056, T32 MH018869, R01 MH81056] NR 71 TC 34 Z9 35 U1 11 U2 39 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1063-3995 EI 1099-0879 J9 CLIN PSYCHOL PSYCHOT JI Clin. Psychol. Psychother. PD SEP-OCT PY 2014 VL 21 IS 5 BP 427 EP 436 DI 10.1002/cpp.1855 PG 10 WC Psychology, Clinical SC Psychology GA AQ6DG UT WOS:000342897900006 PM 23918764 ER PT J AU Bhatia, RS Dudzinski, DM Milford, CE Picard, MH Weiner, RB AF Bhatia, Rajan Sacha Dudzinski, David M. Milford, Creagh E. Picard, Michael H. Weiner, Rory B. TI Educational Intervention to Reduce Inappropriate Transthoracic Echocardiograms: The Need for Sustained Intervention SO ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES LA English DT Article DE appropriate use criteria; transthoracic echocardiography; feedback; resident education ID APPROPRIATE USE CRITERIA; CARDIOLOGY FOUNDATION/AMERICAN SOCIETY; TEMPORAL TRENDS; TECHNOLOGY; MEDICARE; IMPACT AB Background: We previously demonstrated that an Appropriate Use Criteria (AUC)-based educational intervention reduced inappropriate transthoracic echocardiograms (TTE) on an inpatient medical service. Whether improved TTE ordering is sustained after discontinuation of the intervention is unknown. Methods: We conducted a prospective, time series analysis of an educational intervention designed to reduce inappropriate TTE. Ordering patterns during the intervention were compared with a preintervention control period and a postintervention period. The goal of the present analysis was to determine the TTE ordering patterns after discontinuation of the educational intervention. The primary outcome was the proportion of inappropriate TTEs. Results: Using the 2011 AUC 99.2% of all TTEs were classifiable. Compared to the control, there was a 26% reduction in the number of TTEs ordered per day during the intervention (3.9 vs. 2.9 TTEs, P < 0.001), but no significant difference between the intervention and postintervention periods (2.9 vs. 3.1, P = 0.23). The intervention produced a decrease in the inappropriate TTE rate and an increase in the appropriate TTE rate. Compared to the intervention, in the postintervention period the rate of inappropriate TTEs increased (5% vs. 11%, P = 0.01) and appropriate TTEs decreased (93% vs. 86%, P = 0.008). The postintervention rate of inappropriate TTEs was similar to the preintervention control period (11% vs. 13%, P = 0.23). Conclusions: Following completion of an AUC-based educational intervention the proportion of inappropriate TTEs increased to the preintervention level. The long-term success of an intervention designed to improve appropriate utilization of TTE requires a sustained effort of education and feedback. C1 [Bhatia, Rajan Sacha; Dudzinski, David M.; Milford, Creagh E.; Picard, Michael H.; Weiner, Rory B.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. RP Bhatia, RS (reprint author), Womens Coll Hosp Inst Hlth Syst Solut & Virtual C, Div Cardiol, 76 Grenville St,6th Floor, Toronto, ON, Canada. EM sacha.bhatia@wchospital.ca OI Picard, Michael/0000-0002-9264-3243 NR 19 TC 13 Z9 13 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0742-2822 EI 1540-8175 J9 ECHOCARDIOGR-J CARD JI Echocardiography-J. Cardiovasc. Ultrasound Allied Tech. PD SEP PY 2014 VL 31 IS 8 BP 916 EP 923 DI 10.1111/echo.12505 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AQ5DS UT WOS:000342826800014 PM 24447139 ER PT J AU Bale, SS Vernetti, L Senutovitch, N Jindal, R Hegde, M Gough, A McCarty, WJ Bakan, A Bhushan, A Shun, TY Golberg, I DeBiasio, R Usta, OB Taylor, DL Yarmush, ML AF Bale, Shyam Sundhar Vernetti, Lawrence Senutovitch, Nina Jindal, Rohit Hegde, Manjunath Gough, Albert McCarty, William J. Bakan, Ahmet Bhushan, Abhinav Shun, Tong Y. Golberg, Inna DeBiasio, Richard Usta, O. Berk Taylor, D. Lansing Yarmush, Martin L. TI In vitro platforms for evaluating liver toxicity SO EXPERIMENTAL BIOLOGY AND MEDICINE LA English DT Review DE Drug-induced liver injury; liver on chip; hepatotoxicity; high content screening; predictive modeling ID DRUG-INDUCED HEPATOTOXICITY; GREEN FLUORESCENT PROTEINS; CONCENTRATION-TIME PROFILES; CULTURED RAT HEPATOCYTES; PLURIPOTENT STEM-CELLS; HUMAN PHARMACOKINETICS; PREDICTIVE MODELS; HEPATIC-CLEARANCE; PHARMACEUTICAL RESEARCH; SANDWICH CONFIGURATION AB The liver is a heterogeneous organ with many vital functions, including metabolism of pharmaceutical drugs and is highly susceptible to injury from these substances. The etiology of drug-induced liver disease is still debated although generally regarded as a continuum between an activated immune response and hepatocyte metabolic dysfunction, most often resulting from an intermediate reactive metabolite. This debate stems from the fact that current animal and invitro models provide limited physiologically relevant information, and their shortcomings have resulted in silent hepatotoxic drugs being introduced into clinical trials, garnering huge financial losses for drug companies through withdrawals and late stage clinical failures. As we advance our understanding into the molecular processes leading to liver injury, it is increasingly clear that (a) the pathologic lesion is not only due to liver parenchyma but is also due to the interactions between the hepatocytes and the resident liver immune cells, stellate cells, and endothelial cells; and (b) animal models do not reflect the human cell interactions. Therefore, a predictive human, invitro model must address the interactions between the major human liver cell types and measure key determinants of injury such as the dosage and metabolism of the drug, the stress response, cholestatic effect, and the immune and fibrotic response. In this mini-review, we first discuss the current state of macro-scale invitro liver culture systems with examples that have been commercialized. We then introduce the paradigm of microfluidic culture systems that aim to mimic the liver with physiologically relevant dimensions, cellular structure, perfusion, and mass transport by taking advantage of micro and nanofabrication technologies. We review the most prominent liver-on-a-chip platforms in terms of their physiological relevance and drug response. We conclude with a commentary on other critical advances such as the deployment of fluorescence-based biosensors to identify relevant toxicity pathways, as well as computational models to create a predictive tool. C1 [Bale, Shyam Sundhar; Jindal, Rohit; Hegde, Manjunath; McCarty, William J.; Bhushan, Abhinav; Golberg, Inna; Usta, O. Berk; Yarmush, Martin L.] Harvard Univ, Shriners Hosp Children, Massachusetts Gen Hosp, Ctr Engn Med,Med Sch, Boston, MA 02114 USA. [Vernetti, Lawrence; Senutovitch, Nina; Gough, Albert; Shun, Tong Y.; DeBiasio, Richard; Taylor, D. Lansing] Univ Pittsburgh, Drug Discovery Inst, Pittsburgh, PA 15260 USA. [Vernetti, Lawrence; Senutovitch, Nina; Gough, Albert; Bakan, Ahmet; Taylor, D. Lansing] Univ Pittsburgh, Dept Computat & Syst Biol, Pittsburgh, PA 15260 USA. RP Yarmush, ML (reprint author), Harvard Univ, Shriners Hosp Children, Massachusetts Gen Hosp, Ctr Engn Med,Med Sch, Boston, MA 02114 USA. EM ireis@sbi.org RI USTA, O. Berk/A-5818-2008; Hegde, Manjunath/M-3038-2014; OI USTA, O. Berk/0000-0001-9328-568X; Hegde, Manjunath/0000-0002-5396-2241; Gough, Albert/0000-0001-6456-0195; McCarty, William/0000-0002-3671-0616 FU NIH [1UH2TR00503-01] FX This work was supported by NIH # 1UH2TR00503-01. NR 115 TC 43 Z9 44 U1 3 U2 51 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1535-3702 EI 1535-3699 J9 EXP BIOL MED JI Exp. Biol. Med. PD SEP PY 2014 VL 239 IS 9 BP 1180 EP 1191 DI 10.1177/1535370214531872 PG 12 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA AQ4MV UT WOS:000342773100010 PM 24764241 ER PT J AU Ganapathi, KA Pittaluga, S Odejide, OO Freedman, AS Jaffe, ES AF Ganapathi, Karthik A. Pittaluga, Stefania Odejide, Oreofe O. Freedman, Arnold S. Jaffe, Elaine S. TI Early lymphoid lesions: conceptual, diagnostic and clinical challenges SO HAEMATOLOGICA LA English DT Review ID B-CELL LYMPHOCYTOSIS; UNDETERMINED SIGNIFICANCE MGUS; PRIMARY CUTANEOUS LYMPHOMAS; PRIMARY FOLLICULAR LYMPHOMA; PRECEDES MULTIPLE-MYELOMA; WHO-EORTC CLASSIFICATION; MARGINAL ZONE LYMPHOMAS; NON-HODGKINS-LYMPHOMA; IN-SITU; MONOCLONAL GAMMOPATHY AB There are no "benign lymphomas", a fact due to the nature of lymphoid cells to circulate and home as part of their normal function. Thus, benign clonal expansions of lymphocytes are only rarely recognized when localized. Recent studies have identified a number of lymphoid proliferations that lie at the interface between benign and malignant. Some of these are clonal proliferations that carry many of the molecular hallmarks of their malignant counterparts, such as BCL2/IGH and CCND1/IGH translocations associated with the in situ forms of follicular lymphoma and mantle cell lymphoma, respectively. There are other clonal B-cell proliferations with low risk of progression; these include the pediatric variants of follicular lymphoma and marginal zone lymphoma. Historically, early or incipient forms of T/NK-cell neoplasia also have been identified, such as lymphomatoid papulosis and refractory celiac disease. More recently an indolent form of T-cell lymphoproliferative disease affecting the gastrointestinal tract has been described. Usually, CD8(+), the clonal cells are confined to the mucosa. The clinical course is chronic, but non-progressive. NK-cell enteropathy is a clinically similar condition, composed of cytologically atypical NK-cells that may involve the stomach, small bowel or colon. Breast implant-associated anaplastic large cell lymphoma is a cytologically alarming lesion that is self-limited if confined to the seroma cavity. Atypical lymphoid proliferations that lie at the border of benign and malignant can serve as instructive models of lymphomagenesis. It is also critical that they be correctly diagnosed to avoid unnecessary and potentially harmful therapy. C1 [Ganapathi, Karthik A.; Pittaluga, Stefania; Jaffe, Elaine S.] NCI, Hematopathol Sect, Ctr Canc Res, Pathol Lab, Boston, MA 20892 USA. [Odejide, Oreofe O.; Freedman, Arnold S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Hematol Oncol, Boston, MA 02115 USA. RP Jaffe, ES (reprint author), NCI, Hematopathol Sect, Ctr Canc Res, Pathol Lab, Boston, MA 20892 USA. EM ejaffe@mail.nih.gov FU Intramural Research Program of the Center for Cancer Research, National Cancer Institute FX This work was supported through the Intramural Research Program of the Center for Cancer Research, National Cancer Institute. NR 107 TC 17 Z9 17 U1 0 U2 3 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD SEP 1 PY 2014 VL 99 IS 9 BP 1421 EP 1432 DI 10.3324/haematol.2014.107938 PG 12 WC Hematology SC Hematology GA AQ5GK UT WOS:000342834900014 PM 25176983 ER PT J AU Murase, K Kim, HT Bascug, ORG Kawano, Y Ryan, J Matsuoka, K Davids, MS Koreth, J Ho, VT Cutler, C Armand, P Alyea, EP Blazar, BR Antin, JH Soiffer, RJ Letai, A Ritz, J AF Murase, Kazuyuki Kim, Haesook T. Bascug, O. R. Gregory Kawano, Yutaka Ryan, Jeremy Matsuoka, Ken-ichi Davids, Matthew S. Koreth, John Ho, Vincent T. Cutler, Corey Armand, Philippe Alyea, Edwin P. Blazar, Bruce R. Antin, Joseph H. Soiffer, Robert J. Letai, Anthony Ritz, Jerome TI Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation SO HAEMATOLOGICA LA English DT Article ID VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; EX-VIVO EXPANSION; SELF-TOLERANCE; DENDRITIC CELLS; FAMILY-MEMBERS; CHRONIC GVHD; B-CELLS; DEATH; BCL-2 AB CD4 regulatory T cells play a critical role in establishment of immune tolerance and prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. The recovery and maintenance of regulatory T cells is dependent on homeostatic factors including the generation of naive regulatory T cells from hematopoietic precursor cells, the proliferation and expansion of mature regulatory T cells, and the survival of regulatory T cells in vivo. In this study, quantitation of mitochondrial apoptotic priming was used to compare susceptibility of regulatory T cells, conventional CD4 T cells and CD8 T cells to intrinsic pathway apoptosis in 57 patients after allogeneic hematopoietic stem cell transplantation and 25 healthy donors. In healthy donors, regulatory T cells are more susceptible to mitochondrial priming than conventional T cells. Mitochondrial priming is increased after hematopoietic stem cell transplantation in all T-cell subsets and particularly in patients with chronic graft-versus-host disease. Regulatory T cells express high levels of CD95 and are also more susceptible than conventional T cells to apoptosis through the extrinsic pathway. However, CD95 expression and extrinsic pathway apoptosis is not increased after hematopoietic stem cell transplantation. Decreased expression of BCL2 and increased expression of BIM, a mitochondrial cell death activator protein, in regulatory T cells contributes to increased mitochondrial priming in this T-cell subset but additional factors likely contribute to increased mitochondrial priming following hematopoietic stem cell transplantation. C1 [Murase, Kazuyuki; Bascug, O. R. Gregory; Kawano, Yutaka; Ryan, Jeremy; Davids, Matthew S.; Koreth, John; Ho, Vincent T.; Cutler, Corey; Armand, Philippe; Alyea, Edwin P.; Antin, Joseph H.; Soiffer, Robert J.; Letai, Anthony; Ritz, Jerome] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Murase, Kazuyuki; Bascug, O. R. Gregory; Kawano, Yutaka; Ryan, Jeremy; Davids, Matthew S.; Koreth, John; Ho, Vincent T.; Cutler, Corey; Armand, Philippe; Alyea, Edwin P.; Antin, Joseph H.; Soiffer, Robert J.; Letai, Anthony; Ritz, Jerome] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Murase, Kazuyuki; Kawano, Yutaka; Ryan, Jeremy; Davids, Matthew S.; Koreth, John; Ho, Vincent T.; Cutler, Corey; Armand, Philippe; Alyea, Edwin P.; Antin, Joseph H.; Soiffer, Robert J.; Letai, Anthony; Ritz, Jerome] Harvard Univ, Sch Med, Boston, MA USA. [Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Kim, Haesook T.; Ritz, Jerome] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA. [Kim, Haesook T.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Matsuoka, Ken-ichi] Okayama Univ, Dept Hematol & Oncol, Okayama 7008530, Japan. [Blazar, Bruce R.] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN USA. [Blazar, Bruce R.] Univ Minnesota, Dept Pediat, Div Blood & Marrow Transplantat, Minneapolis, MN 55455 USA. [Ritz, Jerome] Harvard Stem Cell Inst, Boston, MA USA. RP Ritz, J (reprint author), Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. EM jerome_ritz@dfci.harvard.edu OI Ritz, Jerome/0000-0001-5526-4669 FU NIH [CA142106, CA183559, CA183560, AI056299]; Jock and Bunny Adams Education and Research Endowment; Ted and Eileen Pasquarello Research Fund FX This study was supported by NIH grants CA142106, CA183559, CA183560, AI056299, the Jock and Bunny Adams Education and Research Endowment and the Ted and Eileen Pasquarello Research Fund. NR 65 TC 5 Z9 5 U1 0 U2 6 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD SEP 1 PY 2014 VL 99 IS 9 BP 1499 EP 1508 DI 10.3324/haematol.2014.104166 PG 10 WC Hematology SC Hematology GA AQ5GK UT WOS:000342834900024 PM 24859877 ER PT J AU Hamadeh, F MacNamara, S Bacon, CM Sohani, AR Swerdlow, SH Cook, JR AF Hamadeh, Fatima MacNamara, Stephen Bacon, Chris M. Sohani, Aliyah R. Swerdlow, Steven H. Cook, James R. TI Gamma heavy chain disease lacks the MYD88 L265p mutation associated with lymphoplasmacytic lymphoma SO HAEMATOLOGICA LA English DT Letter DE gamma heavy chain disease; lymphoplasmacytic lymphoma; MYD88 L265P; mutation ID WALDENSTROMS MACROGLOBULINEMIA; LYMPHOPROLIFERATIVE DISORDERS; DISTINCT C1 [Hamadeh, Fatima; MacNamara, Stephen; Cook, James R.] Cleveland Clin, Cleveland, OH 44106 USA. [Bacon, Chris M.] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Sohani, Aliyah R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Swerdlow, Steven H.] Univ Pittsburgh, Pittsburgh, PA USA. RP Cook, JR (reprint author), Cleveland Clin, Cleveland, OH 44106 USA. EM cookj2@ccf.org NR 15 TC 3 Z9 4 U1 0 U2 2 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD SEP 1 PY 2014 VL 99 IS 9 BP E154 EP E155 DI 10.3324/haematol.2014.108688 PG 2 WC Hematology SC Hematology GA AQ5GK UT WOS:000342834900003 PM 24859878 ER PT J AU Arnason, T Liang, WY Alfaro, E Kelly, P Chung, DC Odze, RD Lauwers, GY AF Arnason, Thomas Liang, Wen-Yih Alfaro, Eduardo Kelly, Paul Chung, Daniel C. Odze, Robert D. Lauwers, Gregory Y. TI Morphology and natural history of familial adenomatous polyposis-associated dysplastic fundic gland polyps SO HISTOPATHOLOGY LA English DT Article DE dysplasia; familial adenomatous polyposis; fundic gland polyp; stomach ID UPPER GASTROINTESTINAL CANCER; HIGH-GRADE DYSPLASIA; GASTRODUODENAL POLYPS; DUODENAL POLYPS; GASTRIC ADENOCARCINOMA; GARDNERS-SYNDROME; COLI GENE; RISK; PREVALENCE; MUTATIONS AB AimsMost patients with familial adenomatous polyposis (FAP) develop gastric fundic gland polyps, with many displaying low-grade dysplasia. This study evaluates the natural history and morphological phenotype of dysplasia in FAP-associated fundic gland polyps. Methods and resultsPatients with FAP and dysplastic fundic gland polyps (n=24) were identified. Twenty-two of 24 FAP-associated dysplastic fundic gland polyps showed a gastric phenotype and two had mixed phenotype. During a mean 6.1-year follow-up (range 0.8-12.6years) and 5.7 endoscopies (range 2-22), one patient (4%) was diagnosed with a fundic gland polyp with high-grade dysplasia, while 23 patients (96%) in this cohort had either no dysplasia or persistent low-grade dysplasia. Contemporary patients with sporadic fundic gland polyps with low-grade dyplasia had similar morphology and outcomes to the FAP-associated fundic gland polyp cohort. Dysplasia in fundic gland polyps (FAP-associated and sporadic) was associated less frequently with intestinal phenotype, high-grade dysplasia and the finding of concurrent or subsequent carcinoma compared to contemporary patients with sporadic gastric dysplasia not occurring in fundic gland polyps. ConclusionsThis cohort of patients with FAP-associated dysplastic fundic gland polyps rarely developed high-grade dysplasia and gastric adenocarcinoma was absent. C1 [Arnason, Thomas; Alfaro, Eduardo; Kelly, Paul; Lauwers, Gregory Y.] Massachusetts Gen Hosp, Gastrointestinal Pathol Serv, Boston, MA 02114 USA. [Arnason, Thomas; Alfaro, Eduardo; Kelly, Paul; Lauwers, Gregory Y.] Harvard Univ, Sch Med, Boston, MA USA. [Arnason, Thomas] Dalhousie Univ, Div Anat Pathol, Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada. [Liang, Wen-Yih] Taipei Vet Gen Hosp, Dept Pathol & Lab Med, Taipei, Taiwan. [Liang, Wen-Yih] Natl Yang Ming Univ, Dept Pathol, Sch Med, Taipei 112, Taiwan. [Kelly, Paul] Royal Victoria Hosp, Dept Pathol, Belfast, Antrim, North Ireland. [Chung, Daniel C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA USA. [Odze, Robert D.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Gastrointestinal Pathol Serv, Boston, MA 02115 USA. RP Arnason, T (reprint author), Queen Elizabeth 2 Hlth Sci Ctr, Div Anat Pathol, 734a,MacKenzie Bldg,5788 Univ Ave, Halifax, NS B3H 1V8, Canada. EM thomas.arna-son@cdha.nshealth.ca FU Royal College of Physicians and Surgeons of Canada; Dalhousie University FX Dr Arnason's fellowship funding was provided through scholarships from the Royal College of Physicians and Surgeons of Canada (Detweiler Traveling Fellowship) and Dalhousie University (McLoughlin Scholarship). NR 43 TC 8 Z9 8 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0309-0167 EI 1365-2559 J9 HISTOPATHOLOGY JI Histopathology PD SEP PY 2014 VL 65 IS 3 BP 353 EP 362 DI 10.1111/his.12393 PG 10 WC Cell Biology; Pathology SC Cell Biology; Pathology GA AQ4ZQ UT WOS:000342811300006 PM 24548295 ER PT J AU Kang, H Purtle, SW Moromiazato, T Gibbons, FK Christopher, KB AF Kang, H. Purtle, S. W. Moromiazato, T. Gibbons, F. K. Christopher, K. B. TI THE ASSOCIATION OF VITAMIN D STATUS AND POST-DISCHARGE OUTCOMES IN CRITICAL ILLNESS SURVIVORS SO INTENSIVE CARE MEDICINE LA English DT Meeting Abstract CT 27th Annual Congress of the European-Society-of-Intensive-Care-Medicine (ESICM) CY SEP 27-OCT 01, 2014 CL Barcelona, SPAIN SP European Soc Intens Care Med C1 [Kang, H.; Christopher, K. B.] Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA. [Purtle, S. W.] Univ Colorado, Aurora, CO USA. [Moromiazato, T.] Hokubu Prefectural Hosp, Dept Med, Nago, Japan. [Gibbons, F. K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0342-4642 EI 1432-1238 J9 INTENS CARE MED JI Intensive Care Med. PD SEP PY 2014 VL 40 SU 1 MA 0644 BP S179 EP S179 PG 1 WC Critical Care Medicine SC General & Internal Medicine GA AP9WM UT WOS:000342432000584 ER PT J AU Simon, TG McKane, CK Gibbons, FK Christopher, KB AF Simon, T. G. McKane, C. K. Gibbons, F. K. Christopher, K. B. TI ACUTE DECOMPENSATION OF CHRONIC LIVER DISEASE AND OUTCOMES IN CRITICAL ILLNESS SO INTENSIVE CARE MEDICINE LA English DT Meeting Abstract CT 27th Annual Congress of the European-Society-of-Intensive-Care-Medicine (ESICM) CY SEP 27-OCT 01, 2014 CL Barcelona, SPAIN SP European Soc Intens Care Med C1 [Simon, T. G.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [McKane, C. K.] Brigham & Womens Hosp, Dept Nursing, Boston, MA 02115 USA. [Gibbons, F. K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Christopher, K. B.] Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0342-4642 EI 1432-1238 J9 INTENS CARE MED JI Intensive Care Med. PD SEP PY 2014 VL 40 SU 1 MA 0079 BP S30 EP S30 PG 1 WC Critical Care Medicine SC General & Internal Medicine GA AP9WM UT WOS:000342432000068 ER PT J AU Wuhlster, S Wijdicks, EF Patel, PV Hemphill, JC Greer, DM Mateen, FJ AF Wuhlster, S. Wijdicks, E. F. Patel, P. V. Hemphill, J. C., III Greer, D. M. Mateen, F. J. TI BRAIN DEATH DETERMINATION IN 91 COUNTRIES: ARE WE THINKING ALIKE? SO INTENSIVE CARE MEDICINE LA English DT Meeting Abstract CT 27th Annual Congress of the European-Society-of-Intensive-Care-Medicine (ESICM) CY SEP 27-OCT 01, 2014 CL Barcelona, SPAIN SP European Soc Intens Care Med C1 [Wuhlster, S.; Mateen, F. J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Wijdicks, E. F.] Mayo Clin, Rochester, MN USA. [Patel, P. V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hemphill, J. C., III] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Greer, D. M.] Yale Univ, New Haven, CT USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0342-4642 EI 1432-1238 J9 INTENS CARE MED JI Intensive Care Med. PD SEP PY 2014 VL 40 SU 1 MA 0490 BP S140 EP S140 PG 1 WC Critical Care Medicine SC General & Internal Medicine GA AP9WM UT WOS:000342432000445 ER PT J AU Ferree, S Neuhaus, V Becker, SJE Jupiter, JB Mudgal, CS Ring, DC AF Ferree, S. Neuhaus, V. Becker, S. J. E. Jupiter, J. B. Mudgal, C. S. Ring, D. C. TI Risk factors for return with a second trigger digit SO JOURNAL OF HAND SURGERY-EUROPEAN VOLUME LA English DT Article DE Trigger digit; second; risk factors; return ID CARPAL-TUNNEL-SYNDROME; STENOSING TENOSYNOVITIS; DIABETES-MELLITUS; STEROID INJECTION; FINGER; THUMB; MANAGEMENT AB The purpose of this study was to determine predictors of return to the same practice with a second idiopathic trigger digit. A total of 2234 patients with Quinnell grade 2 or greater (objective triggering) of one or more digits were retrospectively analysed. A total of 490 of 2234 (22%) patients returned to the same practice with a second trigger digit, with an average follow-up time of 2.1 years (range, 7 days to 10 years). Predictors of return with a second trigger digit included carpal tunnel syndrome, Type 1 diabetes mellitus and duration of follow-up in years. Patients diagnosed with idiopathic trigger digit can be advised that about one in five will return to the same practice with another trigger digit, with approximately double the risk in patients that have carpal tunnel syndrome or Type 1 diabetes. C1 [Ferree, S.; Neuhaus, V.; Becker, S. J. E.; Jupiter, J. B.; Mudgal, C. S.; Ring, D. C.] Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Boston, MA 02114 USA. RP Ring, DC (reprint author), Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA. EM dring@partners.org RI Becker, Stephanie/N-5761-2014; OI Neuhaus, Valentin/0000-0003-4012-5628 FU "Gottfried und Julia Bangerter-Rhyner-Stiftung", Switzerland FX VN was supported by the "Gottfried und Julia Bangerter-Rhyner-Stiftung", Switzerland, for Scientific Research. NR 26 TC 4 Z9 4 U1 1 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1753-1934 EI 2043-6289 J9 J HAND SURG-EUR VOL JI J. Hand Surg.-Eur. Vol. PD SEP PY 2014 VL 39 IS 7 BP 704 EP 707 DI 10.1177/1753193412469129 PG 4 WC Orthopedics; Surgery SC Orthopedics; Surgery GA AQ4NU UT WOS:000342776000004 PM 23186861 ER PT J AU Zimmerman, RM Jupiter, JB AF Zimmerman, R. M. Jupiter, J. B. TI Instability of the distal radioulnar joint SO JOURNAL OF HAND SURGERY-EUROPEAN VOLUME LA English DT Review DE Distal radioulnar joint; instability; reconstruction ID TRIANGULAR FIBROCARTILAGE COMPLEX; SAUVE-KAPANDJI PROCEDURE; EXTENSOR-CARPI-ULNARIS; DARRACH PROCEDURE; RADIUS FRACTURES; COMPUTERIZED-TOMOGRAPHY; INTEROSSEOUS MEMBRANE; RHEUMATOID-ARTHRITIS; PERIPHERAL TEARS; RECONSTRUCTION AB The distal radioulnar joint is a complex structure necessary for forearm motion and force transmission across the wrist. Anatomic and biomechanical advances have revealed broad contributions to distal radioulnar joint stability and refined our understanding of the forces acting across it. Instability often co-occurs with other modes of pathology, such as arthrosis or malunion; and appropriate diagnosis and treatment require a comprehensive understanding of all contributing factors. Distal radioulnar joint instability can be broadly categorized as primary, post-traumatic or post-surgical. Treatment strategies include percutaneous, arthroscopic, soft-tissue, osteotomy and arthroplasty techniques. The purpose of this article is to review distal radioulnar joint instability and its management. C1 [Zimmerman, R. M.; Jupiter, J. B.] Massachusetts Gen Hosp, Hand & Upper Extrem Serv, Boston, MA 02114 USA. RP Jupiter, JB (reprint author), Massachusetts Gen Hosp, Hand & Upper Extrem Serv, Suite 2100 Yawkey Bldg,55 Fruit St, Boston, MA 02114 USA. EM jjupiter1@partners.org NR 81 TC 8 Z9 9 U1 1 U2 8 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1753-1934 EI 2043-6289 J9 J HAND SURG-EUR VOL JI J. Hand Surg.-Eur. Vol. PD SEP PY 2014 VL 39 IS 7 BP 727 EP 738 DI 10.1177/1753193414527052 PG 12 WC Orthopedics; Surgery SC Orthopedics; Surgery GA AQ4NU UT WOS:000342776000008 PM 24619248 ER PT J AU Cummings, BM Macklin, EA Yager, PH Sharma, A Noviski, N AF Cummings, Brian M. Macklin, Eric A. Yager, Phoebe H. Sharma, Amita Noviski, Natan TI Potassium Abnormalities in a Pediatric Intensive Care Unit: Frequency and Severity SO JOURNAL OF INTENSIVE CARE MEDICINE LA English DT Article DE hyperkalemia; hypokalemia; intensive care units; pediatric; hemolysis ID HOSPITALIZED-PATIENTS; FACTITIOUS HYPERKALEMIA; SERUM POTASSIUM; HYPOKALEMIA; CHILDREN; RISK; GENDER; AGE AB Background: Potassium abnormalities are common in critically ill patients. We describe the spectrum of potassium abnormalities in our tertiary-level pediatric intensive care unit (PICU). Methods: Retrospective observational cohort of all the patients admitted to a single-center tertiary PICU over a 1-year period. Medical records and laboratory results were obtained through a central electronic data repository. Results: A total of 512 patients had a potassium measurement. Of a total of 4484 potassium measurements, one-third had abnormal values. Hypokalemia affected 40% of the admissions. Mild hypokalemia (3-3.4 mmol/L) affected 24% of the admissions. Moderate or severe hypokalemia (K <3.0 mmol/L) affected 16% of the admissions. Hyperkalemia affected 29% of the admissions. Mild hyperkalemia (5.1-6.0 mmol/L) affected 17% of the admissions. Moderate or severe hyperkalemia (>6.0 mmol/L) affected 12%. Hemolysis affected 2% of all the samples and 24% of hyperkalemic values. On univariate analysis, severity of hypokalemia was associated with mortality (odds ratio 2.2, P = .003). Conclusions: Mild potassium abnormalities are common in the PICU. Repeating hemolyzed hyperkalemic samples may be beneficial. Guidance in monitoring frequencies of potassium abnormalities in pediatric critical care is needed. C1 [Cummings, Brian M.; Yager, Phoebe H.; Noviski, Natan] Massachusetts Gen Hosp, Div Pediat Crit Care Med, Boston, MA 02114 USA. [Macklin, Eric A.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. [Sharma, Amita] Yawkey Ctr Outpatient Care MGH, Div Pediat Nephrol, Boston, MA USA. RP Noviski, N (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Pediat Crit Care Med, 175 Cambridge St,CPZS 524, Boston, MA 02114 USA. EM nnoviski@partners.org OI Macklin, Eric/0000-0003-1618-3502 FU Harvard Catalyst \ The Harvard Clinical and Translational Science Center (National Center for Research Resources); Harvard Catalyst \ The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health) [8UL1TR000170-05]; Harvard Catalyst \ The Harvard Clinical and Translational Science Center (Harvard University) FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was conducted with support from Harvard Catalyst vertical bar The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award 8UL1TR000170-05 and financial contributions from Harvard University and its affiliated academic health care centers). NR 27 TC 1 Z9 1 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0885-0666 EI 1525-1489 J9 J INTENSIVE CARE MED JI J. Intensive Care Med. PD SEP-OCT PY 2014 VL 29 IS 5 BP 269 EP 274 DI 10.1177/0885066613491708 PG 6 WC Critical Care Medicine SC General & Internal Medicine GA AQ4WL UT WOS:000342801300004 PM 23753253 ER PT J AU Yaffe, K Kurella-Tamura, M Ackerson, L Hoang, TD Anderson, AH Duckworth, M Go, AS Krousel-Wood, M Kusek, JW Lash, JP Ojo, A Robinson, N Sehgal, AR Sondheimer, JH Steigerwalt, S Townsend, RR AF Yaffe, Kristine Kurella-Tamura, Manjula Ackerson, Lynn Hoang, Tina D. Anderson, Amanda H. Duckworth, Mark Go, Alan S. Krousel-Wood, Marie Kusek, John W. Lash, James P. Ojo, Akinlolu Robinson, Nancy Sehgal, Ashwini R. Sondheimer, James H. Steigerwalt, Susan Townsend, Raymond R. CA CRIC Study Investigators TI Higher Levels of Cystatin C Are Associated with Worse Cognitive Function in Older Adults with Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort Cognitive Study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE cystatin C; cognition; chronic kidney disease ID GLOMERULAR-FILTRATION-RATE; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; SERUM CREATININE; BODY-COMPOSITION; ELDERLY PERSONS; RISK-FACTOR; IMPAIRMENT; HEALTH; BRAIN AB ObjectivesTo determine the association between cognition and levels of cystatin C in persons with chronic kidney disease (CKD). DesignProspective observational study. SettingChronic Renal Insufficiency Cohort Cognitive Study. ParticipantsIndividuals with a baseline cognitive assessment completed at the same visit as serum cystatin C measurement (N=821; mean age 64.9, 50.6% male, 48.6% white). MeasurementsLevels of serum cystatin C were categorized into tertiles; cognitive function was assessed using six neuropsychological tests. Scores on these tests were compared across tertiles of cystatin C using linear regression and logistic regression to examine the association between cystatin C level and cognitive performance (1 standard deviation difference from the mean). ResultsAfter multivariable adjustment for age, race, education, and medical comorbidities in linear models, higher levels of cystatin C were associated with worse cognition on the modified Mini-Mental State Examination, Buschke Delayed Recall, Trail-Making Test Part (Trails) A and Part B, and Boston Naming (P<.05 for all). This association remained statistically significant for Buschke Delayed Recall (P=.01) and Trails A (P=.03) after additional adjustment for estimated glomerular filtration rate (eGFR). The highest tertile of cystatin C was associated with greater likelihood of poor performance on Trails A (odds ratio (OR)=2.17, 95% confidence interval (CI)=1.16-4.06), Trails B (OR=1.89, 95% CI=1.09-3.27), and Boston Naming (OR=1.85, 95% CI=1.07-3.19) than the lowest tertile after multivariate adjustment in logistic models. ConclusionIn individuals with CKD, higher serum cystatin C levels were associated with worse cognition and greater likelihood of poor cognitive performance on attention, executive function, and naming. Cystatin C is a marker of cognitive impairment and may be associated with cognition independent of eGFR. C1 [Yaffe, Kristine] Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Kurella-Tamura, Manjula] Stanford Univ, Sch Med, Div Nephrol, Palo Alto, CA 94304 USA. [Kurella-Tamura, Manjula] Palo Alto Vet Affairs Med Ctr, Palo Alto, CA USA. [Ackerson, Lynn; Go, Alan S.] Kaiser Permanente, Div Res, Oakland, CA USA. [Hoang, Tina D.] Northern Calif Ctr Res & Educ, San Francisco, CA USA. [Anderson, Amanda H.; Robinson, Nancy] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Duckworth, Mark; Townsend, Raymond R.] Univ Penn, Renal Electrolyte & Hypertens Div, Perelman Sch Med, Philadelphia, PA 19104 USA. [Krousel-Wood, Marie] Tulane Univ, Dept Med, New Orleans, LA 70118 USA. [Krousel-Wood, Marie] Tulane Univ, Dept Epidemiol, New Orleans, LA 70118 USA. [Krousel-Wood, Marie] Ochsner Clin Fdn, Ctr Hlth Res, New Orleans, LA USA. [Kusek, John W.] NIDDK, NIH, Bethesda, MD 20892 USA. [Lash, James P.] Univ Illinois, Coll Med, Dept Med, Chicago, IL USA. [Ojo, Akinlolu] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA. [Ojo, Akinlolu] Univ Michigan, Sch Med, Dept Nephrol, Ann Arbor, MI USA. [Sehgal, Ashwini R.] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA. [Sehgal, Ashwini R.] Case Western Reserve Univ, Dept Biomed Eth, Cleveland, OH 44106 USA. [Sehgal, Ashwini R.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA. [Sondheimer, James H.] Wayne State Univ, Sch Med, Dept Internal Med, Detroit, MI 48201 USA. [Steigerwalt, Susan] St John Hosp & Med Ctr, Div Nephrol & Hypertens, Dept Med, Detroit, MI USA. [Steigerwalt, Susan] St John Hosp & Med Ctr, Chron Kidney Dis Clin, Detroit, MI USA. RP Yaffe, K (reprint author), Univ Calif San Francisco, 4150 Clement St,Box 181, San Francisco, CA 94121 USA. EM kristine.yaffe@ucsf.edu RI Kurella Tamura, Manjula/C-8284-2014 OI Kurella Tamura, Manjula/0000-0001-5227-2479 FU National Institutes of Health (NIH); National Institute of Diabetes and Digestive and Kidney Diseases [U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK 061028, U01DK060980, U01DK060963, U01DK 060902, R01DK069406]; Perelman School of Medicine at the University of Pennsylvania [NIH/NCATS UL1TR000003]; Johns Hopkins University [UL1 TR-000424]; University of Maryland [GCRC M01 RR-16500]; Clinical and Translational Science Collaborative of Cleveland; National Center for Advancing Translational Sciences component of the NIH [UL1TR000439]; NIH Roadmap for Medical Research; Michigan Institute for Clinical and Health Research [UL1TR000433]; University of Illinois at Chicago [CTSA UL1RR029879]; Tulane University Translational Research in Hypertension and Renal Biology [P30GM 103337]; Kaiser NIH/NCRR [UCSF-CTSI UL1 RR-024131] FX Dr. Yaffe is a consultant for Novartis and serves on data safety monitoring boards for Takeda, Inc. and a study sponsored by the National Institutes of Health (NIH) and on the Beeson Scientific Advisory Board.; Funding for the CRIC Study was obtained under a cooperative agreement from the National Institute of Diabetes and Digestive and Kidney Diseases (U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK 061028, U01DK060980, U01DK060963, and U01DK 060902). This work was also supported in part by the Perelman School of Medicine at the University of Pennsylvania (Clinical and Translational Science Award NIH/NCATS UL1TR000003), Johns Hopkins University (UL1 TR-000424), the University of Maryland (GCRC M01 RR-16500), the Clinical and Translational Science Collaborative of Cleveland, UL1TR000439 from the National Center for Advancing Translational Sciences component of the NIH and NIH Roadmap for Medical Research, the Michigan Institute for Clinical and Health Research (UL1TR000433), the University of Illinois at Chicago (CTSA UL1RR029879), Tulane University Translational Research in Hypertension and Renal Biology (P30GM 103337), Kaiser NIH/NCRR (UCSF-CTSI UL1 RR-024131). The CRIC COG ancillary study is supported by National Institute of Diabetes and Digestive and Kidney Diseases Grant R01DK069406. NR 48 TC 4 Z9 4 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD SEP PY 2014 VL 62 IS 9 BP 1623 EP 1629 DI 10.1111/jgs.12986 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AQ3VZ UT WOS:000342722900001 PM 25125225 ER PT J AU Wichmann, MA Cruickshanks, KJ Carlsson, CM Chappell, R Fischer, ME Klein, BEK Klein, R Tsai, MY Schubert, CR AF Wichmann, Margarete A. Cruickshanks, Karen J. Carlsson, Cynthia M. Chappell, Rick Fischer, Mary E. Klein, Barbara E. K. Klein, Ronald Tsai, Michael Y. Schubert, Carla R. TI Long-Term Systemic Inflammation and Cognitive Impairment in a Population-Based Cohort SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE cognition; dementia; inflammation; epidemiology; population-based ID C-REACTIVE PROTEIN; ALZHEIMERS ASSOCIATION WORKGROUPS; CARDIOVASCULAR-DISEASE; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; SICKNESS BEHAVIOR; OLDER-ADULTS; HEARING-LOSS; BEAVER DAM; LATE-LIFE AB ObjectivesEvidence suggests inflammation is associated with cognitive impairment, but previous epidemiological studies have reported conflicting results. DesignProspective population-based cohort. SettingEpidemiology of Hearing Loss Study participants. ParticipantsIndividuals without cognitive impairment in 1998-2000 (N=2,422; 1,947 with necessary data). MeasurementsCognitive impairment (Mini-Mental State Examination score <24 or diagnosis of dementia) was ascertained in 1998-2000, 2003-2005, and 2009-2010. Serum C-reactive protein (CRP) and interleukin-6 (IL-6) were measured in 1988-1990, 1998-2000, and 2009-2010; tumor necrosis factor-alpha was measured from 1998-2000. ResultsParticipants with high CRP in 1988-1990 and 1998-2000 had lower risk of cognitive impairment than those with low CRP at both time points (hazard ratio (HR)=0.46, 95% confidence interval (CI)=0.26-0.80). Risk did not differ according to 10-year IL-6 profile or baseline inflammation category in the whole cohort. In sensitivity analyses restricted to statin nonusers, those with high IL-6 at both times had greater risk of cognitive impairment than those with low IL-6 at both times (HR=3.35, 95% CI=1.09-10.30). In secondary analyses, each doubling of IL-6 change over 20years was associated with greater odds of cognitive impairment in 2009-2010 in the whole cohort (odds ratio (OR)=1.40, 95% CI=1.04-1.89), whereas a doubling of CRP change over 20years was associated with cognitive impairment only in statin nonusers (OR=1.32, 95% CI=1.06-1.65). ConclusionWith data collected over 20years, this study demonstrated greater likelihood of cognitive impairment in individuals with repeated high or increasing IL-6. The inconsistent CRP findings may reflect effects of statin medications, survival effects, or adverse effects associated with chronically low CRP. Further studies of long-term inflammation and cognitive impairment are needed. C1 [Wichmann, Margarete A.; Cruickshanks, Karen J.] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI USA. [Wichmann, Margarete A.; Carlsson, Cynthia M.] Univ Wisconsin, Dept Med, Div Geriatr & Gerontol, Madison, WI USA. [Wichmann, Margarete A.] Univ Wisconsin, Inst Aging, Madison, WI USA. [Cruickshanks, Karen J.; Fischer, Mary E.; Klein, Barbara E. K.; Klein, Ronald; Schubert, Carla R.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA. [Carlsson, Cynthia M.; Chappell, Rick] Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA. [Carlsson, Cynthia M.] US Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Chappell, Rick] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI USA. [Chappell, Rick] Univ Wisconsin, Dept Stat, Madison, WI 53706 USA. [Tsai, Michael Y.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA. RP Wichmann, MA (reprint author), VA GRECC D4211, 2500 Overlook Terrace, Madison, WI 53705 USA. EM mwichmann@wisc.edu FU National Institute on Aging (NIA) [R37AG011099]; National Eye Institute [U10EY06594]; National Institute of Diabetes and Digestive and Kidney Diseases [DK073217]; NIA [R01AG021917]; National Eye Institute; National Institute on Deafness and Other Communication Disorders; Research to Prevent Blindness; [T32AG000213] FX This work was supported by R37AG011099 (Karen J. Cruickshanks) from the National Institute on Aging (NIA); U10EY06594 (Ronald Klein, Barbara E. K. Klein) from the National Eye Institute; DK073217 (Ronald Klein) from the National Institute of Diabetes and Digestive and Kidney Diseases; R01AG021917 (Karen J. Cruickshanks) from the NIA, National Eye Institute, and National Institute on Deafness and Other Communication Disorders; and an unrestricted grant from Research to Prevent Blindness. Margarete A. Wichmann is currently supported by a postdoctoral traineeship (T32AG000213). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health (NIH). NR 54 TC 16 Z9 18 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD SEP PY 2014 VL 62 IS 9 BP 1683 EP 1691 DI 10.1111/jgs.12994 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AQ3VZ UT WOS:000342722900008 PM 25123210 ER PT J AU Robinson, TN Dunn, CL Adams, JC Hawkins, CL Tran, ZV Raeburn, CD Moss, M AF Robinson, Thomas N. Dunn, Christina L. Adams, Jill C. Hawkins, Carrie L. Tran, Zung V. Raeburn, Christopher D. Moss, Marc TI Tryptophan Supplementation and Postoperative Delirium-A Randomized Controlled Trial SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE delirium; organic brain syndrome; geriatric surgery; acute confusion ID INTENSIVE-CARE-UNIT; ELDERLY-PATIENTS; SUBTYPES; PATIENT; RISK; MEDICATIONS; VALIDATION; OUTCOMES; SURGERY AB ObjectivesTo determine whether the postoperative administration of tryptophan would be beneficial for elderly adults undergoing surgery who are at risk of developing postoperative delirium. DesignRandomized, double-blind, placebo-controlled trial. SettingDenver Veterans Affairs Medical Center. ParticipantsIndividuals aged 60 and older undergoing major elective operations requiring a postoperative intensive care unit (ICU) admission (n=325). InterventionL-tryptophan, 1g orally three times a day or placebo was started after surgery and continued for up to 3days postoperatively. MeasurementsDelirium and its motor subtypes were measured using the Confusion Assessment Method-Intensive Care Unit (CAM-ICU) and the Richmond Agitation and Sedation Scale. The primary outcome for between-group comparison was the incidence of excitatory (mixed and hyperactive) postoperative delirium. The secondary outcomes for comparison were the incidence and duration of overall postoperative delirium. ResultsThe overall incidence of postoperative delirium was 39% (95% confidence interval=34-44%) (n=116). Seventeen percent of participants in the tryptophan group and 9% in the placebo group had excitatory delirium (P=.18), and the duration of excitatory delirium was 3.31.7days for tryptophan and 3.1 +/- 1.9days for placebo (P=.74). Forty percent of participants in the tryptophan group and 37% in the placebo group had overall delirium (P=.60), and the duration of overall delirium was 2.9 +/- 1.8days for tryptophan and 2.4 +/- 1.6days for placebo (P=.17). ConclusionPostoperative tryptophan supplementation in older adults undergoing major elective operations requiring postoperative ICU admission did not reduce the incidence or duration of postoperative excitatory delirium or overall delirium. C1 [Robinson, Thomas N.; Dunn, Christina L.; Raeburn, Christopher D.] Univ Colorado, Dept Surg, Aurora, CO 80045 USA. [Robinson, Thomas N.; Raeburn, Christopher D.] Denver Vet Affairs Med Ctr, Dept Surg, Denver, CO USA. [Adams, Jill C.; Hawkins, Carrie L.] Denver Vet Affairs Med Ctr, Dept Nursing, Denver, CO USA. [Tran, Zung V.] Univ Colorado, Dept Biostat, Aurora, CO 80045 USA. [Moss, Marc] Univ Colorado, Dept Med, Aurora, CO 80045 USA. RP Robinson, TN (reprint author), Univ Colorado, Sch Med, MS C313,12631 East 17th Ave, Aurora, CO 80045 USA. EM thomas.robinson@ucdenver.edu OI Tran, Zung/0000-0002-9322-9562 FU National Institute on Aging (NIA) [K23AG034632]; American Geriatrics Society; National Institutes of Health [K24-HL-089223] FX Paul B. Beeson Award, National Institute on Aging (NIA), K23AG034632 (TNR); Dennis W. Jahnigen Award, American Geriatrics Society (TNR); National Institutes of Health K24-HL-089223 (MM). NR 36 TC 5 Z9 5 U1 2 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD SEP PY 2014 VL 62 IS 9 BP 1764 EP 1771 DI 10.1111/jgs.12972 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AQ3VZ UT WOS:000342722900020 PM 25112175 ER PT J AU Nakagawa, S Clark, EM Cobbs, EL Livote, E Awan, KS Blackstone, KA Lindenberger, EC AF Nakagawa, Shunichi Clark, Elizabeth M. Cobbs, Elizabeth L. Livote, Elayne Awan, Kanwal S. Blackstone, Karen A. Lindenberger, Elizabeth C. TI PROMOTING ADVANCE CARE PLANNING DOCUMENTATION FOR VETERANS THROUGH AN INNOVATIVE ELECTRONIC MEDICAL RECORD TEMPLATE SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter ID END C1 [Nakagawa, Shunichi] Columbia Univ, Dept Med, Med Ctr, Adult Palliat Care Serv, New York, NY 10027 USA. [Clark, Elizabeth M.] Montefiore Med Ctr, Div Geriatr, Bronx, NY 10467 USA. [Cobbs, Elizabeth L.; Blackstone, Karen A.] George Washington Univ, Dept Med, Div Geriatr & Palliat Med, Washington, DC USA. [Cobbs, Elizabeth L.; Awan, Kanwal S.; Blackstone, Karen A.] Vet Affairs Med Ctr, Washington, DC 20422 USA. [Livote, Elayne] QualityMetric Inc, Lincoln, RI USA. [Awan, Kanwal S.] Johns Hopkins Bayview Med Ctr, Baltimore, MD USA. [Lindenberger, Elizabeth C.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Lindenberger, Elizabeth C.] James J Peters VA Med Ctr, Educ & Clin Ctr, Bronx, NY USA. RP Nakagawa, S (reprint author), Columbia Univ, Dept Med, Med Ctr, Adult Palliat Care Serv, New York, NY 10027 USA. NR 6 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD SEP PY 2014 VL 62 IS 9 BP 1811 EP 1813 DI 10.1111/jgs.13008 PG 3 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AQ3VZ UT WOS:000342722900036 PM 25243695 ER PT J AU Boneschansker, L Yan, J Wong, E Briscoe, DM Irimia, D AF Boneschansker, Leo Yan, Jun Wong, Elisabeth Briscoe, David M. Irimia, Daniel TI Microfluidic platform for the quantitative analysis of leukocyte migration signatures SO NATURE COMMUNICATIONS LA English DT Article ID NEUTROPHIL MIGRATION; CELL-MIGRATION; IN-VIVO; CHEMOTACTIC FACTORS; ACTIVE MOVEMENT; T-CELLS; INTERLEUKIN-8; GRADIENTS; RESPONSES; C5A AB Leukocyte migration into tissues is characteristic of inflammation. It is usually measured in vitro as the average displacement of populations of cells towards a chemokine gradient, not acknowledging other patterns of cell migration. Here, we designed and validated a microfluidic migration platform to simultaneously analyse four qualitative migration patterns: chemoattraction, -repulsion, -kinesis and -inhibition, using single-cell quantitative metrics of direction, speed, persistence and fraction of cells responding. We find that established chemokines, complement component 5a and IL-8 induce chemoattraction and repulsion in equal proportions, resulting in the dispersal of cells. These migration signatures are characterized by high persistence and speed and are independent of the chemokine dose or receptor expression. Furthermore, we find that twice as many T lymphocytes migrate away than towards stromal cell-derived factor 1 and their directional migration patterns are not persistent. Overall, our platform helps discover migratory signature responses and uncovers an avenue for precise characterization of leukocyte migration and therapeutic modulators. C1 [Boneschansker, Leo; Briscoe, David M.] Boston Childrens Hosp, Dept Med, Transplant Res Program, Boston, MA 02115 USA. [Boneschansker, Leo; Briscoe, David M.] Boston Childrens Hosp, Dept Med, Div Nephrol, Boston, MA 02115 USA. [Boneschansker, Leo; Briscoe, David M.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Boneschansker, Leo; Yan, Jun; Wong, Elisabeth; Irimia, Daniel] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg,BioMEMS Resource Ctr,Shriners Hosp Chil, Boston, MA 02129 USA. RP Briscoe, DM (reprint author), Boston Childrens Hosp, Dept Med, Transplant Res Program, Boston, MA 02115 USA. EM david.briscoe@childrens.harvard.edu; dirimia@hms.harvard.edu OI Irimia, Daniel/0000-0001-7347-2082 FU BioMEMS Resource Center [EB002503]; National Institutes of Health (NIH) [P30-HD18655]; NIH [GM092804, AI04675, AI092305, T32DK07726, T32AI007529]; Shriners Hospitals for Children research grant; Groningen International Program of Science in Medicine (GIPS-M) at the University of Groningen, The Netherlands FX We thank Bashar Hamza, M.S. for help with the HL-60 cells and microfabrication. All microfabrication was performed at the National Institute of Biomedical Imaging and Bioengineering (NIBIB) funded, BioMEMS Resource Center (EB002503). We thank Matthew Hilbert, Namrata Jain, Nora Kochupurakkal for technical support with the purification of leukocyte subpopulations. Flow cytometry was performed in the IDDRC Stem Cell Core Facility at Boston Children's Hospital that is supported by National Institutes of Health (NIH) award P30-HD18655. This project was funded by NIH grants GM092804 to D.I. and AI04675 and AI092305 to D.M.B. and Shriners Hospitals for Children research grant to D.I. L.B. was partially funded by a grant from Groningen International Program of Science in Medicine (GIPS-M) at the University of Groningen, The Netherlands and by NIH grants T32DK07726 and T32AI007529. NR 56 TC 24 Z9 24 U1 2 U2 36 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD SEP PY 2014 VL 5 AR 4787 DI 10.1038/ncomms5787 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AQ6MX UT WOS:000342928500005 PM 25183261 ER PT J AU Hong, GS Diao, S Chang, JL Antaris, AL Chen, CX Zhang, B Zhao, S Atochin, DN Huang, PL Andreasson, KI Kuo, CJ Dai, HJ AF Hong, Guosong Diao, Shuo Chang, Junlei Antaris, Alexander L. Chen, Changxin Zhang, Bo Zhao, Su Atochin, Dmitriy N. Huang, Paul L. Andreasson, Katrin I. Kuo, Calvin J. Dai, Hongjie TI Through-skull fluorescence imaging of the brain in a new near-infrared window SO NATURE PHOTONICS LA English DT Article ID WALLED CARBON NANOTUBES; MAGNETIC-RESONANCE ANGIOGRAPHY; IN-VIVO; BLOOD-FLOW; QUANTUM DOTS; 2-PHOTON MICROSCOPY; WAVELENGTH RANGE; II FLUORESCENCE; THINNED-SKULL; MICE AB To date, brain imaging has largely relied on X-ray computed tomography and magnetic resonance angiography, with their limited spatial resolution and long scanning times. Fluorescence-based brain imaging in the visible and traditional near-infrared regions (400-900 nm) is an alternative, but at present it requires craniotomy, cranial windows and skull-thinning techniques, and the penetration depth is limited to 1-2 mm due to light scattering. Here, we report through-scalp and through-skull fluorescence imaging of mouse cerebral vasculature without craniotomy, utilizing the intrinsic photoluminescence of single-walled carbon nanotubes in the 1.3-1.4 mu m near-infrared window (NIR-Ila window). Reduced photon scattering in this spectral region allows fluorescence imaging to a depth of >2 mm in mouse brain with sub-10-mu m resolution. An imaging rate of similar to 5.3 frames per second allows for dynamic recording of blood perfusion in the cerebral vessels with sufficient temporal resolution, providing real-time assessment of a blood flow anomaly in a mouse middle cerebral artery occlusion stroke model. C1 [Hong, Guosong; Diao, Shuo; Antaris, Alexander L.; Chen, Changxin; Zhang, Bo; Zhao, Su; Dai, Hongjie] Stanford Univ, Dept Chem, Stanford, CA 94305 USA. [Chang, Junlei; Kuo, Calvin J.] Stanford Univ, Sch Med, Div Hematol, Stanford, CA 94305 USA. [Atochin, Dmitriy N.; Huang, Paul L.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA. [Atochin, Dmitriy N.; Huang, Paul L.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol, Charlestown, MA 02129 USA. [Andreasson, Katrin I.] Stanford Univ, Med Ctr, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA. RP Kuo, CJ (reprint author), Stanford Univ, Sch Med, Div Hematol, Stanford, CA 94305 USA. EM cjkuo@stanford.edu; hdai@stanford.edu RI Chang, Junlei/P-8782-2014; Atochin, Dmitriy/Q-3150-2016 FU National Cancer Institute of the US National Institutes of Health (NIH) [5R01CA135109-02]; American Heart Association (Innovative Science Award); NIH [1R01NS064517]; William S. Johnson Fellowship FX This study was supported by the National Cancer Institute of the US National Institutes of Health (NIH, grant 5R01CA135109-02, to H.D.), the American Heart Association (Innovative Science Award to C.J.K.), the NIH (grant 1R01NS064517, to C.J.K.) and a William S. Johnson Fellowship (to G.H.). The authors thank J. M. Pauly, D. Wong and T. Zhang for discussions. NR 46 TC 113 Z9 114 U1 29 U2 165 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1749-4885 EI 1749-4893 J9 NAT PHOTONICS JI Nat. Photonics PD SEP PY 2014 VL 8 IS 9 BP 723 EP 730 DI 10.1038/NPHOTON.2014.166 PG 8 WC Optics; Physics, Applied SC Optics; Physics GA AQ2FB UT WOS:000342600100016 PM 27642366 ER PT J AU Kulke, M AF Kulke, Matthew TI Neuroendocrine Tumors: Answers-and Questions SO ONCOLOGY-NEW YORK LA English DT Editorial Material C1 [Kulke, Matthew] Dana Farber Canc Inst, Program Neuroendocrine & Carcinoid Tumors, Boston, MA 02115 USA. [Kulke, Matthew] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Kulke, Matthew] Harvard Univ, Sch Med, Boston, MA USA. RP Kulke, M (reprint author), Dana Farber Canc Inst, Program Neuroendocrine & Carcinoid Tumors, Boston, MA 02115 USA. NR 8 TC 0 Z9 0 U1 0 U2 0 PU UBM MEDICA PI NORWALK PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA SN 0890-9091 J9 ONCOLOGY-NY JI Oncology-NY PD SEP PY 2014 VL 28 IS 9 BP 758 EP 760 PG 3 WC Oncology SC Oncology GA AQ1PJ UT WOS:000342553000003 PM 25224472 ER PT J AU Janiszewska, M Beca, F Polyak, K AF Janiszewska, Michalina Beca, Francisco Polyak, Kornelia TI Tumor Heterogeneity: The Lernaean Hydra of Oncology? SO ONCOLOGY-NEW YORK LA English DT Editorial Material ID BREAST-CANCER; MATHEMATICAL-THEORY; HSP90; RECOMMENDATIONS; COMMUNICATION; RESISTANCE; MECHANISMS; DIVERSITY; THERAPY C1 [Janiszewska, Michalina; Beca, Francisco; Polyak, Kornelia] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Janiszewska, Michalina; Beca, Francisco; Polyak, Kornelia] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Janiszewska, Michalina; Beca, Francisco; Polyak, Kornelia] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Beca, Francisco] Univ Porto, IPATIMUP, Inst Mol Pathol & Immunol, P-4100 Oporto, Portugal. [Polyak, Kornelia] Harvard Stem Cell Inst & Broad Inst, Cambridge, MA USA. RP Janiszewska, M (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 18 TC 4 Z9 4 U1 0 U2 3 PU UBM MEDICA PI NORWALK PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA SN 0890-9091 J9 ONCOLOGY-NY JI Oncology-NY PD SEP PY 2014 VL 28 IS 9 BP 781 EP 784 PG 4 WC Oncology SC Oncology GA AQ1PJ UT WOS:000342553000008 PM 25224477 ER PT J AU Li, D Pant, S Ryan, DP Laheru, D Bahary, N Dragovich, T Hosein, PJ Rolfe, L Saif, MW LaValle, J Yu, KH Lowery, MA Allen, A O'Reilly, EM AF Li, D. Pant, S. Ryan, D. P. Laheru, D. Bahary, N. Dragovich, T. Hosein, P. J. Rolfe, L. Saif, M. W. LaValle, J. Yu, K. H. Lowery, M. A. Allen, A. O'Reilly, E. M. TI A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression SO PANCREATOLOGY LA English DT Article DE Gemcitabine-refractory; Pancreas adenocarcinoma; CO-1.01; hENT1; Biomarker; Disease-control rate ID EQUILIBRATIVE NUCLEOSIDE TRANSPORTER-1; RANDOMIZED CONTROLLED-TRIAL; FOLINIC ACID; CANCER; OXALIPLATIN; CHEMOTHERAPY; RESECTION; SURVIVAL; FLUOROURACIL AB Background: Nucleotide transporters such as human equilibrative nucleoside transporter-1 (hENT1) play a major role in transporting gemcitabine into cells. CO-1.01 (gemcitabine-5'-elaidate) is a novel cytotoxic agent consisting of a fatty acid derivative of gemcitabine, which is transported intracellularly independent of hENT1. CO-1.01 was postulated to have efficacy as a second-line treatment in gemcitabine-refractory pancreatic adenocarcinoma in patients with negative tumor hENT1 expression. Methods: Eligibility criteria included patients with either a newly procured or archival biopsy tumor confirming the absence of hENT1 and either gemcitabine-refractory metastatic pancreas adenocarcinoma or with progression of disease following resection during or within 3 months of adjuvant gemcitabine therapy. Patients were treated with intravenous infusion of CO-1.01 dosed at 1250 mg/m(2) on Days 1, 8, and 15 of a 4-week cycle. The primary end point was disease control rate (DCR). Results: Nineteen patients were enrolled of which 18 patients were evaluable for efficacy assessment. Thirteen patients (68%) had liver metastases, 6 (32%) had lymph node metastases, and 10 (53%) had lung metastases. Two of 18 patients (11%) achieved disease control. The median survival time was 4.3 (95% CI 2.1-8.1) months. All patients experienced at least one treatment-related adverse event with the majority of events being mild or moderate. Conclusion: This study did not meet its primary endpoint and no efficacy signal was identified for CO-1.01 in treating progressive metastatic pancreas adenocarcinoma. Copyright (C) 2014, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd. All rights reserved. C1 [Li, D.; LaValle, J.; Yu, K. H.; Lowery, M. A.; O'Reilly, E. M.] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA. [Pant, S.] Peggy & Charles Stephenson Oklahoma Canc Ctr, Oklahoma City, OK USA. [Ryan, D. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Laheru, D.] Sydney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Bahary, N.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. [Dragovich, T.] Univ Arizona, Ctr Canc, Tucson, AZ USA. [Hosein, P. J.] Sylvester Comprehens Canc Ctr, Miami, FL USA. [Rolfe, L.; Allen, A.] Clovis Oncol, Cambridge, England. [Rolfe, L.; Allen, A.] Clovis Oncol, San Francisco, CA USA. [Saif, M. W.] Columbia Univ, Coll Phys & Surg, New York, NY USA. RP O'Reilly, EM (reprint author), Mem Sloan Kettering Canc Ctr, Dept Med, Gastrointestinal Med Oncol Serv, 300 East 66th St, New York, NY 10065 USA. EM oreillye@mskcc.org OI Lowery, Maeve/0000-0003-1354-7606 FU Clovis Oncology FX Funding: Clovis Oncology supported this work. NR 22 TC 3 Z9 3 U1 0 U2 4 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1424-3903 EI 1424-3911 J9 PANCREATOLOGY JI Pancreatology PD SEP-OCT PY 2014 VL 14 IS 5 BP 398 EP 402 DI 10.1016/j.pan.2014.07.003 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AQ7AN UT WOS:000342965100015 PM 25278310 ER PT J AU Zheng, YH Yin, LH Grahn, THM Ye, AF Zhao, YR Zhang, QY AF Zheng, Yi-Hu Yin, Li-Hui Grahn, Tan Hooi Min Ye, Ai-Fang Zhao, Yan-Rong Zhang, Qi-Yu TI Anticancer Effects of Baicalein on Hepatocellular Carcinoma Cells SO PHYTOTHERAPY RESEARCH LA English DT Article DE baicalein; hepatocellular carcinoma; beta-catenin ID PROTEIN-KINASE; INHIBITION; DEGRADATION; INSULIN AB The therapeutic potential of baicalein against hepatoma cells was evaluated in vitro and in vivo. In cell viability assays, baicalein showed significant cytotoxicity against the hepatocellular carcinoma cell lines H22, Bel-7404, and Hep G2 and moderate cytotoxicity against immortalized human hepatocytes. Baicalein induced G0/G1-phase arrest in hepatocellular carcinoma cells, inhibited AKT, and promoted the degradation of beta-catenin and cyclin D1 without activation of GSK-3 beta. Furthermore, baicalein significantly inhibited H22 xenograft tumor growth without causing obvious adverse effects on weight or liver and spleen weight indexes in ICR mice. Immunohistochemical analysis showed that the inhibition of tumor growth in baicalein-treated mice was associated with decreased AKT, beta-catenin, and cyclin D1 expression ex vivo. Our data indicate that baicalein might regulate cyclin D1 transcription via a beta-catenin-dependent mechanism, leading to cell cycle arrest at G0/G1 phase and impaired cancer cell proliferation. These results suggest that baicalein is a potential candidate for the treatment of hepatocellular carcinoma. Copyright (C) 2014 John Wiley & Sons, Ltd. C1 [Zheng, Yi-Hu; Zhao, Yan-Rong; Zhang, Qi-Yu] Wenzhou Med Univ, Dept Gen Surg, Affiliated Hosp 1, Wenzhou 325002, Zhejiang, Peoples R China. [Yin, Li-Hui; Ye, Ai-Fang] Wenzhou Med Univ, Lab Internal Med, Affiliated Hosp 1, Wenzhou, Peoples R China. [Grahn, Tan Hooi Min] Harvard Univ, Sch Med, Joslin Diabet Ctr, Dept Med, Boston, MA 02115 USA. RP Zhang, QY (reprint author), Wenzhou Med Univ, Dept Gen Surg, Affiliated Hosp 1, Nan Bai Xiang St, Wenzhou 325002, Zhejiang, Peoples R China. EM zjsurgery@gmail.com FU Zhejiang Provincial Top Key Discipline in Surgery and Wenzhou Key Laboratory Project in Surgery FX This study was sponsored by Zhejiang Provincial Top Key Discipline in Surgery and Wenzhou Key Laboratory Project in Surgery. NR 19 TC 14 Z9 18 U1 2 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0951-418X EI 1099-1573 J9 PHYTOTHER RES JI Phytother. Res. PD SEP PY 2014 VL 28 IS 9 BP 1342 EP 1348 DI 10.1002/ptr.5135 PG 7 WC Chemistry, Medicinal; Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA AQ4VS UT WOS:000342799100012 PM 24596136 ER PT J AU Mak-McCully, RA Deiss, SR Rosen, BQ Jung, KY Sejnowski, TJ Bastuji, H Rey, M Cash, SS Bazhenov, M Halgren, E AF Mak-McCully, Rachel A. Deiss, Stephen R. Rosen, Burke Q. Jung, Ki-Young Sejnowski, Terrence J. Bastuji, Helene Rey, Marc Cash, Sydney S. Bazhenov, Maxim Halgren, Eric TI Synchronization of Isolated Downstates (K-Complexes) May Be Caused by Cortically-Induced Disruption of Thalamic Spindling SO PLOS COMPUTATIONAL BIOLOGY LA English DT Article ID SLEEP SLOW OSCILLATION; RETICULAR NUCLEUS; NEOCORTICAL NEURONS; CALCIUM-CHANNEL; BASAL FOREBRAIN; LESS-THAN-1 HZ; IN-VIVO; THALAMOCORTICAL OSCILLATIONS; CORTICOTHALAMIC FEEDBACK; SYNAPTIC DEPRESSION AB Sleep spindles and K-complexes (KCs) define stage 2 NREM sleep (N2) in humans. We recently showed that KCs are isolated downstates characterized by widespread cortical silence. We demonstrate here that KCs can be quasi-synchronous across scalp EEG and across much of the cortex using electrocorticography (ECOG) and localized transcortical recordings (bipolar SEEG). We examine the mechanism of synchronous KC production by creating the first conductance based thalamocortical network model of N2 sleep to generate both spontaneous spindles and KCs. Spontaneous KCs are only observed when the model includes diffuse projections from restricted prefrontal areas to the thalamic reticular nucleus (RE), consistent with recent anatomical findings in rhesus monkeys. Modeled KCs begin with a spontaneous focal depolarization of the prefrontal neurons, followed by depolarization of the RE. Surprisingly, the RE depolarization leads to decreased firing due to disrupted spindling, which in turn is due to depolarization-induced inactivation of the low-threshold Ca2+ current (I-T). Further, although the RE inhibits thalamocortical (TC) neurons, decreased RE firing causes decreased TC cell firing, again because of disrupted spindling. The resulting abrupt removal of excitatory input to cortical pyramidal neurons then leads to the downstate. Empirically, KCs may also be evoked by sensory stimuli while maintaining sleep. We reproduce this phenomenon in the model by depolarization of either the RE or the widely-projecting prefrontal neurons. Again, disruption of thalamic spindling plays a key role. Higher levels of RE stimulation also cause downstates, but by directly inhibiting the TC neurons. SEEG recordings from the thalamus and cortex in a single patient demonstrated the model prediction that thalamic spindling significantly decreases before KC onset. In conclusion, we show empirically that KCs can be widespread quasi-synchronous cortical downstates, and demonstrate with the first model of stage 2 NREM sleep a possible mechanism whereby this widespread synchrony may arise. C1 [Mak-McCully, Rachel A.; Halgren, Eric] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Deiss, Stephen R.] Univ Calif San Diego, Comp Sci & Engn Dept, San Diego, CA 92103 USA. [Rosen, Burke Q.; Halgren, Eric] Univ Calif San Diego, Dept Radiol, San Diego, CA 92103 USA. [Jung, Ki-Young] Seoul Natl Univ, Coll Med, Dept Neurol, Seoul, South Korea. [Sejnowski, Terrence J.] Univ Calif San Diego, Div Biol Sci, San Diego, CA 92103 USA. [Sejnowski, Terrence J.] Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA. [Bastuji, Helene] INSERM, Lyon Neurosci Res Ctr, U1028, F-69008 Lyon, France. [Bastuji, Helene] CNRS, UMR5292, Lyon, France. [Bastuji, Helene] Univ Lyon 1, F-69365 Lyon, France. [Bastuji, Helene] Hosp Civils Lyon, Hop Neurol, Unite Hypnol, Serv Neurol Fonct & Epileptol, Bron, France. [Rey, Marc] Aix Marseille Univ, Timone Hosp, APHM, Clin Neurophysiol Sleep Unit, Marseille, France. [Cash, Sydney S.] Harvard Univ, Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA. [Cash, Sydney S.] Harvard Univ, Sch Med, Boston, MA USA. [Bazhenov, Maxim] Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA. [Halgren, Eric] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. RP Mak-McCully, RA (reprint author), Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. EM rmakmccu@ucsd.edu FU NIH [R01 MH099645, R01 EB009282]; ONR (MURI) [N000141310672]; NSF GRFP; Chateaubriand Fellowship FX This work was funded by NIH R01 MH099645, R01 EB009282 (http://www.nih.gov/), ONR (MURI) N000141310672 (http://www.onr.navy.mil/), NSF GRFP (http://www.nsfgrfp.org/) and Chateaubriand Fellowship (http://www.chateaubriand-fellowship.org/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 90 TC 1 Z9 1 U1 3 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-734X EI 1553-7358 J9 PLOS COMPUT BIOL JI PLoS Comput. Biol. PD SEP PY 2014 VL 10 IS 9 AR e1003855 DI 10.1371/journal.pcbi.1003855 PG 25 WC Biochemical Research Methods; Mathematical & Computational Biology SC Biochemistry & Molecular Biology; Mathematical & Computational Biology GA AQ7PO UT WOS:000343011700045 PM 25255217 ER PT J AU Beecham, GW Hamilton, K Naj, AC Martin, ER Huentelman, M Myers, AJ Corneveaux, JJ Hardys, J VonsatteI, JP Younkin, SG Bennett, DA De Jager, PL Larson, EB Crane, PK Kamboh, MI Kofler, JK Mash, DC Duque, L Gilbertl, JR Gwirtsman, H Buxbaum, JD Kramer, P Dickson, DW Farrer, LA Frosch, MP Ghetti, B Haines, JL Hyman, BT Kuku, WA Mayeux, RP Pericak-Vancel, MA Schneider, JA Trojanowski, JQ Reiman, EM Schellenberg, GD Montine, TJ AF Beecham, Gary W. Hamilton, Kara Naj, Adam C. Martin, Eden R. Huentelman, Matt Myers, Amanda J. Corneveaux, Jason J. Hardys, John Vonsatte, Jean-Paul, I Younkin, Steven G. Bennett, David A. De Jager, Philip L. Larson, Eric B. Crane, Paul K. Kamboh, M. Ilyas Kofler, Julia K. Mash, Deborah C. Duque, Linda Gilbertl, John R. Gwirtsman, Harry Buxbaum, Joseph D. Kramer, Patricia Dickson, Dennis W. Farrer, Lindsay A. Frosch, Matthew P. Ghetti, Bernardino Haines, Jonathan L. Hyman, Bradley T. Kuku, Walter A. Mayeux, Richard P. Pericak-Vancel, Margaret A. Schneider, Julie A. Trojanowski, John Q. Reiman, Eric M. Schellenberg, Gerard D. Montine, Thomas J. CA ADGC TI Genome-Wide Association Meta-analysis of Neuropathologic Features of Alzheimer's Disease and Related Dementias SO PLOS GENETICS LA English DT Article ID SUSCEPTIBILITY LOCI; COMMON VARIANTS; PROTEIN; RISK; DIAGNOSIS; GENOTYPES; BRAIN; CD2AP; EPHA1; CD33 AB Alzheimer's disease (AD) and related dementias are a major public health challenge and present a therapeutic imperative for which we need additional insight into molecular pathogenesis. We performed a genome-wide association study and analysis of known genetic risk loci for AD dementia using neuropathologic data from 4,914 brain autopsies. Neuropathologic data were used to define clinico-pathologic AD dementia or controls, assess core neuropathologic features of AD (neuritic plaques, NPs; neurofibrillary tangles, NFTs), and evaluate commonly co-morbid neuropathologic changes: cerebral amyloid angiopathy (CAA), Lewy body disease (LBD), hippocampal sclerosis of the elderly (HS), and vascular brain injury (VBI). Genome-wide significance was observed for clinico-pathologic AD dementia, NPs, NFTs, CAA, and LBD with a number of variants in and around the apolipoprotein E gene (APOE). GaINAc transferase 7 (GALNT7), ATP-Binding Cassette, Sub-Family G (WHITE), Member 1 (ABCG1), and an intergenic region on chromosome 9 were associated with NP score; and Potassium Large Conductance Calcium-Activated Channel, Subfamily M, Beta Member 2 (KCNMB2) was strongly associated with HS. Twelve of the 21 non-APOE genetic risk loci for clinically-defined AD dementia were confirmed in our clinico-pathologic sample: CR1, BlN1, CLU, MS4A6A, PlCALM, ABCA7, CD33, PTK2B, SORL1, MEF2C, ZCWPW1, and CASS4 with 9 of these 12 loci showing larger odds ratio in the clinico-pathologic sample. Correlation of effect sizes for risk of AD dementia with effect size for NFTs or NPs showed positive correlation, while those for risk of VBI showed a moderate negative correlation. The other co-morbid neuropathologic features showed only nominal association with the known AD loci. Our results discovered new genetic associations with specific neuropathologic features and aligned known genetic risk for AD dementia with specific neuropathologic changes in the largest brain autopsy study of AD and related dementias. C1 [Beecham, Gary W.; Hamilton, Kara; Martin, Eden R.; Gilbertl, John R.; Pericak-Vancel, Margaret A.] Univ Miami, John P Hussman Inst Human Genom, Miami, FL USA. [Naj, Adam C.] Univ Penn, Div Epidemiol, Philadelphia, PA 19104 USA. [Huentelman, Matt; Corneveaux, Jason J.] Translat Genom Res Inst, Neurogen Div, Phoenix, AZ USA. [Myers, Amanda J.] Univ Miami, Dept Psychiat & Behav Sci, Miami, FL USA. [Hardys, John] UCL, Dept Mol Neurosci, London, England. [Vonsatte, Jean-Paul, I] Columbia Univ, New York Brain Bank, New York, NY USA. [Younkin, Steven G.; Dickson, Dennis W.] Mayo Clin, Coll Med, Dept Neurosci, Jacksonville, FL 32224 USA. [Bennett, David A.; Schneider, Julie A.] Rush Univ, Dept Neurol Sci, Chicago, IL 60612 USA. [De Jager, Philip L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurol & Psychiat, Boston, MA 02115 USA. [Larson, Eric B.] Grp Hlth Res Inst, Seattle, WA USA. [Crane, Paul K.] Univ Washington, Dept Med, Seattle, WA USA. [Kamboh, M. Ilyas] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA. [Kofler, Julia K.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA. [Mash, Deborah C.; Duque, Linda] Univ Miami, Dept Neurol, Miami, FL USA. [Gwirtsman, Harry] Vanderbilt Univ, Dept Psychiat, Nashville, TN 37235 USA. [Buxbaum, Joseph D.] Mt Sinai Hosp, Dept Psychiat, New York, NY 10029 USA. [Kramer, Patricia] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Frosch, Matthew P.] Massachusetts Gen Hosp, CS Kubik Lab Neuropathol, Charlestown, MA USA. [Ghetti, Bernardino] Indiana Univ, Dept Pathol & Lab Med, Indianapolis, IN 46204 USA. [Haines, Jonathan L.] Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA. [Hyman, Bradley T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA. [Kuku, Walter A.] Univ Washington, Dept Epidemiol, Natl Alzheimers Coordinating Ctr, Seattle, WA 98195 USA. [Mayeux, Richard P.] Columbia Univ, Dept Neurol, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY USA. [Schneider, Julie A.] Rush Univ, Med Ctr, Dept Pathol Neuropathol, Chicago, IL 60612 USA. [Trojanowski, John Q.; Schellenberg, Gerard D.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA. [Reiman, Eric M.] Banner Alzheimers Inst, Arizona Alzheimers Consortium, Phoenix, AZ USA. [Reiman, Eric M.] Univ Arizona, Dept Psychiat, Phoenix, AZ USA. [Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. RP Beecham, GW (reprint author), Univ Miami, John P Hussman Inst Human Genom, Miami, FL USA. EM tmontine@uw.edu RI Hardy, John/C-2451-2009; Tsuang, Debby/L-7234-2016; OI Farrer, Lindsay/0000-0001-5533-4225; Kukull, Walter/0000-0001-8761-9014; Kamboh, M. Ilyas/0000-0002-3453-1438; Tsuang, Debby/0000-0002-4716-1894; Buxbaum, Joseph/0000-0001-8898-8313 FU National Institutes of Health, National Institute on Aging (NIH-NIA) [U01 AG032984, RC2 AG036528, U01 AG016976, U24 AG021886, U24 AG026395, U24 AG026390]; Banner Sun Health Research Institute [P30 AG019610]; Boston University [P30 AG013846, U01 AG10483, R01 CA129769, R01 MH080295, R01 AG017173, R01 AG025259, R01AG33193]; Columbia University [P50 AG008702, R37 AG015473]; Duke University [P30 AG028377, AG05128]; Emory University [AG025688]; Group Health Research Institute [U01 AG06781, U01 HG004610]; Indiana University [P30 AG10133]; Johns Hopkins University [P50 AG005146, R01 AG020688]; Massachusetts General Hospital [P50 AG005134]; Mayo Clinic [P50 AG016574]; Mount Sinai School of Medicine [P50 AG005138, P01 AG002219]; New York University [P30 AG08051, MO1RR00096, UL1 RR029893, 5R01AG012101, 5R01AG022374, 5R01AG013616, 1RC2AG036502, 1R01AG035137]; Northwestern University [P30 AG013854]; Oregon Health & Science University [P30 AG008017, R01 AG026916]; Rush University [P30 AG010161, R01 AG019085, R01 AG15819, R01 AG17917, R01 AG30146]; TGen [R01 NS059873]; University of Alabama at Birmingham [P50 AG016582, UL1RR02777]; University of Arizona [R01 AG031581]; University of California, Davis [P30 AG010129]; University of California, Irvine [P50 AG016573, P50, P50 AG016575, P50 AG016576, P50 AG016577]; University of California, Los Angeles [P50 AG016570]; University of California, San Diego [P50 AG005131]; University of California, San Francisco [P50 AG023501, P01 AG019724]; University of Kentucky [P30 AG028383, AG05144]; University of Michigan [P50 AG008671]; University of Pennsylvania [P30 AG010124]; University of Pittsburgh [P50 AG005133, AG030653]; University of Southern California [P50 AG005142]; University of Texas Southwestern [P30 AG012300]; University of Miami [R01 AG027944, AG010491, AG027944, AG021547, AG019757]; University of Washington [P50 AG005136]; Vanderbilt University [R01 AG019085]; Washington University [P50 AG005681, P01 AG03991]; NINDS [NS39764, NIMH MH60451]; Glaxo Smith Kline; Kronos Science; NIA [AG041232, U01 AG024904, RC2 AG036535, K01 AG030514]; Banner Alzheimer's Foundation; Johnnie B. Byrd Sr. Alzheimer's Institute; Medical Research Council; state of Arizona; local NHS trusts; Newcastle University; Higher Education Funding Council for England (HEFCE); Alzheimer's Research Trust (ART); BRACE; North Bristol NHS Trust Research and Innovation Department; DeNDRoN; Stichting MS Research; Brain Net Europe; Hersenstichting Nederland Breinbrekend Werk; International Parkinson Fonds; Internationale Stiching Alzheimer Onderzoek; Northern California Institute for Research and Education; Abbott; AstraZeneca AB; Bayer Schering Pharma AG; Bristol-Myers Squibb; Eisai Global Clinical Development; Elan Corporation; Genentech; GE Healthcare; GlaxoSmithKline; Innogenetics; Johnson and Johnson; Eli Lilly and Co.; Medpace, Inc.; Merck and Co., Inc.; Novartis AG; Pfizer Inc; F. Hoffman-La Roche; Schering-Plough; Synarc, Inc.; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Dana Foundation; National Institute of Biomedical Imaging and Bioengineering; Alzheimer's Association [IIRG-08-89720, IIRG-05-14147]; US Department of Veterans Affairs Administration, Office of Research and Development, Biomedical Laboratory Research Program FX The National Institutes of Health, National Institute on Aging (NIH-NIA) supported this work through the following grants: ADGC, U01 AG032984, RC2 AG036528; NACC, U01 AG016976; NCRAD, U24 AG021886; NIA LOAD, U24 AG026395, U24 AG026390; Banner Sun Health Research Institute P30 AG019610; Boston University, P30 AG013846, U01 AG10483, R01 CA129769, R01 MH080295, R01 AG017173, R01 AG025259, R01AG33193; Columbia University, P50 AG008702, R37 AG015473; Duke University, P30 AG028377, AG05128; Emory University, AG025688; Group Health Research Institute, U01 AG06781, U01 HG004610; Indiana University, P30 AG10133; Johns Hopkins University, P50 AG005146, R01 AG020688; Massachusetts General Hospital, P50 AG005134; Mayo Clinic, P50 AG016574; Mount Sinai School of Medicine, P50 AG005138, P01 AG002219; New York University, P30 AG08051, MO1RR00096, UL1 RR029893, 5R01AG012101, 5R01AG022374, 5R01AG013616, 1RC2AG036502, 1R01AG035137; Northwestern University, P30 AG013854; Oregon Health & Science University, P30 AG008017, R01 AG026916; Rush University, P30 AG010161, R01 AG019085, R01 AG15819, R01 AG17917, R01 AG30146; TGen, R01 NS059873; University of Alabama at Birmingham, P50 AG016582, UL1RR02777; University of Arizona, R01 AG031581; University of California, Davis, P30 AG010129; University of California, Irvine, P50 AG016573, P50, P50 AG016575, P50 AG016576, P50 AG016577; University of California, Los Angeles, P50 AG016570; University of California, San Diego, P50 AG005131; University of California, San Francisco, P50 AG023501, P01 AG019724; University of Kentucky, P30 AG028383, AG05144; University of Michigan, P50 AG008671; University of Pennsylvania, P30 AG010124; University of Pittsburgh, P50 AG005133, AG030653; University of Southern California, P50 AG005142; University of Texas Southwestern, P30 AG012300; University of Miami, R01 AG027944, AG010491, AG027944, AG021547, AG019757; University of Washington, P50 AG005136; Vanderbilt University, R01 AG019085; and Washington University, P50 AG005681, P01 AG03991. The Kathleen Price Bryan Brain Bank at Duke University Medical Center is funded by NINDS grant # NS39764, NIMH MH60451 and by Glaxo Smith Kline. Genotyping of the TGEN2 cohort was supported by Kronos Science. The TGen series was also funded by NIA grant AG041232, the Banner Alzheimer's Foundation, The Johnnie B. Byrd Sr. Alzheimer's Institute, the Medical Research Council, and the state of Arizona and also includes samples from the following sites: Newcastle Brain Tissue Resource (funding via the Medical Research Council, local NHS trusts and Newcastle University), MRC London Brain Bank for Neurodegenerative Diseases (funding via the Medical Research Council), South West Dementia Brain Bank (funding via numerous sources including the Higher Education Funding Council for England (HEFCE), Alzheimer's Research Trust (ART), BRACE as well as North Bristol NHS Trust Research and Innovation Department and DeNDRoN), The Netherlands Brain Bank (funding via numerous sources including Stichting MS Research, Brain Net Europe, Hersenstichting Nederland Breinbrekend Werk, International Parkinson Fonds, Internationale Stiching Alzheimer Onderzoek), Institut de Neuropatologia, Servei Anatomia Patologica, Universitat de Barcelona. ADNI Funding for ADNI is through the Northern California Institute for Research and Education by grants from Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson and Johnson, Eli Lilly and Co.; , Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough, Synarc, Inc., Alzheimer's Association, Alzheimer's Drug Discovery Foundation, the Dana Foundation, and by the National Institute of Biomedical Imaging and Bioengineering and NIA grants U01 AG024904, RC2 AG036535, K01 AG030514. Support was also from the Alzheimer's Association (LAF, IIRG-08-89720; MAP-V, IIRG-05-14147) and the US Department of Veterans Affairs Administration, Office of Research and Development, Biomedical Laboratory Research Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 31 TC 38 Z9 38 U1 1 U2 15 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7390 EI 1553-7404 J9 PLOS GENET JI PLoS Genet. PD SEP PY 2014 VL 10 IS 9 AR e1004606 DI 10.1371/journal.pgen.1004606 PG 15 WC Genetics & Heredity SC Genetics & Heredity GA AQ7OY UT WOS:000343009600029 PM 25188341 ER PT J AU Binagwaho, A Nutt, CT Mugwaneza, P Wagner, CM Nsanzimana, S AF Binagwaho, Agnes Nutt, Cameron T. Mugwaneza, Placidie Wagner, Claire M. Nsanzimana, Sabin TI Convergence of Mortality Rates among Patients on Antiretroviral Therapy in South Africa and North America SO PLOS MEDICINE LA English DT Editorial Material ID SUB-SAHARAN AFRICA; ADHERENCE C1 [Binagwaho, Agnes] Minist Hlth Rwanda, Kigali, Rwanda. [Binagwaho, Agnes] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA. [Binagwaho, Agnes] Geisel Sch Med Dartmouth, Hanover, NH USA. [Nutt, Cameron T.] Partners Hlth, Boston, MA USA. [Mugwaneza, Placidie; Nsanzimana, Sabin] Rwanda Biomed Ctr, HIV & Other Sexually Transmitted Infect Div, Kigali, Rwanda. [Wagner, Claire M.] Dana Farber Canc Inst, Ctr Global Canc Med, Boston, MA 02115 USA. RP Binagwaho, A (reprint author), Minist Hlth Rwanda, Kigali, Rwanda. EM agnes_binagwaho@hms.harvard.edu NR 18 TC 2 Z9 2 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1549-1676 J9 PLOS MED JI PLos Med. PD SEP PY 2014 VL 11 IS 9 AR e1001719 DI 10.1371/journal.pmed.1001719 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA AQ6FO UT WOS:000342905700020 PM 25202913 ER PT J AU Hyle, EP Jani, IV Lehe, J Su, AE Wood, R Quevedo, J Losina, E Bassett, IV Pei, PP Paltiel, AD Resch, S Freedberg, KA Peter, T Walensky, RP AF Hyle, Emily P. Jani, Ilesh V. Lehe, Jonathan Su, Amanda E. Wood, Robin Quevedo, Jorge Losina, Elena Bassett, Ingrid V. Pei, Pamela P. Paltiel, A. David Resch, Stephen Freedberg, Kenneth A. Peter, Trevor Walensky, Rochelle P. TI The Clinical and Economic Impact of Point-of-Care CD4 Testing in Mozambique and Other Resource-Limited Settings: A Cost-Effectiveness Analysis SO PLOS MEDICINE LA English DT Article ID ANTIRETROVIRAL TREATMENT PROGRAMS; LOW-INCOME COUNTRIES; SOUTH-AFRICA; FOLLOW-UP; COTE-DIVOIRE; PERFORMANCE EVALUATION; ART INITIATION; HIV DIAGNOSIS; PIMA CD4; THERAPY AB Background Point-of-care CD4 tests at HIV diagnosis could improve linkage to care in resource-limited settings. Our objective is to evaluate the clinical and economic impact of point-of-care CD4 tests compared to laboratory-based tests in Mozambique. Methods and Findings We use a validated model of HIV testing, linkage, and treatment (CEPAC-International) to examine two strategies of immunological staging in Mozambique: (1) laboratory-based CD4 testing (LAB-CD4) and (2) point-of-care CD4 testing (POC-CD4). Model outcomes include 5-y survival, life expectancy, lifetime costs, and incremental cost-effectiveness ratios (ICERs). Input parameters include linkage to care (LAB-CD4, 34%; POC-CD4, 61%), probability of correctly detecting antiretroviral therapy (ART) eligibility (sensitivity: LAB-CD4, 100%; POC-CD4, 90%) or ART ineligibility (specificity: LAB-CD4, 100%; POC-CD4, 85%), and test cost (LAB-CD4, US$10; POC-CD4, US$24). In sensitivity analyses, we vary POC-CD4-specific parameters, as well as cohort and setting parameters to reflect a range of scenarios in sub-Saharan Africa. We consider ICERs less than three times the per capita gross domestic product in Mozambique (US$570) to be cost-effective, and ICERs less than one times the per capita gross domestic product in Mozambique to be very cost-effective. Projected 5-y survival in HIV-infected persons with LAB-CD4 is 60.9% (95% CI, 60.9%-61.0%), increasing to 65.0% (95% CI, 64.9%-65.1%) with POC-CD4. Discounted life expectancy and per person lifetime costs with LAB-CD4 are 9.6 y (95% CI, 9.6-9.6 y) and US$2,440 (95% CI, US$2,440-US$2,450) and increase with POC-CD4 to 10.3 y (95% CI, 10.3-10.3 y) and US$2,800 (95% CI, US$2,790-US$2,800); the ICER of POC-CD4 compared to LAB-CD4 is US$500/year of life saved (YLS) (95% CI, US$480-US$520/YLS). POC-CD4 improves clinical outcomes and remains near the very cost-effective threshold in sensitivity analyses, even if point-of-care CD4 tests have lower sensitivity/specificity and higher cost than published values. In other resource-limited settings with fewer opportunities to access care, POC-CD4 has a greater impact on clinical outcomes and remains cost-effective compared to LAB-CD4. Limitations of the analysis include the uncertainty around input parameters, which is examined in sensitivity analyses. The potential added benefits due to decreased transmission are excluded; their inclusion would likely further increase the value of POC-CD4 compared to LAB-CD4. Conclusions POC-CD4 at the time of HIV diagnosis could improve survival and be cost-effective compared to LAB-CD4 in Mozambique, if it improves linkage to care. POC-CD4 could have the greatest impact on mortality in settings where resources for HIV testing and linkage are most limited.Please see later in the article for the Editors' Summary Editors' Summary Background AIDS has already killed about 36 million people, and a similar number of people (mostly living in low- and middle-income countries) are currently infected with HIV, the virus that causes AIDS. HIV destroys immune system cells (including CD4 cells, a type of lymphocyte), leaving infected individuals susceptible to other infections. Early in the AIDS epidemic, HIV-infected individuals usually died within ten years of infection. After effective antiretroviral therapy (ART) became available in 1996, HIV infection became a chronic condition for people living in high-income countries, but because ART was expensive, HIV/AIDS remained a fatal disease in low- and middle-income countries. In 2003, the international community began to work towards achieving universal ART coverage, and by the end of 2012, 61% of HIV-positive people (nearly 10 million individuals) living low- and middle-income countries who were eligible for treatmentbecause their CD4 cell count had fallen below 350 cells/mm(3) of blood or they had developed an AIDS-defining conditionwere receiving treatment. Why Was This Study Done? In sub-Saharan Africa nearly 50% of HIV-infected people eligible for treatment remain untreated, in part because of poor linkage between HIV diagnosis and clinical care. After patients receive a diagnosis of HIV infection, their eligibility for ART initiation is determined by sending a blood sample away to a laboratory for a CD4 cell count (the current threshold for treatment is a CD4 count below 500/mm(3), although low- and middle-income countries have yet to update their national guidelines from the threshold CD4 count below 350/mm(3)). Patients have to return to the clinic to receive their test results and to initiate ART if they are eligible for treatment. Unfortunately, many patients are lost during this multistep process in resource-limited settings. Point-of-care CD4 tests at HIV diagnosistests that are done on the spot and provide results the same daymight help to improve linkage to care in such settings. Here, the researchers use a mathematical model to assess the clinical outcomes and cost-effectiveness of point-of-care CD4 testing at the time of HIV diagnosis compared to laboratory-based testing in Mozambique, where about 1.5 million HIV-positive individuals live. What Did the Researchers Do and Find? The researchers used a validated model of HIV testing, linkage, and treatment called the Cost-Effectiveness of Preventing AIDS Complications-International (CEPAC-I) model to compare the clinical impact, costs, and cost-effectiveness of point-of-care and laboratory CD4 testing in newly diagnosed HIV-infected patients in Mozambique. They used published data to estimate realistic values for various model input parameters, including the probability of linkage to care following the use of each test, the accuracy of the tests, and the cost of each test. At a CD4 threshold for treatment of 250/mm(3), the model predicted that 60.9% of newly diagnosed HIV-infected people would survive five years if their immunological status was assessed using the laboratory-based CD4 test, whereas 65% would survive five years if the point-of-care test was used. Predicted life expectancies were 9.6 and 10.3 years with the laboratory-based and point-of-care tests, respectively, and the per person lifetime costs (which mainly reflect treatment costs) associated with the two tests were US$2,440 and $US2,800, respectively. Finally, the incremental cost-effectiveness ratiocalculated as the incremental costs of one therapeutic intervention compared to another divided by the incremental benefitswas US$500 per year of life saved, when comparing use of the point-of-care test with a laboratory-based test. What Do These Findings Mean? These findings suggest that, compared to laboratory-based CD4 testing, point-of-care testing at HIV diagnosis could improve survival for HIV-infected individuals in Mozambique. Because the per capita gross domestic product in Mozambique is US$570, these findings also indicate that point-of-care testing would be very cost-effective compared to laboratory-based testing (an incremental cost-effectiveness ratio less than one times the per capita gross domestic product is regarded as very cost-effective). As with all modeling studies, the accuracy of these findings depends on the assumptions built into the model and on the accuracy of the input parameters. However, the point-of-care strategy averted deaths and was estimated to be cost-effective compared to the laboratory-based test over a wide range of input parameter values reflecting Mozambique and several other resource-limited settings that the researchers modeled. Importantly, these sensitivity analyses suggest that point-of-care CD4 testing is likely to have the greatest impact on HIV-related deaths and be economically efficient in settings in sub-Saharan Africa with the most limited health care resources, provided point-of-care CD4 testing improves the linkage to care for HIV-infected people. Additional Information Please access these websites via the online version of this summary at http://dx.doi.org/10.1371/journal.pmed.1001725. The World Health Organization provides information on all aspects of HIV/AIDS (in several languages); its Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infections: Recommendations for a Public Health Approach, which highlights the potential of point-of-care tests to improve the linkage of newly diagnosed HIV-infected patients to care, is available Information is available from the US National Institute of Allergy and Infectious Diseases on HIV infection and AIDS NAM/aidsmap provides basic information about HIV/AIDS, and summaries of recent research findings on HIV care and treatment; it has a fact sheet on CD4 testing Information is available from Avert, an international AIDS charity, on many aspects of HIV/AIDS, including information on starting, monitoring, and switching treatment and on HIV and AIDS in sub-Saharan Africa (in English and Spanish) The UNAIDS Report on the Global AIDS Epidemic 2013 provides up-to-date information about the AIDS epidemic and efforts to halt it Personal stories about living with HIV/AIDS are available through Avert, Nam/aidsmap, and Healthtalkonline C1 [Hyle, Emily P.; Su, Amanda E.; Losina, Elena; Bassett, Ingrid V.; Pei, Pamela P.; Freedberg, Kenneth A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Boston, MA 02114 USA. [Hyle, Emily P.; Bassett, Ingrid V.; Freedberg, Kenneth A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Hyle, Emily P.; Freedberg, Kenneth A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. [Jani, Ilesh V.] Inst Nacl Saude, Maputo, Mozambique. [Lehe, Jonathan; Quevedo, Jorge; Peter, Trevor] Clinton Hlth Access Initiat, Maputo, Mozambique. [Wood, Robin] Univ Cape Town, Fac Hlth Sci, Desmond Tutu HIV Ctr, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa. [Wood, Robin] Univ Cape Town, Fac Hlth Sci, Dept Med, ZA-7925 Cape Town, South Africa. [Losina, Elena; Bassett, Ingrid V.; Freedberg, Kenneth A.; Walensky, Rochelle P.] Harvard Univ, Sch Med, Ctr AIDS Res, Boston, MA USA. [Losina, Elena] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA. [Paltiel, A. David] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA. [Resch, Stephen] Harvard Univ, Sch Publ Hlth, Ctr Hlth Decis Sci, Boston, MA 02115 USA. [Freedberg, Kenneth A.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Walensky, Rochelle P.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA. RP Hyle, EP (reprint author), Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Boston, MA 02114 USA. EM ehyle@partners.org FU National Institute of Allergy and Infectious Disease [T32 AI 007433, R01 AI058736, R01 MH090326, R01 AI0932690]; Harvard University Center for AIDS Research (CFAR), an NIH [P30 AI060354]; NIH, NIAID; NIH, NCI; NIH, NICHD; NIH, NHLBI; NIH, NIDA; NIH, NIMH; NIH, NIA; NIH, FIC; NIH, OAR; UK Department for International Development (DFID); Clinton Health Access Initiative(CHAI) FX This research has been supported by National Institute of Allergy and Infectious Disease [T32 AI 007433; R01 AI058736; R01 MH090326; R01 AI0932690]. This publication was made possible with help from the Harvard University Center for AIDS Research (CFAR), an NIH funded program (P30 AI060354), which is supported by the following NIH Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, FIC, and OAR. Additional funding was available from UK Department for International Development (DFID). This work was partially funded by Clinton Health Access Initiative(CHAI). CHAI was involved with original collection of data as published in the Lancet (Jani et al. Lancet 2011; 378: 1572-9). Of the funders, only CHAI had a role in data analysis (as it related to input data from the original trial), decision to publish, and preparation of the manuscript. In advance of the analysis, CHAI agreed to full publication of any findings, regardless of the final outcome and conclusions. NR 73 TC 20 Z9 20 U1 1 U2 18 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1549-1676 J9 PLOS MED JI PLos Med. PD SEP PY 2014 VL 11 IS 9 AR e1001725 DI 10.1371/journal.pmed.1001725 PG 15 WC Medicine, General & Internal SC General & Internal Medicine GA AQ6FO UT WOS:000342905700026 PM 25225800 ER PT J AU Abdelhakim, AH Salgado, EN Fu, XF Pasham, M Nicastro, D Kirchhausen, T Harrison, SC AF Abdelhakim, Aliaa H. Salgado, Eric N. Fu, Xiaofeng Pasham, Mithun Nicastro, Daniela Kirchhausen, Tomas Harrison, Stephen C. TI Structural Correlates of Rotavirus Cell Entry SO PLOS PATHOGENS LA English DT Article ID ENTER MA104 CELLS; MEMBRANE PENETRATION; PROTEIN VP7; ENDOCYTOSIS; ATTACHMENT; TRYPSIN; SPIKE; GANGLIOSIDES; TOMOGRAPHY; COMPLEX AB Cell entry by non-enveloped viruses requires translocation into the cytosol of a macromolecular complex-for double-strand RNA viruses, a complete subviral particle. We have used live-cell fluorescence imaging to follow rotavirus entry and penetration into the cytosol of its similar to 700 angstrom inner capsid particle ("double-layered particle'', DLP). We label with distinct fluorescent tags the DLP and each of the two outer-layer proteins and track the fates of each species as the particles bind and enter BSC-1 cells. Virions attach to their glycolipid receptors in the host cell membrane and rapidly become inaccessible to externally added agents; most particles that release their DLP into the cytosol have done so by similar to 10 minutes, as detected by rapid diffusional motion of the DLP away from residual outer-layer proteins. Electron microscopy shows images of particles at various stages of engulfment into tightly fitting membrane invaginations, consistent with the interpretation that rotavirus particles drive their own uptake. Electron cryotomography of membrane-bound virions also shows closely wrapped membrane. Combined with high resolution structural information about the viral components, these observations suggest a molecular model for membrane disruption and DLP penetration. C1 [Abdelhakim, Aliaa H.; Salgado, Eric N.; Harrison, Stephen C.] Boston Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA. [Abdelhakim, Aliaa H.; Salgado, Eric N.; Pasham, Mithun; Kirchhausen, Tomas; Harrison, Stephen C.] Harvard Univ, Sch Med, Boston, MA USA. [Fu, Xiaofeng; Nicastro, Daniela] Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02254 USA. [Pasham, Mithun; Kirchhausen, Tomas] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA. [Harrison, Stephen C.] Howard Hughes Med Inst, Boston, MA 02115 USA. RP Harrison, SC (reprint author), Boston Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA. EM harrison@crystal.harvard.edu FU NIH [R37 CA13202, AI07245]; New England Regional Center of Excellence in Biodefense and Emerging Infectious Diseases [U54 AI057159] FX The work was supported by NIH Grant R37 CA13202 (to SCH) and by funds to TK from U54 AI057159 (New England Regional Center of Excellence in Biodefense and Emerging Infectious Diseases, D. Kasper, PI). ENS acknowledges support from NIH Training Grant AI07245. SCH is a Howard Hughes Medical Institute Investigator. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 49 TC 5 Z9 5 U1 0 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7366 EI 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD SEP PY 2014 VL 10 IS 9 AR e1004355 DI 10.1371/journal.ppat.1004355 PG 16 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA AQ7QP UT WOS:000343014600018 PM 25211455 ER PT J AU Brown, AO Mann, B Gao, GL Hankins, JS Humann, J Giardina, J Faverio, P Restrepo, MI Halade, GV Mortensen, EM Lindsey, ML Hanes, M Happel, KI Nelson, S Bagby, GJ Lorent, JA Cardinal, P Granados, R Esteban, A LeSaux, CJ Tuomanen, EI Orihuela, CJ AF Brown, Armand O. Mann, Beth Gao, Geli Hankins, Jane S. Humann, Jessica Giardina, Jonathan Faverio, Paola Restrepo, Marcos I. Halade, Ganesh V. Mortensen, Eric M. Lindsey, Merry L. Hanes, Martha Happel, Kyle I. Nelson, Steve Bagby, Gregory J. Lorent, Jose A. Cardinal, Pablo Granados, Rosario Esteban, Andres LeSaux, Claude J. Tuomanen, Elaine I. Orihuela, Carlos J. TI Streptococcus pneumoniae Translocates into the Myocardium and Forms Unique Microlesions That Disrupt Cardiac Function SO PLOS PATHOGENS LA English DT Article ID PLATELET-ACTIVATING-FACTOR; COMMUNITY-ACQUIRED PNEUMONIA; BACTERIAL-CELL WALL; VENTRICULAR-TACHYCARDIA; PNEUMOCOCCAL MENINGITIS; LAMININ RECEPTOR; GENOME SEQUENCE; RISK; RECOGNITION; ASSOCIATION AB Hospitalization of the elderly for invasive pneumococcal disease is frequently accompanied by the occurrence of an adverse cardiac event; these are primarily new or worsened heart failure and cardiac arrhythmia. Herein, we describe previously unrecognized microscopic lesions (microlesions) formed within the myocardium of mice, rhesus macaques, and humans during bacteremic Streptococcus pneumoniae infection. In mice, invasive pneumococcal disease (IPD) severity correlated with levels of serum troponin, a marker for cardiac damage, the development of aberrant cardiac electrophysiology, and the number and size of cardiac microlesions. Microlesions were prominent in the ventricles, vacuolar in appearance with extracellular pneumococci, and remarkable due to the absence of infiltrating immune cells. The pore-forming toxin pneumolysin was required for microlesion formation but Interleukin-1 beta was not detected at the microlesion site ruling out pneumolysin-mediated pyroptosis as a cause of cell death. Antibiotic treatment resulted in maturing of the lesions over one week with robust immune cell infiltration and collagen deposition suggestive of long-term cardiac scarring. Bacterial translocation into the heart tissue required the pneumococcal adhesin CbpA and the host ligands Laminin receptor (LR) and Platelet-activating factor receptor. Immunization of mice with a fusion construct of CbpA or the LR binding domain of CbpA with the pneumolysin toxoid L460D protected against microlesion formation. We conclude that microlesion formation may contribute to the acute and long-term adverse cardiac events seen in humans with IPD. C1 [Brown, Armand O.; Orihuela, Carlos J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. [Mann, Beth; Gao, Geli; Humann, Jessica; Giardina, Jonathan; Tuomanen, Elaine I.] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA. [Hankins, Jane S.] St Jude Childrens Res Hosp, Dept Hematol, Memphis, TN 38105 USA. [Faverio, Paola] Univ Milano Bicocca, Monza, Italy. [Faverio, Paola] San Gerardo Hosp, Dept Resp Med, Monza, Italy. [Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, Dept Med, San Antonio, TX USA. [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Halade, Ganesh V.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Mortensen, Eric M.] Univ Texas SW Med Ctr Dallas, Med Serv, Vet Affairs North Texas Hlth Care Syst, Dallas, TX 75390 USA. [Mortensen, Eric M.] Univ Texas SW Med Ctr Dallas, Dept Internal Med & Clin Sci, Dallas, TX 75390 USA. [Lindsey, Merry L.] Univ Mississippi, Med Ctr, Dept Physiol & Biophys, Jackson, MS 39216 USA. [Hanes, Martha] Univ Texas Hlth Sci Ctr San Antonio, Dept Lab Anim Resources, San Antonio, TX 78229 USA. [Happel, Kyle I.; Nelson, Steve; Bagby, Gregory J.] Louisiana State Univ, Dept Physiol, Hlth Sci Ctr, New Orleans, LA USA. [Happel, Kyle I.; Nelson, Steve; Bagby, Gregory J.] Louisiana State Univ, Sect Pulm Crit Care Med, Hlth Sci Ctr, New Orleans, LA USA. [Lorent, Jose A.; Cardinal, Pablo; Granados, Rosario; Esteban, Andres] Hosp Univ Getafe, CIBER Enfermedades Resp, Madrid, Spain. [LeSaux, Claude J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Cardiol, San Antonio, TX 78229 USA. RP Brown, AO (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. EM orihuela@uthscsa.edu OI Mortensen, Eric/0000-0002-3880-5563; Tuomanen, Elaine/0000-0003-0349-8716 FU American Heart Association [IRG14560023]; National Institute of Health (NIH) [HL108054]; NIH [AI27913, 268201000036C (N01-HV-00244), AT006704, AA009803, HL096054, RR00164]; American Lebanese Syrian Associated Charities; Biomedical Laboratory Research and Development Service of the Veterans Affairs Office of Research and Development [5I01BX000505]; [HL075360] FX This study was supported by grants from the American Heart Association IRG14560023 and National Institute of Health (NIH) HL108054 to CJO. Support was also obtained from NIH AI27913 and the American Lebanese Syrian Associated Charities to FIT, NIH 268201000036C (N01-HV-00244) for the San Antonio Cardiovascular Proteomics Center and HL075360 and the Biomedical Laboratory Research and Development Service of the Veterans Affairs Office of Research and Development Award 5I01BX000505 to MLL, NIH AT006704 to GVH, NIH AA009803 to SN, NIH HL096054 to MIR, and RR00164 for the Tulane National Primate Research Center. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 46 TC 22 Z9 22 U1 1 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7366 EI 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD SEP PY 2014 VL 10 IS 9 AR e1004383 DI 10.1371/journal.ppat.1004383 PG 14 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA AQ7QP UT WOS:000343014600040 PM 25232870 ER PT J AU Buchanan, A Sachs, A Toler, T Tsipis, J AF Buchanan, Amanda Sachs, Amy Toler, Tomi Tsipis, Judith TI NIPT: current utilization and implications for the future of prenatal genetic counseling SO PRENATAL DIAGNOSIS LA English DT Article ID DOWN-SYNDROME; DIAGNOSIS; IMPLEMENTATION; ATTITUDES AB BackgroundNon-invasive prenatal testing (NIPT) for select fetal trisomies became clinically available in 2011. When it was introduced, there were no recommendations from the major governing bodies in prenatal genetics regarding its incorporation. PurposeWe sought to determine how genetic counselors have incorporated NIPT into clinical practice and how NIPT has changed the informed consent process. MethodsWe distributed an anonymous, online survey to National Society of Genetic Counselors (NSGC) members in October 2012. ResultsThere were 181 respondents who indicated they incorporated NIPT into their practice with the majority (94.1%) offering it to patients with high risk pregnancies. Of the respondents, 45.1% indicated that there should be a separate informed consent form for NIPT. Respondents indicated that a discussion about NIPT with a patient should highlight that it is a screening test, the detection rate is superior to that of maternal serum screening, it screens for specific conditions, and a positive NIPT result should be confirmed with a diagnostic test. ConclusionFollowing data collection, the American Congress of Obstetricians and Gynecologists, the American College of Medical Genetics, and NSGC released practice guidelines surrounding NIPT. Our results demonstrate that most genetic counselors have been offering NIPT consistent with these guidelines. (c) 2014 John Wiley & Sons, Ltd. C1 [Buchanan, Amanda; Tsipis, Judith] Brandeis Univ, Genet Counseling Program, Waltham, MA 02453 USA. [Buchanan, Amanda; Sachs, Amy] Tufts Med Ctr, Div Maternal Fetal Med, Boston, MA USA. [Toler, Tomi] Massachusetts Gen Hosp, Div Med Genet, Boston, MA 02114 USA. RP Buchanan, A (reprint author), Brandeis Univ, Genet Counseling Program, Waltham, MA 02453 USA. EM abuchanan@tuftsmedicalcenter.org OI Toler, Tomi/0000-0002-1637-8310 FU Genetic Counseling Program at Brandeis University; Graduate School of Arts and Sciences at Brandeis University FX Funding sources: This study was funded by the Genetic Counseling Program at Brandeis University and the Graduate School of Arts and Sciences at Brandeis University. NR 29 TC 13 Z9 13 U1 1 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0197-3851 EI 1097-0223 J9 PRENATAL DIAG JI Prenat. Diagn. PD SEP PY 2014 VL 34 IS 9 BP 850 EP 857 DI 10.1002/pd.4382 PG 8 WC Genetics & Heredity; Obstetrics & Gynecology SC Genetics & Heredity; Obstetrics & Gynecology GA AQ3GK UT WOS:000342678800006 PM 24711206 ER PT J AU Wei, M Marino, J Trowell, A Zhang, HP Peraino, JS Rajasekera, PV Madsen, JC Sachs, DH Huang, CA Benichou, G Wang, ZR AF Wei, Min Marino, Jose Trowell, Aaron Zhang, Huiping Peraino, Jaclyn Stromp Rajasekera, Priyani V. Madsen, Joren C. Sachs, David H. Huang, Christene A. Benichou, Gilles Wang, Zhirui TI Diphtheria toxin-based recombinant murine IL-2 fusion toxin for depleting murine regulatory T cells in vivo SO PROTEIN ENGINEERING DESIGN & SELECTION LA English DT Article DE murine IL-2; fusion toxin; diphtheria toxin; Tregs; Pichia Pastoris expression ID PICHIA-PASTORIS; PORCINE CTLA-4; IMMUNOTOXIN; EXPRESSION; IMMUNITY; MICE AB Regulatory T cells (Tregs) are a subpopulation of CD4(+) T cells which suppress immune responses of effector cells and are known to play a very important role in protection against autoimmune disease development, induction of transplantation tolerance and suppression of effective immune response against tumor cells. An effective in vivo Treg depletion agent would facilitate Treg-associated studies across many research areas. In this study, we have developed diphtheria toxin-based monovalent and bivalent murine IL-2 fusion toxins for depleting murine IL-2 receptor positive cells including CD25(+) Treg in vivo. Their potencies were assessed by in vitro protein synthesis inhibition and cell proliferation inhibition assays using a murine CD25(+) CTLL-2 cell line. Surprisingly, in contrast to our previously developed recombinant fusion toxins, the monovalent isoform (DT390-mIL-2) was approximately 4-fold more potent than its bivalent counterpart (DT390-bi-mIL-2). Binding analysis by flow cytometry demonstrated that the monovalent isoform bound stronger than the bivalent version. In vivo Treg depletion with the monovalent murine IL-2 fusion toxin was performed using C57BL/6J (B6) mice. Spleen Treg were significantly depleted with a maximum reduction of similar to 70% and detectable as early as 12 h after the last injection. The spleen Treg numbers were reduced until Day 3 and returned to control levels by Day 7. We believe that this monovalent murine IL-2 fusion toxin will be an effective in vivo murine Treg depleter. C1 [Wei, Min; Zhang, Huiping; Peraino, Jaclyn Stromp; Rajasekera, Priyani V.; Madsen, Joren C.; Sachs, David H.; Huang, Christene A.; Wang, Zhirui] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA. [Wei, Min; Marino, Jose; Trowell, Aaron; Zhang, Huiping; Peraino, Jaclyn Stromp; Rajasekera, Priyani V.; Madsen, Joren C.; Sachs, David H.; Huang, Christene A.; Benichou, Gilles; Wang, Zhirui] Harvard Univ, Sch Med, Boston, MA USA. [Wei, Min; Zhang, Huiping; Peraino, Jaclyn Stromp; Rajasekera, Priyani V.; Sachs, David H.; Huang, Christene A.; Wang, Zhirui] MGH DF HCC Recombinant Prot Express & Purificat C, Boston, MA USA. [Marino, Jose; Trowell, Aaron; Madsen, Joren C.; Benichou, Gilles] Massachusetts Gen Hosp, Transplant Res Ctr, Boston, MA 02114 USA. [Madsen, Joren C.] Massachusetts Gen Hosp, Div Cardiac Surg, Boston, MA 02114 USA. RP Wang, ZR (reprint author), Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA. EM zhirui.wang@tbrc.mgh.harvard.edu NR 14 TC 1 Z9 2 U1 1 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1741-0126 EI 1741-0134 J9 PROTEIN ENG DES SEL JI Protein Eng. Des. Sel. PD SEP PY 2014 VL 27 IS 9 BP 289 EP 295 DI 10.1093/protein/gzu034 PG 7 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology GA AQ8AS UT WOS:000343043600003 PM 25147093 ER PT J AU Lynn, SK Barrett, LF AF Lynn, Spencer K. Barrett, Lisa Feldman TI "Utilizing" Signal Detection Theory SO PSYCHOLOGICAL SCIENCE LA English DT Article DE signal detection theory; utility; perception; decision making ID RESPONSE BIAS; PERCEPTUAL CATEGORIZATION; RECOGNITION MEMORY; DECISION-MAKING; BASE-RATE; DISCRIMINATION; ADDICTION; JUDGMENTS; MODELS AB What do inferring what a person is thinking or feeling, judging a defendant's guilt, and navigating a dimly lit room have in common? They involve perceptual uncertainty (e. g., a scowling face might indicate anger or concentration, for which different responses are appropriate) and behavioral risk (e. g., a cost to making the wrong response). Signal detection theory describes these types of decisions. In this tutorial, we show how incorporating the economic concept of utility allows signal detection theory to serve as a model of optimal decision making, going beyond its common use as an analytic method. This utility approach to signal detection theory clarifies otherwise enigmatic influences of perceptual uncertainty on measures of decision-making performance (accuracy and optimality) and on behavior (an inverse relationship between bias magnitude and sensitivity optimizes utility). A "utilized" signal detection theory offers the possibility of expanding the phenomena that can be understood within a decision-making framework. C1 [Lynn, Spencer K.; Barrett, Lisa Feldman] Northeastern Univ, Dept Psychol, Boston, MA 02115 USA. [Barrett, Lisa Feldman] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Barrett, Lisa Feldman] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [Barrett, Lisa Feldman] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Lynn, SK (reprint author), Northeastern Univ, 360 Huntington Ave, Boston, MA 02115 USA. EM s.lynn@neu.edu FU National Institutes of Health [R01MH093394, DP1OD003312]; U.S. Army Research Institute for the Behavioral and Social Sciences [W5J9CQ-12-C-0028, W91WAW-08-C-0018] FX Preparation of this manuscript was supported by the National Institutes of Health (Grant R01MH093394 to S. K. Lynn, Grant DP1OD003312 to L. F. Barrett) and the U.S. Army Research Institute for the Behavioral and Social Sciences (Contract W5J9CQ-12-C-0028 to S. K. Lynn, Contract W91WAW-08-C-0018 to L. F. Barrett). The views, opinions, and findings contained in this article are those of the authors and should not be construed as an official National Institutes of Health or Department of the Army position, policy, or decision, unless so designated by other documents. NR 38 TC 20 Z9 20 U1 6 U2 40 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0956-7976 EI 1467-9280 J9 PSYCHOL SCI JI Psychol. Sci. PD SEP PY 2014 VL 25 IS 9 BP 1663 EP 1673 DI 10.1177/0956797614541991 PG 11 WC Psychology, Multidisciplinary SC Psychology GA AQ6LK UT WOS:000342923600001 PM 25097061 ER PT J AU Meyersohn, NM Avery, LL AF Meyersohn, Nandini M. Avery, Laura L. TI Imaging of latrogenic Conditions of the Thorax SO RADIOLOGIC CLINICS OF NORTH AMERICA LA English DT Article DE latrogenic; Thoracic complications; Device lead fracture; Catheter placement; Medical procedures ID PULMONARY VEIN STENOSIS; ATRIAL-FIBRILLATION; CATHETER ABLATION; PREVENTION; ASPIRATION; PSEUDOANEURYSM; ACUPUNCTURE; RADIOGRAPHY; MANAGEMENT AB Common medical interventions performed by cardiologists, radiologists, surgeons, dentists, and alternative practitioners can result in complications within the thorax that lead to significant patient morbidity. Prompt radiologic identification of iatrogenic complications of medical procedures in the thorax is essential to guide patient triage and treatment. Understanding the approach to common thoracic interventions and the placement of thoracic medical devices can aid radiologists in the evaluation of iatrogenic complications. C1 [Meyersohn, Nandini M.] Massachusetts Gen Hosp, Dept Diagnost Radiol, Boston, MA 02114 USA. [Avery, Laura L.] Massachusetts Gen Hosp, Dept Diagnost Radiol, Div Emergency Radiol, Boston, MA 02114 USA. RP Avery, LL (reprint author), Massachusetts Gen Hosp, Dept Diagnost Radiol, Div Emergency Radiol, 55 Fruit St,FND 2-210, Boston, MA 02114 USA. EM Lavery@partners.org NR 21 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0033-8389 EI 1557-8275 J9 RADIOL CLIN N AM JI Radiol. Clin. N. Am. PD SEP PY 2014 VL 52 IS 5 BP 913 EP + DI 10.1016/j.rcl.2014.05.005 PG 17 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AQ5XS UT WOS:000342882500002 PM 25173652 ER PT J AU Lehnert, B Moshiri, M Osman, S Khandelwal, S Elojeimy, S Bhargava, P Katz, DS AF Lehnert, Bruce Moshiri, Mariam Osman, Sherif Khandelwal, Saurabh Elojeimy, Saeed Bhargava, Puneet Katz, Douglas S. TI Imaging of Complications of Common Bariatric Surgical Procedures SO RADIOLOGIC CLINICS OF NORTH AMERICA LA English DT Article DE Obesity; Bariatric surgery complications; Roux en Y; Sleeve gastrectomy; Gastric banding; Laparoscopy ID ROUX-EN-Y; GASTRIC BYPASS-SURGERY; LAPAROSCOPIC SLEEVE GASTRECTOMY; SMALL-BOWEL OBSTRUCTION; MORBID-OBESITY; INTERNAL HERNIA; WEIGHT-LOSS; LEAK COMPLICATIONS; ANASTOMOTIC LEAKS; NORMAL ANATOMY AB Several techniques for the surgical management of obesity are available to bariatric surgeons. These interventions are performed more frequently with worsening of the obesity epidemic. Radiologists should be familiar with the surgical techniques, normal postoperative appearances, and potential complications for which imaging may be employed to establish a diagnosis to optimize patient care. C1 [Lehnert, Bruce; Moshiri, Mariam; Osman, Sherif; Elojeimy, Saeed; Bhargava, Puneet] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA. [Khandelwal, Saurabh] Univ Washington, Sch Med, Dept Surg, Seattle, WA 98195 USA. [Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA 98108 USA. [Katz, Douglas S.] Winthrop Univ Hosp, Dept Radiol, Mineola, NY 11501 USA. RP Moshiri, M (reprint author), Univ Washington, Sch Med, Dept Radiol, Box 357115,1959 Northeast Pacific St, Seattle, WA 98195 USA. EM Moshiri@uw.edu OI Bhargava, Puneet/0000-0002-3849-9666 NR 81 TC 1 Z9 1 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0033-8389 EI 1557-8275 J9 RADIOL CLIN N AM JI Radiol. Clin. N. Am. PD SEP PY 2014 VL 52 IS 5 BP 1071 EP + DI 10.1016/j.rcl.2014.05.009 PG 17 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AQ5XS UT WOS:000342882500009 PM 25173659 ER PT J AU Moshiri, M Osman, S Bhargava, P Maximin, S Robinson, TJ Katz, DS AF Moshiri, Mariam Osman, Sherif Bhargava, Puneet Maximin, Suresh Robinson, Tracy J. Katz, Douglas S. TI Imaging Evaluation of Maternal Complications Associated with Repeat Cesarean Deliveries SO RADIOLOGIC CLINICS OF NORTH AMERICA LA English DT Article DE Cesarean delivery; Cesarean complications; Repeat cesarean; Uterine rupture; Scar pregnancy; Uterine dehiscence; Scar niche ID ABDOMINAL-WALL ENDOMETRIOSIS; UTERINE SCAR DEHISCENCE; OF-THE-LITERATURE; PLACENTA-ACCRETA; NEONATAL-OUTCOMES; ECTOPIC PREGNANCY; ARTERIOVENOUS-MALFORMATION; SONOGRAPHIC DETECTION; MANAGEMENT OPTIONS; NONPREGNANT WOMEN AB The rate of cesarean deliveries continues to rise, while the rate of vaginal delivery after cesarean birth continues to decline. Many women now tend to undergo multiple cesarean deliveries, and therefore the associated chronic maternal morbidities are of growing concern. Accurate diagnosis of these conditions is crucial in maternal and fetal well-being. Many of these complications are diagnosed by imaging, and radiologists should be aware of the type and imaging appearances of these conditions. C1 [Moshiri, Mariam; Osman, Sherif; Bhargava, Puneet; Maximin, Suresh] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA. [Bhargava, Puneet; Maximin, Suresh] VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA 98108 USA. [Robinson, Tracy J.] Seattle Radiologists PS, Seattle, WA 98104 USA. [Katz, Douglas S.] Winthrop Univ Hosp, Dept Radiol, Mineola, NY 11501 USA. RP Moshiri, M (reprint author), Univ Washington, Sch Med, Dept Radiol, Box 357115,1959 Northeast Pacific St, Seattle, WA 98195 USA. EM Moshiri@uw.edu OI Bhargava, Puneet/0000-0002-3849-9666 NR 77 TC 3 Z9 3 U1 1 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0033-8389 EI 1557-8275 J9 RADIOL CLIN N AM JI Radiol. Clin. N. Am. PD SEP PY 2014 VL 52 IS 5 BP 1117 EP + DI 10.1016/j.rcl.2014.05.010 PG 20 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AQ5XS UT WOS:000342882500012 PM 25173662 ER PT J AU Gross, BA Chiocca, EA AF Gross, Bradley A. Chiocca, E. Antonio TI Neoplasm Development After Stereotactic Radiosurgery for Arteriovenous Malformations SO WORLD NEUROSURGERY LA English DT Editorial Material DE Arteriovenous malformation; Complication; Gamma knife; Radiosurgery; Tumor ID TERM-FOLLOW-UP; GAMMA-KNIFE RADIOSURGERY; NATURAL-HISTORY; RISK; HEMORRHAGE; COMPLICATIONS; METAANALYSIS; IRRADIATION; MANAGEMENT; SURGERY C1 [Gross, Bradley A.; Chiocca, E. Antonio] Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA 02163 USA. [Gross, Bradley A.] Brigham & Womens Faulkner Hosp, Inst Neurosci, Boston, MA USA. [Chiocca, E. Antonio] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA. RP Chiocca, EA (reprint author), Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA 02163 USA. EM EAChiocca@partners.org NR 23 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1878-8750 EI 1878-8769 J9 WORLD NEUROSURG JI World Neurosurg. PD SEP-OCT PY 2014 VL 82 IS 3-4 BP 304 EP 306 DI 10.1016/j.wneu.2013.02.040 PG 3 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA AQ6HV UT WOS:000342912300059 PM 23416772 ER PT J AU Kim, MK Choi, HJ Kwon, I Pierson, RN Cooper, DKC Soulillou, JP O'Connell, PJ Vabres, B Maeda, N Hara, H Scobie, L Gianello, P Takeuchi, Y Yamada, K Hwang, ES Kim, SJ Park, CG AF Kim, Mee Kum Choi, Hyuk Jin Kwon, Ivo Pierson, Richard N., III Cooper, David K. C. Soulillou, Jean-Paul O'Connell, Philip J. Vabres, Bertrand Maeda, Naoyuki Hara, Hidetaka Scobie, Linda Gianello, Pierre Takeuchi, Yasuhiro Yamada, Kazuhiko Hwang, Eung-Soo Kim, Sang Joon Park, Chung-Gyu TI The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of xenocorneal transplantation SO XENOTRANSPLANTATION LA English DT Review DE consensus statement; cornea; ethics; international Guideline; regulation; xenocorneal transplantation; xenotransplantation ID PORCINE ISLET PRODUCTS; CORNEAL XENOTRANSPLANTATION; LUNG TRANSPLANTATION; IMMUNE PRIVILEGE; KNOCKOUT PIGS; ALPHA-GAL; IN-VITRO; TRANSMISSION; CELLS; XENOGRAFTS AB To develop an international consensus regarding the appropriate conditions for undertaking clinical trials in xenocorneal transplantation, here we review specific ethical, logistical, scientific, and regulatory issues regarding xenocorneal transplantation, and propose guidelines for conduct of clinical xenocorneal transplantation trials. These proposed guidelines are modeled on the published consensus statement of the International Xenotransplantation Association regarding recommended guidelines for conduct of clinical islet xenotransplantation. It is expected that this initial consensus statement will be revised over time in response to scientific advances in the field, and changes in the regulatory framework based on accumulating clinical experience. C1 [Kim, Mee Kum; Choi, Hyuk Jin] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul 110799, South Korea. [Kim, Mee Kum; Choi, Hyuk Jin] Seoul Natl Univ Hosp, Biomed Res Inst, Lab Ocular Regenerat Med & Immunol, Seoul Artificial Eye Ctr, Seoul 110744, South Korea. [Kim, Mee Kum; Choi, Hyuk Jin; Kwon, Ivo; Hwang, Eung-Soo; Park, Chung-Gyu] Seoul Natl Univ, Coll Med, Xenotransplantat Res Ctr, Seoul 110799, South Korea. [Kim, Mee Kum; Choi, Hyuk Jin; Kwon, Ivo; Hwang, Eung-Soo; Park, Chung-Gyu] Seoul Natl Univ Hosp, Clin Res Inst, Seoul 110744, South Korea. [Kwon, Ivo] Ewha Womans Univ, Sch Med, Dept Med Educ, Seoul, South Korea. [Pierson, Richard N., III] Univ Maryland, Med Ctr, Dept Surg, Baltimore, MD 21201 USA. [Cooper, David K. C.] Thomas E Starzl Transplantat Inst, Dept Surg, Pittsburgh, PA USA. [Soulillou, Jean-Paul] Univ Nantes, Fac Med, Nantes, France. [O'Connell, Philip J.] Westmead Hosp, Ctr Transplant & Renal Res, Westmead Millennium Inst, Westmead, NSW 2145, Australia. [Vabres, Bertrand] CHU Nantes, Serv Ophtalmol, F-44035 Nantes 01, France. [Maeda, Naoyuki] Osaka Univ, Sch Med, Dept Ophthalmol, Osaka, Japan. [Hara, Hidetaka] Univ Pittsburgh, Thomas E Starzl Transplantat Inst, Pittsburgh, PA USA. [Scobie, Linda] Glasgow Caledonian Univ, Dept Life Sci, Glasgow G4 0BA, Lanark, Scotland. [Gianello, Pierre] Catholic Univ Louvain, B-1200 Brussels, Belgium. [Takeuchi, Yasuhiro] UCL, MRC UCL Ctr Med Mol Virol, London, England. [Takeuchi, Yasuhiro] UCL, Wohl Virion Ctr, Div Infect & Immun, London, England. [Yamada, Kazuhiko] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA USA. [Hwang, Eung-Soo; Park, Chung-Gyu] Seoul Natl Univ, Coll Med, Dept Microbiol & Immunol, Seoul 110799, South Korea. [Kim, Sang Joon] Myong Ji Hosp, Organ Transplantat Ctr, Goyang City, South Korea. RP Park, CG (reprint author), Seoul Natl Univ, Canc Res Inst, Xenotransplantat Res Ctr, Dept Biomed Sci,Dept Microbiol & Immunol,Coll Med, 103 Daehak Ro, Seoul 110799, South Korea. EM chgpark@snu.ac.kr OI Park, Chung-Gyu/0000-0003-4083-8791; Hwang, Eung Soo/0000-0001-9562-4577 FU Korea Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea [HI13C0954] FX The authors wish to thank Keith Wonnacott at the US Food and Drug Administration for his perspective and opinions as an intramural subject matter expert to allow this document reflects our response to the invited advice. This study was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (Project No. HI13C0954). NR 54 TC 9 Z9 9 U1 3 U2 25 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0908-665X EI 1399-3089 J9 XENOTRANSPLANTATION JI Xenotransplantation PD SEP-OCT PY 2014 VL 21 IS 5 BP 420 EP 430 DI 10.1111/xen.12129 PG 11 WC Medicine, Research & Experimental; Transplantation SC Research & Experimental Medicine; Transplantation GA AQ5FP UT WOS:000342832400002 PM 25176471 ER PT J AU Yeh, H Machaidze, Z Wamala, I Fraser, JW Navarro-Alvarez, N Kim, K Schuetz, C Shi, S Zhu, A Hertl, M Elias, N Farkash, EA Vagefi, PA Varma, M Smith, RN Robson, SC Van Cott, EM Sachs, DH Markmann, JF AF Yeh, Heidi Machaidze, Zurab Wamala, Isaac Fraser, James W. Navarro-Alvarez, Nalu Kim, Karen Schuetz, Christian Shi, Shuai Zhu, Alexander Hertl, Martin Elias, Nahel Farkash, Evan A. Vagefi, Parsia A. Varma, Manish Smith, Rex Neal Robson, Simon C. Van Cott, Elizabeth M. Sachs, David H. Markmann, James F. TI Increased transfusion-free survival following auxiliary pig liver xenotransplantation SO XENOTRANSPLANTATION LA English DT Article DE coagulopathy; liver xenotransplantation; thrombocytopenia ID VON-WILLEBRAND-FACTOR; GENE-KNOCKOUT PIGS; HUMAN PLATELETS; IN-VITRO; ISCHEMIA/REPERFUSION INJURY; HEART-TRANSPLANTATION; ENDOTHELIAL-CELLS; FACTOR-VII; BABOONS; THYMOGLOBULIN AB BackgroundPig to baboon liver xenotransplantation typically results in severe thrombocytopenia and coagulation disturbances, culminating in death from hemorrhage within 9days, in spite of continuous transfusions. We studied the contribution of anticoagulant production and clotting pathway deficiencies to fatal bleeding in baboon recipients of porcine livers. MethodsBy transplanting liver xenografts from 1,3-galactosyltransferase gene-knockout (GalT-KO) miniature swine donors into baboons as auxiliary organs, leaving the native liver in place, we provided the full spectrum of primate clotting factors and allowed in vivo mixing of porcine and primate coagulation systems. ResultsRecipients of auxiliary liver xenografts develop severe thrombocytopenia, comparable to recipients of conventional orthotopic liver xenografts and consistent with hepatic xenograft sequestration. However, baboons with both pig and native livers do not exhibit clinical signs of bleeding and maintain stable blood counts without transfusion for up to 8 consecutive days post-transplantation. Instead, recipients of auxiliary liver xenografts undergo graft failure or die of sepsis, associated with thrombotic microangiopathy in the xenograft, but not the native liver. ConclusionOur data indicate that massive hemorrhage in the setting of liver xenotransplantation might be avoided by supplementation with primate clotting components. However, coagulation competent hepatic xenograft recipients may be predisposed to graft loss related to small vessel thrombosis and ischemic necrosis. C1 [Yeh, Heidi; Machaidze, Zurab; Wamala, Isaac; Fraser, James W.; Navarro-Alvarez, Nalu; Kim, Karen; Schuetz, Christian; Shi, Shuai; Zhu, Alexander; Hertl, Martin; Elias, Nahel; Farkash, Evan A.; Vagefi, Parsia A.; Varma, Manish; Smith, Rex Neal; Sachs, David H.; Markmann, James F.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Robson, Simon C.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA. [Van Cott, Elizabeth M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Yeh, H (reprint author), Massachusetts Gen Hosp, Dept Surg, 55 Fruit St,White 516, Boston, MA 02114 USA. EM hyeh@partners.org RI Schuetz, Christian/K-5234-2013 OI Schuetz, Christian/0000-0002-6828-4543 FU NIH from NIDDK [K08DKO 94965-02] FX HY is supported in part by NIH Grant K08DKO 94965-02 from the NIDDK. NR 35 TC 10 Z9 10 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0908-665X EI 1399-3089 J9 XENOTRANSPLANTATION JI Xenotransplantation PD SEP-OCT PY 2014 VL 21 IS 5 BP 454 EP 464 DI 10.1111/xen.12111 PG 11 WC Medicine, Research & Experimental; Transplantation SC Research & Experimental Medicine; Transplantation GA AQ5FP UT WOS:000342832400005 PM 25130043 ER PT J AU Lin, HK Yusin, JS AF Lin, H. K. Yusin, J. S. TI A protracted case of diarrhoea caused by Cryptosporidium in a non-immunocompromised patient SO ALLERGOLOGIA ET IMMUNOPATHOLOGIA LA English DT Letter ID UNITED-STATES; INFECTION; PATHOGENS; CHILDREN C1 [Lin, H. K.; Yusin, J. S.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Div Allergy & Immunol, Los Angeles, CA 90073 USA. RP Lin, HK (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Div Allergy & Immunol, 11301 Wilshire Blvd,111R, Los Angeles, CA 90073 USA. EM hlin2004@yahoo.com NR 8 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER DOYMA SL PI BARCELONA PA TRAVESERA DE GARCIA, 17-21, BARCELONA, 08021, SPAIN SN 0301-0546 EI 1578-1267 J9 ALLERGOL IMMUNOPATH JI Allergol. Immunopath. PD SEP-OCT PY 2014 VL 42 IS 5 BP 500 EP 501 DI 10.1016/j.aller.2013.02.015 PG 2 WC Allergy; Immunology SC Allergy; Immunology GA AQ1IY UT WOS:000342536300019 PM 23791507 ER PT J AU Lee, RJ Cohen, NA AF Lee, Robert J. Cohen, Noam A. TI Sinonasal solitary chemosensory cells "taste" the upper respiratory environment to regulate innate immunity SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY LA English DT Article ID ANTIMICROBIAL RESISTANCE PATTERNS; SUBMUCOSAL GLAND SECRETION; LIQUID INTERFACE CULTURES; ENDOSCOPIC SINUS SURGERY; CHRONIC RHINOSINUSITIS; SWEET TASTE; SUBSTANCE-P; FLUID SECRETION; CYSTIC-FIBROSIS; UMAMI TASTE AB Background: It is not fully understood how sinonasal epithelial cells detect the presence of pathogens and activate innate defense responses necessary for protecting the upper airway from infection. One mechanism is through bitter taste receptors (T2Rs), which are expressed in the sinonasal cavity. One T2R isoform, T2R38, is expressed in ciliated cells and detects quorum-sensing molecules from gram-negative bacteria, activating antimicrobial nitric oxide production. More recent studies have examined the role of T2Rs expressed in a sinonasal cell type that has only recently been identified in humans, the solitary chemosensory cell (SCC). We sought to provide an overview of SCCs and taste receptor function in human sinonasal defense as well as implications for chronic rhinosinusitis (CRS). Methods: A literature review of the current knowledge of SCCs and taste receptors in sinonasal physiology and CRS was conducted. Results: Human sinonasal SCCs express both bitter T2R and sweet T1R2/3 receptors. Activation of SCC T2Rs activates a calcium signal that propagates to the surrounding epithelial cells and causes secretion of antimicrobial peptides. T1R2/3 sweet receptor activation by physiological airway surface liquid (ASL) glucose concentrations attenuates the T2R response, likely as a mechanism to prevent full activation of the T2R pathway except during times of infection, when pathogens may consume ASL glucose and reduce its concentration. Conclusion: SCCs appear to be important mediators of upper airway innate immunity, as the SCC T2Rs regulate antimicrobial peptide secretion, but further study is needed to determine the specific T2R isoforms involved as well as whether polymorphisms in these isoforms affect susceptibility to infection or patient outcomes in CRS. The inhibitory role of T1R2/3 sweet receptor suggests that T1R2/3 blockers may have therapeutic potential in some CRS patients, particularly those with diabetes mellitus. However, further clinical study of the relationship between infection and T1R2/3 genotype is required. C1 [Lee, Robert J.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Philadelphia VA Med Ctr, Surg Serv, Philadelphia, PA USA. RP Cohen, NA (reprint author), Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Ravdin Bldg 5th Floor,3400 Spruce St, Philadelphia, PA 19104 USA. EM noam.cohen@uphs.upenn.edu OI Cohen, Noam/0000-0002-9462-3932; Lee, Robert/0000-0001-5826-6686 FU Flight Attendants Medical Research Institute [082478]; RLG Foundation, Inc. FX Funded by a grant (to NA Cohen) from the Flight Attendants Medical Research Institute (082478) and a philanthropic contribution from the RLG Foundation, Inc. The authors have no conflicts of interest to declare pertaining to this article NR 136 TC 12 Z9 13 U1 1 U2 10 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1945-8924 EI 1945-8932 J9 AM J RHINOL ALLERGY JI Am. J. Rhinol. Allergy PD SEP-OCT PY 2014 VL 28 IS 5 BP 366 EP 373 DI 10.2500/ajra.2014.28.4077 PG 8 WC Otorhinolaryngology SC Otorhinolaryngology GA AQ4FI UT WOS:000342748300008 PM 25198020 ER PT J AU Banglawala, SM Mulligan, JK Psaltis, AJ Wang, EW Nguyen, SA Mulligan, RM Crosby, BL Schlosser, RJ AF Banglawala, Sarfaraz M. Mulligan, Jennifer K. Psaltis, Alkis J. Wang, Eric W. Nguyen, Shaun A. Mulligan, Ryan M. Crosby, Brittany L. Schlosser, Rodney J. TI Impact of intraoperative hydrodebrider treatment on postoperative sinonasal inflammation SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY LA English DT Article ID CHRONIC RHINOSINUSITIS; SURFACTANT; SURGERY AB Background: The impact of intraoperative hydrodebrider sinus irrigation (HSI) during endoscopic sinus surgery (ESS) on postoperative inflammation, endoscopy, and patient-reported outcomes has not been studied. Methods: A clinical trial of 12 patients with symmetric chronic rhinosinusitis were prospectively randomized to HSI on one side after undergoing bilateral ESS. The contralateral side was not treated with any irrigation and served as an internal control. Preoperative computed tomography, endoscopic, 22-item Sino-Nasal Outcome Test (SNOT-22), and symptom visual analog scale (VAS) scores for each side were obtained. At 1 and 3 months postsurgery, endoscopy, SNOT-22, and sinus VAS were recorded. Sinonasal mucus levels of interleukin (IL)-6, IL-10, IL-17a, and tumor necrosis factor (TNF) alpha were measured at the time of surgery, 1 and 3 months, postoperatively, from each side. Results: VAS scores improved on both sides (p < 0.05) and SNOT-22 improved at all postoperative time points (p < 0.05). Endoscopic scores of HSI-treated sides did not improve compared with baseline. HSI had no additional significant impact on postoperative VAS at any time point. HSI significantly decreased IL-17a levels when compared with the control side at 1 month (p = 0.034) and 3 months (p = 0.031). No significant change was seen in TNF-alpha, IL-6, or IL-10 on either side at any time point. Conclusion: Intraoperative HSI at the time of ESS failed to establish any improvement in postoperative endoscopy or most local cytokine levels after ESS. C1 [Banglawala, Sarfaraz M.; Mulligan, Jennifer K.; Psaltis, Alkis J.; Wang, Eric W.; Nguyen, Shaun A.; Mulligan, Ryan M.; Crosby, Brittany L.; Schlosser, Rodney J.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Div Rhinol & Sinus Surg, Charleston, SC 29425 USA. [Mulligan, Jennifer K.; Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Dept Surg, Charleston, SC USA. RP Schlosser, RJ (reprint author), Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Div Rhinol & Sinus Surg, Charleston, SC 29425 USA. EM schlossr@musc.edu OI Wang, Eric/0000-0002-1180-5854 FU Medtronic FX Funded by a grant from Medtronic; SM Banglawala, JK Mullingan, AJ Psaltis, EW Wang, SA Nguyen, RM Mulligan, BL Crosby, and RJ Schlosser, received grant support form Medtronic NR 19 TC 1 Z9 1 U1 0 U2 0 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1945-8924 EI 1945-8932 J9 AM J RHINOL ALLERGY JI Am. J. Rhinol. Allergy PD SEP-OCT PY 2014 VL 28 IS 5 BP 438 EP 442 DI 10.2500/ajra.2014.28.4073 PG 5 WC Otorhinolaryngology SC Otorhinolaryngology GA AQ4FI UT WOS:000342748300021 PM 25198033 ER PT J AU Kasahara, T Jang, YJ Racicot, L Panagopoulos, D Liang, SH Ciufolini, MA AF Kasahara, Takahito Jang, Young Jin Racicot, Leanne Panagopoulos, Dimitrios Liang, Steven H. Ciufolini, Marco A. TI Iodonium Metathesis Reactions SO ANGEWANDTE CHEMIE-INTERNATIONAL EDITION LA English DT Article DE hypervalent iodine; iodonium salts; metathesis ID HYPERVALENT IODINE REAGENTS; DIARYLIODONIUM SALTS; ORGANIC-SYNTHESIS; OPTIMIZATION; CHEMISTRY AB A metathesis reaction occurs when a diaryliodonium triflate is heated with an aryl iodide, resulting in the formation of a new diaryliodonium triflate. C1 [Kasahara, Takahito; Jang, Young Jin; Racicot, Leanne; Panagopoulos, Dimitrios; Ciufolini, Marco A.] Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada. [Liang, Steven H.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02114 USA. [Liang, Steven H.] Massachusetts Gen Hosp, Div Nucl Med & Med Imaging, Boston, MA 02114 USA. RP Ciufolini, MA (reprint author), Univ British Columbia, Dept Chem, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada. EM ciufi@chem.ubc.ca FU University of British Columbia; Canada Research Chair Program; NSERC; CFI; BCKDF; UBC FYF Fellowship; Vanier Fellowship; Onassis Foundation Scholarship FX We thank the University of British Columbia, the Canada Research Chair Program, NSERC, CFI, and BCKDF for support. T. K. is a recipient of a UBC FYF Fellowship; L. R., of a Vanier Fellowship; D. P., of an Onassis Foundation Scholarship. NR 26 TC 10 Z9 10 U1 2 U2 16 PU WILEY-V C H VERLAG GMBH PI WEINHEIM PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY SN 1433-7851 EI 1521-3773 J9 ANGEW CHEM INT EDIT JI Angew. Chem.-Int. Edit. PD SEP 1 PY 2014 VL 53 IS 36 BP 9637 EP 9639 DI 10.1002/anie.201405594 PG 3 WC Chemistry, Multidisciplinary SC Chemistry GA AQ3FZ UT WOS:000342677000041 PM 25044208 ER PT J AU O'Malley, AJ Elwert, F Rosenquist, JN Zaslavsky, AM Christakis, NA AF O'Malley, A. James Elwert, Felix Rosenquist, J. Niels Zaslavsky, Alan M. Christakis, Nicholas A. TI Estimating Peer Effects in Longitudinal Dyadic Data Using Instrumental Variables SO BIOMETRICS LA English DT Article DE Body-mass index; Causality; Directed acyclic graphs; Dyad; Genes; Homophily; Instrumental variable; Longitudinal; Mendelian randomization; Peer effect; Social network; Two-stage least squares ID LARGE SOCIAL NETWORK; CAUSAL INFERENCE; IDENTIFICATION; BEHAVIOR; SPREAD; ASSOCIATION AB The identification of causal peer effects (also known as social contagion or induction) from observational data in social networks is challenged by two distinct sources of bias: latent homophily and unobserved confounding. In this paper, we investigate how causal peer effects of traits and behaviors can be identified using genes (or other structurally isomorphic variables) as instrumental variables (IV) in a large set of data generating models with homophily and confounding. We use directed acyclic graphs to represent these models and employ multiple IV strategies and report three main identification results. First, using a single fixed gene (or allele) as an IV will generally fail to identify peer effects if the gene affects past values of the treatment. Second, multiple fixed genes/alleles, or, more promisingly, time-varying gene expression, can identify peer effects if we instrument exclusion violations as well as the focal treatment. Third, we show that IV identification of peer effects remains possible even under multiple complications often regarded as lethal for IV identification of intra-individual effects, such as pleiotropy on observables and unobservables, homophily on past phenotype, past and ongoing homophily on genotype, inter-phenotype peer effects, population stratification, gene expression that is endogenous to past phenotype and past gene expression, and others. We apply our identification results to estimating peer effects of body mass index (BMI) among friends and spouses in the Framingham Heart Study. Results suggest a positive causal peer effect of BMI between friends. C1 [O'Malley, A. James] Geisel Sch Med Dartmouth, Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH 03766 USA. [Elwert, Felix] Univ Wisconsin, Dept Sociol, Ctr Demog & Ecol, Madison, WI 53706 USA. [Rosenquist, J. Niels] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Zaslavsky, Alan M.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [Christakis, Nicholas A.] Yale Univ, Yale Inst Network Sci, Dept Sociol, New Haven, CT 06520 USA. RP O'Malley, AJ (reprint author), Geisel Sch Med Dartmouth, Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH 03766 USA. EM james.omalley@dartmouth.edu FU NIH grants [R01 AG024448, P01 AG031093]; Pioneer Portfolio of the Robert Wood Johnson Foundation; National Heart, Lung, and Blood Institute (NHLBI); Boston University [N01-HC-25195]; NHLBI [N02-HL-64278]; NIH dbGap [780] FX Research for the paper was supported by NIH grants R01 AG024448 and P01 AG031093 and by a grant from the Pioneer Portfolio of the Robert Wood Johnson Foundation. The Framingham Heart Study is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with Boston University (Contract No. N01-HC-25195). This manuscript was not prepared in collaboration with investigators of the Framingham Heart Study and does not necessarily reflect the opinions or views of the Framingham Heart Study, Boston University, or NHLBI. Funding for SHARe Affymetrix genotyping was provided by NHLBI Contract N02-HL-64278. Data was downloaded from NIH dbGap, project #780, with accession phs000153.SocialNetwork.v6.p5.c2.NPU. NR 32 TC 6 Z9 7 U1 2 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0006-341X EI 1541-0420 J9 BIOMETRICS JI Biometrics PD SEP PY 2014 VL 70 IS 3 BP 506 EP 515 DI 10.1111/biom.12172 PG 10 WC Biology; Mathematical & Computational Biology; Statistics & Probability SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational Biology; Mathematics GA AQ3AI UT WOS:000342660700005 PM 24779654 ER PT J AU Baek, JH Eisner, LR Nierenberg, AA AF Baek, Ji Hyun Eisner, Lori R. Nierenberg, Andrew A. TI EPIDEMIOLOGY AND COURSE OF UNIPOLAR MANIA: RESULTS FROM THE NATIONAL EPIDEMIOLOGIC SURVEY ON ALCOHOL AND RELATED CONDITIONS (NESARC) SO DEPRESSION AND ANXIETY LA English DT Article DE bipolar disorder; epidemiology; unipolar mania ID MAJOR DEPRESSIVE DISORDER; BIPOLAR-I DISORDER; ANXIETY DISORDERS; PERSONALITY-DISORDERS; FOLLOW-UP; COOCCURRENCE; COMORBIDITY; SUBTYPE AB BackgroundUnipolar mania (UM), in which only manic episodes occur during the course of illness, may be an important clinical manifestation of bipolar disorder that is under-recognized and understudied. The aim of this study is, for the first time, to examine the prevalence of UM and its clinical characteristics in the community. MethodsAmong a total of 1,411 subjects with bipolar I disorder, we evaluated the prevalence of UM using three different criteria proposed in previous studies. We compared the clinical characteristics of subjects with UM to those with a more classic bipolar presentation with mania and lifetime major depressive episode (MDE). We additionally explored the proportion of subjects with UM who later experience at least one MDE during a 3-year follow-up period and determined risk factors for converting from UM to classic bipolar disorder. ResultsThe prevalence rate of UM among those with bipolar disorder ranged from 5.0 to 7.2% depending on the criteria. UM was more common in male and nonwhite subjects. About half of individuals with UM experienced subthreshold depression. Individuals with UM had lower rates of comorbid anxiety disorders or attention deficit hyperactivity disorder (ADHD). During the follow-up, about 18% of subjects with UM experienced MDEs. Male, nonwhite, comorbid generalized anxiety disorder and ADHD predicted an increased transition from UM to classic bipolar disorder. Subthreshold depression was not associated with the risk of the transition. ConclusionsUM is an infrequent but clinically distinct subtype of bipolar I disorder. Further research delineating the characteristics of UM is warranted. (C) 2014 Wiley Periodicals, Inc. C1 [Baek, Ji Hyun; Eisner, Lori R.; Nierenberg, Andrew A.] Massachusetts Gen Hosp, Bipolar Clin, Boston, MA 02114 USA. [Baek, Ji Hyun; Eisner, Lori R.; Nierenberg, Andrew A.] Massachusetts Gen Hosp, Res Program, Boston, MA 02114 USA. [Eisner, Lori R.; Nierenberg, Andrew A.] Harvard Univ, Dept Psychiat, Sch Med, Boston, MA 02114 USA. RP Nierenberg, AA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Bipolar Clin, 50 Staniford St,Suite 580, Boston, MA 02114 USA. EM anierenberg@partners.org NR 27 TC 2 Z9 2 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 EI 1520-6394 J9 DEPRESS ANXIETY JI Depress. Anxiety PD SEP PY 2014 VL 31 IS 9 BP 746 EP 755 DI 10.1002/da.22261 PG 10 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA AQ3DC UT WOS:000342668100005 PM 24677651 ER PT J AU Tsaih, SW Holl, K Jia, S Kaldunski, M Tschannen, M He, H Andrae, JW Li, SH Stoddard, A Wiederhold, A Parrington, J da Silva, MR Galione, A Meigs, J Hoffmann, RG Simpson, P Jacob, H Hessner, M Woods, LCS AF Tsaih, Shirng-Wern Holl, Katie Jia, Shuang Kaldunski, Mary Tschannen, Michael He, Hong Andrae, Jaime Wendt Li, Shun-Hua Stoddard, Alex Wiederhold, Andrew Parrington, John da Silva, Margarida Ruas Galione, Antony Meigs, James Hoffmann, Raymond G. Simpson, Pippa Jacob, Howard Hessner, Martin Woods, Leah C. Solberg CA Meta-Anal Glucose Insulin-Related TI Identification of a Novel Gene for Diabetic Traits in Rats, Mice, and Humans SO GENETICS LA English DT Article ID HETEROGENEOUS STOCK MICE; PANCREATIC BETA-CELLS; ADENINE-DINUCLEOTIDE PHOSPHATE; SCALE ASSOCIATION ANALYSIS; IDENTIFY CANDIDATE GENES; GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; GK RAT; GLUCOSE-HOMEOSTASIS; INSULIN SENSITIVITY AB The genetic basis of type 2 diabetes remains incompletely defined despite the use of multiple genetic strategies. Multiparental populations such as heterogeneous stocks (HS) facilitate gene discovery by allowing fine mapping to only a few megabases, significantly decreasing the number of potential candidate genes compared to traditional mapping strategies. In the present work, we employed expression and sequence analysis in HS rats (Rattus norvegicus) to identify Tpcn2 as a likely causal gene underlying a 3.1-Mb locus for glucose and insulin levels. Global gene expression analysis on liver identified Tpcn2 as the only gene in the region that is differentially expressed between HS rats with glucose intolerance and those with normal glucose regulation. Tpcn2 also maps as a cis-regulating expression QTL and is negatively correlated with fasting glucose levels. We used founder sequence to identify variants within this region and assessed association between 18 variants and diabetic traits by conducting a mixed-model analysis, accounting for the complex family structure of the HS. We found that two variants were significantly associated with fasting glucose levels, including a nonsynonymous coding variant within Tpcn2. Studies in Tpcn2 knockout mice demonstrated a significant decrease in fasting glucose levels and insulin response to a glucose challenge relative to those in wild-type mice. Finally, we identified variants within Tpcn2 that are associated with fasting insulin in humans. These studies indicate that Tpcn2 is a likely causal gene that may play a role in human diabetes and demonstrate the utility of multiparental populations for positionally cloning genes within complex loci. C1 [Tsaih, Shirng-Wern; Holl, Katie; Jia, Shuang; Kaldunski, Mary; Tschannen, Michael; He, Hong; Andrae, Jaime Wendt; Stoddard, Alex; Hoffmann, Raymond G.; Simpson, Pippa; Jacob, Howard; Hessner, Martin; Woods, Leah C. Solberg] Med Coll Wisconsin, Human & Mol Genet Ctr, Milwaukee, WI 53226 USA. [Holl, Katie; Jia, Shuang; Kaldunski, Mary; He, Hong; Li, Shun-Hua; Stoddard, Alex; Wiederhold, Andrew; Hoffmann, Raymond G.; Simpson, Pippa; Jacob, Howard; Hessner, Martin; Woods, Leah C. Solberg] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA. [Parrington, John; da Silva, Margarida Ruas; Galione, Antony] Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England. [Meigs, James] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Div Gen Med, Boston, MA 02114 USA. RP Woods, LCS (reprint author), Med Coll Wisconsin, TBRC, C2315,8701 Watertown Plank Rd, Milwaukee, WI 53226 USA. EM lsolberg@mcw.edu FU Advancing a Healthier Wisconsin Research; Children's Research Institute Pilot and Innovation award; Individualized Medicine Institute at the Medical College of Wisconsin; Medical Research Council (United Kingdom) [G0901521]; [R01 DK-088975]; [K24 DK080140] FX We thank Shawn Levy and Melanie Robinson from Vanderbilt University (currently at Hudson Alpha, Inc.) for running the 10K genotyping arrays. We thank Caitlin O'Meara and Josef Lazar for helpful discussions regarding follow-up studies of Tpcn2. This work was funded by grant R01 DK-088975 (to L. C. S. W.), a Basic Research Award from Advancing a Healthier Wisconsin Research (to L. C. S. W.), a Children's Research Institute Pilot and Innovation award (to L. C. S. W.), and funding from the Individualized Medicine Institute at the Medical College of Wisconsin (to L. C. S. W.). MAGIC lookup was funded by grant K24 DK080140 (to J.M.). Knockout mice were created using funding from the Medical Research Council (United Kingdom) programme grant G0901521 (to J.P.). NR 76 TC 14 Z9 14 U1 0 U2 16 PU GENETICS SOCIETY AMERICA PI BETHESDA PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA SN 0016-6731 EI 1943-2631 J9 GENETICS JI Genetics PD SEP PY 2014 VL 198 IS 1 BP 17 EP + DI 10.1534/genetics.114.162982 PG 21 WC Genetics & Heredity SC Genetics & Heredity GA AQ1VC UT WOS:000342570300003 PM 25236446 ER PT J AU Penson, RT Moore, KM Fleming, GF Braly, P Schimp, V Nguyen, H Matulonis, UA Banerjee, S Haluska, P Gore, M Bodurka, DC Hozak, RR Joshi, A Xu, YH Schwartz, JD McGuire, WP AF Penson, Richard T. Moore, Kathleen M. Fleming, Gini F. Braly, Patricia Schimp, Veronica Nguyen, Hoa Matulonis, Ursula A. Banerjee, Susana Haluska, Paul Gore, Martin Bodurka, Diane C. Hozak, Rebecca R. Joshi, Adarsh Xu, Yihuan Schwartz, Jonathan D. McGuire, William P. TI A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma SO GYNECOLOGIC ONCOLOGY LA English DT Article DE Angiogenesis; Antiangiogenic; VEGF; Clear cell; Resistant ID ENDOTHELIAL GROWTH-FACTOR; TUMOR ANGIOGENESIS; FACTOR RECEPTOR-2; CANCER; BEVACIZUMAB; RESISTANCE; INHIBITORS; AFFINITY; TRIAL AB Objective. Vascular endothelial growth factor (VEGF) receptor-mediated signaling contributes to ovarian cancer pathogenesis. Elevated VEGF expression is associated with poor clinical outcomes. We investigated ramucirumab, a fully human anti-VEGFR-2 antibody, in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Primary endpoints were progression-free survival at 6 months (PFS-6) and confirmed objective response rate (ORR). Methods. Women who received >= 1 platinum-based chemotherapeutic regimen and had a platinum-free interval of <12 months with measurable disease were eligible. Patients received 8 mg/kg ramucirumab intravenously every 2 weeks. Results. Sixty patients were treated; one patient remained on study as of September 2013. The median age was 62 years (range: 27-80), and median number of prior regimens was 3. Forty-five (75%) patients had platinum refractory/resistant disease. Thirty-nine patients (65.0%) had serous tumors. PFS-6 was 25.0% (n = 15/60, 95% CI: 14.7-37.9%). Best overall response was: partial response 5.0% (n = 3/60), stable disease 56.7% (n = 34/60), and progressive disease 33.3% (n = 20/60). The most common treatment-emergent adverse events possibly related to study drug were headache (65.0%; 10.0% Grade >= 3) fatigue (56.7%; 33% Grade >= 3) diarrhea (283%; 1.7% Grade >= 3), hypertension (25.0%; 3.3% Grade >= 3), and nausea (20.0%; no Grade >= 3). Two patients experienced intestinal perforations (3.3% Grade >= 3). Pharmacodynamic analyses revealed changes in several circulating VEGF proteins following initial ramucirumab infusion, including increased VEGF-A, PIGF and decreased sVEGFR-2. Conclusions. Although antitumor activity was observed, the predetermined efficacy endpoints were not met. (C) 2014 Elsevier Inc. All rights reserved. C1 [Penson, Richard T.] Massachusetts Gen Hosp, Dana Farber Harvard Canc Ctr, Boston, MA 02114 USA. [Moore, Kathleen M.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Fleming, Gini F.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA. [Braly, Patricia] Hematol & Oncol Specialists LLC, Marrero, LA USA. [Schimp, Veronica] MD Anderson Canc Ctr, Orlando, FL USA. [Nguyen, Hoa] Gynecol Oncol Associates Inc, Hollywood, FL USA. [Matulonis, Ursula A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Banerjee, Susana] Royal Marsden Hosp, Surrey, England. [Haluska, Paul] Mayo Clin, Rochester, MN USA. [Gore, Martin] Royal Marsden Hosp, London SW3 6JJ, England. [Bodurka, Diane C.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Hozak, Rebecca R.; Joshi, Adarsh] Eli Lilly & Co, Indianapolis, IN 46285 USA. [Xu, Yihuan; Schwartz, Jonathan D.] ImClone Syst, Bridgewater, NJ USA. [McGuire, William P.] Inova Fairfax Hosp, Falls Church, VA 22042 USA. RP McGuire, WP (reprint author), Inova Fairfax Hosp, Falls Church, VA 22042 USA. FU Eli Lilly and Company FX Research support: The study was sponsored by Eli Lilly and Company. NR 23 TC 7 Z9 8 U1 0 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0090-8258 EI 1095-6859 J9 GYNECOL ONCOL JI Gynecol. Oncol. PD SEP PY 2014 VL 134 IS 3 BP 478 EP 485 DI 10.1016/j.ygyno.2014.06.029 PG 8 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA AQ1OL UT WOS:000342550600010 PM 25016924 ER PT J AU Wik, E Trovik, J Kusonmano, K Birkeland, E Raeder, MB Pashtan, I Hoivik, EA Krakstad, C Werner, HMJ Holst, F Mjos, S Halle, MK Mannelqvist, M Mauland, KK Oyan, AM Stefansson, IM Petersen, K Simon, R Cherniack, AD Meyerson, M Kalland, KH Akslen, LA Salvesen, HB AF Wik, E. Trovik, J. Kusonmano, K. Birkeland, E. Raeder, M. B. Pashtan, I. Hoivik, E. A. Krakstad, C. Werner, H. M. J. Holst, F. Mjos, S. Halle, M. K. Mannelqvist, M. Mauland, K. K. Oyan, A. M. Stefansson, I. M. Petersen, K. Simon, R. Cherniack, A. D. Meyerson, M. Kalland, K. H. Akslen, L. A. Salvesen, H. B. TI Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations SO GYNECOLOGIC ONCOLOGY LA English DT Article DE Endometrial Carcinoma Recurrence Score; ECARS; PI3K; Epithelial-mesenchymal transition; Prognosis ID HUMAN BREAST-TUMORS; VASCULAR INVASION; MOLECULAR PORTRAITS; CELL-PROLIFERATION; CANCER; EXPRESSION; PROGNOSIS; SIGNATURE; THERAPY; PATHWAY AB Purpose. Our previously reported 29-gene expression signature identified an aggressive subgroup of endometrial cancer patients with PI3K activation. We here wanted to validate these findings by independent patient series. Patients and Methods. The 29-gene expression signature was assessed in fresh frozen tumor tissue from 280 primary endometrial carcinomas (three independent cohorts), 19 metastatic lesions and in 333 primary endometrial carcinomas using TCGA data, and expression was related to clinico-pathologic features and survival. The 29-gene signature was assessed by real-time quantitative PCR, DNA oligonucleotide microarrays, or RNA sequencing. PI3K alterations were assessed by immunohistochemistry, DNA microarrays, DNA sequencing, SNP arrays or fluorescence in situ hybridization. A panel of markers of epithelial-mesenchymal transition (EMT) was also correlated to the 29-gene signature score. Results. High 29-gene Endometrial Carcinoma Recurrence Score (ECARS) values consistently validated to identify patients with aggressive clinico-pathologic phenotype and reduced survival. Within the presumed favorable subgroups of low grade, endometrioid tumors confined to the uterus, high ECARS still predicted a poor prognosis. The score was higher in metastatic compared to primary lesions (P<0.001) and was significantly associated with potential measures of P13K activation, markers of EMT and vascular invasion as an indicator of metastatic spread (all P < 0.001). Conclusions. ECARS validates to identify aggressive endometrial carcinomas in multiple, independent patients cohorts. The higher signature score in metastatic compared to primary lesions, and the potential link to PI3K activation and EMT, support further studies of ECARS in relation to response to P13K and EMT inhibitors in clinical trials of metastatic endometrial carcinoma. (C) 2014 Elsevier Inc. All rights reserved. C1 [Wik, E.; Birkeland, E.; Mannelqvist, M.; Stefansson, I. M.; Akslen, L. A.] Univ Bergen, Ctr Canc Biomarkers CCBIO, Dept Clin Med, N-5021 Bergen, Norway. [Wik, E.; Birkeland, E.; Mannelqvist, M.; Stefansson, I. M.; Akslen, L. A.] Haukeland Hosp, Gade Inst, Dept Pathol, N-5021 Bergen, Norway. [Trovik, J.; Kusonmano, K.; Raeder, M. B.; Hoivik, E. A.; Krakstad, C.; Werner, H. M. J.; Holst, F.; Mjos, S.; Halle, M. K.; Mauland, K. K.; Salvesen, H. B.] Haukeland Hosp, Dept Obstet & Gynecol, N-5021 Bergen, Norway. [Trovik, J.; Raeder, M. B.; Hoivik, E. A.; Krakstad, C.; Werner, H. M. J.; Holst, F.; Mjos, S.; Halle, M. K.; Mauland, K. K.; Kalland, K. H.; Salvesen, H. B.] Univ Bergen, Ctr Canc Biomarkers CCBIO, Dept Clin Sci, N-5021 Bergen, Norway. [Kusonmano, K.; Petersen, K.] Univ Bergen, Computat Biol Unit, N-5021 Bergen, Norway. [Pashtan, I.] Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA USA. [Oyan, A. M.; Kalland, K. H.] Haukeland Hosp, Dept Microbiol, N-5021 Bergen, Norway. [Simon, R.] Univ Med Ctr Hamburg Eppendorf, Dept Pathol, Hamburg, Germany. [Cherniack, A. D.; Meyerson, M.] MIT & Harvard, Broad Inst, Cambridge, MA 02142 USA. [Meyerson, M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Meyerson, M.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. RP Wik, E (reprint author), Univ Bergen, Haukeland Univ Hosp, Ctr Canc Biomarkers CCBIO, Dept Clin Med, N-5021 Bergen, Norway. EM elisabeth.wik@med.uib.no RI Kalland, Karl-Henning/B-9445-2017; Akslen, Lars /C-1202-2017; salvesen, Helga/C-1187-2017; OI Kalland, Karl-Henning/0000-0003-4486-2334; Akslen, Lars /0000-0003-2710-9543; salvesen, Helga/0000-0002-4438-8831; Halle, Mari/0000-0002-2660-8271; Holst, Frederik/0000-0002-5928-2175; Krakstad, Camilla/0000-0002-0174-8139 FU Helse Vest; Research Council of Norway; Norwegian Cancer Society; University of Bergen; Harald Andersens Legal FX Helse Vest, Research Council of Norway, The Norwegian Cancer Society, University of Bergen, and Harald Andersens Legal supported this study. NR 38 TC 3 Z9 3 U1 0 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0090-8258 EI 1095-6859 J9 GYNECOL ONCOL JI Gynecol. Oncol. PD SEP PY 2014 VL 134 IS 3 BP 599 EP 606 DI 10.1016/j.ygyno.2014.06.026 PG 8 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA AQ1OL UT WOS:000342550600030 PM 24995579 ER PT J AU Robinson, EM Lee, SM Zollfrank, A Jurchak, M Frost, D Grace, P AF Robinson, Ellen M. Lee, Susan M. Zollfrank, Angelika Jurchak, Martha Frost, Debra Grace, Pamela TI Enhancing Moral Agency: Clinical Ethics Residency for Nurses SO HASTINGS CENTER REPORT LA English DT Article ID REFLECTIVE PRACTICE; DYING PATIENTS; DISTRESS; CARE; SENSITIVITY; SKILLS AB One antidote to moral distress is stronger moral agencythat is, an enhanced ability to act to bring about change. The Clinical Ethics Residency for Nurses, an educational program developed and run in two large northeastern academic medical centers with funding from the Health Resources and Services Administration, intended to strengthen nurses' moral agency. Drawing on Improving Competencies in Clinical Ethics Consultation: An Education Guide, by the American Society for Bioethics and Humanities, and on the goals of the nursing profession, CERN sought to change attitudes, increase knowledge, and develop skills to act on one's knowledge. One of the key insights the faculty members brought to the design of this program is that knowledge of clinical ethics is not enough to develop moral agency. In addition to lecture-style classes, CERN employed a variety of methods based in adult learning theory, such as active application of ethics knowledge to patient scenarios in classroom discussion, simulation, and the clinical practicum. Overwhelmingly, the feedback from the participants (sixty-seven over three years of the program) indicated that CERN achieved transformative learning. C1 [Robinson, Ellen M.; Zollfrank, Angelika] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Robinson, Ellen M.] Hosp Optimum Care Eth Comm, Toronto, ON, Canada. [Robinson, Ellen M.] Yvonne Munn Nursing Res Ctr, Boston, MA USA. [Lee, Susan M.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Jurchak, Martha] Brigham & Womens Hosp, Eth Serv, Boston, MA 02115 USA. [Jurchak, Martha] Harvard Univ, Med Sch, Cambridge, MA 02138 USA. [Frost, Debra] Massachusetts Gen Hosp, Patient Care Serv Off Qual & Safety, Boston, MA 02114 USA. [Grace, Pamela] Boston Coll, William F Connell Sch Nursing, Chestnut Hill, MA 02167 USA. RP Robinson, EM (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. FU Division of Nursing (DN); Bureau of Health Professions (BHPr); Health Resources and Services Administration (HRSA); Department of Health and Human Services (DHHS) [D11HP18974]; Nurse Education, Practice, Quality, and Retention FX This project is supported by funds from the Division of Nursing (DN), Bureau of Health Professions (BHPr), Health Resources and Services Administration (HRSA), Department of Health and Human Services (DHHS) under D11HP18974, Nurse Education, Practice, Quality, and Retention. The information or content and conclusions are those of the authors and should not be construed as the official position or policy of, nor should any official endorsement be inferred by, the DN, BHPr, HRSA, DHHS, or U.S. government. NR 27 TC 3 Z9 3 U1 3 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0093-0334 EI 1552-146X J9 HASTINGS CENT REP JI Hastings Cent. Rep. PD SEP-OCT PY 2014 VL 44 IS 5 BP 12 EP 20 DI 10.1002/hast.353 PG 9 WC Ethics; Health Care Sciences & Services; Medical Ethics; Social Sciences, Biomedical SC Social Sciences - Other Topics; Health Care Sciences & Services; Medical Ethics; Biomedical Social Sciences GA AQ3BW UT WOS:000342664700009 PM 25231657 ER PT J AU Osguthorpe, JD AF Osguthorpe, John David TI In vitro allergy testing SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE allergy; hypersensitivity; immediate; in vitro; immunologic tests; skin tests; nasal provocation tests ID TEST RESPONSES; RHINITIS; UPDATE; PEANUT AB BackgroundHistory and physical examination are the first, and most important steps, in the evaluation of a patient suspected of having an allergy. The diagnosis can be confirmed with either skin or serum testing for evidence of immunoglobulin E (IgE)-mediated reactivity. MethodsThe recent literature on serum-based testing for the detection and quantitation of allergen specific IgE (sIgE) was reviewed, identifying where available the best practices from high level of evidence studies and/or physician organization guidelines. ResultsCurrent practices for documenting sIgE are detailed, including enzyme-linked immunoassays on conventional extracts (standardized or not), similar on microarrays of highly purified or recombinant allergens, and basophil activation testing. ConclusionSerum testing is an equal alternative to skin testing for establishing the presence of IgE-mediated sensitivity and for identifying the allergens involved. Like skin testing, limitations include the availability of fully detailed allergenic extracts, particularly for foods, drugs, and occupational agents, and the possibility of non-IgE mediated issues. (C) 2014 ARS-AAOA, LLC. C1 [Osguthorpe, John David] Vet Adm Hosp, Dept Surg, Charleston, SC USA. RP Osguthorpe, JD (reprint author), Ralph Johnson VA Med Ctr, Surg Serv 112, 109 Bee St, Charleston, SC 29401 USA. EM josguth@gmail.com NR 25 TC 2 Z9 2 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD SEP PY 2014 VL 4 SU 2 SI SI BP S46 EP S50 DI 10.1002/alr.21384 PG 5 WC Otorhinolaryngology SC Otorhinolaryngology GA AQ3GJ UT WOS:000342678700008 PM 25182355 ER PT J AU Cooley, CL Jagannathan, JP Kurra, V Tirumani, SH Saboo, SS Ramaiya, NH Shinagare, AB AF Cooley, Christine L. Jagannathan, Jyothi P. Kurra, Vikram Tirumani, Sree Harsha Saboo, Sachin S. Ramaiya, Nikhil H. Shinagare, Atul B. TI Imaging Features and Metastatic Pattern of Non-IVC Retroperitoneal Leiomyosarcomas: Are They Different From IVC Leiomyosarcomas? SO JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY LA English DT Article DE leiomyosarcoma; retroperitoneal; inferior vena cava; imaging features; metastatic pattern ID INFERIOR VENA-CAVA; SOFT-TISSUE SARCOMA; OUTCOMES; SERIES AB Purpose: The purposes of this study were to describe the imaging features and metastatic pattern of non-inferior vena cava (IVC) retroperitoneal leiomyosarcomas (non-IVC LMS) and to compare them with those of IVC leiomyosarcomas (IVC LMS) to assess any differences between the 2 groups. Materials and Methods: In this institutional review board-approved, Health Insurance Portability and Accountability Act-compliant retrospective study, all 56 patients with pathologically confirmed primary retroperitoneal leiomyosarcoma (34 non-IVC LMS and 22 IVC LMS) seen at our tertiary cancer center during a 10-year period were included. All available imaging of primary tumor (18 non-IVC LMS and 19 IVC LMS) and follow-up imaging studies (on all 56 patients) were reviewed in consensus by 2 fellowship-trained oncoradiologists. Imaging features and metastatic spread of non-IVC LMS were described and compared with those of IVC LMS. Continuous variables were compared using the Student t test, binary variables with the Fisher exact test, and survival using the log-rank test. Results: Non-inferior vena cava retroperitoneal leiomyosarcomas had a mean size of 11.3 cm (range, 3.7-27 cm) and most commonly occurred in the perirenal space (16/18). Primary tumors were hyperattenuating to muscle (11/18) and showed heterogeneous enhancement (17/18). Lungs (22/34), peritoneum (18/34), and liver (18/34) were the most common metastatic sites. There was no significant difference between the imaging features and metastatic pattern of non-IVC and IVC LMS. Although non-IVC LMS presented at a more advanced stage (P < 0.002), there was statistically non-significant trend toward better median survival of non-IVC LMS (P = 0.07). Conclusions: Non-inferior vena cava retroperitoneal leiomyosarcomas are large heterogeneous tumors arising in the perirenal space and frequently metastasize to lungs, peritoneum, and liver. From a radiologist's perspective, non-IVC LMS behave similar to IVC-LMS. C1 [Cooley, Christine L.; Jagannathan, Jyothi P.; Kurra, Vikram; Tirumani, Sree Harsha; Ramaiya, Nikhil H.] Dana Farber Canc Inst, Dept Imaging, Boston, MA 02215 USA. [Cooley, Christine L.; Jagannathan, Jyothi P.; Tirumani, Sree Harsha; Saboo, Sachin S.; Ramaiya, Nikhil H.; Shinagare, Atul B.] Harvard Univ, Brigham & Womens Hosp, Dept Radiol, Sch Med, Boston, MA 02115 USA. RP Shinagare, AB (reprint author), Dana Farber Canc Inst, Dept Imaging, 450 Brookline Ave, Boston, MA 02215 USA. EM ashinagare@partners.org NR 15 TC 3 Z9 3 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0363-8715 EI 1532-3145 J9 J COMPUT ASSIST TOMO JI J. Comput. Assist. Tomogr. PD SEP-OCT PY 2014 VL 38 IS 5 BP 687 EP 692 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AQ3DM UT WOS:000342669300010 PM 24834891 ER PT J AU Khawaja, RDA Singh, S Lira, D Bippus, R Do, S Padole, A Pourjabbar, S Koehler, T Shepard, JA Kalra, MK AF Khawaja, Ranish Deedar Ali Singh, Sarabjeet Lira, Diego Bippus, Rolf Do, Synho Padole, Atul Pourjabbar, Sarvenaz Koehler, Thomas Shepard, Jo-Anne Kalra, Mannudeep K. TI Role of Compressive Sensing Technique in Dose Reduction for Chest Computed Tomography: A Prospective Blinded Clinical Study SO JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY LA English DT Article DE chest CT; iterative reconstruction technique; sparse-sampling technique; radiation dose reduction ID ITERATIVE RECONSTRUCTION TECHNIQUE; IMAGE-RECONSTRUCTION; RADIATION-EXPOSURE; CT AB Purpose: The purpose of this study was to assess pulmonary lesion detection, diagnostic confidence, and noise reduction in sparse-sampled (SpS) computed tomographic (CT) data of submillisievert (SubmSv) chest CT reconstructed with iterative reconstruction technique (IRT). Materials and Methods: This Human Insurance Portability and Accountability-compliant, institutional review board-approved prospective study was performed using SpS-SubmSv IRT chest CT in 10 non-obese patients (body-mass index, 21-35 kg/m(2); age range, 26-90 years). Written informed consent was obtained. The patients were scanned at standard-dose CT (mean [SD] volumetric CT dose index, 6 [0.9] mGy; mean [SD] dose-length product, 208 +/- 44 mGy . cm; and mean [SD] effective dose, 3 [0.6] mSv) and at SubmSv dose (1.8 [0.2] mGy, 67 [2] mGy . cm, 0.9 [0.03] mSv, respectively) on a Philips 128-slice CT scanner with double z-sampling. Sparse angular sampling data were reconstructed using 25% of the angular projections from the SubmSv sinogram to reduce the number of views and radiation dose by approximately 4-fold. Hence, the patients were scanned and then, simulation-based sparse sampling was performed with a resultant dose hypothetical SpS scan estimated mathematically (0.2 mSv). From each patient data, 3 digital imaging and communications in medicine series were generated: SpS-SubmSv with IRT, fully sampled SubmSv filtered back projection (FBP), and fully sampled standard-dose FBP (SD-FBP). Two radiologists independently assessed these image series for detection of lung lesions, visibility of small structures, and diagnostic acceptability. Objective noise was measured in the thoracic aorta, and noise spectral density was obtained for SpS-SubmSv IRT, SubmSv-FBP, and SD-FBP. Results: The SpS-SubmSv IRT resulted in 75% (0.2/0.9 mSv) and 92% (0.2/2.9 mSv) dose reduction, when compared with the fully sampled SubmSv-FBP and SD-FBP, respectively. Images of SpS-SubmSv displayed all 46 lesions (most < 1 cm, 30 lung nodules, 7 ground glass opacities, 9 emphysema) seen on the SubmSv-FBP and SD-FBP data sets. Lesion margins with sparse-sampled data were deemed acceptable compared with both SubmSv-FBP and SD-FBP. Overall diagnostic confidence was maintained with SpS-SubmSv IRT despite the presence of minor pixilation artifacts in 3 of 10 cases. The SpS-SubmSv IRT showed 63% and 38% noise reduction when compared with SubmSv-FBP (P < 0.0001) and SD-FBP (P < 0.01), respectively, with no significant change in Hounsfield unit values (P > 0.05). Noise-spectral density showed that SpS-SubmSv IRT gives a linear decrease over frequency in the semilog plot and an exponential decrease of noise power over frequency compared with SubmSv-FBP and SD-FBP. Conclusions: More than 90% dose reduction could be achieved with one-fourth sparse-sampled and SubmSv chest CT examination when reconstructed with IRT. Chest CT dose at one fourth of a millisievert with SpS is possible with optimal lesion detection and diagnostic confidence for the evaluation of pulmonary findings. C1 [Khawaja, Ranish Deedar Ali; Singh, Sarabjeet; Lira, Diego; Do, Synho; Padole, Atul; Pourjabbar, Sarvenaz; Shepard, Jo-Anne; Kalra, Mannudeep K.] Massachusetts Gen Hosp, Div Thorac Radiol, MGH Imaging, Boston, MA 02114 USA. [Khawaja, Ranish Deedar Ali; Singh, Sarabjeet; Lira, Diego; Do, Synho; Padole, Atul; Pourjabbar, Sarvenaz; Shepard, Jo-Anne; Kalra, Mannudeep K.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Bippus, Rolf; Koehler, Thomas] Philips Technol GmbH, Innovat Technol, Hamburg, Germany. RP Khawaja, RDA (reprint author), Massachusetts Gen Hosp, Div Thorac Radiol, MGH Imaging, 25 New Chardon St,4th Floor, Boston, MA 02114 USA. EM rkhawaja@mgh.harvard.edu FU Radiological Society of North America; GE Healthcare; Philips Healthcare; Society of Thoracic Radiology FX Financial Disclosures: Dr Singh has received research funding from Radiological Society of North America, GE Healthcare, Philips Healthcare, and Society of Thoracic Radiology. Dr Do received funding from Philips Healthcare. Drs Koehler and Bippus are employees of Philips Technologie GmbH. None of the other coauthors have any other pertinent financial disclosure in relation to this study. NR 27 TC 0 Z9 0 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0363-8715 EI 1532-3145 J9 J COMPUT ASSIST TOMO JI J. Comput. Assist. Tomogr. PD SEP-OCT PY 2014 VL 38 IS 5 BP 760 EP 767 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AQ3DM UT WOS:000342669300021 PM 24834892 ER PT J AU Santiago, J Mansbach, JM Chou, SC Delgado, C Piedra, PA Sullivan, AF Espinola, JA Camargo, CA AF Santiago, Jonathan Mansbach, Jonathan M. Chou, Shih-Chuan Delgado, Carlos Piedra, Pedro A. Sullivan, Ashley F. Espinola, Janice A. Camargo, Carlos A., Jr. TI Racial/Ethnic Differences in the Presentation and Management of Severe Bronchiolitis SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID RESPIRATORY SYNCYTIAL VIRUS; INTENSIVE-CARE-UNIT; EMERGENCY-DEPARTMENT; PROSPECTIVE-MULTICENTER; CLINICAL PATHWAY; AFRICAN-AMERICAN; CHILDREN; ASTHMA; INFANTS; STATES AB BACKGROUND AND OBJECTIVEBronchiolitis is the leading cause of hospitalization for US infants and is associated with increased risk of childhood asthma. Although studies have shown differences in the presentation and management of asthma across race/ethnicity, it is unclear if such differences are present for bronchiolitis. We examined if racial/ethnic differences exist in the presentation and management of severe bronchiolitis. METHODSWe performed a 16-center, prospective cohort study from 2007 to 2010. Children <2 years old hospitalized with a diagnosis of bronchiolitis were included. A structured interview, chart review, and 1-week phone follow-up were completed. Multivariable logistic regression was used to examine the independent association between race/ethnicity and diagnostic imaging, treatment (eg, albuterol, corticosteroids, and continuous positive airway pressure/intubation), management (eg, intensive care unit admission and length of stay), discharge on inhaled corticosteroids, and bronchiolitis relapse. RESULTSAmong 2130 patients, 818 (38%) were non-Hispanic white (NHW), 511 (24%) were non-Hispanic black (NHB), and 801 (38%) were Hispanic. Compared with all groups, NHB children were most likely to receive albuterol before admission (odds ratio [OR]: 1.58; 95% confidence interval [CI]: 1.20-2.07) and least likely to receive chest x-rays during hospitalization (OR: 0.66; 95% CI: 0.49-0.90). Hispanic children were most likely to be discharged on inhaled corticosteroids (OR: 1.92; 95% CI: 1.19-3.10). CONCLUSIONWe observed differences between NHW and minority children regarding preadmission albuterol use, inpatient diagnostic imaging, and prescription of inhaled corticosteroids at discharge, practices that deviate from the American Academy of Pediatrics guidelines. The causes of these differences require further study, but they support implementation of care pathways for severe bronchiolitis. Journal of Hospital Medicine 2014;9:565-572. (c) 2014 Society of Hospital Medicine C1 [Santiago, Jonathan] Yale Univ, Sch Med, New Haven, CT USA. [Mansbach, Jonathan M.] Boston Childrens Hosp, Dept Med, Boston, MA USA. [Chou, Shih-Chuan] Yale New Haven Med Ctr, Dept Emergency Med, New Haven, CT 06504 USA. [Delgado, Carlos] Childrens Healthcare Atlanta Egleston, Dept Pediat Emergency Med, Atlanta, GA USA. [Piedra, Pedro A.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. [Sullivan, Ashley F.; Espinola, Janice A.; Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. RP Camargo, CA (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, 326 Cambridge St,Suite 410, Boston, MA 02114 USA. EM ccamargo@partners.org FU National Institutes of Health (Bethesda, MD) [U01 AI-67693] FX This study was supported by the grant U01 AI-67693 (Camargo) from the National Institutes of Health (Bethesda, MD). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health. The authors have no financial relationships relevant to this article or conflicts of interest to disclose. Mr. Santiago conceptualized the analysis, interpreted the data, drafted the initial manuscript, and approved the final manuscript as submitted. Dr. Mansbach conceptualized and designed the initial study, coordinated data collection at 1 of the sites, critically reviewed the manuscript, and approved the final manuscript as submitted. Dr. Chou was responsible for analysis and interpretation of data, critically reviewed the manuscript, and approved the final manuscript as submitted. Dr. Delgado coordinated data collection at 1 of the sites, critically reviewed the manuscript, and approved the final manuscript as submitted. Dr. Piedra conceptualized and designed the initial study, coordinated virology testing, critically reviewed the manuscript, and approved the final manuscript as submitted. Ms. Sullivan coordinated data collection at all sites, critically reviewed the manuscript, and approved the final manuscript as submitted. Ms. Espinola was responsible for data management, analysis and interpretation of data, drafting of the initial manuscript, and approved the final manuscript as submitted. Dr. Camargo conceptualized and designed the initial study, assisted with data analysis and interpretation of data, critically reviewed the manuscript, and approved the final manuscript as submitted. NR 35 TC 1 Z9 1 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD SEP PY 2014 VL 9 IS 9 BP 565 EP 572 DI 10.1002/jhm.2223 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA AQ3GN UT WOS:000342679100003 PM 24913444 ER PT J AU Sayer, NA Noorbaloochi, S Frazier, P Pennebaker, JW Orazem, RJ Schnurr, PP Murdoch, M Carlson, KF Gravely, A Litz, B AF Sayer, Nina A. Noorbaloochi, Siamak Frazier, Patricia Pennebaker, James W. Orazem, Robert J. Schnurr, Paula P. Murdoch, Maureen Carlson, Kathleen F. Gravely, Amy Litz, Brett TI Randomized Controlled Trial of Online Expressive Writing for Veteran Reintegration Difficulty SO JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS LA English DT Meeting Abstract C1 [Sayer, Nina A.; Noorbaloochi, Siamak; Orazem, Robert J.; Murdoch, Maureen; Gravely, Amy] Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Frazier, Patricia] Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA. [Schnurr, Paula P.] White River Junct VA Med Ctr, Natl Ctr PTSD, White River Jct, VT 05009 USA. [Carlson, Kathleen F.] Portland VA Med Ctr, Ctr Improve Vet Involvement Care, Portland, OR 97239 USA. [Litz, Brett] VA Boston Healthcare Syst, Boston, MA USA. RI Sayer, Nina/E-3249-2016 NR 0 TC 0 Z9 0 U1 1 U2 8 PU INT CTR MENTAL HEALTH POLICY & ECONOMICS-ICMPE PI MILANO PA VIA DANIELE CRESPI 7, MILANO, 20123, ITALY SN 1091-4358 J9 J MENT HEALTH POLICY JI J. Ment. Health Policy Econ. PD SEP PY 2014 VL 17 SU 1 BP S19 EP S20 PG 2 WC Health Policy & Services; Psychiatry SC Health Care Sciences & Services; Psychiatry GA AQ3ZF UT WOS:000342731300040 ER PT J AU Heneghan, AF Pierre, JF Tandee, K Shanmuganayagam, D Wang, XY Reed, JD Steele, JL Kudsk, KA AF Heneghan, Aaron F. Pierre, Joseph F. Tandee, Kanokwan Shanmuganayagam, Dhanansayan Wang, Xinying Reed, Jess D. Steele, James L. Kudsk, Kenneth A. TI Parenteral Nutrition Decreases Paneth Cell Function and Intestinal Bactericidal Activity While Increasing Susceptibility to Bacterial Enteroinvasion SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION LA English DT Article DE parenteral nutrition; Paneth cells; small intestine; innate immunity; cryptdins; microbiome ID UPPER RESPIRATORY-TRACT; MAJOR ABDOMINAL-TRAUMA; PHOSPHOLIPASE A(2); MUCOSAL IMMUNITY; LYMPHOID-TISSUE; ANTIMICROBIAL PEPTIDES; SEPTIC MORBIDITY; INNATE IMMUNITY; MESSENGER-RNA; DEFENSINS AB Introduction: Parenteral nutrition (PN) increases the risk of infection in patients with contraindication to enteral feeding. Paneth cells produce and secrete antimicrobial products that protect the mucosa from pathogens. Their loss is associated with increased host-pathogen interactions, mucosal inflammation, and altered microbiome composition. Hypothesis: We hypothesized that PN reduces Paneth cell product expression, and these changes would reduce bactericidal properties of tissue secretions following cholinergic stimulation, increase mucosal enteroinvasion, and shift the intestinal microbiome. Method: Experiment 1: Male ICR mice were randomized to Chow (n = 8) or PN (n = 8). Ileum tissue was collected for Paneth cell antimicrobial expression using RT-PCR, stimulated with a cholinergic agonist degranulate Paneth cells bactericidal activity, or used to assess bacterial enteroinvasion in EVISC. Experiment 2: Mice were randomized to Chow (n = 11) or PN (n = 8) and ileum washing was collected for 16s pyrosequencing analysis. Results: Compared to Chow, PN decreased tissue expression of REGIII-g (p < 0.002), lysozyme (p < 0.002), and cryptdin-4 (p < 0.03). At the phylum level, PN decreased total Firmicutes but increased total Bacteroidetes, and Proteobacteria. Functionally, secretions from PN tissue was less bactericidal (p < 0.03) and demonstrated increased susceptibility to enteroinvasion by E coli (p < 0.02). Conclusion: PN without enteral nutrition impairs innate mucosal immune function. Tissue expression of Paneth cell antimicrobial proteins decreases associated with compositional shifts to the microbiome, decreased bactericidal activity of mucosal secretions and greater susceptibility of to enteroinvasion by E coli. These changes may explain in-part the increased risk of infection in parenterally fed patients. C1 [Heneghan, Aaron F.; Pierre, Joseph F.; Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Surg Serv, Madison, WI USA. [Heneghan, Aaron F.; Pierre, Joseph F.; Wang, Xinying; Kudsk, Kenneth A.] Univ Wisconsin, Dept Surg, Madison, WI 53792 USA. [Tandee, Kanokwan; Steele, James L.] Univ Wisconsin, Dept Food Sci, Madison, WI 53792 USA. [Shanmuganayagam, Dhanansayan; Reed, Jess D.] Univ Wisconsin, Dept Anim Sci, Reed Res Grp, Madison, WI 53792 USA. [Wang, Xinying] Nanjing Univ, Jinling Hosp, Dept Surg, Nanjing 210008, Jiangsu, Peoples R China. RP Kudsk, KA (reprint author), Univ Wisconsin, Dept Surg, 600 Highland Ave H4-736, Madison, WI 53792 USA. EM Kudsk@surgery.wisc.edu FU Biomedical Laboratory Research & Development Service of the VA Office of Research and Development [I01BX001672] FX The project described was supported by award I01BX001672 from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development. NR 52 TC 17 Z9 17 U1 0 U2 10 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0148-6071 EI 1941-2444 J9 JPEN-PARENTER ENTER JI J. Parenter. Enter. Nutr. PD SEP PY 2014 VL 38 IS 7 BP 817 EP 824 DI 10.1177/0148607113497514 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA AQ4KE UT WOS:000342764100007 PM 23894173 ER PT J AU Faraone, SV Spencer, TJ Madras, BK Zhang-James, Y Biederman, J AF Faraone, S. V. Spencer, T. J. Madras, B. K. Zhang-James, Y. Biederman, J. TI Dopamine transporter imaging: nonindependence of regional measures Response SO MOLECULAR PSYCHIATRY LA English DT Letter C1 [Faraone, S. V.; Zhang-James, Y.] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA. [Faraone, S. V.; Zhang-James, Y.] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY 13210 USA. [Spencer, T. J.; Biederman, J.] Harvard Univ, Sch Med, Dept Psychiat,Massachusetts Gen Hosp, Pediat Psychopharmacol Unit,Psychiat Serv, Boston, MA 02115 USA. [Madras, B. K.] New England Primate Res Ctr, Div Neurosci, Southborough, MA USA. [Madras, B. K.] Harvard Univ, Sch Med, Boston, MA USA. RP Faraone, SV (reprint author), SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA. EM sfaraone@childpsychresearch.org OI Faraone, Stephen/0000-0002-9217-3982 NR 4 TC 0 Z9 0 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 EI 1476-5578 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD SEP PY 2014 VL 19 IS 9 BP 964 EP 965 DI 10.1038/mp.2014.26 PG 4 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA AQ4DN UT WOS:000342742700006 PM 24686137 ER PT J AU Ruderfer, DM Fanous, AH Ripke, S McQuillin, A Amdur, RL Gejman, PV O'Donovan, MC Andreassen, OA Djurovic, S Hultman, CM Kelsoe, JR Jamain, S Landen, M Leboyer, M Nimgaonkar, V Nurnberger, J Smoller, JW Craddock, N Corvin, A Sullivan, PF Holmans, P Sklar, P Kendler, KS AF Ruderfer, D. M. Fanous, A. H. Ripke, S. McQuillin, A. Amdur, R. L. Gejman, P. V. O'Donovan, M. C. Andreassen, O. A. Djurovic, S. Hultman, C. M. Kelsoe, J. R. Jamain, S. Landen, M. Leboyer, M. Nimgaonkar, V. Nurnberger, J. Smoller, J. W. Craddock, N. Corvin, A. Sullivan, P. F. Holmans, P. Sklar, P. Kendler, K. S. CA Schizophrenia Working Grp Psychiat Bipolar Disorder Working Grp Psych Cross-Disorder Working Grp Psychia TI Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia SO MOLECULAR PSYCHIATRY LA English DT Article DE bipolar; clinical symptoms; cross disorder; polygenic; schizophrenia ID GENOME-WIDE ASSOCIATION; ROSCOMMON FAMILY; SYMPTOMS; INTERVIEW; ILLNESS; RISK; RELIABILITY; RATIONALE; RELATIVES; HISTORY AB Bipolar disorder and schizophrenia are two often severe disorders with high heritabilities. Recent studies have demonstrated a large overlap of genetic risk loci between these disorders but diagnostic and molecular distinctions still remain. Here, we perform a combined genome-wide association study (GWAS) of 19 779 bipolar disorder (BP) and schizophrenia (SCZ) cases versus 19 423 controls, in addition to a direct comparison GWAS of 7129 SCZ cases versus 9252 BP cases. In our case-control analysis, we identify five previously identified regions reaching genome-wide significance (CACNA1C, IFI44L, MHC, TRANK1 and MAD1L1) and a novel locus near PIK3C2A. We create a polygenic risk score that is significantly different between BP and SCZ and show a significant correlation between a BP polygenic risk score and the clinical dimension of mania in SCZ patients. Our results indicate that first, combining diseases with similar genetic risk profiles improves power to detect shared risk loci and second, that future direct comparisons of BP and SCZ are likely to identify loci with significant differential effects. Identifying these loci should aid in the fundamental understanding of how these diseases differ biologically. These findings also indicate that combining clinical symptom dimensions and polygenic signatures could provide additional information that may someday be used clinically. C1 [Ruderfer, D. M.; Sklar, P.] Mt Sinai Sch Med, Dept Psychiat, Div Psychiat Genom, New York, NY 10024 USA. [Ruderfer, D. M.; Fanous, A. H.; Amdur, R. L.] Washington DC VA Med Ctr, Washington, DC USA. [Ruderfer, D. M.; Fanous, A. H.] Georgetown Univ, Sch Med, Dept Psychiat, Washington, DC USA. [Fanous, A. H.; Kendler, K. S.] Virginia Commonwealth Univ, Dept Psychiat, Sch Med, Richmond, VA USA. [Ripke, S.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA. [Ripke, S.] Harvard Univ, Sch Med, Boston, MA USA. [Ripke, S.] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA USA. [McQuillin, A.] UCL, Mental Hlth Sci Unit, Mol Psychiat Lab, London, England. [Gejman, P. V.] NorthShore Univ HealthSyst, Dept Psychiat & Behav Sci, Evanston, IL USA. [Gejman, P. V.] Univ Chicago, Evanston, IL USA. [O'Donovan, M. C.; Craddock, N.; Holmans, P.] Cardiff Univ, Sch Med, Dept Psychol Med & Neurol, MRC Ctr Neuropsychiat Genet & Genom, Cardiff CF10 3AX, S Glam, Wales. [Andreassen, O. A.; Djurovic, S.] Oslo Univ Hosp, Div Mental Hlth & Addict, KG Jebsen Ctr Psychosis Res, NORMENT, Oslo, Norway. [Andreassen, O. A.; Djurovic, S.] Univ Oslo, Inst Clin Med, Oslo, Norway. [Hultman, C. M.; Landen, M.] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden. [Kelsoe, J. R.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Kelsoe, J. R.] Vet Affairs San Diego Healthcare Syst, Special Treatment & Evaluat Program, Dept Psychiat, San Diego, CA USA. [Leboyer, M.] INSERM, U955, Creteil, France. [Leboyer, M.] Univ Paris Est, Fac Med, AP HP, Creteil, France. [Leboyer, M.] Fdn Fondamental, ENBREC Grp, Dept Psychiat, Hop H Mondor A Chenevier, Creteil, France. [Landen, M.] Univ Gothenburg, Inst Neurosci & Physiol, Gothenburg, Sweden. [Nimgaonkar, V.] Univ Pittsburgh, Sch Med, Dept Psychiat, WPIC, Pittsburgh, PA USA. [Nurnberger, J.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA. [Smoller, J. W.] Broad Inst, Stanley Ctr Psychiat Res, Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Boston, MA USA. [Corvin, A.] Univ Dublin Trinity Coll, Dept Psychiat, Neuropsychiat Genet Res Grp, Dublin 2, Ireland. [Corvin, A.] Univ Dublin Trinity Coll, Inst Mol Med, Dublin 2, Ireland. [Sullivan, P. F.] Univ North Carolina Chapel Hill, Dept Genet, Raleigh, NC USA. [Holmans, P.] Cardiff Univ, Sch Med, Biostat & Bioinformat Unit, Cardiff CF10 3AX, S Glam, Wales. [Kendler, K. S.] Virginia Commonwealth Univ, Sch Med, Dept Human & Mol Genet, Virginia Inst Psychiat & Behav Genet, Richmond, VA USA. RP Sklar, P (reprint author), Mt Sinai Sch Med, Dept Psychiat, Div Psychiat Genom, New York, NY 10024 USA. EM pamela.sklar@mssm.edu; kendler@vcu.edu RI Holmans, Peter/F-4518-2015; Zhang, Peng/N-2920-2014; Ruderfer, Douglas/M-5795-2016; McQuillin, Andrew/C-1623-2008; OI Nurnberger, John/0000-0002-7674-1767; Holmans, Peter/0000-0003-0870-9412; Zhang, Peng/0000-0003-1182-1392; Ruderfer, Douglas/0000-0002-2365-386X; McQuillin, Andrew/0000-0003-1567-2240; Jamain, Stephane/0000-0002-4321-4100; Corvin, Aiden/0000-0001-6717-4089; Andreassen, Ole A./0000-0002-4461-3568 FU Medical Research Council [G0800509, G0801418, G1000708]; NIMH NIH HHS [R01 MH097276, U01 MH094432] NR 50 TC 56 Z9 56 U1 12 U2 31 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 EI 1476-5578 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD SEP PY 2014 VL 19 IS 9 BP 1017 EP 1024 DI 10.1038/mp.2013.138 PG 8 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA AQ4DN UT WOS:000342742700013 PM 24280982 ER PT J AU Doraiswamy, PM Sperling, RA Johnson, K Reiman, EM Wong, TZ Sabbagh, MN Sadowsky, CH Fleisher, AS Carpenter, A Joshi, AD Lu, M Grundman, M Mintun, MA Skovronsky, DM Pontecorvo, MJ AF Doraiswamy, P. M. Sperling, R. A. Johnson, K. Reiman, E. M. Wong, T. Z. Sabbagh, M. N. Sadowsky, C. H. Fleisher, A. S. Carpenter, A. Joshi, A. D. Lu, M. Grundman, M. Mintun, M. A. Skovronsky, D. M. Pontecorvo, M. J. CA AV45-A11 Study Grp TI Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study SO MOLECULAR PSYCHIATRY LA English DT Article DE alzheimer's disease; amyloid; cognitive decline; florbetapir; MCI; PET ID ALZHEIMERS ASSOCIATION WORKGROUPS; PITTSBURGH COMPOUND-B; NEUROIMAGING INITIATIVE PROGRESS; PLACEBO-CONTROLLED TRIAL; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; A-BETA; DISEASE; IMPAIRMENT; RECOMMENDATIONS AB This study was designed to evaluate whether subjects with amyloid beta (A beta) pathology, detected using florbetapir positron emission tomorgraphy (PET), demonstrated greater cognitive decline than subjects without A beta pathology. Sixty-nine cognitively normal (CN) controls, 52 with recently diagnosed mild cognitive impairment (MCI) and 31 with probable Alzheimer's disease (AD) dementia were included in the study. PET images obtained in these subjects were visually rated as positive (A beta+) or negative (A beta-), blind to diagnosis. Fourteen percent (10/69) of CN, 37% (19/52) of MCI and 68% (21/31) of AD were A beta+. The primary outcome was change in ADAS-Cog score in MCI subjects after 36 months; however, additional outcomes included change on measures of cognition, function and diagnostic status. A beta+ MCI subjects demonstrated greater worsening compared with A beta-subjects on the ADAS-Cog over 36 months (5.66 +/- 1.47 vs -0.71 +/- 1.09, P = 0.0014) as well as on the mini-mental state exam (MMSE), digit symbol substitution (DSS) test, and a verbal fluency test (P < 0.05). Similar to MCI subjects, A beta+ CN subjects showed greater decline on the ADAS-Cog, digit-symbol-substitution test and verbal fluency (P < 0.05), whereas A beta+ AD patients showed greater declines in verbal fluency and the MMSE (P < 0.05). A beta+ subjects in all diagnostic groups also showed greater decline on the CDR-SB (P < 0.04), a global clinical assessment. A beta+ subjects did not show significantly greater declines on the ADCS-ADL or Wechsler Memory Scale. Overall, these findings suggest that in CN, MCI and AD subjects, florbetapir PET A beta+ subjects show greater cognitive and global deterioration over a 3-year follow-up than A beta- subjects do. C1 [Doraiswamy, P. M.; Wong, T. Z.] Duke Univ, Med Ctr, Durham, NC USA. [Sperling, R. A.; Johnson, K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Reiman, E. M.; Fleisher, A. S.] Banner Alzheimers Inst, Phoenix, AZ USA. [Sabbagh, M. N.] Banner Sun Hlth Res Inst, Sun City, AZ USA. [Sadowsky, C. H.] Nova SE Univ, Ft Lauderdale, FL 33314 USA. [Fleisher, A. S.; Grundman, M.] Univ Calif San Diego, San Diego, CA 92103 USA. [Carpenter, A.; Joshi, A. D.; Lu, M.; Mintun, M. A.; Skovronsky, D. M.; Pontecorvo, M. J.] Avid Radiopharmaceut, Philadelphia, PA USA. [Grundman, M.] Global R&D Partners, San Diego, CA USA. RP Doraiswamy, PM (reprint author), Duke Univ, Med Ctr, Duke South Hosp, Room 3550,1000 Trent Dr, Durham, NC 27708 USA. EM murali.doraiswamy@duke.edu; pontecorvo@avidrp.com FU Duke University from NIA; NIMH; NINDS; NHLBI; University of California (ADCS); Northern California Research Institute (ADNI); Avid/Lilly; Elan; Bristol-Myers; Ono; Sanofi; Novartis; Medivation and Neuronetrix; University of California; National University of Singapore; University of Cambridge; Royal College of Psychiatrists; Radiologic Society of North America; Alzheimer's Association; Alzheimer's Foundation of America; Postgraduate Press; Medivation; Bristol Myers; Accera; Piramal; Grifols; Baxter; Nutricia; Great Falls Living; Sonexa; Schering; TauRx; Genomind; Shire; Neuroptix; Bayer; Neuronetrix; Otsuka; AstraZeneca; Envivo; Targacept; Abbvie; Neurocog Trials; Lundbeck and Edwards Hospital; Bristol-Myers-Squib; Janssen (JanssenAI); Pfizer; Celgene; Ceregene; BMS; Lilly; Wyeth; Janssen; Avid; Genentech and Eisai FX PMD has received research grants through Duke University from NIA, NIMH, NINDS, NHLBI, University of California (ADCS), Northern California Research Institute (ADNI), Avid/Lilly, Elan, Bristol-Myers, Ono, Sanofi, Novartis, Medivation and Neuronetrix in the recent past. He has received advisory or speaking fees from the University of California, National University of Singapore, University of Cambridge, Royal College of Psychiatrists, Radiologic Society of North America, Alzheimer's Association, Alzheimer's Foundation of America, Postgraduate Press, Avid/Lilly, Medivation, Bristol Myers, Accera, Piramal, Grifols, Baxter, Nutricia, Great Falls Living, Sonexa, Schering, TauRx, Baxter, Elan, Genomind, Shire, Neuroptix, Bayer, Neuronetrix, Otsuka, AstraZeneca, Envivo, Targacept, Abbvie, Neurocog Trials, Lundbeck and Edwards Hospital. He received publishing royalties from a book. He owns stock in Sonexa, Clarimedix, Maxwell Health and Adverse Events Inc, whose products are not discussed in this manuscript. RAS has served as a site investigator for Avid, BMS, Elan, Janssen, Pfizer and Wyeth and as a consultant to Bayer, BMS, Elan, Eisai, Janssen, Pfizer, Roche and Wyeth and as an unpaid consultant to Avid. She has received speaking honoraria from Prizer, Janssen, Eli Lilly and Bayer. KJ was a co-investigator in the trial and has consulted for GE Healthcare, Bayer- Schering, Pfizer, Elan/Janssen and Seimens. KJ has received research support from Avid/ Lilly, Bristol-Myers-Squib, Janssen (JanssenAI) and Pfizer. EMR has served as a scientific advisor to Sygnis, AstraZeneca, Bayer, Eisai, Elan, Eli Lilly, GlaxoSmithKline, Intellect, Link Medicine, Novartis, Siemens and Takeda. He has had research contracts with NIA the Arizona Department of Health Services, AstraZeneca and Avid. TZW has served as a scientific advisor for Lilly and a site co-investigator on Avid studies. MNS has served in a consulting or advisory capacity for Lilly, Amerisciences, Takeda, Eisai, Pfizer, GSK and has received royalties from Wiley and Amerisciences. He has received contracts and grants from Celgene, Ceregene, Bayer, Baxter, BMS, Lilly, Pfizer, Wyeth, Janssen, Elan, Avid, Genentech and Eisai. CHS has served on speaker bureaus for Novartis, Forest, Accera and as a consultant to Lilly. ASF has served as a consultant to Lilly and Avid, and received grant funding from Avid. AC, ADJ, ML, MAM, DMS and MJP are employees of Avid, a division of Eli Lilly, and except for ML, formerly held Avid stock or options. MG has served as a consultant to Acumen, Adamas, ALSP, Avid, Astra-Zeneca, Biogen Idec, Elan, Helicon, Intellect Neurosciences, Janssen Alzheimer Immunotherapy, J&J, Lilly, Medimmune, Neurophage, Neurogenetic Pharmaceuticals, Phloronol and Teva and on advisory boards for Helicon, Nutricia North America and Bristol Myers Squibb. MG owns stock in Prothena, and formerly held Avid stock options. NR 42 TC 44 Z9 44 U1 1 U2 7 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 EI 1476-5578 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD SEP PY 2014 VL 19 IS 9 BP 1044 EP 1051 DI 10.1038/mp.2014.9 PG 8 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA AQ4DN UT WOS:000342742700017 PM 24614494 ER PT J AU Su, ZQ Labaj, PP Li, S Thierry-Mieg, J Thierry-Mieg, D Shi, W Wang, C Schroth, GP Setterquist, RA Thompson, JF Jones, WD Xiao, WH Xu, WH Jensen, RV Kelly, R Xu, J Conesa, A Furlanello, C Gao, HL Hong, HX Jafari, N Letovsky, S Liao, Y Lu, F Oakeley, EJ Peng, ZY Praul, CA Santoyo-Lopez, J Scherer, A Shi, T Smyth, GK Staedtler, F Sykacek, P Tan, XX Thompson, EA Vandesompele, J Wang, MD Wang, J Wolfinger, RD Zavadil, J Auerbach, SS Bao, WJ Binder, H Blomquist, T Brilliant, MH Bushel, PR Cain, WM Catalano, JG Chang, CW Chen, T Chen, G Chen, R Chierici, M Chu, TM Clevert, DA Deng, YP Derti, A Devanarayan, V Dong, ZR Dopazo, J Du, TT Fang, H Fang, YX Fasold, M Fernandez, A Fischer, M Furio-Tari, P Fuscoe, JC Caiment, F Gaj, S Gandara, J Gao, H Ge, WG Gondo, Y Gong, BS Gong, MH Gong, ZL Green, B Guo, C Guo, L Guo, LW Hadfield, J Hellemans, J Hochreiter, S Jia, MW Jian, M Johnson, CD Kay, S Kleinjans, J Lababidi, S Levy, S Li, QZ Li, L Li, L Li, P Li, Y Li, HQ Li, JY Li, SY Lin, SM Lopez, FJ Lu, X Luo, H Ma, XW Meehan, J Megherbi, DB Mei, N Mu, B Ning, BT Pandey, A Perez-Florido, J Perkins, RG Peters, R Phan, JH Pirooznia, M Qian, F Qing, T Rainbow, L Rocca-Serra, P Sambourg, L Sansone, SA Schwartz, S Shah, R Shen, J Smith, TM Stegle, O Stralis-Pavese, N Stupka, E Suzuki, Y Szkotnicki, LT Tinning, M Tu, BM van Deft, J Vela-Boza, A Venturini, E Walker, SJ Wan, LQ Wang, W Wang, JH Wang, J Wieben, ED Willey, JC Wu, PY Xuan, J Yang, Y Ye, Z Yin, Y Yu, Y Yuan, YC Zhang, J Zhang, KK Zhang, WQ Zhang, WW Zhang, YY Zhao, C Zheng, YT Zhou, YM Zumbo, P Tong, WD Kreil, DP Mason, CE Shi, LM AF Su, Zhenqiang Labaj, Pawel P. Li, Sheng Thierry-Mieg, Jean Thierry-Mieg, Danielle Shi, Wei Wang, Charles Schroth, Gary P. Setterquist, Robert A. Thompson, John F. Jones, Wendell D. Xiao, Wenzhong Xu, Weihong Jensen, Roderick V. Kelly, Reagan Xu, Joshua Conesa, Ana Furlanello, Cesare Gao, Hanlin Hong, Huixiao Jafari, Nadereh Letovsky, Stan Liao, Yang Lu, Fei Oakeley, Edward J. Peng, Zhiyu Praul, Craig A. Santoyo-Lopez, Javier Scherer, Andreas Shi, Tieliu Smyth, Gordon K. Staedtler, Frank Sykacek, Peter Tan, Xin-Xing Thompson, E. Aubrey Vandesompele, Jo Wang, May D. Wang, Jian Wolfinger, Russell D. Zavadil, Jiri Auerbach, Scott S. Bao, Wenjun Binder, Hans Blomquist, Thomas Brilliant, Murray H. Bushel, Pierre R. Cain, Weimin Catalano, Jennifer G. Chang, Ching-Wei Chen, Tao Chen, Geng Chen, Rong Chierici, Marco Chu, Tzu-Ming Clevert, Djork-Arne Deng, Youping Derti, Adnan Devanarayan, Viswanath Dong, Zirui Dopazo, Joaquin Du, Tingting Fang, Hong Fang, Yongxiang Fasold, Mario Fernandez, Anita Fischer, Matthias Furio-Tari, Pedro Fuscoe, James C. Caiment, Florian Gaj, Stan Gandara, Jorge Gao, Huan Ge, Weigong Gondo, Yoichi Gong, Binsheng Gong, Meihua Gong, Zhuolin Green, Bridgett Guo, Chao Guo, Lei Guo, Li-Wu Hadfield, James Hellemans, Jan Hochreiter, Sepp Jia, Meiwen Jian, Min Johnson, Charles D. Kay, Suzanne Kleinjans, Jos Lababidi, Samir Levy, Shawn Li, Quan-Zhen Li, Li Li, Li Li, Peng Li, Yan Li, Haiqing Li, Jianying Li, Shiyong Lin, Simon M. Lopez, Francisco J. Lu, Xin Luo, Heng Ma, Xiwen Meehan, Joseph Megherbi, Dalila B. Mei, Nan Mu, Bing Ning, Baitang Pandey, Akhilesh Perez-Florido, Javier Perkins, Roger G. Peters, Ryan Phan, John H. Pirooznia, Mehdi Qian, Feng Qing, Tao Rainbow, Lucille Rocca-Serra, Philippe Sambourg, Laure Sansone, Susanna-Assunta Schwartz, Scott Shah, Ruchir Shen, Jie Smith, Todd M. Stegle, Oliver Stralis-Pavese, Nancy Stupka, Elia Suzuki, Yutaka Szkotnicki, Lee T. Tinning, Matthew Tu, Bimeng van Deft, Joost Vela-Boza, Alicia Venturini, Elisa Walker, Stephen J. Wan, Liqing Wang, Wei Wang, Jinhui Wang, Jun Wieben, Eric D. Willey, James C. Wu, Po-Yen Xuan, Jiekun Yang, Yong Ye, Zhan Yin, Ye Yu, Ying Yuan, Yate-Ching Zhang, John Zhang, Ke K. Zhang, Wenqian Zhang, Wenwei Zhang, Yanyan Zhao, Chen Zheng, Yuanting Zhou, Yiming Zumbo, Paul Tong, Weida Kreil, David P. Mason, Christopher E. Shi, Leming TI A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control Consortium SO NATURE BIOTECHNOLOGY LA English DT Article ID GENE-EXPRESSION ANALYSIS; GENOME ANNOTATION; ARRAYS; TRANSCRIPTOME; CALIBRATION; ALIGNER; PROJECT; CELLS; BIAS; PCR AB We present primary results from the Sequencing Quality Control (SEQC) project, coordinated by the US Food and Drug Administration. Examining Illumina HiSeq, Life Technologies SOLiD and Roche 454 platforms at multiple laboratory sites using reference RNA samples with built-in controls, we assess RNA sequencing (RNA-seq) performance for junction discovery and differential expression profiling and compare it to microarray and quantitative PCR (qPCR) data using complementary metrics. At all sequencing depths, we discover unannotated exon-exon junctions, with >80% validated by qPCR. We find that measurements of relative expression are accurate and reproducible across sites and platforms if specific-filters are used. In contrast, RNA-seq and microarrays do not provide accurate absolute measurements, and gene-specific biases are observed for all examined platforms, including qPCR. Measurement performance depends on the platform and data analysis pipeline, and variation is large for transcript-level profiling. The complete SEQC data sets, comprising >100 billion reads (10Tb), provide unique resources for evaluating RNA-seq analyses for clinical and regulatory settings. C1 [Su, Zhenqiang; Kelly, Reagan; Xu, Joshua; Hong, Huixiao; Chang, Ching-Wei; Chen, Tao; Fang, Hong; Fuscoe, James C.; Ge, Weigong; Gong, Binsheng; Green, Bridgett; Guo, Lei; Guo, Li-Wu; Li, Yan; Meehan, Joseph; Mei, Nan; Ning, Baitang; Perkins, Roger G.; Qian, Feng; Shen, Jie; Wan, Liqing; Xuan, Jiekun; Zhang, Wenqian; Tong, Weida; Shi, Leming] US FDA, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA. [Labaj, Pawel P.; Sykacek, Peter; Stralis-Pavese, Nancy; Kreil, David P.] Boku Univ Vienna, Chair Bioinformat Res Grp, Vienna, Austria. [Li, Sheng; Gandara, Jorge; Zumbo, Paul; Mason, Christopher E.] Weill Cornell Med Coll, Dept Physiol & Biophys, New York, NY USA. [Li, Sheng; Zumbo, Paul; Mason, Christopher E.] Weill Cornell Med Coll, HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsau, New York, NY USA. [Thierry-Mieg, Jean; Thierry-Mieg, Danielle] NCBI, NIH, Bethesda, MD USA. [Shi, Wei; Liao, Yang; Smyth, Gordon K.] Walter & Eliza Hall Inst Med Res, Bioinformat Div, Parkville, Vic, Australia. [Shi, Wei] Univ Melbourne, Dept Comp & Informat Syst, Parkville, Vic 3052, Australia. [Wang, Charles] Loma Linda Univ, Ctr Genom, Sch Med, Loma Linda, CA 92350 USA. [Wang, Charles] Loma Linda Univ, Div Microbiol & Mol Genet, Sch Med, Loma Linda, CA 92350 USA. [Schroth, Gary P.] Illumina Inc, Hayward, CA USA. [Setterquist, Robert A.] Life Technol Corp, Austin, TX USA. [Thompson, John F.] Claritas Genom, Cambridge, MA USA. [Jones, Wendell D.] Express Anal Inc, Durham, NC USA. [Xiao, Wenzhong] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Xiao, Wenzhong; Xu, Weihong] Stanford Genome Technol Ctr, Palo Alto, CA USA. [Jensen, Roderick V.] Virginia Tech, Dept Biol Sci, Blacksburg, VA USA. [Conesa, Ana; Dopazo, Joaquin; Furio-Tari, Pedro] Ctr Invest Principe Felipe, Computat Genom Program, Valencia, Spain. [Furlanello, Cesare; Chierici, Marco] Fdn Bruno Kessler, Trento, Trento, Italy. [Gao, Hanlin; Wang, Jinhui] City Hope Natl Med Ctr, DNA Sequencing Solexa Core, Beckman Res Inst, City Hope Comprehens Canc Ctr, Duarte, CA 91010 USA. [Jafari, Nadereh] Northwestern Univ, Ctr Genet Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Letovsky, Stan] SynapDx Corp, Lexington, MA USA. [Liao, Yang] Univ Melbourne, Dept Med Biol, Parkville, Vic 3052, Australia. [Lu, Fei; Tan, Xin-Xing; Szkotnicki, Lee T.] GE Healthcare SeqWright Genom Serv, Houston, TX USA. [Oakeley, Edward J.; Staedtler, Frank; Fernandez, Anita] Novartis Inst Biomed Res, Basel, Switzerland. [Peng, Zhiyu; Dong, Zirui; Gao, Huan; Gong, Meihua; Gong, Zhuolin; Jian, Min; Li, Shiyong; Tu, Bimeng; Wang, Jun; Yin, Ye; Zhang, Wenqian; Zhang, Wenwei; Zhang, Yanyan] BGI Shenzhen, Bei Shan Ind Zone, Shenzhen, Guangdong, Peoples R China. [Praul, Craig A.] Penn State Univ, University Pk, PA 16802 USA. [Santoyo-Lopez, Javier; Lopez, Francisco J.; Perez-Florido, Javier; Vela-Boza, Alicia] Genom & Bioinformat Platform Andalusia, Med Genome Project, Seville, Spain. [Santoyo-Lopez, Javier] Univ Edinburgh, Edinburgh Genom, Edinburgh, Midlothian, Scotland. [Scherer, Andreas; Tinning, Matthew] Australian Genome Res Facil Ltd, Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia. [Scherer, Andreas] Spheromics, Kontiolahti, Finland. [Shi, Tieliu; Chen, Geng; Li, Peng; Zhao, Chen] E China Normal Univ, Inst Biomed Sci, Ctr Bioinformat & Computat Biol, Shanghai Key Lab Regulatory Biol, Shanghai 200062, Peoples R China. [Shi, Tieliu; Chen, Geng; Li, Peng; Zhao, Chen] E China Normal Univ, Sch Life Sci, Shanghai 200062, Peoples R China. [Smyth, Gordon K.] Univ Melbourne, Dept Math & Stat, Parkville, Vic 3052, Australia. [Thompson, E. Aubrey] Mayo Clin Jacksonville, Dept Canc Biol, Jacksonville, FL 32224 USA. [Vandesompele, Jo; Hellemans, Jan] Biogazelle, Zwijnaarde, Belgium. [Wang, May D.; Phan, John H.] GeorgiaTech, Dept Biomed Engn, Atlanta, GA USA. [Wang, May D.; Phan, John H.] Emory Univ, Atlanta, GA 30322 USA. [Wang, Jian; Yang, Yong] Eli Lilly & Co, Lilly Corp Ctr, Res Informat, Indianapolis, IN 46285 USA. [Wolfinger, Russell D.; Bao, Wenjun; Chu, Tzu-Ming; Li, Li] SAS Inst Inc, Cary, NC USA. [Zavadil, Jiri; Venturini, Elisa] NYU, Langone Med Ctr, NYU Genome Technol Ctr, New York, NY USA. [Zavadil, Jiri] NYU, Langone Med Ctr, NYU Ctr Hlth Informat & Bioinformat, Dept Pathol, New York, NY USA. [Zavadil, Jiri] Int Agcy Res Canc, Mol Mech & Biomarkers Grp, F-69372 Lyon, France. [Auerbach, Scott S.; Bushel, Pierre R.; Li, Jianying] NIEHS, NIH, Res Triangle Pk, NC 27709 USA. [Binder, Hans] Univ Leipzig, Interdisciplinary Ctr Bioinformat, D-04109 Leipzig, Germany. [Blomquist, Thomas; Willey, James C.] Univ Toledo, Div Pulm & Crit Care Med, Dept Med, Med Coll Ohio, Toledo, OH 43606 USA. [Brilliant, Murray H.] Marshfield Clin Res Fdn, Ctr Human Genet, Marshfield, WI USA. [Cain, Weimin; Du, Tingting; Jia, Meiwen; Qing, Tao; Yu, Ying; Zheng, Yuanting] Fudan Univ, Sch Pharm, Shanghai 200433, Peoples R China. [Catalano, Jennifer G.] US FDA, Off Cellular Tissue & Gene Therapies, CBER, Bethesda, MD 20014 USA. [Chen, Rong; Li, Li] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, Icahn Inst Genom & Multiscale Biol, New York, NY 10029 USA. [Clevert, Djork-Arne; Hochreiter, Sepp] Johannes Kepler Univ Linz, Inst Bioinformat, A-4040 Linz, Austria. [Deng, Youping] Rush Univ, Ctr Canc, Dept Internal Med, Chicago, IL 60612 USA. [Derti, Adnan] Novartis Inst Biomed Res, Cambridge, MA USA. [Devanarayan, Viswanath] AbbVie Inc, Global Pharmaceut R&D, Souderton, PA USA. [Dopazo, Joaquin] CIBER Enfermedades Raras CIBERER, Valencia, Spain. [Dopazo, Joaquin] CIPF, Funct Genom Node INB, Valencia, Spain. [Fang, Yongxiang; Kay, Suzanne; Rainbow, Lucille] Univ Liverpool, Ctr Genom Res, Liverpool L69 3BX, Merseyside, England. [Fasold, Mario] ecSeq Bioinformat, Leipzig, Germany. [Fischer, Matthias] Univ Cologne, Dept Pediat Oncol & Hematol, D-50931 Cologne, Germany. [Fischer, Matthias] Univ Cologne, Ctr Mol Med CMMC, D-50931 Cologne, Germany. [Caiment, Florian; Gaj, Stan; Kleinjans, Jos; van Deft, Joost] Maastricht Univ, Dept Toxicogenom, Maastricht, Netherlands. [Gondo, Yoichi] RIKEN BioResource Ctr, Tsukuba, Ibaraki, Japan. [Guo, Chao] City Hope Natl Med Ctr, Beckman Res Inst, Funct Genom Core, Duarte, CA 91010 USA. [Hadfield, James] Univ Cambridge, Li Ka Shing Ctr, Canc Res UK Cambridge Inst, Cambridge, England. [Johnson, Charles D.; Schwartz, Scott] Texas A&M AgriLife Res, College Stn, TX USA. [Lababidi, Samir] US FDA, CBER, Rockville, MD 20857 USA. [Levy, Shawn] HudsonAlpha Inst Biotechnol, Huntsville, AL USA. [Li, Quan-Zhen] Univ Texas SW Med Ctr Dallas, UTSW, Dallas, TX 75390 USA. [Li, Haiqing; Mu, Bing; Yuan, Yate-Ching] City Hope Natl Med Ctr, Beckman Res Inst, Bioinformat Core, Duarte, CA 91010 USA. [Lin, Simon M.] Nationwide Childrens Hosp, Res Inst, Columbus, OH USA. [Lu, Xin] AbbVie Inc, Global Pharmaceut R&D, N Chicago, IL USA. [Luo, Heng] Univ Arkansas, UALR UAMS Joint Bioinformat Grad Program, Little Rock, AR 72204 USA. [Ma, Xiwen] Eli Lilly & Co, Lilly Corp Ctr, Discovery Stat, Indianapolis, IN 46285 USA. [Megherbi, Dalila B.] Univ Massachusetts, Dept Elect & Comp Engn, CMINDS Res Ctr, Lowell, MA USA. [Pandey, Akhilesh] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD USA. [Pandey, Akhilesh] Inst Bioinformat, Bangalore, Karnataka, India. [Peters, Ryan] Partek Inc, St Louis, MO USA. [Pirooznia, Mehdi] Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA. [Rocca-Serra, Philippe; Sansone, Susanna-Assunta] Univ Oxford, Oxford e Res Ctr, Oxford, England. [Sambourg, Laure] UJF Grenoble, CNRS TIMC IMAG 1, UMR 5525, Computat & Math Biol BCM, Grenoble, France. [Shah, Ruchir] SRA Int Inc, Durham, NC USA. [Smith, Todd M.] Geospiza Inc, Seattle, WA USA. [Stegle, Oliver] European Bioinformat Inst, European Mol Biol Lab, Cambridge, England. [Stupka, Elia] Ist Sci San Raffaele, Ctr Translat Genom & Bioinformat, I-20132 Milan, Italy. [Suzuki, Yutaka] Univ Tokyo, Dept Med Genome Sci, Chiba, Japan. [Walker, Stephen J.] Wake Forest Univ, Wake Forest Inst Regenerat Med, Winston Salem, NC 27109 USA. [Wang, Wei] Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA. [Wang, Jun] Univ Copenhagen, Dept Biol, Copenhagen, Denmark. [Wang, Jun] King Abdulaziz Univ, Jeddah 21413, Saudi Arabia. [Wang, Jun] Univ Copenhagen, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark. [Wieben, Eric D.] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN USA. [Wu, Po-Yen] Georgia Inst Technol, Sch Elect & Comp Engn, Atlanta, GA 30332 USA. [Ye, Zhan] Marshfield Clin Res Fdn, Biomed Informat Res Ctr, Marshfield, WI USA. [Zhang, John] Zhejiang Univ Technol, Zhijiang Coll, Ctr Big Data Res, Hangzhou, Zhejiang, Peoples R China. [Zhang, Ke K.] Univ N Dakota, Sch Med, Dept Pathol, Grand Forks, ND 58202 USA. [Zhou, Yiming] Digomics LLC, Brookline, MA USA. [Kreil, David P.] Univ Warwick, Coventry CV4 7AL, W Midlands, England. [Shi, Leming] Fudan Univ, State Key Lab Genet Engn, Shanghai 200433, Peoples R China. [Shi, Leming] Fudan Univ, Sch Life Sci, MOE Key Lab Contemporary Anthropol, Shanghai 200433, Peoples R China. [Shi, Leming] Fudan Univ, Sch Pharm, Shanghai 200433, Peoples R China. [Shi, Leming] Fudan Zhangjiang Ctr Clin Genom, Shanghai, Peoples R China. [Shi, Leming] Zhanjiang Ctr Translat Med, Shanghai, Peoples R China. RP Shi, LM (reprint author), US FDA, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA. EM david.krell@boku.ac.at; chm2042@med.cornell.edu; leming.shi@gmail.com RI Labaj, Pawel/N-5425-2014; Guo, Chao/B-2647-2010; caiment, florian/N-7623-2015; Gondo, Yoichi/A-5375-2016; Wang, Jun/C-8434-2016; Luo, Heng/D-3616-2016; Gong, Binsheng/E-2306-2015; Smyth, Gordon/B-5276-2008; THIERRY-MIEG, Jean/F-1975-2017; Conesa Cegarra, Ana/A-9559-2014; Kleinjans, Jos/E-7241-2015; Kreil, D/O-1783-2013; Wang, Jun/B-9503-2016; OI Guo, Chao/0000-0002-6673-0933; Gondo, Yoichi/0000-0003-2184-6489; Wang, Jun/0000-0002-8540-8931; Luo, Heng/0000-0001-5192-8878; Gong, Binsheng/0000-0002-8724-5435; Smyth, Gordon/0000-0001-9221-2892; THIERRY-MIEG, Jean/0000-0002-0396-6789; Stupka, Elia/0000-0003-3154-4011; Stegle, Oliver/0000-0002-8818-7193; Conesa Cegarra, Ana/0000-0001-9597-311X; Johnson, Charles/0000-0003-3892-7082; Hochreiter, Sepp/0000-0001-7449-2528; Kreil, D/0000-0001-7538-2056; Chierici, Marco/0000-0001-9791-9301; Wang, Jun/0000-0002-2113-5874; MEI, NAN/0000-0002-3501-9014 FU China's Program of Global Experts; US National Institutes of Health (NIH) [R01CA163256, R01HG006798, R01NS076465, R44HG005297, U54CA119338, PO1HG00205, R24GM102656]; Intramural Research Program of the NIH, National Library of Medicine, National Institute of Environmental Health Sciences (NIEHS) [Z01 ES102345-04]; Shriners Research Grant [85500]; Australia National Health and Medical Research Council (NHMRC) [1023454]; Victorian State Government Operational Infrastructure Support (Australia); National 973 Key Basic Research Program of China [2010CB945401]; National Natural Science Foundation of China [31240038, 31071162]; Science and Technology Commission of Shanghai Municipality [11DZ2260300] FX All SEQC (MAQC-III) participants freely donated their time and reagents for the completion and analyses of the project. Many participants contributed to the sometimes-heated discussions on the topic of this paper during numerous e-mail exchanges, teleconferences and face-to-face project meetings. The common conclusions and recommendations reported in this paper evolved from this extended discourse. The authors gratefully acknowledge support by the National Center for Biotechnology Information (NCBI)'s Supercomputing Center, the FDA's Supercomputing Center, China's National Supercomputing Center of Tianjin, the Vienna Scientific Cluster High Performance Computing Facility (VSC), the Vienna Science and Technology Fund (WWTF), Baxter, the Austrian Institute of Technology, and the Austrian Centre of Biopharmaceutical Technology. This work was supported in part by China's Program of Global Experts. This work was supported in part by the US National Institutes of Health (NIH) grants R01CA163256, R01HG006798, R01NS076465, R44HG005297, U54CA119338, PO1HG00205, R24GM102656 and the Intramural Research Program of the NIH, National Library of Medicine, National Institute of Environmental Health Sciences (NIEHS) Z01 ES102345-04, Shriners Research Grant 85500, an Australia National Health and Medical Research Council (NH&MRC) Project grant (1023454) and Victorian State Government Operational Infrastructure Support (Australia), the National 973 Key Basic Research Program of China (2010CB945401), the National Natural Science Foundation of China (31240038 and 31071162), and the Science and Technology Commission of Shanghai Municipality (11DZ2260300). We greatly appreciate SAS Institute, Inc. for kindly hosting several face-to-face meetings of the SEQC (MAQC-III) project. NR 46 TC 118 Z9 119 U1 20 U2 126 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1087-0156 EI 1546-1696 J9 NAT BIOTECHNOL JI Nat. Biotechnol. PD SEP PY 2014 VL 32 IS 9 BP 903 EP 914 DI 10.1038/nbt.2957 PG 12 WC Biotechnology & Applied Microbiology SC Biotechnology & Applied Microbiology GA AQ2FD UT WOS:000342600300030 ER PT J AU Goldstein, JI Jarskog, LF Hilliard, C Alfirevic, A Duncan, L Fourches, D Huang, HL Lek, M Neale, BM Ripke, S Shianna, K Szatkiewicz, JP Tropsha, A van den Oord, EJCG Cascorbi, I Dettling, M Gazit, E Goff, DC Holden, AL Kelly, DL Malhotra, AK Nielsen, J Pirmohamed, M Rujescu, D Werge, T Levy, DL Josiassen, RC Kennedy, JL Lieberman, JA Daly, MJ Sullivan, PF AF Goldstein, Jacqueline I. Jarskog, L. Fredrik Hilliard, Chris Alfirevic, Ana Duncan, Laramie Fourches, Denis Huang, Hailiang Lek, Monkol Neale, Benjamin M. Ripke, Stephan Shianna, Kevin Szatkiewicz, Jin P. Tropsha, Alexander van den Oord, Edwin J. C. G. Cascorbi, Ingolf Dettling, Michael Gazit, Ephraim Goff, Donald C. Holden, Arthur L. Kelly, Deanna L. Malhotra, Anil K. Nielsen, Jimmi Pirmohamed, Munir Rujescu, Dan Werge, Thomas Levy, Deborah L. Josiassen, Richard C. Kennedy, James L. Lieberman, Jeffrey A. Daly, Mark J. Sullivan, Patrick F. TI Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles SO NATURE COMMUNICATIONS LA English DT Article ID GENOME-WIDE ASSOCIATION; RHEUMATOID-ARTHRITIS; GENOTYPE IMPUTATION; POPULATION; VARIANTS; DISEASE; RISK; HLA-B38; GENE AB Clozapine is a particularly effective antipsychotic medication but its use is curtailed by the risk of clozapine-induced agranulocytosis/granulocytopenia (CIAG), a severe adverse drug reaction occurring in up to 1% of treated individuals. Identifying genetic risk factors for CIAG could enable safer and more widespread use of clozapine. Here we perform the largest and most comprehensive genetic study of CIAG to date by interrogating 163 cases using genomewide genotyping and whole-exome sequencing. We find that two loci in the major histocompatibility complex are independently associated with CIAG: a single amino acid in HLA-DQB1 (126Q) (P = 4.7 x 10(-14), odds ratio (OR) = 0.19, 95% confidence interval (CI) = 0.12-0.29) and an amino acid change in the extracellular binding pocket of HLA-B (158T) (P = 6.4 x 10(-10), OR = 3.3, 95% CI = 2.3-4.9). These associations dovetail with the roles of these genes in immunogenetic phenotypes and adverse drug responses for other medications, and provide insight into the pathophysiology of CIAG. C1 [Goldstein, Jacqueline I.; Duncan, Laramie; Huang, Hailiang; Lek, Monkol; Neale, Benjamin M.; Ripke, Stephan; Daly, Mark J.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA. [Alfirevic, Ana; Pirmohamed, Munir] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool L69 3BX, Merseyside, England. [Fourches, Denis; Tropsha, Alexander] Univ N Carolina, Eshelman Sch Pharm, Div Chem Biol & Med Chem, Lab Mol Modeling, Chapel Hill, NC 27599 USA. [Neale, Benjamin M.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA. [Neale, Benjamin M.; Ripke, Stephan] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA 02142 USA. [Shianna, Kevin] New York Genome Ctr, New York, NY 10013 USA. [Szatkiewicz, Jin P.; Sullivan, Patrick F.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA. [van den Oord, Edwin J. C. G.] Virginia Commonwealth Univ, Ctr Biomarker Res & Personalized Med, Richmond, VA 23298 USA. [Cascorbi, Ingolf] Univ Hosp Schleswig Holstein, Inst Expt & Clin Pharmacol, D-24105 Kiel, Germany. [Dettling, Michael] Charite, Dept Psychiat & Psychotherapy, D-14050 Berlin, Germany. [Gazit, Ephraim] Tel Aviv Univ, Chaim Sheba Med Ctr, Tissue Typing Lab, IL-6997801 Ramat Aviv, Israel. [Goff, Donald C.] NYU, Dept Psychiat, New York, NY 10016 USA. [Holden, Arthur L.] Int SAE Consortium Ltd, Chicago, IL 60631 USA. [Kelly, Deanna L.] Univ Maryland, Maryland Psychiat Res Ctr, Baltimore, MD 21228 USA. [Malhotra, Anil K.] Feinstein Inst Med Res, Manhasset, NY 11030 USA. [Malhotra, Anil K.] Hofstra NS LIJ Sch Med, Hempstead, NY 11549 USA. [Malhotra, Anil K.] Zucker Hillside Hosp, Glen Oaks, NY 11004 USA. [Nielsen, Jimmi] Aalborg Univ Hosp, DK-9000 Aalborg, Denmark. [Nielsen, Jimmi] Aalborg Univ, Dept Clin Med, DK-9000 Aalborg, Denmark. [Rujescu, Dan] Univ Halle, Dept Psychiat, D-06112 Halle, Germany. [Rujescu, Dan] Univ Munich, Dept Psychiat, D-80336 Munich, Germany. [Werge, Thomas] Univ Copenhagen, Dept Clin Med, DK-1165 Copenhagen, Denmark. [Werge, Thomas] Mental Hlth Serv Copenhagen, MHC Sct Hans, Inst Biol Psychiat, DK-4000 Copenhagen, Denmark. [Werge, Thomas] iPSYCH, Lundbeck Fdn Initiat Integrat Psychiat Res, DK-8000 Roskilde, Denmark. [Levy, Deborah L.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Levy, Deborah L.] McLean Hosp, Psychol Res Lab, Belmont, MA 02478 USA. [Josiassen, Richard C.] Drexel Univ, Dept Psychiat, Philadelphia, PA 19104 USA. [Kennedy, James L.] Ctr Addict & Mental Hlth, Toronto, ON M5T 1R8, Canada. [Lieberman, Jeffrey A.] Columbia Univ, Dept Psychiat, New York, NY 10032 USA. [Lieberman, Jeffrey A.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. [Sullivan, Patrick F.] Karolinska Inst, Dept Med Epidemiol & Biostat, SE-17177 Stockholm, Sweden. RP Sullivan, PF (reprint author), Univ N Carolina, Dept Psychiat, Chapel Hill, NC 27599 USA. EM mjdaly@atgu.mgh.harvard.edu; pfsulliv@med.unc.edu RI Pirmohamed, Munir/H-6004-2011; OI Pirmohamed, Munir/0000-0002-7534-7266; Goldstein, Jacqueline/0000-0003-1902-6916; Huang, Hailiang/0000-0003-1461-5762 FU US National Institute of Mental Health via the American Recovery and Reinvestment Act [R01 MH080403]; National Science Foundation [ABI 10-567] FX We thank Drs Thomas Lehner (NIMH) and David Goldstein (Duke University) for their help on this project. We acknowledge the assistance of Dr Michael Karukin (Teva Pharmaceuticals) and Drs Rafael Muniz and Vinod Kumar (Novartis) for help in accessing US national clozapine registries. We thank Drs Stanton Gerson (Department of Hematology, Case Western Reserve), Armond Goldman (Department of Immunology, University of Texas Galveston), and Nancy Berliner (Department of Hematology, Harvard University) for providing input on mechanisms of agranulocytosis. M. P. is NIHR Senior Investigator. This project was funded by R01 MH080403 (P.F.S., E.J.C.G.V.D.O.) from the US National Institute of Mental Health via the American Recovery and Reinvestment Act of 2009. D.F. and A.T. acknowledge the support from National Science Foundation grant ABI 10-567. NR 41 TC 26 Z9 27 U1 1 U2 6 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD SEP PY 2014 VL 5 AR 4757 DI 10.1038/ncomms5757 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AQ6MO UT WOS:000342927300001 PM 25187353 ER PT J AU Kumar, V Cheng, SC Johnson, MD Smeekens, SP Wojtowicz, A Giamarellos-Bourboulis, E Karjalainen, J Franke, L Withoff, S Plantinga, TS de Veerdonk, FLV van der Meer, JWM Joosten, LAB Sokol, H Bauer, H Herrmann, BG Bochud, PY Marchetti, O Perfect, JR Xavier, RJ Kullberg, BJ Wijmenga, C Netea, MG AF Kumar, Vinod Cheng, Shih-Chin Johnson, Melissa D. Smeekens, Sanne P. Wojtowicz, Agnieszka Giamarellos-Bourboulis, Evangelos Karjalainen, Juha Franke, Lude Withoff, Sebo Plantinga, Theo S. de Veerdonk, Frank L. van van der Meer, Jos W. M. Joosten, Leo A. B. Sokol, Harry Bauer, Hermann Herrmann, Bernhard G. Bochud, Pierre-Yves Marchetti, Oscar Perfect, John R. Xavier, Ramnik J. Kullberg, Bart Jan Wijmenga, Cisca Netea, Mihai G. TI Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia SO NATURE COMMUNICATIONS LA English DT Article ID GENOME-WIDE ASSOCIATION; RHEUMATOID-ARTHRITIS; CELIAC-DISEASE; ALBICANS; EPIDEMIOLOGY; CANDIDIASIS; PATHWAY; RISK; LOCI; POLYMORPHISMS AB Candidaemia is the fourth most common cause of bloodstream infection, with a high mortality rate of up to 40%. Identification of host genetic factors that confer susceptibility to candidaemia may aid in designing adjunctive immunotherapeutic strategies. Here we hypothesize that variation in immune genes may predispose to candidaemia. We analyse 118,989 single-nucleotide polymorphisms (SNPs) across 186 loci known to be associated with immune-mediated diseases in the largest candidaemia cohort to date of 217 patients of European ancestry and a group of 11,920 controls. We validate the significant associations by comparison with a disease-matched control group. We observe significant association between candidaemia and SNPs in the CD58 (P = 1.97 x 10(-11); odds ratio (OR) = 4.68), LCE4A-C1orf68 (P = 1.98 x 10(-10); OR = 4.25) and TAGAP (P = 1.84 x 10(-8); OR = 2.96) loci. Individuals carrying two or more risk alleles have an increased risk for candidaemia of 19.4-fold compared with individuals carrying no risk allele. We identify three novel genetic risk factors for candidaemia, which we subsequently validate for their role in antifungal host defence. C1 [Kumar, Vinod; Karjalainen, Juha; Franke, Lude; Withoff, Sebo; Wijmenga, Cisca] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, NL-9700 RB Groningen, Netherlands. [Cheng, Shih-Chin; Smeekens, Sanne P.; Plantinga, Theo S.; de Veerdonk, Frank L. van; van der Meer, Jos W. M.; Joosten, Leo A. B.; Kullberg, Bart Jan; Netea, Mihai G.] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, NL-6500 HB Nijmegen, Netherlands. [Cheng, Shih-Chin; Smeekens, Sanne P.; Plantinga, Theo S.; de Veerdonk, Frank L. van; van der Meer, Jos W. M.; Joosten, Leo A. B.; Kullberg, Bart Jan; Netea, Mihai G.] Radboud Univ Nijmegen, Radboud Ctr Infect Dis, NL-6500 HB Nijmegen, Netherlands. [Johnson, Melissa D.; Perfect, John R.] Duke Univ, Med Ctr, Durham, NC 27710 USA. [Johnson, Melissa D.; Perfect, John R.] Campbell Univ, Sch Pharm, Dept Clin Res, Buies Creek, NC 27506 USA. [Wojtowicz, Agnieszka; Bochud, Pierre-Yves; Marchetti, Oscar] Ctr Hosp Univ Vaudoises, Serv Malad Infect, CH-1011 Lausanne, Switzerland. [Giamarellos-Bourboulis, Evangelos] Univ Athens, Sch Med, Dept Internal Med 4, Athens 12462, Greece. [Giamarellos-Bourboulis, Evangelos] Jena Univ Hosp, Ctr Sepsis Control & Care, D-07747 Jena, Germany. [Sokol, Harry; Xavier, Ramnik J.] MIT, Broad Inst, Cambridge, MA 02142 USA. [Sokol, Harry; Xavier, Ramnik J.] Harvard Univ, Cambridge, MA 02142 USA. [Sokol, Harry; Xavier, Ramnik J.] Harvard Univ, Sch Med, Ctr Computat & Integrat Biol, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Sokol, Harry; Xavier, Ramnik J.] Harvard Univ, Sch Med, Gastrointestinal Unit, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bauer, Hermann; Herrmann, Bernhard G.] Max Planck Inst Mol Genet, D-14195 Berlin, Germany. RP Kumar, V (reprint author), Univ Groningen, Univ Med Ctr Groningen, Dept Genet, NL-9700 RB Groningen, Netherlands. EM v.kumar@umcg.nl; mihai.netea@radboudumc.nl RI Plantinga, Theo/A-6895-2015; van de Veerdonk, Frank/C-7256-2008; van der Meer, Jos/C-8521-2013; Franke, Lude/P-7036-2016; Wijmenga, Cisca/D-2173-2009; Karjalainen, Juha/P-8624-2016; Cheng, Shih-Chin/H-4567-2015; Joosten, Leo/H-3138-2015; Kullberg, Bart Jan/C-8520-2013; Netea, Mihai/N-5155-2014; Smeekens, Sanne/G-8307-2011; OI van de Veerdonk, Frank/0000-0002-1121-4894; van der Meer, Jos/0000-0001-5120-3690; Franke, Lude/0000-0002-5159-8802; Cheng, Shih-Chin/0000-0003-1251-8774; Johnson, Melissa/0000-0002-6606-9460; Smeekens, Sanne/0000-0002-7835-914X; sokol, harry/0000-0002-2914-1822; Giamarellos-Bourboulis, Evangelos/0000-0003-4713-3911 FU Netherlands Organization for Scientific Research (NWO-VENI) [916.10.135]; European Research Council [ERC-310372, ERC-671274]; Dutch Digestive Diseases Foundation [MLDS WO11-30]; National Institutes of Health [K23AI51537] FX This work was supported by the Netherlands Organization for Scientific Research (NWO-VENI grant 916.10.135 to L.F.), the European Research Council (Consolidator Grant, ERC-310372 to M.G.N., and Advanced Grant, ERC-671274 to C.W.) and the Dutch Digestive Diseases Foundation (MLDS WO11-30 to C.W.). Research reported in this publication was also supported by the National Institutes of Health under award number K23AI51537 (to M.D.J.). We thank Mathieu Platteel, Astrid Maatman and Gosia Trynka for assisting in the RNA and DNA analysis, and array experiments (Immunochip and gene expression). We also thank Thierry Calandra, Jacques Bille, Frederic Tissot, Frederic Lamoth, Christina Orasch, Philippe Eggimann (Lausanne), Chloe Kaech, Martin Siegemund, Ursula Fluckiger (Basel), Stefan Zimmerli (Bern) and all other members of the Funginos group involved in the validation study. We thank Jackie Senior for editing the final version of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 41 TC 17 Z9 17 U1 1 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD SEP PY 2014 VL 5 AR 4675 DI 10.1038/ncomms5675 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AQ5HL UT WOS:000342838300001 PM 25197941 ER PT J AU Chao, LL Kriger, S Buckley, S Ng, P Mueller, SG AF Chao, Linda L. Kriger, Stephen Buckley, Shannon Ng, Peter Mueller, Susanne G. TI Effects of low-level sarin and cyclosarin exposure on hippocampal subfields in Gulf War Veterans SO NEUROTOXICOLOGY LA English DT Article DE Magnetic resonance imaging; Hippocampus; Sarin; Cyclosarin; Gulf War veterans ID POSTTRAUMATIC-STRESS-DISORDER; MILD COGNITIVE IMPAIRMENT; SURFACE-BASED ANALYSIS; HIGH-RESOLUTION MRI; US ARMY VETERANS; ALZHEIMERS-DISEASE; AUTOMATED SEGMENTATION; T2-WEIGHTED MRI; HUMAN BRAIN; APO E4 AB Background: More than 100,000 US troops were potentially exposed to chemical warfare agents sarin (GB) and cyclosarin (GF) when an ammunition dump at Khamisiyah, Iraq was destroyed during the 1991 Gulf War (GW). We previously reported reduced hippocampal volume in GW veterans with suspected GB/GF exposure relative to matched, unexposed GW veterans estimated from 1.5 T magnetic resonance images (MRI). Here we investigate, in a different cohort of GW veterans, whether low-level GB/GE exposure is associated with structural alterations in specific hippocampal subfields, estimated from 4 T MRI. Methods: The Automatic Segmentation of Hippocampal Subfields (ASHS) technique was used to quantify CA1, CA2, CA3 and dentate gyrus (DG), and subiculum (SUB) subfields volumes from high-resolution T2-weighted images acquired on a 4 T MR scanner in 56 GW veterans with suspected GB/GF exposure and 56 "matched" unexposed GW veterans (mean age 49 +/- 7 years). Results: GB/GE exposed veterans had smaller CA2 (p = 0.003) and CA3/DG (p = 0.01) subfield volumes compared to matched, unexposed GW veterans. There were no group difference in total hippocampal volume, quantified with FreeSurfer, and no dose-response relationship between estimated levels of GB/CF exposure and total hippocampal or subfield volume. Conclusions: These findings extend our previous report of structural alterations in the hippocampi of GW veterans with suspected GB/GF exposure to volume changes in the CA2, CA3, and DG hippocampal subfields in a different cohort of GW veterans with suspected GB/GF exposure. Published by Elsevier Inc. C1 [Chao, Linda L.; Kriger, Stephen; Buckley, Shannon; Ng, Peter; Mueller, Susanne G.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94121 USA. [Chao, Linda L.; Mueller, Susanne G.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Chao, Linda L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Chao, LL (reprint author), 4150 Clement St,114M, San Francisco, CA 94121 USA. EM linda.chao@ucsf.edu FU Department of Defense grant [DAMD17-01-1-0764]; Department of Defense Gulf War Illnesses Research Program; US Army Medical Research and Materiel Command; Department of Veterans Affairs grant VA GWI [B3776]; VA grant [I01BX007080] FX The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the Army, Department of Defense, or Department of Veterans Affairs. This study also supported by Department of Defense grant DAMD17-01-1-0764 entitled 'Magnetic Resonance and Spectroscopy of the Human Brain in Gulf War Illness', awarded to the Northern California Institute for Research and Education from the Department of Defense Gulf War Illnesses Research Program, US Army Medical Research and Materiel Command and a Department of Veterans Affairs grant VA GWI No. B3776 entitled 'Effects of Gulf War Illness on Brain Structure Function and Metabolism: MRI/MRS at 4 T', and VA grant No. I01BX007080 entitled 'Longitudinal Assessment of Gulf War Veterans with Suspected Sarin Exposure' awarded to Dr. Michael Weiner. This material is the result of work supported with resources and the use of facilities at the San Francisco Veterans Affairs Medical Center. The authors would like to thank Dr. Michael Weiner for his support and the Gulf War veterans who participated in these studies. NR 63 TC 7 Z9 7 U1 1 U2 15 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0161-813X EI 1872-9711 J9 NEUROTOXICOLOGY JI Neurotoxicology PD SEP PY 2014 VL 44 BP 263 EP 269 DI 10.1016/j.neuro.2014.07.003 PG 7 WC Neurosciences; Pharmacology & Pharmacy; Toxicology SC Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology GA AQ2XY UT WOS:000342654500028 PM 25058901 ER PT J AU Morone, NE Abebe, KZ Morrow, LA Weiner, DK AF Morone, Natalia E. Abebe, Kaleab Z. Morrow, Lisa A. Weiner, Debra K. TI Pain and Decreased Cognitive Function Negatively Impact Physical Functioning in Older Adults with Knee Osteoarthritis SO PAIN MEDICINE LA English DT Article DE Cognitive Function; Knee Pain; Physical Function; Chronic Pain ID LOW-BACK-PAIN; LOWER-EXTREMITY FUNCTION; GAIT SPEED; PERFORMANCE BATTERY; EXECUTIVE FUNCTION; CLINIC PATIENTS; DISABILITY; IMPAIRMENT; DYSFUNCTION; COMMUNITY AB ObjectiveWe hypothesized that among community-dwelling older adults without dementia with advanced chronic knee osteoarthritis (OA) pain: 1) higher levels of self-reported pain would be associated with decreased executive cognitive function and decreased physical function; and 2) decreased cognitive function would be associated with decreased physical function. MethodsSubstudy on 79 older adults who were participants in a Veterans Affairs clinical trial of periosteal stimulation therapy for advanced painful knee OA. Participants were 60 years, had radiographic evidence of Kellgren-Lawrence 3 or 4 knee OA on a standing anterior-posterior X-ray, had pain of at least moderate intensity and of at least 3 months' duration, and knee pain severity greater than pain severity in other parts of the body. Measures included computerized cognitive tests of executive function, pain, and physical function (gait speed and stair climbing). ResultsAs pain scores worsened, gait speed and stair climbing worsened (P=0.007 and P=0.035, respectively). Lower performance on the executive function tests was also significantly associated with decreased gait speed and stair climbing (P=0.002 and P=0.014, respectively). We did not find a significant relationship between pain and cognitive function. We explored the relationship between pain and physical function adjusted for executive functioning and found that pain was no longer associated with gait speed (P=0.06). ConclusionWorse pain scores and executive function scores were associated with worse physical function in older adults with painful knee OA. This suggests that slower gait speed in patients could be an indication to clinicians to monitor their patient's cognitive function. Executive function in particular affected the relationship between gait speed and pain, suggesting a possible mediating relationship. C1 [Morone, Natalia E.; Weiner, Debra K.] VA Pittsburgh Healthcare Syst, GRECC, Pittsburgh, PA 15240 USA. [Morone, Natalia E.; Abebe, Kaleab Z.] Univ Pittsburgh, Ctr Res Hlth Care, Div Gen Internal Med, Pittsburgh, PA USA. [Morone, Natalia E.; Abebe, Kaleab Z.; Weiner, Debra K.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA. [Morrow, Lisa A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Div Geriatr, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA. RP Morone, NE (reprint author), VA Pittsburgh Healthcare Syst, GRECC, Univ Dr,Bldg 30,Mail Code 00GR U, Pittsburgh, PA 15240 USA. EM Natalia.Morone@va.gov OI Abebe, Kaleab/0000-0002-3644-8419 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, a Rehabilitation Research and Development Merit Award [A6614-R]; Geriatric Research Education and Clinical Center of the Veterans Affairs Pittsburgh Healthcare System FX This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, a Rehabilitation Research and Development Merit Award (A6614-R), and a pilot grant from the Geriatric Research Education and Clinical Center of the Veterans Affairs Pittsburgh Healthcare System. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. NR 33 TC 1 Z9 1 U1 7 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD SEP PY 2014 VL 15 IS 9 BP 1481 EP 1487 DI 10.1111/pme.12483 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA AQ2QA UT WOS:000342631300007 PM 25040845 ER PT J AU Barlow, DH Ellard, KK Sauer-Zavala, S Bullis, JR Carl, JR AF Barlow, David H. Ellard, Kristen K. Sauer-Zavala, Shannon Bullis, Jacqueline R. Carl, Jenna R. TI The Origins of Neuroticism SO PERSPECTIVES ON PSYCHOLOGICAL SCIENCE LA English DT Review DE neuroticism; temperament ID ADULT HIPPOCAMPAL NEUROGENESIS; PITUITARY-ADRENOCORTICAL AXIS; COMMON PSYCHIATRIC-DISORDERS; IMMEDIATE-EARLY GENES; HIGH TRAIT ANXIETY; PERCEIVED CONTROL; CHILD MALTREATMENT; PERSONALITY-TRAITS; AVOIDANCE-BEHAVIOR; RHESUS-MONKEYS AB In this article, we provide a fresh perspective on the developmental origins of neuroticisma dimension of temperament marked by elevated stress reactivity resulting in the frequent experience of negative emotions. This negative affectivity is accompanied by a pervasive perception that the world is a dangerous and threatening place, along with beliefs about one's inability to manage or cope with challenging events. Historically, neuroticism has been viewed as a stable, genetically based trait. However, recent understanding of ongoing gene-environment interactions that occur throughout the life span suggests there may be a more complex and dynamic etiology. Thus, the purpose of this article is to offer a theory for understanding the development of neuroticism that integrates genetic, neurobiological, and environmental contributions to this trait. Given the strong correlation between neuroticism and the development of negative health outcomesmost notably, the full range of anxiety and mood disordersan enhanced understanding of how neuroticism originates has implications for the treatment and prevention of a broad range of pathologies and, perhaps, even for the prevention of neuroticism itself. C1 [Barlow, David H.; Sauer-Zavala, Shannon; Bullis, Jacqueline R.; Carl, Jenna R.] Boston Univ, Ctr Anxiety & Related Disorders, Boston, MA 02215 USA. [Barlow, David H.; Sauer-Zavala, Shannon; Bullis, Jacqueline R.; Carl, Jenna R.] Boston Univ, Dept Psychol, Boston, MA 02215 USA. [Ellard, Kristen K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cambridge, MA 02138 USA. RP Barlow, DH (reprint author), Boston Univ, Ctr Anxiety & Related Disorders, 648 Beacon St,6th Floor, Boston, MA 02215 USA. EM dhbarlow@bu.edu NR 158 TC 28 Z9 28 U1 15 U2 47 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1745-6916 EI 1745-6924 J9 PERSPECT PSYCHOL SCI JI Perspect. Psychol. Sci. PD SEP PY 2014 VL 9 IS 5 BP 481 EP 496 DI 10.1177/1745691614544528 PG 16 WC Psychology, Multidisciplinary SC Psychology GA AQ2RO UT WOS:000342636000003 PM 26186755 ER PT J AU Gard, T AF Gard, Tim TI Different neural correlates of facing pain with mindfulness: Contributions of strategy and skill Comment on "Facing the experience of pain: A neuropsychological perspective" by Fabbro and Crescentini SO PHYSICS OF LIFE REVIEWS LA English DT Editorial Material DE Pain modulation; Mindfulness; Neural mechanisms; Experience; Skill; Strategy ID MEDITATION-RELATED PAIN; BRAIN MECHANISMS; PERCEPTION; ACTIVATION; ANALGESIA; HEALTH C1 [Gard, Tim] Maastricht Univ, Fac Psychol & Neurosci, NL-6229 EV Maastricht, Netherlands. [Gard, Tim] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Charlestown, MA USA. [Gard, Tim] Univ Giessen, Bender Inst Neuroimaging, D-35390 Giessen, Germany. RP Gard, T (reprint author), Maastricht Univ, Fac Psychol & Neurosci, Oxfordlaan 55, NL-6229 EV Maastricht, Netherlands. EM tgard@nmr.mgh.harvard.edu NR 25 TC 1 Z9 1 U1 1 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1571-0645 EI 1873-1457 J9 PHYS LIFE REV JI Phys. Life Rev. PD SEP PY 2014 VL 11 IS 3 BP 564 EP 566 DI 10.1016/j.plrev.2014.07.003 PG 3 WC Biology; Biophysics SC Life Sciences & Biomedicine - Other Topics; Biophysics GA AQ1KW UT WOS:000342541300037 PM 25022214 ER PT J AU Gomez, DI Twahirwa, M Schlesinger, LS Restrepo, BI AF Gomez, Diana I. Twahirwa, Marcel Schlesinger, Larry S. Restrepo, Blanca I. TI Reduced Mycobacterium tuberculosis association with monocytes from diabetes patients that have poor glucose control (vol 93, pg 192, 2013) SO TUBERCULOSIS LA English DT Correction C1 [Gomez, Diana I.; Restrepo, Blanca I.] UTHlth Houston, Div Epidemiol, Sch Publ Hlth Brownsville, Brownsville, TX USA. [Twahirwa, Marcel] Doctors Hosp Renaissance, Joslin Diabet Ctr, Edinburg, TX USA. [Schlesinger, Larry S.] Ohio State Univ, Ctr Microbial Interface Biol, Columbus, OH 43210 USA. [Schlesinger, Larry S.] Ohio State Univ, Dept Microbial Infect & Immun, Columbus, OH 43210 USA. RP Restrepo, BI (reprint author), Univ Texas Brownsville, UTHlth Houston Sch Publ Hlth, 80 Ft Brown,SPH Bldg, Brownsville, TX 78520 USA. EM Diana.i.gomez@gmail.com; m.twahirwa@dhr-rgv.com; larry.schlesinger@osumc.edu; blanca.i.restrepo@uth.tmc.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1472-9792 J9 TUBERCULOSIS JI Tuberculosis PD SEP PY 2014 VL 94 IS 5 BP 533 EP 533 DI 10.1016/j.tube.2014.08.006 PG 1 WC Immunology; Microbiology; Respiratory System SC Immunology; Microbiology; Respiratory System GA AQ2NP UT WOS:000342623800014 ER PT J AU Rasmussen, DD Alexander, L Malone, J Federoff, D Froehlich, JC AF Rasmussen, Dennis D. Alexander, Laura Malone, Julia Federoff, David Froehlich, Janice C. TI The alpha(2)-adrenergic receptor agonist, clonidine, reduces alcohol drinking in alcohol-preferring (P) rats SO ALCOHOL LA English DT Article DE Clonidine; Alcohol; Ethanol; Norepinephrine; Noradrenergic; P rat ID STRESS-INDUCED REINSTATEMENT; POSITIVE REINFORCING PROPERTIES; DOPAMINE-BETA-HYDROXYLASE; CHRONIC DAILY ETHANOL; ANXIETY DISORDERS; ALPHA-1-ADRENERGIC ANTAGONIST; NORADRENERGIC MEDIATION; LABORATORY RATS; PRAZOSIN; SEEKING AB Evidence suggests that noradrenergic signaling may play a role in mediating alcohol-drinking behavior in both rodents and humans. We have investigated this possibility by administering clonidine to alcoholdrinking rats selectively bred for alcohol preference (P line). Clonidine is an alpha(2)-adrenergic receptor agonist which, at low doses, inhibits notadrenergic signaling by decreasing norepinephrine release from presynaptic noradrenergic neurons.. Adult male P rats were given 24 h access to food and water and scheduled access to a 15% (v/v) alcohol solution for 2 h daily. Rats received intra-peritoneal (IP).injections with clonidine (0, 10, 20, 40, or 80 mu g/kg body weight [BM, 10-11 rats/treatment group) once/day at 30 min prior to onset of the daily 2 h alcohol access period for 2 consecutive days. Clonidine, in doses of 40 or 80 mu g/kg BW, significantly reduced alcohol intake on both days of treatment (p < 0.001). Two weeks later, rats were treated with clonidine for 5 consecutive days and clonidine, in doses of 40 or 80 mu g/kg BW, reduced alcohol intake on all 5 treatment days (p < 0.001). Clonidine did not alter water consumption during the daily 2 h free-choice between alcohol and Water. In a separate group of male P rats, clonidine (40 gg/kg BW) suppressed intake of a saccharin solution (0.04 g/L). These results are consistent with and complement our previous findings that the aradrenergic receptor antagonist, prazosin, decreases voluntary alcohol drinking in alcohol-preferring rats, but suggests that effects of clonidine may not be specific for alcohol. The results suggest that although activation of the noradrenergic system plays an important role in mediating voluntary alcohol drinking, care is needed in selecting which drugs to use to suppress central noradrenergic signaling in order to maximize the selectivity of the drugs for treating alcohol-use disorders. Published by Elsevier Inc. C1 [Rasmussen, Dennis D.] VA Puget Sound Hlth Care Syst, VISN Mental Illness Res Educ & Clin Ctr 20, Seattle, WA USA. [Rasmussen, Dennis D.] Univ Washington, Seattle, WA 98195 USA. [Alexander, Laura; Malone, Julia; Federoff, David; Froehlich, Janice C.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. RP Rasmussen, DD (reprint author), VA Med Ctr, 116 MIRECC,1660 S Columbian Way, Seattle, WA 98108 USA. EM drasmuss@u.washington.edu FU VA Puget Sound Health Care System, Seattle, Washington; National Institutes of Health [AA017839, AA10567, AA13881, AA10709, AA007611, AA018604] FX This material is based upon work supported in part by resources from the VA Puget Sound Health Care System, Seattle, Washington, and by National Institutes of Health Grants AA017839, AA10567, and AA13881 (DDR); AA10709 and AA007611 (JCF); and AA018604 (JCF and DDR). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Alcohol Abuse and Alcoholism or the National Institutes of Health. NR 48 TC 3 Z9 3 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-8329 EI 1873-6823 J9 ALCOHOL JI Alcohol PD SEP PY 2014 VL 48 IS 6 BP 543 EP 549 DI 10.1016/j.alcohol.2014.07.002 PG 7 WC Substance Abuse; Pharmacology & Pharmacy; Toxicology SC Substance Abuse; Pharmacology & Pharmacy; Toxicology GA AP8LT UT WOS:000342331200004 PM 25085719 ER PT J AU Roh, SW Hoeppner, SS Stoecker, LE Evins, AE AF Roh, S. W. Hoeppner, S. S. Stoecker, L. E. Evins, A. E. TI NICOTINE AND COGNITION IN SCHIZOPHRENIA SO ALCOHOL AND ALCOHOLISM LA English DT Meeting Abstract C1 [Roh, S. W.] Seoul Natl Hosp, Dept Mental Hlth Res, Seoul, South Korea. [Roh, S. W.; Hoeppner, S. S.; Stoecker, L. E.; Evins, A. E.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Addict Med, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0735-0414 EI 1464-3502 J9 ALCOHOL ALCOHOLISM JI Alcohol Alcohol. PD SEP PY 2014 VL 49 SU 1 MA SY22-5 PG 1 WC Substance Abuse SC Substance Abuse GA AP8TO UT WOS:000342352100256 ER PT J AU Bernhardson, AS Bailey, JR Solomon, DJ Stanley, M Provencher, MT AF Bernhardson, Andrew S. Bailey, James R. Solomon, Daniel J. Stanley, Mark Provencher, Matthew T. TI Glenoid Bone Loss in the Setting of an Anterior Labroligamentous Periosteal Sleeve Avulsion Tear SO AMERICAN JOURNAL OF SPORTS MEDICINE LA English DT Article DE glenoid; bone loss; anterior instability; anterior labroligamentous periosteal sleeve avulsion (ALPSA) ID SHOULDER INSTABILITY; ARTHROSCOPIC FINDINGS; DISLOCATION; LESIONS; REPAIR; LABRUM; JOINT AB Background: Glenoid bone loss is a factor that has been inversely associated with the success of shoulder instability repair. Recently, patients with an anterior labroligamentous periosteal sleeve avulsion (ALPSA) lesion have also been identified as having a higher failure rate after surgical repair. Purpose: To determine differences in the amount of glenoid bone loss and to compare demographic factors of instability in patients with and without ALPSA tears. Study Design: Case-control study; Level of evidence, 3. Methods: Over a 3-year period, all patients (N = 83) who were treated for anterior shoulder instability at a single institution were reviewed retrospectively. A total of 39 (47%) were identified as having an ALPSA lesion and 44 (53%) as having no ALPSA tear. Glenoid bone loss was determined in 2 ways: (1) radiographically by 3-dimensional computed tomography (3D CT) (humeral head digitally subtracted by 3 blinded observers) and (2) with arthroscopic techniques at the time of surgery. Demographic data such as the time from the initial instability event to advanced imaging and surgery were noted. These data were then analyzed with the Student t test to determine any significant differences between the 2 groups. Results: The patients with an ALPSA lesion had more preoperative instability events than those without (8.2 vs 3.6, respectively; P = .04). The mean glenoid bone loss measured by 3D CT was 12.7% (range, 0%-22.3%) for those with ALPSA tears versus 6.25% (range, 0%-23.1%) for those without (P = .002). The mean duration of total instability for those with ALPSA tears was 42.9 months versus 46.3 months for those without (P = .95). Lastly, the mean bone loss based on arthroscopic measures was 11.4% for patients with ALPSA tears and 4.3% for those without ALPSA tears (P = .017). From the existing magnetic resonance imaging/arthrography scans reviewed, 82% of patients could be correctly identified as having an ALPSA lesion. Conclusion: Patients with anterior shoulder instability who have an ALPSA lesion have nearly twice the amount of glenoid bone loss as those with a standard Bankart tear (no ALPSA lesion). Patients with ALPSA lesions had statistically more instability events, and this may be an additional factor in either developing an ALPSA lesion or glenoid bone loss or both. C1 [Bernhardson, Andrew S.; Bailey, James R.; Solomon, Daniel J.; Stanley, Mark; Provencher, Matthew T.] Naval Med Ctr San Diego, San Diego, CA USA. RP Provencher, MT (reprint author), Massachusetts Gen Hosp, Sports Med Serv, 175 Cambridge St,4th Floor, Boston, MA 02114 USA. EM MattProvencher@gmail.com NR 26 TC 3 Z9 3 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0363-5465 EI 1552-3365 J9 AM J SPORT MED JI Am. J. Sports Med. PD SEP PY 2014 VL 42 IS 9 BP 2136 EP 2140 DI 10.1177/0363546514539912 PG 5 WC Orthopedics; Sport Sciences SC Orthopedics; Sport Sciences GA AP9GQ UT WOS:000342387400013 PM 25028704 ER PT J AU Bellmunt, J Orsola, A Leow, JJ Wiegel, T De Santis, M Horwich, A AF Bellmunt, J. Orsola, A. Leow, J. J. Wiegel, T. De Santis, M. Horwich, A. CA ESMO Guidelines Working Grp TI Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up SO ANNALS OF ONCOLOGY LA English DT Article ID TRANSITIONAL-CELL CARCINOMA; EAU INTERNATIONAL CONSULTATION; INVASIVE UROTHELIAL CARCINOMA; SELECTIVE ORGAN PRESERVATION; DOXORUBICIN PLUS GEMCITABINE; COLONY-STIMULATING FACTOR; LONG-TERM-SURVIVAL; EORTC RISK TABLES; PHASE-III TRIAL; ADJUVANT CHEMOTHERAPY C1 [Bellmunt, J.; Leow, J. J.] Univ Hosp Mar IMIM, Dept Med Oncol, Barcelona, Spain. [Bellmunt, J.; Leow, J. J.] Brigham & Womens Hosp, Dana Farber Canc Inst, Bladder Canc Ctr, Boston, MA 02115 USA. [Orsola, A.] Vall Hebron Univ Hosp, Dept Urol, Barcelona, Spain. [Wiegel, T.] Univ Hosp Ulm, Dept Radio Oncol, Ulm, Germany. [De Santis, M.] Kaiser Franz Josef Spital, Ludwig Boltzmann Inst Appl Canc Res, Vienna, Austria. [Horwich, A.] Inst Canc Res, Sutton, Surrey, England. [Horwich, A.] Royal Marsden Hosp, Sutton, Surrey, England. RP Bellmunt, J (reprint author), ESMO Guidelines Working Grp, ESMO Head Off, Via L Taddei 4, CH-6962 Viganello Lugano, Switzerland. FU Pierre Fabre; Pierre Fabre Oncology; Amgen; Astellas; Bayer; Celgene; Dendreon; Ferring; GlaxoSmithKline; Janssen Cilag; Novartis; Pfizer; Roche; Sanofi; Shionogi; Takeda; Teva/Oncogenex FX JB has reported Advisory board for and lecture fees from Pierre Fabre. MdS has reported study grants from Pierre Fabre Oncology; she also reported Honoraria and Consultancy fees from Amgen, Astellas, Bayer, Celgene, Dendreon, Ferring, GlaxoSmithKline, Janssen Cilag, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, Shionogi, Takeda and Teva/Oncogenex. AO, JL, TW and AH have reported no potential conflicts of interest. NR 48 TC 23 Z9 23 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD SEP PY 2014 VL 25 SU 3 BP 40 EP 48 DI 10.1093/annonc/mdu223 PG 9 WC Oncology SC Oncology GA AP8UM UT WOS:000342354800005 ER PT J AU Agarwal, N Di Lorenzo, G Sonpavde, G Bellmunt, J AF Agarwal, N. Di Lorenzo, G. Sonpavde, G. Bellmunt, J. TI New agents for prostate cancer SO ANNALS OF ONCOLOGY LA English DT Article DE prostate cancer; novel agents ID PHASE-I TRIAL; ANDROGEN RECEPTOR MUTATIONS; CIRCULATING TUMOR-CELLS; MEMBRANE ANTIGEN; MONOCLONAL-ANTIBODY; INCREASED SURVIVAL; END-POINTS; OPEN-LABEL; IMMUNOTHERAPY; DOCETAXEL AB The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has been revolutionized by the arrival of multiple novel agents in the past 2 years. Immunotherapy in the form of sipuleucel-T, androgen axis inhibitors, including abiraterone acetate and enzalutamide, a chemotherapeutic agent, cabazitaxel, and a radiopharmaceutical, radium-223, have all yielded incremental extensions of survival and have been recently approved. A number of other agents appear promising in early studies, suggesting that the armamentarium against castrate-resistant prostate cancer is likely to continue to expand. Emerging androgen pathway inhibitors include androgen synthesis inhibitors (TAK700), androgen receptor inhibitors (ARN-509, ODM-201), AR DNA binding domain inhibitors (EPI-001), selective AR downregulators or SARDs (AZD-3514), and agents that inhibit both androgen synthesis and receptor binding (TOK-001/galeterone). Promising immunotherapeutic agents include poxvirus vaccines and CTLA-4 inhibitor (ipilimumab). Biologic agents targeting the molecular drivers of disease are also being investigated as single agents, including cabozantinib (Met and VEGFR2 inhibitor) and tasquinimod (angiogenesis and immune modulatory agent). Despite the disappointing results seen from studies evaluating docetaxel in combination with other agents, including GVAX, anti-angiogentic agents (bevacizumab, aflibercept, lenalinomide), a SRC kinase inhibitor (dasatinib), endothelin receptor antagonists (atrasentan, zibotentan), and high-dose calcitriol (DN-101), the results from the trial evaluating docetaxel in combination with the clusterin antagonist, custirsen, are eagerly awaited. New therapeutic hurdles consist of discovering new targets, understanding resistance mechanisms, the optimal sequencing and combinations of available agents, as well as biomarkers predictive for benefit. Novel agents targeting bone metastases are being developed following the success of zoledronic acid and denosumab. Finally, all of these modalities do not appear curative, suggesting that clinical trial enrollment and a better understanding of biology remain of paramount importance. C1 [Agarwal, N.] Univ Utah Huntsman Canc Inst, Div Med Oncol, Salt Lake City, UT USA. [Di Lorenzo, G.] Univ Naples Federico II, Genitourinary Canc Sect, Dept Endocrinol & Med Oncol, Naples, Italy. [Sonpavde, G.] Univ Alabama Birmingham UAB Comprehens Canc Ctr, Div Hematol Oncol, Dept Med, Birmingham, AL USA. [Bellmunt, J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Bellmunt, J.] Harvard Univ, Sch Med, Boston, MA USA. [Bellmunt, J.] Univ Hosp del Mar IMIM, Barcelona, Spain. RP Bellmunt, J (reprint author), Univ Hosp Del Mar, Dept Med Oncol, Paseig Maritim 25-29, Barcelona, Spain. EM joaquim.bellmunt@gmail.com FU Amgen; Bristol-Myers Squibb; Dendreon; GlaxoSmithKline; ImClone Systems; Medivation; Merrimack; Millennium; Novartis; Pfizer; Spectrum Pharmaceutical; BMS; Celgene; Bellicum Pharmaceuticals; Sanofi-Aventis FX NA: research support from Amgen, Bristol-Myers Squibb; Dendreon, GlaxoSmithKline, ImClone Systems, Medivation, Merrimack, Millennium, Novartis, Pfizer, Spectrum Pharmaceutical. Honorarium from Dendreon. JB: research support before April 2013 from Pfizer; Advisory boards of Astellas, Novartis, Dendreon, Pfizer; Speaker for Janssen, Sanofi-Aventis, Amgen, Novartis, GSK. GDL: advisory Boards of Novartis, Pfizer and Sanofi-Aventis. Speaker for GSK, Janssen. GS: research support from BMS, Celgene, Bellicum Pharmaceuticals, Sanofi-Aventis; Advisory boards of Astellas, Novartis, Dendreon, Pfizer; Speaker for Janssen, Sanofi-Aventis, Amgen. NR 76 TC 21 Z9 22 U1 1 U2 23 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD SEP PY 2014 VL 25 IS 9 BP 1700 EP 1709 DI 10.1093/annonc/mdu038 PG 11 WC Oncology SC Oncology GA AP8UB UT WOS:000342353600005 PM 24658665 ER PT J AU Basu, A Jenkins, AJ Stoner, JA Thorpe, SR Klein, RL Lopes-Virella, MF Garvey, WT Lyons, TJ AF Basu, Arpita Jenkins, Alicia J. Stoner, Julie A. Thorpe, Suzanne R. Klein, Richard L. Lopes-Virella, Maria F. Garvey, W. Timothy Lyons, Timothy J. CA DCCT EDIC Res Grp TI Plasma total homocysteine and carotid intima-media thickness in type 1 diabetes: A prospective study SO ATHEROSCLEROSIS LA English DT Article DE homocysteine; intima-media thickness; type 1 diabetes ID REDUCTASE GENE POLYMORPHISM; CHRONIC KIDNEY-DISEASE; MACROVASCULAR COMPLICATIONS; RISK-FACTORS; CARDIOVASCULAR EVENTS; ENDOTHELIAL FUNCTION; DCCT/EDIC COHORT; FOLIC-ACID; FOLLOW-UP; MELLITUS AB Objective: Plasma total homocysteine (tHcy) has been positively associated with carotid intima-media thickness (IMT) in non-diabetic populations and in a few cross-sectional studies of diabetic patients. We investigated cross-sectional and prospective associations of a single measure of tHcy with common and internal carotid IMT over a 6-year period in type 1 diabetes. Research design and methods: tHcy levels were measured once, in plasma obtained in 1997-1999 from patients (n = 599) in the Epidemiology of Diabetes Interventions and Complications (EDIC) study, the observational follow-up of the Diabetes Control and Complications Trial (DCCT). Common and internal carotid IMT were determined twice, in EDIC "Year 6" (1998-2000) and "Year 12" (2004-2006), using B-mode ultra-sonography. Results: After adjustment, plasma tHcy [median (interquartile range): 6.2 (5.1, 7.5) mu mol/L] was significantly correlated with age, diastolic blood pressure, renal dysfunction, and smoking (all p < 0.05). In an unadjusted model only, increasing quartiles of tHcy correlated with common and internal carotid IMT, again at both EDIC time-points (p < 0.01). However, multivariate logistic regression revealed no significant associations between increasing quartiles of tHcy and the 6-year change in common and internal carotid IMT (highest vs. lowest quintile) when adjusted for conventional risk factors. Conclusions: In a type 1 diabetes cohort from the EDIC study, plasma tHcy measured in samples drawn in 1997-1999 was associated with measures of common and internal carotid IMT measured both one and seven years later, but not with IMT progression between the two time-points. The data do not support routine measurement of tHcy in people with Type 1 diabetes. (C) 2014 Elsevier Ireland Ltd. All rights reserved. C1 [Basu, Arpita] Oklahoma State Univ, Dept Nutrit Sci, Stillwater, OK 74078 USA. [Jenkins, Alicia J.] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia. [Jenkins, Alicia J.] Queens Univ Belfast, Ctr Med Expt, Belfast BT7 1NN, Antrim, North Ireland. [Stoner, Julie A.] Univ Oklahoma, Hlth Sci Ctr, Dept Biostat & Epidemiol, Oklahoma City, OK USA. [Thorpe, Suzanne R.] Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA. [Klein, Richard L.; Lopes-Virella, Maria F.] Med Univ S Carolina, Div Endocrinol, Charleston, SC 29425 USA. [Klein, Richard L.; Lopes-Virella, Maria F.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL USA. [Lyons, Timothy J.] Univ Oklahoma, Hlth Sci Ctr, Endocrinol Sect, Oklahoma City, OK USA. [DCCT EDIC Res Grp] Box NDIC EDIC, Bethesda, MD 20892 USA. RP Lyons, TJ (reprint author), Queens Univ Belfast, Ctr Med Expt, Sch Med Dent & Biomed Sci, ICS Block A,Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland. EM t.lyons@qub.ac.uk RI Jenkins, Alicia/N-2482-2015 FU American Diabetes Association [7-12-CT-46]; Juvenile Diabetes Foundation International [41998272, 996001]; National Institutes of Health [PO1 HL55782]; Diabetes Research and Wellness Foundation (Fairfax, VA); Division of Diabetes Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Disease [U01 DK094176, U01 DK094157, 1982-93]; National Eye Institute; National Institute of Neurologic Disorders and Stroke; Genetic Clinical Research Centers Program; Clinical Translational Science Center Program, Bethesda, Maryland, USA; National Institutes of Health NIH [PO1 HL55782, RO1DK080043]; Juvenile Diabetes Research Foundation [996001, 4-1998-272, 197028]; Diabetes Research and Wellness Foundation, Inc. (Fairfax, Virginia); Presbyterian Health Foundation of Oklahoma City FX Funding was provided by the American Diabetes Association, Juvenile Diabetes Foundation International (41998272, 996001), National Institutes of Health (PO1 HL55782), and the Diabetes Research and Wellness Foundation (Fairfax, VA).; DCCT/EDIC has been supported by U01 Cooperative Agreement grants (1982-93, 2011-2016), and contracts (1982-2011) with the Division of Diabetes Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Disease (U01 DK094176 and U01 DK094157), and through support by the National Eye Institute, the National Institute of Neurologic Disorders and Stroke, the Genetic Clinical Research Centers Program (1993-2007), and Clinical Translational Science Center Program (2006-present), Bethesda, Maryland, USA. The authors thank DCCT/EDIC patients, study nurses and co-ordinators. Technical assistance of Karina Moller, Kevin Joyce, Yanis Bellil, Lyle Walton, Leslie Potter, Andrea Semler, Jenny Smith, Leslie Nichols, Hillarie Stecker and Azar Dashti is acknowledged.; Grants were provided by: the American Diabetes Association (7-12-CT-46), the National Institutes of Health NIH (PO1 HL55782 to WTG, and RO1DK080043 to TJL), Juvenile Diabetes Research Foundation (# 4-1998-272, 996001, and 197028), the Diabetes Research and Wellness Foundation, Inc. (Fairfax, Virginia), and the Presbyterian Health Foundation of Oklahoma City. No other potential conflicts of interest relevant to this article were reported. The authors would like to thank John W. Baynes, PhD, for helpful discussions. NR 43 TC 5 Z9 5 U1 0 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 EI 1879-1484 J9 ATHEROSCLEROSIS JI Atherosclerosis PD SEP PY 2014 VL 236 IS 1 BP 188 EP 195 DI 10.1016/j.atherosclerosis.2014.07.001 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AP9PP UT WOS:000342412000027 PM 25063949 ER PT J AU Adams, TG Badran, BW George, MS AF Adams, Thomas G., Jr. Badran, Bashar W. George, Mark S. TI Integration of Cortical Brain Stimulation and Exposure and Response Prevention for Obsessive-compulsive Disorder (OCD) SO BRAIN STIMULATION LA English DT Letter ID TRANSCRANIAL MAGNETIC STIMULATION; CONTROLLED TRIAL; INHIBITION C1 [Adams, Thomas G., Jr.; Badran, Bashar W.; George, Mark S.] Med Univ S Carolina, Charleston, SC USA. [Adams, Thomas G., Jr.; George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Adams, Thomas G., Jr.] Univ Arkansas, Fayetteville, AR 72701 USA. RP Adams, TG (reprint author), 67 President St, Charleston, SC 29425 USA. EM tomadams@uark.edu NR 9 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD SEP-OCT PY 2014 VL 7 IS 5 BP 764 EP 765 DI 10.1016/j.brs.2014.06.010 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AP8XL UT WOS:000342362600023 PM 25048526 ER PT J AU Kefford, R Hamid, O Robert, C Ribas, A Wolchock, JD Hodi, FS Joshua, AM Hwu, WJ Gangadhar, TC Patnaik, A Hersey, P Weber, J Joseph, R Gergich, K Li, X Chun, P Ebbinghaus, S Kang, SP Daud, A AF Kefford, R. Hamid, O. Robert, C. Ribas, A. Wolchock, J. D. Hodi, F. S. Joshua, A. M. Hwu, W. -J. Gangadhar, T. C. Patnaik, A. Hersey, P. Weber, J. Joseph, R. Gergich, K. Li, X. Chun, P. Ebbinghaus, S. Kang, S. P. Daud, A. TI Randomized comparison of two doses of the anti-programmed death-1 monoclonal antibody MK-3475 for ipilimumab (IPI)-refractory and IPI-naive melanoma SO BRITISH JOURNAL OF DERMATOLOGY LA English DT Meeting Abstract CT 15th World Congress on Cancers of the Skin CY SEP 03-06, 2014 CL Edinburgh, SCOTLAND C1 [Kefford, R.] Westmead Hosp, Sydney, NSW, Australia. [Kefford, R.] Melanoma Inst, Sydney, NSW, Australia. [Hamid, O.] Angeles Clin & Res Inst, Los Angeles, CA USA. [Robert, C.] Inst Gustave Roussy, Paris, France. [Ribas, A.] David Geffen UCLA Sch Med, Los Angeles, CA USA. [Wolchock, J. D.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Hodi, F. S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Joshua, A. M.] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada. [Hwu, W. -J.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Gangadhar, T. C.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Patnaik, A.] START, San Antonio, TX USA. [Hersey, P.] Univ Sydney, Sydney, NSW 2006, Australia. [Weber, J.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [Joseph, R.] Mayo Clin, Ctr Canc, Jacksonville, FL 32224 USA. [Gergich, K.; Li, X.; Chun, P.; Ebbinghaus, S.; Kang, S. P.] Merck Sharp & Dohme Corp, Whitehouse Stn, NJ USA. [Daud, A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-0963 EI 1365-2133 J9 BRIT J DERMATOL JI Br. J. Dermatol. PD SEP PY 2014 VL 171 SU 4 SI SI MA 097 BP 44 EP 44 PG 1 WC Dermatology SC Dermatology GA AQ3HA UT WOS:000342680900098 ER PT J AU Dummer, R Flaherty, K Kefford, R Ascierto, PA Moutouh-de Parseval, M Wasserman, E Schadendorf, D AF Dummer, R. Flaherty, K. Kefford, R. Ascierto, P. A. Moutouh-de Parseval, L. Wasserman, E. Schadendorf, D. TI The development of the BRAF inhibitor encorafenib (LGX818) and mitogen-activated protein kinase kinase inhibitor binimetinib (MEK162) in patients with metastatic melanoma SO BRITISH JOURNAL OF DERMATOLOGY LA English DT Meeting Abstract CT 15th World Congress on Cancers of the Skin CY SEP 03-06, 2014 CL Edinburgh, SCOTLAND C1 [Dummer, R.] Univ Zurich Hosp, CH-8091 Zurich, Switzerland. [Flaherty, K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kefford, R.] Univ Sydney, Westmead Inst Canc Res, Melanoma Inst Australia, Sydney, NSW 2006, Australia. [Kefford, R.] Univ Sydney, Westmead Hosp, Sydney, NSW 2006, Australia. [Ascierto, P. A.] Natl Canc Inst, Naples, Italy. [Moutouh-de Parseval, L.] Novartis Pharma AG, Basel, Switzerland. [Wasserman, E.] Novartis Pharmaceut, E Hanover, NJ USA. [Schadendorf, D.] Univ Hosp Essen, Essen, Germany. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-0963 EI 1365-2133 J9 BRIT J DERMATOL JI Br. J. Dermatol. PD SEP PY 2014 VL 171 SU 4 SI SI MA 150 BP 67 EP 68 PG 2 WC Dermatology SC Dermatology GA AQ3HA UT WOS:000342680900150 ER PT J AU Pusztaszeri, MP Krane, JF Cibas, ES Daniels, G Faquin, WC AF Pusztaszeri, Marc P. Krane, Jeffrey F. Cibas, Edmund S. Daniels, Gilbert Faquin, William C. TI FNAB of Benign Thyroid Nodules With Papillary Hyperplasia SO CANCER CYTOPATHOLOGY LA English DT Article DE fine-needle aspiration; thyroid; cytopathology; cytology; papillary thyroid carcinoma; papillary hyperplasia; papillary lesions ID FINE-NEEDLE-ASPIRATION; NUCLEAR GROOVES; MARGINAL VACUOLES; PSAMMOMA BODIES; BETHESDA SYSTEM; CARCINOMA; CYTOLOGY; DIAGNOSIS; PITFALL; LESIONS AB BACKGROUND: Benign thyroid nodules with papillary hyperplasia (BTN-PH) are sometimes misinterpreted cytologically as papillary thyroid carcinoma (PTC). We evaluated a fine-needle aspiration biopsy (FNAB) series of BTN-PH to identify the causes of diagnostic error and to better define its cytologic criteria. METHODS: A total of 48 FNAB cases of histologically confirmed BTN-PHs from 44 patients were identified from our archives. The available cytological and histological slides were reviewed and scored for 10 cytomorphological features. Fifteen FNAB cases of classical PTC were also reviewed for comparison. RESULTS: The FNAB diagnoses for the 48 BTN-PHs were: benign, 18; suspicious for malignancy (S-PTC), 12); atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS), 10; follicular neoplasm, 5; malignant (PTC), 2; and nondiagnostic, 1. The extent of PH in the corresponding histology was highest in FNAB cases diagnosed as S-PTC/PTC versus all other categories (54% vs 27%; P=.0084). Papillary cytoarchitectural features were present in 53% of FNAB cases overall and in 89% of cases diagnosed as S-PTC/PTC (P=.0093). Nuclei were smaller in FNABs of BTN-PH compared with PTC (mean diameter/range, 8.2/6-12 vs 14.2/7-26 mu m, respectively; P=.0001). Twenty-six percent of BTN-PHs contained cytoplasmic pigment. All FNAB cases diagnosed as S-PTC/PTC had focal nuclear atypia including grooves (87.5%), enlargement and crowding (75%), and chromatin pallor and pseudoinclusions (25%); however, the extent of nuclear atypia was significantly less than in the control group of PTCs (P<.0001). CONCLUSIONS: BTN-PH represents a significant pitfall in thyroid FNABs in which it can be misinterpreted as S-PTC/PTC. Cytologic clues to this pitfall include limited and variable nuclear atypia, small nuclear size, and cytoplasmic pigment. (C) 2014 American Cancer Society. C1 [Pusztaszeri, Marc P.] Univ Hosp Geneva, Dept Pathol, Geneva, Switzerland. [Krane, Jeffrey F.; Cibas, Edmund S.; Daniels, Gilbert; Faquin, William C.] Harvard Univ, Sch Med, Boston, MA USA. [Krane, Jeffrey F.; Cibas, Edmund S.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Daniels, Gilbert] Massachusetts Gen Hosp, Thyroid Unit, Boston, MA 02114 USA. [Daniels, Gilbert] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Faquin, William C.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Faquin, WC (reprint author), Massachusetts Gen Hosp, Dept Pathol, Warren 219,55 Fruit St, Boston, MA 02114 USA. EM wfaquin@partners.org FU Nuovo-Soldati Foundation FX Marc P. Pusztaszeri received support from the Nuovo-Soldati Foundation for a visiting fellowship to Massachusetts General Hospital, Boston, Massachusetts. NR 48 TC 3 Z9 3 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1934-662X EI 1934-6638 J9 CANCER CYTOPATHOL JI Cancer Cytopathol. PD SEP PY 2014 VL 122 IS 9 BP 666 EP 677 DI 10.1002/cncy.21441 PG 12 WC Oncology; Pathology SC Oncology; Pathology GA AP8PG UT WOS:000342340300006 PM 24891128 ER PT J AU Nahrendorf, M Swirski, FK AF Nahrendorf, Matthias Swirski, Filip K. TI Imaging Systemic Inflammation in Patients With Acute Myocardial Infarction SO CIRCULATION-CARDIOVASCULAR IMAGING LA English DT Editorial Material DE Editorials; fluorodeoxyglucose F18; hematopoiesis; macrophages; monocytes; positron-emission tomography; spleen ID IRON-OXIDE; ATHEROSCLEROSIS; RESERVOIR; MONOCYTES C1 [Nahrendorf, Matthias; Swirski, Filip K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA USA. RP Nahrendorf, M (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, 185 Cambridge St,Suite 5-210, Boston, MA 02114 USA. EM mnahrendorf@mgh.harvard.edu; fswirski@mgh.harvard.edu NR 16 TC 0 Z9 1 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-9651 EI 1942-0080 J9 CIRC-CARDIOVASC IMAG JI Circ.-Cardiovasc. Imaging PD SEP PY 2014 VL 7 IS 5 BP 762 EP 764 DI 10.1161/CIRCIMAGING.114.002410 PG 3 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA AQ0SG UT WOS:000342492400002 PM 25227235 ER PT J AU Wang, Z Jia, HB Tian, JW Soeda, T Vergallo, R Minami, Y Lee, H Aguirre, A Fujimoto, JG Jang, IK AF Wang, Zhao Jia, Haibo Tian, Jinwei Soeda, Tsunenari Vergallo, Rocco Minami, Yoshiyasu Lee, Hang Aguirre, Aaron Fujimoto, James G. Jang, Ik-Kyung TI Computer-Aided Image Analysis Algorithm to Enhance In Vivo Diagnosis of Plaque Erosion by Intravascular Optical Coherence Tomography SO CIRCULATION-CARDIOVASCULAR IMAGING LA English DT Article DE acute coronary syndrome; tomography, optical coherence ID SUDDEN CORONARY DEATH; THROMBOSIS; QUANTIFICATION; RUPTURE AB Background-Recent reports show that plaque erosion can be diagnosed in vivo using optical coherence tomography in patients with acute coronary syndrome. However, quantitative optical coherence tomographic image criteria for computer-aided diagnosis of plaque erosion have not been established. Methods and Results-A total of 42 patients with acute coronary syndrome caused by plaque erosion were included. Plaque erosion was identified according to the previously established optical coherence tomography criteria. Both optical properties and morphological features of the focal-eroded region as well as erosion-adjacent region were analyzed using a custom-designed computer algorithm. Noneroded fibrous plaques remote from the erosion site within the same vessel were used as controls. Eroded plaques have significantly lower surface intensity (P<0.001), lower region of interest intensity (P<0.001), lower surface normalized SD (P<0.001), lower region of interest normalized SD (P<0.001), higher optical attenuation (P<0.001), larger tissue protrusion area (P<0.001), and greater surface roughness (P<0.001) when compared with control plaques. Erosion-adjacent regions also have lower region of interest normalized SD (P=0.008), higher attenuation (P<0.001), and greater surface roughness (P=0.005). Using a logistic regression model built on the quantitative features, plaque erosion can be accurately classified against intact fibrous plaques. There was low inter-and intraobserver variability associated with the algorithm-assisted quantitative assessment. Conclusions-Plaque erosion has distinctive optical properties and morphological features when compared with noneroded fibrous plaques. Quantitative image analysis may enhance diagnostic accuracy for plaque erosion in vivo. C1 [Wang, Zhao; Fujimoto, James G.] MIT, Dept Elect Engn & Comp Sci, Elect Res Lab, Cambridge, MA 02139 USA. [Jia, Haibo; Tian, Jinwei] Harbin Med Univ, Affiliated Hosp 2, Dept Cardiol, Harbin, Peoples R China. [Jia, Haibo; Tian, Jinwei; Soeda, Tsunenari; Vergallo, Rocco; Minami, Yoshiyasu; Aguirre, Aaron; Jang, Ik-Kyung] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA. [Lee, Hang] Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Biostat Ctr, Boston, MA USA. [Aguirre, Aaron] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiol, Boston, MA 02115 USA. RP Jang, IK (reprint author), Massachusetts Gen Hosp, Div Cardiol, 55 Fruit St,GRB 800, Boston, MA 02114 USA. EM ijang@partners.org RI Wang, Zhao/E-3515-2015 OI Wang, Zhao/0000-0002-3628-5699 FU LightLab Imaging/St. Jude Medical; National Science Foundation of China; Italian Society of Cardiology; Dr John Nam optical coherence tomography fellowship grant; Michael and Kathryn Park FX This work was supported by grants from LightLab Imaging/St. Jude Medical (Dr Jang), the National Science Foundation of China (Dr Jia and Dr Tian), and the Italian Society of Cardiology (Dr Vergallo) as well as by Dr John Nam optical coherence tomography fellowship grant and by Michael and Kathryn Park. NR 21 TC 2 Z9 2 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-9651 EI 1942-0080 J9 CIRC-CARDIOVASC IMAG JI Circ.-Cardiovasc. Imaging PD SEP PY 2014 VL 7 IS 5 BP 805 EP 810 DI 10.1161/CIRCIMAGING.114.002084 PG 6 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA AQ0SG UT WOS:000342492400008 PM 25034595 ER PT J AU Kim, DH Handschumacher, MD Levine, RA Sun, BJ Jang, JY Yang, DH Kang, JW Song, JM Kang, DH Lim, TH Song, JK AF Kim, Dae-Hee Handschumacher, Mark D. Levine, Robert A. Sun, Byung Joo Jang, Jeong Yoon Yang, Dong Hyun Kang, Joon-Won Song, Jong-Min Kang, Duk-Hyun Lim, Tae-Hwan Song, Jae-Kwan TI Aortic Valve Adaptation to Aortic Root Dilatation Insights Into the Mechanism of Functional Aortic Regurgitation From 3-Dimensional Cardiac Computed Tomography SO CIRCULATION-CARDIOVASCULAR IMAGING LA English DT Article DE aortic aneurysm; aortic regurgitation; aortic valve insufficiency; computed tomography; three dimensional imaging ID TRANSESOPHAGEAL ECHOCARDIOGRAPHY; MITRAL REGURGITATION; GEOMETRY; ANATOMY; REPAIR; INCOMPETENCE; REPLACEMENT; LEAFLETS; ANEURYSM; SINUSES AB Background-The 3-dimensional relationship between aortic root and cusp is essential to understand the mechanism of aortic regurgitation (AR) because of aortic root dilatation (ARD). We sought to test the hypothesis that the stretched cusps in ARD enlarge to compensate for ARD. Methods and Results-Computed tomography imaged 92 patients (57 with ARD, 29 with moderate to severe AR, 28 without significant AR) and 35 normal controls. Specialized 3-dimensional software measured individual cusp surface areas relative to maximal mid-sinus cross-sectional area and minimal 3-dimensional annular area, coaptation area fraction, and asymmetry of sinus volumes and intercommissural distances. Total open cusp surface area increased (P<0.001) from 7.6 +/- 1.4 cm(2)/m(2) in normals to 12.9 +/- 2.2 cm(2)/m(2) in AR-negative and 15.2 +/- 3.3 cm(2)/m(2) in AR-positive patients. However, the ratio of closed cusp surface area to maximal mid-sinus area, reflecting cusp adaptation, decreased from normals to AR-negative to AR-positive patients (1.38 +/- 0.20, 1.15 +/- 0.15, 0.88 +/- 0.15; P<0.001), creating the lowest coaptation area fraction. Cusp distensibility (closed diastolic versus open area) decreased from 20% in controls and AR-negative patients to 5% in AR-positive patients (P<0.001). Multivariate determinants of AR and coaptation area fraction reflected both sinus size and cusp-to-annular adaptation. ARD was also progressively asymmetrical with root size, and individual cusp surface areas failed to match this asymmetry. Conclusions-Aortic cusp enlargement occurs in ARD, but cusp adaptation and distensibility become limited in prominent, asymmetrical ARD, leading to AR. Optimal AR repair tailored to individual patient anatomy can benefit from appreciating valve adaptation and 3-dimensional relationships; understanding cusp adaptation mechanisms may ultimately provide therapeutic opportunities to improve such compensation. C1 [Kim, Dae-Hee; Sun, Byung Joo; Jang, Jeong Yoon; Yang, Dong Hyun; Kang, Joon-Won; Song, Jong-Min; Kang, Duk-Hyun; Lim, Tae-Hwan; Song, Jae-Kwan] Univ Ulsan, Coll Med, Cardiac Imaging Ctr, Asan Med Ctr Heart Inst, Seoul 138736, South Korea. [Handschumacher, Mark D.; Levine, Robert A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Ultrasound Lab, Boston, MA USA. RP Song, JK (reprint author), Univ Ulsan, Coll Med, Cardiac Imaging Ctr, Asan Med Ctr Heart Inst, 388-1 Poongnap Dong, Seoul 138736, South Korea. EM jksong@amc.seoul.kr FU Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea [2012-0539]; Leducq Foundation MITRAL Network, Paris, France [07CVD04]; Asan Medical Center FX This study was supported by a grant (2012-0539) from the Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea. Initial 3-dimensional programming was supported in part by the Leducq Foundation MITRAL Network (grant 07CVD04), Paris, France (to M.D. Handschumacher, R.A. Levine), then customized for these hypotheses under the sponsorship of the Asan Medical Center. NR 39 TC 2 Z9 2 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-9651 EI 1942-0080 J9 CIRC-CARDIOVASC IMAG JI Circ.-Cardiovasc. Imaging PD SEP PY 2014 VL 7 IS 5 BP 828 EP U122 DI 10.1161/CIRCIMAGING.113.001976 PG 16 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA AQ0SG UT WOS:000342492400011 PM 25051951 ER PT J AU Epstein, AM Joynt, KE Jha, AK Orav, EJ AF Epstein, Arnold M. Joynt, Karen E. Jha, Ashish K. Orav, E. John TI Access to Coronary Artery Bypass Graft Surgery Under Pay for Performance Evidence From the Premier Hospital Quality Incentive Demonstration SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE coronary artery bypass grafting; pay for performance ID DUTY HOUR REFORM; FOR-PERFORMANCE; MEDICARE BENEFICIARIES; ADMINISTRATIVE DATA; RISK ADJUSTMENT; HEALTH-CARE; MORTALITY; OUTCOMES; INTERVENTION; ASSOCIATION AB Background-Although pay for performance (P4P) has become common, many worry that P4P will lead providers to avoid offering surgical procedures to the sickest patients out of concern that poor outcomes will lead to financial penalties. Methods and Results-We used Medicare data to compare change in rates of coronary artery bypass graft surgery between 2002 to 2003 and 2008 to 2009 among patients with acute myocardial infarction (AMI) admitted to 126 hospitals participating in Medicare's Premier Hospital Quality Incentive Demonstration P4P program with patients in 848 control hospitals participating in public reporting through the Health Quality Alliance. We examined rates for all patients with AMI and those in the top decile of predicted mortality based on demographics, medical comorbidities, and AMI characteristics. We identified 91 393 patients admitted for AMI in Premier hospitals and 502 536 Medicare patients admitted for AMI in control hospitals. Coronary artery bypass graft surgery rates for patients with AMI in Premier decreased from 13.6% in 2002 to 2003 to 10.4% in 2008 to 2009; there was a comparable decrease in non-Premier hospitals (13.6%-10.6%; P value for comparison of changes between Premier and non-Premier, 0.67). Coronary artery bypass graft surgery rates for high-risk patients in Premier decreased from 8.4% in FY 2002 to 203 to 8.2% in 2008 to 2009. Patterns were similar in non-Premier hospitals (8.4%-8.3%; P value for comparison of changes between Premier and non-Premier, 0.82). Conclusions-Our results show no evidence of a deleterious effect of P4P on access to coronary artery bypass graft surgery for high-risk patients with AMI. These results should be reassuring to those concerned about the potential negative effect of P4P on high-risk patients. C1 [Epstein, Arnold M.; Joynt, Karen E.; Jha, Ashish K.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Orav, E. John] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Epstein, Arnold M.; Jha, Ashish K.; Orav, E. John] Brigham & Womens Hosp, Dept Med, Div Gen Med, Boston, MA 02115 USA. [Joynt, Karen E.] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA. [Joynt, Karen E.; Jha, Ashish K.] VA Boston Healthcare Syst, Dept Med, Boston, MA USA. RP Epstein, AM (reprint author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA. EM aepstein@hsph.harvard.edu FU Robert Wood Johnson Foundation; National Heart, Lung, and Blood Institute [1K23HL109177-01] FX This work was supported by a grant from the Robert Wood Johnson Foundation. The funder had no role in the design or conduct of the study, the analysis or interpretation of the results, or the creation of the article. Dr Joynt was additionally supported by grant 1K23HL109177-01 from the National Heart, Lung, and Blood Institute. NR 23 TC 3 Z9 3 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7705 EI 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD SEP PY 2014 VL 7 IS 5 BP 727 EP 734 DI 10.1161/CIRCOUTCOMES.114.001024 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AP8YL UT WOS:000342365200016 PM 25160840 ER PT J AU Hasegawa, K Tsugawa, Y Camargo, CA Brown, DFM AF Hasegawa, Kohei Tsugawa, Yusuke Camargo, Carlos A., Jr. Brown, David F. M. TI Frequent Utilization of the Emergency Department for Acute Heart Failure Syndrome A Population-Based Study SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE emergency service; hospital; epidemiology; heart failure; recurrence ID UNITED-STATES; ASTHMA; HEALTH; CARE; ASSOCIATION; MANAGEMENT; OUTCOMES; ADULTS; HOSPITALIZATIONS; DEPRESSION AB Background-Although most research on patients with acute heart failure syndrome (AHFS) has focused on readmissions, this may provide an incomplete picture of health-care utilization. We examined the proportion and characteristics of patients with frequent emergency department (ED) visits for AHFS and associated health-care utilization. Methods and Results-A retrospective cohort study of adults with at least 1 ED visit for AHFS between 2010 and 2011 was performed, derived from population-based multipayer data of state ED and inpatient databases for 2 large and diverse states, California and Florida. The analytic sample comprised 113 033 patients with 175 491 ED visits for AHFS. During the 1-year follow-up period, 30.8% of patients had >= 2 (frequent) visits, accounting for 55.4% (95% confidence interval, 55.2-55.5%) of all ED visits for AHFS. In the multivariable model, significant predictors of frequent ED visits were non-Hispanic black race, Hispanic ethnicity, Medicaid insurance, and lower median household income (all P<0.001). At the visit level, patients with frequent ED visits accounted for 55.0% (95% confidence interval, 54.8-5.3%) of all AHFS hospitalizations via ED. Total charges for AHFS were $3.08 billion (95% confidence interval, $3.03-3.14 billion) in Florida alone; patients with frequent ED visits accounted for 53.3% of total charges (95% confidence interval, 53.2-53.3%). Conclusions-In this large cohort study, we found that one third (31%) of ED patients with AHFS had frequent ED visits for this condition and that minority race/ethnicity and lower socioeconomic status were associated with frequent ED visits. Individuals with frequent ED visits accounted for the majority of ED visits, hospitalizations, and hospital charges. C1 [Hasegawa, Kohei; Camargo, Carlos A., Jr.; Brown, David F. M.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Hasegawa, Kohei; Camargo, Carlos A., Jr.; Brown, David F. M.] Harvard Univ, Sch Med, Boston, MA USA. [Tsugawa, Yusuke] Harvard Interfac Initiat Hlth Policy, Cambridge, MA USA. RP Hasegawa, K (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, 326 Cambridge St,Suite 410, Boston, MA 02114 USA. EM khasegawa1@partners.org FU Eleanor and Miles Shore Fellowship Program (Boston, MA); Honjo International Scholarship Foundation (Tokyo, Japan) FX Dr Hasegawa was supported, in part, by Eleanor and Miles Shore Fellowship Program (Boston, MA). Dr Tsugawa was supported, in part, by Honjo International Scholarship Foundation (Tokyo, Japan). The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the article. NR 38 TC 8 Z9 8 U1 3 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7705 EI 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD SEP PY 2014 VL 7 IS 5 BP 735 EP 742 DI 10.1161/CIRCOUTCOMES.114.000949 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AP8YL UT WOS:000342365200017 PM 25139183 ER PT J AU Chirinos, JA Khan, A Bansal, N Dries, DL Feldman, HI Ford, V Anderson, AH Kallem, R Lash, JP Ojo, A Schreiber, M Sheridan, A Strelsin, J Teal, V Roy, J Pan, Q Go, AS Townsend, RR AF Chirinos, Julio A. Khan, Abigail Bansal, Nisha Dries, Daniel L. Feldman, Harold I. Ford, Virginia Anderson, Amanda H. Kallem, Radhakrishna Lash, James P. Ojo, Akinlolu Schreiber, Martin Sheridan, Angela Strelsin, Jillian Teal, Valerie Roy, Jason Pan, Qiang Go, Alan S. Townsend, Raymond R. CA CRIC Study Investigators TI Arterial Stiffness, Central Pressures, and Incident Hospitalized Heart Failure in the Chronic Renal Insufficiency Cohort Study SO CIRCULATION-HEART FAILURE LA English DT Article DE heart failure; pulse wave analysis; renal insufficiency; chronic; vascular stiffness ID CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; CENTRAL PULSE PRESSURE; AORTIC PRESSURE; WAVE-FORM; CARDIOVASCULAR EVENTS; SERUM CREATININE; RISK; ATHEROSCLEROSIS; MORTALITY AB Background-Chronic kidney disease is associated with an increased risk of heart failure (HF). We aimed to evaluate the role of large artery stiffness, brachial, and central blood pressure as predictors of incident hospitalized HF in the Chronic Renal Insufficiency Cohort (CRIC), a multiethnic, multicenter prospective observational study of patients with chronic kidney disease. Methods and Results-We studied 2602 participants who were free of HF at baseline. Carotid-femoral pulse wave velocity (CF-PWV; the gold standard index of large artery stiffness), brachial, and central pressures (estimated via radial tonometry and a generalized transfer function) were assessed at baseline. Participants were prospectively followed up to assess the development of new-onset hospitalized HF. During 3.5 years of follow-up, 154 participants had a first hospital admission for HF. CF-PWV was a significant independent predictor of incident hospitalized HF. When compared with the lowest tertile, the hazard ratios among subjects in the middle and top CF-PWV tertiles were 2.33 (95% confidence interval, 1.37-3.97; P=0.002) and 5.24 (95% confidence interval, 3.22-8.53; P<0.0001), respectively. After adjustment for multiple confounders, the hazard ratios for the middle and top CF-PWV tertiles were 1.95 (95% confidence interval, 0.92-4.13; P=0.079) and 3.01 (95% confidence interval, 1.45-6.26; P=0.003), respectively. Brachial systolic and pulse pressure were also independently associated with incident hospitalized HF, whereas central pressures were less consistently associated with this end point. The association between CF-PWV and incident HF persisted after adjustment for systolic blood pressure. Conclusions-Large artery stiffness is an independent predictor of incident HF in chronic kidney disease, an association with strong biological plausibility given the known effects of large artery stiffening of left ventricular pulsatile load. C1 [Chirinos, Julio A.; Khan, Abigail; Dries, Daniel L.; Ford, Virginia; Kallem, Radhakrishna; Sheridan, Angela; Roy, Jason; Townsend, Raymond R.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Chirinos, Julio A.] Philadelphia VA Med Ctr, Dept Med, Philadelphia, PA USA. [Bansal, Nisha] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Feldman, Harold I.; Anderson, Amanda H.; Teal, Valerie] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Lash, James P.] Univ Illinois, Dept Med, Chicago, IL USA. [Ojo, Akinlolu] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. [Schreiber, Martin] Cleveland Clin Fdn, Dept Med, Cleveland, OH USA. [Roy, Jason] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Pan, Qiang] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Go, Alan S.] Kaiser Permanente Calif, Dept Med, Dept Epidemiol & Biostat, Div Res, Oakland, CA USA. RP Chirinos, JA (reprint author), Univ Penn, Perelman Sch Med, Rm 8B111,Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM julio.chirinos@uphs.upenn.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, U01DK060902]; Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award NIH/NCATS [UL1TR000003]; Johns Hopkins University [UL1 TR-000424]; University of Maryland [GCRC M01 RR-16500]; Clinical and Translational Science Collaborative of Cleveland from National Center for Advancing Translational Sciences component of the National Institutes of Health (NIH) [UL1TR000439]; NIH roadmap for Medical Research; Michigan Institute for Clinical and Health Research [UL1TR000433]; University of Illinois at Chicago Clinical and Translational Science Award [UL1RR029879]; Tulane University [P30GM103337]; Kaiser Permanente National Institutes of Health/National Center for Research Resourced University of California; San Francisco/Clinical and Translational Science Institute [UL1 RR-024131] FX Funding for the CRIC Study was obtained under a cooperative agreement from National Institute of Diabetes and Digestive and Kidney Diseases (U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, and U01DK060902). In addition, this work was supported, in part, by the Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award NIH/NCATS UL1TR000003, Johns Hopkins University UL1 TR-000424, University of Maryland GCRC M01 RR-16500, Clinical and Translational Science Collaborative of Cleveland, UL1TR000439 from the National Center for Advancing Translational Sciences component of the National Institutes of Health (NIH) and NIH roadmap for Medical Research, Michigan Institute for Clinical and Health Research UL1TR000433, University of Illinois at Chicago Clinical and Translational Science Award UL1RR029879, Tulane University Translational Research in Hypertension and Renal Biology P30GM103337, Kaiser Permanente National Institutes of Health/National Center for Research Resourced University of California, San Francisco/Clinical and Translational Science Institute UL1 RR-024131. NR 43 TC 14 Z9 15 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD SEP PY 2014 VL 7 IS 5 BP 709 EP 716 DI 10.1161/CIRCHEARTFAILURE.113.001041 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AQ0RR UT WOS:000342490900004 PM 25059422 ER PT J AU Willoughby, BL Favero, M Mochida, GH Braaten, EB AF Willoughby, Brian L. Favero, Marcus Mochida, Ganeshwaran H. Braaten, Ellen B. TI Neuropsychological Function in a Child with 18p Deletion Syndrome: A Case Report SO COGNITIVE AND BEHAVIORAL NEUROLOGY LA English DT Article DE 18p deletion syndrome; neuropsychology; genetic syndrome; developmental disorder; neuropsychological assessment ID MOLECULAR CHARACTERIZATION; INDIVIDUALS AB We report the neuropsychological profile of a 4-year-old boy with the rare 18p deletion syndrome. We used a battery of standardized tests to assess his development in intellect, language, visuomotor integration, academic readiness, socialization, and emotional and behavioral health. The results showed borderline intellectual function except for low average nonverbal reasoning skills. He had stronger receptive than expressive language skills, although both were well below his age group. He had impaired visuomotor integration and pre-academic skills such as letter identification. Emotional and behavioral findings indicated mild aggressiveness, anxiety, low frustration tolerance, and executive function weaknesses, especially at home. Interestingly, he showed social strengths, responding to joint attention and sharing enjoyment with his examiner. With its assessment of development in many domains, this case report is among the first to characterize the neuropsychological and psychiatric function of a young child with 18p deletion syndrome. We discuss the implications of our findings for clinical practice. C1 [Willoughby, Brian L.; Favero, Marcus; Braaten, Ellen B.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Mochida, Ganeshwaran H.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Willoughby, BL (reprint author), Massachusetts Gen Hosp, Dev Neuropediat Unit, 151 Merrimac St,5th Floor, Boston, MA 02114 USA. EM bwilloughby@partners.org FU NINDS NIH HHS [R01 NS035129] NR 16 TC 1 Z9 1 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1543-3633 EI 1543-3641 J9 COGN BEHAV NEUROL JI Cogn. Behav. Neurol. PD SEP PY 2014 VL 27 IS 3 BP 160 EP 165 PG 6 WC Behavioral Sciences; Clinical Neurology SC Behavioral Sciences; Neurosciences & Neurology GA AQ2KW UT WOS:000342615700006 PM 25237747 ER PT J AU Liu, SM Xi, YN Bettaieb, A Matsuo, K Matsuo, I Kulkarni, RN Haj, FG AF Liu, Siming Xi, Yannan Bettaieb, Ahmed Matsuo, Kosuke Matsuo, Izumi Kulkarni, Rohit N. Haj, Fawaz G. TI Disruption of Protein-Tyrosine Phosphatase 1B Expression in the Pancreas Affects beta-Cell Function SO ENDOCRINOLOGY LA English DT Article ID STIMULATED INSULIN-SECRETION; GLUCOSE-HOMEOSTASIS; ENDOPLASMIC-RETICULUM; TRANSLATIONAL CONTROL; DIABETES-MELLITUS; ISLET DYSFUNCTION; GENE-EXPRESSION; LEPTIN ACTION; IN-VIVO; RECEPTOR AB Protein-tyrosine phosphatase 1B (PTP1B) is a physiological regulator of glucose homeostasis and energy balance. However, the role of PTP1B in pancreatic endocrine function remains largely unknown. To investigate the metabolic role of pancreatic PTP1B, we generated mice with pancreas PTP1B deletion (panc-PTP1B KO). Mice were fed regular chow or a high-fat diet, and metabolic parameters, insulin secretion and glucose tolerance were determined. On regular chow, panc-PTP1B KO and control mice exhibited comparable glucose tolerance whereas aged panc-PTP1B KO exhibited mild glucose intolerance. Furthermore, high-fat feeding promoted earlier impairment of glucose tolerance and attenuated glucose-stimulated insulin secretion in panc-PTP1B KO mice. The secretory defect in glucose-stimulated insulin secretion was recapitulated in primary islets ex vivo, suggesting that the effects were likely cell-autonomous. At the molecular level, PTP1B deficiency in vivo enhanced basal and glucose-stimulated tyrosyl phosphorylation of EphA5 in islets. Consistently, PTP1B overexpression in the glucose-responsive MIN6 beta-cell line attenuated EphA5 tyrosyl phosphorylation, and substrate trapping identified EphA5 as a PTP1B substrate. In summary, these studies identify a novel role for PTP1B in pancreatic endocrine function. C1 [Liu, Siming; Xi, Yannan; Bettaieb, Ahmed; Matsuo, Kosuke; Matsuo, Izumi; Haj, Fawaz G.] Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA. [Kulkarni, Rohit N.] Harvard Univ, Sch Med, Dept Med, Joslin Diabet Ctr, Boston, MA 02215 USA. [Haj, Fawaz G.] Univ Calif Davis, Dept Internal Med, Div Endocrinol Diabet & Metab, Sacramento, CA 95817 USA. Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95817 USA. RP Haj, FG (reprint author), Univ Calif Davis, Dept Nutr, 3135 Meyer Hall, Davis, CA 95616 USA. EM fghaj@ucdavis.edu FU Juvenile Diabetes Research Foundation [1-2009-337]; National Institutes of Health [R56DK084317, R01DK090492]; DK [RO167536] FX This work was supported by research grant from the Juvenile Diabetes Research Foundation (1-2009-337) and National Institutes of Health Grants R56DK084317 and R01DK090492 to F.G.H. Research in the Kulkarni laboratory is funded by DK RO167536. NR 56 TC 4 Z9 5 U1 0 U2 6 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0013-7227 EI 1945-7170 J9 ENDOCRINOLOGY JI Endocrinology PD SEP PY 2014 VL 155 IS 9 BP 3329 EP 3338 DI 10.1210/en.2013-2004 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AP8QQ UT WOS:000342344300014 PM 24956127 ER PT J AU Jun, HJ Roy, J Smith, TB Wood, LB Lane, K Woolfenden, S Punko, D Bronson, RT Haigis, KM Breton, S Charest, A AF Jun, Hyun Jung Roy, Jeremy Smith, Tegan B. Wood, Levi B. Lane, Keara Woolfenden, Steve Punko, Diana Bronson, Roderick T. Haigis, Kevin M. Breton, Sylvie Charest, Al TI ROS1 Signaling Regulates Epithelial Differentiation in the Epididymis SO ENDOCRINOLOGY LA English DT Article ID TYROSINE KINASE RECEPTOR; C-ROS; POSTNATAL-DEVELOPMENT; RAT EPIDIDYMIS; KNOCKOUT MICE; HOMOLOGOUS RECOMBINATION; OXIDATIVE STRESS; EXPRESSION; CELLS; PATHWAY AB The initial segment (IS) of the epididymis plays an essential role in male fertility. The IS epithelium is undifferentiated and nonfunctional at birth. Prior to puberty, the epithelium undergoes differentiation that leads to the formation of a fully functional organ. However, the mechanistic details of this program are not well understood. To explore this further, we used genetic engineering to create a kinase dead allele of the ROS1 receptor tyrosine kinase in mice and studied the effects of ROS1 tyrosine kinase activity on the differentiation of the IS epithelium. We show that the expression and activation of ROS1 coincides with the onset of differentiation and is exclusively located in the IS of the maturing and adult mouse epididymides. Here we demonstrate that the differentiation of the IS is dependent on the kinase activity of ROS1 and its downstream effector MEK1/2-ERK1/2 signaling axis. Using genetic engineering, we show that germ line ablation of ROS1 kinase activity leads to a failure of the IS epithelium to differentiate, and as a consequence sperm maturation and infertility were dramatically perturbed. Pharmacological inhibition of ROS1 kinase activity in the developing epididymis, however, only delayed differentiation transiently and did not result in infertility. Our results demonstrate that ROS1 kinase activity and the ensuing MEK1/2-ERK1/2 signaling are necessary for the postnatal development of the IS epithelium and that a sustained ablation of ROS1 kinase activity within the critical window of terminal differentiation abrogate the function of the epididymis and leads to sterility. C1 [Jun, Hyun Jung; Woolfenden, Steve; Punko, Diana; Charest, Al] Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA. [Lane, Keara; Charest, Al] MIT, Ctr Canc Res, Cambridge, MA 02139 USA. [Roy, Jeremy; Smith, Tegan B.; Breton, Sylvie] Massachusetts Gen Hosp, Program Membrane Biol, Boston, MA 02114 USA. [Roy, Jeremy; Smith, Tegan B.; Breton, Sylvie] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA. [Roy, Jeremy; Smith, Tegan B.; Breton, Sylvie] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Wood, Levi B.; Haigis, Kevin M.] Massachusetts Gen Hosp, Mol Pathol Unit, Boston, MA 02114 USA. [Bronson, Roderick T.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Charest, Al] Tufts Univ, Sch Med, Dept Neurosurg, Boston, MA 02111 USA. [Charest, Al] Tufts Univ, Sch Med, Genet Program, Boston, MA 02111 USA. RP Charest, A (reprint author), MORI, Tufts Med Ctr, 800 Washington St,Box 5609, Boston, MA 02111 USA. EM alain.charest@tufts.edu FU National Institutes of Health [NCI U01 CA141556, RO1 DK085715-05]; American Cancer Society Research Scholar Award [117409]; Massachusetts General Hospital Charles; Ann Sanders Research Scholar Award FX This work was supported by National Institutes of Health Grants NCI U01 CA141556 (to A.C.) and RO1 DK085715-05 (to S.B.), the American Cancer Society Research Scholar Award 117409 (to A.C.), and by the Massachusetts General Hospital Charles and Ann Sanders Research Scholar Award. NR 51 TC 7 Z9 7 U1 1 U2 7 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0013-7227 EI 1945-7170 J9 ENDOCRINOLOGY JI Endocrinology PD SEP PY 2014 VL 155 IS 9 BP 3661 EP 3673 DI 10.1210/en.2014-1341 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AP8QQ UT WOS:000342344300042 PM 24971615 ER PT J AU Palacios, N Fitzgerald, K Roberts, AL Hart, JE Weisskopf, MG Schwarzschild, MA Ascherio, A Laden, F AF Palacios, Natalia Fitzgerald, Kathryn Roberts, Andrea L. Hart, Jaime E. Weisskopf, Marc G. Schwarzschild, Michael A. Ascherio, Alberto Laden, Francine TI A Prospective Analysis of Airborne Metal Exposures and Risk of Parkinson Disease in the Nurses' Health Study Cohort SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID DIETARY IRON; LEAD-EXPOSURE; MANGANESE; ASSOCIATION; DISORDERS; PARAQUAT; WELDERS; MANEB; WOMEN AB Background: Exposure to metals has been implicated in the pathogenesis of Parkinson disease (PD). OBJECTIVES: We sought to examine in a large prospective study of female nurses whether exposure to airborne metals was associated with risk of PD. METHODS: We linked the U.S. Environmental Protection Agency (EPA)'s Air Toxics tract-level data with the Nurses' Health Study, a prospective cohort of female nurses. Over the course of 18 years of follow-up from 1990 through 2008, we identified 425 incident cases of PD. We examined the association of risk of PD with the following metals that were part of the first U.S. EPA collections in 1990, 1996, and 1999: arsenic, antimony, cadmium, chromium, lead, manganese, mercury, and nickel. To estimate hazard ratios (HRs) and 95% CIs, we used the Cox proportional hazards model, adjusting for age, smoking, and population density. RESULTS: In adjusted models, the HR for the highest compared with the lowest quartile of each metal ranged from 0.78 (95% CI: 0.59, 1.04) for chromium to 1.33 (95% CI: 0.98, 1.79) for mercury. CONCLUSIONS: Overall, we found limited evidence for the association between adulthood ambient exposure to metals and risk of PD. The results for mercury need to be confirmed in future studies. C1 [Palacios, Natalia; Fitzgerald, Kathryn; Roberts, Andrea L.; Weisskopf, Marc G.; Ascherio, Alberto; Laden, Francine] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Palacios, Natalia; Hart, Jaime E.; Ascherio, Alberto; Laden, Francine] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA. [Palacios, Natalia; Hart, Jaime E.; Ascherio, Alberto; Laden, Francine] Harvard Univ, Sch Med, Boston, MA USA. [Hart, Jaime E.; Ascherio, Alberto] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Schwarzschild, Michael A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Palacios, N (reprint author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 655 Huntington Ave, Boston, MA 02115 USA. EM palacios@hsph.harvard.edu OI Roberts, Andrea/0000-0001-5023-4399 FU National Institue of Environmental Health Sciences (NIEHS)/National Institutes of Health (NIH) [1K01ES019183]; Department of Defense [W81XWH-11-1-0150]; NIH; NIH (NIEHS) [R01 ES017017]; NIH (National Cancer Institute) [P01 CA87969] FX This work was supported by a K01 award (1K01ES019183) from the National Institue of Environmental Health Sciences (NIEHS)/National Institutes of Health (NIH) to N.P. M. A. S. received funding from the Department of Defense (W81XWH-11-1-0150). A. A. received funding from the NIH. F. L. received funding from the NIH (NIEHS R01 ES017017 and the National Cancer Institute P01 CA87969). NR 31 TC 9 Z9 10 U1 3 U2 17 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD SEP PY 2014 VL 122 IS 9 BP 933 EP 938 DI 10.1289/ehp.1307218 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA AO9XT UT WOS:000341714600021 PM 24905870 ER PT J AU Vermeulen, R Portengen, L Silverman, DT Garshick, E Steenland, K AF Vermeulen, Roel Portengen, Lutzen Silverman, Debra T. Garshick, Eric Steenland, Kyle TI Meta-Analysis of Lung Cancer Risk from Exposure to Diesel Exhaust: Vermeulen et al. Respond SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Letter ID TRUCKING INDUSTRY C1 [Vermeulen, Roel; Portengen, Lutzen] Univ Utrecht, Utrecht, Netherlands. [Silverman, Debra T.] NCI, Rockville, MD USA. [Garshick, Eric] VA Boston Healthcare Syst, Boston, MA USA. [Steenland, Kyle] Emory Univ, Atlanta, GA 30322 USA. RP Vermeulen, R (reprint author), Univ Utrecht, Utrecht, Netherlands. EM r.c.h.vermeulen@uu.nl RI Vermeulen, Roel/F-8037-2011 OI Vermeulen, Roel/0000-0003-4082-8163 NR 4 TC 4 Z9 4 U1 2 U2 5 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD SEP PY 2014 VL 122 IS 9 BP A230 EP A231 DI 10.1289/ehp.1408482R PG 2 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA AO9XT UT WOS:000341714600002 PM 25181539 ER PT J AU Stein, EA Giugliano, RP Koren, MJ Raal, FJ Roth, EM Weiss, R Sullivan, D Wasserman, SM Somaratne, R Kim, JB Yang, JY Liu, T Albizem, M Scott, R Sabatine, MS AF Stein, Evan A. Giugliano, Robert P. Koren, Michael J. Raal, Frederick J. Roth, Eli M. Weiss, Robert Sullivan, David Wasserman, Scott M. Somaratne, Ransi Kim, Jae B. Yang, Jingyuan Liu, Thomas Albizem, Moetaz Scott, Rob Sabatine, Marc S. CA PROFICIO Investigators TI Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials SO EUROPEAN HEART JOURNAL LA English DT Article DE Proprotein convertase subtilizin/kexin type 9; Low-density lipoprotein cholesterol; Randomized controlled trials ID DENSITY-LIPOPROTEIN CHOLESTEROL; SUBTILISIN/KEXIN TYPE 9; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; CORONARY-HEART-DISEASE; LDL CHOLESTEROL; RANDOMIZED-TRIAL; SERINE-PROTEASE; DOUBLE-BLIND; ATORVASTATIN; STATIN AB Aims Prior trials with monoclonal antibodies to proprotein convertase subtilizin/kexin type 9 (PCSK9) reported robust low density lipoprotein cholesterol (LDL-C) reductions. However, the ability to detect potentially beneficial changes in other lipoproteins such as lipoprotein (a), triglycerides, high-density lipoprotein cholesterol (HDL-C), and apolipoprotein (Apo) A1, and adverse events (AEs) was limited by sample sizes of individual trials. We report a pooled analysis from four phase 2 studies of evolocumab (AMG 145), a monoclonal antibody to PCSK9. Methods and results The trials randomized 1359 patients to various doses of subcutaneous evolocumab every 2 weeks (Q2W) or 4 weeks (Q4W), placebo, or ezetimibe for 12weeks; 1252 patients contributed to efficacy and 1314, to safety analyses. Mean percentage (95% CI) reductions in LDL-C vs. placebo ranged from 40.2% (44.6%, 35.8%) to 59.3% (63.7%, 54.8%) among the evolocumab groups (all P < 0.001). Statistically significant reductions in apolipoprotein B (Apo B), non-high-density lipoprotein cholesterol (non-HDL-C), triglycerides and lipoprotein (a) [Lp(a)], and increases in HDL-C were also observed. Adverse events (AEs) and serious AEs with evolocumab were reported in 56.8 and 2.0% of patients, compared with 49.2% and 1.2% with placebo. Adjudicated cardiac and cerebrovascular events were reported in 0.3 and 0% in the placebo and 0.9 and 0.3% in the evolocumab arms, respectively. Conclusion In addition toLDL-Creduction, evolocumab, dosed either Q2W or Q4W, demonstrated significant and favourable changes in other atherogenic and anti-atherogenic lipoproteins, and was well tolerated over the 12-week treatment period. C1 [Stein, Evan A.] Metab & Atherosclerosis Res Ctr, Cincinnati, OH 45227 USA. [Giugliano, Robert P.; Sabatine, Marc S.] Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA. [Koren, Michael J.] Jacksonville Ctr Clin Res, Jacksonville, FL USA. [Raal, Frederick J.] Univ Witwatersrand, Carbohydrate & Lipid Metab Res Unit, Johannesburg, South Africa. [Roth, Eli M.] Sterling Res Grp, Cincinnati, OH USA. [Weiss, Robert] Maine Res Assoc, Auburn, ME USA. [Sullivan, David] Royal Prince Alfred Hosp, Dept Clin Biochem, Camperdown, NSW 2050, Australia. [Wasserman, Scott M.; Somaratne, Ransi; Kim, Jae B.; Yang, Jingyuan; Liu, Thomas; Albizem, Moetaz; Scott, Rob] Amgen Inc, Thousand Oaks, CA 91320 USA. RP Stein, EA (reprint author), Metab & Atherosclerosis Res Ctr, Cincinnati, OH 45227 USA. EM esteinmrl@aol.com OI Scott, Robert/0000-0001-8266-1061 FU Amgen, Inc. FX This work was supported by Amgen, Inc. NR 26 TC 49 Z9 50 U1 0 U2 13 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD SEP 1 PY 2014 VL 35 IS 33 BP 2249 EP 2259 DI 10.1093/eurheartj/ehu085 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AP7BV UT WOS:000342233600018 PM 24598985 ER PT J AU Katie, H Eve, D Patricia, A Steve, A Brian, N Jeremy, C Ivy, R Robert, C Barbara, M Angela, W Philip, O AF Katie, Hor Eve, Diefenbach Patricia, Anderson Steve, Alexander Brian, Nankivell Jeremy, Chapman Ivy, Rosales Robert, Colvin Barbara, Murphy Angela, Webster Philip, O'Connell TI PROTEOMIC ANALYSIS IDENTIFIES A SPECIFIC EARLY URINE PROTEIN SIGNATURE FOR THE DEVELOPMENT OF CHRONIC ALLOGRAFT INJURY SO IMMUNOLOGY AND CELL BIOLOGY LA English DT Meeting Abstract CT 32nd Annual Scientific Meeting of the Transplantation-Society-of-Australia-and-New-Zealand CY JUN 10-13, 2014 CL ANU Campus, Canberra, AUSTRALIA SP Transplantat Soc Australia & New Zealand HO ANU Campus C1 [Katie, Hor; Philip, O'Connell] Westmead Hosp, Westmead Millennium Inst, Ctr Transplant & Renal Res, Sydney, NSW, Australia. [Katie, Hor] Univ Sydney, Sch Med, Sydney, NSW 2006, Australia. [Eve, Diefenbach] Westmead Hosp, Westmead Millennium Inst, Prote Facil, Sydney, NSW, Australia. [Patricia, Anderson; Brian, Nankivell; Jeremy, Chapman; Angela, Webster] Westmead Hosp, Dept Renal Med, Sydney, NSW, Australia. [Steve, Alexander] Childrens Hosp Westmead, Ctr Kidney Res, Sydney, NSW, Australia. [Ivy, Rosales; Robert, Colvin] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Barbara, Murphy] Icahn Sch Med Mt Sinai, Dept Nephrol, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0818-9641 EI 1440-1711 J9 IMMUNOL CELL BIOL JI Immunol. Cell Biol. PD SEP PY 2014 VL 92 IS 8 BP A17 EP A17 PG 1 WC Cell Biology; Immunology SC Cell Biology; Immunology GA AP9CP UT WOS:000342376300042 ER PT J AU Yeung, A Slipp, LE Niles, H Jacquart, J Chow, CL Fava, M Denninger, JW Benson, H Fricchione, GL AF Yeung, Albert Slipp, Lauren E. Niles, Halsey Jacquart, Jolene Chow, Choi-Ling Fava, Maurizio Denninger, John W. Benson, Herbert Fricchione, Gregory L. TI Effectiveness of the Relaxation Response-Based Group Intervention for Treating Depressed Chinese American Immigrants: A Pilot Study SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH LA English DT Article DE depression; Chinese; relaxation response; mind-body; group intervention ID RANDOMIZED CONTROLLED-TRIAL; PERCEIVED SOCIAL SUPPORT; MIND-BODY INTERVENTION; TAI-CHI EXERCISE; COGNITIVE THERAPY; PSYCHOMETRIC CHARACTERISTICS; MULTIDIMENSIONAL SCALE; RATING-SCALE; STRESS; HEALTH AB Background: This study examined the feasibility, safety and efficacy of an 8-week Relaxation Response (RR)-based group. Methods: Twenty-two depressed Chinese American immigrants were recruited. Outcomes measures were response and remission rates, the Hamilton Rating Scale for Depression, Clinical Global Impressions Scale, Quality of Life Enjoyment and Satisfaction Questionnaire, and the Multidimensional Scale of Perceived Social Support Scale. Results: Participants (N = 22) were 82% female, mean age was 53 (+/- 12). After intervention, completers (N = 15) showed a 40% response rate and a 27% remission rate, and statistically significant improvement in most outcome measures. Discussion: The RR-based group is feasible and safe in treating Chinese American immigrants with depression. C1 [Yeung, Albert; Slipp, Lauren E.; Niles, Halsey; Jacquart, Jolene; Denninger, John W.; Benson, Herbert; Fricchione, Gregory L.] Massachusetts Gen Hosp, Benson Henry Inst Mind Body Med, Boston, MA 02114 USA. [Yeung, Albert; Chow, Choi-Ling] South Cove Community Hlth Ctr, Boston, MA 02111 USA. [Yeung, Albert; Fava, Maurizio] Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA. [Yeung, Albert; Fava, Maurizio; Denninger, John W.; Fricchione, Gregory L.] Harvard Univ, Dept Psychiat, Sch Med, Boston, MA 02115 USA. [Benson, Herbert] Harvard Univ, Dept Med, Sch Med, Boston, MA 02115 USA. RP Yeung, A (reprint author), Massachusetts Gen Hosp, Benson Henry Inst Mind Body Med, 151 Merrimac St, Boston, MA 02114 USA. EM ayeung@mgh.harvard.edu; lslipp@partners.org; halsey.niles@gmail.com; jjacquart@mgh.harvard.edu; ochow@scchc.org; mfava@mgh.harvard.edu; jdenninger@mgh.harvard.edu; hbenson@mgh.harvard.edu; gfricchione@mgh.harvard.edu FU Centers for Disease Control and Prevention [5R01DP000339] FX This research was supported by Centers for Disease Control and Prevention (grant number 5R01DP000339). NR 81 TC 1 Z9 1 U1 3 U2 13 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1660-4601 J9 INT J ENV RES PUB HE JI Int. J. Environ. Res. Public Health PD SEP PY 2014 VL 11 IS 9 BP 9186 EP 9201 DI 10.3390/ijerph110909186 PG 16 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA AP4DN UT WOS:000342027500035 PM 25198683 ER PT J AU Savoia, E Agboola, F Biddinger, PD AF Savoia, Elena Agboola, Foluso Biddinger, Paul D. TI A Conceptual Framework to Measure Systems' Performance during Emergency Preparedness Exercises SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH LA English DT Article DE emergency preparedness; emergency preparedness exercise; exercise evaluation; measuring preparedness; performance measurement AB Large-scale public health emergencies require a sophisticated, coordinated response involving multiple entities to protect health and minimize suffering. However, the rarity of such emergencies presents a barrier to gathering observational data about the effectiveness of the public health response before such events occur. For this reason, public health practitioners increasingly have relied on simulated emergencies, known as. exercises. as proxies to test their emergency capabilities. However, the formal evaluation of performance in these exercises, historically has been inconsistent, and there is little research to describe how data acquired from simulated emergencies actually support conclusions about the quality of the public health emergency response system. Over the past six years, we have designed and evaluated more than seventy public health emergency exercises, collaborating with public health agencies, hospitals and others to test a wide variety of systems and their capabilities. Using the data and experience that we gathered, we have developed a conceptual framework that describes the essential elements necessary to consider when applying performance measurement science to public health emergency exercises. We suggest that this framework may assist practitioners and researchers who wish to better measure performance in exercises and to improve public health emergency preparedness. C1 [Savoia, Elena] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Savoia, Elena; Agboola, Foluso; Biddinger, Paul D.] Harvard Univ, Sch Publ Hlth, Div Policy Translat & Leadership Dev, Boston, MA 02115 USA. [Biddinger, Paul D.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. RP Savoia, E (reprint author), Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. EM esavoia@hsph.harvard.edu; fagboola@hsph.harvard.edu; pbiddinger@partners.org FU U.S. Centers for Disease Control and Prevention (CDC) [5PO1TP000307-05] FX We acknowledge funding support from the U.S. Centers for Disease Control and Prevention (CDC) supplement to grant number 5PO1TP000307-05 Preparedness and Emergency Response Research Center-Linking Assessment to Measurement and Performance in Public Health Emergency Preparedness Exercises. The content of this publication as well as the views and discussions expressed in these paper are solely those of the authors and do not necessarily represent the views of any partner organizations, the CDC or the U.S. Department of Health and Human Services nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. NR 21 TC 2 Z9 2 U1 0 U2 8 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1660-4601 J9 INT J ENV RES PUB HE JI Int. J. Environ. Res. Public Health PD SEP PY 2014 VL 11 IS 9 BP 9713 EP 9723 DI 10.3390/ijerph110909712 PG 11 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA AP4DN UT WOS:000342027500066 ER PT J AU Barshes, NR Gold, B Garcia, A Bechara, CF Pisimisis, G Kougias, P AF Barshes, Neal R. Gold, Benjamin Garcia, Aimee Bechara, Carlos F. Pisimisis, George Kougias, Panos TI Minor Amputation and Palliative Wound Care as a Strategy to Avoid Major Amputation in Patients With Foot Infections and Severe Peripheral Arterial Disease SO INTERNATIONAL JOURNAL OF LOWER EXTREMITY WOUNDS LA English DT Article DE palliative care; diabetic foot infection ID LOWER-EXTREMITY AMPUTATION; CLASSIFICATION-SYSTEM; SURGEONS; LIMB; SOCIETY; LIFE; END AB Foot infections occurring in patients with severe peripheral arterial disease (PAD) who are not considered candidates for revascularization and limb salvage efforts are generally treated with major amputations. Herein we describe our early experiences in managing foot infections with minor amputations and palliative wound care as a strategy to avoid the functional disability often associated with major amputations. Patients with severe PAD that underwent minor amputations and subsequent palliative wound care for moderate/severe infections were paired with age-matched controls with PAD that underwent primary major amputations for foot infections. Eleven patients who underwent minor amputations and palliative wound care of 13 limbs were compared to an age-matched cohort of 12 patients undergoing 13 major amputations.The median age was 80 years in both groups. Survival at 1 and 2 years did not differ significantly between groups. All patients who were ambulatory and/or independently living remained so following palliative management; in contrast, major amputation changed ambulatory status in 75% of patients and independent living status in 50%. Palliative management did not result in ascending/systemic sepsis or progressive necrosis. The need for reoperations was uncommon in both groups. In summary, minor amputations and operative drainage with subsequent palliative wound care appears to be a safe management option in patients with severe PAD and moderate or severe foot infections that are not candidates for revascularization. Palliative management may result in less functional impairment than major amputation. C1 [Barshes, Neal R.; Gold, Benjamin; Garcia, Aimee; Bechara, Carlos F.; Pisimisis, George; Kougias, Panos] Baylor Coll Med, Houston, TX 77030 USA. RP Barshes, NR (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Div Vasc & Endovasc Surg, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. EM nbarshes@bcm.tmc.edu NR 27 TC 8 Z9 9 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1534-7346 EI 1552-6941 J9 INT J LOW EXTR WOUND JI Int. J. Low. Extrem. Wounds PD SEP PY 2014 VL 13 IS 3 BP 211 EP 219 DI 10.1177/1534734614543663 PG 9 WC Dermatology; Surgery SC Dermatology; Surgery GA AP9GZ UT WOS:000342388300007 PM 25049375 ER PT J AU Abazeed, M Xu, C Adams, D Tamayo, P Loeffler, J Suh, J Meyerson, M Wong, K Hammerman, P AF Abazeed, M. Xu, C. Adams, D. Tamayo, P. Loeffler, J. Suh, J. Meyerson, M. Wong, K. Hammerman, P. TI NRF2 Is a Novel Oncogene and Biomarker of Therapeutic Resistance in Non-Small Cell Lung Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Abazeed, M.; Suh, J.] Cleveland Clin Fdn, Cleveland, OH 44195 USA. [Xu, C.; Meyerson, M.; Wong, K.; Hammerman, P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Adams, D.; Tamayo, P.] Broad Inst, Cambridge, MA USA. [Loeffler, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 224 BP S104 EP S105 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400236 ER PT J AU Abazeed, M Adams, D Tamayo, P Yard, B Loeffler, J Suh, J Meyerson, M Hammerman, P Schreiber, S AF Abazeed, M. Adams, D. Tamayo, P. Yard, B. Loeffler, J. Suh, J. Meyerson, M. Hammerman, P. Schreiber, S. TI The Radiogenomic Landscape of Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Abazeed, M.; Suh, J.] Cleveland Clin Fdn, Cleveland, OH 44195 USA. [Adams, D.; Tamayo, P.] Broad Inst, Cambridge, MA USA. [Yard, B.] Cleveland Clin, Cleveland, OH 44106 USA. [Loeffler, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Meyerson, M.; Hammerman, P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Schreiber, S.] Harvard Univ, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 66 BP S34 EP S34 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400077 ER PT J AU Aizer, AA Goldsmith, T Weyman, E Kim, M Holman, A Adams, J Kim, V Busse, PM Shusharina, N Lu, H DeLaney, TF Chan, AW AF Aizer, A. A. Goldsmith, T. Weyman, E. Kim, M. Holman, A. Adams, J. Kim, V. Busse, P. M. Shusharina, N. Lu, H. DeLaney, T. F. Chan, A. W. TI Assessment of Trismus After Chemoradiation for Nasopharyngeal Cancer: A Prospective Phase 2 Trial SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Aizer, A. A.] Harvard Radiat Oncol Program, Boston, MA USA. [Goldsmith, T.; Weyman, E.; Holman, A.; Adams, J.; Kim, V.; Busse, P. M.; Shusharina, N.; Lu, H.; DeLaney, T. F.; Chan, A. W.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kim, M.] Harvard Radiat Oncol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2810 BP S531 EP S531 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402027 ER PT J AU Al-Halabi, H Paetzold, P Olsen, C Bortfeld, T Willers, H AF Al-Halabi, H. Paetzold, P. Olsen, C. Bortfeld, T. Willers, H. TI A Contralateral Esophagus Sparing Technique to Limit Severe Esophagitis Associated With Concurrent Chemoradiation Therapy in Lung Cancer Patients SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Al-Halabi, H.; Paetzold, P.; Olsen, C.; Bortfeld, T.; Willers, H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3159 BP S668 EP S668 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402375 ER PT J AU Alcorn, SR Nilsson, K Dieckmann, K McNutt, TR Chen, MJ Ermoian, RP Ford, EC MacDonald, S Nechesnyuk, A Tryggestad, EJ Smith, K Villar, RC Winey, B Terezakis, SA AF Alcorn, S. R. Nilsson, K. Dieckmann, K. McNutt, T. R. Chen, M. J. Ermoian, R. P. Ford, E. C. MacDonald, S. Nechesnyuk, A. Tryggestad, E. J. Smith, K. Villar, R. C. Winey, B. Terezakis, S. A. TI Predictors of Setup Accuracy in Image-Guided CNS Radiation Therapy: Prospective Data From a Multinational Pediatrics Consortium SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Alcorn, S. R.] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. [Nilsson, K.] Univ Uppsala Hosp, Dept Radiat Oncol, Uppsala, Sweden. [Dieckmann, K.] Univ Klin Strahlentherapie & Strahlenbiol, A-1090 Vienna, Austria. [McNutt, T. R.; Smith, K.] Johns Hopkins Univ, Baltimore, MD USA. [Chen, M. J.] Grp Apoio Adolescente & Crianca Canc, BR-04558040 Sao Paulo, Brazil. [Ermoian, R. P.; Ford, E. C.] Univ Washington, Seattle, WA 98195 USA. [MacDonald, S.; Winey, B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nechesnyuk, A.] Fed Sci Clin Ctr Childrens Hematol Oncol & Immuno, Moscow, Russia. [Tryggestad, E. J.] Mayo Clin, Rochester, MD USA. [Villar, R. C.] Hosp Clin Sao Paulo, Sao Paulo, Brazil. [Terezakis, S. A.] Johns Hopkins Sch Med, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3302 BP S723 EP S723 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402517 ER PT J AU Bair, R Cimbak, N Wakefield, C Bair, E Viswanathan, AN AF Bair, R. Cimbak, N. Wakefield, C. Bair, E. Viswanathan, A. N. TI Radiopaque Polymer Hydrogel Used as a Fiducial Marker in Gynecologic Brachytherapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Bair, R.] Univ Chicago, Chicago, IL 60637 USA. [Bair, R.; Cimbak, N.; Wakefield, C.; Viswanathan, A. N.] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Hosp, Boston, MA USA. [Bair, E.] Univ N Carolina, Chapel Hill, NC USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2744 BP S505 EP S505 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331401645 ER PT J AU Baldini, EH Bosch, W Abrams, RA Roberge, D Olsen, JR Haas, RL Catton, CN Indelicato, DJ DeLaney, TF Wang, D AF Baldini, E. H. Bosch, W. Abrams, R. A. Roberge, D. Olsen, J. R. Haas, R. L. Catton, C. N. Indelicato, D. J. DeLaney, T. F. Wang, D. TI Retroperitoneal Sarcoma (RPS) Target Volume and Organ at Risk (OAR) Contour Delineation Agreement Among RTOG Sarcoma Radiation Oncologists SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Baldini, E. H.] Brigham & Womens Dana Farber Canc Ctr, Boston, MA USA. [Bosch, W.; Olsen, J. R.] Washington Univ, St Louis, MO USA. [Abrams, R. A.; Wang, D.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Roberge, D.] Ctr Hosp Univ Montreal, Montreal, PQ, Canada. [Haas, R. L.] Netherlands Canc Inst, Amsterdam, Netherlands. [Catton, C. N.] Princess Margaret Canc Ctr, Toronto, ON, Canada. [Indelicato, D. J.] Univ Florida, Med Ctr, Jacksonville, FL 32209 USA. [DeLaney, T. F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 253 BP S116 EP S117 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400265 ER PT J AU Beard, CJ Jeldres, C Odem-Davis, K Hoffman, KE Martin, NE Nguyen, PL Porter, CR Sweeney, CJ Kollmannsberger, C Nichols, CR AF Beard, C. J. Jeldres, C. Odem-Davis, K. Hoffman, K. E. Martin, N. E. Nguyen, P. L. Porter, C. R. Sweeney, C. J. Kollmannsberger, C. Nichols, C. R. TI Variation in Patterns of Care in the United States for Clinical Stage I Seminoma: Results From the National Cancer Data Base (1998-2011) SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Beard, C. J.; Martin, N. E.; Nguyen, P. L.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Jeldres, C.; Odem-Davis, K.; Porter, C. R.; Nichols, C. R.] Virginia Mason Med Ctr, Seattle, WA 98101 USA. [Hoffman, K. E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Sweeney, C. J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kollmannsberger, C.] BC Canc Agcy, Vancouver, BC, Canada. RI Martin, Neil/E-2193-2014 OI Martin, Neil/0000-0002-8164-8516 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2651 BP S469 EP S469 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331401552 ER PT J AU Berbeco, RI Korideck, H Kumar, R Sridhar, S Detappe, A Ngwa, W Makrigiorgos, M AF Berbeco, R. I. Korideck, H. Kumar, R. Sridhar, S. Detappe, A. Ngwa, W. Makrigiorgos, M. TI Targeted Gold Nanoparticles as Vascular Disrupting Agents During Radiation Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Berbeco, R. I.; Korideck, H.; Detappe, A.; Ngwa, W.; Makrigiorgos, M.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Berbeco, R. I.; Korideck, H.; Detappe, A.; Ngwa, W.; Makrigiorgos, M.] Harvard Univ, Sch Med, Boston, MA USA. [Kumar, R.; Sridhar, S.] Northeastern Univ, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 2 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 1098 BP S198 EP S198 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400457 ER PT J AU Bhatt, AD Jacobson, A Lee, RY Giraud, C Schwab, J Hornicek, F Nielsen, P Choy, E Harmon, D DeLaney, TF Chen, YE AF Bhatt, A. D. Jacobson, A. Lee, R. Y. Giraud, C. Schwab, J. Hornicek, F. Nielsen, P. Choy, E. Harmon, D. DeLaney, T. F. Chen, Y. E. TI High-Dose Proton Beam Boosted Radiation Therapy in the Management of Non-Skull Base Chondrosarcomas SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Bhatt, A. D.; Jacobson, A.; Lee, R. Y.; Giraud, C.; Schwab, J.; Hornicek, F.; Nielsen, P.; Choy, E.; Harmon, D.; DeLaney, T. F.; Chen, Y. E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3411 BP S766 EP S767 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331403015 ER PT J AU Braunstein, LZ Chen, Y Lee, SW Mauch, PM Ng, AK AF Braunstein, L. Z. Chen, Y. Lee, S. W. Mauch, P. M. Ng, A. K. TI Predictive Factors for Ophthalmic Toxicity in Patients Receiving Radiation Therapy for Ocular Adnexal or Periorbital Lymphoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Braunstein, L. Z.] Harvard Radiat Oncol Program, Boston, MA USA. [Chen, Y.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Lee, S. W.; Mauch, P. M.; Ng, A. K.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3182 BP S676 EP S677 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402398 ER PT J AU Braunstein, LZ Brock, JE Chen, Y Truong, L Russo, AL Arvold, ND Harris, JR AF Braunstein, L. Z. Brock, J. E. Chen, Y. Truong, L. Russo, A. L. Arvold, N. D. Harris, J. R. TI Invasive Lobular Carcinoma (ILC) of the Breast: Local Recurrence (LR) After Breast-Conserving Therapy (BCT) by Subtype Approximation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Braunstein, L. Z.] Harvard Radiat Oncol Program, Boston, MA USA. [Brock, J. E.; Truong, L.; Russo, A. L.; Harris, J. R.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Chen, Y.; Harris, J. R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Russo, A. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Russo, A. L.] Harvard Med Sch Program, Boston, MA USA. [Arvold, N. D.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2067 BP S243 EP S244 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400568 ER PT J AU Braunstein, LZ Niemierko, A Shenouda, M Truong, L Sadek, BT Abi-Raad, RF Wong, JS Punglia, RS Taghian, AG Bellon, JR AF Braunstein, L. Z. Niemierko, A. Shenouda, M. Truong, L. Sadek, B. T. Abi-Raad, R. F. Wong, J. S. Punglia, R. S. Taghian, A. G. Bellon, J. R. TI Outcome Following Local-Regional Recurrence (LRR) in Women With Early-Stage Breast Cancer: Impact of Biologic Subtype SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Braunstein, L. Z.] Harvard Radiat Oncol Program, Boston, MA USA. [Niemierko, A.; Shenouda, M.; Sadek, B. T.; Abi-Raad, R. F.; Taghian, A. G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Truong, L.; Wong, J. S.; Bellon, J. R.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Punglia, R. S.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. RI Sadek, Betro/I-7734-2013 OI Sadek, Betro/0000-0003-0119-7207 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 1030 BP S170 EP S170 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400390 ER PT J AU Burkeen, J Alexander, BM Horvath, MC Christianson, LW Dyer, MA Dunn, IF Golby, AJ Johnson, MD Claus, EB Chiocca, EA Lee, EQ Lin, NU Marcus, KJ Friesen, S Mannarino, EG Wagar, M Hacker, FL Arvold, ND AF Burkeen, J. Alexander, B. M. Horvath, M. C. Christianson, L. W. Dyer, M. A. Dunn, I. F. Golby, A. J. Johnson, M. D. Claus, E. B. Chiocca, E. A. Lee, E. Q. Lin, N. U. Marcus, K. J. Friesen, S. Mannarino, E. G. Wagar, M. Hacker, F. L. Arvold, N. D. TI Lower-Dose Stereotactic Radiosurgery for Small Brain Metastases: Local Control and Toxicity SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Burkeen, J.; Alexander, B. M.; Horvath, M. C.; Christianson, L. W.; Dyer, M. A.; Dunn, I. F.; Golby, A. J.; Johnson, M. D.; Claus, E. B.; Chiocca, E. A.; Lee, E. Q.; Lin, N. U.; Marcus, K. J.; Friesen, S.; Mannarino, E. G.; Wagar, M.; Hacker, F. L.; Arvold, N. D.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2261 BP S320 EP S321 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331401165 ER PT J AU Chan, AW Kim, M Aizer, AA McBride, SM Weyman, E Liebsch, NJ AF Chan, A. W. Kim, M. Aizer, A. A. McBride, S. M. Weyman, E. Liebsch, N. J. TI Refinement and Individualization of Clinical Target Volume Delineation in Nasopharyngeal Carcinoma: A 22-Year Clinical Experience SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Chan, A. W.; Kim, M.; Aizer, A. A.; McBride, S. M.; Weyman, E.; Liebsch, N. J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2809 BP S530 EP S531 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402026 ER PT J AU Chandra, RA Miller, C Skolny, M Warren, L Horick, N Jammallo, L Sadek, B Shenouda, M O'Toole, J Specht, M Taghian, A AF Chandra, R. A. Miller, C. Skolny, M. Warren, L. Horick, N. Jammallo, L. Sadek, B. Shenouda, M. O'Toole, J. Specht, M. Taghian, A. TI Radiation Therapy Risk Factors for the Development of Lymphedema in Patients Treated With Regional Lymph Node Irradiation for Breast Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Chandra, R. A.; Warren, L.] Harvard Univ, Sch Med, Harvard Radiat Oncol Program, Boston, MA USA. [Miller, C.] Harvard Univ, Sch Med, Boston, MA USA. [Skolny, M.; Horick, N.; Jammallo, L.; Sadek, B.; Shenouda, M.; O'Toole, J.; Specht, M.; Taghian, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2030 BP S229 EP S230 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400532 ER PT J AU Chen, AB Li, L Cronin, A Schrag, D AF Chen, A. B. Li, L. Cronin, A. Schrag, D. TI Comparative Effectiveness of Intensity-Modulated Versus 3D Conformal Radiation for Stage III Non-small Cell Lung Cancer in the Medicare Population SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Chen, A. B.; Li, L.; Cronin, A.; Schrag, D.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 301 BP S138 EP S138 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400313 ER PT J AU Cheney, MD Chen, Y Lim, R Winrich, BK Grosu, AL Trofimov, AV Depauw, N Shih, HA Schwab, JH Hornicek, FJ DeLaney, TF AF Cheney, M. D. Chen, Y. Lim, R. Winrich, B. K. Grosu, A. L. Trofimov, A. V. Depauw, N. Shih, H. A. Schwab, J. H. Hornicek, F. J. DeLaney, T. F. TI 18F-FMISO PET/CT Visualization of Tumor Hypoxia in Patients With Chordoma of the Mobile and Sacrococcygeal Spine SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Cheney, M. D.] Harvard Radiat Oncol Program, Boston, MA USA. [Chen, Y.; Lim, R.; Winrich, B. K.; Grosu, A. L.; Trofimov, A. V.; Depauw, N.; Shih, H. A.; Schwab, J. H.; Hornicek, F. J.; DeLaney, T. F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Depauw, N.] Univ Wollongong, Wollongong, NSW, Australia. NR 0 TC 0 Z9 0 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3379 BP S753 EP S753 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402593 ER PT J AU Cheney, MD Lam, T Jaehn, BA Damato, AL Krishnan, MS Balboni, TA AF Cheney, M. D. Lam, T. Jaehn, B. A. Damato, A. L. Krishnan, M. S. Balboni, T. A. TI Re-irradiation for Spinal Metastases: A Single-Institution Series Examining Radiation Myelopathy and Disease Outcomes SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Cheney, M. D.] Harvard Radiat Oncol Program, Boston, MA USA. [Lam, T.; Jaehn, B. A.; Damato, A. L.; Krishnan, M. S.; Balboni, T. A.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3226 BP S693 EP S693 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402441 ER PT J AU Chin, JY Sethi, RV Goebel, CP Rapalino, O Tarbell, NJ Yock, TI MacDonald, SM AF Chin, J. Y. Sethi, R. V. Goebel, C. P. Rapalino, O. Tarbell, N. J. Yock, T. I. MacDonald, S. M. TI Incidence of Optic Nerve Involvement in Pediatric Intracranial Germ Cell Tumors SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Chin, J. Y.] Harvard Radiat Oncol Program, Boston, MA USA. [Sethi, R. V.] Harvard Univ, Sch Med, Boston, MA USA. [Goebel, C. P.; Rapalino, O.; Tarbell, N. J.; Yock, T. I.; MacDonald, S. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3297 BP S721 EP S721 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402512 ER PT J AU Choi, NC Chun, TT Niemierko, A Ancukiewicz, M Fidias, PM Mathisen, DJ Fischman, AJ AF Choi, N. C. Chun, T. T. Niemierko, A. Ancukiewicz, M. Fidias, P. M. Mathisen, D. J. Fischman, A. J. TI Metabolic Response of Lung Cancer Measured With F-18-FDG PET at Sequential Intervals After Radiochemotherapy (RT plus CT) and Its Predictive Power for Tumor Control: Primary Tumor Versus Involved Regional Lymph Node SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Choi, N. C.; Chun, T. T.; Niemierko, A.; Ancukiewicz, M.; Fidias, P. M.; Mathisen, D. J.; Fischman, A. J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 1133 BP S212 EP S212 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400491 ER PT J AU Daartz, J Shih, HA Chapman, PH Loeffler, JS Bussiere, MR AF Daartz, J. Shih, H. A. Chapman, P. H. Loeffler, J. S. Bussiere, M. R. TI Technical Aspects of a Proton Stereotactic Radiosurgery Program SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Daartz, J.; Shih, H. A.; Chapman, P. H.; Loeffler, J. S.; Bussiere, M. R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3817 BP S927 EP S928 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331403419 ER PT J AU Damato, AL Molodowitch, C Bhagwat, M Buzurovic, I Devlin, PM Friesen, S Hansen, J Lee, LJ Nguyen, PL O'Farrell, D Viswanathan, AN Williams, C Cormack, RA Killoran, JH AF Damato, A. L. Molodowitch, C. Bhagwat, M. Buzurovic, I. Devlin, P. M. Friesen, S. Hansen, J. Lee, L. J. Nguyen, P. L. O'Farrell, D. Viswanathan, A. N. Williams, C. Cormack, R. A. Killoran, J. H. TI Review of High-Dose-Rate (HDR) Brachytherapy Plan Errors: Effect of Software-Aided Verification on Effectiveness and Efficiency of the Physics Plan Quality Assurance (QA) Process SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Damato, A. L.; Molodowitch, C.; Bhagwat, M.; Buzurovic, I.; Devlin, P. M.; Friesen, S.; Hansen, J.; Lee, L. J.; Nguyen, P. L.; O'Farrell, D.; Viswanathan, A. N.; Williams, C.; Cormack, R. A.; Killoran, J. H.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 278 BP S127 EP S128 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400290 ER PT J AU Depauw, N Batin, E Daartz, J MacDonald, S Kooy, H Lu, H AF Depauw, N. Batin, E. Daartz, J. MacDonald, S. Kooy, H. Lu, H. TI A Novel Proton Pencil Beam Scanning Technique for Postmastectomy Chest Wall Irradiation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Depauw, N.; Batin, E.; Daartz, J.; MacDonald, S.; Kooy, H.; Lu, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Depauw, N.] Univ Wollongong, Wollongong, NSW, Australia. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3829 BP S932 EP S932 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331403431 ER PT J AU Dyer, MA Yeap, BY Kovtun, K Kuhlthau, KA Miller, KK Oh, KS Klibanski, A Swearingen, B Loeffler, JS Shih, HA AF Dyer, M. A. Yeap, B. Y. Kovtun, K. Kuhlthau, K. A. Miller, K. K. Oh, K. S. Klibanski, A. Swearingen, B. Loeffler, J. S. Shih, H. A. TI Quality of Life in Patients Treated With Surgery Alone Versus Surgery and Radiation for Nonfunctioning Pituitary Adenomas SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Dyer, M. A.] Harvard Radiat Oncol Program, Boston, MA USA. [Yeap, B. Y.; Kuhlthau, K. A.; Miller, K. K.; Oh, K. S.; Klibanski, A.; Swearingen, B.; Loeffler, J. S.; Shih, H. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kovtun, K.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2207 BP S300 EP S300 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331401112 ER PT J AU Eaton, BR Esiashvili, N Kim, S Patterson, B Weyman, E Thornton, LT Kasper, H Mazewski, C MacDonald, T Ebb, D MacDonlad, S Tarbell, N Yock, T AF Eaton, B. R. Esiashvili, N. Kim, S. Patterson, B. Weyman, E. Thornton, L. T. Kasper, H. Mazewski, C. MacDonald, T. Ebb, D. MacDonlad, S. Tarbell, N. Yock, T. TI Clinical Outcomes Among Children With Standard Risk Medulloblastoma in Proton and Photon Treated Cohorts SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Eaton, B. R.; Esiashvili, N.; Kim, S.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Patterson, B.; Mazewski, C.; MacDonald, T.] Emory Univ, Atlanta, GA 30322 USA. [Patterson, B.; Mazewski, C.; MacDonald, T.] Childrens Healthcare Atlanta, Aflac Canc & Blood Disorders Ctr, Atlanta, GA USA. [Weyman, E.; Thornton, L. T.; Kasper, H.; Ebb, D.; MacDonlad, S.; Tarbell, N.; Yock, T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 245 BP S113 EP S113 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400257 ER PT J AU Epperly, M Shinde, A Rhieu, B Berhane, H Guinan, E Parmar, K Wang, H Franicola, D Zhang, X Dixon, T Greenberger, JS AF Epperly, M. Shinde, A. Rhieu, B. Berhane, H. Guinan, E. Parmar, K. Wang, H. Franicola, D. Zhang, X. Dixon, T. Greenberger, J. S. TI Intraoral GS-Nitroxide JP4-039 in Novel F15 Emulsion Ameliorates Irradiation-Induced Mucositis in Tumor Bearing Fanconi Anemia (FA) (Fancd2-/-) C57BL/6 Mice SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Epperly, M.; Shinde, A.; Rhieu, B.; Berhane, H.; Wang, H.; Franicola, D.; Zhang, X.; Dixon, T.; Greenberger, J. S.] Univ Pittsburgh, Pittsburgh, PA USA. [Berhane, H.; Guinan, E.; Parmar, K.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3442 BP S777 EP S778 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331403046 ER PT J AU Evans, JR Zhao, S Daignault-Newton, S Sanda, M Michalski, J Sandler, HM Kuban, DA Ciezki, JP Kaplan, ID Zietman, AL Hembroff, L Feng, F Suy, S Mantz, CA Collins, S Hamstra, DA AF Evans, J. R. Zhao, S. Daignault-Newton, S. Sanda, M. Michalski, J. Sandler, H. M. Kuban, D. A. Ciezki, J. P. Kaplan, I. D. Zietman, A. L. Hembroff, L. Feng, F. Suy, S. Mantz, C. A. Collins, S. Hamstra, D. A. TI Comparative Effectiveness Analysis of Patient-Reported Quality of Life (QOL) After Stereotactic Body Radiation Therapy as Compared to Intensity Modulated Radiation Therapy or Low-Dose-Rate Brachytherapy up to 2 Years After Treatment SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Evans, J. R.; Zhao, S.; Daignault-Newton, S.; Feng, F.] Univ Michigan Radiat Oncol, Ann Arbor, MI USA. [Sanda, M.] Emory Univ, Atlanta, GA 30322 USA. [Michalski, J.] Washington Univ, Med Ctr, St Louis, MO USA. [Sandler, H. M.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Kuban, D. A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Ciezki, J. P.] Cleveland Clin, Cleveland, OH 44106 USA. [Kaplan, I. D.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Zietman, A. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hembroff, L.] Michigan State Univ, E Lansing, MI 48824 USA. [Suy, S.; Collins, S.] Georgetown Univ, Washington, DC USA. [Mantz, C. A.] 21st Century Oncol, Ft Myers, FL USA. RI Sanda, Martin/B-2023-2015 NR 0 TC 0 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2494 BP S409 EP S409 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331401398 ER PT J AU Giantsoudi, D Sethi, RV Yeap, B Yock, TI Tarbell, NJ Paganetti, H MacDonald, SM AF Giantsoudi, D. Sethi, R. V. Yeap, B. Yock, T. I. Tarbell, N. J. Paganetti, H. MacDonald, S. M. TI Symptomatic Treatment Change in Medulloblastoma Patients After Proton RT: LET Distributions and RBE Associations SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3810 BP S924 EP S925 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331403412 ER PT J AU Golden, DW Spektor, A Krishnan, MS Thaker, NG Mancini, BR Braunstein, S Mohindra, P Hung, AY Kharofa, JR Ye, JC Du, KL Jimenez, RB AF Golden, D. W. Spektor, A. Krishnan, M. S. Thaker, N. G. Mancini, B. R. Braunstein, S. Mohindra, P. Hung, A. Y. Kharofa, J. R. Ye, J. C. Du, K. L. Jimenez, R. B. TI Implementation and Evaluation of a Multi-institutional Radiation Oncology Clerkship Curriculum: A Report From the Radiation Oncology Education Collaborative Study Group SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Golden, D. W.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA. [Spektor, A.; Krishnan, M. S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Spektor, A.; Krishnan, M. S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Thaker, N. G.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Mancini, B. R.] Yale Univ, Sch Med, New Haven, CT USA. [Braunstein, S.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Mohindra, P.] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA. [Hung, A. Y.] Oregon Hlth & Sci Univ, Portland, OR USA. [Kharofa, J. R.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Ye, J. C.] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA. [Du, K. L.] NYU, Sch Med, New York, NY USA. [Jimenez, R. B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2990 BP S600 EP S600 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402206 ER PT J AU Gray, PJ Lin, C Jemal, A Efstathiou, JA AF Gray, P. J. Lin, C. Jemal, A. Efstathiou, J. A. TI Recent Trends in the Management of Localized Prostate Cancer: Results From the National Cancer Data Base SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Gray, P. J.; Efstathiou, J. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lin, C.; Jemal, A.] Amer Canc Soc, Atlanta, GA 30329 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2553 BP S431 EP S432 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331401455 ER PT J AU Gray, PJ Lin, C Jemal, A Efstathiou, JA AF Gray, P. J. Lin, C. Jemal, A. Efstathiou, J. A. TI Modern Practice Patterns and Survival for Testicular Seminoma: Results from the National Cancer Data Base SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Gray, P. J.; Efstathiou, J. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lin, C.; Jemal, A.] Amer Canc Soc, Atlanta, GA 30329 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 291 BP S133 EP S133 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400303 ER PT J AU Haas-Kogan, D Douglas, J London, WB Van Ryn, CJM von Allmen, D Davidoff, AM Villablanca, JG Matthay, KK DuBois, SG Kreissman, SG La Quaglia, MP Park, JR AF Haas-Kogan, D. Douglas, J. London, W. B. Van Ryn, C. J. McCauley von Allmen, D. Davidoff, A. M. Villablanca, J. G. Matthay, K. K. DuBois, S. G. Kreissman, S. G. La Quaglia, M. P. Park, J. R. TI Extent of Lymph Node Radiation Coverage in High-Risk Neuroblastoma Does Not Affect Clinical Outcome: A-Report From the COG A3973 Study SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Haas-Kogan, D.; Matthay, K. K.; DuBois, S. G.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Douglas, J.] Indiana Univ, Bloomington, IN USA. [London, W. B.] Dana Farber Canc Inst, Boston, MA 02115 USA. [von Allmen, D.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Davidoff, A. M.] St Jude Childrens Res Hosp, Memphis, TN 38105 USA. [Villablanca, J. G.] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. [Kreissman, S. G.] Duke Univ, Med Ctr, Durham, NC USA. [La Quaglia, M. P.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Park, J. R.] Seattle Childrens Hosp, Seattle, WA USA. EM cvanryn@cog.ufl.edu NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 247 BP S114 EP S114 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400260 ER PT J AU Hattangadi, JA Murphy, J Sanghvi, P Recht, A Punglia, RS AF Hattangadi, J. A. Murphy, J. Sanghvi, P. Recht, A. Punglia, R. S. TI A 25-Year Epidemiologic Study of Medical Malpractice Claims in Radiation Oncology SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Hattangadi, J. A.; Murphy, J.; Sanghvi, P.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Recht, A.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Punglia, R. S.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3368 BP S749 EP S749 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402582 ER PT J AU Hearn, JW Yard, BD Adams, DJ Tamayo, P Schreiber, SL Meyerson, ML Hammerman, PS Abazeed, ME AF Hearn, J. W. Yard, B. D. Adams, D. J. Tamayo, P. Schreiber, S. L. Meyerson, M. L. Hammerman, P. S. Abazeed, M. E. TI Integrative Radiogenomic Profiling Identifies BRAF Mutations as Novel Radiotherapeutic Targets in Adenocarcinomas of the Lung SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Hearn, J. W.; Abazeed, M. E.] Cleveland Clin, Dept Radiat Oncol, Cleveland, OH 44106 USA. [Yard, B. D.] Cleveland Clin, Cleveland, OH 44106 USA. [Adams, D. J.; Tamayo, P.; Schreiber, S. L.; Meyerson, M. L.; Hammerman, P. S.] Broad Inst MIT & Harvard, Cambridge, MA USA. [Schreiber, S. L.] Harvard Univ, Cambridge, MA 02138 USA. [Meyerson, M. L.; Hammerman, P. S.] Dana Farber Canc Inst, Cambridge, MA USA. [Meyerson, M. L.] Brigham & Womens Hosp, Cambridge, MA USA. [Abazeed, M. E.] Cleveland Clin, Dept Translat Hematol & Oncol Res, Cleveland, OH 44106 USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 219 BP S101 EP S102 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400231 ER PT J AU Hong, TS Moughan, J Garofalo, M Bendell, J Berger, AC Oldenburg, NB Anne, PA Perera, F Lee, RJ Jabbour, SK Nowlan, A DeNittis, AS Crane, CH AF Hong, T. S. Moughan, J. Garofalo, M. Bendell, J. Berger, A. C. Oldenburg, N. B. Anne, P. A. Perera, F. Lee, R. J. Jabbour, S. K. Nowlan, A. DeNittis, A. S. Crane, C. H. TI Efficacy Outcomes from RTOG 0822: A Phase II Study of Neoadjuvant IMRT with Capecitabine (c) and Oxaliplatin (o) in Patients with Locally Advanced Rectal Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Hong, T. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Moughan, J.] Ctr Stat, Radiat Therapy Oncol Grp, Philadelphia, PA USA. [Garofalo, M.] Univ Maryland, Baltimore, MD 21201 USA. [Bendell, J.] Sarrah Cannon Res Inst, Nashville, TN USA. [Berger, A. C.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. [Oldenburg, N. B.] North Main Radiat Oncol, Providence, RI USA. [Anne, P. A.] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA. [Perera, F.] London Reg Canc Program Western Ontario, London, ON, Canada. [Lee, R. J.] Intermt Med Ctr, Murray, UT USA. [Jabbour, S. K.] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA. [Nowlan, A.] Piedmont Hosp, Atlanta, GA USA. [DeNittis, A. S.] Main Line CCOP, Wynnewood, PA USA. [Crane, C. H.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 36 BP S21 EP S21 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400047 ER PT J AU Hou, Y Hermann, G Lewis, JH Aerts, HJ Baldini, EH Chen, AB Colson, YL Hacker, FL Killoran, J Kozono, DE Wee, JO Mak, RH AF Hou, Y. Hermann, G. Lewis, J. H. Aerts, H. J. Baldini, E. H. Chen, A. B. Colson, Y. L. Hacker, F. L. Killoran, J. Kozono, D. E. Wee, J. O. Mak, R. H. TI Outcomes and Toxicity After Lung Stereotactic Body Radiation Therapy (SBRT) in Patients (Pts) With a History of Prior Lung Resection or Radiofrequency Ablation (RFA) SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Hou, Y.; Hermann, G.; Lewis, J. H.; Aerts, H. J.; Baldini, E. H.; Chen, A. B.; Hacker, F. L.; Killoran, J.; Kozono, D. E.; Mak, R. H.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Lewis, J. H.; Aerts, H. J.; Baldini, E. H.; Chen, A. B.; Colson, Y. L.; Hacker, F. L.; Killoran, J.; Kozono, D. E.; Wee, J. O.; Mak, R. H.] Harvard Univ, Sch Med, Boston, MA USA. [Colson, Y. L.; Wee, J. O.] Brigham & Womens Hosp, Div Thorac Surg, Boston, MA 02115 USA. RI Aerts, Hugo/P-6350-2015 OI Aerts, Hugo/0000-0002-2122-2003 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3140 BP S660 EP S660 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402356 ER PT J AU Huang, P Jacobson, A Giraud, C Choy, E Harmon, D DeLaney, TF Chen, Y AF Huang, P. Jacobson, A. Giraud, C. Choy, E. Harmon, D. DeLaney, T. F. Chen, Y. TI Outcomes of Head and Neck Osteosarcoma: Ten-Year Experience at a Single Institution SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Huang, P.; Jacobson, A.; Giraud, C.; DeLaney, T. F.; Chen, Y.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Huang, P.] Taipei Vet Gen Hosp, Ctr Canc, Taipei, Taiwan. [Choy, E.; Harmon, D.] Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA 02114 USA. [Choy, E.; Harmon, D.; DeLaney, T. F.; Chen, Y.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3389 BP S757 EP S758 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402603 ER PT J AU Hurwitz, M Williams, CL Mishra, P Dhou, S Lewis, J AF Hurwitz, M. Williams, C. L. Mishra, P. Dhou, S. Lewis, J. TI Investigation of a Respiratory Motion Model Based on an External Surrogate Signal With a Digital Phantom and Realistic Patient Breathing SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Hurwitz, M.; Williams, C. L.; Mishra, P.; Dhou, S.; Lewis, J.] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Ctr, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3617 BP S846 EP S846 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331403221 ER PT J AU Jacobson, A Giraud, C Hornicek, F Raskin, K Schwab, J Mullen, J Harmon, D Choy, E Nielsen, G DeLaney, T Chen, Y AF Jacobson, A. Giraud, C. Hornicek, F. Raskin, K. Schwab, J. Mullen, J. Harmon, D. Choy, E. Nielsen, G. DeLaney, T. Chen, Y. TI Outcomes of Patients With Synovial Sarcomas Treated With Multimodality Therapy: A Single-Institution Review SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Jacobson, A.; Giraud, C.; Hornicek, F.; Raskin, K.; Schwab, J.; Mullen, J.; Harmon, D.; Choy, E.; Nielsen, G.; DeLaney, T.; Chen, Y.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3403 BP S763 EP S764 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331403007 ER PT J AU Jimenez, RB Chin, JY Tseng, YD Adams, J Yock, TI Ebb, D Tarbell, NJ MacDonald, SM AF Jimenez, R. B. Chin, J. Y. Tseng, Y. D. Adams, J. Yock, T. I. Ebb, D. Tarbell, N. J. MacDonald, S. M. TI Proton Radiation Therapy for Pediatric Craniopharyngioma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Jimenez, R. B.; Chin, J. Y.; Tseng, Y. D.] Harvard Radiat Oncol Program, Boston, MA USA. [Adams, J.; Yock, T. I.; Ebb, D.; Tarbell, N. J.; MacDonald, S. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3306 BP S725 EP S725 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402521 ER PT J AU Keane, FK Chen, Y Neville, B Tishler, RB Schoenfeld, JD Catalano, P Margalit, DN AF Keane, F. K. Chen, Y. Neville, B. Tishler, R. B. Schoenfeld, J. D. Catalano, P. Margalit, D. N. TI The Prognostic Significance of T-Stage and N-Stage in Patients With Squamous Cell Carcinoma of the Oropharynx (OPSCC) in the HPV Era SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Keane, F. K.] Harvard Radiat Oncol Program, Boston, MA USA. [Chen, Y.; Catalano, P.] Dana Farber Harvard Canc Ctr, Boston, MA USA. [Neville, B.] Brigham & Womens Hosp, Ariadne Labs, Boston, MA 02115 USA. [Tishler, R. B.; Schoenfeld, J. D.; Margalit, D. N.] Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2765 BP S513 EP S513 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331401666 ER PT J AU Kim, M Aizer, AA Weyman, E McBride, SM Wirth, L Clark, J Rothenberg, SM Busse, PM Chan, AW AF Kim, M. Aizer, A. A. Weyman, E. McBride, S. M. Wirth, L. Clark, J. Rothenberg, S. M. Busse, P. M. Chan, A. W. TI Sequential Versus Concurrent Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma: A US-Based Study SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Kim, M.; Aizer, A. A.] Harvard Radiat Oncol Program, Boston, MA USA. [Weyman, E.; Wirth, L.; Clark, J.; Rothenberg, S. M.; Busse, P. M.; Chan, A. W.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [McBride, S. M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2806 BP S529 EP S529 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402023 ER PT J AU Korideck, H Kumar, R Herter-Sprie, G Wong, K Srinivas, S Kozona, D Berbeco, R Makrigiorgos, M Ngwa, W AF Korideck, H. Kumar, R. Herter-Sprie, G. Wong, K. Srinivas, S. Kozona, D. Berbeco, R. Makrigiorgos, M. Ngwa, W. TI Intratracheal Delivery of Gold Nanoparticles for Radiation Therapy in Murine Lung Adenocarcinoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Korideck, H.; Kumar, R.; Herter-Sprie, G.; Wong, K.; Srinivas, S.; Kozona, D.; Berbeco, R.; Makrigiorgos, M.; Ngwa, W.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Korideck, H.; Wong, K.; Kozona, D.; Berbeco, R.; Makrigiorgos, M.; Ngwa, W.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Kumar, R.; Srinivas, S.] Northeastern Univ, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3855 BP S942 EP S943 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331403457 ER PT J AU Kozono, DE Kushwaha, D O'Leary, C Cron, KR Zhu, K Merzon, D D'Andrea, AD AF Kozono, D. E. Kushwaha, D. O'Leary, C. Cron, K. R. Zhu, K. Merzon, D. D'Andrea, A. D. TI Whole Genome RNAi Screens Identify USP9X Inhibition as a Strategy for NSCLC Radiosensitization SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Kozono, D. E.; Kushwaha, D.; O'Leary, C.; Cron, K. R.; Zhu, K.; Merzon, D.; D'Andrea, A. D.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 220 BP S102 EP S102 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400232 ER PT J AU Lam, T Uno, H Krishnan, MS Cheney, M Balboni, TA AF Lam, T. Uno, H. Krishnan, M. S. Cheney, M. Balboni, T. A. TI Adverse Outcomes After Palliative Radiation Therapy for Uncomplicated Spine Metastases: Role of Spinal Instability and Single-Fraction Radiation Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Lam, T.; Balboni, T. A.] Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA USA. [Uno, H.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Krishnan, M. S.] Dana Farber South Shore Hosp, Dept Radiat Oncol, Boston, MA USA. [Cheney, M.] Harvard Radiat Oncol Program, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3239 BP S697 EP S698 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402454 ER PT J AU Lautenschlaeger, T Efstathiou, JA Shipley, WU Meng, W McElroy, J Paly, JJ Ibrahim, A Nguyen, P Volinia, S Saylor, P Clayman, RH Clinton, S Mortazavi, A Wu, C Chakravarti, A AF Lautenschlaeger, T. Efstathiou, J. A. Shipley, W. U. Meng, W. McElroy, J. Paly, J. J. Ibrahim, A. Nguyen, P. Volinia, S. Saylor, P. Clayman, R. H. Clinton, S. Mortazavi, A. Wu, C. Chakravarti, A. TI Novel Predictive MicroRNA Signature in the Setting of Selective Trimodality Bladder Preservation Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Lautenschlaeger, T.; Meng, W.; McElroy, J.; Ibrahim, A.; Nguyen, P.; Volinia, S.; Clinton, S.; Mortazavi, A.; Chakravarti, A.] Ohio State Univ, Columbus, OH 43210 USA. [Efstathiou, J. A.; Shipley, W. U.; Paly, J. J.; Saylor, P.; Clayman, R. H.; Wu, C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Meng, Wei/J-2753-2015; Mortazavi, Amir/E-3701-2011 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2635 BP S462 EP S462 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331401536 ER PT J AU Li, A Chen, X Zhang, Q Kirsch, DG Petersen, I DeLaney, T Freeman, C Trotti, A Hitchcock, YJ Wang, D AF Li, A. Chen, X. Zhang, Q. Kirsch, D. G. Petersen, I. DeLaney, T. Freeman, C. Trotti, A. Hitchcock, Y. J. Wang, D. TI A Comparison of 6 IGRT Modalities Used for Soft-Tissue Sarcoma of the Extremity in RTOG 0630 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Li, A.; Chen, X.; Wang, D.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Zhang, Q.] RTOG Stat Ctr, Philadelphia, PA USA. [Kirsch, D. G.] Duke Univ, Med Ctr, Durham, NC USA. [Petersen, I.] Mayo Clin, Rochester, MN USA. [DeLaney, T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Freeman, C.] McGill Univ, Montreal, PQ, Canada. [Trotti, A.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Hitchcock, Y. J.] Univ Utah, Huntsman Canc Hosp, Salt Lake City, UT USA. [Wang, D.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3583 BP S831 EP S832 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331403187 ER PT J AU Li, PC Liebsch, NJ Niemierko, A Shih, HA AF Li, P. C. Liebsch, N. J. Niemierko, A. Shih, H. A. TI Radiation Tolerance of the Optic Pathway After Fractionated Proton Radiation Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Li, P. C.] Harvard Univ, Sch Med, Boston, MA USA. [Liebsch, N. J.; Niemierko, A.; Shih, H. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2216 BP S303 EP S304 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331401121 ER PT J AU Lin, C Gray, PJ Jemal, A Efstathiou, JA AF Lin, C. Gray, P. J. Jemal, A. Efstathiou, J. A. TI Radiation Therapy for Clinically Node-Positive Prostate Cancer and Survival: Results from the National Cancer Data Base SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Lin, C.; Jemal, A.] Amer Canc Soc, Atlanta, GA 30329 USA. [Gray, P. J.] Harvard Radiat Oncol Program, Boston, MA USA. [Efstathiou, J. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 19 BP S13 EP S14 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400030 ER PT J AU Logie, N Jimenez, RB Pulenzas, N Denise, C Wong, E Ghosh, S Son, C Shih, HA Wong, WW Chow, EL Fairchild, AM AF Logie, N. Jimenez, R. B. Pulenzas, N. Denise, C. Wong, E. Ghosh, S. Son, C. Shih, H. A. Wong, W. W. Chow, E. L. Fairchild, A. M. TI Dose Fractionation Schedule Correlates With Survival in Whole-Brain Reirradiation: An International Pooled Analysis SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Logie, N.; Ghosh, S.; Fairchild, A. M.] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada. [Jimenez, R. B.; Shih, H. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Pulenzas, N.; Wong, E.; Chow, E. L.] Odette Canc Ctr, Toronto, ON, Canada. [Denise, C.; Wong, W. W.] Mayo Clin Arizona, Scottsdale, AZ USA. [Son, C.] Univ Chicago, Chicago, IL 60637 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3244 BP S699 EP S700 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402459 ER PT J AU Mahal, BA Aizer, AA Ziehr, DR Hyatt, AS Choueiri, TK Jim, HC Hoffman, KE Sweeney, CJ Beard, CJ D'Amico, AV Martin, NE Kim, SP Trinh, Q Nguyen, PL AF Mahal, B. A. Aizer, A. A. Ziehr, D. R. Hyatt, A. S. Choueiri, T. K. Jim, H. C. Hoffman, K. E. Sweeney, C. J. Beard, C. J. D'Amico, A. V. Martin, N. E. Kim, S. P. Trinh, Q. Nguyen, P. L. TI The Impact of Race on Prostate-Cancer Specific Mortality Among Men With Low-Risk Disease: Potential Implications for Active Surveillance SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Mahal, B. A.; Ziehr, D. R.] Harvard Univ, Sch Med, Boston, MA USA. [Aizer, A. A.] Harvard Radiat Oncol Program, Boston, MA USA. [Hyatt, A. S.; Choueiri, T. K.; Sweeney, C. J.; Beard, C. J.; D'Amico, A. V.; Martin, N. E.; Nguyen, P. L.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Jim, H. C.] Univ Calif Los Angeles, Los Angeles, CA USA. [Hoffman, K. E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Kim, S. P.] Yale Univ, Canc Outcomes & Publ Policy Effectiveness Res Ctr, New Haven, CT USA. [Trinh, Q.] Brigham & Womens Hosp, Boston, MA 02115 USA. RI Martin, Neil/E-2193-2014 OI Martin, Neil/0000-0002-8164-8516 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2596 BP S448 EP S448 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331401498 ER PT J AU Mahal, BA Aizer, AA Ziehr, DR Hyatt, AS Sammon, JD Schmid, M Choueiri, TK Hoffman, KE Hu, JC Sweeney, CJ Beard, CJ D'Amico, AV Martin, NE Kim, SP Trinh, Q Nguyen, PL AF Mahal, B. A. Aizer, A. A. Ziehr, D. R. Hyatt, A. S. Sammon, J. D. Schmid, M. Choueiri, T. K. Hoffman, K. E. Hu, J. C. Sweeney, C. J. Beard, C. J. D'Amico, A. V. Martin, N. E. Kim, S. P. Trinh, Q. Nguyen, P. L. TI Racial Disparities in the Management of African American Men With Intermediate- to High-Risk Prostate Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Mahal, B. A.; Ziehr, D. R.] Harvard Univ, Sch Med, Boston, MA USA. [Aizer, A. A.] Harvard Radiat Oncol Program, Boston, MA USA. [Hyatt, A. S.; Choueiri, T. K.; Sweeney, C. J.; Beard, C. J.; D'Amico, A. V.; Martin, N. E.; Nguyen, P. L.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Sammon, J. D.] Vattikuti Urol Inst, Detroit, MI USA. [Schmid, M.; Trinh, Q.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Hoffman, K. E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Hu, J. C.] Univ Calif Los Angeles, Los Angeles, CA USA. [Kim, S. P.] Yale Univ, Canc Outcomes & Publ Policy Effectiveness Res Ctr, New Haven, CT USA. RI Martin, Neil/E-2193-2014 OI Martin, Neil/0000-0002-8164-8516 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2591 BP S446 EP S446 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331401493 ER PT J AU Mak, KS Mannarino, EG Richards, WG Mak, RH Chen, AB Kozono, DE Gill, RR Sugarbaker, DJ Baldini, EH AF Mak, K. S. Mannarino, E. G. Richards, W. G. Mak, R. H. Chen, A. B. Kozono, D. E. Gill, R. R. Sugarbaker, D. J. Baldini, E. H. TI Patterns of Local Recurrence for Mesothelioma Patients Treated With Extrapleural Pneumonectomy and Radiation Therapy Using the Electron-Photon Technique: The Dosimetric Challenges of Electron-Photon Match Lines and Blocks SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Mak, K. S.] Harvard Radiat Oncol Program, Boston, MA USA. [Mannarino, E. G.; Mak, R. H.; Chen, A. B.; Kozono, D. E.; Baldini, E. H.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Richards, W. G.; Gill, R. R.; Sugarbaker, D. J.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3010 BP S608 EP S609 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402226 ER PT J AU Mak, KS Chen, Y Catalano, PJ Puriglia, RS Wong, JS Truong, L Bellon, JR AF Mak, K. S. Chen, Y. Catalano, P. J. Puriglia, R. S. Wong, J. S. Truong, L. Bellon, J. R. TI Dosimetric Inhomogeneity Predicts for Long-Term Breast Pain Following Breast-Conserving Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Mak, K. S.] Harvard Radiat Oncol Program, Boston, MA USA. [Chen, Y.; Catalano, P. J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Puriglia, R. S.; Wong, J. S.; Truong, L.; Bellon, J. R.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2004 BP S219 EP S219 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400506 ER PT J AU Mak, KS Mannarino, EG Lee, LK Raut, CJ Devlin, PM Marcus, KJ DeLaney, TF Baldini, EH AF Mak, K. S. Mannarino, E. G. Lee, L. K. Raut, C. J. Devlin, P. M. Marcus, K. J. DeLaney, T. F. Baldini, E. H. TI Bowel Bag Dose-Volume Parameters and Acute Gastrointestinal (GI) Toxicity during Preoperative Radiation Therapy (RT) for Retroperitoneal Sarcoma (RPS) SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Mak, K. S.] Harvard Radiat Oncol Program, Boston, MA USA. [Mannarino, E. G.; Raut, C. J.; Devlin, P. M.; Marcus, K. J.; Baldini, E. H.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Lee, L. K.; DeLaney, T. F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 255 BP S117 EP S118 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400267 ER PT J AU Martin, NE Massey, L Stowell, C Huland, H AF Martin, N. E. Massey, L. Stowell, C. Huland, H. TI Defining a Standard Set of Patient-Centered Outcomes for Men With Localized Prostate Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Martin, N. E.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Martin, N. E.; Massey, L.; Stowell, C.] Int Consortium Hlth Outcomes Measurement, Cambridge, MA USA. [Huland, H.] Univ Med Ctr Hamburg Eppendorf, Martini Klin, Hamburg, Germany. RI Martin, Neil/E-2193-2014 OI Martin, Neil/0000-0002-8164-8516 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2986 BP S598 EP S599 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402202 ER PT J AU Mirabeau-Beale, KL Ferguson, C Swaroop, M Skolny, M Horick, N Miller, C O'Toole, J Taghian, A AF Mirabeau-Beale, K. L. Ferguson, C. Swaroop, M. Skolny, M. Horick, N. Miller, C. O'Toole, J. Taghian, A. TI Quality of Life (QOL) in Women With Breast Cancer Enrolled on a Prospective Lymphedema Screening Protocol SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Mirabeau-Beale, K. L.] Harvard Radiat Oncol Program, Boston, MA USA. [Ferguson, C.; Swaroop, M.; Skolny, M.; Horick, N.; Miller, C.; O'Toole, J.; Taghian, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2085 BP S250 EP S251 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400585 ER PT J AU Mitin, T George, A Zietman, AL Kaufman, DS Uzzo, R Dreicer, R Heney, N Wallace, HJ Souhami, L Dobelbower, MC Sandler, HM Shipley, W AF Mitin, T. George, A. Zietman, A. L. Kaufman, D. S. Uzzo, R. Dreicer, R. Heney, N. Wallace, H. J. Souhami, L. Dobelbower, M. C. Sandler, H. M. Shipley, W. TI Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder Preserving Combined Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of RTOG 9906 and 0233 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Mitin, T.] Oregan Hlth & Sci Univ, Portland, OR USA. [George, A.] Radiat Therapy Oncol Grp, Philadelphia, PA USA. [Zietman, A. L.; Kaufman, D. S.; Heney, N.; Shipley, W.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Uzzo, R.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Dreicer, R.] Cleveland Clin, Cleveland, OH 44106 USA. [Wallace, H. J.] Univ Vermont, Burlington, VT USA. [Souhami, L.] Ctr Univ Sante McGill, Montreal, PQ, Canada. [Dobelbower, M. C.] Univ Alabama Birmingham, Birmingham, AL USA. [Sandler, H. M.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 289 BP S132 EP S132 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400301 ER PT J AU Mitra, D Cimbak, NC Lee, LJ Viswanathan, AN AF Mitra, D. Cimbak, N. C. Lee, L. J. Viswanathan, A. N. TI Lymphedema: Is It Associated With Lymph-Node Involvement in Endometrial Cancer? SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Mitra, D.; Cimbak, N. C.; Lee, L. J.; Viswanathan, A. N.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3285 BP S716 EP S717 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402500 ER PT J AU Mitra, D Nout, R Creutzberg, C Lee, LJ Cimbak, NC Viswanathan, AN AF Mitra, D. Nout, R. Creutzberg, C. Lee, L. J. Cimbak, N. C. Viswanathan, A. N. TI Does Adding Vaginal Brachytherapy (VB) to External Beam (EB) Increase Rectal Bleeding?: Comparing Results of Combined EB plus VB to the PORTEC-2 Data for EB Alone and VB Alone SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Mitra, D.; Lee, L. J.; Cimbak, N. C.; Viswanathan, A. N.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Nout, R.; Creutzberg, C.] Leiden Univ, Med Ctr, Leiden, Netherlands. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3271 BP S710 EP S711 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402486 ER PT J AU Moghanaki, D Cheuk, AV Fosmire, HF Lutz, ST Anscher, MS Hagan, MP Dawson, GA AF Moghanaki, D. Cheuk, A. V. Fosmire, H. F. Lutz, S. T. Anscher, M. S. Hagan, M. P. Dawson, G. A. TI Availability of Single-Fraction Palliative Radiation Therapy for Cancer Patients Receiving End-of-Life Care Within the Veterans Healthcare Administration SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Moghanaki, D.] Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA USA. [Moghanaki, D.; Anscher, M. S.; Hagan, M. P.] Virginia Commonwealth Univ, Richmond, VA USA. [Cheuk, A. V.; Dawson, G. A.] James J Peters Vet Affairs Med Ctr, New York, NY USA. [Cheuk, A. V.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Fosmire, H. F.] Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN USA. [Lutz, S. T.] Blanchard Valley Reg Canc Ctr, Findlay, OH USA. [Hagan, M. P.] US Dept Vet Affairs, Natl Radiat Oncol Program, Richmond, VA USA. [Dawson, G. A.] Vet Affairs New Jersey Healthcare Syst, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3218 BP S689 EP S690 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402433 ER PT J AU Moteabbed, M Trofimov, A Sharp, GC Wang, Y Zietman, AL Efstathiou, JA Lu, H AF Moteabbed, M. Trofimov, A. Sharp, G. C. Wang, Y. Zietman, A. L. Efstathiou, J. A. Lu, H. TI Robustness of Proton Therapy Versus IMRT to Interfractional Variations for Prostate Cancer Treatments SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Moteabbed, M.; Trofimov, A.; Sharp, G. C.; Wang, Y.; Zietman, A. L.; Efstathiou, J. A.; Lu, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3854 BP S942 EP S942 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331403456 ER PT J AU Mouw, K Van Allen, E O'Connor, K Wagle, N Kim, P Al-Ahmadie, H Zhu, C Ostravnaya, I Iyer, G Signoretti, S Reuter, V Getz, G Kantoff, PW Bochner, B Choueiri, TK Bajorin, DF Gabriel, S D'Andrea, A Garraway, L Rosenberg, JE AF Mouw, K. Van Allen, E. O'Connor, K. Wagle, N. Kim, P. Al-Ahmadie, H. Zhu, C. Ostravnaya, I. Iyer, G. Signoretti, S. Reuter, V. Getz, G. Kantoff, P. W. Bochner, B. Choueiri, T. K. Bajorin, D. F. Gabriel, S. D'Andrea, A. Garraway, L. Rosenberg, J. E. TI Somatic ERCC2 Mutations Confer Cisplatin Sensitivity in Muscle-Invasive Urothelial Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Mouw, K.] Harvard Radiat Oncol Program, Boston, MA USA. [Van Allen, E.; O'Connor, K.; Wagle, N.; Kantoff, P. W.; Choueiri, T. K.; D'Andrea, A.; Garraway, L.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kim, P.; Al-Ahmadie, H.; Ostravnaya, I.; Iyer, G.; Reuter, V.; Bochner, B.; Bajorin, D. F.; Rosenberg, J. E.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Zhu, C.; Getz, G.; Gabriel, S.] Broad Inst MIT & Harvard, Cambridge, MA USA. [Signoretti, S.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 189 BP S88 EP S88 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400201 ER PT J AU Nguyen, PL Shin, H Yousefi, K Thompson, DJ Hornberger, J Hyatt, AS Badani, KK Morgan, T Feng, FY AF Nguyen, P. L. Shin, H. Yousefi, K. Thompson, D. J. Hornberger, J. Hyatt, A. S. Badani, K. K. Morgan, T. Feng, F. Y. TI Impact of a Genomic Classifier of Metastatic Risk on Post prostatectomy Treatment Recommendations by Radiation Oncologists and Urologists SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Nguyen, P. L.; Hyatt, A. S.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Shin, H.; Yousefi, K.] GenomeDx Biosci, Vancouver, BC, Canada. [Thompson, D. J.] EMMES Canada, Burnaby, BC, Canada. [Hornberger, J.] Cedar Associates, Menlo Pk, CA USA. [Badani, K. K.] Columbia Univ, Med Ctr, New York, NY USA. [Morgan, T.; Feng, F. Y.] Univ Michigan, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2580 BP S442 EP S442 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331401482 ER PT J AU Ngwa, W Altundal, Y Korideck, H Kumar, R Sridhar, S Cormack, R Makrigiorgos, M AF Ngwa, W. Altundal, Y. Korideck, H. Kumar, R. Sridhar, S. Cormack, R. Makrigiorgos, M. TI Radiation Therapy Biomaterials for Response Assessment and Nodal Detection (Brand) SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Ngwa, W.; Korideck, H.; Sridhar, S.; Cormack, R.; Makrigiorgos, M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Ngwa, W.; Altundal, Y.] Univ Massachusetts, Lowell, MA USA. [Kumar, R.; Sridhar, S.] Northeastern Univ, Boston, MA 02115 USA. [Kumar, R.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3642 BP S856 EP S856 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331403246 ER PT J AU Ngwa, W Moreau, M Asana, L AF Ngwa, W. Moreau, M. Asana, L. TI Radiation Oncology in Resource-Poor Settings: Challenges and Opportunities for Humanitarian or Collaborative Cancer Care, Research, and Education SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Ngwa, W.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Ngwa, W.; Moreau, M.] Univ Massachusetts Lowell, Lowell, MA USA. [Asana, L.] African Renaissance Ambassador, Orlando, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2998 BP S603 EP S604 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402214 ER PT J AU Niska, JR Wolfgang, JA Hahn, PF Wo, JY Zhu, AX Hong, TS AF Niska, J. R. Wolfgang, J. A. Hahn, P. F. Wo, J. Y. Zhu, A. X. Hong, T. S. TI Impact of Intravenous Contrast Enhancement Phase on Target Definition for Hepatocellular Carcinoma (HCC) and Intrahepatic Cholangiocarcinoma (IHC): Observations From Patients Enrolled on a Prospective Phase 2 Trial SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Niska, J. R.; Wolfgang, J. A.; Hahn, P. F.; Wo, J. Y.; Zhu, A. X.; Hong, T. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2398 BP S373 EP S374 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331401302 ER PT J AU Park, HS Schoenfeld, JD Vega, RBM Shive, M Hartman, RI Ogembo, R Mucci, LA AF Park, H. S. Schoenfeld, J. D. Vega, R. B. Mailhot Shive, M. Hartman, R. I. Ogembo, R. Mucci, L. A. TI Effect of Primary Treatment Modality on the Association Between Statins and Prostate Cancer Recurrence: An Updated Meta-analysis SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Park, H. S.] Yale Univ, Sch Med, New Haven, CT USA. [Schoenfeld, J. D.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Vega, R. B. Mailhot] Mt Auburn Hosp, Cambridge, MA USA. [Shive, M.] Univ Calif Los Angeles, Los Angeles, CA USA. [Hartman, R. I.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Ogembo, R.] Northeastern Univ, Boston, MA 02115 USA. [Mucci, L. A.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2491 BP S408 EP S408 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331401395 ER PT J AU Patel, C Michaelson, E Chen, Y Silver, B Ng, AK Mauch, PM AF Patel, C. Michaelson, E. Chen, Y. Silver, B. Ng, A. K. Mauch, P. M. TI Long-Term Competing Mortality in Early-Stage Hodgkin Lymphoma: Reduced Mortality Risk in Patients Treated in the Modern Era SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Patel, C.; Michaelson, E.; Silver, B.; Ng, A. K.; Mauch, P. M.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Chen, Y.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 139 BP S65 EP S66 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400150 ER PT J AU Pham, HT Hu, C Michaelson, MD Dahl, DM Wu, C Whittington, RM Swanson, GP Vuky, J Lee, RJ Souhami, L Chang, BK George, A Sandler, HM Shipley, W AF Pham, H. T. Hu, C. Michaelson, M. D. Dahl, D. M. Wu, C. Whittington, R. M. Swanson, G. P. Vuky, J. Lee, R. J. Souhami, L. Chang, B. K. George, A. Sandler, H. M. Shipley, W. TI The Initial Report of RTOG 0524: Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates With Muscle-Invasive Bladder Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Pham, H. T.; Vuky, J.] Virginia Mason Med Ctr, Seattle, WA 98101 USA. [Hu, C.; George, A.] Stat Grp, Radiat Therapy Oncol Grp, Philadelphia, PA USA. [Michaelson, M. D.; Dahl, D. M.; Wu, C.; Shipley, W.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Whittington, R. M.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Swanson, G. P.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Vuky, J.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Lee, R. J.] Intermt Med Inst, Salt Lake City, UT USA. [Souhami, L.] McGill Univ, Ctr Hlth, Montreal, PQ, Canada. [Chang, B. K.] Radiat Oncol Associates, Ft Wayne, IN USA. [Sandler, H. M.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 288 BP S132 EP S132 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400300 ER PT J AU Phillips, J Aizer, A Chen, M Zhang, D Hirsch, M Richie, J Tempany, C Williams, S Hegde, J Loffredo, M D'Amico, A AF Phillips, J. Aizer, A. Chen, M. Zhang, D. Hirsch, M. Richie, J. Tempany, C. Williams, Si Hegde, J. Loffredo, M. D'Amico, A. TI The Impact of Differing Gleason Scores at Biopsy on the Odds of Upgrading and the Risk of Death From Prostate Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Phillips, J.; Aizer, A.] Harvard Radiat Oncol Program, Boston, MA USA. [Chen, M.; Zhang, D.] Univ Connecticut, Storrs, CT USA. [Hirsch, M.; Richie, J.; Tempany, C.; Williams, Si] Brigham & Womens Hosp, Boston, MA 02115 USA. [Hegde, J.] Harvard Univ, Sch Med, Boston, MA USA. [Loffredo, M.; D'Amico, A.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2480 BP S403 EP S404 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331401384 ER PT J AU Phillips, J Chen, M Zhang, D Loffredo, M Kantoff, P D'Amico, A AF Phillips, J. Chen, M. Zhang, D. Loffredo, M. Kantoff, P. D'Amico, A. TI Percent Positive Biopsy Cores and the Risk of Death from Prostate Cancer in Men Treated with Radiation and Androgen Deprivation Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Phillips, J.] Harvard Radiat Oncol Program, Boston, MA USA. [Chen, M.; Zhang, D.] Univ Connecticut, Storrs, CT USA. [Loffredo, M.; Kantoff, P.; D'Amico, A.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 343 BP S155 EP S155 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400355 ER PT J AU Poorvu, PD Sadow, CA Townamchai, K Damato, AL Lee, LJ Viswanathan, AN AF Poorvu, P. D. Sadow, C. A. Townamchai, K. Damato, A. L. Lee, L. J. Viswanathan, A. N. TI "Loops" Versus "Bowel Bag": Which Is Better for Bowel Contouring in Gynecologic Cancer Patients Receiving IMRT to the Para-Aortic Nodes? SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Poorvu, P. D.; Townamchai, K.; Damato, A. L.; Lee, L. J.; Viswanathan, A. N.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. [Poorvu, P. D.; Townamchai, K.; Damato, A. L.; Lee, L. J.; Viswanathan, A. N.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Sadow, C. A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2726 BP S498 EP S498 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331401627 ER PT J AU Pretz, J Barysauskas, C Raut, CP Hornick, JL Morgan, JA Butrynski, JE Marcus, KJ Devlin, PM Ready, JE Ferrone, ML George, S Baldini, EH AF Pretz, J. Barysauskas, C. Raut, C. P. Hornick, J. L. Morgan, J. A. Butrynski, J. E. Marcus, K. J. Devlin, P. M. Ready, J. E. Ferrone, M. L. George, S. Baldini, E. H. TI Localized Adult Ewing Sarcoma (ES): Improved Outcomes With Ifosfamide and Etoposide (IE) Added to Cyclophosphamide, Doxorubicin, and Vincristine (CAV) Chemotherapy (CT) SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Pretz, J.; Barysauskas, C.; Raut, C. P.; Morgan, J. A.; Butrynski, J. E.; Marcus, K. J.; Devlin, P. M.; Ready, J. E.; Ferrone, M. L.; George, S.; Baldini, E. H.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Pretz, J.; Raut, C. P.; Hornick, J. L.; Marcus, K. J.; Devlin, P. M.; Ready, J. E.; Ferrone, M. L.; Baldini, E. H.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3374 BP S751 EP S752 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402588 ER PT J AU Rahman, R Catalano, PJ Norden, AD Wen, PY Reardon, DA Lee, EQ Nayak, L Beroukhim, R Dunn, IF Golby, AJ Johnson, MD Claus, EB Chiocca, EA Alexander, BM Arvold, ND AF Rahman, R. Catalano, P. J. Norden, A. D. Wen, P. Y. Reardon, D. A. Lee, E. Q. Nayak, L. Beroukhim, R. Dunn, I. F. Golby, A. J. Johnson, M. D. Claus, E. B. Chiocca, E. A. Alexander, B. M. Arvold, N. D. TI Toxicity, Hospitalization Burden, and Survival Among Glioblastoma Patients Receiving Chemoradiation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Rahman, R.] Harvard Univ, Sch Med, Boston, MA USA. [Catalano, P. J.; Norden, A. D.; Wen, P. Y.; Reardon, D. A.; Lee, E. Q.; Nayak, L.; Beroukhim, R.; Dunn, I. F.; Golby, A. J.; Johnson, M. D.; Claus, E. B.; Chiocca, E. A.; Alexander, B. M.; Arvold, N. D.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2183 BP S290 EP S290 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331401088 ER PT J AU Raldow, A Wo, JY Wolfgang, JA Zhu, AX Hong, TS AF Raldow, A. Wo, J. Y. Wolfgang, J. A. Zhu, A. X. Hong, T. S. TI Tolerability of Liver Re-irradiation With Stereotactic Radiation Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Raldow, A.] Harvard Radiat Oncol Program, Boston, MA USA. [Wo, J. Y.; Wolfgang, J. A.; Zhu, A. X.; Hong, T. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2399 BP S374 EP S374 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331401303 ER PT J AU Rose, B Jiang, W Punglia, RS AF Rose, B. Jiang, W. Punglia, R. S. TI Effect of Involved Lymph Node Size on Cancer-Specific Mortality in Women With Node-Positive Breast Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Rose, B.] Harvard Radiat Oncol Program, Boston, MA USA. [Jiang, W.; Punglia, R. S.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2142 BP S274 EP S274 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331401048 ER PT J AU Rottmann, J Kozono, D Mak, R Chen, A Hacker, FL Berbeco, RI AF Rottmann, J. Kozono, D. Mak, R. Chen, A. Hacker, F. L. Berbeco, R. I. TI Verification Real-Time Image Acquisition System (VERITAS) SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Rottmann, J.; Kozono, D.; Mak, R.; Chen, A.; Hacker, F. L.; Berbeco, R. I.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Rottmann, J.; Kozono, D.; Mak, R.; Chen, A.; Hacker, F. L.; Berbeco, R. I.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3733 BP S892 EP S893 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331403337 ER PT J AU Samiee, S Ahmed, S Hui, K Gryfe, R Pollett, A Cino, M Gingras-Hill, G Ng, A Hodgson, D AF Samiee, S. Ahmed, S. Hui, K. Gryfe, R. Pollett, A. Cino, M. Gingras-Hill, G. Ng, A. Hodgson, D. TI Colorectal Cancer Screening in Cancer Survivors Treated With Radiation Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Samiee, S.; Hodgson, D.] Princess Margaret Hosp, Dept Radiat Med, Toronto, ON M4X 1K9, Canada. [Ahmed, S.; Hui, K.; Gingras-Hill, G.] Princess Margaret Hosp, Clin Res Program, Dept Radiat Med, Toronto, ON M4X 1K9, Canada. [Gryfe, R.] Mt Sinai Hosp, Dept Surg, Toronto, ON, Canada. [Pollett, A.] Mt Sinai Hosp, Dept Pathol, Toronto, ON, Canada. [Cino, M.] Toronto Western Hosp, Dept Gastroenterol, Toronto, ON M5T 2S8, Canada. [Ng, A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3283 BP S716 EP S716 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402498 ER PT J AU Schuemann, JP Dowdell, S Grassberger, C Min, C Paganetti, H AF Schuemann, J. P. Dowdell, S. Grassberger, C. Min, C. Paganetti, H. TI Site-Specific Range Uncertainties Due to by Dose Calculation Algorithms for Proton Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Schuemann, J. P.; Grassberger, C.; Paganetti, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Dowdell, S.] Illawarra Canc Care Ctr, Wollongong, NSW, Australia. [Min, C.] Yonsei Univ, Seoul 120749, South Korea. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 48 BP S26 EP S26 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400059 ER PT J AU Sethi, R Giantsoudi, D Raiford, M Malhi, I Niemierko, A Rapalino, O Caruso, P Yock, TI Tarbell, NJ Paganetti, H MacDonald, S AF Sethi, R. Giantsoudi, D. Raiford, M. Malhi, I. Niemierko, A. Rapalino, O. Caruso, P. Yock, T. I. Tarbell, N. J. Paganetti, H. MacDonald, S. TI Patterns of Failure Following Proton Therapy in Medulloblastoma: LET Distributions and RBE Associations for Relapses SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Sethi, R.; Caruso, P.] Harvard Univ, Sch Med, Boston, MA USA. [Giantsoudi, D.; Raiford, M.; Malhi, I.; Niemierko, A.; Rapalino, O.; Yock, T. I.; Tarbell, N. J.; Paganetti, H.; MacDonald, S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3295 BP S720 EP S720 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402510 ER PT J AU Shenouda, MN Goldberg, SI Sadek, BT Raad, RFA Keruakous, AR Taghian, AG AF Shenouda, M. N. Goldberg, S. I. Sadek, B. T. Raad, R. F. Abi Keruakous, A. R. Taghian, A. G. TI Contralateral Breast Cancer: Risk Factors, Characteristics, and Prognostic Implications SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Shenouda, M. N.; Goldberg, S. I.; Sadek, B. T.; Raad, R. F. Abi; Keruakous, A. R.; Taghian, A. G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2028 BP S229 EP S229 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400530 ER PT J AU Shusharina, N Sharp, GC Fullerton, B Adams, J Chan, AW AF Shusharina, N. Sharp, G. C. Fullerton, B. Adams, J. Chan, A. W. TI Evaluation of Proton Therapy for Advanced Head and Neck Cancer With Respect to Changing Heterogeneity SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Shusharina, N.; Sharp, G. C.; Fullerton, B.; Adams, J.; Chan, A. W.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2840 BP S543 EP S543 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402057 ER PT J AU Sineshaw, H Gray, PJ Efstathiou, JA Jemal, A AF Sineshaw, H. Gray, P. J. Efstathiou, J. A. Jemal, A. TI Patterns of Radiation Therapy and Androgen Deprivation Therapy Utilization After Radical Prostatectomy: Results From the National Cancer Data Base (2005-2011) SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Sineshaw, H.; Jemal, A.] Amer Canc Soc, Atlanta, GA 30329 USA. [Gray, P. J.] Harvard Radiat Oncol Program, Boston, MA USA. [Efstathiou, J. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 287 BP S131 EP S132 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400299 ER PT J AU Spektor, A Liu, S Jackson, E Pellman, D AF Spektor, A. Liu, S. Jackson, E. Pellman, D. TI Micronuclei-Induced DNA Damage and Mutagenesis in Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Spektor, A.] Harvard Radiat Oncol Program, Boston, MA USA. [Spektor, A.; Liu, S.; Jackson, E.; Pellman, D.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3451 BP S781 EP S781 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331403055 ER PT J AU Tanguturi, S Wo, JY Zietman, AL Blaszkowsky, LS Kwak, E Berger, D Cusack, JC Hong, TS AF Tanguturi, S. Wo, J. Y. Zietman, A. L. Blaszkowsky, L. S. Kwak, E. Berger, D. Cusack, J. C. Hong, T. S. TI Outcomes With Full Dose Re-irradiation With Curative Intent for Secondary Anorectal Cancers Following Prostatic Radiation Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Tanguturi, S.; Wo, J. Y.; Zietman, A. L.; Blaszkowsky, L. S.; Kwak, E.; Berger, D.; Cusack, J. C.; Hong, T. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2461 BP S396 EP S397 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331401365 ER PT J AU Tanguturi, S Wen, PY Reardon, DA Lee, EQ Nayak, L Christianson, LW Horvath, MC Dunn, IF Golby, AJ Johnson, MD Claus, EB Chiocca, EA Ligon, KL Alexander, BM Arvold, ND AF Tanguturi, S. Wen, P. Y. Reardon, D. A. Lee, E. Q. Nayak, L. Christianson, L. W. Horvath, M. C. Dunn, I. F. Golby, A. J. Johnson, M. D. Claus, E. B. Chiocca, E. A. Ligon, K. L. Alexander, B. M. Arvold, N. D. TI Hypofractionated (HRT) Versus Standard (SRT) Radiation Therapy With or Without Temozolomide (T) for Elderly Patients With Glioblastoma (GBM) SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Tanguturi, S.; Wen, P. Y.; Reardon, D. A.; Lee, E. Q.; Nayak, L.; Christianson, L. W.; Horvath, M. C.; Dunn, I. F.; Golby, A. J.; Johnson, M. D.; Claus, E. B.; Chiocca, E. A.; Ligon, K. L.; Alexander, B. M.; Arvold, N. D.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 1022 BP S166 EP S166 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400382 ER PT J AU Tseng, YD Uno, H Hughes, ME Niland, JC Wong, Y Theriault, R Marcom, PK Moy, B Breslin, T Edge, SB Wilson, JL Punglia, RS AF Tseng, Y. D. Uno, H. Hughes, M. E. Niland, J. C. Wong, Y. Theriault, R. Marcom, P. K. Moy, B. Breslin, T. Edge, S. B. Wilson, J. L. Punglia, R. S. TI Association Between Breast Cancer Biological Subtype and Risk of Locoregional Recurrence A Mastectomy in Node-Negative Patients SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Tseng, Y. D.] Harvard Radiat Oncol Program, Boston, MA USA. [Uno, H.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Hughes, M. E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Niland, J. C.] City Hope Natl Med Ctr, Dept Biostat, Duarte, CA 91010 USA. [Wong, Y.] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA. [Theriault, R.] Univ Texas MD Anderson Canc Ctr, Dept Gen Oncol, Houston, TX 77030 USA. [Marcom, P. K.] Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA. [Moy, B.] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA. [Breslin, T.] Northwestern Lake Forest Hosp, Div Surg Oncol, Dept Surg, Lake Forest, IL USA. [Edge, S. B.] Baptist Canc Ctr, Memphis, TN USA. [Wilson, J. L.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Punglia, R. S.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2068 BP S244 EP S244 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400569 ER PT J AU Vega, RM Kim, J Hollander, A Hattangadi, JA Michalski, J Tarbell, NJ Yock, T Bussiere, M MacDonald, S AF Vega, R. Mailhot Kim, J. Hollander, A. Hattangadi, J. A. Michalski, J. Tarbell, N. J. Yock, T. Bussiere, M. MacDonald, S. TI Cost-Effectiveness Analysis of Proton Versus Photon Therapy With Respect to Risk of Growth Hormone Deficiency SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Vega, R. Mailhot] Mt Auburn Hosp, Cambridge, MA USA. [Kim, J.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Hollander, A.; Michalski, J.] Washington Univ, St Louis, MO USA. [Hattangadi, J. A.] Univ Calif San Diego, San Diego, CA 92103 USA. [Tarbell, N. J.; Yock, T.; Bussiere, M.; MacDonald, S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2952 BP S585 EP S585 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402168 ER PT J AU Wang, H Jacobson, A Harmon, D Michaelson, J DeLaney, TF Chen, Y AF Wang, H. Jacobson, A. Harmon, D. Michaelson, J. DeLaney, T. F. Chen, Y. TI Prognostic Factors in Alveolar Soft-Part Sarcoma: A SEER Analysis SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Wang, H.; Jacobson, A.; Harmon, D.; Michaelson, J.; DeLaney, T. F.; Chen, Y.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Wang, H.] Peking Union Med Coll, Beijing 100021, Peoples R China. [Harmon, D.; Michaelson, J.; DeLaney, T. F.; Chen, Y.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3385 BP S755 EP S756 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402599 ER PT J AU Warren, L Guo, H Regan, MM Nakhlis, F Yeh, ED Jacene, HA Hirshfield-Bartek, J Overmoyer, BA Bellon, JR AF Warren, L. Guo, H. Regan, M. M. Nakhlis, F. Yeh, E. D. Jacene, H. A. Hirshfield-Bartek, J. Overmoyer, B. A. Bellon, J. R. TI Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Local-Regional Management SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Warren, L.] Harvard Radiat Oncol Program, Boston, MA USA. [Guo, H.; Regan, M. M.; Nakhlis, F.; Yeh, E. D.; Jacene, H. A.; Hirshfield-Bartek, J.; Overmoyer, B. A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Bellon, J. R.] Brigham & Womens Hosp, Boston, MA 02115 USA. RI Guo, Hao/E-8921-2015 OI Guo, Hao/0000-0003-1658-0989 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2144 BP S275 EP S275 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331401050 ER PT J AU Willers, H Wang, M Han, J Kern, A Hulskotter, M Krause, M Baumann, M Benes, C Efstathiou, J Settleman, J AF Willers, H. Wang, M. Han, J. Kern, A. Huelskoetter, M. Krause, M. Baumann, M. Benes, C. Efstathiou, J. Settleman, J. TI Chromatin Condensation Mediated by EGFR and Aurora B Protects KRAS-Mutant Lung Cancer Cells Against Ionizing Radiation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Willers, H.; Wang, M.; Han, J.; Kern, A.; Huelskoetter, M.; Efstathiou, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Krause, M.; Baumann, M.] Tech Univ Dresden, D-01062 Dresden, Germany. [Benes, C.; Settleman, J.] Massachusetts Gen Hosp, Canc Ctr, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 223 BP S104 EP S104 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400235 ER PT J AU Wo, JY Depauw, N Symonifka, J Kooy, H Hong, TS AF Wo, J. Y. Depauw, N. Symonifka, J. Kooy, H. Hong, T. S. TI Dosimetric Analysis of Proton Pencil Beam Scanning Radiation Therapy Versus Dose Painted Intensity Modulated Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Wo, J. Y.; Depauw, N.; Symonifka, J.; Kooy, H.; Hong, T. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2466 BP S398 EP S398 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331401370 ER PT J AU Wong, AC Stock, S Schrag, D Kahn, KL Salz, T Charlton, ME Rogers, SO Keating, NL Goodman, KA AF Wong, A. C. Stock, S. Schrag, D. Kahn, K. L. Salz, T. Charlton, M. E. Rogers, S. O. Keating, N. L. Goodman, K. A. TI Physicians' Beliefs About the Benefits and Risks of Adjuvant Therapies for Stage II and Stage III Colorectal Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Wong, A. C.] Univ Chicago, Chicago, IL 60637 USA. [Stock, S.] Coll Holy Cross, Worcester, MA 01610 USA. [Schrag, D.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kahn, K. L.] RAND, Los Angeles, CA USA. [Kahn, K. L.] Univ Calif Los Angeles, Los Angeles, CA USA. [Salz, T.; Goodman, K. A.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Charlton, M. E.] Univ Iowa, Iowa City, IA USA. [Charlton, M. E.] Iowa City Vet Affairs Med Ctr, Iowa City, IA USA. [Rogers, S. O.] Temple Univ, Sch Med, Philadelphia, PA 19122 USA. [Keating, N. L.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Keating, N. L.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2965 BP S590 EP S591 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402181 ER PT J AU Woody, NM Durand, P Naik, M Elegbede, A Duraes, E Suzanne, CB Dietz, J Djohan, R Tendulkar, RD AF Woody, N. M. Durand, P. Naik, M. Elegbede, A. Duraes, E. Suzanne, C. B. Dietz, J. Djohan, R. Tendulkar, R. D. TI Impact of Breast Radiotherapy on Late Toxicities and Reoperation Following Mastectomy With Tissue Expander Based Reconstruction SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Woody, N. M.; Durand, P.; Naik, M.; Duraes, E.; Dietz, J.; Djohan, R.; Tendulkar, R. D.] Cleveland Clin, Cleveland, OH 44106 USA. [Elegbede, A.] Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA. [Suzanne, C. B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 94 BP S46 EP S46 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400105 ER PT J AU Yip, D Liebsch, NJ Busse, PM Kim, MB Adams, JD Deschler, DG Lin, DT Varvares, MA Chan, AW AF Yip, D. Liebsch, N. J. Busse, P. M. Kim, M. B. Adams, J. D. Deschler, D. G. Lin, D. T. Varvares, M. A. Chan, A. W. TI Proton Beam Therapy for Unresectable Adenoid Cystic Carcinoma of the Nasopharynx SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Yip, D.; Liebsch, N. J.; Busse, P. M.; Kim, M. B.; Adams, J. D.; Chan, A. W.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Deschler, D. G.; Lin, D. T.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Varvares, M. A.] St Louis Univ, Sch Med, St Louis, MO USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2854 BP S548 EP S548 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402071 ER PT J AU Yip, DD DeLaney, TF Jacobson, A Hornicek, FJ Schwab, JH Mauceri, TC Chen, Y AF Yip, D. D. DeLaney, T. F. Jacobson, A. Hornicek, F. J. Schwab, J. H. Mauceri, T. C. Chen, Y. TI Review of Experience and Outcome of Dural Plaque Brachytherapy:2000-2013 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Yip, D. D.; DeLaney, T. F.; Jacobson, A.; Hornicek, F. J.; Schwab, J. H.; Mauceri, T. C.; Chen, Y.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 3392 BP S758 EP S759 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331402606 ER PT J AU Yip, S McCall, K Aristophanous, M Chen, A Aerts, H Berbeco, R AF Yip, S. McCall, K. Aristophanous, M. Chen, A. Aerts, H. Berbeco, R. TI The Effect Of Respiratory Motion On Pet Imaging Of Tumor Heterogeneity In Non-small Cell Lung Cancer (NSCLC) SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Yip, S.; Chen, A.; Aerts, H.; Berbeco, R.] Brigham & Womens Hosp, Dana Farber Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Yip, S.; McCall, K.; Chen, A.; Aerts, H.; Berbeco, R.] Harvard Univ, Sch Med, Boston, MA USA. [McCall, K.] Dana Farber Inst, Dept Radiol, Boston, MA USA. [Aristophanous, M.] Univ Texas MD Anderson Canc Ctr, Div Radiat Oncol, Dept Radiat Phys, Houston, TX 77030 USA. RI Aerts, Hugo/P-6350-2015 OI Aerts, Hugo/0000-0002-2122-2003 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 47 BP S25 EP S26 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400058 ER PT J AU Zhao, S Evans, JR Daignault-Newton, S Sanda, MG Michalski, J Sandler, HM Kuban, DA Ciezki, JP Kaplan, ID Zietman, AL Feng, FY Hembroff, L Suy, S Mantz, CA Collins, S Hamstra, DA AF Zhao, S. Evans, J. R. Daignault-Newton, S. Sanda, M. G. Michalski, J. Sandler, H. M. Kuban, D. A. Ciezki, J. P. Kaplan, I. D. Zietman, A. L. Feng, F. Y. Hembroff, L. Suy, S. Mantz, C. A. Collins, S. Hamstra, D. A. TI Early Quality of Life (QOL) Declines Correlate With Later QOL After Intensity Modulated Radiation Therapy, Low-Dose-Rate Brachytherapy, or Stereotactic Radiation for Prostate Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Zhao, S.; Evans, J. R.; Daignault-Newton, S.; Feng, F. Y.; Hamstra, D. A.] Univ Michigan, Ann Arbor, MI 48109 USA. [Sanda, M. G.] Emory Univ, Atlanta, GA 30322 USA. [Michalski, J.] Washington Univ, Med Ctr, St Louis, MO USA. [Sandler, H. M.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Kuban, D. A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Ciezki, J. P.] Cleveland Clin, Cleveland, OH 44106 USA. [Kaplan, I. D.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Zietman, A. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hembroff, L.] Michigan State Univ, E Lansing, MI 48824 USA. [Suy, S.; Collins, S.] Georgetown Univ, Washington, DC USA. [Mantz, C. A.] 21st Century Oncol, Ft Myers, FL USA. RI Sanda, Martin/B-2023-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 181 BP S84 EP S85 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400193 ER PT J AU Ziehr, DR Gu, X Mahal, BA Aizer, AA Hyatt, AS Nguyen, PL AF Ziehr, D. R. Gu, X. Mahal, B. A. Aizer, A. A. Hyatt, A. S. Nguyen, P. L. TI Exogenous Insulin Therapy Is Associated With Increased Prostate Cancer Mortality in Men With Type 2 Diabetes Mellitus SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Ziehr, D. R.; Mahal, B. A.] Harvard Univ, Boston, MA 02115 USA. [Gu, X.; Aizer, A. A.; Hyatt, A. S.; Nguyen, P. L.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 2608 BP S452 EP S452 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331401510 ER PT J AU Ziehr, DR Chen, M Zhang, D Braccioforte, MH Moran, BJ Mahal, BA Hyatt, AS Beard, CJ D'Amico, AV Hoffman, KE Martin, NE Nguyen, PL AF Ziehr, D. R. Chen, M. Zhang, D. Braccioforte, M. H. Moran, B. J. Mahal, B. A. Hyatt, A. S. Beard, C. J. D'Amico, A. V. Hoffman, K. E. Martin, N. E. Nguyen, P. L. TI Association of Androgen Deprivation Therapy with Excess Cardiovascular-Specific Mortality in Men with Prostate Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 14-17, 2014 CL San Francisco, CA SP Amer Soc Radiat Oncol C1 [Ziehr, D. R.; Mahal, B. A.] Harvard Univ, Sch Med, Boston, MA USA. [Chen, M.; Zhang, D.] Univ Connecticut, Storrs, CT USA. [Braccioforte, M. H.; Moran, B. J.] Chicago Prostate Ctr, Westmont, IL USA. [Hyatt, A. S.; Beard, C. J.; D'Amico, A. V.; Martin, N. E.; Nguyen, P. L.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Hoffman, K. E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. RI Martin, Neil/E-2193-2014 OI Martin, Neil/0000-0002-8164-8516 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD SEP 1 PY 2014 VL 90 SU 1 MA 23 BP S15 EP S15 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AP8LV UT WOS:000342331400034 ER PT J AU Bhatia, RS Dudzinski, DM Malhotra, R Milford, CE Sanborn, DMY Picard, MH Weiner, RB AF Bhatia, R. Sacha Dudzinski, David M. Malhotra, Rajeev Milford, Creagh E. Sanborn, Danita M. Yoerger Picard, Michael H. Weiner, Rory B. TI Educational Intervention to Reduce Outpatient Inappropriate Echocardiograms A Randomized Control Trial SO JACC-CARDIOVASCULAR IMAGING LA English DT Article DE appropriate use criteria; medical education; transthoracic echocardiography ID APPROPRIATE USE CRITERIA; TRANSTHORACIC ECHOCARDIOGRAPHY; STRESS ECHOCARDIOGRAPHY; TRANSESOPHAGEAL; QUALITY; TRENDS; IMPACT AB OBJECTIVES This study sought to prospectively study the impact of an appropriate use criteria (AUC)-based educational intervention on outpatient transthoracic echocardiography (TTE) ordering by physicians-in-training. BACKGROUND AUC were developed in response to concerns about inappropriate utilization. It is unknown whether an educational intervention can reduce inappropriate outpatient TTE. METHODS We conducted a randomized control trial in which physicians-in-training were randomized to an AUC-based educational intervention or a control group at an academic medical center in Boston, Massachusetts. The primary end-points were the rates of inappropriate and appropriate TTE. RESULTS For the cardiology physicians-in-training, the proportion of inappropriate TIE was significantly lower in the intervention than in the control group (13% vs. 34%, p < 0.001). As a corollary, the proportion of appropriate TTE ordered by the intervention group was significantly higher than that of the control group (81% vs. 58%, p < 0.001). The odds of ordering an appropriate TTE in the cardiology intervention group was 2.7(95% confidence interval [CI]: 1.5 to 5.1, p = 0.002) relative to the control group. The internal medicine physicians-in-training ordered a small number of TTE overall, and there was a trend toward significant odds of ordering an appropriate TTE in the intervention group relative to the control group (odds ratio [OR]: 8.1, 95% CI: 0.95 to 69.0, p = 0.055). Six clinical scenarios accounted for 75% of all inappropriate TTE, with the 3 most common inappropriate indications being routine surveillance (<1 year) of known cardiomyopathy without a change in clinical status, routine surveillance of known small pericardial effusion, and routine surveillance of ventricular function with known coronary artery disease and no change in clinical status. CONCLUSIONS In cardiology fellows with a high rate of ordering inappropriate TTE, an AUC-based educational and feedback intervention reduced the proportion of inappropriate outpatient TTE and increased the proportion of appropriate outpatient TTE. (Educational Intervention to Reduce Outpatient Inappropriate Transthoracic Echocardiograms; NCT01944202) (C) 2014 by the American College of Cardiology Foundation. C1 [Bhatia, R. Sacha] Womens Coll Hosp, Inst Hlth Syst Solut & Virtual Care, Toronto, ON, Canada. [Dudzinski, David M.; Malhotra, Rajeev; Milford, Creagh E.; Sanborn, Danita M. Yoerger; Picard, Michael H.; Weiner, Rory B.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA. RP Weiner, RB (reprint author), Massachusetts Gen Hosp, Div Cardiol, Yawkey Suite 5B,55 Fruit St, Boston, MA 02114 USA. EM rweiner@partners.org OI Picard, Michael/0000-0002-9264-3243 FU Partners Healthcare Center of Expertise in Patient Care Quality and Safety Research Grant FX This study was supported by a Partners Healthcare Center of Expertise in Patient Care Quality and Safety Research Grant, however, they had no role in the design/conduct of the study; data collection/analysis; or preparation, review, or approval of the manuscript. All authors have reported that they have no relationships relevant to the contents of this paper to disclose. NR 18 TC 18 Z9 18 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-878X EI 1876-7591 J9 JACC-CARDIOVASC IMAG JI JACC-Cardiovasc. Imag. PD SEP PY 2014 VL 7 IS 9 BP 857 EP 866 DI 10.1016/j.jcmg.2014.04.014 PG 10 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA AP7PB UT WOS:000342268100001 PM 25129520 ER PT J AU Emami, H Vijayakumar, J Subramanian, S Vucic, E Singh, P MacNabb, MH Corsini, E Hoffmann, U Bathon, JM Solomon, DH Tawakol, A AF Emami, Hamed Vijayakumar, Jayanthi Subramanian, Sharath Vucic, Esad Singh, Parmanand MacNabb, Megan H. Corsini, Erin Hoffmann, Udo Bathon, Joan M. Solomon, Daniel H. Tawakol, Ahmed TI Arterial F-18-FDG Uptake in Rheumatoid Arthritis Correlates With Synovial Activity SO JACC-CARDIOVASCULAR IMAGING LA English DT Letter ID INFLAMMATION C1 [Tawakol, Ahmed] Massachusetts Gen Hosp, Div Cardiol, Cardiac MR PET CT Program, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Tawakol, A (reprint author), Massachusetts Gen Hosp, Div Cardiol, Cardiac MR PET CT Program, 165 Cambridge St,Suite 400, Boston, MA 02114 USA. EM atawakol@partners.org NR 4 TC 9 Z9 9 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-878X EI 1876-7591 J9 JACC-CARDIOVASC IMAG JI JACC-Cardiovasc. Imag. PD SEP PY 2014 VL 7 IS 9 BP 959 EP 960 DI 10.1016/j.jcmg.2014.03.018 PG 2 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA AP7PB UT WOS:000342268100017 PM 25212803 ER PT J AU Frigerio, A Cavallari, P Frigeni, M Pedrocchi, A Sarasola, A Ferrante, S AF Frigerio, Alice Cavallari, Paolo Frigeni, Marta Pedrocchi, Alessandra Sarasola, Andrea Ferrante, Simona TI Surface Electromyographic Mapping of the Orbicularis Oculi Muscle for Real-Time Blink Detection SO JAMA FACIAL PLASTIC SURGERY LA English DT Article ID PARALYZED FACE; DYNAMIC REHABILITATION; ELECTRICAL-STIMULATION; FACIAL MUSCULATURE; ELECTRONIC CONTROL; EYELID MOVEMENTS; RABBIT; SIDE; ASYMMETRY; SYSTEM AB IMPORTANCE Facial paralysis is a life-altering condition that significantly impairs function, appearance, and communication. Facial rehabilitation via closed-loop pacing represents a potential but as yet theoretical approach to reanimation. A first critical step toward closed-loop facial pacing in cases of unilateral paralysis is the detection of healthy movements to use as a trigger to prosthetically elicit automatic artificial movements on the contralateral side of the face. OBJECTIVES To test and to maximize the performance of an electromyography (EMG)-based blink detection system for applications in closed-loop facial pacing. DESIGN, SETTING, AND PARTICIPANTS Blinking was detected across the periocular region by means of multichannel surface EMG at an academic neuroengineering and medical robotics laboratory among 15 healthy volunteers. MAIN OUTCOMES AND MEASURES Real-time blink detection was accomplished by mapping the surface of the orbicularis oculi muscle on one side of the face with a multichannel surface EMG. The biosignal from each channel was independently processed; custom software registered a blink when an amplitude-based or slope-based suprathreshold activity was detected. The experiments were performed when participants were relaxed and during the production of particular orofacial movements. An F1 score metric was used to analyze software performance in detecting blinks. RESULTS The maximal software performance was achieved when a blink was recorded from the superomedial orbit quadrant. At this recording location, the median F1 scores were 0.89 during spontaneous blinking, 0.82 when chewing gum, 0.80 when raising the eyebrows, and 0.70 when smiling. The overall performance of blink detection was significantly better at the superomedial quadrant (F1 score, 0.75) than at the traditionally used inferolateral quadrant (F1 score, 0.40) (P < .05). CONCLUSIONS AND RELEVANCE Electromyographic recording represents an accurate tool to detect spontaneous blinks as part of closed-loop facial pacing systems. The early detection of blink activitymay allow real-time pacing via rapid triggering of contralateral muscles. Moreover, an EMG detection system can be integrated in external devices and in implanted neuroprostheses. A potential downside to this approach involves cross talk from adjacent muscles, which can be notably reduced by recording from the superomedial quadrant of the orbicularis oculi muscle and by applying proper signal processing. C1 [Frigerio, Alice; Cavallari, Paolo; Frigeni, Marta] Univ Milan, Dept Pathophysiol & Transplantat, Human Physiol Sect, Milan, Italy. [Frigerio, Alice] Harvard Univ, Massachusetts Eye & Ear Infirm,Dept Otol & Laryng, Facial Nerve Ctr,Carolyn & Peter Lynch Ctr Laser, Div Facial Plast & Reconstruct Surg,Sch Med, Boston, MA 02114 USA. [Pedrocchi, Alessandra; Sarasola, Andrea; Ferrante, Simona] Politecn Milan, Neuroengn & Med Robot Lab, Dept Elect Informat & Bioengn, I-20133 Milan, Italy. RP Frigerio, A (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm,Dept Otol & Laryng, Facial Nerve Ctr,Carolyn & Peter Lynch Ctr Laser, Div Facial Plast & Reconstruct Surg,Sch Med, 243 Charles St, Boston, MA 02114 USA. EM alice_frigerio@meei.harvard.edu RI Ferrante, Simona/K-4122-2016; Pedrocchi, Alessandra/A-6634-2012; OI Ferrante, Simona/0000-0002-7835-1965; Pedrocchi, Alessandra/0000-0001-9957-2786; Frigerio, Alice/0000-0001-9202-9553; Cavallari, Paolo/0000-0003-3160-9030 NR 21 TC 2 Z9 3 U1 1 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6076 EI 2168-6092 J9 JAMA FACIAL PLAST SU JI JAMA Facial Plast. Surg. PD SEP-OCT PY 2014 VL 16 IS 5 BP 335 EP 342 DI 10.1001/jamafacial.2014.283 PG 8 WC Surgery SC Surgery GA AP8VN UT WOS:000342357500005 PM 25033260 ER PT J AU De Guzman, V Ballif, CL Maurer, R Hartnick, CJ Raol, N AF De Guzman, Vanessa Ballif, Catherine L. Maurer, Rie Hartnick, Christopher J. Raol, Nikhila TI Validation of the Dyspnea Index in Adolescents With Exercise-Induced Paradoxical Vocal Fold Motion SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article ID CORD DYSFUNCTION; ASTHMA; CHILDREN; STRIDOR AB IMPORTANCE Paradoxical vocal fold motion (PVFM) affects almost 1 million adolescents in the United States. However, to date, no disease-specific objective measure exists to assess symptom severity and response to treatment in adolescents with exercise-induced PVFM. OBJECTIVES To validate the Dyspnea Index (DI) quality-of-life instrument (previously validated for adults with breathing disorders) in children aged 12 to 18 years with exercise-induced PVFM and to determine the minimum significant DI change corresponding to patient-reported or caregiver-reported improvement or worsening of symptoms. DESIGN, SETTING, AND PARTICIPANTS A longitudinal study of 56 patients (age range, 12-18 years) diagnosed as having exercise-induced PVFM and their caregivers from February 1, 2013, to September 30, 2013, in an outpatient pediatric otolaryngology office practice. INTERVENTIONS The DI was administered to patients and caregivers, with items modified to reflect the perspective of caregivers. MAIN OUTCOMES AND MEASURES Appropriate DI change was measured to reflect improvement or worsening of symptoms. Test-retest reliability was accomplished by having a subset of patients and caregivers complete the instrument twice within 2 weeks before therapy. Internal consistency was assessed by calculation of Cronbach a. Discriminant validity and convergent validity were determined by comparing DIs with assessment of global change in symptoms. RESULTS The patient and caregiver mean (SD) DI changes were -12.9 (9.6) and -14.7 (9.3), respectively (P < .001 for both). Reliability was established by test-retest analysis with an intraclass correlation coefficient of 0.8 and by calculation of Cronbach a = 0.80, demonstrating internal consistency. Discriminant validity was determined by assessing for a significant DI change when patients globally perceived that a change existed after treatment (P < .001). A DI change of 8 or higher (P < .001) correlated with patient-reported significant change. Convergent validity was demonstrated by evaluating for significant DI change when no change was reported following treatment (P < .001). CONCLUSIONS AND RELEVANCE The DI appears to be a valid and reliable instrument to assess quality of life in exercise-induced pediatric PVFM. A DI change of 8 or higher seems significant. This instrument can serve as an objective tool to assess change in exercise-induced pediatric PVFM following speech therapy. C1 [De Guzman, Vanessa; Ballif, Catherine L.; Maurer, Rie; Hartnick, Christopher J.; Raol, Nikhila] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. [Hartnick, Christopher J.; Raol, Nikhila] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. RP Ballif, CL (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. EM Christopher_hartnick@meei.harvard.edu NR 27 TC 2 Z9 2 U1 1 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6181 EI 2168-619X J9 JAMA OTOLARYNGOL JI JAMA Otolaryngol-Head Neck Surg. PD SEP PY 2014 VL 140 IS 9 BP 823 EP 828 DI 10.1001/jamaoto.2014.1405 PG 6 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA AP8VS UT WOS:000342358000006 PM 25104182 ER PT J AU Emerick, KS Herr, MW Lin, DT Santos, F Deschler, DG AF Emerick, Kevin S. Herr, Marc W. Lin, Derrick T. Santos, Felipe Deschler, Daniel G. TI Supraclavicular Artery Island Flap for Reconstruction of Complex Parotidectomy, Lateral Skull Base, and Total Auriculectomy Defects SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article ID TEMPORAL BONE RESECTION; FREE TISSUE TRANSFER; NECK RECONSTRUCTION; HEAD; EVOLUTION; SURGERY; EAR AB IMPORTANCE There are limited data on the use of the supraclavicular artery island flap (SCAIF) for parotid and lateral skull base (LSB) surgery. This flap can be an important reconstructive tool for these procedures. OBJECTIVE To describe the use of the SCAIF for parotid and LSB surgery and its success, as well as important technique modifications for successful use of the flap in this setting. DESIGN, SETTING, AND PARTICIPANTS Retrospective single-institution review from July 1, 2011, to September 30, 2013, of patients in a tertiary care referral center. A prospectively collected institutional database was reviewed to identify patients who received SCAIF reconstruction for parotid and/or LSB surgery. Forty-six SCAIF reconstructions were identified; 16 were performed for the indication of parotidectomy or LSB surgery. INTERVENTIONS The SCAIF reconstruction for parotid and/or LSB surgery. MAIN OUTCOMES AND MEASURES Indication for reconstruction, flap viability, flap size, reconstruction site complication, and donor site complication. RESULTS Resection was performed for advanced cutaneous malignant tumor in 10 patients, primary salivary gland malignant tumor in 4 patients, and chronic infection and mastoid cutaneous fistula in 2 patients. All defects were complex, involving multiple subsites; 5 patients underwent facial nerve resection and 4 had previous radiation therapy. No complete flap loss occurred. One partial flap loss occurred. The average flap island size was 7 x 10 cm. No major complications occurred. Two minor reconstruction site complications and 3 donor site seromas occurred. CONCLUSIONS AND RELEVANCE The SCAIF can be successfully and reliably used for complex defects following parotid and LSB surgery. There are 3 important technique modifications to help facilitate rotation and coverage of this region. C1 [Emerick, Kevin S.; Herr, Marc W.; Lin, Derrick T.; Deschler, Daniel G.] Massachusetts Eye & Ear Infirm, Div Head & Neck Surg Oncol & Reconstruct, Boston, MA 02114 USA. [Emerick, Kevin S.; Herr, Marc W.; Lin, Derrick T.; Santos, Felipe; Deschler, Daniel G.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Santos, Felipe] Massachusetts Eye & Ear Infirm, Div Otol & Neurotol, Boston, MA 02114 USA. RP Emerick, KS (reprint author), Massachusetts Eye & Ear Infirm, Div Head & Neck Surg Oncol & Reconstruct, 243 Charles St, Boston, MA 02114 USA. EM kevin_emerick@meei.harvard.edu OI Santos, Felipe/0000-0002-3523-665X NR 18 TC 7 Z9 7 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6181 EI 2168-619X J9 JAMA OTOLARYNGOL JI JAMA Otolaryngol-Head Neck Surg. PD SEP PY 2014 VL 140 IS 9 BP 861 EP 866 DI 10.1001/jamaoto.2014.1394 PG 6 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA AP8VS UT WOS:000342358000012 PM 25104080 ER PT J AU Paruch, JL Ko, CY Bilimoria, KY AF Paruch, Jennifer L. Ko, Clifford Y. Bilimoria, Karl Y. TI A Case for Improving Measurement of Intraoperative Iatrogenic Injuries SO JAMA SURGERY LA English DT Editorial Material ID ADVERSE EVENTS C1 [Paruch, Jennifer L.; Ko, Clifford Y.; Bilimoria, Karl Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Paruch, Jennifer L.] Univ Chicago, Pritzker Sch Med, Dept Surg, Chicago, IL 60637 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Surg, Chicago, IL 60611 USA. [Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Northwestern Inst Comparat Effectiveness Res Onco, Chicago, IL 60611 USA. RP Paruch, JL (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St, Chicago, IL 60611 USA. EM jparuch@facs.org NR 7 TC 2 Z9 2 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD SEP PY 2014 VL 149 IS 9 BP 887 EP 888 DI 10.1001/jamasurg.2013.5237 PG 2 WC Surgery SC Surgery GA AP9HG UT WOS:000342389000001 PM 25006838 ER PT J AU Malinoski, D AF Malinoski, Darren TI How to Help Hispanic Families Benefit From Organ Donation After a Tragedy SO JAMA SURGERY LA English DT Editorial Material ID ATTITUDES; BELIEFS C1 [Malinoski, Darren] Portland VA Med Ctr, Operat Care Div, Portland, OR 97207 USA. [Malinoski, Darren] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA. RP Malinoski, D (reprint author), Portland VA Med Ctr, Operat Care Div, POB 1034,P3SURG, Portland, OR 97207 USA. EM darren.malinoski@va.gov NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD SEP PY 2014 VL 149 IS 9 BP 903 EP 903 DI 10.1001/jamasurg.2014.1029 PG 1 WC Surgery SC Surgery GA AP9HG UT WOS:000342389000007 PM 25103028 ER PT J AU Patel, MS Zatarain, J De La Cruz, S Sally, MB Ewing, T Crutchfield, M Enestvedt, CK Malinoski, DJ AF Patel, Madhukar S. Zatarain, John De La Cruz, Salvador Sally, Mitchell B. Ewing, Tyler Crutchfield, Megan Enestvedt, C. Kristian Malinoski, Darren J. TI The Impact of Meeting Donor Management Goals on the Number of Organs Transplanted per Expanded Criteria Donor A Prospective Study From the UNOS Region 5 Donor Management Goals Workgroup SO JAMA SURGERY LA English DT Article ID SURVIVAL; RECIPIENTS AB IMPORTANCE The shortage of organs available for transplant has led to the use of expanded criteria donors (ECDs) to extend the donor pool. These donors are older and have more comorbidities and efforts to optimize the quality of their organs are needed. OBJECTIVE To determine the impact of meeting a standardized set of critical care end points, or donor management goals (DMGs), on the number of organs transplanted per donor in ECDs. DESIGN, SETTING, AND PARTICIPANTS Prospective interventional study from February 2010 to July 2013 of all ECDs managed by the 8 organ procurement organizations in the southwestern United States (United Network for Organ Sharing Region 5). INTERVENTIONS Implementation of 9 DMGs as a checklist to guide the management of every ECD. The DMGs represented normal cardiovascular, pulmonary, renal, and endocrine end points. Meeting the DMG bundle was defined a priori as achieving any 7 of the 9 end points and was recorded at the time of referral to the organ procurement organization, at the time of authorization for donation, 12 to 18 hours later, and prior to organ recovery. MAIN OUTCOMES AND MEASURES The primary outcome measure was 3 or more organs transplanted per donor and binary logistic regression was used to identify independent predictors with P <.05. RESULTS There were 671 ECDs with a mean (SD) number of 2.1 (1.3) organs transplanted per donor. Ten percent of the ECDs had met the DMG bundle at referral, 15% at the time of authorization, 33% at 12 to 18 hours, and 45% prior to recovery. Forty-three percent had 3 or more organs transplanted per donor. Independent predictors of 3 or more organs transplanted per donor were older age (odds ratio [OR] = 0.95 per year [95% CI, 0.93-0.97]), increased creatinine level (OR = 0.73 permg/dL [95% CI, 0.63-0.85]), DMGs met prior to organ recovery (OR = 1.90 [95% CI, 1.35-2.68]), and a change in the number of DMGs achieved from referral to organ recovery (OR = 1.11 per additional DMG [95% CI, 1.00-1.23]). CONCLUSIONS AND RELEVANCE Meeting DMGs prior to organ recovery with ECDs is associated with achieving 3 or more organs transplanted per donor. An increase in the number of critical care end points achieved throughout the care of a potential donor by both donor hospital and organ procurement organization is also associated with an increase in organ yield. C1 [Patel, Madhukar S.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Zatarain, John; De La Cruz, Salvador; Sally, Mitchell B.; Crutchfield, Megan; Malinoski, Darren J.] Portland VA Med Ctr, Surg Crit Care Sect, Portland, OR 97207 USA. [Zatarain, John; De La Cruz, Salvador; Sally, Mitchell B.; Enestvedt, C. Kristian; Malinoski, Darren J.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA. [Ewing, Tyler] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA. RP Malinoski, DJ (reprint author), Portland VA Med Ctr, Surg Crit Care Sect, POB 1034,P3SURG, Portland, OR 97207 USA. EM darren.malinoski@va.gov FU Health Resources and Services Administration [234-2005-37011C, R380T10586] FX This work was supported in part by Health Resources and Services Administration contract 234-2005-37011C and grant R380T10586. NR 13 TC 15 Z9 15 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD SEP PY 2014 VL 149 IS 9 BP 969 EP 975 DI 10.1001/jamasurg.2014.967 PG 7 WC Surgery SC Surgery GA AP9HG UT WOS:000342389000025 PM 25054379 ER PT J AU Brawner, BM AF Brawner, Bridgette M. TI A Multilevel Understanding of HIV/AIDS Disease Burden Among African American Women SO JOGNN-JOURNAL OF OBSTETRIC GYNECOLOGIC AND NEONATAL NURSING LA English DT Article DE African Americans; conceptual model; disease prevention; health disparities; HIV; AIDS; risk factors; socioeconomic factors; underserved populations; vulnerable; women ID SEXUALLY-TRANSMITTED INFECTIONS; RACIAL RESIDENTIAL SEGREGATION; INJECTION-DRUG USERS; HIV RISK BEHAVIOR; UNITED-STATES; SOCIAL DETERMINANTS; EDUCATIONAL-ATTAINMENT; PSYCHOLOGICAL DISTRESS; SEX PARTNERS; VIRAL LOAD AB Disproportionate HIV/AIDS rates among African American women have been examined extensively, primarily from an individual-centered focus. Beyond individual behaviors, factors such as the hyperincarceration of African American men and geographically concentrated disadvantage may better explain inequitable disease burden. In this article I propose a conceptual model of individual, social, and structural factors that influence HIV transmission among African American women. The model can be used to develop comprehensive assessments and guide prevention programs in African American communities. C1 [Brawner, Bridgette M.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. RP Brawner, BM (reprint author), Univ Penn, Ctr Hlth Equ Res, Ctr Global Womens Hlth, Sch Nursing, 418 Curie Blvd,4th Floor,Room 419, Philadelphia, PA 19104 USA. EM brawnerb@nursing.upenn.edu FU Research Education Institute for Diverse Scholars, National Institute of Mental Health [5R25MH087217-04] FX Supported by Research Education Institute for Diverse Scholars, National Institute of Mental Health (5R25MH087217-04). The content is solely the responsibility of the author and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health. The author thanks Barbara J. Guthrie and Jean J. Schensul for review and feedback on the conceptual model. NR 95 TC 3 Z9 3 U1 5 U2 17 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-2175 EI 1552-6909 J9 JOGNN-J OBST GYN NEO JI JOGNN PD SEP-OCT PY 2014 VL 43 IS 5 BP 633 EP 643 DI 10.1111/1552-6909.12481 PG 11 WC Nursing; Obstetrics & Gynecology SC Nursing; Obstetrics & Gynecology GA AP9GH UT WOS:000342386500014 PM 25139057 ER PT J AU Florez, JC AF Florez, Jose C. TI It's Not Black and White: Individualizing Metformin Treatment in Type 2 Diabetes SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Editorial Material ID GLYCATED HEMOGLOBIN; GLYCEMIC CONTROL; AFRICAN-AMERICANS; GENETIC ANCESTRY; ASSOCIATION; PHARMACOGENOMICS; HYPERGLYCEMIA; MANAGEMENT; STATEMENT; ALGORITHM C1 [Florez, Jose C.] Harvard Univ, Sch Med, Ctr Human Genet Res,Broad Inst,Dept Med, Massachusetts Gen Hosp,Program Med & Populat Gene, Boston, MA 02114 USA. [Florez, Jose C.] Harvard Univ, Sch Med, Broad Inst,Dept Med,Diabet Res Ctr,Diabet Unit, Massachusetts Gen Hosp,Program Med & Populat Gene, Boston, MA 02114 USA. RP Florez, JC (reprint author), Massachusetts Gen Hosp, Diabet Unit, Ctr Human Genet Res, Simches Res Bldg,CPZN 5-250,185 Cambridge St, Boston, MA 02114 USA. EM jcflorez@mgh.harvard.edu NR 20 TC 1 Z9 1 U1 0 U2 1 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD SEP PY 2014 VL 99 IS 9 BP 3125 EP 3128 DI 10.1210/jc.2014-2733 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AP8PQ UT WOS:000342341400047 PM 25192381 ER PT J AU Putman, MS Milliren, CE Derrico, N Uluer, A Sicilian, L Lapey, A Sawicki, G Gordon, CM Bouxsein, ML Finkelstein, JS AF Putman, Melissa S. Milliren, Carly E. Derrico, Nicholas Uluer, Ahmet Sicilian, Leonard Lapey, Allen Sawicki, Gregory Gordon, Catherine M. Bouxsein, Mary L. Finkelstein, Joel S. TI Compromised Bone Microarchitecture and Estimated Bone Strength in Young Adults With Cystic Fibrosis SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID QUANTITATIVE COMPUTED-TOMOGRAPHY; VIVO HR-PQCT; DISTAL RADIUS; MINERAL DENSITY; POSTMENOPAUSAL WOMEN; TRABECULAR BONE; VERTEBRAL FRACTURES; CORTICAL BONE; TIBIA; PREVALENCE AB Context: Young adults with cystic fibrosis (CF) are at risk for low bone density and fractures, but the underlying alterations in bone microarchitecture that may contribute to their increased fracture risk are currently unknown. Objective: The main goal of this study was to use high-resolution peripheral quantitative computed tomography (HR-pQCT) to characterize the bone microarchitecture, volumetric bone mineral density (vBMD), and estimated strength of the radius and tibia in young adults with CF compared with healthy volunteers. Design and Setting: This was a cross-sectional study at an outpatient clinical research center within a tertiary academic medical center. Participants: Thirty young adults with CF, 18 to 40 years of age, were evaluated and compared with 60 healthy volunteers matched by age (+/- 2 years), gender, and race. Main Outcome Measures: The primary outcomes were HR-pQCT-derived cortical and trabecular vBMD, bone microarchitecture, and estimates of bone strength. Results: At the radius and tibia, young adults with CF had smaller bone cross-sectional area and lower vBMD. Cortical and trabecular microarchitecture were compromised at both sites, most notably involving the trabecular bone of the tibia. These differences translated into lower estimated bone strength both at the radius and tibia. After accounting for body mass index differences, young adults with CF had lower bone area and estimated bone strength at the radius and had compromised trabecular microarchitecture and lower total and trabecular vBMD and estimated bone strength at the tibia. Alterations in trabecular bone density and microarchitecture and estimated strength measures of the tibia were also greater than expected based on dual-energy x-ray absorptiometry-derived areal BMD differences. Conclusions: Young adults with CF have compromised bone microarchitecture and lower estimated bone strength at both the radius and tibia, even after accounting for their smaller body size. These skeletal deficits likely explain the higher fracture risk observed in young adults with CF. C1 [Putman, Melissa S.; Derrico, Nicholas; Bouxsein, Mary L.; Finkelstein, Joel S.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. [Sicilian, Leonard] Massachusetts Gen Hosp, Dept Med, Div Pulm, Boston, MA 02114 USA. [Lapey, Allen] Massachusetts Gen Hosp, Dept Pediat, Div Pulm, Boston, MA 02114 USA. [Putman, Melissa S.; Gordon, Catherine M.] Boston Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA. [Uluer, Ahmet; Sawicki, Gregory] Boston Childrens Hosp, Div Resp Dis, Boston, MA 02115 USA. [Milliren, Carly E.] Boston Childrens Hosp, Clin Res Ctr, Boston, MA 02115 USA. [Gordon, Catherine M.] Hasbro Childrens Hosp, Div Adolescent Med, Providence, RI 02903 USA. [Gordon, Catherine M.] Hasbro Childrens Hosp, Div Endocrinol, Providence, RI 02903 USA. RP Putman, MS (reprint author), Massachusetts Gen Hosp, Endocrine Unit, 50 Blossom St,THR 1051, Boston, MA 02114 USA. EM msputman@partners.org FU National Institutes of Health T32 award; Endocrine Society Amgen Fellowship Award; National Center For Research Resources Shared Equipment Grant [1S10RR023405-01]; Harvard Clinical and Translational Science Center [8 UL1 TR000170-05, 1 UL1TR001102-01, 1 UL1RR025758-04] FX This work was supported by a National Institutes of Health T32 award and the Endocrine Society Amgen Fellowship Award. A Vertex Pharmaceuticals Investigator Initiated Studies Grant provided partial support for procedures in this study. The HR-pQCT measurements were made possible by a National Center For Research Resources Shared Equipment Grant (1S10RR023405-01). This project was also supported by the Harvard Clinical and Translational Science Center, Grant Numbers 8 UL1 TR000170-05, 1 UL1TR001102-01, and 1 UL1RR025758-04. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Center For Research Resources, the National Center for Advancing Translational Science, or the National Institutes of Health. NR 36 TC 15 Z9 15 U1 0 U2 1 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD SEP PY 2014 VL 99 IS 9 BP 3399 EP 3407 DI 10.1210/jc.2014-1982 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AP8PQ UT WOS:000342341400081 PM 24926955 ER PT J AU Diem, SJ Joffe, H Larson, JC Tsai, JN Guthrie, KA LaCroix, AZ Ensrud, KE Freeman, EW Leder, BZ AF Diem, Susan J. Joffe, Hadine Larson, Joseph C. Tsai, Joy N. Guthrie, Katherine A. LaCroix, Andrea Z. Ensrud, Kristine E. Freeman, Ellen W. Leder, Benjamin Z. TI Effects of Escitalopram on Markers of Bone Turnover: A Randomized Clinical Trial SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID TRANSPORTER INHIBITION EVIDENCE; MINERAL DENSITY; SEROTONIN 5-HYDROXYTRYPTAMINE; POSTMENOPAUSAL WOMEN; DEPRESSIVE SYMPTOMS; OLDER WOMEN; FRACTURES; RATES; DENOSUMAB; RISK AB Context: Recent observational studies have suggested that the use of selective serotonin reuptake inhibitors is associated with an increased fracture risk and an accelerated bone loss, although conflicting results have been reported. Furthermore, because many of these studies have been performed in depressed women, confounding by indication may influence these findings. Objective: The objective of the study was to determine whether selective serotonin reuptake inhibitors affect bone metabolism Design: This was a randomized controlled trial. Setting: The study was conducted in four US clinical sites. Participants: Healthy peri-and postmenopausal women participated in the study. Intervention: The intervention was escitalopram (10-20 mg/d) for the treatment of vasomotor symptoms. Main Outcome Measures: Serum carboxyterminal collagen crosslinks (CTX) and serum amino-terminal propeptide of type I collagen (P1NP) were measured. Results: One hundred forty-one peri-or postmenopausal nondepressed women (mean age 53.7 y, SD 4.1) had baseline and 8-week follow-up samples available for analysis and were included in the study (69 escitalopram, 72 placebo). The groups were balanced across a broad range of baseline characteristics, including age, race, body mass index, smoking status, and mood symptoms. The between-group differences in the change in CTX and P1NP from baseline to week 8 were compared by a repeated-measures linear regression model adjusted for race, clinical center, and baseline measurement. Treatment with escitalopram reduced serum P1NP by 1.02 ng/mL on average [95% confidence interval (CI) -5.17, 3.12] compared with a reduction of 1.88 ng/mL (95% CI -4.82, 1.06) in the placebo group (P = .65). Similarly, serum CTX decreased 0.02 ng/mL on average (95% CI -0.05, 0.01) in the escitalopram group compared with 0.00 ng/mL(95% CI -0.02,0.02) in the placebo group(P = .24). The results were similar when the analysis was restricted to those women whose adherence to study medication was 70% or greater. Conclusions: Although the study was limited to 8 weeks, these results suggest that escitalopram does not significantly alter bone metabolism in the short term. C1 [Diem, Susan J.; Ensrud, Kristine E.] Univ Minnesota, Minneapolis, MN 55415 USA. [Joffe, Hadine] Brigham & Womens Hosp, Boston, MA 02115 USA. [Joffe, Hadine] Dana Farber Canc Inst, Boston, MA 02115 USA. [Larson, Joseph C.; LaCroix, Andrea Z.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. [Tsai, Joy N.; Leder, Benjamin Z.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Ensrud, Kristine E.] Minneapolis Vet Affairs Hlth Care Syst, Minneapolis, MN 55417 USA. [Freeman, Ellen W.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Diem, SJ (reprint author), 1100 Washington Ave South,Suite 201, Minneapolis, MN 55415 USA. EM sdiem@umn.edu FU National Institute of Aging; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Center for Complementary and Alternative Medicine; Office of Research on Women's Health [U01 AG032656, U01AG032659, U01AG032669, U01AG032699, U01AG032700]; Indiana Clinical and Translational Sciences Institute; National Institutes of Health, National Center for Research Resources, Clinical and Translational Sciences Award [UL1 RR025761] FX This work was supported by a cooperative agreement issued by the National Institute of Aging, in collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Center for Complementary and Alternative Medicine, and the Office of Research on Women's Health Grants U01 AG032656, U01AG032659, U01AG032669, U01AG032699, and U01AG032700. At the University of Indiana site, the project was supported in part with funding from the Indiana Clinical and Translational Sciences Institute, funded in part by Grant UL1 RR025761 from the National Institutes of Health, National Center for Research Resources, Clinical and Translational Sciences Award. Escitalopram and matching placebo pills were provided by Forest Research Institute. NR 20 TC 5 Z9 5 U1 1 U2 2 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD SEP PY 2014 VL 99 IS 9 BP E1732 EP E1737 DI 10.1210/jc.2014-2288 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AP8PQ UT WOS:000342341400022 PM 25014001 ER PT J AU Ananthakrishnan, AN Cagan, A Gainer, VS Cheng, SC Cai, TX Szolovits, P Shaw, SY Churchill, S Karlson, EW Murphy, SN Kohane, I Liao, KP AF Ananthakrishnan, Ashwin N. Cagan, Andrew Gainer, Vivian S. Cheng, Su-Chun Cai, Tianxi Szolovits, Peter Shaw, Stanley Y. Churchill, Susanne Karlson, Elizabeth W. Murphy, Shawn N. Kohane, Isaac Liao, Katherine P. TI Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease SO JOURNAL OF CROHNS & COLITIS LA English DT Article DE Crohn's disease; Ulcerative colitis; Sclerosing cholangitis; Cancer; Colorectal cancer ID ELECTRONIC MEDICAL-RECORDS; POPULATION-BASED COHORT; GENOMICS EMERGE NETWORK; CROHNS-DISEASE; RHEUMATOID-ARTHRITIS; ULCERATIVE-COLITIS; NATURAL-HISTORY; HEALTH RECORDS; RISK; DIAGNOSIS AB Introduction: Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) frequently co-occur. PSC is associated with increased risk for colorectal cancer (CRC). However, whether PSC is associated with increased risk of extraintestinal cancers or affects mortality in an IBD cohort has not been examined previously. Methods: In a multi-institutional IBD cohort of IBD, we established a diagnosis of PSC using a novel algorithm incorporating narrative and codified data with high positive and negative predictive value. Our primary outcome was occurrence of extraintestinal and digestive tract cancers. Mortality was determined through monthly linkage to the social security master death index. Results: In our cohort of 5506 patients with CD and 5522 patients with UC, a diagnosis of PSC was established in 224 patients (2%). Patients with IBD PSC were younger and more likely to be male compared to IBD patients without PSC; three-quarters had UC. IBD-PSC patients had significantly increased overall risk of cancers compared to patients without PSC (OR 4.36, 95% CI 2.99-6.37). Analysis of specific cancer types revealed that a statistically significant excess risk for digestive tract cancer (OR 10.40, 95% CI 6.86-15.76), pancreatic cancer (OR 11.22, 95% CI 4.11-30.62), colorectal cancer (OR 5.00, 95% CI 2.80-8.95), and cholangiocarcinoma (OR 55.31, 95% CI 22.20-137.80) but not for other solid organ or hematologic malignancies. Conclusions: PSC is associated with increased risk of colorectal and pancreatobiliary cancer but not with excess risk of other solid organ cancers. (C) 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved. C1 [Ananthakrishnan, Ashwin N.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA. [Ananthakrishnan, Ashwin N.; Shaw, Stanley Y.; Karlson, Elizabeth W.; Murphy, Shawn N.; Kohane, Isaac; Liao, Katherine P.] Harvard Univ, Sch Med, Boston, MA USA. [Cheng, Su-Chun; Cai, Tianxi] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Cagan, Andrew; Gainer, Vivian S.; Murphy, Shawn N.] Partners HealthCare, Res IS & Comp, Charlestown, MA USA. [Kohane, Isaac] Childrens Hosp, Boston, MA 02115 USA. [Szolovits, Peter] MIT, Cambridge, MA 02139 USA. [Shaw, Stanley Y.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Churchill, Susanne; Kohane, Isaac] Brigham & Womens Hosp, i2b2 Natl Ctr Biomed Comp, Boston, MA 02115 USA. [Karlson, Elizabeth W.; Liao, Katherine P.] Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA. [Murphy, Shawn N.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Ananthakrishnan, AN (reprint author), Massachusetts Gen Hosp, Crohns & Colitis Ctr, 165 Cambridge St,9th Floor, Boston, MA 02114 USA. EM aananthakrishnan@partners.org OI Szolovits, Peter/0000-0001-8411-6403 FU NIH [U54-LM008748, K08 AR060257, K24 AR052403, P60 AR047782, R01 AR049880]; American Gastroenterological Association; US National Institutes of Health [K23 DK097142]; Harold and Duval Bowen Fund FX The study was supported by NIH U54-LM008748. A.N.A. is supported by funding from the American Gastroenterological Association and from the US National Institutes of Health (K23 DK097142). K.P.L. is supported by NIH K08 AR060257 and the Harold and Duval Bowen Fund. E.W.K. is supported by grants from the NIH (K24 AR052403, P60 AR047782, R01 AR049880). NR 41 TC 14 Z9 14 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1873-9946 EI 1876-4479 J9 J CROHNS COLITIS JI J. Crohns Colitis PD SEP 1 PY 2014 VL 8 IS 9 BP 956 EP 963 DI 10.1016/j.crohns.2014.01.019 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AP7NV UT WOS:000342264900006 PM 24559536 ER PT J AU D'Ambrosio, A Barker, FG AF D'Ambrosio, Anthony Barker, Fred G., II TI AANS/CNS Section on Tumors SO JOURNAL OF NEURO-ONCOLOGY LA English DT Editorial Material C1 [D'Ambrosio, Anthony] Neurosurg New Jersey, Ridgewood, NJ 07450 USA. [Barker, Fred G., II] Massachusetts Gen Hosp, Neurosurg Serv, Boston, MA 02114 USA. [Barker, Fred G., II] Harvard Univ, Sch Med, Dept Surg Neurosurg, Boston, MA USA. RP D'Ambrosio, A (reprint author), Neurosurg New Jersey, 1200 East Ridgewood Ave, Ridgewood, NJ 07450 USA. EM dambrosio@neurosurgerynj.com; barker@helix.mgh.harvard.edu NR 0 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X EI 1573-7373 J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD SEP PY 2014 VL 119 IS 3 SI SI BP 449 EP 450 DI 10.1007/s11060-014-1590-3 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA AP9TD UT WOS:000342421900001 PM 25182603 ER PT J AU Waziri, A Curry, WT AF Waziri, Allen Curry, William T. TI Development of the AANS/CNS joint Section on Tumors: challenges and opportunities SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE Section on tumors; Development; Advocacy AB Over the 30 years since the formation of the AANS/CNS Section on Tumors, the breadth and scope of our activities have continued to expand. An initial focus on education and collaboration between those members of the neurosurgical community dedicated to the care of patients with neurological tumors has broadened to include development of international relationships, participation in clinical trials and efforts to define standards of care and quality metrics. As we navigate the rapidly changing environment of health care, the Section on Tumors will occupy a central role in promoting advocacy, establishing collaboration, providing education, and supporting research for the community of neurosurgeons dedicated to the care of patients with neurological tumors. This article will provide an update and status report on the development of the Section on Tumors, followed by a brief discussion of the challenges and opportunities emerging at the onset of our fourth decade of service. C1 [Waziri, Allen] Inova Neurosci Inst, Dept Neurosurg, Falls Church, VA 22042 USA. [Curry, William T.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Curry, William T.] Harvard Univ, Sch Med, Boston, MA USA. RP Waziri, A (reprint author), Inova Neurosci Inst, Dept Neurosurg, Falls Church, VA 22042 USA. EM allen.waziri@inova.org NR 5 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X EI 1573-7373 J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD SEP PY 2014 VL 119 IS 3 SI SI BP 577 EP 581 DI 10.1007/s11060-014-1542-y PG 5 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA AP9TD UT WOS:000342421900013 PM 25074368 ER PT J AU Lau, D Barker, FG Aghi, MK AF Lau, Darryl Barker, Fred G., II Aghi, Manish K. TI Awards, lectures, and fellowships sponsored by the AANS/CNS Section on Tumors SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE American Association for Neurological Surgeons; Congress of Neurological Surgeons; Awards ID PUBLICATION; MEETINGS AB A major goal of the Section on Tumors of the American Association of Neurological Surgery (AANS) and Congress of Neurological Surgeons (CNS) since it was founded in 1984 has been to foster both education and research in the field of brain tumor treatment and development. In support of this goal, the Section sponsors a number of awards, named lectures, and fellowships at the annual meetings of the AANS and CNS. In this article, we describe the awards given by the AANS/CNS Section on Tumors since its foundation, the recipients of the awards, and their philanthropic donors. The subsequent history of awardees and their work is briefly examined. Specifically for the Preuss and Mahaley Awards, this article also examines the rates of publication among the award-winning abstracts and achievement of grant funding by awardees. C1 [Lau, Darryl; Aghi, Manish K.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA. [Barker, Fred G., II] Massachusetts Gen Hosp, Neurosurg Serv, Boston, MA 02114 USA. [Barker, Fred G., II] Harvard Univ, Sch Med, Dept Surg Neurosurg, Boston, MA USA. RP Aghi, MK (reprint author), Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave Room M779, San Francisco, CA 94143 USA. EM aghim@neurosurg.ucsf.edu NR 9 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X EI 1573-7373 J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD SEP PY 2014 VL 119 IS 3 SI SI BP 583 EP 591 DI 10.1007/s11060-014-1469-3 PG 9 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA AP9TD UT WOS:000342421900014 PM 24893731 ER PT J AU Lang, FF Barker, FG AF Lang, Frederick F. Barker, Fred G., II TI A history of the AANS/CNS Section on Tumors Biennial Satellite Symposium SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE Tumor Section; History; Brain tumor AB The Biennial Satellite Tumor Symposium is the flagship meeting of the AANS/CNS Section on Tumors. The year 2013 marked the 10th Tumor Section Biennial Satellite Tumor Symposium, a significant milestone warranting retrospection on the origin and development of the Satellite Tumor Symposium. This article provides a brief history of the Section on Tumors Biennial Satellite Tumor Symposium, including insights into the structure and evolution of the meeting, and recognizes some of the members of the AANS/CNS Section on Tumors who have contributed to Satellite meetings over the years. C1 [Lang, Frederick F.] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA. [Barker, Fred G., II] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Barker, Fred G., II] Harvard Univ, Sch Med, Boston, MA USA. RP Lang, FF (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Box 442, Houston, TX 77030 USA. EM flang@mdanderson.org FU NCI NIH HHS [P50 CA127001] NR 1 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X EI 1573-7373 J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD SEP PY 2014 VL 119 IS 3 SI SI BP 593 EP 600 DI 10.1007/s11060-014-1506-2 PG 8 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA AP9TD UT WOS:000342421900015 PM 25081975 ER PT J AU Wyte-Lake, T Bowman, C Needleman, J Dougherty, M Scarrott, DN Dobalian, A AF Wyte-Lake, Tamar Bowman, Candice Needleman, Jack Dougherty, Mary Scarrott, Diana N. Dobalian, Aram TI IMPACT OF VANA ACADEMIC-PRACTICE PARTNERSHIP PARTICIPATION ON EDUCATIONAL MOBILITY DECISIONS AND TEACHING ASPIRATIONS OF NURSES SO JOURNAL OF PROFESSIONAL NURSING LA English DT Article DE Career mobility; Faculty, nursing/supply and distribution; Continuing education; Bachelor's degree; Master's; Nurses; Nursing ID CAPACITY; ADDRESS AB This study reports findings assessing the influence of the Department of Veterans Affairs Nursing Academy (VANA) academic practice partnership program on nurse decision making regarding educational mobility and teaching aspirations. We conducted national surveys with nursing faculty from VANA partnership sites in 2011 (N = 133) and 2012 (N = 74). Faculty who spent more hours per week in the VANA role and who reported an increase in satisfaction with their participation in VANA were more likely to have been influenced by their VANA experience in choosing to pursue a higher degree (p < .05). Sixty-nine percent of VANA faculty reported that they would be very interested in staying on as a VANA faculty member if the program should continue. Six measures were positively associated with VANA's influence on the desire to continue as faculty beyond the VANA pilot; support from VANA colleagues, quality of VANA students, amount of guidance with curriculum development, availability of administrative support, support for improving teaching methods, and overall satisfaction with VANA experience (p < .05). As the popularity of academic practice partnerships grows and their list of benefits is further enumerated, motivating nurses to pursue both higher degrees and faculty roles should be listed among them based on results reported here. Published by Elsevier Inc. C1 [Wyte-Lake, Tamar; Bowman, Candice; Scarrott, Diana N.; Dobalian, Aram] VEMEC, Sepulveda, CA 91343 USA. [Wyte-Lake, Tamar; Bowman, Candice; Dobalian, Aram] VA Greater Los Angeles Healthcare Syst, HSR&D Ctr Study Healthcare Provider Behav, Sepulveda, CA USA. [Needleman, Jack; Dobalian, Aram] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Dougherty, Mary] Dept Vet Affairs, Off Acad Affiliat, Washington, DC USA. [Dobalian, Aram] Univ Calif Los Angeles, Sch Nursing, VEMEC, Los Angeles, CA 90024 USA. RP Wyte-Lake, T (reprint author), VEMEC, 16111 Plummer St,MS-152, Sepulveda, CA 91343 USA. EM tamar.wyte@va.gov RI Needleman, Jack/I-5461-2013 OI Needleman, Jack/0000-0002-2875-0589 FU Department of VA; Veterans Health Administration; Office of Academic Affiliations; Office of Nursing Services FX This material is based upon work supported by the Department of VA, Veterans Health Administration, Offices of Academic Affiliations, and Nursing Services. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of VA or the U.S. government. NR 22 TC 0 Z9 0 U1 2 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 8755-7223 EI 1532-8481 J9 J PROF NURS JI J. Prof. Nurs. PD SEP-OCT PY 2014 VL 30 IS 5 BP 383 EP 391 DI 10.1016/j.profnurs.2014.01.009 PG 9 WC Nursing SC Nursing GA AP8LE UT WOS:000342329700005 PM 25223286 ER PT J AU Adler, JT Smith, AD Yeh, H Markmann, JF Nguyen, LL AF Adler, Joel T. Smith, Ann D. Yeh, Heidi Markmann, James F. Nguyen, Louis L. TI Temporal Analysis of Market Competition and Density in Renal Transplantation Volume and Outcomes SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT Annual Clinical Congress of the American-College-of-Surgeons CY OCT 26-30, 2014 CL San Francisco, CA SP Amer Clin Surg C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD SEP PY 2014 VL 219 IS 3 SU S BP S143 EP S143 PG 1 WC Surgery SC Surgery GA AP9ST UT WOS:000342420900304 ER PT J AU DePeralta, DK Wei, L Harriman, G Greenwood, J Westlin, WF Harwood, J Bhat, S Kapeller, R Fuchs, BC Tanabe, KK AF DePeralta, Danielle K. Wei, Lan Harriman, Geraldine Greenwood, Jeremy Westlin, William F. Harwood, James Bhat, Sathesh Kapeller, Rosana Fuchs, Bryan C. Tanabe, Kenneth K. TI Liver Selective Acetyl-CoA Carboxylase Inhibition Inhibits Hepatocellular Carcinoma in a Cirrhosis Model SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT Annual Clinical Congress of the American-College-of-Surgeons CY OCT 26-30, 2014 CL San Francisco, CA SP Amer Clin Surg C1 [DePeralta, Danielle K.; Wei, Lan; Harriman, Geraldine; Greenwood, Jeremy; Westlin, William F.; Harwood, James; Bhat, Sathesh; Kapeller, Rosana; Fuchs, Bryan C.; Tanabe, Kenneth K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD SEP PY 2014 VL 219 IS 3 SU S BP S23 EP S24 PG 2 WC Surgery SC Surgery GA AP9ST UT WOS:000342420900029 ER PT J AU Hotta, R Thomas, AR Pan, WH Belkind-Gerson, J Goldstein, AM AF Hotta, Ryo Thomas, Alyssa R. Pan, Weihua Belkind-Gerson, Jaime Goldstein, Allan M. TI Transplantation of Enteric Neuronal Precursors to Restore Enteric Innervation in Hirschsprung Disease SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT Annual Clinical Congress of the American-College-of-Surgeons CY OCT 26-30, 2014 CL San Francisco, CA SP Amer Clin Surg C1 [Hotta, Ryo; Thomas, Alyssa R.; Pan, Weihua; Belkind-Gerson, Jaime; Goldstein, Allan M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD SEP PY 2014 VL 219 IS 3 SU S BP S134 EP S134 PG 1 WC Surgery SC Surgery GA AP9ST UT WOS:000342420900282 ER PT J AU Jarrett, CM Milford, C Weinberg, I Rassi, AN Chubiz, J Cambria, RP Jaff, MR Ferris, T AF Jarrett, Craig M. Milford, Creagh Weinberg, Ido Rassi, Andrew N. Chubiz, Jessica Cambria, Richard P. Jaff, Michael R. Ferris, Timothy TI Measuring and Improving Appropriateness of Carotid Endarterectomy and Stenting in Clinical Practice SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT Annual Clinical Congress of the American-College-of-Surgeons CY OCT 26-30, 2014 CL San Francisco, CA SP Amer Clin Surg C1 [Jarrett, Craig M.; Milford, Creagh; Weinberg, Ido; Rassi, Andrew N.; Chubiz, Jessica; Cambria, Richard P.; Jaff, Michael R.; Ferris, Timothy] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD SEP PY 2014 VL 219 IS 3 SU S BP S97 EP S97 PG 1 WC Surgery SC Surgery GA AP9ST UT WOS:000342420900200 ER PT J AU Kinnier, CV Chung, JW Paruch, JL Wayne, JD Ross, MI Winchester, DP Bilimoria, KY AF Kinnier, Christine V. Chung, Jeanette W. Paruch, Jennifer L. Wayne, Jeffrey D. Ross, Merrick I. Winchester, David P. Bilimoria, Karl Y. TI Does Hospital Proficiency Vary for Melanoma Sentinel Lymph Node Biopsies? An Evaluation of Hospital-Level Adjusted Node Positivity Rates and Outcomes SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT Annual Clinical Congress of the American-College-of-Surgeons CY OCT 26-30, 2014 CL San Francisco, CA SP Amer Clin Surg C1 Northwestern Univ, Chicago, IL 60611 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD SEP PY 2014 VL 219 IS 3 SU S BP S99 EP S99 PG 1 WC Surgery SC Surgery GA AP9ST UT WOS:000342420900205 ER PT J AU Lancaster, RT Twerdahl, E Mohebali, J Ergul, E Kwolek, CJ Conrad, MF Cambria, RP Patel, VI AF Lancaster, Robert T. Twerdahl, Eric Mohebali, Jahan Ergul, Emel Kwolek, Christopher J. Conrad, Mark F. Cambria, Richard P. Patel, Virendra I. TI Risk-Stratified Analysis of Open vs Fenestrated Repair of Complex Abdominal Aortic Aneurysms SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT Annual Clinical Congress of the American-College-of-Surgeons CY OCT 26-30, 2014 CL San Francisco, CA SP Amer Clin Surg C1 [Lancaster, Robert T.; Twerdahl, Eric; Mohebali, Jahan; Ergul, Emel; Kwolek, Christopher J.; Conrad, Mark F.; Cambria, Richard P.; Patel, Virendra I.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD SEP PY 2014 VL 219 IS 3 SU S BP S160 EP S160 PG 1 WC Surgery SC Surgery GA AP9ST UT WOS:000342420900340 ER PT J AU Lancaster, RT Twerdahl, E Mukhopadhyay, S Mohebali, J Kwolek, CJ Conrad, MF Cambria, RP Patel, VI AF Lancaster, Robert T. Twerdahl, Eric Mukhopadhyay, Shankha Mohebali, Jahan Kwolek, Christopher J. Conrad, Mark F. Cambria, Richard P. Patel, Virendra I. TI A Risk Prediction Model for Perioperative Mortality after Open Complex Aortic Aneurysm Repair SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT Annual Clinical Congress of the American-College-of-Surgeons CY OCT 26-30, 2014 CL San Francisco, CA SP Amer Clin Surg C1 [Lancaster, Robert T.; Twerdahl, Eric; Mukhopadhyay, Shankha; Mohebali, Jahan; Kwolek, Christopher J.; Conrad, Mark F.; Cambria, Richard P.; Patel, Virendra I.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD SEP PY 2014 VL 219 IS 3 SU S BP S153 EP S153 PG 1 WC Surgery SC Surgery GA AP9ST UT WOS:000342420900325 ER PT J AU Mavros, M Velmahos, GC Larentzakis, A Yeh, DD Fagenholz, PJ DeMoya, M King, DR Lee, J Kaafarani, HMA AF Mavros, Michail Velmahos, George C. Larentzakis, Andreas Yeh, Daniel D. Fagenholz, Peter J. DeMoya, Marc King, David R. Lee, Jarone Kaafarani, Haytham M. A. TI Benchmarking the Quality of Intraoperative Surgical Care: Risk-Adjustment for Procedure Complexity and Previous Surgery is Crucial SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT Annual Clinical Congress of the American-College-of-Surgeons CY OCT 26-30, 2014 CL San Francisco, CA SP Amer Clin Surg C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. Medstar Washington Hosp Ctr, Washington, DC USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD SEP PY 2014 VL 219 IS 3 SU S BP S97 EP S98 PG 2 WC Surgery SC Surgery GA AP9ST UT WOS:000342420900202 ER PT J AU Peacock, ZS Schwab, JH Faquin, WC Hornicek, FJ Ebb, DH Kaban, LB AF Peacock, Zachary S. Schwab, Joseph H. Faquin, William C. Hornicek, Francis J. Ebb, David H. Kaban, Leonard B. TI Genetic Analysis of Giant Cell Tumors of the Axial/Appendicular and Maxillofacial Skeleton SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT Annual Clinical Congress of the American-College-of-Surgeons CY OCT 26-30, 2014 CL San Francisco, CA SP Amer Clin Surg C1 [Peacock, Zachary S.; Schwab, Joseph H.; Faquin, William C.; Hornicek, Francis J.; Ebb, David H.; Kaban, Leonard B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD SEP PY 2014 VL 219 IS 3 SU S BP S70 EP S70 PG 1 WC Surgery SC Surgery GA AP9ST UT WOS:000342420900138 ER PT J AU Richman, JS Henderson, W Bronsert, M Monk, T Hawn, MT AF Richman, Joshua S. Henderson, William Bronsert, Michael Monk, Terri Hawn, Mary T. TI Evaluating the Surgical Apgar Score in the Veterans Administration (VA) SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT Annual Clinical Congress of the American-College-of-Surgeons CY OCT 26-30, 2014 CL San Francisco, CA SP Amer Clin Surg C1 [Richman, Joshua S.; Henderson, William; Bronsert, Michael; Monk, Terri; Hawn, Mary T.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD SEP PY 2014 VL 219 IS 3 SU S BP S98 EP S98 PG 1 WC Surgery SC Surgery GA AP9ST UT WOS:000342420900203 ER PT J AU Rosenberg, LM Yoon, CH Bertagnolli, MM Cho, NL AF Rosenberg, Laura M. Yoon, Charles H. Bertagnolli, Monica M. Cho, Nancy L. TI Sorafenib Suppresses Translation in Desmoid Tumors via Inhibition of mTOR Signaling SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT Annual Clinical Congress of the American-College-of-Surgeons CY OCT 26-30, 2014 CL San Francisco, CA SP Amer Clin Surg C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD SEP PY 2014 VL 219 IS 3 SU S BP S129 EP S130 PG 2 WC Surgery SC Surgery GA AP9ST UT WOS:000342420900272 ER PT J AU Jammallo, LS Miller, CL Horick, NK Skolny, MN O'Toole, J Specht, MC Taghian, AG AF Jammallo, Lauren S. Miller, Cynthia L. Horick, Nora K. Skolny, Melissa N. O'Toole, Jean Specht, Michelle C. Taghian, Alphonse G. TI Factors Associated With Fear of Lymphedema After Treatment for Breast Cancer SO ONCOLOGY NURSING FORUM LA English DT Article DE lymphedema; breast cancer; fear; Perometer; quality of life ID QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; UPPER-LIMB LYMPHEDEMA; ARM LYMPHEDEMA; BIOELECTRICAL-IMPEDANCE; AXILLARY DISSECTION; PHYSICAL-ACTIVITY; SEPARATING FACT; RISK-FACTORS; FOLLOW-UP AB Purpose/Objectives: To identify demographic and treatment characteristics associated with postoperative fear of lymphedema. Design: Prospective cohort study. Setting: Outpatient breast clinic at a comprehensive cancer center in the northeastern United States. Sample: 324 patients undergoing treatment for unilateral breast cancer. Methods: Women with breast cancer were prospectively screened for lymphedema (relative volume change of 10% or greater) preoperatively and every three to eight months postoperatively via Perometer arm volume measurements. Fear was simultaneously evaluated via questionnaire. Multivariate linear mixed-effects regression models were used to identify factors associated with mean postoperative fear score and to plot the average fear score over time within axillary surgery type subgroups. Main Research Variables: Postoperative fear of lymphedema. Findings: Higher preoperative fear score (p < 0.0001), younger age at diagnosis (p = 0.0038), and axillary lymph node dissection (ALND) (p < 0.0001) were significantly associated with higher mean postoperative fear score. The average fear score changed nonlinearly over time (p < 0.0001), decreasing from preoperative to 24 months postoperative and leveling thereafter. Conclusions: Preoperative fear, younger age at diagnosis, and ALND may contribute to postoperative fear of lymphedema. Implications for Nursing: Individualized education that begins preoperatively, continues throughout treatment, and is re-emphasized 24 months postoperatively may help minimize fear of lymphedema. C1 [Jammallo, Lauren S.; Miller, Cynthia L.; Skolny, Melissa N.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Horick, Nora K.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. [O'Toole, Jean] Massachusetts Gen Hosp, Dept Phys & Occupat Therapy, Boston, MA 02114 USA. [Specht, Michelle C.] Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA. [Taghian, Alphonse G.] Harvard Univ, Sch Med, Dept Radiat Oncol, Cambridge, MA 02138 USA. [Taghian, Alphonse G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Jammallo, LS (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. EM ataghian@partners.org FU National Cancer Institute [R01CA139118]; Adele McKinnon Research Fund for Breast Cancer Related Lymphedema [P50CA089393] FX Lauren S. Jammallo, BS, is a clinical research coordinator II and Cynthia L. Miller, BS, is a clinical research coordinator, both in the Department of Radiation Oncology; Nora K. Horick, MS, is a biostatistician at the Biostatistics Center; Melissa N. Skolny, MSHA, is a project manager in the Department of Radiation Oncology; Jean O'Toole, PT, MPH, CLT-LANA, is a physical therapist in the Department of Physical and Occupational Therapy; and Michelle C. Specht, MD, is a surgeon in the Division of Surgical Oncology, all at Massachusetts General Hospital in Boston; and Alphonse G. Taghian, MD, PhD, is a professor in the Department of Radiation Oncology at Harvard Medical School and director of Breast Radiation Oncology at Massachusetts General Hospital. This study was supported, in part, by awards from the National Cancer Institute (No. R01CA139118) and the Adele McKinnon Research Fund for Breast Cancer Related Lymphedema (No. P50CA089393) to Alphonse G. Taghian, MD, PhD. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. Taghian can be reached at ataghian@partners.org, with copy to editor at ONFEditor@ons.org. (Submitted October 2013. Accepted for publication March 12, 2014.) NR 55 TC 2 Z9 2 U1 1 U2 12 PU ONCOLOGY NURSING SOC PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 0190-535X EI 1538-0688 J9 ONCOL NURS FORUM JI Oncol. Nurs. Forum PD SEP PY 2014 VL 41 IS 5 BP 473 EP 483 DI 10.1188/14.ONF.473-483 PG 11 WC Oncology; Nursing SC Oncology; Nursing GA AP8ZB UT WOS:000342366800006 PM 25158653 ER PT J AU Kelly, JF Greene, MC AF Kelly, John F. Greene, M. Claire TI Where There's a Will There's a Way: A Longitudinal Investigation of the Interplay Between Recovery Motivation and Self-Efficacy in Predicting Treatment Outcome SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS LA English DT Article DE self-efficacy; motivation; treatment; theory; young adults ID ALCOHOL; BEHAVIOR; RELAPSE; MODEL AB The psychological construct of self-efficacy plays a key role in both general, as well as addiction-specific, models of health behavior change and is well supported empirically. As a predictor of treatment outcome it has proven useful; however, to further clarify the nature and role of self-efficacy in predicting the complexities of addiction recovery, it would seem crucial also to consider an individuals' motivation to carry out that future behavior, because the degree to which a measure of self-efficacy predicts behavior may be contingent upon whether that individual is also motivated to enact it. To this end, we tested an interaction model of self-efficacy and motivation on treatment outcome. Young adults (N = 302; M = 20 years; 74% male) undergoing residential substance use disorder treatment were assessed at treatment intake, discharge, and 3, 6, and 12 months postdischarge on self-efficacy (SE), motivation for sobriety (MS), and percent days abstinent (PDA). Hierarchical linear modeling (HLM) results revealed main effects for abstinence SE and MS across time, but a significant interaction was detected, indicating that the influence of SE on PDA depended on MS. Further analysis revealed that for patients high in SE the level of MS made a small, but significant, difference on PDA, whereas for those low in SE, high MS made a substantial difference, such that their outcome was not different than patients with high SE. Findings highlight conceptual nuances in SE theory; and, clinically, convey optimism that, even if a patient reports low confidence in their ability to remain abstinent, it does not necessarily follow that they will have poor outcome, especially if they have a strong recovery motivation. C1 [Kelly, John F.; Greene, M. Claire] Massachusetts Gen Hosp, Dept Psychiat, Ctr Addict Med, Boston, MA 02114 USA. [Kelly, John F.; Greene, M. Claire] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Kelly, JF (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Ctr Addict Med, 60 Staniford St, Boston, MA 02114 USA. EM jkelly11@partners.org FU NIAAA NIH HHS [R21 AA018185, R21AA01815-01A2]; NIDA NIH HHS [T32 DA007292] NR 23 TC 7 Z9 7 U1 1 U2 12 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0893-164X EI 1939-1501 J9 PSYCHOL ADDICT BEHAV JI Psychol. Addict. Behav. PD SEP PY 2014 VL 28 IS 3 BP 928 EP 934 DI 10.1037/a0034727 PG 7 WC Substance Abuse; Psychology, Multidisciplinary SC Substance Abuse; Psychology GA AP6YA UT WOS:000342223300032 PM 24274437 ER PT J AU Alter, G Ackerman, ME AF Alter, Galit Ackerman, Margaret E. TI An antibody tag-team: driving neutralization through escape SO TRENDS IN IMMUNOLOGY LA English DT Editorial Material ID IMMUNOGEN DESIGN; VACCINE; HIV-1; INDUCTION; EPITOPE; B12 AB HIV rapidly mutates to escape antibody detection, and B cells counter this mutation by continual evolution to restore recognition, serendipitously resulting in the evolution of neutralizing activity in a fraction of infected individuals. A recent Cell paper describes how antibody repertoires stochastically collaborated, shaping the viral swarm and utilizing viral immune evasion to their advantage. C1 [Alter, Galit] MIT, Massachusetts Gen Hosp, Ragon Inst, Cambridge, MA 02139 USA. [Alter, Galit] Harvard Univ, Cambridge, MA 02139 USA. [Ackerman, Margaret E.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA. RP Alter, G (reprint author), MIT, Massachusetts Gen Hosp, Ragon Inst, 77 Massachusetts Ave, Cambridge, MA 02139 USA. EM galter@partners.org; margaret.e.ackerman@dartmouth.edu NR 10 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1471-4906 EI 1471-4981 J9 TRENDS IMMUNOL JI Trends Immunol. PD SEP PY 2014 VL 35 IS 9 BP 403 EP 405 DI 10.1016/j.it.2014.07.009 PG 3 WC Immunology SC Immunology GA AP7PT UT WOS:000342269900001 PM 25131302 ER PT J AU Kanold, PO Nelken, I Polley, DB AF Kanold, Patrick O. Nelken, Israel Polley, Daniel B. TI Local versus global scales of organization in auditory cortex SO TRENDS IN NEUROSCIENCES LA English DT Review DE auditory cortex; frequency; homogeneity; maps; heterogeneity; layers; electrophysiology; imaging; calcium; resolution; scale ID PRIMARY VISUAL-CORTEX; INTRINSIC OPTICAL SIGNALS; TONOTOPIC ORGANIZATION; FUNCTIONAL-ORGANIZATION; IN-VIVO; ORIENTATION SELECTIVITY; QUANTITATIVE-ANALYSIS; SYNAPTIC MECHANISMS; NEIGHBORING NEURONS; CORTICAL-NEURONS AB Topographic organization is a hallmark of sensory cortical organization. Topography is robust at spatial scales ranging from hundreds of microns to centimeters, but can dissolve at the level of neighboring neurons or subcellular compartments within a neuron. This dichotomous spatial organization is especially pronounced in the mouse auditory cortex, where an orderly tonotopic map can arise from heterogeneous frequency tuning between local neurons. Here, we address a debate surrounding the robustness of tonotopic organization in the auditory cortex that has persisted in some form for over 40 years. Drawing from various cortical areas, cortical layers, recording methodologies, and species, we describe how auditory cortical circuitry can simultaneously support a globally systematic, yet locally heterogeneous representation of this fundamental sound property. C1 [Kanold, Patrick O.] Univ Maryland, Syst Res Inst, Dept Biol, College Pk, MD 20742 USA. [Kanold, Patrick O.] Univ Maryland, Program Neurosci & Cognit Sci, College Pk, MD 20742 USA. [Nelken, Israel] Hebrew Univ Jerusalem, Silberman Inst Life Sci & Edmond, Dept Neurobiol, IL-91904 Jerusalem, Israel. [Nelken, Israel] Hebrew Univ Jerusalem, Lily Safra Ctr Brain Sci, IL-91904 Jerusalem, Israel. [Polley, Daniel B.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA. [Polley, Daniel B.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. RP Kanold, PO (reprint author), Univ Maryland, Syst Res Inst, Dept Biol, College Pk, MD 20742 USA. EM pkanold@umd.edu OI Kanold, Patrick/0000-0002-7529-5435; Polley, Daniel/0000-0002-5120-2409 FU National Institutes of Health (NIH) [R01DC009607, R01DC009836]; Israel Science Foundation (ISF); US Israel Binational Science Foundation (BSF); European Research Council (ERC) [RATLAND-340063] FX P.O.K. is supported by National Institutes of Health (NIH) R01DC009607. D.B.P. is supported by NIH R01DC009836. I.N. is supported by grants from the Israel Science Foundation (ISF), the US Israel Binational Science Foundation (BSF), and the European Research Council (ERC Grant Agreement RATLAND-340063). NR 92 TC 14 Z9 14 U1 6 U2 23 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0166-2236 J9 TRENDS NEUROSCI JI Trends Neurosci. PD SEP PY 2014 VL 37 IS 9 BP 502 EP 510 DI 10.1016/j.tins.2014.06.003 PG 9 WC Neurosciences SC Neurosciences & Neurology GA AP7QK UT WOS:000342271600006 PM 25002236 ER PT J AU Kuhlthau, KA Mistry, KB Forrest, CB Dougherty, D AF Kuhlthau, Karen A. Mistry, Kamila B. Forrest, Christopher B. Dougherty, Denise TI Advancing the Science of Measurement in Pediatric Quality of Care SO ACADEMIC PEDIATRICS LA English DT Editorial Material ID IMPROVEMENT C1 [Kuhlthau, Karen A.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA. [Kuhlthau, Karen A.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Mistry, Kamila B.; Dougherty, Denise] Agcy Healthcare Res & Qual, Rockville, MD USA. [Forrest, Christopher B.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. RP Kuhlthau, KA (reprint author), Massachusetts Gen Hosp, Dept Pediat, 100 Cambridge St,15th Floor, Boston, MA 02114 USA. EM kkuhlthau@mgh.harvard.edu FU AHRQ HHS [U18HS20408] NR 28 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1876-2859 EI 1876-2867 J9 ACAD PEDIATR JI Acad. Pediatr. PD SEP-OCT PY 2014 VL 14 IS 5 SU S BP S1 EP S3 PG 3 WC Pediatrics SC Pediatrics GA AP2KE UT WOS:000341900300001 PM 25169448 ER PT J AU Foight, GW Ryan, JA Gulla, SV Letai, A Keating, AE AF Foight, Glenna Wink Ryan, Jeremy A. Gulla, Stefano V. Letai, Anthony Keating, Amy E. TI Designed BH3 Peptides with High Affinity and Specificity for Targeting Mcl-1 in Cells SO ACS CHEMICAL BIOLOGY LA English DT Article ID RATIONAL DESIGN; BCL-2; APOPTOSIS; INHIBITORS; PROTEINS; LEUKEMIA; DISCOVERY; ABT-737; POTENT; SENSITIVITY AB Mcl-1 is overexpressed in many cancers and can confer resistance to cell-death signaling in refractory disease. Molecules that specifically inhibit Mcl-1 hold potential for diagnosing and disrupting Mcl-1-dependent cell survival. We selected three peptides from a yeast-surface display library that showed moderate specificity and affinity for binding to Mcl-1 over Bfl-1, Bc1-x(L), Bcl-2, and Bcl-w. Specificity for Mcl-1 was improved by introducing threonine at peptide position 2e. The most specific peptide, MS1, bound Mcl-1 with 40-fold or greater specificity over four other human Bcl-2 paralogs. In BH3 profiling assays, MS1 caused depolarization in several human Md-1-dependent cell lines with EC50 values of mu M, contrasted with EC50 values of >100 mu M for Bcl-2-, Bd-x(L)-, or Bfl-l-dependent cell lines. MS1 is at least 30-fold more potent in this assay than the previously used Mcl-1 targeting reagent NoxaA BH3. These peptides can be used to detect Mcl-1 dependency in cells and provide leads for developing Mcl-1 targeting therapeutics. C1 [Foight, Glenna Wink; Gulla, Stefano V.; Keating, Amy E.] MIT, Dept Biol, Cambridge, MA 02139 USA. [Ryan, Jeremy A.; Letai, Anthony] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. [Letai, Anthony] Harvard Univ, Dept Biol Chem & Mol Pharmacol, Sch Med, Boston, MA 02115 USA. RP Keating, AE (reprint author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA. EM keating@mit.edu RI Foight, Glenna/J-6032-2015 OI Foight, Glenna/0000-0003-3749-7092 FU NIGMS [R01-GM084181, P50-GM068762, P01-CA129980]; NSF FX We thank the Koch Institute Biopolymers and Proteomics Facility for peptide synthesis and the Koch Institute Flow Cytometry Core at MIT for assistance with cell sorting and analysis. This work was supported by NIGMS awards R01-GM084181, P50-GM068762, and P01-CA129980, and G.W.F. was supported by an NSF Graduate Research Fellowship. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 36 TC 16 Z9 16 U1 3 U2 16 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1554-8929 EI 1554-8937 J9 ACS CHEM BIOL JI ACS Chem. Biol. PD SEP PY 2014 VL 9 IS 9 BP 1962 EP 1968 DI 10.1021/cb500340w PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA AP5LR UT WOS:000342121200008 PM 25052212 ER PT J AU Lei, S Zavala-Flores, L Garcia-Garcia, A Nandakumar, R Huang, Y Madayiputhiya, N Stanton, RC Dodds, ED Powers, R Franco, R AF Lei, Shulei Zavala-Flores, Laura Garcia-Garcia, Aracely Nandakumar, Renu Huang, Yuting Madayiputhiya, Nandakumar Stanton, Robert C. Dodds, Eric D. Powers, Robert Franco, Rodrigo TI Alterations in Energy/Redox Metabolism Induced by Mitochondrial and Environmental Toxins: A Specific Role for Glucose-6-Phosphate-Dehydrogenase and the Pentose Phosphate Pathway in Paraquat Toxicity SO ACS CHEMICAL BIOLOGY LA English DT Article ID DOPAMINERGIC CELL-DEATH; MAGNETIC-RESONANCE-SPECTROSCOPY; NEUROTRANSMITTER AMINO-ACIDS; HUMAN NEUROBLASTOMA-CELLS; NITRIC-OXIDE SYNTHASE; COMPLEX I INHIBITION; N-SH CELLS; PARKINSONS-DISEASE; OXIDATIVE STRESS; TYROSINE-HYDROXYLASE AB Parkinson's disease (PD) is a multifactorial disorder with a complex etiology including genetic risk factors, environmental exposures, and aging. While energy failure and oxidative stress have largely been associated with the loss of dopaminergic cells in PD and the toxicity induced by mitochondrial/environmental toxins, very little is known regarding the alterations in energy metabolism associated with mitochondrial dysfunction and their causative role in cell death progression. In this study, we investigated the alterations in the energy/redox-metabolome in dopaminergic cells exposed to environmental/mitochondrial toxins (paraquat, rotenone, 1-methyl-4-phenylpyridinium [MPP+], and 6-hydroxydopamine [6-OHDA]) in order to identify common and/or different mechanisms of toxicity. A combined metabolomics approach using nuclear magnetic resonance (NMR) and direct-infusion electrospray ionization mass spectrometry (DI-ESI-MS) was used to identify unique metabolic profile changes in response to these neurotoxins. Paraquat exposure induced the most profound alterations in the pentose phosphate pathway (PPP) metabolome. C-13-glucose flux analysis corroborated that PPP metabolites such as glucose-6-phosphate, fructose-6-phosphate, glucono-1,5-lactone, and erythrose-4-phosphate were increased by paraquat treatment, which was paralleled by inhibition of glycolysis and the TCA cycle. Proteomic analysis also found an increase in the expression of glucose-6-phosphate dehydrogenase (G6PD), which supplies reducing equivalents by regenerating nicotinamide adenine dinucleotide phosphate (NADPH) levels. Overexpression of G6PD selectively increased paraquat toxicity, while its inhibition with 6-aminonicotinamide inhibited paraquat-induced oxidative stress and cell death. These results suggest that paraquat "hijacks" the PPP to increase NADPH reducing equivalents and stimulate paraquat redox cycling, oxidative stress, and cell death. Our study clearly demonstrates that alterations in energy metabolism, which are specific for distinct mitochondiral/ environmental toxins, are not bystanders to energy failure but also contribute significant to cell death progression. C1 [Lei, Shulei; Huang, Yuting; Dodds, Eric D.; Powers, Robert] Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA. [Nandakumar, Renu; Madayiputhiya, Nandakumar] Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA. [Zavala-Flores, Laura; Garcia-Garcia, Aracely; Powers, Robert; Franco, Rodrigo] Univ Nebraska, Redox Biol Ctr, Lincoln, NE 68588 USA. [Zavala-Flores, Laura; Garcia-Garcia, Aracely; Franco, Rodrigo] Univ Nebraska, Sch Vet Med & Biomed Sci, Lincoln, NE 68588 USA. [Stanton, Robert C.] Harvard Univ, Div Res, Joslin Diabet Ctr, Sch Med, Boston, MA 02115 USA. RP Powers, R (reprint author), Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA. EM rpowers3@unl.edu; rfrancocruz2@unl.edu RI Dodds, Eric/G-4254-2011; Franco, Rodrigo/D-9470-2013 OI Franco, Rodrigo/0000-0003-3241-8615 FU National Institutes of Health, Centers of Biomedical Research Excellence (COBRE) [P20RR17675, P30 GM103335]; American Heart Association [12SDG12090015]; Research Council Interdisciplinary Grant; University of Nebraska-Lincoln; NIH [RR015468-01] FX This work was supported by the National Institutes of Health Grants P20RR17675 and P30 GM103335, Centers of Biomedical Research Excellence (COBRE), the Scientist Development Grant of the American Heart Association (12SDG12090015), the Research Council Interdisciplinary Grant, and the Life Sciences Grant Program of the University of Nebraska-Lincoln. Research was performed in facilities renovated with support from the NIH under Grant RR015468-01. We thank the Flow Cytometry Core Facility at the Nebraska Center for Virology for the access to flow cytometry instrumentation. We also acknowledge B. Worley and D. D. Marshall for assisting in the preparation of the manuscript. NR 108 TC 12 Z9 12 U1 3 U2 28 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1554-8929 EI 1554-8937 J9 ACS CHEM BIOL JI ACS Chem. Biol. PD SEP PY 2014 VL 9 IS 9 BP 2032 EP 2048 DI 10.1021/cb400894a PG 17 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA AP5LR UT WOS:000342121200019 PM 24937102 ER PT J AU Hahn, J Wickham, SFJ Shih, WM Perrault, SD AF Hahn, Jaeseung Wickham, Shelley F. J. Shih, William M. Perrault, Steven D. TI Addressing the Instability of DNA Nanostructures in Tissue Culture SO ACS NANO LA English DT Article DE DNA nanotechnology; DNA origami; cells; in vitro; tissue culture; nuclease; stability; structural integrity; cation; nanorobot ID DOUBLE-CROSSOVER MOLECULES; IN-VIVO STABILITY; DEOXYRIBONUCLEASE-I; NANOSCALE SHAPES; FOLDING DNA; ORIGAMI; MICE AB DNA nanotechnology is an advanced technique that could contribute diagnostic, therapeutic, and biomedical research devices to nanomedicine. Although such devices are often developed and demonstrated using in vino tissue culture models, these conditions may not be compatible with DNA nanostructure integrity and function. The purpose of this study was to characterize the sensitivity of 3D DNA nanostructures produced via the origami method to the in vitro tissue culture environment and identify solutions to prevent loss of nanostructure integrity. We examined whether the physiological cation concentrations of cell culture medium and the nucleases present in fetal bovine serum (FBS) used as a medium supplement result in denaturation and digestion, respectively. DNA nanostructure denaturation due to cation depletion was design- and time-dependent, with one of four tested designs remaining intact after 24 h at 37 degrees C. Adjustment of medium by addition of MgSO4 prevented denaturation. Digestion of nanostructures by FBS nucleases in Mg2+-adjusted medium did not appear design-dependent and became significant within 24 h and when medium was supplemented with greater than 5% FBS. We estimated that medium supplemented with 10% FBS contains greater than 256 U/L equivalent of DNase I activity in digestion of DNA nanostructures. Heat inactivation at 75 degrees C and inclusion of actin protein in medium inactivated and inhibited nuclease activity, respectively. We examined the impact of medium adjustments on cell growth, viability, and phenotype. Adjustment of Mg2+ to 6 mM did not appear to have a detrimental impact on cells. Heat inactivation was found to be incompatible with in vitro tissue culture, whereas inclusion of actin had no observable effect on growth and viability. In two in vitro assays, immune cell activation and nanoparticle endocytosis, we show that using conditions compatible with cell phenotype and nanostructure integrity is critical for obtaining reliable experimental data. Our study thus describes considerations that are vital for researchers undertaking in vitro tissue culture studies with DNA nanostructures and some potential solutions for ensuring that nanostructure integrity and functions are maintained during experiments. C1 [Hahn, Jaeseung] MIT, Harvard Massachusetts Inst Technol MIT Div Hlth S, Cambridge, MA 02139 USA. [Hahn, Jaeseung; Wickham, Shelley F. J.; Shih, William M.; Perrault, Steven D.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Hahn, Jaeseung; Wickham, Shelley F. J.; Shih, William M.; Perrault, Steven D.] Harvard Univ, Sch Med, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA. [Hahn, Jaeseung; Wickham, Shelley F. J.; Shih, William M.; Perrault, Steven D.] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Perrault, SD (reprint author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. EM steven.perrault@wyss.harvard.edu FU National Science Foundation; Canadian Institutes of Health Research; Wyss Institute Technology Development Fellowship; NIH; Wyss Institute at Harvard; National Science Foundation Graduate Research Fellowship [1122374]; Wyss Institute FX J.H. holds a National Science Foundation Graduate Research Fellowship, S.D.P. holds a Canadian Institutes of Health Research Fellowship and a Wyss Institute Technology Development Fellowship, and this work was supported by an NIH grant to W.M.S. and by the Wyss Institute at Harvard. This material is based upon work supported by the National Science Foundation Graduate Research Fellowship under Grant No. 1122374. We thank the Wyss Institute for support of this project. NR 34 TC 42 Z9 42 U1 8 U2 66 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1936-0851 EI 1936-086X J9 ACS NANO JI ACS Nano PD SEP PY 2014 VL 8 IS 9 BP 8765 EP 8775 DI 10.1021/nn503513p PG 11 WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary SC Chemistry; Science & Technology - Other Topics; Materials Science GA AP6JP UT WOS:000342184400007 PM 25136758 ER PT J AU Ginat, DT Bhama, P Cunnane, ME Hadlock, TA AF Ginat, D. T. Bhama, P. Cunnane, M. E. Hadlock, T. A. TI Facial Reanimation Procedures Depicted on Radiologic Imaging SO AMERICAN JOURNAL OF NEURORADIOLOGY LA English DT Review ID EYELID IMPLANTS; GOLD WEIGHT; MUSCLE; PARALYSIS; LAGOPHTHALMOS; COMPLICATIONS; MANAGEMENT; GRAFTS; PALSY; FACE AB Various facial reanimation procedures can be performed for treating patients with chronic facial nerve paralysis. The radiologic imaging features of static and dynamic techniques are reviewed in this article with clinical correlation, including brow lift, eyelid weights and springs, gracilis free flaps, fascia lata grafts, temporalis flaps, and Gore-Tex suspension slings. Although the anatomic alterations resulting from facial reanimation surgery may not necessarily be the focus of the imaging examination, it is important to recognize such changes and be familiar with MR imaging compatibility of the associated implanted materials. Furthermore, imaging is sometimes used to specifically evaluate the postoperative results, such as vessel patency following free gracilis transfer. C1 [Ginat, D. T.] Massachusetts Gen Hosp, Dept Radiol, Div Neuroradiol, Boston, MA 02114 USA. [Bhama, P.; Hadlock, T. A.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. [Cunnane, M. E.] Massachusetts Eye & Ear Infirm, Div Facial Plast & Reconstruct Surg, Boston, MA 02114 USA. [Cunnane, M. E.] Massachusetts Eye & Ear Infirm, Dept Radiol, Boston, MA 02114 USA. RP Ginat, DT (reprint author), Univ Chicago, Dept Radiol, 5841 S Maryland Ave,MC 2026,Rm P220, Chicago, IL 60637 USA. EM ginatd01@gmail.com NR 26 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC NEURORADIOLOGY PI DENVILLE PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA SN 0195-6108 EI 1936-959X J9 AM J NEURORADIOL JI Am. J. Neuroradiol. PD SEP PY 2014 VL 35 IS 9 BP 1662 EP 1666 DI 10.3174/ajnr.A3684 PG 5 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA AO8XU UT WOS:000341639900003 PM 23945230 ER PT J AU Hirsch, JA Schaefer, PW Romero, JM Rabinov, JD Sanelli, PC Manchikanti, L AF Hirsch, J. A. Schaefer, P. W. Romero, J. M. Rabinov, J. D. Sanelli, P. C. Manchikanti, L. TI Comparative Effectiveness Research SO AMERICAN JOURNAL OF NEURORADIOLOGY LA English DT Article ID INTERVENTIONAL PAIN MANAGEMENT; CLINICAL-RESEARCH; HEALTH-CARE AB The goal of comparative effectiveness research is to improve health care while dealing with the seemingly ever-rising cost. An understanding of comparative effectiveness research as a core topic is important for neuroradiologists. It can be used in a variety of ways. Its goal is to look at alternative methods of interacting with a clinical condition, ideally, while improving delivery of care. While the Patient-Centered Outcome Research initiative is the most mature US-based foray into comparative effectiveness research, it has been used more robustly in decision-making in other countries for quite some time. The National Institute for Health and Clinical Excellence of the United Kingdom is a noteworthy example of comparative effectiveness research in action. C1 [Hirsch, J. A.; Schaefer, P. W.; Romero, J. M.; Rabinov, J. D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA. [Sanelli, P. C.] NewYork Presbyterian Hosp, Weill Cornell Med Coll, Dept Radiol, New York, NY USA. [Manchikanti, L.] Pain Management Ctr Paducah, Paducah, KY USA. [Manchikanti, L.] Univ Louisville, Dept Anesthesiol & Perioperat Med, Louisville, KY 40292 USA. RP Hirsch, JA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA. EM Hirsch@snisonline.org NR 21 TC 6 Z9 7 U1 0 U2 3 PU AMER SOC NEURORADIOLOGY PI DENVILLE PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA SN 0195-6108 EI 1936-959X J9 AM J NEURORADIOL JI Am. J. Neuroradiol. PD SEP PY 2014 VL 35 IS 9 BP 1677 EP 1680 DI 10.3174/ajnr.A3985 PG 4 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA AO8XU UT WOS:000341639900005 PM 24874531 ER PT J AU Chandra, RV Leslie-Mazwi, TM Mehta, BP Yoo, AJ Rabinov, JD Pryor, JC Hirsch, JA Nogueira, RG AF Chandra, R. V. Leslie-Mazwi, T. M. Mehta, B. P. Yoo, A. J. Rabinov, J. D. Pryor, J. C. Hirsch, J. A. Nogueira, R. G. TI Transarterial Onyx Embolization of Cranial Dural Arteriovenous Fistulas: Long-Term Follow-Up SO AMERICAN JOURNAL OF NEURORADIOLOGY LA English DT Article ID CORTICAL VENOUS DRAINAGE; NATURAL-HISTORY; ENDOVASCULAR TREATMENT; CLINICAL ARTICLE; CLASSIFICATION; EXPERIENCE; SHUNTS; REFLUX AB BACKGROUND AND PURPOSE: Endovascular therapy with liquid embolic agents is a common treatment strategy for cranial dural arteriovenous fistulas. This study evaluated the long-term effectiveness of transarterial Onyx as the single embolic agent for curative embolization of noncavernous cranial dural arteriovenous fistulas. MATERIALS AND METHODS: We performed a retrospective review of 40 consecutive patients with 41 cranial dural arteriovenous fistulas treated between March 2006 and June 2012 by using transarterial Onyx ernbolization with intent to cure. The mean age was 57 years; one-third presented with intracranial hemorrhage. Most (85%) had cortical venous drainage. Once angiographic cure was achieved, long-term treatment effectiveness was assessed with USA and clinical follow-up. RESULTS: Forty-nine embolization sessions were performed; 85% of cranial dural arteriovenous fistulas were treated in a single session. The immediate angiographic cure rate was 95%. The permanent neurologic complication rate was 2% (mild facial palsy). Thirty-five of the 38 patients with initial cure underwent short-term follow-up DSA (median, 4 months). The short-term recurrence rate was only 6% (2/35). All patients with occlusion at short-term DSA undergoing long-term DSA (median, 28 months) had durable occlusion. No patient with long-term clinical follow-up (total, 117 patient-years; median, 45 months) experienced hemorrhage. CONCLUSIONS: Transarterial embolization with Onyx as the single embolic agent results in durable long-term cure of noncavernous cranial dural arteriovenous fistulas. Recurrence rates are low on short-term follow-up, and all patients with angiographic occlusion on short-term DSA follow-up have experienced a durable long-term cure. Thus, angiographic cure should be defined at short-term follow-up angiography instead of at the end of the final embolization session. Finally, long-term DSA follow-up may not be necessary if occlusion is demonstrated on short-term angiographic follow-up. C1 [Chandra, R. V.] Monash Univ, Serv Neuroradiol, Melbourne, Vic 3004, Australia. [Chandra, R. V.] Monash Univ, Neurovasc Surg Serv, Melbourne, Vic 3004, Australia. [Chandra, R. V.] Monash Univ, Dept Diagnost Imaging, Melbourne, Vic 3004, Australia. [Chandra, R. V.] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia. [Leslie-Mazwi, T. M.; Mehta, B. P.; Yoo, A. J.; Rabinov, J. D.; Hirsch, J. A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuroendovasc Serv,Div Diagnost Neuroradiol, Boston, MA USA. [Leslie-Mazwi, T. M.; Mehta, B. P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol,Div Diagnost Neuroradiol, Boston, MA USA. [Yoo, A. J.; Rabinov, J. D.; Hirsch, J. A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Div Diagnost Neuroradiol, Boston, MA USA. [Pryor, J. C.] Boston Univ, Dept Intervent Neuroradiol, Boston, MA 02215 USA. [Nogueira, R. G.] Emory Univ, Sch Med, Neuroendovasc Serv, Grady Mem Hosp,Marcus Stroke & Neurosci Ctr, Atlanta, GA USA. [Nogueira, R. G.] Emory Univ, Sch Med, Neurocrit Care Serv, Grady Mem Hosp,Marcus Stroke & Neurosci Ctr, Atlanta, GA USA. RP Nogueira, RG (reprint author), 80 Jesse Hill Dr SE Room 398, Atlanta, GA 30303 USA. EM raul.g.nogueira@emory.edu NR 23 TC 6 Z9 6 U1 0 U2 2 PU AMER SOC NEURORADIOLOGY PI DENVILLE PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA SN 0195-6108 EI 1936-959X J9 AM J NEURORADIOL JI Am. J. Neuroradiol. PD SEP PY 2014 VL 35 IS 9 BP 1793 EP 1797 DI 10.3174/ajnr.A3938 PG 5 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA AO8XU UT WOS:000341639900024 PM 24742807 ER PT J AU Patel, SH Cunnane, ME Juliano, AF Vangel, MG Kazlas, MA Moonis, G AF Patel, S. H. Cunnane, M. E. Juliano, A. F. Vangel, M. G. Kazlas, M. A. Moonis, G. TI Imaging Appearance of the Lateral Rectus-Superior Rectus Band in 100 Consecutive Patients without Strabismus SO AMERICAN JOURNAL OF NEURORADIOLOGY LA English DT Article ID ORBITAL CONNECTIVE-TISSUE; PULLEY SYSTEM; EYE SYNDROME; INFECTIONS; ANATOMY AB BACKGROUND AND PURPOSE: The lateral rectus-superior rectus band is an orbital connective tissue structure that has been implicated in a form of strabismus termed sagging eye syndrome. Our purpose was to define the normal MR imaging and CT appearance of this band in patients without strabismus. MATERIALS AND METHODS: Orbital MR imaging and CT examinations in 100 consecutive patients without strabismus were evaluated. Readers graded the visibility of the lateral rectus-superior rectus band on coronal T1WI, coronal STIR, and coronal CT images. Readers determined whether the band demonstrated superotemporal bowing or any discontinuities and whether a distinct lateral levator aponeurosis was seen. Reader agreement was assessed by kappa coefficients. Association between imaging metrics and patient age/sex was calculated by using the Fisher exact test. RESULTS: The lateral rectus-superior rectus band was visible in 95% of coronal T1WI, 68% of coronal STIR sequences, and 70% of coronal CT scans. Ninety-five percent of these bands were seen as a continuous, arc-like structure extending from the superior rectus/levator palpebrae muscle complex to the lateral rectus muscle; 24% demonstrated superotemporal bowing; and in 82% of orbits, a distinct lateral levator aponeurosis was visible. Increasing patient age was negatively associated with lateral rectus-superior rectus band visibility (P = .03), positively associated with lateral rectus-superior rectus band superotemporal bowing (P = .03), and positively associated with lateral levator aponeurosis visibility (P = .01). CONCLUSIONS: The lateral rectus-superior rectus band is visible in most patients without strabismus on coronal T1WI. The age effect with respect to its visibility and superotemporal bowing could represent age-related connective tissue degeneration. C1 [Patel, S. H.; Cunnane, M. E.; Juliano, A. F.; Moonis, G.] Massachusetts Eye & Ear Infirm, Dept Radiol, Boston, MA 02114 USA. [Kazlas, M. A.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA. [Vangel, M. G.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. [Kazlas, M. A.] Boston Childrens Hosp, Dept Ophthalmol, Boston, MA USA. RP Patel, SH (reprint author), Massachusetts Eye & Ear Infirm, Dept Radiol, 243 Charles St, Boston, MA 02114 USA. EM spatel57@partners.org NR 15 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC NEURORADIOLOGY PI DENVILLE PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA SN 0195-6108 EI 1936-959X J9 AM J NEURORADIOL JI Am. J. Neuroradiol. PD SEP PY 2014 VL 35 IS 9 BP 1830 EP 1835 DI 10.3174/ajnr.A3943 PG 6 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA AO8XU UT WOS:000341639900030 PM 24763418 ER PT J AU Blashill, AJ Safren, SA AF Blashill, Aaron J. Safren, Steven A. TI Skin Cancer Risk Behaviors Among US Men: The Role of Sexual Orientation SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID ADOLESCENTS AB The current study assessed skin cancer risk behaviors by sexual orientation in a nationally representative prospective sample of US men (n = 1767), sampled at ages 16 and 29 years. At age 16 years, sexual minority men were 3.9 times as likely as heterosexual men to indoor tan. Participants did not significantly differ in the use of sunscreen or the frequency of outdoor tanning. Thus, sexual minority men might be an at-risk group for developing skin cancers because of their indoor tanning behaviors. C1 [Blashill, Aaron J.; Safren, Steven A.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Blashill, Aaron J.; Safren, Steven A.] Harvard Univ, Sch Med, Boston, MA USA. RP Blashill, AJ (reprint author), 1 Bowdoin Sq,7th Floor, Boston, MA 02118 USA. EM Ablashill@mgh.harvard.edu FU Eunice Kennedy Shriver National Institute of Child Health and Human Development [P01-HD31921]; National Institute of Mental Health of the National Institutes of Health [K23MH096647, K24MH094214] FX This research uses data from Add Health, a program project directed by Kathleen Mullan Harris and designed by J. Richard Udry, Peter S. Bearman, and Kathleen Mullan Harris at the University of North Carolina at Chapel Hill, and funded by grant P01-HD31921 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, with cooperative funding from 23 other federal agencies and foundations. No direct support was received from grant P01-HD31921 for this analysis. Research reported in this publication was supported by the National Institute of Mental Health of the National Institutes of Health under award numbers K23MH096647, to A. J. Blashill, and K24MH094214, to S. A. Safren. NR 9 TC 9 Z9 9 U1 0 U2 8 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD SEP PY 2014 VL 104 IS 9 BP 1640 EP 1641 DI 10.2105/AJPH.2014.301993 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP1XB UT WOS:000341864400028 PM 25033138 ER PT J AU Adamkiewicz, G Spengler, JD Harley, AE Stoddard, A Yang, M Alvarez-Reeves, M Sorensen, G AF Adamkiewicz, Gary Spengler, John D. Harley, Amy E. Stoddard, Anne Yang, May Alvarez-Reeves, Marty Sorensen, Glorian TI Environmental Conditions in Low-Income Urban Housing: Clustering and Associations With Self-Reported Health SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID INTEGRATED PEST-MANAGEMENT; NEW-YORK-CITY; ALLERGEN CONCENTRATIONS; SOCIOECONOMIC-STATUS; COCKROACH ALLERGEN; RACIAL-DIFFERENCES; BUILT ENVIRONMENT; AIR-POLLUTION; MENTAL-HEALTH; UNITED-STATES AB Objectives. We explored prevalence and clustering of key environmental conditions in low-income housing and associations with self-reported health. Methods. The Health in Common Study, conducted between 2005 and 2009, recruited participants (n = 828) from 20 low-income housing developments in the Boston area. We interviewed 1 participant per household and conducted a brief inspection of the unit (apartment). We created binary indexes and a summed index for household exposures: mold, combustion by-products, secondhand smoke, chemicals, pests, and inadequate ventilation. We used multivariable logistic regression to examine the associations between each index and household characteristics and between each index and self-reported health. Results. Environmental problems were common; more than half of homes had 3 or more exposure-related problems (median summed index = 3). After adjustment for household-level demographics, we found clustering of problems in site (P < .01) for pests, combustion byproducts, mold, and ventilation. Higher summed index values were associated with higher adjusted odds of reporting fair-poor health (odds ratio = 2.7 for highest category; P < .008 for trend). Conclusions. We found evidence that indoor environmental conditions in multifamily housing cluster by site and that cumulative exposures may be associated with poor health. C1 [Adamkiewicz, Gary; Spengler, John D.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02215 USA. [Sorensen, Glorian] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02215 USA. [Harley, Amy E.] Univ Wisconsin, Joseph J Zilber Sch Publ Hlth, Milwaukee, WI 53201 USA. [Stoddard, Anne; Yang, May] New England Res Inst, Watertown, MA 02172 USA. [Alvarez-Reeves, Marty] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA. RP Adamkiewicz, G (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Landmark Ctr West, 401 Pk Dr,Room 404K, Boston, MA 02215 USA. EM gadamkie@hsph.harvard.edu FU National Cancer Institute [R01 CA111310-01A1] FX This research was supported by the National Cancer Institute (grant R01 CA111310-01A1 to G. S.). NR 37 TC 10 Z9 10 U1 4 U2 27 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD SEP PY 2014 VL 104 IS 9 BP 1650 EP 1656 DI 10.2105/AJPH.2013.301253 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP1XB UT WOS:000341864400030 PM 24028244 ER PT J AU Chodos, AH Ahalt, C Cenzer, IS Myers, J Goldenson, J Williams, BA AF Chodos, Anna H. Ahalt, Cyrus Cenzer, Irena Stijacic Myers, Janet Goldenson, Joe Williams, Brie A. TI Older Jail Inmates and Community Acute Care Use SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID EMERGENCY-DEPARTMENT; HEALTH-CARE; FUNCTIONAL STATUS; SCREENING-TEST; ADULTS; MANAGEMENT; VALIDITY; SENIORS; ILLNESS; RISK AB Objectives. We examined older jail inmates' predetainment acute care use (emergency department or hospitalization in the 3 months before arrest) and their plans for using acute care after release. Methods. We performed a cross-sectional study of 247 jail inmates aged 55 years or older assessing sociodemographic characteristics, health, and geriatric conditions associated with predetainment and anticipated postrelease acute care use. Results. We found that 52% of older inmates reported predetainment acute care use and 47% planned to use the emergency department after release. In modified Poisson regression, homelessness was independently associated with predetainment use (relative risk = 1.42; 95% confidence interval = 1.10, 1.83) and having a primary care provider was inversely associated with planned use (relative risk = 0.69; 95% confidence interval = 0.53, 0.89). Conclusions. The Affordable Care Act has expanded Medicaid eligibility to all persons leaving jail in an effort to decrease postrelease acute care use in this high-risk population. Jail-to-community transitional care models that address the health, geriatric, and social factors prevalent in older adults leaving jail, and that focus on linkages to housing and primary care, are needed to enhance the impact of the act on acute care use for this population. C1 [Chodos, Anna H.; Ahalt, Cyrus; Cenzer, Irena Stijacic; Williams, Brie A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Myers, Janet] Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA. [Goldenson, Joe] San Francisco Dept Publ Hlth, Jail Hlth Serv, San Francisco, CA USA. [Williams, Brie A.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Williams, BA (reprint author), Univ Calif San Francisco, Box 1265,Suite 380,3333 Calif St Laurel Hts, San Francisco, CA 94143 USA. EM brie.williams@ucsf.edu FU National Institute of Aging [K23AG033102]; Jacob and Valeria Langeloth Foundation; UCSF Claude D. Pepper Older Americans Independence Center; National Palliative Care Research Center; UCSF Program for the Aging Century; National Institute on Aging at the National Institutes of Health [T32 AG000212-21] FX B. A. Williams was supported in part by the National Institute of Aging (K23AG033102), The Jacob and Valeria Langeloth Foundation, UCSF Claude D. Pepper Older Americans Independence Center, the National Palliative Care Research Center, and The UCSF Program for the Aging Century. A. H. Chodos was supported by grant T32 AG000212-21 from the National Institute on Aging at the National Institutes of Health. NR 41 TC 3 Z9 3 U1 6 U2 10 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD SEP PY 2014 VL 104 IS 9 BP 1728 EP 1733 DI 10.2105/AJPH.2014.301952 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP1XB UT WOS:000341864400041 PM 25033146 ER PT J AU Henwood, PC Mackenzie, DC Rempell, JS Murray, AF Leo, MM Dean, AJ Liteplo, AS Noble, VE AF Henwood, Patricia C. Mackenzie, David C. Rempell, Joshua S. Murray, Alice F. Leo, Megan M. Dean, Anthony J. Liteplo, Andrew S. Noble, Vicki E. TI A Practical Guide to Self-Sustaining Point-of-Care Ultrasound Education Programs in Resource-Limited Settings SO ANNALS OF EMERGENCY MEDICINE LA English DT Article ID HEALTH NEEDS-ASSESSMENT; DEVELOPING-COUNTRIES; COMPACT ULTRASOUND; DEVELOPING-WORLD; ULTRASONOGRAPHY; RECOMMENDATIONS; CHALLENGES; SONOGRAPHY; DIAGNOSIS; AID AB The value of point-of-care ultrasound education in resource-limited settings is increasingly recognized, though little guidance exists on how to best construct a sustainable training program. Herein we offer a practical overview of core factors to consider when developing and implementing a point-of-care ultrasound education program in a resource-limited setting. Considerations include analysis of needs assessment findings, development of locally relevant curriculum, access to ultrasound machines and related technological and financial resources, quality assurance and follow-up plans, strategic partnerships, and outcomes measures. Well-planned education programs in these settings increase the potential for long-term influence on clinician skills and patient care. C1 [Henwood, Patricia C.; Rempell, Joshua S.] Brigham & Womens Hosp, Dept Emergency Med, Div Emergency Ultrasound, Boston, MA 02115 USA. [Mackenzie, David C.; Liteplo, Andrew S.; Noble, Vicki E.] Massachusetts Gen Hosp, Div Emergency Ultrasound, Dept Emergency Med, Boston, MA 02114 USA. [Murray, Alice F.] Boston Med Ctr, Dept Pediat Emergency Med, Boston, MA USA. [Leo, Megan M.] Boston Med Ctr, Dept Emergency Med, Boston, MA USA. [Dean, Anthony J.] Univ Penn Hlth Syst, Emergency Ultrasound Div, Dept Emergency Med, Philadelphia, PA USA. RP Henwood, PC (reprint author), Brigham & Womens Hosp, Dept Emergency Med, Div Emergency Ultrasound, 75 Francis St, Boston, MA 02115 USA. EM trish.henwood@gmail.com OI Mackenzie, David/0000-0002-5535-9964 NR 48 TC 6 Z9 6 U1 4 U2 12 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD SEP PY 2014 VL 64 IS 3 BP 277 EP 285 DI 10.1016/j.annemergmed.2014.04.013 PG 9 WC Emergency Medicine SC Emergency Medicine GA AP0GG UT WOS:000341738700014 PM 24875894 ER PT J AU Mckee, A AF McKee, A. TI Chronic traumatic encephalopathy: the military setting SO BRAIN PATHOLOGY LA English DT Meeting Abstract CT 18th International Congress of Neuropathology CY SEP 14-18, 2014 CL Rio de Janeiro, BRAZIL C1 [McKee, A.] VA Boston Healthcare Syst, Boston, MA USA. [McKee, A.] Boston Univ, Sch Med, Alzheimer Dis Ctr, Dept Neurol, Boston, MA 02118 USA. [McKee, A.] Boston Univ, Sch Med, Alzheimer Dis Ctr, Dept Pathol & Lab Med, Boston, MA 02118 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1015-6305 EI 1750-3639 J9 BRAIN PATHOL JI Brain Pathol. PD SEP PY 2014 VL 24 SU 1 SI SI BP 18 EP 19 PG 2 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA AP6CT UT WOS:000342165800066 ER PT J AU Rachamimov, A AF Rachamimov, A. TI Molecular pathology of schwannomas SO BRAIN PATHOLOGY LA English DT Meeting Abstract CT 18th International Congress of Neuropathology CY SEP 14-18, 2014 CL Rio de Janeiro, BRAZIL C1 [Rachamimov, A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1015-6305 EI 1750-3639 J9 BRAIN PATHOL JI Brain Pathol. PD SEP PY 2014 VL 24 SU 1 SI SI BP 22 EP 22 PG 1 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA AP6CT UT WOS:000342165800083 ER PT J AU Bieniek, KF Stein, TD Alvarez, VE Fry, BT Dickson, DW McKee, AC AF Bieniek, K. F. Stein, T. D. Alvarez, V. E. Fry, B. T. Dickson, D. W. McKee, A. C. TI Chronic traumatic encephalopathy and amyotrophic lateral sclerosis SO BRAIN PATHOLOGY LA English DT Meeting Abstract CT 18th International Congress of Neuropathology CY SEP 14-18, 2014 CL Rio de Janeiro, BRAZIL C1 [Bieniek, K. F.; Dickson, D. W.] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA. [Bieniek, K. F.] Mayo Clin, Mayo Grad Sch, Rochester, MN USA. [Stein, T. D.; McKee, A. C.] VA Boston Healthcare Syst, Boston, MA USA. [Stein, T. D.; McKee, A. C.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA. [Stein, T. D.; Alvarez, V. E.; Fry, B. T.; McKee, A. C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Stein, T. D.; McKee, A. C.] Boston Univ, Sch Med, Alzheimer Dis Ctr, Boston, MA 02118 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1015-6305 EI 1750-3639 J9 BRAIN PATHOL JI Brain Pathol. PD SEP PY 2014 VL 24 SU 1 SI SI MA P27-01 BP 84 EP 84 PG 1 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA AP6CT UT WOS:000342165800300 ER PT J AU Borisovskaya, A Pascualy, M Borson, S AF Borisovskaya, Anna Pascualy, Marcella Borson, Soo TI Cognitive and Neuropsychiatric Impairments in Alzheimer's Disease: Current Treatment Strategies SO CURRENT PSYCHIATRY REPORTS LA English DT Article DE Alzheimer's disease; Caregiver support; Cooperative dementia care; Cognitive interventions; Neuropsychiatric symptoms; Agitation; Cognitive enhancers ID NURSING-HOME RESIDENTS; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIALS; DOUBLE-BLIND; BEHAVIORAL SYMPTOMS; CHOLINESTERASE-INHIBITORS; DEMENTIA CARE; PSYCHOLOGICAL SYMPTOMS; PHYSICAL-ACTIVITY; CAREGIVER BURDEN AB This update on Alzheimer's disease (AD) discusses treatment strategies for cognitive and neuropsychiatric symptoms (such as agitation, psychosis, anxiety, and depression) common in this illness, emphasizing in particular nonpharmacologic strategies such as cognitive interventions, physical exercise, and psychotherapy. We provide an overview of cognitive enhancers and their combination strategies and medications commonly used for treatment of neuropsychiatric symptoms in AD. Finally, we give recommendations for providing support to caregivers and suggest how to identify caregiver/patient pairs most in need of intensive dementia care services. C1 [Borisovskaya, Anna; Pascualy, Marcella] Univ Washington, Dept Psychiat & Behav Sci, VA Puget Sound Healthcare Syst, Seattle, WA 98108 USA. [Borson, Soo] Univ Washington, Dept Psychiat & Behav Sci Emerita, Palm Springs, CA 92264 USA. RP Borson, S (reprint author), Univ Washington, Dept Psychiat & Behav Sci Emerita, 2375 S Toledo Ave, Palm Springs, CA 92264 USA. EM anna.borisovskaya@va.gov; Marcella.pascualy@va.gov; soob@uw.edu NR 93 TC 6 Z9 6 U1 5 U2 44 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3812 EI 1535-1645 J9 CURR PSYCHIAT REP JI Curr. Psychiatry Rep. PD SEP PY 2014 VL 16 IS 9 AR 470 DI 10.1007/s11920-014-0470-z PG 9 WC Psychiatry SC Psychiatry GA AP1KF UT WOS:000341827400008 PM 25023513 ER PT J AU Janney, CA Bauer, MS Kilbourne, AM AF Janney, Carol A. Bauer, Mark S. Kilbourne, Amy M. TI Self-Management and Bipolar Disorder-A Clinician's Guide to the Literature 2011-2014 SO CURRENT PSYCHIATRY REPORTS LA English DT Article DE Self-management; Bipolar; Peer-led; Physical activity; Weight loss; Mobile technologies ID SERIOUS MENTAL-ILLNESS; RANDOMIZED CONTROLLED-TRIAL; CARDIOVASCULAR-DISEASE RISK; OF-THE-LITERATURE; RECOVERY PROGRAM; HEALTH-CARE; WEIGHT-LOSS; PSYCHOEDUCATION PROGRAM; COLLABORATIVE CARE; PHYSICAL-ACTIVITY AB This review provides clinicians and individuals with bipolar disorder (BD) with an overview of evidence-based skills shown to be effective in BD and amenable to self-management including psychoeducation; monitoring moods, medications, and social function; sleep hygiene; setting goals and relapse plans; and healthy lifestyles (physical activity, healthy eating, weight loss and management, medical comorbidities). Currently available self-management resources for BD are summarized by mode of delivery (workbooks, mobile technologies, internet, and peer-led interventions). Regardless of the self-management intervention/topic, the research suggests that personally tailored interventions of longer duration and greater frequency may be necessary to achieve the maximal benefit among individuals with BD. Means to support these self-management interventions as self-sustaining identities are critically needed. Hopefully, the recent investment in patient-centered research and care will result in best practices for the self-management of BD by mode of delivery. Since self-management of BD should complement rather than replace medical care, clinicians need to partner with their patients to incorporate and support advances in self-management for individuals with BD. C1 [Janney, Carol A.; Kilbourne, Amy M.] VA Ann Arbor Ctr Clin Management Res CCMR, Ann Arbor, MI USA. [Bauer, Mark S.] VA Boston Healthcare Syst, Boston, MA USA. [Kilbourne, Amy M.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA. [Janney, Carol A.; Kilbourne, Amy M.] Ctr Clin Management Res, VA HSR&D, Ann Arbor, MI 48105 USA. [Kilbourne, Amy M.] VA Natl Qual Enhancement Res Initiat QUERI, Iowa City, IA USA. [Bauer, Mark S.] Harvard Univ, Sch Med, Boston, MA USA. [Bauer, Mark S.] VA Boston Healthcare Syst, Ctr Healthcare Org & Implementat Res CHOIR, Boston, MA 02130 USA. [Janney, Carol A.] VA Ann Arbor Healthcare Syst, Ctr Clin Management Res, NCRC, Ann Arbor, MI 48109 USA. RP Janney, CA (reprint author), VA Ann Arbor Healthcare Syst, Ctr Clin Management Res, NCRC, 2800 Plymouth Rd,Bldg 16, Ann Arbor, MI 48109 USA. EM carol.janney@va.gov FU VA Center for Clinical Management Research, Health Services Research and Development FX CAJ was supported by the VA Center for Clinical Management Research, Health Services Research and Development as a post-doctoral fellow at the VA Ann Arbor Healthcare System. NR 114 TC 7 Z9 7 U1 5 U2 20 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3812 EI 1535-1645 J9 CURR PSYCHIAT REP JI Curr. Psychiatry Rep. PD SEP PY 2014 VL 16 IS 9 AR 485 DI 10.1007/s11920-014-0485-5 PG 15 WC Psychiatry SC Psychiatry GA AP1KF UT WOS:000341827400011 PM 25123130 ER PT J AU Baugh, CM Robbins, CA Stern, RA McKee, AC AF Baugh, Christine M. Robbins, Clifford A. Stern, Robert A. McKee, Ann C. TI Current Understanding of Chronic Traumatic Encephalopathy SO CURRENT TREATMENT OPTIONS IN NEUROLOGY LA English DT Review DE Chronic traumatic encephalopathy (CTE); Concussion; Brain trauma; Traumatic brain injury (TBI); APOE; Biomarker; Tau; Football ID FOOTBALL LEAGUE PLAYERS; REPETITIVE HEAD-INJURY; ALZHEIMERS-DISEASE; BRAIN-INJURY; SPORT; TAU; ASSOCIATION; PREVALENCE; CONCUSSION; AFTERMATH AB Chronic traumatic encephalopathy (CTE) is a unique neurodegenerative disease found in individuals with a history of repetitive head impacts. The neuropathology of CTE is increasingly well defined. Prospective, longitudinal studies with post-mortem neuropathologic validation as well as in vivo diagnostic techniques are needed in order to advance the understanding of CTE clinically. Given the large number of individuals who incur concussions and other forms of brain trauma, this is an important area for scientific and public health inquiry. C1 [Baugh, Christine M.; Robbins, Clifford A.; Stern, Robert A.; McKee, Ann C.] Boston Univ, Sch Med, CTE Ctr, Boston, MA 02118 USA. [Baugh, Christine M.; Stern, Robert A.; McKee, Ann C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA. [Stern, Robert A.; McKee, Ann C.] Boston Univ, Alzheimers Dis Ctr, Boston, MA 02118 USA. [McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA. [McKee, Ann C.] VA Boston Healthcare Syst, Boston, MA USA. RP Stern, RA (reprint author), Boston Univ, Sch Med, CTE Ctr, 72 E Concord St,Suite B7800, Boston, MA 02118 USA. EM bobstern@bu.edu OI Stern, Robert/0000-0002-5008-077X FU NIH; Athena Diagnostics FX Christine M. Baugh and Clifford A. Robbins declare that their institution has received R01 grant support from the NIH. Robert A. Stern declares that his institution has received R01 grant support from the NIH. Dr. Stern also declares the receipt of consulting fees from Athena Diagnostics, as well as gifts to his institution from the National Football League, the Andlinger Foundation, and the NFL Players Association. Dr. Stern also receives royalties from Psychological Assessment Resources, Inc., for psychological tests developed, and he has received consulting fees from law firms in cases involving sports-related brain trauma. Ann C. McKee declares that she has no conflict of interest. NR 55 TC 15 Z9 15 U1 4 U2 30 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1092-8480 EI 1534-3138 J9 CURR TREAT OPTION NE JI Curr. Treat. Options Neurol. PD SEP PY 2014 VL 16 IS 9 AR UNSP 306 DI 10.1007/s11940-014-0306-5 PG 13 WC Clinical Neurology SC Neurosciences & Neurology GA AP6SN UT WOS:000342208000002 PM 25023937 ER PT J AU Marshall, AL Connors, JM AF Marshall, Ariela L. Connors, Jean-Marie TI Anticoagulation for Noncardiac Indications in Neurologic Patients: Comparative Use of Non-Vitamin K Oral Anticoagulants, Low-Molecular-Weight Heparins, and Warfarin SO CURRENT TREATMENT OPTIONS IN NEUROLOGY LA English DT Review DE Anticoagulation; Venous thromboembolism; Ischemic stroke; Intracranial malignancy; Spinal cord injury; Antiphospholipid antibody syndrome; Cerebral venous sinus thrombosis ID DEEP-VEIN THROMBOSIS; SPINAL-CORD-INJURY; CLINICAL-PRACTICE GUIDELINES; ACUTE VENOUS THROMBOEMBOLISM; ACUTE ISCHEMIC-STROKE; RANDOMIZED CONTROLLED-TRIAL; BRAIN-TUMORS; UNFRACTIONATED HEPARIN; ANTITHROMBOTIC THERAPY; ATRIAL-FIBRILLATION AB Patients with neurologic disorders may develop a wide variety of thromboembolic events, both as a primary manifestation and as a consequence of their underlying neurologic condition. There are many available options for anticoagulation, ranging from warfarin to the parenteral subcutaneously administered anticoagulants to the non-vitamin K oral anticoagulants (NOACs). Warfarin is orally available, well-studied, and easily reversible in the setting of bleeding, but has a prolonged onset of action, measured in days, and equally slow offset; requires frequent monitoring for dose titration; and has multiple drug-drug and food-drug interactions. Parenteral heparin-based anticoagulants are well-studied and have more predictable pharmacokinetics but are often more expensive, only partially reversible, and require daily injections, which can be difficult for patients to tolerate over long periods of time. The NOACs are easy to administer and have predictable pharmacokinetics but are expensive, not easily reversible, and are not as extensively studied. Specific agents are preferable in some defined neurologic conditions. For acute ischemic stroke, we do not recommend immediate anticoagulation with any agent. For patients with intracranial malignancy (either primary or metastatic), we recommend a low-molecular-weight heparin (LMWH) rather than warfarin or a NOAC. For thromboembolic disease in the setting of spinal cord injury, warfarin, LMWH, or the NOACs are reasonable options. In the setting of VTE or stroke related to antiphospholipid antibody syndrome (APS), we recommend long-term warfarin anticoagulation with an INR goal of 2-3, pending the results of ongoing research involving the NOACs. For cerebral venous sinus thrombosis not related to malignancy or APS, we recommend the use of LMWH in the acute setting, followed by at least three months of warfarin. In this article, we discuss the pharmacology, pathophysiology, and comparative research that served as a basis for our recommendations. C1 [Marshall, Ariela L.; Connors, Jean-Marie] Dana Farber Canc Inst, Dept Hematol & Med Oncol, Boston, MA 02215 USA. [Connors, Jean-Marie] Brigham & Womens Hosp, Dept Hematol, Boston, MA 02115 USA. RP Marshall, AL (reprint author), Dana Farber Canc Inst, Dept Hematol & Med Oncol, 450 Brookline Ave,Smith 353, Boston, MA 02215 USA. EM ariela_marshall@dfci.harvard.edu; jconnors@partners.org FU Boehringer Ingelheim FX Jean-Marie Connors declares the receipt of personal fees from Boehringer Ingelheim. NR 80 TC 2 Z9 2 U1 1 U2 7 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1092-8480 EI 1534-3138 J9 CURR TREAT OPTION NE JI Curr. Treat. Options Neurol. PD SEP PY 2014 VL 16 IS 9 AR 309 DI 10.1007/s11940-014-0309-2 PG 15 WC Clinical Neurology SC Neurosciences & Neurology GA AP6SN UT WOS:000342208000003 PM 25038005 ER PT J AU Richter, JM Pino, MS Austin, TR Campbell, E Szymonifka, J Russo, AL Hong, TS Borger, D Iafrate, AJ Chung, DC AF Richter, James M. Pino, Maria Simona Austin, Thomas R. Campbell, Emily Szymonifka, Jackie Russo, Andrea L. Hong, Theodore S. Borger, Darrell Iafrate, A. John Chung, Daniel C. TI Genetic Mechanisms in Interval Colon Cancers SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Colon cancer; MSI; Colonoscopy; Lynch syndrome ID NONPOLYPOSIS COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; COLONOSCOPIC POLYPECTOMY; BRAF MUTATION; RISK; PREVENTION; POLYP; SURVEILLANCE; GUIDELINES; ADENOMAS AB The factors underlying the development of interval colon cancers are not well defined and are likely heterogeneous. We sought to determine whether there are distinct molecular properties associated with interval colon cancers. Colon cancers diagnosed within 5 years of a complete and well-prepped colonoscopic examination were identified over a 7-year period at a single institution. The clinical and pathological features of the tumors were defined. Analysis of DNA mismatch repair (MMR) and genotyping of a panel of oncogenes associated with colon cancer were performed. Forty-two interval colon cancers were diagnosed at an average age of 70 years. 69 % of tumors were located in the right colon. 41 % of tumors exhibited DNA microsatellite instability (MSI). Loss of staining of DNA MMR proteins by immunohistochemistry (IHC) was confirmed in 82 % of the MSI-positive tumors. Among tumors with abnormal MSI and IHC, 54 % exhibited somatic methylation of the MLH1 promoter, but the remaining 43 % exhibited molecular features indicative of underlying Lynch syndrome (LS). The frequency of somatic mutations in the KRAS, BRAF, NRAS, and PIK3CA oncogenes was similar between interval cancer cases and controls. Interval colon cancers are not distinguished by the activation of the KRAS, NRAS, BRAF, or PIK3CA oncogenic pathways. However, MSI pathway defects are present in a significant proportion of interval colon cancers. Underlying LS may explain nearly half of these MSI-positive cases, and the remaining cases appear to represent sporadic serrated pathway tumors. C1 [Richter, James M.; Pino, Maria Simona; Austin, Thomas R.; Campbell, Emily; Chung, Daniel C.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. [Szymonifka, Jackie] Ctr Biostat, Boston, MA 02114 USA. [Russo, Andrea L.] Brigham & Womens Hosp, Harvard Radiat Oncol Program, Boston, MA 02115 USA. [Hong, Theodore S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Clark Ctr Radiat Oncol, Boston, MA 02114 USA. [Borger, Darrell; Iafrate, A. John] Massachusetts Gen Hosp, Mol Pathol Lab, Boston, MA 02114 USA. RP Chung, DC (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit, GRJ 704,50 Blossom St, Boston, MA 02114 USA. EM jrichter@partners.org; pinosimmi@gmail.com; tom.r.austin@gmail.com; ejcampbell@partners.org; jszymonifka@partners.org; andrea.l.russo@gmail.com; tshong1@partners.org; dborger@partners.org; aiafrate@partners.org; dchung@partners.org FU Kate J. and Dorothy L. Clapp Fund; Oliver S., and Jennie R. Donaldson Charitable Trust FX Authors received grant support from Kate J. and Dorothy L. Clapp Fund (DCC), Oliver S., and Jennie R. Donaldson Charitable Trust (JMR). NR 33 TC 6 Z9 6 U1 2 U2 5 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD SEP PY 2014 VL 59 IS 9 BP 2255 EP 2263 DI 10.1007/s10620-014-3134-2 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AP4ZA UT WOS:000342088300053 PM 24705641 ER PT J AU Gaspard, N Hirsch, LJ LaRoche, SM Hahn, CD Westover, MB AF Gaspard, Nicolas Hirsch, Lawrence J. LaRoche, Suzette M. Hahn, Cecil D. Westover, M. Brandon CA Critical Care EEG Monitoring Res TI Interrater agreement for Critical Care EEG Terminology SO EPILEPSIA LA English DT Article DE Continuous EEG monitoring; EEG terminology; Periodic patterns; Rhythmic patterns; Interrater agreement; Intensive care; Critical care; PLEDs; GPEDs ID PERIODIC EPILEPTIFORM DISCHARGES; ILL PATIENTS; PATTERNS; CLASSIFICATION; RELIABILITY AB ObjectiveThe interpretation of critical care electroencephalography (EEG) studies is challenging because of the presence of many periodic and rhythmic patterns of uncertain clinical significance. Defining the clinical significance of these patterns requires standardized terminology with high interrater agreement (IRA). We sought to evaluate IRA for the final, published American Clinical Neurophysiology Society (ACNS)-approved version of the critical care EEG terminology (2012 version). Our evaluation included terms not assessed previously and incorporated raters with a broad range of EEG reading experience. MethodsAfter reviewing a set of training slides, 49 readers independently completed a Web-based test consisting of 11 identical questions for each of 37 EEG samples (407 questions). Questions assessed whether a pattern was an electrographic seizure; pattern location (main term 1), pattern type (main term 2); and presence and classification of eight other key features (plus modifiers, sharpness, absolute and relative amplitude, frequency, number of phases, fluctuation/evolution, and the presence of triphasic morphology). ResultsIRA statistics ( values) were almost perfect (90-100%) for seizures, main terms 1 and 2, the +S modifier (superimposed spikes/sharp waves or sharply contoured rhythmic delta activity), sharpness, absolute amplitude, frequency, and number of phases. Agreement was substantial for the +F (superimposed fast activity) and +R (superimposed rhythmic delta activity) modifiers (66% and 67%, respectively), moderate for triphasic morphology (58%), and fair for evolution (21%). SignificanceIRA for most terms in the ACNS critical care EEG terminology is high. These terms are suitable for multicenter research on the clinical significance of critical care EEG patterns. A PowerPoint slide summarizing this article is available for download in the Supporting Information section . C1 [Gaspard, Nicolas; Hirsch, Lawrence J.] Yale Univ, Sch Med, Comprehens Epilepsy Ctr, Dept Neurol, New Haven, CT 06520 USA. [LaRoche, Suzette M.] Emory Univ, Dept Neurol, Atlanta, GA USA. [Hahn, Cecil D.] Hosp Sick Children, Div Neurol, Toronto, ON M5G 1X8, Canada. [Hahn, Cecil D.] Univ Toronto, Toronto, ON, Canada. [Westover, M. Brandon] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Gaspard, N (reprint author), Yale Univ, Sch Med, Comprehens Epilepsy Ctr, POB 208018,LLCI 716, New Haven, CT 06520 USA. EM nicolas.gaspard@yale.edu RI Hahn, Cecil/J-3372-2016 OI Hahn, Cecil/0000-0002-0887-8761 FU American Epilepsy Society/Epilepsy Foundation; Epilepsy Foundation; UCB-Pharma; Upsher-Smith; Lundbeck; GlaxoSmithKline RSC Diagnostics; NeuroPace FX All authors are members of the CCEMRC. The CCEMRC received infrastructure support from the American Epilepsy Society/Epilepsy Foundation. NG received support from the Epilepsy Foundation. LJH received research support for investigator-initiated studies from UCB-Pharma, Upsher-Smith, and Lundbeck; consultation fees for advising from Lundbeck, Upsher-Smith, GlaxoSmithKline RSC Diagnostics, and NeuroPace; royalties for authoring chapters for UpToDate-Neurology, and for coauthoring the book Atlas of EEG in Critical Care, by Hirsch and Brenner, 2010. SML received research support from UCB and royalties from Demos Publishing. CDH received research support from the Canadian Institutes of Health Research, The Hospital for Sick Children Foundation, and the PSI Foundation. MBW received support from the American Brain Foundation and royalties for coauthoring the book Pocket Neurology, LWW, 2010. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. NR 20 TC 27 Z9 27 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0013-9580 EI 1528-1167 J9 EPILEPSIA JI Epilepsia PD SEP PY 2014 VL 55 IS 9 BP 1366 EP 1373 DI 10.1111/epi.12653 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA AP7CY UT WOS:000342236600012 PM 24888711 ER PT J AU Lee, WJ Sobrin, L Kang, MH Seong, M Kim, YJ Yi, JH Miller, JW Cho, HY AF Lee, W. J. Sobrin, L. Kang, M. H. Seong, M. Kim, Y. J. Yi, J-H Miller, J. W. Cho, H. Y. TI Ischemic diabetic retinopathy as a possible prognostic factor for chronic kidney disease progression SO EYE LA English DT Article ID STAGE RENAL-DISEASE; RISK-FACTORS; NEPHROPATHY; PREVALENCE; MELLITUS; SYSTEM AB Purpose To assess the value of diabetic retinopathy (DR) severity as a possible predictive prognostic factor for the progression of chronic kidney disease (CKD). Patients and methods Retrospective cohort study. Patients (51) who were initially diagnosed with DR and CKD were enrolled and their medical records were evaluated. The following ophthalmic factors were assessed by fluorescein angiography at the initial visit: area of capillary nonperfusion, presence of neovascularization and vitreous hemorrhage, and DR grade. The effect of these factors on CKD progression over the 2-year period of the study, defined as doubling of serum creatinine or the development of end-stage renal disease requiring dialysis or renal transplant, was evaluated. Results The study included 51 patients with DR and CKD; of these, 11 patients (21.6%) were found to have proliferative DR (PDR) and seven patients (13.7%) had high-risk PDR at baseline. Patients with ischemic DR, who showed extensive capillary nonperfusion (>= 10 optic disc areas) in the retina, had a greater risk for CKD progression (hazard ratio = 6.64; P = 0.002). Conclusion We found that extensive capillary nonperfusion in the retina greatly increased the risk of progression of CKD in patients with DR. This suggests that the retina and the kidney may have shared risk factors for microvascular disease secondary to diabetes mellitus, and emphasizes the need for a team approach to diabetes care. C1 [Lee, W. J.; Kang, M. H.; Seong, M.; Kim, Y. J.; Cho, H. Y.] Hanyang Univ, Hanyang Univ Guri Hosp, Coll Med, Dept Ophthalmol, Guri City, South Korea. [Sobrin, L.; Miller, J. W.; Cho, H. Y.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA. [Yi, J-H] Hanyang Univ, Hanyang Univ Guri Hosp, Coll Med, Dept Nephrol, Guri City, South Korea. RP Cho, HY (reprint author), Hanyang Univ, Hanyang Univ Guri Hosp, Coll Med, Dept Ophthalmol, Guri City, South Korea. EM hycho@hanyang.ac.kr OI Sobrin, Lucia/0000-0003-1575-0819 NR 24 TC 5 Z9 5 U1 1 U2 6 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-222X EI 1476-5454 J9 EYE JI Eye PD SEP PY 2014 VL 28 IS 9 BP 1119 EP 1125 DI 10.1038/eye.2014.130 PG 7 WC Ophthalmology SC Ophthalmology GA AP4QX UT WOS:000342064400011 PM 24993319 ER PT J AU Renella, R Carnevale, J Schneider, KA Hornick, JL Rana, HQ Janeway, KA AF Renella, R. Carnevale, J. Schneider, K. A. Hornick, J. L. Rana, H. Q. Janeway, K. A. TI Exploring the association of succinate dehydrogenase complex mutations with lymphoid malignancies SO FAMILIAL CANCER LA English DT Article DE Lymphoma; Malignancy; Cancer predisposition; Succinate dehydrogenase ID RENAL-CELL CARCINOMA; GENE-MUTATIONS; PARAGANGLIOMA; SDHB; CANCER; PHEOCHROMOCYTOMA; DYSFUNCTION; LEUKEMIA AB The succinate dehydrogenase (SDH) complex exerts a fundamental role in mitochondrial cellular respiration and mutations in its encoding genes (SDHA, SDHB, SDHC, SDHD, collectively referred to as SDHx) lead to a number of inherited endocrine cancer predisposition syndromes, including familial paraganglioma/pheochromocytoma. Recent studies suggest a possible role for the SDH complex and other mitochondrial enzymes in the pathogenesis of hematological malignancy. Our aim was to search and identify pedigrees of patients affected by germline SHDx mutations treated at our institution for endocrine and other tumors, and seek to identify cases of hematological malignancy. We also analyzed cancer genome databases for reported cases of SDHx mutations outside of endocrine neoplasms. We report of two unrelated pedigrees carrying SDHx mutations with members affected by lymphomas. Sequencing data revealed one case of chronic lymphocytic leukemia with a SDHB mutation. This novel set of observations demonstrates the need for collaborative databases of patients with endocrine cancers with SDHx mutations, and the investigation of their role in hematological (lymphoid) malignancy. C1 [Renella, R.; Carnevale, J.; Janeway, K. A.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Renella, R.; Hornick, J. L.; Rana, H. Q.; Janeway, K. A.] Harvard Univ, Sch Med, Boston, MA USA. [Schneider, K. A.] Dana Farber Canc Inst, PCRP, Boston, MA 02115 USA. [Hornick, J. L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Rana, H. Q.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Renella, R (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave, Boston, MA 02115 USA. EM Raffaele_Renella@dfci.harvard.edu OI Rana, Huma/0000-0002-1598-6752 NR 20 TC 2 Z9 2 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1389-9600 EI 1573-7292 J9 FAM CANCER JI Fam. Cancer PD SEP PY 2014 VL 13 IS 3 BP 507 EP 511 DI 10.1007/s10689-014-9725-4 PG 5 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA AP6GQ UT WOS:000342176000022 PM 24781345 ER PT J AU Mohammad, O Osser, DN AF Mohammad, Othman Osser, David N. TI The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Algorithm for Acute Mania SO HARVARD REVIEW OF PSYCHIATRY LA English DT Article DE algorithm; bipolar disorder; management; mania; psychopharmacology ID PLACEBO-CONTROLLED TRIAL; BIPOLAR-I-DISORDER; PALIPERIDONE EXTENDED-RELEASE; ADJUNCTIVE ORAL ZIPRASIDONE; CHRONIC DIVALPROEX SODIUM; PSYCHOTIC MOOD DISORDERS; RANDOMIZED OPEN-LABEL; LONG-TERM TREATMENT; GRAY-MATTER VOLUME; DOUBLE-BLIND AB This new algorithm for the pharmacotherapy of acute mania was developed by the Psychopharmacology Algorithm Project at the Harvard South Shore Program. The authors conducted a literature search in PubMed and reviewed key studies, other algorithms and guidelines, and their references. Treatments were prioritized considering three main considerations: (1) effectiveness in treating the current episode, (2) preventing potential relapses to depression, and (3) minimizing side effects over the short and long term. The algorithm presupposes that clinicians have made an accurate diagnosis, decided how to manage contributing medical causes (including substance misuse), discontinued antidepressants, and considered the patient's childbearing potential. We propose different algorithms for mixed and nonmixed mania. Patients with mixed mania may be treated first with a second-generation antipsychotic, of which the first choice is quetiapine because of its greater efficacy for depressive symptoms and episodes in bipolar disorder. Valproate and then either lithium or carbamazepinemay be added. For nonmixedmania, lithium is the first-line recommendation. A second-generation antipsychotic can be added. Again, quetiapine is favored, but if quetiapine is unacceptable, risperidone is the next choice. Olanzapine is not considered a first-line treatment due to its long-term side effects, but it could be second-line. If the patient, whether mixed or nonmixed, is still refractory to the above medications, then depending on what has already been tried, consider carbamazepine, haloperidol, olanzapine, risperidone, and valproate first tier; aripiprazole, asenapine, and ziprasidone second tier; and clozapine third tier (because of its weaker evidence base and greater side effects). Electroconvulsive therapy may be considered at any point in the algorithm if the patient has a history of positive response or is intolerant of medications. C1 [Mohammad, Othman] Harvard Univ, Sch Med, Boston, MA USA. [Mohammad, Othman] Boston Childrens Hosp, Boston, MA USA. [Osser, David N.] VA Boston Healthcare Syst, Brockton Div, Brockton, MA 02301 USA. RP Osser, DN (reprint author), VA Boston Healthcare Syst, Brockton Div, 940 Belmont St, Brockton, MA 02301 USA. EM David.Osser@va.gov NR 191 TC 6 Z9 7 U1 2 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1067-3229 EI 1465-7309 J9 HARVARD REV PSYCHIAT JI Harv. Rev. Psychiatr. PD SEP-OCT PY 2014 VL 22 IS 5 BP 274 EP 294 DI 10.1097/HRP.0000000000000018 PG 21 WC Psychiatry SC Psychiatry GA AP6GF UT WOS:000342174900003 PM 25188733 ER PT J AU Dilwali, S Patel, PB Roberts, DS Basinsky, GM Harris, GJ Emerick, KS Stankovic, KM AF Dilwali, Sonam Patel, Pratik B. Roberts, Daniel S. Basinsky, Gina M. Harris, Gordon J. Emerick, Kevin S. Stankovic, Konstantina M. TI Primary culture of human Schwann and schwannoma cells: Improved and simplified, protocol SO HEARING RESEARCH LA English DT Article ID HIGHLY ENRICHED CULTURES; FIBROBLAST-GROWTH-FACTOR; VESTIBULAR SCHWANNOMAS; ACOUSTIC NEUROMAS; PERIPHERAL-NERVE; NATURAL-HISTORY; TUMOR SIZE; EXPRESSION; PURIFICATION; INHIBITION AB Primary culture of human Schwann cells (SCs) and vestibular schwannoma (VS) cells are invaluable tools to investigate SC physiology and VS pathobiology, and to devise effective pharmacotherapies against VS, which are sorely needed. However, existing culture protocols, in aiming to create robust, pure cultures, employ methods that can lead to loss of biological characteristics of the original cells, potentially resulting in misleading biological findings. We have developed a minimally manipulative method to culture primary human SC and VS cells, without the use of selective mitogens, toxins, or time-consuming and potentially transformative laboratory techniques. Schwann cell purity was quantified longitudinally using S100 staining in SC cultures derived from the great auricular nerve and VS cultures followed for 7 and 12 weeks, respectively. SC cultures retained approximately >= 85% purity for 2 weeks. VS cultures retained approximately >= 80% purity for the majority of the span of 12 weeks, with maximal purity of 87% at 2 weeks. The VS cultures showed high level of biological similarity (68% on average) to their respective parent tumors, as assessed using a protein array featuring 41 growth factors and receptors. Apoptosis rate in vitro negatively correlated with tumor volume. Our results, obtained using a faster, simplified culturing method than previously utilized, indicate that highly pure, primary human SC and VS cultures can be established with minimal manipulation, reaching maximal purity at 2 weeks of culture. The VS cultures recapitulate the parent tumors' biology to a great degree, making them relevant models to investigate VS pathobiology. (C) 2014 Elsevier B.V. All rights reserved. C1 [Dilwali, Sonam; Stankovic, Konstantina M.] MIT, Harvard Mit Div Hlth Sci & Technol, Speech & Hearing Biosci & Technol Program, Cambridge, MA 02139 USA. [Patel, Pratik B.; Roberts, Daniel S.; Emerick, Kevin S.; Stankovic, Konstantina M.] Harvard Univ, Sch Med, Dept Otol & Latyngol, Boston, MA 02115 USA. [Dilwali, Sonam; Patel, Pratik B.; Roberts, Daniel S.; Emerick, Kevin S.; Stankovic, Konstantina M.] Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA 02114 USA. [Dilwali, Sonam; Patel, Pratik B.; Roberts, Daniel S.; Emerick, Kevin S.; Stankovic, Konstantina M.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. [Basinsky, Gina M.; Harris, Gordon J.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Stankovic, KM (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM konstantina_stankovic@meei.harvard.edu OI Patel, Pratik/0000-0003-0070-2638 FU National Institute on Deafness and Other Communication Disorders (IDCD) [T32 DC00038, K08DC010419]; Bertarelli Foundation FX This research was supported by National Institute on Deafness and Other Communication Disorders (IDCD) Grants T32 DC00038 (S.D., K.M.S) and K08DC010419 (K.M.S.), and the Bertarelli Foundation (K.M.S.). We are grateful to Drs. McKenna and Barker for assisting in VS specimen collection. NR 33 TC 8 Z9 8 U1 1 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-5955 EI 1878-5891 J9 HEARING RES JI Hear. Res. PD SEP PY 2014 VL 315 BP 25 EP 33 DI 10.1016/j.heares.2014.05.006 PG 9 WC Audiology & Speech-Language Pathology; Neurosciences; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Neurosciences & Neurology; Otorhinolaryngology GA AP2LC UT WOS:000341902700003 PM 24910344 ER PT J AU Fitzpatrick, Z Gyorgy, B Skog, J Maguire, CA AF Fitzpatrick, Zachary Gyoergy, Bence Skog, Johan Maguire, Casey A. TI Extracellular Vesicles as Enhancers of Virus Vector-Mediated Gene Delivery SO HUMAN GENE THERAPY LA English DT Editorial Material C1 [Fitzpatrick, Zachary; Gyoergy, Bence; Maguire, Casey A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02129 USA. [Fitzpatrick, Zachary; Gyoergy, Bence; Maguire, Casey A.] Harvard Univ, Sch Med, Neurosci Program, Boston, MA 02129 USA. [Fitzpatrick, Zachary] Louisiana State Univ, Baton Rouge, LA 70803 USA. [Gyoergy, Bence] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA. [Skog, Johan] Exosome Diagnost Inc, Cambridge, MA 02139 USA. RP Maguire, CA (reprint author), Massachusetts Gen Hosp, Dept Neurol, 149 13th St,Room 6-404A, Charlestown, MA 02129 USA. EM cmaguire@mgh.harvard.edu NR 4 TC 5 Z9 5 U1 0 U2 4 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1043-0342 EI 1557-7422 J9 HUM GENE THER JI Hum. Gene Ther. PD SEP PY 2014 VL 25 IS 9 BP 785 EP 786 DI 10.1089/hum.2014.082 PG 2 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA AP5YY UT WOS:000342155800003 PM 25244570 ER PT J AU Su, LB Su, CW Qi, YJ Yang, GL Zhang, M Cherayil, BJ Zhang, XC Shi, HN AF Su, Libo Su, Chien-wen Qi, Yujuan Yang, Guilian Zhang, Mei Cherayil, Bobby J. Zhang, Xichen Shi, Hai Ning TI Coinfection with an Intestinal Helminth Impairs Host Innate Immunity against Salmonella enterica Serovar Typhimurium and Exacerbates Intestinal Inflammation in Mice SO INFECTION AND IMMUNITY LA English DT Article ID ALTERNATIVELY ACTIVATED MACROPHAGES; NEUTROPHIL RECRUITMENT; SEROTYPE TYPHIMURIUM; INFECTION; EXPRESSION; COLITIS; CELLS; RESPONSES; KC; INFILTRATION AB Salmonella enterica serovar Typhimurium is a Gram-negative food-borne pathogen that is a major cause of acute gastroenteritis in humans. The ability of the host to control such bacterial pathogens may be influenced by host immune status and by concurrent infections. Helminth parasites are of particular interest in this context because of their ability to modulate host immune responses and because their geographic distribution coincides with those parts of the world where infectious gastroenteritis is most problematic. To test the hypothesis that helminth infection may negatively regulate host mucosal innate immunity against bacterial enteropathogens, a murine coinfection model was established by using the intestinal nematode Heligmosomoides polygyrus and S. Typhimurium. We found that mice coinfected with S. Typhimurium and H. polygyrus developed more severe intestinal inflammation than animals infected with S. Typhimurium alone. The enhanced susceptibility to Salmonella-induced intestinal injury in coinfected mice was found to be associated with diminished neutrophil recruitment to the site of bacterial infection that correlated with decreased expression of the chemoattractants CXCL2/macrophage inflammatory protein 2 (MIP-2) and CXCL1/keratinocyte-derived chemokine (KC), poor control of bacterial replication, and exacerbated intestinal inflammation. The mechanism of helminth-induced inhibition of MIP-2 and KC expression involved interleukin-10 (IL-10) and, to a lesser extent, IL-4 and IL-13. Ly6G antibody-mediated depletion of neutrophils reproduced the adverse effects of H. polygyrus on Salmonella infection. Our results suggest that impaired neutrophil recruitment is an important contributor to the enhanced severity of Salmonella enterocolitis associated with helminth coinfection. C1 [Su, Libo; Su, Chien-wen; Qi, Yujuan; Zhang, Mei; Cherayil, Bobby J.; Shi, Hai Ning] Massachusetts Gen Hosp, Mucosal Immunol & Biol Res Ctr, Charlestown, MA 02129 USA. [Su, Libo; Su, Chien-wen; Qi, Yujuan; Zhang, Mei; Cherayil, Bobby J.; Shi, Hai Ning] Harvard Univ, Sch Med, Charlestown, MA USA. [Su, Libo; Zhang, Xichen] Jilin Univ, Coll Vet Med, Jilin, Peoples R China. [Yang, Guilian] Jilin Agr Univ, Jilin, Peoples R China. RP Shi, HN (reprint author), Massachusetts Gen Hosp, Mucosal Immunol & Biol Res Ctr, Charlestown, MA 02129 USA. EM shiha@helix.mgh.harvard.edu FU National Institutes of Health [DK082427, AI089700]; Nutrition Obesity Research Center at Harvard [P30 DK040561] FX This study was supported by grants from the National Institutes of Health (DK082427 to H.N.S. and AI089700 to B.J.C.) and from the Nutrition Obesity Research Center at Harvard (P30 DK040561). NR 38 TC 8 Z9 9 U1 2 U2 14 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 EI 1098-5522 J9 INFECT IMMUN JI Infect. Immun. PD SEP PY 2014 VL 82 IS 9 BP 3855 EP 3866 DI 10.1128/IAI.02023-14 PG 12 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AP2VB UT WOS:000341932700034 PM 24980971 ER PT J AU Zanoni, BC Gandhi, RT AF Zanoni, Brian C. Gandhi, Rajesh T. TI Update on Opportunistic Infections in the Era of Effective Antiretroviral Therapy SO INFECTIOUS DISEASE CLINICS OF NORTH AMERICA LA English DT Article DE HIV; Opportunistic infections; Antiretroviral therapy; Diagnostics ID PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RECONSTITUTION INFLAMMATORY SYNDROME; HUMAN-IMMUNODEFICIENCY-VIRUS; LATENT TUBERCULOSIS INFECTION; GAMMA RELEASE ASSAYS; MULTIDRUG-RESISTANT TUBERCULOSIS; PNEUMOCYSTIS-JIROVECII PNEUMONIA; XPERT MTB/RIF ASSAY; LATERAL FLOW ASSAY; CRYPTOCOCCAL MENINGITIS AB Despite enormous improvements in effectiveness of treatment for HIV infection, opportunistic infections continue to occur in those who have not yet been diagnosed with HIV and in those who are not receiving anti-retroviral therapy. This review focuses on tuberculosis and cryptococcal infections, the most common opportunistic infections (OIs) in patients living with human immunodeficiency virus infection around the world, as well as on new developments in progressive multifocal leukoencephalopathy and pneumocystis pneumonia. In the sections on these conditions, updates on diagnosis, treatment, and complications, as well as information on when to start anti-retroviral therapy is provided. The article concludes with a discussion of new data on 2 vaccine-preventable Ols, human papillomavirus and varicella-zoster virus. C1 [Zanoni, Brian C.; Gandhi, Rajesh T.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Zanoni, Brian C.; Gandhi, Rajesh T.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Gandhi, Rajesh T.] Massachusetts Gen Hosp, Ragon Inst, Boston, MA 02114 USA. RP Gandhi, RT (reprint author), Massachusetts Gen Hosp, Div Infect Dis, GRJ 504,55 Fruit St, Boston, MA 02114 USA. EM RGANDHl@mgh.harvard.edu FU NIAID NIH HHS [UM1 AI069412, P30 AI060354] NR 100 TC 2 Z9 3 U1 1 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0891-5520 EI 1557-9824 J9 INFECT DIS CLIN N AM JI Infect. Dis. Clin. North Am. PD SEP PY 2014 VL 28 IS 3 BP 501 EP + PN 1 PG 19 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AP2JS UT WOS:000341899100013 PM 25151568 ER PT J AU Sheth, KN Rosand, J AF Sheth, Kevin N. Rosand, Jonathan TI Targeting the Immune System in Intracerebral Hemorrhage SO JAMA NEUROLOGY LA English DT Editorial Material ID MOUSE MODEL; FINGOLIMOD; GLYBURIDE; STROKE C1 [Sheth, Kevin N.] Yale Univ, Sch Med, Dept Neurol, Div Neurocrit Care & Emergency Neurol, New Haven, CT 06510 USA. [Rosand, Jonathan] Massachusetts Gen Hosp, Div Neurocrit Care & Emergency Neurol, Ctr Human Genet Res, Boston, MA 02140 USA. RP Rosand, J (reprint author), Massachusetts Gen Hosp, Div Neurocrit Care & Emergency Neurol, Ctr Human Genet Res, 185 Cambridge St,CPZN 6818, Boston, MA 02140 USA. EM jrosand@partners.org NR 11 TC 3 Z9 3 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD SEP PY 2014 VL 71 IS 9 BP 1083 EP 1084 DI 10.1001/jamaneurol.2014.1653 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA AP3LK UT WOS:000341977300002 PM 25004375 ER PT J AU Fitzgerald, KC O'Reilly, EJ Falcone, GJ McCullough, ML Park, Y Kolonel, LN Ascherio, A AF Fitzgerald, Kathryn C. O'Reilly, EIlis J. Falcone, Guido J. McCullough, Marjorie L. Park, Yikyung Kolonel, Laurence N. Ascherio, Alberto TI Dietary omega-3 Polyunsaturated Fatty Acid Intake and Risk for Amyotrophic Lateral Sclerosis SO JAMA NEUROLOGY LA English DT Article ID FOOD-FREQUENCY QUESTIONNAIRE; HEALTH-AMERICAN-ASSOCIATION; SOCIETY CANCER PREVENTION; BASE-LINE CHARACTERISTICS; RETIRED-PERSONS DIET; MOTOR-NEURON DISEASE; VITAMIN-E INTAKE; NATIONAL-INSTITUTES; POOLED ANALYSIS; LINOLENIC ACID AB IMPORTANCE Amyotrophic lateral sclerosis (ALS) is a severe progressive disease that cannot be prevented or cured. Diet-derived long-chain polyunsaturated fatty acids (PUFAs) are incorporated in brain lipids and modulate oxidative and inflammatory processes and could thus affect ALS risk and progression. OBJECTIVE To examine the association between omega-6 and omega-3 PUFA consumption and ALS risk. DESIGN, SETTING, AND PARTICIPANTS Longitudinal analyses based on 1 002 082 participants (479 114 women and 522 968 men) in 5 prospective cohorts: the National Institutes of Health-AARP Diet and Health Study, the Cancer Prevention Study II Nutrition Cohort, the Health Professionals Follow-up Study, the Multiethnic Cohort Study, and the Nurses' Health Study. Diet was assessed via food frequency questionnaire developed or modified for each cohort. Participants were categorized into cohort-specific quintiles of intake of energy-adjusted dietary variables. MAIN OUTCOMES AND MEASURES Cohort-specific multivariable-adjusted risk ratios (RRs) of ALS incidence or death estimated by Cox proportional hazards regression and pooled using random-effects methods. RESULTS A total of 995 ALS cases were documented during the follow-up. A greater omega-3 PUFA intake was associated with a reduced risk for ALS. The pooled, multivariable-adjusted RR for the highest to the lowest quintile was 0.66 (95% CI, 0.53-0.81; P < .001 for trend). Consumption of both a-linolenic acid (RR, 0.73; 95% CI, 0.59-0.89; P = .003 for trend) and marine omega-3 PUFAs (RR, 0.84; 95% CI, 0.65-1.08; P = .03 for trend) contributed to this inverse association. Intakes of omega-6 PUFA were not associated with ALS risk. CONCLUSIONS AND RELEVANCE Consumption of foods high in omega-3 PUFAs may help prevent or delay the onset of ALS. C1 [Fitzgerald, Kathryn C.; O'Reilly, EIlis J.; Ascherio, Alberto] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Falcone, Guido J.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [McCullough, Marjorie L.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA. [Park, Yikyung] NCI, Nutr Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Kolonel, Laurence N.] Univ Hawaii, Ctr Canc, Program Epidemiol, Honolulu, HI 96822 USA. [Falcone, Guido J.; Ascherio, Alberto] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [O'Reilly, EIlis J.; Ascherio, Alberto] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA. [O'Reilly, EIlis J.; Ascherio, Alberto] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Fitzgerald, KC (reprint author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave,Bldg 2,3rd Floor, Boston, MA 02115 USA. EM hpkcf@channing.harvard.edu RI Falcone, Guido/L-2287-2016 OI Falcone, Guido/0000-0002-6407-0302 FU National Institute of Neurological Diseases and Stroke [R01 NS045893]; National Cancer Institute [P01 CA87969, P01 CA055075]; ALS Therapy Alliance Foundation FX This work was supported by grant R01 NS045893 from the National Institute of Neurological Diseases and Stroke, grants P01 CA87969 and P01 CA055075 from the National Cancer Institute, and a grant from the ALS Therapy Alliance Foundation. NR 51 TC 20 Z9 21 U1 0 U2 9 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD SEP PY 2014 VL 71 IS 9 BP 1102 EP 1110 DI 10.1001/jamaneurol.2014.1214 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA AP3LK UT WOS:000341977300006 PM 25023276 ER PT J AU Thomas, JB Brier, MR Bateman, RJ Snyder, AZ Benzinger, TL Xiong, CJ Raichle, M Holtzman, DM Sperling, RA Mayeux, R Ghetti, B Ringman, JM Salloway, S McDade, E Rossor, MN Ourselin, S Schofield, PR Masters, CL Martins, RN Weiner, MW Thompson, PM Fox, NC Koeppe, RA Jack, CR Mathis, CA Oliver, A Blazey, TM Moulder, K Buckles, V Hornbeck, R Chhatwal, J Schultz, AP Goate, AM Fagan, AM Cairns, NJ Marcus, DS Morris, JC Ances, BM AF Thomas, Jewell B. Brier, Matthew R. Bateman, Randall J. Snyder, Abraham Z. Benzinger, Tammie L. Xiong, Chengjie Raichle, Marcus Holtzman, David M. Sperling, Reisa A. Mayeux, Richard Ghetti, Bernardino Ringman, John M. Salloway, Stephen McDade, Eric Rossor, Martin N. Ourselin, Sebastien Schofield, Peter R. Masters, Colin L. Martins, Ralph N. Weiner, Michael W. Thompson, Paul M. Fox, Nick C. Koeppe, Robert A. Jack, Clifford R., Jr. Mathis, Chester A. Oliver, Angela Blazey, Tyler M. Moulder, Krista Buckles, Virginia Hornbeck, Russ Chhatwal, Jasmeer Schultz, Aaron P. Goate, Alison M. Fagan, Anne M. Cairns, Nigel J. Marcus, Daniel S. Morris, John C. Ances, Beau M. TI Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease SO JAMA NEUROLOGY LA English DT Article ID RESTING-STATE FMRI; MILD COGNITIVE IMPAIRMENT; GLOBAL SIGNAL; NETWORK; BIOMARKERS; FLUCTUATIONS; DEPOSITION; REGRESSION; MOTION; RISK AB IMPORTANCE Autosomal dominant Alzheimer disease (ADAD) is caused by rare genetic mutations in 3 specific genes in contrast to late-onset Alzheimer disease (LOAD), which has a more polygenetic risk profile. OBJECTIVE To assess the similarities and differences in functional connectivity changes owing to ADAD and LOAD. DESIGN, SETTING, AND PARTICIPANTS We analyzed functional connectivity in multiple brain resting state networks (RSNs) in a cross-sectional cohort of participants with ADAD (n = 79) and LOAD (n = 444), using resting-state functional connectivity magnetic resonance imaging at multiple international academic sites. MAIN OUTCOMES AND MEASURES For both types of AD, we quantified and compared functional connectivity changes in RSNs as a function of dementia severity measured by the Clinical Dementia Rating Scale. In ADAD, we qualitatively investigated functional connectivity changes with respect to estimated years from onset of symptoms within 5 RSNs. RESULTS A decrease in functional connectivity with increasing Clinical Dementia Rating scores were similar for both LOAD and ADAD in multiple RSNs. Ordinal logistic regression models constructed in one type of Alzheimer disease accurately predicted clinical dementia rating scores in the other, further demonstrating the similarity of functional connectivity loss in each disease type. Among participants with ADAD, functional connectivity in multiple RSNs appeared qualitatively lower in asymptomatic mutation carriers near their anticipated age of symptom onset compared with asymptomatic mutation noncarriers. CONCLUSIONS AND RELEVANCE Resting-state functional connectivity magnetic resonance imaging changes with progressing AD severity are similar between ADAD and LOAD. Resting-state functional connectivity magnetic resonance imaging may be a useful end point for LOAD and ADAD therapy trials. Moreover, the disease process of ADAD may be an effective model for the LOAD disease process. C1 [Thomas, Jewell B.; Brier, Matthew R.; Bateman, Randall J.; Raichle, Marcus; Holtzman, David M.; Oliver, Angela; Buckles, Virginia; Fagan, Anne M.; Cairns, Nigel J.; Morris, John C.; Ances, Beau M.] Washington Univ, Dept Neurol, St Louis, MO 63110 USA. [Snyder, Abraham Z.; Benzinger, Tammie L.; Raichle, Marcus; Blazey, Tyler M.; Hornbeck, Russ; Marcus, Daniel S.] Washington Univ, Dept Radiol, St Louis, MO 63110 USA. [Xiong, Chengjie] Washington Univ, Div Biostat, St Louis, MO 63110 USA. [Raichle, Marcus] Washington Univ, Dept Anat & Neurobiol, St Louis, MO 63110 USA. [Sperling, Reisa A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Massachusetts Gen Hosp,Dept Neurol, Boston, MA 02115 USA. [Mayeux, Richard] Columbia Univ, Med Ctr, Dept Neurol, New York, NY USA. [Ghetti, Bernardino] Indiana Univ, Dept Pathol & Lab Med, Bloomington, IN 47405 USA. [Ringman, John M.] Univ Calif Los Angeles, David Geffen Sch Med, Easton Ctr Alzheimers Dis Res, Dept Neurol, Los Angeles, CA 90095 USA. [Salloway, Stephen] Brown Univ, Warren Alpert Med Sch, Dept Neurol, Providence, RI 02912 USA. [Salloway, Stephen] Brown Univ, Warren Alpert Med Sch, Dept Psychiat, Providence, RI 02912 USA. [McDade, Eric] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Rossor, Martin N.; Ourselin, Sebastien] UCL, Inst Neurol, Dementia Res Ctr, London, England. [Schofield, Peter R.] Neurosci Res Australia, Sydney, NSW, Australia. [Schofield, Peter R.] Univ New S Wales, Sch Med Sci, Sydney, NSW, Australia. [Masters, Colin L.] Univ Melbourne, Mental Hlth Res Inst, Melbourne, Vic, Australia. [Martins, Ralph N.] Edith Cowan Univ, Sch Med Sci, Joondalup, Australia. [Weiner, Michael W.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA. [Weiner, Michael W.; Goate, Alison M.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Thompson, Paul M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Thompson, Paul M.] Univ Calif Los Angeles, David Geffen Sch Med, Imaging Genet Ctr, Lab Neuroimaging,Dept Psychiat, Los Angeles, CA 90095 USA. [Fox, Nick C.] UCL, Inst Neurol, Dept Neurodegenerat, Dementia Res Ctr, London, England. [Koeppe, Robert A.] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA. [Jack, Clifford R., Jr.] Mayo Clin, Dept Radiol, Rochester, MN USA. [Mathis, Chester A.] Univ Pittsburgh, Dept Radiol, Pittsburgh, PA 15260 USA. [Moulder, Krista] Washington Univ, Dept Psychiat, St Louis, MO 63110 USA. [Chhatwal, Jasmeer; Schultz, Aaron P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol,Martinos Ctr Biomed Imaging, Boston, MA USA. RP Ances, BM (reprint author), Washington Univ, Dept Neurol, 660 S Euclid Ave,POB 8111, St Louis, MO 63110 USA. EM bances@wustl.edu RI Fox, Nick/B-1319-2009; Jack, Clifford/F-2508-2010; OI Fox, Nick/0000-0002-6660-657X; Jack, Clifford/0000-0001-7916-622X; Ances, Beau/0000-0003-3862-7397 FU National Institute on Aging [U19-AG032438]; National Institute of Mental Health [K23MH081786, R21MH099979]; National Institute of Nursing Research [R01NR014449, R01NR012657, R01NR012907]; National Institute of Neurological Disorders and Stroke [P30NS048056, P50 AG05681, P01 AG03991, P01 AG026276]; Medical Research Council [G0601846, MR/J01107X/1]; National Institute for Health Research Queen Square Dementia Biomedical Research Unit; Washington University in St Louis Alzheimer's Disease Research Center Genetics Core; National Institutes of Health [R01-AG011378, U01-HL096917, U01-AG024904, R01 AG041851, R01 AG37551, R01AG043392, U01-AG06786, P50AG005681, P01AG003991, P01AG026276, U19AG032438]; Engineering and Physical Sciences Research Council [EP/H046410/1, EP/J020990/1, EP/K005278]; EUFP7 project at the National Institute for Health Research University College London Hospitals Biomedical Research Centre High Impact Initiative [FP7-ICT-2011-9601055] FX This work was funded by grants U19-AG032438 from the National Institute on Aging; K23MH081786 and R21MH099979 from the National Institute of Mental Health; R01NR014449, R01NR012657, and R01NR012907 from the National Institute of Nursing Research; P30NS048056, P50 AG05681, P01 AG03991, and P01 AG026276 from the National Institute of Neurological Disorders and Stroke; and G0601846 from the Medical Research Council. The study was also supported by the National Institute for Health Research Queen Square Dementia Biomedical Research Unit and the Washington University in St Louis Alzheimer's Disease Research Center Genetics Core. Dr Jack received grants R01-AG011378, U01-HL096917, U01-AG024904, R01 AG041851, R01 AG37551, R01AG043392, and U01-AG06786 from the National Institutes of Health. Dr Morris received grants P50AG005681, P01AG003991, P01AG026276, and U19AG032438 from the National Institutes of Health. Dr Ourselin received grants EP/H046410/1, EP/J020990/1, and EP/K005278 from the Engineering and Physical Sciences Research Council; MR/J01107X/1 from the the Medical Research Council; and FP7-ICT-2011-9601055 from the EUFP7 project at the National Institute for Health Research University College London Hospitals Biomedical Research Centre High Impact Initiative. NR 43 TC 23 Z9 24 U1 2 U2 12 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD SEP PY 2014 VL 71 IS 9 BP 1111 EP 1122 DI 10.1001/jamaneurol.2014.1654 PG 12 WC Clinical Neurology SC Neurosciences & Neurology GA AP3LK UT WOS:000341977300007 PM 25069482 ER PT J AU Peskind, ER Li, G Shofer, JB Millard, SP Leverenz, JB Yu, CE Raskind, MA Quinn, JF Galasko, DR Montine, TJ AF Peskind, Elaine R. Li, Ge Shofer, Jane B. Millard, Steven P. Leverenz, James B. Yu, Chang-En Raskind, Murray A. Quinn, Joseph F. Galasko, Douglas R. Montine, Thomas J. TI Influence of Lifestyle Modifications on Age-Related Free Radical Injury to Brain SO JAMA NEUROLOGY LA English DT Article ID ALZHEIMERS-DISEASE; GENDER-DIFFERENCES; IN-VIVO; F-2-ISOPROSTANES; ISOPROSTANES; FLUID; PATHOLOGY; INCREASE; STRESS; DAMAGE AB IMPORTANCE The Healthy Brain Initiative 2013-2018 seeks to optimize brain health as we age. Free radical injury is an important effector of molecular and cellular stress in the aging brain that derives from multiple sources. OBJECTIVE To identify potentially modifiable risk factors associated with increased markers of brain oxidative stress. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional, academic multicenter study consisted of 320 research volunteers (172 women) aged 21 to 100 years who were medically healthy and cognitively normal. MAIN OUTCOMES AND MEASURES Free radical injury to the brain was assessed using cerebrospinal fluid (CSF) F-2-isoprostane (F-2-IsoP) concentrations correlated with age, sex, race, cigarette smoking, body mass index, inheritance of the epsilon 4 allele of the apolipoprotein E gene (APOE), and CSF biomarkers of Alzheimer disease. RESULTS The concentration of CSF F-2-IsoP increased with age by approximately 3 pg/mL (approximately 10%) from age 45 to 71 years in medically healthy, cognitively normal adults (P < .001). The CSF F-2-IsoP concentration increased by approximately more than 10% for every 5-U increase in body mass index (P < .001). Current smoking had an approximately 3-fold greater effect on CSF F-2-IsoPs compared with age (P < .001). Women had greater mean CSF F2-IsoP concentrations than men at all ages after adjusting for other factors (P = .02). Neither the concentration of CSF Alzheimer disease biomarkers nor inheritance of the APOE epsilon 4 allele was associated with the CSF F-2-IsoP concentration in this group of medically healthy, cognitively normal adults (P > .05). The association between CSF F-2-IsoP concentrations and race was not significant after controlling for the effect of current smoking status (P = .45). CONCLUSIONS AND RELEVANCE Our results are consistent with an age-related increase in free radical injury in the human brain and uniquely suggest that this form of injury may be greater in women than in men. Our results also highlighted 2 lifestyle modifications (ie, body mass index and smoking) that would have an even greater effect on suppressing free radical injury to the brain than would suppressing the processes of aging. These results inform efforts to achieve success in the Healthy Brain Initiative 2013-2018. C1 [Peskind, Elaine R.; Li, Ge; Leverenz, James B.; Raskind, Murray A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Peskind, Elaine R.; Shofer, Jane B.; Millard, Steven P.; Leverenz, James B.; Raskind, Murray A.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. [Leverenz, James B.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Yu, Chang-En] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Yu, Chang-En] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Quinn, Joseph F.] Vet Affairs Parkinsons Dis Res Educ & Clin Ctr, Portland, OR USA. [Galasko, Douglas R.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. [Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. RP Montine, TJ (reprint author), Univ Washington, Dept Pathol, POB 357470, Seattle, WA 98195 USA. EM tmontine@u.washington.edu FU National Institutes of Health [P50AG05136, P30AG008017, P50AG005131]; Nancy and Buster Alvord Endowment FX This work was generously supported by the National Institutes of Health grants P50AG05136, P30AG008017, and P50AG005131 and the Nancy and Buster Alvord Endowment. NR 27 TC 5 Z9 7 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD SEP PY 2014 VL 71 IS 9 BP 1150 EP 1154 DI 10.1001/jamaneurol.2014.1428 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA AP3LK UT WOS:000341977300011 PM 25048271 ER PT J AU Grace, AM Ahn, R Konstantopoulos, WM AF Grace, Aimee M. Ahn, Roy Konstantopoulos, Wendy Macias TI Integrating Curricula on Human Trafficking Into Medical Education and Residency Training SO JAMA PEDIATRICS LA English DT Editorial Material ID GIRLS; WOMEN C1 [Grace, Aimee M.] Childrens Natl Hlth Syst, Washington, DC 20010 USA. [Ahn, Roy; Konstantopoulos, Wendy Macias] Massachusetts Gen Hosp, Dept Emergency Med, Div Global Hlth & Human Rights, Boston, MA 02114 USA. [Ahn, Roy; Konstantopoulos, Wendy Macias] Harvard Univ, Sch Med, Boston, MA USA. RP Grace, AM (reprint author), Childrens Natl Hlth Syst, 111 Michigan Ave NW, Washington, DC 20010 USA. EM agrace@stanfordalumni.org FU PHS HHS [D55HP23194] NR 9 TC 5 Z9 5 U1 0 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6203 EI 2168-6211 J9 JAMA PEDIATR JI JAMA Pediatr. PD SEP PY 2014 VL 168 IS 9 BP 793 EP 794 DI 10.1001/jamapediatrics.2014.999 PG 2 WC Pediatrics SC Pediatrics GA AO8AS UT WOS:000341575200003 PM 25048726 ER PT J AU Gupta, P Kacmarek, RM Wetzel, RC AF Gupta, Punkaj Kacmarek, Robert M. Wetzel, Randall C. TI It Is Too Early to Declare Early or Late Rescue High-Frequency Oscillatory Ventilation Dead Reply SO JAMA PEDIATRICS LA English DT Letter ID CONVENTIONAL MECHANICAL VENTILATION; PEDIATRIC RESPIRATORY-FAILURE; DISTRESS-SYNDROME C1 [Gupta, Punkaj] Univ Arkansas, Med Ctr, Div Pediat Crit Care, Little Rock, AR 72204 USA. [Gupta, Punkaj] Univ Arkansas, Med Ctr, Div Pediat Cardiol, Little Rock, AR 72204 USA. [Kacmarek, Robert M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA. [Wetzel, Randall C.] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Dept Anesthesiol & Crit Care Med, Los Angeles, CA 90033 USA. RP Gupta, P (reprint author), Univ Arkansas Med Sci, Arkansas Childrens Hosp, Coll Med, Pediat Cardiol & Crit Care Med Div, 1 Childrens Way,Slot 512-3, Little Rock, AR 72202 USA. EM pgupta2@uams.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6203 EI 2168-6211 J9 JAMA PEDIATR JI JAMA Pediatr. PD SEP PY 2014 VL 168 IS 9 BP 863 EP 863 PG 1 WC Pediatrics SC Pediatrics GA AO8AS UT WOS:000341575200020 PM 25179022 ER PT J AU Blosnich, JR Dichter, ME Cerulli, C Batten, SV Bossarte, RM AF Blosnich, John R. Dichter, Melissa E. Cerulli, Catherine Batten, Sonja V. Bossarte, Robert M. TI Disparities in Adverse Childhood Experiences Among Individuals With a History of Military Service SO JAMA PSYCHIATRY LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; SEXUAL-ABUSE; SUICIDAL-BEHAVIOR; HOUSEHOLD DYSFUNCTION; MENTAL-HEALTH; ALCOHOL-ABUSE; LIFE-SPAN; RISK; COMBAT; US AB IMPORTANCE Adverse childhood experiences (ACEs) are associated with several adulthood health problems, such as self-directed violence. For some individuals, enlistment in the military may be an instrumental act to escape adverse household environments; however, to our knowledge prevalence of ACEs among persons with a history of military service has not been documented in the United States using population-based data. OBJECTIVE To compare the prevalence of ACEs among individuals with and without a history of military service. DESIGN, SETTING, AND PARTICIPANTS Data are from the 2010 Behavioral Risk Factor Surveillance System. Computer-assisted telephone interviews were conducted with population-based samples of noninstitutionalized US adults from January 1 through December 31, 2010. Analyses were limited to respondents who received the ACE module (n = 60 598). Participants were categorized by history of military service and whether a respondent was 18 years of age in 1973. MAIN OUTCOMES AND MEASURES History of military service was defined by active duty service, veteran status, or training for the Reserves or National Guard. The ACE inventory assessed 11 negative experiences before the age of 18 years. Weighted chi(2) tests and multiple logistic regression analyses were used to examine differences in ACEs by history of military service, era of service, and sex. RESULTS Those with military experience had greater odds of any difference in prevalence of ACEs. In the all-volunteer era, men with military service had a higher prevalence of ACEs in all 11 categories than men without military service. Notably, in the all-volunteer era, men with military service had twice the odds of reporting forced sex before the age of 18 years (odds ratio, 2.19; 95% CI, 1.34-3.57) compared with men without military service. In the draft era, the only difference among men was household drug use, in which men with a history of military service had a significantly lower prevalence than men without a history of military service (2.1% vs 3.3%; P = .003). Fewer differences were observed among women in the all-volunteer and draft eras. CONCLUSIONS AND RELEVANCE Differences in ACEs by era and sex lend preliminary support that enlistment may serve as an escape from adversity for some individuals, at least among men. Further research is needed to understand how best to support service members and veterans who may have experienced ACEs. C1 [Blosnich, John R.; Cerulli, Catherine; Bossarte, Robert M.] Univ Rochester, Dept Psychiat, Rochester, NY USA. [Blosnich, John R.] Vet Affairs Pittsburgh Healthcare Syst, Dept Vet Affairs, Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15240 USA. [Dichter, Melissa E.] Philadelphia Vet Affairs Med Ctr, Dept Vet Affairs, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. [Dichter, Melissa E.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. [Cerulli, Catherine] Univ Rochester, Susan B Anthony Ctr Womens Leadership, Rochester, NY USA. [Batten, Sonja V.] Mental Hlth Serv, Dept Vet Affairs Cent Off, Washington, DC USA. [Batten, Sonja V.] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA. [Bossarte, Robert M.] Ctr Excellence Suicide Prevent, Vet Integrated Serv Network 2, Dept Vet Affairs, Canandaigua, NY USA. RP Blosnich, JR (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Dept Vet Affairs, Ctr Hlth Equity Res & Promot, Univ Dr C 151C-U,Bldg 30, Pittsburgh, PA 15240 USA. EM john.blosnich@va.gov FU National Research Service Award from National Institute of Mental Health [T32MH020061]; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [10-202] FX This work was partially supported by National Research Service Award T32MH020061 from the National Institute of Mental Health and the Department of Veterans Affairs Office of Academic Affiliations (Dr Blosnich) and Career Development Award 10-202 from the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (Dr Dichter). NR 43 TC 34 Z9 34 U1 2 U2 14 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD SEP PY 2014 VL 71 IS 9 BP 1041 EP 1048 DI 10.1001/jamapsychiatry.2014.724 PG 8 WC Psychiatry SC Psychiatry GA AP0SV UT WOS:000341775300010 PM 25054690 ER PT J AU Bichara, DA Malchau, E Sillesen, NH Cakmak, S Nielsen, GP Muratoglu, OK AF Bichara, David A. Malchau, Erik Sillesen, Nanna H. Cakmak, Selami Nielsen, G. Petur Muratoglu, Orhun K. TI Vitamin E-Diffused Highly Cross-Linked UHMWPE Particles Induce Less Osteolysis Compared to Highly Cross-Linked Virgin UHMWPE Particles In Vivo SO JOURNAL OF ARTHROPLASTY LA English DT Article DE UHMWPE; vitamin E; particle-induced osteolysis; murine calvarial model; polyethylene wear debris ID MOLECULAR-WEIGHT POLYETHYLENE; TOTAL JOINT REPLACEMENT; TOTAL HIP REPLACEMENTS; ALPHA-TOCOPHEROL; WEAR DEBRIS; OXIDATION; COMPONENTS; ARTHROPLASTY; RESISTANCE; DECREASE AB Recent in vitro findings suggest that UHMWPE wear particles containing vitamin E (VE) may have reduced biologic activity and decreased osteolytic potential. We hypothesized that particles from VE-stabilized, radiation cross-linked UHMWPE would cause less osteolysis in a murine calvarial bone model when compared to virgin gamma irradiated cross-linked UHMWPE. Groups received equal amount of particulate debris overlaying the calvarium for 10 days. Calvarial bone was examined using high resolution micro-CT and histomorphometric analyses. There was a statistically significant difference between virgin (12.2% +/- 8%) and VE-UHMWPE (3% +/- 1.4%) groups in regards to bone resorption (P = 0.005) and inflammatory fibrous tissue overlaying the calvaria (0.48 vs. 0.20, P < 0.0001). These results suggest that VE-UHMWPE particles have reduced osteolytic potential in vivo when compared to virgin UHMWPE. (C) 2014 Elsevier Inc. All rights reserved. C1 [Bichara, David A.; Malchau, Erik; Sillesen, Nanna H.; Cakmak, Selami; Muratoglu, Orhun K.] Massachusetts Gen Hosp, Harris Orthopaed Lab, Boston, MA 02114 USA. [Bichara, David A.; Nielsen, G. Petur; Muratoglu, Orhun K.] Harvard Univ, Sch Med, Boston, MA USA. [Nielsen, G. Petur] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Muratoglu, OK (reprint author), Massachusetts Gen Hosp, 55 Fruit St,GRJ 1231, Boston, MA 02114 USA. NR 36 TC 6 Z9 6 U1 0 U2 20 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0883-5403 EI 1532-8406 J9 J ARTHROPLASTY JI J. Arthroplast. PD SEP PY 2014 VL 29 IS 9 SU S BP 232 EP 237 DI 10.1016/j.arth.2014.03.044 PG 6 WC Orthopedics SC Orthopedics GA AP6BS UT WOS:000342163100025 PM 24998319 ER PT J AU Schmidt, PM Sheridan, RL Moore, CL Scuba, SC King, BT Morrissey, PM Cancio, LC AF Schmidt, Patricia M. Sheridan, Robert L. Moore, Christina L. Scuba, Steve C. King, Booker T. Morrissey, Paul M. Cancio, Leopoldo C. TI From Baghdad to Boston: International Transfer of Burned Children in Time of War SO JOURNAL OF BURN CARE & RESEARCH LA English DT Article ID CARE; IRAQ; AFGHANISTAN AB A large portion of the casualties admitted to military hospitals on the battlefield in Iraq consists of children, of whom 13% had burns. The U. S. Army Combat Support Hospital (CSH) in Baghdad, faced with an influx of such patients, successfully transferred selected burned children by commercial airlines to the Shriners Hospital for Children in Boston, Massachusetts (SHC-B). The authors aimed to document this process, from both an ethical and a procedural standpoint. Care was conducted in six phases: 1) admission to the CSH; 2) selection for transfer; 3) burn care at the CSH; 4) travel to the United States; 5) burn care at the SHC-B; 6) return to Iraq. Transfer and SHC-B care were funded by charitable organizations. A review of patient records was performed. Eight acutely burned pediatric patients participated in this program. All were successfully transferred, treated at SHC-B, and returned to Iraq. They ranged in age from 1.7 to 17 years and in burn size from 6 to 53% of the TBSA. At SHC-B, the hospital length of stay was 14 to 132 days; up to 23 visits to the operating room were performed for acute and reconstructive burn surgery. The cost of war includes the care of injured civilians, and includes burned children. For selected patients, transfer out of the combat zone is one method of fulfilling this obligation. C1 [Schmidt, Patricia M.; Moore, Christina L.; King, Booker T.; Cancio, Leopoldo C.] US Army Inst Surg Res, Burn Ctr, Ft Sam Houston, TX 78234 USA. [Sheridan, Robert L.] Shriners Hosp Children, Burn Surg Serv, Boston, MA USA. [Sheridan, Robert L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Scuba, Steve C.] Walter Reed Natl Mil Med Ctr, Dept Nursing, Bethesda, MD USA. [Morrissey, Paul M.] US Army Med Act, Dept Pediat, Ft Drum, NY USA. RP Cancio, LC (reprint author), US Army Inst Surg Res, 3698 Chambers Pass, Ft Sam Houston, TX 78234 USA. FU Iraqi Children's Project FX P.M.M. is the president of the Iraqi Children's Project, a not-for-profit corporation that paid travel and living expenses for the children in this study. He does not receive salary or other benefits from the corporation, and he does not have any ownership interest in it. The other authors declare no conflict of interest. NR 17 TC 2 Z9 2 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1559-047X EI 1559-0488 J9 J BURN CARE RES JI J. Burn Care Res. PD SEP-OCT PY 2014 VL 35 IS 5 BP 369 EP 373 DI 10.1097/BCR.0b013e3182a366f1 PG 5 WC Emergency Medicine; Dermatology; Surgery SC Emergency Medicine; Dermatology; Surgery GA AP5CZ UT WOS:000342098600018 PM 24121805 ER PT J AU Henry, CA Nowinski, L Koesterer, K Ferrone, C Spybrook, J Bauman, M AF Henry, Charles A. Nowinski, Lisa Koesterer, Karmen Ferrone, Christine Spybrook, Jessaca Bauman, Margaret TI Low Rates of Depressed Mood and Depression Diagnoses in a Clinic Review of Children and Adolescents with Autistic Disorder SO JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY LA English DT Article ID SPECTRUM DISORDERS; INTELLECTUAL DISABILITY; PSYCHIATRIC-DISORDERS; INFANTILE-AUTISM; SYMPTOMS; BEHAVIOR; ADULTS; CHILDHOOD; ANXIETY AB Objectives: The purpose of this study was to investigate the prevalence of depression diagnoses and related clinical data in an outpatient sample of youth with autistic disorder. Methods: Records of 123 psychiatrically referred children and adolescents with a Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR) diagnosis of autistic disorder were examined. Mood disorder diagnoses and chief complaints along with family mood disorder history were the primary variables analyzed. Results: Four subjects (3%) presented with depressed mood. Irritability complaints were frequent (n = 78, 63%). Six subjects (5%) received a mood disorder diagnosis; all with mood disorder, not otherwise specified. No subjects received a depressive disorder diagnosis. Family history of mood disorders was common. Conclusions: Findings raise questions about the appropriate characterization and potential misdiagnoses of depression in youth with autistic disorder. C1 [Henry, Charles A.; Nowinski, Lisa; Koesterer, Karmen] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02445 USA. [Ferrone, Christine] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02445 USA. [Spybrook, Jessaca] Western Michigan Univ, Dept Evaluat Measurement & Res Dept, Kalamazoo, MI 49008 USA. [Bauman, Margaret] Boston Univ, Dept Pathol & Lab Med, Boston, MA 02215 USA. RP Henry, CA (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 1 Brookline Pl 426, Boston, MA 02445 USA. EM charles_henry@hms.harvard.edu NR 32 TC 2 Z9 2 U1 4 U2 11 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1044-5463 EI 1557-8992 J9 J CHILD ADOL PSYCHOP JI J. Child Adolesc. Psychopharmacol. PD SEP PY 2014 VL 24 IS 7 BP 403 EP 406 DI 10.1089/cap.2014.0024 PG 4 WC Pediatrics; Pharmacology & Pharmacy; Psychiatry SC Pediatrics; Pharmacology & Pharmacy; Psychiatry GA AP6CD UT WOS:000342164200007 PM 25198799 ER PT J AU Salley, CG Gerhardt, CA Fairclough, DL Patenaude, AF Kupst, MJ Barrera, M Vannatta, K AF Salley, Christina G. Gerhardt, Cynthia A. Fairclough, Diane L. Patenaude, Andrea F. Kupst, Mary J. Barrera, Maru Vannatta, Kathryn TI Social Self-Perception Among Pediatric Brain Tumor Survivors Compared With Peers SO JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS LA English DT Article DE pediatric; brain tumor; self-perception; self-report; social behavior ID CHILDHOOD; CHILDREN; ACCURACY; CANCER; POPULATIONS; COMPETENCE; ADJUSTMENT; TEACHER; MODELS; SPSS AB Objective: To assess self-perceptions of social behavior among children treated for a brain tumor and comparison children. To investigate group differences in the accuracy of children's self-perceptions as measured by discrepancies between self and peer reports of social behavior and to understand if these phenomena differ by gender. Method: Self and peer reports of social behavior were obtained in the classrooms of 116 children who were treated for an intracranial tumor. Social behaviors were assessed using the Revised Class Play, which generates indices for 5 behavioral subscales: Leadership-popularity, Prosocial, Aggressive-disruptive, Sensitive-isolated, and Victimization. A child matched for gender, race, and age was selected from each survivor's classroom to serve as a comparison. Abbreviated IQ scores were obtained in participants' homes. Results: Relative to comparison children, those who had undergone treatment for a brain tumor overestimated their level of Leadership-popularity and underestimated levels of Sensitive-isolated behaviors and Victimization by peers. Female survivors were more likely than male survivors to underestimate Sensitive-isolated behaviors and Victimization. Conclusion: Following treatment for a brain tumor, children (particularly girls) may be more likely than healthy children to underestimate peer relationship difficulties. These discrepancies should be considered when obtaining self-report from survivors and developing interventions to improve social functioning. C1 [Salley, Christina G.] Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, New York, NY 10022 USA. [Gerhardt, Cynthia A.; Vannatta, Kathryn] Nationwide Childrens Hosp, Ctr Biobehav Hlth, Res Inst, Columbus, OH USA. [Gerhardt, Cynthia A.; Vannatta, Kathryn] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA. [Fairclough, Diane L.] Univ Colorado, Dept Biostat & Informat, Denver, CO 80202 USA. [Patenaude, Andrea F.] Dana Farber Canc Inst, Ctr Canc Genet & Prevent, Boston, MA 02115 USA. [Patenaude, Andrea F.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Kupst, Mary J.] Childrens Hosp Milwaukee, Dept Pediat, Milwaukee, WI USA. [Kupst, Mary J.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Barrera, Maru] Hosp Sick Children, Dept Psychol, Toronto, ON M5G 1X8, Canada. [Barrera, Maru] Hosp Sick Children, Div Hematol Oncol, Toronto, ON M5G 1X8, Canada. [Barrera, Maru] Univ Toronto, Dept Publ Hlth & Behav Sci, Toronto, ON, Canada. RP Salley, CG (reprint author), Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, 641 Lexington Ave,7th Floor, New York, NY 10022 USA. EM salleyc@mskcc.org FU American Cancer Society [RSGPB-03-098-01-PBP]; National Cancer Institute [RO3 CA097740-02] FX This work was supported by awards from the American Cancer Society (RSGPB-03-098-01-PBP) and the National Cancer Institute (RO3 CA097740-02). NR 28 TC 7 Z9 7 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0196-206X EI 1536-7312 J9 J DEV BEHAV PEDIATR JI J. Dev. Behav. Pediatr. PD SEP PY 2014 VL 35 IS 7 BP 427 EP 434 PG 8 WC Behavioral Sciences; Psychology, Developmental; Pediatrics SC Behavioral Sciences; Psychology; Pediatrics GA AP1EV UT WOS:000341810600003 PM 25127341 ER PT J AU Zavotsky, KE Wolf, LA Baker, KM Carman, MJ Clark, PR Langkeit, K Lenehan, G Moon, M AF Zavotsky, Kathleen E. Wolf, Lisa A. Baker, Kathy M. Carman, Margaret J. Clark, Paul R. Langkeit, Kevin Lenehan, Gail Moon, Michael TI BENEFITS TO ED NURSES PARTICIPATING IN INTERDISCIPLINARY RESEARCH SO JOURNAL OF EMERGENCY NURSING LA English DT Article C1 [Zavotsky, Kathleen E.] Robert Wood Johnson Univ Hosp, New Brunswick, NJ USA. [Wolf, Lisa A.] Emergency Nurses Assoc, Inst Emergency Nursing Res, Des Plaines, IL USA. [Baker, Kathy M.] VCU Hlth Syst, Richmond, VA USA. [Carman, Margaret J.] Duke Univ, Sch Nursing, Durham, NC USA. [Clark, Paul R.] Norton Healthcare Inst Nursing, Louisville, KY USA. [Langkeit, Kevin] Intermt Med Ctr, Emergency Dept, Bountiful, UT USA. [Lenehan, Gail] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Moon, Michael] Univ Incarnate Word, Sch Nursing, San Antonio, TX USA. RP Wolf, LA (reprint author), 915 Lee St,110 Middle St, Des Plaines, IL 60016 USA. EM lwolf@ena.org NR 1 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0099-1767 EI 1527-2966 J9 J EMERG NURS JI J. Emerg. Nurs. PD SEP PY 2014 VL 40 IS 5 BP 512 EP 514 DI 10.1016/j.jen.2014.06.008 PG 3 WC Emergency Medicine; Nursing SC Emergency Medicine; Nursing GA AP3HI UT WOS:000341965800026 PM 25194657 ER PT J AU Tosti, R Ilyas, AM Mellema, JJ Guitton, TG Ring, D AF Tosti, Rick Ilyas, Asif M. Mellema, Jos J. Guitton, Thierry G. Ring, David CA Sci Variation Grp TI Interobserver Variability in the Treatment of Little Finger Metacarpal Neck Fractures SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Article DE Boxer fracture; interobserver agreement; metacarpal; little finger; variability ID BOXERS FRACTURES; ANGULATION; SHAFT AB Purpose To address the null hypothesis that surgeons shown radiographs of little finger metacarpal neck fractures with measured fracture angulation would recommend surgery as often as surgeons shown unmarked radiographs. Methods Members of the Science of Variation Group, an international collaboration of fully trained orthopedic and trauma surgeons, were asked to review 20 little finger metacarpal neck fracture cases, which included a vignette and 3 high-quality radiographs. Members were then randomized to review radiographs with or without measured fracture angulation on the lateral view and select operative or nonoperative management. Results Surgeons shown radiographs with measured angulation were more likely to recommend surgery, and there was less variability among these surgeons, particularly for fractures with less angular deformity. Conclusions Measured fracture angulation has a small but significant influence on treatment recommendations for little finger metacarpal neck fractures. Copyright (C) 2014 by the American Society for Surgery of the Hand. All rights reserved. C1 [Tosti, Rick] Temple Univ, Sch Med, Dept Orthopaed Surg & Sports Med, Philadelphia, PA 19140 USA. Thomas Jefferson Univ, Rothman Inst, Philadelphia, PA 19107 USA. Massachusetts Gen Hosp, Dept Orthopaed Surg, Hand & Upper Extrem Serv, Boston, MA 02114 USA. RP Tosti, R (reprint author), Temple Univ, Sch Med, Dept Orthopaed Surg & Sports Med, 3401 N Broad St, Philadelphia, PA 19140 USA. EM rtosti@temple.edu RI Calcagni, Maurizio/C-9769-2012; Page, Richard/K-6327-2015; Fernandes, C/F-9839-2012; OI adolfsson, lars/0000-0001-7873-3093; Calcagni, Maurizio/0000-0003-4372-0561; Page, Richard/0000-0002-2225-7144; Fernandes, C/0000-0003-0146-6091; Borris, Lars/0000-0002-0527-1518; Kennedy, Stephen/0000-0001-8177-4988; Frihagen, Frede/0000-0002-4811-669X; Haverkamp, Daniel/0000-0001-7360-9763; Guitton, Thierry/0000-0002-2599-1985; Soong, Maximillian/0000-0003-0333-8181; Bainbridge, Lionel/0000-0001-7987-2845 NR 11 TC 3 Z9 3 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0363-5023 EI 1531-6564 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD SEP PY 2014 VL 39 IS 9 BP 1722 EP 1727 DI 10.1016/j.jhsa.2014.05.023 PG 6 WC Orthopedics; Surgery SC Orthopedics; Surgery GA AP4GZ UT WOS:000342036500009 PM 25034789 ER PT J AU Hageman, MGJS Kinaci, A Ju, K Guitton, TG Mudgal, CS Ring, D AF Hageman, Michiel G. J. S. Kinaci, Ahmet Ju, Kevin Guitton, Thierry G. Mudgal, Chaitanya S. Ring, David CA Sci Variation Grp TI Carpal Tunnel Syndrome: Assessment of Surgeon and Patient Preferences and Priorities for Decision-Making SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Article DE Assessment of needs; carpal tunnel syndrome; shared decision-making ID SUPPORT FRAMEWORK AB Purpose This study tested the null hypothesis that there are no differences between the preferences of hand surgeons and those patients with carpal tunnel syndrome (CTS) facing decisions about management of CTS (ie, the preferred content of a decision aid). Methods One hundred three hand surgeons of the Science. of Variation Group and 79 patients with CTS completed a survey about their priorities and preferences in decision making regarding the management of CTS. The questionnaire was structured according the Ottawa Decision Support Framework for the development of a decision aid. Results Important areas on which patient and hand surgeon interests differed included a preference for nonpainful, nonoperative treatment and confirmation of the diagnosis with electrodiagnostic testing. For patients, the main disadvantage of nonoperative treatment was that it was likely to be only palliative and temporary. Patients preferred, on average, to take the lead in decision making, whereas physicians preferred shared decision making. Patients and physicians agreed on the value of support from family and other physicians in the decision-making process. Conclusions There were some differences between patient and surgeon priorities and preferences regarding decision making for CTS, particularly the risks and benefits of diagnostic and therapeutic procedures. Copyright (C) 2014 by the American Society for Surgery of the Hand. All rights reserved. C1 [Hageman, Michiel G. J. S.; Kinaci, Ahmet; Ju, Kevin; Guitton, Thierry G.; Mudgal, Chaitanya S.; Ring, David; Sci Variation Grp] Massachusetts Gen Hosp, Yawkey Ctr, Orthopaed Hand Serv, Boston, MA 02114 USA. RP Ring, D (reprint author), Massachusetts Gen Hosp, Yawkey Ctr, Orthopaed Hand Serv, Suite 2100,55 Fruit St, Boston, MA 02114 USA. EM dring@partners.org RI Fernandes, C/F-9839-2012; OI Fernandes, C/0000-0003-0146-6091; Kennedy, Stephen/0000-0001-8177-4988; Guitton, Thierry/0000-0002-2599-1985; Ring, David/0000-0002-6506-4879 FU Dutch research grants from Marti-Keunig Eckhart Stichting; Anna Foundation FX M.G.H. is supported by Dutch research grants from Marti-Keunig Eckhart Stichting and Anna Foundation. NR 9 TC 7 Z9 7 U1 1 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0363-5023 EI 1531-6564 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD SEP PY 2014 VL 39 IS 9 BP 1799 EP 1804 DI 10.1016/j.jhsa.2014.05.035 PG 6 WC Orthopedics; Surgery SC Orthopedics; Surgery GA AP4GZ UT WOS:000342036500021 PM 25087865 ER PT J AU Moradi, A Kachooei, AR Mudgal, CS AF Moradi, Ali Kachooei, Amir Reza Mudgal, Chaitanya S. TI Acute Calcium Deposits in the Hand and Wrist SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Editorial Material ID OF-THE-LITERATURE; PERIARTHRITIS; TENDINITIS; PERITENDINITIS; WOMEN C1 Mashhad Univ Med Sci, Dept Orthoped Surg, Mashhad, Iran. Massachusetts Gen Hosp, Orthopaed Hand Serv, Boston, MA 02114 USA. RP Mudgal, CS (reprint author), Massachusetts Gen Hosp, Yawkey Ctr, Dept Orthoped, Orthopaed Hand Serv, Suite 2100,55 Fruit St, Boston, MA 02114 USA. EM cmudgal@partners.org NR 12 TC 2 Z9 2 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0363-5023 EI 1531-6564 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD SEP PY 2014 VL 39 IS 9 BP 1854 EP 1857 DI 10.1016/j.jhsa.2014.06.011 PG 4 WC Orthopedics; Surgery SC Orthopedics; Surgery GA AP4GZ UT WOS:000342036500031 PM 25037507 ER PT J AU Waljas, M Iverson, GL Lange, RT Liimatainen, S Hartikainen, KM Dastidar, P Soimakallio, S Ohman, J AF Waljas, Minna Iverson, Grant L. Lange, Rael T. Liimatainen, Suvi Hartikainen, Kaisa M. Dastidar, Prasun Soimakallio, Seppo Ohman, Juha TI Return to Work Following Mild Traumatic Brain Injury SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Article; Proceedings Paper CT 3rd Federal Interagency Conference on Traumatic Brain Injury CY JUN 13-15, 2011 CL Washington, DC DE mild traumatic brain injury; outcome; return to work ID MINOR HEAD-INJURY; POSTTRAUMATIC-STRESS-DISORDER; SATISFACTION 12 MONTHS; ILLNESS PERCEPTIONS; GENERAL HEALTH; RISK-FACTORS; RELIABILITY; ABNORMALITIES; DEPRESSION; SYMPTOMS AB Objective: To examine factors relating to return to work (RTW) following mild traumatic brain injury (mTBI). Participants: One hundred and nine patients (Age: M = 37.4 years, SD = 13.2; 52.3% women) who sustained an mTBI. Design: Inception cohort design with questionnaires and neuropsychological testing completed approximately 3 to 4 weeks postinjury. Setting: Emergency Department of Tampere University Hospital, Finland. Main Outcome Measures: Self-report (postconcussion symptoms, depression, fatigue, and general health) and neurocognitive measures (attention and memory). Results: The cumulative RTW rates were as follows: 1 week = 46.8%, 2 weeks = 59.6%, 3 weeks = 67.0%, 4 weeks = 70.6%, 2 months = 91.7%, and 1 year = 97.2%. Four variables were significant predictors of the number of days to RTW: age, multiple bodily injuries, intracranial abnormality at the day of injury, and fatigue ratings (all P <.001). The largest amount of variance accounted for by these variables in the prediction of RTW was at 30 days following injury (P <.001, R-2 = 0.504). Participants who returned to work fewer than 30 days after injury (n = 82, 75.2%) versus more than 30 days (n = 27, 24.8%) did not differ on demographic or neuropsychological variables. Conclusions: The vast majority of this cohort returned to work within 2 months. Predictors of slower RTW included age, multiple bodily injuries, intracranial abnormality at the day of injury, and fatigue. C1 [Waljas, Minna; Ohman, Juha] Tampere Univ Hosp, Dept Neurosurg, FIN-3521 Tampere, Finland. [Waljas, Minna; Hartikainen, Kaisa M.; Dastidar, Prasun; Soimakallio, Seppo; Ohman, Juha] Univ Tampere, Sch Med, FIN-33101 Tampere, Finland. [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA. [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA. [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA. [Lange, Rael T.] Def & Vet Brain Injury Ctr, Bethesda, MD USA. [Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA. [Liimatainen, Suvi] Tampere Univ Hosp, Dept Neurosci & Rehabil & Emergency, Dept Acuta, FIN-3521 Tampere, Finland. [Dastidar, Prasun; Soimakallio, Seppo] Pirkanmaa Hosp Dist, Med Imaging Ctr, Tampere, Finland. RP Waljas, M (reprint author), Tampere Univ Hosp, Dept Neurosurg, POB 2000, FIN-3521 Tampere, Finland. EM minna.waljas@gmail.com OI Ohman, Juha/0000-0002-6592-1367 NR 52 TC 9 Z9 9 U1 1 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-9701 EI 1550-509X J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD SEP-OCT PY 2014 VL 29 IS 5 BP 443 EP 450 DI 10.1097/HTR.0000000000000002 PG 8 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AP2GW UT WOS:000341891700013 PM 24263178 ER PT J AU Richard, MLL Sato, S Suzuki, E Williams, S Nowling, TK Zhang, XK AF Richard, Mara L. Lennard Sato, Shuzo Suzuki, Eiji Williams, Sarah Nowling, Tamara K. Zhang, Xian K. TI The Fli-1 Transcription Factor Regulates the Expression of CCL5/RANTES SO JOURNAL OF IMMUNOLOGY LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; RNA ENCODING RANTES; NF-KAPPA-B; CYTOKINE RANTES; GENE-EXPRESSION; RENAL-DISEASE; DNA-BINDING; ETS FAMILY; DECREASED EXPRESSION; ENDOTHELIAL-CELLS AB The friend leukemia insertion site 1 (Fli-1) transcription factor, an Ets family member, is implicated in the pathogenesis of systemic lupus erythematosus in human patients and murine models of lupus. Lupus-prone mice with reduced Fli-1 expression have significantly less nephritis, prolonged survival, and decreased infiltrating inflammatory cells into the kidney. Inflammatory chemokines, including CCL5, are critical for attracting inflammatory cells. In this study, decreased CCL5 mRNA expression was observed in kidneys of lupus-prone NZM2410 mice with reduced Fli-1 expression. CCL5 protein expression was significantly decreased in endothelial cells transfected with Fli-1-specific small interfering RNA compared with controls. Fli-1 binds to endogenous Ets binding sites in the distal region of the CCL5 promoter. Transient transfection assays demonstrate that Fli-1 drives transcription from the CCL5 promoter in a dose-dependent manner. Both Ets1, another Ets family member, and Fli-1 drive transcription from the CCL5 promoter, although Fli-1 transactivation was significantly stronger. Ets1 acts as a dominant-negative transcription factor for Fli-1, indicating that they may have at least one DNA binding site in common. Systematic deletion of DNA binding sites demonstrates the importance of the sites located within a 225-bp region of the promoter. Mutation of the Fli-1 DNA binding domain significantly reduces transactivation of the CCL5 promoter by Fli-1. We identified a novel regulator of transcription for CCL5. These results suggest that Fli-1 is a novel and critical regulator of proinflammatory chemokines and affects the pathogenesis of disease through the regulation of factors that recruit inflammatory cells to sites of inflammation. C1 [Richard, Mara L. Lennard; Sato, Shuzo; Suzuki, Eiji; Nowling, Tamara K.; Zhang, Xian K.] Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA. [Williams, Sarah; Nowling, Tamara K.; Zhang, Xian K.] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC 29403 USA. RP Zhang, XK (reprint author), Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, 96 Jonathan Lucas St,Suite 912,MSC637, Charleston, SC 29425 USA. EM zhangjo@musc.edu FU National Institutes of Health (National Institute of Arthritis and Musculoskeletal and Skin Diseases) [AR056670]; South Carolina Clinical and Translational Research Institute Voucher Pilot Program National Institutes of Health/National Center for Research Resources [UL1 RR029882, UL1 TR000062] FX This work was supported in part by the National Institutes of Health (National Institute of Arthritis and Musculoskeletal and Skin Diseases, AR056670 to X.K.Z.) and South Carolina Clinical and Translational Research Institute Voucher Pilot Program National Institutes of Health/National Center for Research Resources Grants UL1 RR029882 and UL1 TR000062. NR 45 TC 7 Z9 7 U1 1 U2 5 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD SEP PY 2014 VL 193 IS 6 BP 2661 EP 2668 DI 10.4049/jimmunol.1302779 PG 8 WC Immunology SC Immunology GA AP1VJ UT WOS:000341859700006 ER PT J AU Li, QS Zeng, M Duan, LJ Voss, JE Smith, AJ Pambuccian, S Shang, L Wietgrefe, S Southern, PJ Reilly, CS Skinner, PJ Zupancic, ML Carlis, JV Piatak, M Waterman, D Reeves, RK Masek-Hammerman, K Derdeyn, CA Alpert, MD Evans, DT Kohler, H Muller, S Robinson, J Lifson, JD Burton, DR Johnson, RP Haase, AT AF Li, Qingsheng Zeng, Ming Duan, Lijie Voss, James E. Smith, Anthony J. Pambuccian, Stefan Shang, Liang Wietgrefe, Stephen Southern, Peter J. Reilly, Cavan S. Skinner, Pamela J. Zupancic, Mary L. Carlis, John V. Piatak, Michael, Jr. Waterman, Diane Reeves, R. Keith Masek-Hammerman, Katherine Derdeyn, Cynthia A. Alpert, Michael D. Evans, David T. Kohler, Heinz Mueller, Sybille Robinson, James Lifson, Jeffrey D. Burton, Dennis R. Johnson, R. Paul Haase, Ashley T. TI Live Simian Immunodeficiency Virus Vaccine Correlate of Protection: Local Antibody Production and Concentration on the Path of Virus Entry SO JOURNAL OF IMMUNOLOGY LA English DT Article ID NEONATAL FC-RECEPTOR; ATTENUATED SIV; RHESUS MACAQUES; MONOCLONAL-ANTIBODIES; CONTROL REPLICATION; IMMUNE-RESPONSES; RESERVE CELLS; T-CELLS; INFECTION; HIV AB We sought design principles for a vaccine to prevent HIV transmission to women by identifying correlates of protection conferred by a highly effective live attenuated SIV vaccine in the rhesus macaque animal model. We show that SIVmac239 Delta nef vaccination recruits plasma cells and induces ectopic lymphoid follicle formation beneath the mucosal epithelium in the rhesus macaque female reproductive tract. The plasma cells and ectopic follicles produce IgG Abs reactive with viral envelope glycoprotein gp41 trimers, and these Abs are concentrated on the path of virus entry by the neonatal FcR in cervical reserve epithelium and in vaginal epithelium. This local Ab production and delivery system correlated spatially and temporally with the maturation of local protection against high-dose pathogenic SIV vaginal challenge. Thus, designing vaccines to elicit production and concentration of Abs at mucosal frontlines could aid in the development of an effective vaccine to protect women against HIV-1. C1 [Li, Qingsheng; Zeng, Ming; Duan, Lijie; Smith, Anthony J.; Shang, Liang; Wietgrefe, Stephen; Southern, Peter J.; Zupancic, Mary L.; Haase, Ashley T.] Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA. [Voss, James E.; Burton, Dennis R.] Scripps Res Inst, Int AIDS Vaccine Initiat Neutralizing Antibody Ct, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA. [Voss, James E.; Burton, Dennis R.] Scripps Res Inst, Ctr HIV AIDS Vaccine Immunol & Immunogen Design, La Jolla, CA 92037 USA. [Voss, James E.; Burton, Dennis R.] MIT, Ragon Inst MGH, Charlestown, MA 02129 USA. [Voss, James E.; Burton, Dennis R.] Harvard Univ, Charlestown, MA 02129 USA. [Pambuccian, Stefan] Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA. [Reilly, Cavan S.] Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA. [Skinner, Pamela J.] Univ Minnesota, Coll Vet Med, Dept Vet & Biomed Sci, St Paul, MN 55108 USA. [Carlis, John V.] Univ Minnesota, Coll Sci & Engn, Dept Comp Sci & Engn, Minneapolis, MN 55455 USA. [Piatak, Michael, Jr.; Lifson, Jeffrey D.] Sci Applicat Int Corp Frederick Inc, Natl Canc Inst, AIDS & Canc Virus Program, Frederick, MD 21702 USA. [Waterman, Diane] ZeptoMetrix Corp, Buffalo, NY 14202 USA. [Reeves, R. Keith; Masek-Hammerman, Katherine; Alpert, Michael D.; Evans, David T.] Harvard Univ, New England Primate Res Ctr, Sch Med, Southborough, MA 01772 USA. [Reeves, R. Keith; Masek-Hammerman, Katherine] Massachusetts Gen Hosp, Dept Med, Infect Dis Unit, Boston, MA 02115 USA. [Derdeyn, Cynthia A.] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30329 USA. [Derdeyn, Cynthia A.] Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30329 USA. [Alpert, Michael D.; Evans, David T.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02115 USA. [Kohler, Heinz] Univ Kentucky, Dept Microbiol & Immunol & Mol Genet, Lexington, KY 40536 USA. [Mueller, Sybille] ImmPheron Inc, Lexington, KY 40509 USA. [Robinson, James] Tulane Univ, Ctr Infect Dis, Dept Pediat, New Orleans, LA 70112 USA. RP Haase, AT (reprint author), Univ Minnesota, Sch Med, Dept Microbiol, MMC 196,420 Delaware St SE, Minneapolis, MN 55455 USA. EM haase001@umn.edu OI Skinner, Pamela/0000-0003-3388-1687 FU International AIDS Vaccine Initiative; National Institutes of Health [AI 086922, AI 071306, RR00168, AI095985, AI 055332, 1UM1AI100663]; Center for HIV/AIDS Vaccine Immunology/HIV Vaccine Trials Network; Ragon Fellowship; National Cancer Institute, National Institutes of Health [HHSN261200800001E]; National Institutes of Health/National Institute of Allergy and Infectious Diseases Reagent Resource Support Program for AIDS Vaccine Development, Quality Biological, Inc., Gaithersburg, MD (National [HHSN272201100023C]; [U19 AI 067854] FX This work was supported by a grant from the International AIDS Vaccine Initiative (to A.T.H.); National Institutes of Health Grants AI 086922 (to A.T.H.), AI 071306 and RR00168 (to R.P.J.), AI095985 (to R.P.J. and A.T.H.), and AI 055332 and 1UM1AI100663 (to D.R.B.); a Center for HIV/AIDS Vaccine Immunology/HIV Vaccine Trials Network Early Stage Investigator award and Grant U19 AI 067854 (to R.K.R.); a Ragon Fellowship (to J.E.V.); and by federal funds from the National Cancer Institute, National Institutes of Health under Contract HHSN261200800001E and the National Institutes of Health/National Institute of Allergy and Infectious Diseases Reagent Resource Support Program for AIDS Vaccine Development, Quality Biological, Inc., Gaithersburg, MD (National Institute of Allergy and Infectious Diseases Division of AIDS Contract HHSN272201100023C). NR 46 TC 28 Z9 28 U1 0 U2 3 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD SEP PY 2014 VL 193 IS 6 BP 3113 EP 3125 DI 10.4049/jimmunol.1400820 PG 13 WC Immunology SC Immunology GA AP1VJ UT WOS:000341859700050 PM 25135832 ER PT J AU Smith, AJ Wietgrefe, SW Shang, L Reilly, CS Southern, PJ Perkey, KE Duan, LJ Kohler, H Muller, S Robinson, J Carlis, JV Li, QS Johnson, RP Haase, AT AF Smith, Anthony J. Wietgrefe, Stephen W. Shang, Liang Reilly, Cavan S. Southern, Peter J. Perkey, Katherine E. Duan, Lijie Kohler, Heinz Mueller, Sybille Robinson, James Carlis, John V. Li, Qingsheng Johnson, R. Paul Haase, Ashley T. TI Live Simian Immunodeficiency Virus Vaccine Correlate of Protection: Immune Complex-Inhibitory Fc Receptor Interactions That Reduce Target Cell Availability SO JOURNAL OF IMMUNOLOGY LA English DT Article ID HIV-1 INFECTION; COMMD PROTEINS; TRANSMISSION; SIV; DEGRADATION; PROPAGATION; MONKEYS; FAMILY; MAVS AB Principles to guide design of an effective vaccine against HIV are greatly needed, particularly to protect women in the pandemic's epicenter in Africa. We have been seeking these principles by identifying correlates of the robust protection associated with SIVmac239 Delta nef vaccination in the SIV-rhesus macaque animal model of HIV-1 transmission to women. We identified one correlate of SIVmac239 Delta nef protection against vaginal challenge as a resident mucosal system for SIV-gp41 trimer Ab production and neonatal FcR-mediated concentration of these Abs on the path of virus entry to inhibit establishment of infected founder populations at the portal of entry. In this study, we identify blocking CD4(+) T cell recruitment to thereby inhibit local expansion of infected founder populations as a second correlate of protection. Virus-specific immune complex interactions with the inhibitory Fc gamma RIIb receptor in the epithelium lining the cervix initiate expression of genes that block recruitment of target cells to fuel local expansion. Immune complex-Fc gamma RIIb receptor interactions at mucosal frontlines to dampen the innate immune response to vaginal challenge could be a potentially general mechanism for the mucosal immune system to sense and modulate the response to a previously encountered pathogen. Designing vaccines to provide protection without eliciting these transmission-promoting innate responses could contribute to developing an effective HIV-1 vaccine. C1 [Smith, Anthony J.; Wietgrefe, Stephen W.; Shang, Liang; Southern, Peter J.; Perkey, Katherine E.; Duan, Lijie; Haase, Ashley T.] Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA. [Reilly, Cavan S.] Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA. [Kohler, Heinz] Univ Kentucky, Dept Microbiol & Immunol & Mol Genet, Lexington, KY 40536 USA. [Mueller, Sybille] ImmPheron Inc, Lexington, KY 40509 USA. [Robinson, James] Tulane Univ, Ctr Infect Dis, Dept Pediat, New Orleans, LA 70112 USA. [Carlis, John V.] Univ Minnesota, Coll Sci & Engn, Dept Comp Sci & Engn, Minneapolis, MN 55455 USA. [Li, Qingsheng] Univ Nebraska, Sch Biol Sci, Nebraska Ctr Virol, Lincoln, NE 68583 USA. [Johnson, R. Paul] Harvard Univ, Sch Med, New England Primate Res Ctr, Southborough, MA 01772 USA. [Johnson, R. Paul] MIT, Ragon Inst MGH, Charlestown, MA 02129 USA. [Johnson, R. Paul] Harvard Univ, Charlestown, MA 02129 USA. [Johnson, R. Paul] Massachusetts Gen Hosp, Dept Med, Infect Dis Unit, Boston, MA 02115 USA. RP Haase, AT (reprint author), Univ Minnesota, Sch Med, Dept Microbiol, MMC 196,420 Delaware St SE, Minneapolis, MN 55455 USA. EM haase001@umn.edu FU National Institutes of Health [AI071306, RR00168]; National Cancer Institute, National Institutes of Health [HHSN261200800001E]; International AIDS Vaccine Initiative FX This work was supported by the International AIDS Vaccine Initiative, National Institutes of Health Grants AI071306 and RR00168, and in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract HHSN261200800001E. NR 26 TC 12 Z9 12 U1 0 U2 2 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD SEP PY 2014 VL 193 IS 6 BP 3126 EP 3133 DI 10.4049/jimmunol.1400822 PG 8 WC Immunology SC Immunology GA AP1VJ UT WOS:000341859700051 PM 25143442 ER PT J AU Balboni, MJ Sullivan, A Enzinger, AC Epstein-Peterson, ZD Tseng, YD Mitchell, C Niska, J Zollfrank, A VanderWeele, TJ Balboni, TA AF Balboni, Michael J. Sullivan, Adam Enzinger, Andrea C. Epstein-Peterson, Zachary D. Tseng, Yolanda D. Mitchell, Christine Niska, Joshua Zollfrank, Angelika VanderWeele, Tyler J. Balboni, Tracy A. TI Nurse and Physician Barriers to Spiritual Care Provision at the End of Life SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Palliative care; religion; spirituality; spiritual care; hidden curriculum ID QUALITY-OF-LIFE; ADVANCED CANCER-PATIENTS; NATIONAL-SURVEY; US PHYSICIANS; MEDICAL-CARE; ASSOCIATIONS; RELIGION; PERSPECTIVES; PERCEPTIONS; ONCOLOGY AB Context. Spiritual care (SC) from medical practitioners is infrequent at the end of life (EOL) despite national standards. Objectives. The study aimed to describe nurses' and physicians' desire to provide SC to terminally ill patients and assess 11 potential SC barriers. Methods. This was a survey-based, multisite study conducted from October 2008 through January 2009. All eligible oncology nurses and physicians at four Boston academic centers were approached for study participation; 339 nurses and physicians participated (response rate = 63%). Results. Most nurses and physicians desire to provide SC within the setting of terminal illness (74% vs. 60%, respectively; P = 0.002); however, 40% of nurses/physicians provide SC less often than they desire. The most highly endorsed barriers were "lack of private space'' for nurses and "lack of time'' for physicians, but neither was associated with actual SC provision. Barriers that predicted less frequent SC for all medical professionals included inadequate training (nurses: odds ratio [OR] = 0.28, 95% confidence interval [CI] = 0.12-0.73, P = 0.01; physicians: OR = 0.49, 95% CI = 0.25-0.95, P = 0.04), "not my professional role'' (nurses: OR = 0.21, 95% CI = 0.07-0.61, P = 0.004; physicians: OR = 0.35, 95% CI = 0.17=0.72, P 0.004), and "power inequity with patient'' (nurses: OR = 0.33, 95% CI = 0.12-0.87, P = 0.03; physicians: OR 0.41, 95% CI = 0.21-0.78, P = 0.007). A minority of nurses and physicians (21% and 49%, P = 0.003, respectively) did not desire SC training. Those less likely to desire SC training reported lower self-ratings of spirituality (nurses: OR = 5.00, 95% CI = 1.82-12.50, P = 0.002; physicians: OR = 3.33, 95% CI = 1.82-5.88, P < 0.001) and male gender (physicians: OR = 3.03, 95% CI = 1.67-5.56, P < 0.001). Conclusion. SC training is suggested to be critical to the provision of SC in accordance with national care quality standards. (C) 2014 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved. C1 [Balboni, Michael J.; Epstein-Peterson, Zachary D.; Niska, Joshua; Balboni, Tracy A.] Harvard Univ, Sch Med, Boston, MA USA. [Balboni, Michael J.; Mitchell, Christine; Balboni, Tracy A.] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA. [Enzinger, Andrea C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Tseng, Yolanda D.; Balboni, Tracy A.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Balboni, Michael J.; Enzinger, Andrea C.; Balboni, Tracy A.] Dana Farber Canc Inst, Ctr Psychosocial Epidemiol & Outcomes Res, Boston, MA 02115 USA. [Balboni, Michael J.; Enzinger, Andrea C.; Balboni, Tracy A.] Dana Farber Canc Inst, McGraw Patterson Ctr Populat Sci, Boston, MA 02115 USA. [Balboni, Michael J.] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA. [Sullivan, Adam; VanderWeele, Tyler J.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [VanderWeele, Tyler J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Tseng, Yolanda D.] Massachusetts Gen Hosp, Harvard Radiat Oncol Program, Boston, MA 02114 USA. [Zollfrank, Angelika] Massachusetts Gen Hosp, Dept Chaplaincy, Boston, MA 02114 USA. RP Balboni, MJ (reprint author), Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Dana 1101,450 Brookline Ave, Boston, MA 02115 USA. EM Michael_Balboni@dfci.harvard.edu FU American Society of Clinical Oncology; HealthCare Chaplaincy award; Templeton Foundation Awards; University of Chicago Program in Religion and Medicine Faculty Scholars Award FX This research was supported in part by an American Society of Clinical Oncology Young Investigator Award and Career Development Award (T. A. B.), a HealthCare Chaplaincy award (T. A. B.), Templeton Foundation Awards (M. J. B. and T. J. V.), and a University of Chicago Program in Religion and Medicine Faculty Scholars Award (M. J. B.). None of the authors have relationships with any entities having financial interest in this topic. NR 30 TC 24 Z9 24 U1 1 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD SEP PY 2014 VL 48 IS 3 BP 400 EP 410 DI 10.1016/j.jpainsymman.2013.09.020 PG 11 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AP3QB UT WOS:000341990700009 PM 24480531 ER PT J AU Abbott, CH Prigerson, HG Maciejewski, PK AF Abbott, Caroline H. Prigerson, Holly G. Maciejewski, Paul K. TI The Influence of Patients' Quality of Life at the End of Life on Bereaved Caregivers' Suicidal Ideation SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Caregiver; cancer; suicidal ideation; quality of life; end of life; bereavement ID ADVANCED CANCER-PATIENTS; INTENSIVE-CARE-UNIT; MENTAL-HEALTH; PSYCHIATRIC-DISORDERS; COMPLICATED GRIEF; ASSOCIATIONS; DEATH; STATES; PLACE; RISK AB Context. Recent studies have shown that patients' quality of life at the end of life (QOL@EOL) affects the psychosocial adjustment of bereaved family caregivers. Objectives. To examine the relationship between patients' QOL@EOL and the suicidal ideation of their surviving bereaved caregivers. Methods. Data were derived from the Coping with Cancer (CwC1) Study, a U.S. National Cancer Institute-funded multicenter prospective cohort investigation of patients with advanced cancer and their caregivers, in which patients were enrolled September 2002 to February 2008. CwC1 data were used to examine changes in suicidal ideation in family caregivers before and after the patient's death (N = 127). Caregiver baseline suicidal ideation was assessed using the Yale Evaluation of Suicidality (YES) Scale a median of 4.1 months pre-loss; caregivers' perception of patients' QOL@EOL was assessed a median of 1.9 months postloss; and caregiver suicidal ideation in bereavement was assessed using the YES a median of 6.5 months postloss. Suicidal ideation was defined as a positive screen on the YES. We used multiple logistic regression analysis to examine the effect of caregivers' perceptions of patients' QOL@EOL on the suicidal ideation of bereaved caregiver's, adjusting for the caregiver's baseline suicidal ideation and confounding influences. Results. Caregivers' perception of patients' QOL@EOL was significantly inversely related to caregivers' suicidal ideation postloss (adjusted odds ratio 0.79, P = 0.023), after we adjusted for caregivers' baseline suicidal ideation, relationship to patient, and years of education. Conclusion. The more caregivers perceive their loved ones' QOL@EOL to be poor, the greater their risk for suicidal ideation in bereavement over and above prior levels of suicidal ideation. Caregivers of patients who have poor QOL@EOL appear to be a group of caregivers to target for reduction of suicidal risk. (C) 2014 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved. C1 [Abbott, Caroline H.; Prigerson, Holly G.] Dana Farber Canc Inst, Ctr Psychosocial Epidemiol & Outcomes Res, Boston, MA 01225 USA. [Prigerson, Holly G.] Harvard Univ, Sch Med, Boston, MA USA. [Maciejewski, Paul K.] Weill Cornell Med Coll, Dept Radiol, Div Geriatr & Palliat Med, New York, NY USA. Weill Cornell Med Coll, Dept Med, New York, NY USA. RP Prigerson, HG (reprint author), Dana Farber Canc Inst, Ctr Psychosocial Epidemiol & Outcomes Res, 1134 Dana Bldg, Boston, MA 01225 USA. EM holly_prigerson@dfci.harvard.edu FU National Institute of Mental Health [MH63892]; National Cancer Institute [CA 106370, CA 156732] FX This study was supported by the following grants to Dr. Prigerson: Grant No. MH63892 from the National Institute of Mental Health and Grants No. CA 106370 and 156732 from the National Cancer Institute. The funding sources had no role in the writing of the manuscript and no authors were paid to write this article. The authors declare no conflicts of interest. NR 23 TC 5 Z9 5 U1 0 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD SEP PY 2014 VL 48 IS 3 BP 459 EP 464 DI 10.1016/j.jpainsymman.2013.09.011 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AP3QB UT WOS:000341990700012 PM 24321508 ER PT J AU Shin, JA Kosiba, JD Traeger, L Greer, JA Temel, JS Pirl, WF AF Shin, Jennifer A. Kosiba, Jesse D. Traeger, Lara Greer, Joseph A. Temel, Jennifer S. Pirl, William F. TI Dyspnea and Panic Among Patients With Newly Diagnosed Non-Small Cell Lung Cancer SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Dyspnea; panic disorder; lung carcinoma; anxiety ID DAILY-LIFE ACTIVITIES; HEALTH QUESTIONNAIRE; AMBULATORY PATIENTS; MENTAL-DISORDERS; PRIME-MD; PREVALENCE; DISABILITY; EXPERIENCE; VALIDATION; DEPRESSION AB Context. Among patients with lung cancer, dyspnea is associated with psychological distress, fatigue, and poor coping. Respiratory symptoms are also a common trigger for panic attacks in the general population. Minimal research has addressed the prevalence of panic disorder or the association of dyspnea with the risk of panic disorder in lung cancer. Objectives. We explored the frequency of panic disorder symptoms and the association of dyspnea with the risk of panic disorder symptoms among patients with newly diagnosed non-small cell lung cancer. Methods. During 2006-2010, consecutive patients presenting for initial consultation at a thoracic oncology clinic completed a survey of current symptoms, including dyspnea and panic disorder symptoms. We evaluated the frequency of panic disorder symptoms. Logistic regression was used to test the association of dyspnea with the risk of panic disorder symptoms, adjusting for age, gender, disease stage, performance status, and major depression symptoms. Results. Among 624 patients (mean age = 63.7; standard deviation = 12.1; 52.6% female), 48.1% reported that breathing was at least somewhat difficult and 11.2% endorsed panic disorder symptoms. Dyspnea was independently associated with higher risk of panic disorder symptoms (odds ratio = 2.19, 95% confidence interval = 1.11-4.31, P = 0.02). Younger age and major depression symptoms also were associated with higher risk (P < 0.01). Conclusion. Almost half of the patients with newly diagnosed non-small cell lung cancer reported dyspnea, and patients with dyspnea were more than twice as likely to endorse panic disorder symptoms relative to patients without dyspnea. Results highlight the need to differentiate panic disorder symptoms among patients who report dyspnea, particularly those who are younger or experiencing major depression symptoms. (C) 2014 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved. C1 [Shin, Jennifer A.; Temel, Jennifer S.] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA. [Kosiba, Jesse D.; Traeger, Lara; Greer, Joseph A.; Pirl, William F.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Shin, JA (reprint author), Massachusetts Gen Hosp, Dept Hematol Oncol, 55 Fruit St, Boston, MA 02114 USA. EM jashin@mgh.harvard.edu FU National Cancer Institute [K23 CA115908, R25 CA092203] FX This research was supported in part by National Cancer Institute grants K23 CA115908 (W. F. P.) and R25 CA092203 (J. A. S.). The authors declare no conflicts of interest. NR 36 TC 5 Z9 5 U1 2 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD SEP PY 2014 VL 48 IS 3 BP 465 EP 470 DI 10.1016/j.jpainsymman.2013.10.021 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AP3QB UT WOS:000341990700013 PM 24766738 ER PT J AU Vig, EK Foglia, MB AF Vig, Elizabeth K. Foglia, Mary Beth TI The Steak Dinner-A Professional Boundary Crossing SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Professional boundaries; codes of professional ethics; professionalism; palliative care AB Maintaining professional boundaries enables clinicians to keep their patients' best interests in mind. Palliative care clinicians may be at risk for professional boundary crossings because of the intimate nature of caring for people with life-threatening illnesses. In some instances, boundary crossings can be beneficial to the patient, but must be considered thoughtfully and with trusted others. We describe the case of a primary care physician and clinic nurse who were asked by a long-time clinic patient, who was now terminally ill, to join him for a steak dinner. We discuss the approach that the physician and nurse took in deciding about whether the boundary crossing was ethically permissible. We also offer sample questions for palliative care clinicians to consider when thinking about their actions. Published by Elsevier Inc. on behalf of American Academy of Hospice and Palliative Medicine. C1 [Vig, Elizabeth K.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Vig, Elizabeth K.; Foglia, Mary Beth] Univ Washington, Seattle, WA 98195 USA. [Foglia, Mary Beth] Vet Hlth Adm, Natl Ctr Eth Hlth Care, Washington, DC USA. RP Vig, EK (reprint author), 1660 S Columbian Way,S182 GEC, Seattle, WA 98108 USA. EM vigster@uw.edu NR 9 TC 0 Z9 0 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD SEP PY 2014 VL 48 IS 3 BP 483 EP 487 DI 10.1016/j.jpainsymman.2013.10.011 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AP3QB UT WOS:000341990700016 PM 24417806 ER PT J AU Prochazka, AV Fink, AS Bartenfeld, D Henderson, WG Nyirenda, C Webb, A Berger, DH Itani, K Whitehill, T Edwards, J Wilson, M Karsonovich, C Parmelee, P AF Prochazka, Allan V. Fink, Aaron S. Bartenfeld, Debra Henderson, William G. Nyirenda, Carsie Webb, Alexandra Berger, David H. Itani, Kamal Whitehill, Thomas Edwards, James Wilson, Mark Karsonovich, Cynthia Parmelee, Patricia TI Patient Perceptions of Surgical Informed Consent: Is Repeat Back Helpful or Harmful? SO JOURNAL OF PATIENT SAFETY LA English DT Article DE informed consent; repeat back; comprehension; satisfaction ID HEALTH LITERACY; SURGERY; MULTICENTER; QUALITY; CHOLECYSTECTOMY; COMMUNICATION; QUESTIONNAIRE; SATISFACTION AB Background: Informed consent (IC) comprehension is suboptimal. Repeat back (RB)-asking the patient to repeat in their own words key elements of the consent-is believed to improve the consent process. Objective: This study aims to assess the impact of RB on patient perceptions of surgical informed consent. Design: Secondary analysis of a randomized trial. Subjects: Elective surgical patients were consented using iMedConsent, the VA's computer-based IC platform. Patients were randomized to RB (IC could not be signed until the patient satisfactorily expressed key elements) or standard iMedConsent (no RB). Measures: A questionnaire was given immediately after IC assessing time for decision, satisfaction with and ease of understanding consent, and the amount of information provided about the proposed surgery (e. g., indications, benefits, risks, and alternatives). Groups were compared with W 2 tests. Results: We enrolled 575 subjects (276 RB and 299 no RB); 92% were men with a mean age of 61.6 years and high school level reading ability. The groups were comparable in their perceptions regarding time to make a decision (RB 88% Strongly Agree (SA), no RB 88% SA; P = 0.61), satisfaction with consent (RB 90% SA, no RB 87% SA; P = 0.27), ease of understanding (RB 69% SA, no RB 67% SA; P = 0.73) receipt of the right amount of information regarding the indications (RB 85% SA, no RB 87%; P = 0.61), the benefits (RB 87% SA, no RB 86% SA; P = 0.29), and the risks (RB 87% SA, no RB 84% SA; P = 0.19) of surgery. More of the RB group felt they received the right amount of information about alternatives to surgery (RB 80% SA) than did the no RB group (69% SA); P = 0.01. Conclusions: Patients were highly satisfied with RB during surgical IC RB is not detrimental to the consent process and may improve informed consent for surgery. C1 [Prochazka, Allan V.; Whitehill, Thomas] Denver VAMC, Denver, CO 80220 USA. [Prochazka, Allan V.; Henderson, William G.; Nyirenda, Carsie; Whitehill, Thomas] Univ Colorado, Hlth Outcomes Program, Aurora, CO USA. [Fink, Aaron S.; Bartenfeld, Debra; Webb, Alexandra] Atlanta VAMC, Decatur, GA USA. [Fink, Aaron S.; Webb, Alexandra] Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30322 USA. [Berger, David H.] Baylor Coll Med, Michael E Debakey VAMC, Houston, TX 77030 USA. [Itani, Kamal] Boston Univ, Boston VA Hlth Care Syst, Boston, MA 02215 USA. [Itani, Kamal] Harvard Univ, Sch Med, Boston, MA USA. [Edwards, James] Portland VA Med Ctr, Portland, OR USA. [Edwards, James] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR USA. [Wilson, Mark] Pittsburgh VAMC, Pittsburgh, PA USA. [Wilson, Mark] Univ Pittsburgh, Dept Surg, Med Ctr, Pittsburgh, PA USA. [Karsonovich, Cynthia] Tampa VAMC, Tampa, FL USA. [Karsonovich, Cynthia] Univ S Florida, Dept Surg, Tampa, FL 33620 USA. [Parmelee, Patricia] Univ Alabama, Dept Psychol, Tuscaloosa, AL 35487 USA. RP Prochazka, AV (reprint author), Denver VAMC, 1055 Clermont, Denver, CO 80220 USA. EM Allan.Prochazka@va.gov FU U.S. Department of Veterans Affairs Health Services Research and Development Service [IAF-05-308-01]; Fink; Prochazka; Henderson FX U.S. Department of Veterans Affairs Health Services Research and Development Service grant IAF-05-308-01. Programming of RB provided by Dialog Medical (Decatur, GA).; Obtaining Funding: Fink, Prochazka, Henderson NR 22 TC 0 Z9 0 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1549-8417 EI 1549-8425 J9 J PATIENT SAF JI J. Patient Saf. PD SEP PY 2014 VL 10 IS 3 BP 140 EP 145 PG 6 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA AP7AW UT WOS:000342230900004 PM 24522223 ER PT J AU Weinberger, LE Sreenivasan, S Garrick, T AF Weinberger, Linda E. Sreenivasan, Shoba Garrick, Thomas TI End-of-Life Mental Health Assessments for Older Aged, Medically Ill Persons With Expressed Desire to Die SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Article ID ASSISTED SUICIDE; SUPREME-COURT; ILLNESS; EUTHANASIA; BEHAVIOR; CANCER; PEOPLE; ADULTS AB In recent years, assisted suicide has been legalized in four states for those who are terminally ill and wish to end their lives with the assistance of lethal doses of medications prescribed by a physician. The ethics-related and legal questions raised by end-of-life suicide and decisional capacity to refuse treatment assessments are complex. In treating patients with end-stage medical conditions or disorders that severely affect the future quality of their lives, clinicians tend to engage in suicide prevention at all costs. Overriding the patient's expressed desire to die conflicts with another value, however, that of the individual's right to autonomy. We provide a framework for understanding these difficult decisions, by providing a review of the epidemiology of suicide in later life; reviewing findings from a unique dataset of suicides among the elderly obtained from the Los Angeles County Coroner's Office, as well as data from states with legalized assisted suicide; presenting a discussion of the two frameworks of suicidal ideation as a pathological versus an existential reaction; and giving a case example that highlights the dilemmas faced by clinicians addressing decisional capacity to refuse treatment in an elderly, medically ill patient who has expressed the wish to die. C1 [Weinberger, Linda E.; Sreenivasan, Shoba] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Weinberger, Linda E.] USC Inst Psychiat Law & Behav Sci, Los Angeles, CA 90086 USA. [Sreenivasan, Shoba] Greater Los Angeles VA Med Ctr, Forens Outreach Serv, Los Angeles, CA USA. [Garrick, Thomas] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Garrick, Thomas] Greater Los Angeles VA Med Ctr, Los Angeles, CA USA. RP Weinberger, LE (reprint author), USC Inst Psychiat Law & Behav Sci, POB 86125, Los Angeles, CA 90086 USA. EM leweinbe@usc.edu NR 43 TC 2 Z9 2 U1 12 U2 44 PU AMER ACAD PSYCHIATRY & LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 1093-6793 EI 1943-3662 J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PD SEP 1 PY 2014 VL 42 IS 3 BP 350 EP 361 PG 12 WC Law; Psychiatry SC Government & Law; Psychiatry GA AP0XJ UT WOS:000341789400010 PM 25187288 ER PT J AU Gillet, VG Solomon, DH Shadick, NA Weinblatt, ME Iannaccone, CK Feldman, S Kim, SC AF Gillet, Victoria G. Solomon, Daniel H. Shadick, Nancy A. Weinblatt, Michael E. Iannaccone, Christine K. Feldman, Sarah Kim, Seoyoung C. TI Behavioral and Clinical Factors Associated with Self-Reported Abnormal Papanicolaou Tests in Rheumatoid Arthritis SO JOURNAL OF WOMENS HEALTH LA English DT Article ID HUMAN-PAPILLOMAVIRUS INFECTION; SYSTEMIC-LUPUS-ERYTHEMATOSUS; CERVICAL-CANCER; WOMEN; RISK; ADOLESCENTS; DISEASE AB Background: Some evidence suggests that women with rheumatoid arthritis (RA) are at increased risk for the development of cervical cancer; however, it is unclear how this increase risk is conferred. We aimed to assess the factors related to abnormal Papanicolaou (Pap) tests in women with RA to determine whether they are similar to those reported for the general population. Methods: A structured questionnaire was mailed to 503 female patients from a longitudinal RA cohort. The survey included items on sociodemographic, behavioral, and gynecological factors. Univariate and multivariable logistic regression models examined the association of self-reported abnormal Pap results with a number of potential behavioral risk factors. Results: The questionnaire response rate was 57.5% (n = 289). Median age was 61 years and 97% had >= 1 Pap test previously. Twenty-nine percent of respondents reported a previous abnormal Pap result. In the multivariable logistic model adjusted for age, number of lifetime sexual partners, age at menarche, birth control use, and history of sexually transmitted disease (STD), ever using birth control (odds ratio [OR] 2.31, 95% confidence interval [CI] 1.18-4.52) and previous STD (OR 3.38, 95% CI 1.70-6.70) were associated with an increased risk of abnormal Pap result. Compared with either the state or national population, a greater proportion of the respondents was older, married, and previous smokers, and completed postsecondary education and obtained a Pap test. Conclusions: In this cross-sectional study, self-reported abnormal Pap results were associated with use of birth control and history of STD in RA patients. C1 [Gillet, Victoria G.; Solomon, Daniel H.; Kim, Seoyoung C.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA. [Solomon, Daniel H.; Shadick, Nancy A.; Weinblatt, Michael E.; Iannaccone, Christine K.; Kim, Seoyoung C.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02120 USA. [Feldman, Sarah] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kim, Seoyoung C.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. RP Kim, SC (reprint author), Brigham & Womens Hosp, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA. EM skim62@partners.org OI Kim, Seoyoung/0000-0002-2517-3579 FU NIH [K23 AR059677, K24 AR055989, P60 AR047782, R01 AR056215]; Bristol Myers Squibb; Crescendo Biosciences; Medimmune; Amgen; Lilly; Pfizer; Novartis; Abbott; Genentech; Millennium; Pharma; Asisa FX VG Gillet, S Feldman, and CK Iannaccone have no conflicts of interest to disclose. This study is funded by Dr. SC Kim's NIH grant K23 AR059677. Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study (BRASS) is funded by Bristol Myers Squibb, Crescendo Biosciences, and Medimmune. DH Solomon is supported by the NIH grants K24 AR055989, P60 AR047782, and R01 AR056215 and received research support from Amgen and Lilly. He serves in unpaid roles on studies sponsored by Pfizer, Novartis, Lilly, and Bristol Myers Squibb. NA Shadick received research support from Abbott, Amgen, and Genentech. ME Weinblatt received research support and served as a consultant to Bristol Myers Squibb, Crescendo Biosciences, and Medimmune. CS Kim is supported by the NIH grant K23 AR059677. She received research support from Pfizer and tuition support for the Pharmacoepidemiology program at the Harvard School of Public Health funded by Pfizer, Millennium, Pharma, and Asisa. NR 18 TC 1 Z9 1 U1 1 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD SEP PY 2014 VL 23 IS 9 BP 771 EP 776 DI 10.1089/jwh.2013.4658 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA AP2UL UT WOS:000341931000010 PM 25203494 ER PT J AU West, RK Moshier, E Lubitz, I Schmeidler, J Godbold, J Cai, WJ Uribarri, J Vlassara, H Silverman, JM Beeri, MS AF West, Rebecca K. Moshier, Erin Lubitz, Irit Schmeidler, James Godbold, James Cai, Weijing Uribarri, Jaime Vlassara, Helen Silverman, Jeremy M. Beeri, Michal Schnaider TI Dietary advanced glycation end products are associated with decline in memory in young elderly SO MECHANISMS OF AGEING AND DEVELOPMENT LA English DT Article DE Dietary advanced glycation end products; Type 2 diabetes; Cognitive decline; Memory; Methylglyoxal ID ALZHEIMERS-DISEASE; VASCULAR DEMENTIA; METHYLGLYOXAL; INDIVIDUALS AB We recently reported that serum methylglyoxal (sMG) is associated with a faster rate of decline in a global measure of cognition in the very elderly. We here provide for the first time evidence in which high levels of dietary AGE (dAGE) are associated with faster rate of decline in memory in 49 initially non-demented young elderly (p = 0.012 in mixed regression models adjusting for sociodemographic and cardiovascular factors). Since modifying the levels of AGEs in the diet may be relatively easy, these preliminary results suggest a simple strategy to diminish cognitive compromise in the elderly and warrant further investigation. (C) 2014 Elsevier Ireland Ltd. All rights reserved. C1 [West, Rebecca K.; Moshier, Erin; Schmeidler, James; Godbold, James; Cai, Weijing; Uribarri, Jaime; Vlassara, Helen; Silverman, Jeremy M.; Beeri, Michal Schnaider] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Lubitz, Irit; Beeri, Michal Schnaider] Joseph Sagol Neurosci Ctr, Chaim Sheba Med Ctr, Ramat Gan, Israel. [Silverman, Jeremy M.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP West, RK (reprint author), Icahn Sch Med Mt Sinai, New York, NY 10029 USA. EM rebecca.west@mssm.edu FU Alzheimer's Association [NIRG-06-25559]; Alzheimer's Disease Research Center of the Mount Sinai School of Medicine; NIH [R01 AG34087, R37 AG023188]; Irma T. Hirschl Scholar Award FX This study was funded by the Alzheimer's Association grant #NIRG-06-25559, the Alzheimer's Disease Research Center of the Mount Sinai School of Medicine, and NIH R01 AG34087 and the Irma T. Hirschl Scholar Award to Dr. Been, and NIH R37 AG023188 to Dr. Vlassara. NR 17 TC 16 Z9 17 U1 3 U2 11 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0047-6374 J9 MECH AGEING DEV JI Mech. Ageing Dev. PD SEP PY 2014 VL 140 BP 10 EP 12 DI 10.1016/j.mad.2014.07.001 PG 3 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA AP7NH UT WOS:000342263500002 PM 25037023 ER PT J AU Li, XH Zhang, D Yang, J Liu, B AF Li, Xinhua Zhang, Da Yang, Jie Liu, Bob TI A study of the short- to long-phantom dose ratios for CT scanning without table translation SO MEDICAL PHYSICS LA English DT Article DE computed tomography (CT); dosimetry; phantom; length; dose ratio ID COMPUTED-TOMOGRAPHY; PRACTICAL APPROACH; RADIATION-THERAPY; DOSIMETRY; SYSTEM; INDEX; FEASIBILITY; EQUATIONS; LENGTH AB Purpose: For CT scanning in the stationary-table modes, AAPM Task Group 111 proposed to measure the midpoint dose on the central and peripheral axes of sufficiently long phantoms. Currently, a long cylindrical phantom is usually not available in many clinical facilities. The use of a long phantom is also challenging because of the heavy weight. In order to shed light on assessing the midpoint dose in CT scanning without table movement, the authors present a study of the short- to long-phantom dose ratios, and perform a cross-comparison of CT dose ratios on different scanner models. Methods: The authors performed Geant4-based Monte Carlo simulations with a clinical CT scanner (Somatom Definition dual source CT, Siemens Healthcare), and modeled dosimetry measurements using a 0.6 cm(3) Farmer type chamber and a 10-cm long pencil ion chamber. The short (15 cm) to long (90 cm) phantom dose ratios were computed for two PMMA diameters (16 and 32 cm), two phantom axes (the center and the periphery), and a range of beam apertures (3-25 cm). The results were compared with the published data of previous studies with other multiple detector CT (MDCT) scanners and cone beam CT (CBCT) scanners. Results: The short- to long-phantom dose ratios changed with beam apertures but were insensitive to beam qualities (80-140 kV, the head and body bowtie filters) and MDCT and CBCT scanner models. Conclusions: The short-to long-phantom dose ratios enable medical physicists to make dosimetry measurements using the standard CT dosimetry phantoms and a Farmer chamber or a 10 cm long pencil chamber, and to assess the midpoint dose in long phantoms. This method provides an effective approach for the dosimetry of CBCT scanning in the stationary-table modes, and is useful for perfusion and interventional CT. (C) 2014 American Association of Physicists in Medicine. C1 [Li, Xinhua; Zhang, Da; Liu, Bob] Massachusetts Gen Hosp, Dept Radiol, Div Diagnost Imaging Phys, Boston, MA 02114 USA. [Li, Xinhua; Zhang, Da; Liu, Bob] Massachusetts Gen Hosp, Dept Radiol, Webster Ctr Adv Res & Educ Radiat, Boston, MA 02114 USA. [Yang, Jie] Pinnacle Hlth Fox Chase Reg Canc Ctr, Harrisburg, PA 17109 USA. RP Liu, B (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Diagnost Imaging Phys, Boston, MA 02114 USA. EM bliu7@mgh.harvard.edu NR 22 TC 4 Z9 4 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD SEP PY 2014 VL 41 IS 9 AR 091912 DI 10.1118/1.4893753 PG 10 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AP6RJ UT WOS:000342204800027 ER PT J AU Liebl, J Paganetti, H Zhu, MY Winey, BA AF Liebl, Jakob Paganetti, Harald Zhu, Mingyao Winey, Brian A. TI The influence of patient positioning uncertainties in proton radiotherapy on proton range and dose distributions SO MEDICAL PHYSICS LA English DT Article DE proton radiotherapy; proton range uncertainties; patient positioning ID 2D/3D IMAGE REGISTRATION; THERAPY; CANCER; TISSUE; SETUP AB Purpose: Proton radiotherapy allows radiation treatment delivery with high dose gradients. The nature of such dose distributions increases the influence of patient positioning uncertainties on their fidelity when compared to photon radiotherapy. The present work quantitatively analyzes the influence of setup uncertainties on proton range and dose distributions. Methods: Thirty-eight clinical passive scattering treatment fields for small lesions in the head were studied. Dose distributions for shifted and rotated patient positions were Monte Carlo-simulated. Proton range uncertainties at the 50%- and 90%-dose falloff position were calculated considering 18 arbitrary combinations of maximal patient position shifts and rotations for two patient positioning methods. Normal tissue complication probabilities (NTCPs), equivalent uniform doses (EUDs), and tumor control probabilities (TCPs) were studied for organs at risk (OARs) and target volumes of eight patients. Results: The authors identified a median 1 sigma proton range uncertainty at the 50%-dose falloff of 2.8 mm for anatomy-based patient positioning and 1.6 mm for fiducial-based patient positioning as well as 7.2 and 5.8 mm for the 90%-dose falloff position, respectively. These range uncertainties were correlated to heterogeneity indices (HIs) calculated for each treatment field (38% < R-2 < 50%). A NTCP increase of more than 10% (absolute) was observed for less than 2.9% (anatomy-based positioning) and 1.2% (fiducial-based positioning) of the studied OARs and patient shifts. For target volumes TCP decreases by more than 10% (absolute) occurred in less than 2.2% of the considered treatment scenarios for anatomy-based patient positioning and were nonexistent for fiducial-based patient positioning. EUD changes for target volumes were up to 35% (anatomy-based positioning) and 16% (fiducial-based positioning). Conclusions: The influence of patient positioning uncertainties on proton range in therapy of small lesions in the human brain as well as target and OAR dosimetry were studied. Observed range uncertainties were correlated with HIs. The clinical practice of using multiple fields with smeared compensators while avoiding distal OAR sparing is considered to be safe. (C) 2014 American Association of Physicists in Medicine. C1 [Liebl, Jakob] EBG MedAustron GmbH, A-2700 Wiener Neustadt, Austria. [Liebl, Jakob; Paganetti, Harald; Zhu, Mingyao; Winey, Brian A.] Massachusetts Gen Hosp, Francis H Burr Proton Therapy Ctr, Boston, MA 02114 USA. [Liebl, Jakob; Paganetti, Harald; Zhu, Mingyao; Winey, Brian A.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Liebl, Jakob] Med Univ Graz, Dept Therapeut Radiol & Oncol, A-8036 Graz, Austria. RP Liebl, J (reprint author), EBG MedAustron GmbH, A-2700 Wiener Neustadt, Austria. EM jakob.liebl@medaustron.at FU NCI NIH HHS [P01 CA021239] NR 19 TC 2 Z9 2 U1 1 U2 7 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD SEP PY 2014 VL 41 IS 9 AR 091711 DI 10.1118/1.4892601 PG 12 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AP6RJ UT WOS:000342204800014 PM 25186386 ER PT J AU Zhang, D Padole, A Li, XH Singh, S Khawaja, RDA Lira, D Liu, TY Shi, JQ Otrakji, A Kalra, MK Xu, XG Liu, B AF Zhang, Da Padole, Atul Li, Xinhua Singh, Sarabjeet Khawaja, Ranish Deedar Ali Lira, Diego Liu, Tianyu Shi, Jim Q. Otrakji, Alexi Kalra, Mannudeep K. Xu, X. George Liu, Bob TI In vitro dose measurements in a human cadaver with abdomen/pelvis CT scans SO MEDICAL PHYSICS LA English DT Article DE CT; radiation dosimetry; dose; human cadaver ID MONTE-CARLO SIMULATIONS; CANCER-RISK ESTIMATION; COMPUTED-TOMOGRAPHY; ANTHROPOMORPHIC PHANTOMS; DOSIMETRY; MODELS; VALIDATION; RANGE AB Purpose: To present a study of radiation dose measurements with a human cadaver scanned on a clinical CT scanner. Methods: Multiple point dose measurements were obtained with high-accuracy Thimble ionization chambers placed inside the stomach, liver, paravertebral gutter, ascending colon, left kidney, and urinary bladder of a human cadaver (183 cm in height and 67.5 kg in weight) whose abdomen/pelvis region was scanned repeatedly with a multidetector row CT. The flat energy response and precision of the dosimeters were verified, and the slight differences in each dosimeter's response were evaluated and corrected to attain high accuracy. In addition, skin doses were measured for radiosensitive organs outside the scanned region with OSL dosimeters: the right eye, thyroid, both nipples, and the right testicle. Three scan protocols were used, which shared most scan parameters but had different kVp and mA settings: 120-kVp automA, 120-kVp 300 mA, and 100-kVp 300 mA. For each protocol three repeated scans were performed. Results: The tube starting angle (TSA) was found to randomly vary around two major conditions, which caused large fluctuations in the repeated point dose measurements: for the 120-kVp 300 mA protocol this angle changed from approximately 110 degrees to 290 degrees, and caused 8% - 25% difference in the point dose measured at the stomach, liver, colon, and urinary bladder. When the fluctuations of the TSA were small (within 5 degrees), the maximum coefficient of variance was approximately 3.3%. The soft tissue absorbed doses averaged from four locations near the center of the scanned region were 27.2 +/- 3.3 and 16.5 +/- 2.7 mGy for the 120 and 100-kVp fixed-mA scans, respectively. These values were consistent with the corresponding size specific dose estimates within 4%. The comparison of the per-100-mAs tissue doses from the three protocols revealed that: (1) dose levels at nonsuperficial locations in the TCM scans could not be accurately deduced by simply scaling the fix-mA doses with local mA values; (2) the general power law relationship between dose and kVp varied from location to location, with the power index ranged between 2.7 and 3.5. The averaged dose measurements at both nipples, which were about 0.6 cm outside the prescribed scan region, ranged from 23 to 27 mGy at the left nipple, and varied from 3 to 20 mGy at the right nipple over the three scan protocols. Large fluctuations over repeated scans were also observed, as a combined result of helical scans of large pitch (1.375) and small active areas of the skin dosimeters. In addition, the averaged skin dose fell off drastically with the distance to the nearest boundary of the scanned region. Conclusions: This study revealed the complexity of CT dose fluctuation and variation with a human cadaver. (C) 2014 American Association of Physicists in Medicine. C1 [Zhang, Da; Padole, Atul; Li, Xinhua; Singh, Sarabjeet; Khawaja, Ranish Deedar Ali; Lira, Diego; Shi, Jim Q.; Otrakji, Alexi; Kalra, Mannudeep K.; Liu, Bob] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Liu, Tianyu; Xu, X. George] Rensselaer Polytech Inst, Nucl Engn Program, Troy, NY 12180 USA. RP Liu, B (reprint author), Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. EM bliu7@mgh.harvard.edu FU NIBIB NIH HHS [R01 EB015478, R01EB015478] NR 45 TC 4 Z9 4 U1 1 U2 3 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD SEP PY 2014 VL 41 IS 9 AR 091911 DI 10.1118/1.4893499 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AP6RJ UT WOS:000342204800026 PM 25186398 ER PT J AU Tardiff, DF Khurana, V Chung, CY Lindquist, S AF Tardiff, Daniel F. Khurana, Vikram Chung, Chee Yeun Lindquist, Susan TI From Yeast to Patient Neurons and Back Again: Powerful New Discovery Platforms SO MOVEMENT DISORDERS LA English DT Article DE alpha-synuclein; Parkinson's disease; phenotypic screen; yeast; human iPS cells; drug target identification ID FAMILIAL PARKINSONS-DISEASE; ALPHA-SYNUCLEIN TOXICITY; PLURIPOTENT STEM-CELLS; LYSOSOMAL DYSFUNCTION; MUTATIONS; ACCUMULATION; HOMEOSTASIS; MODELS; LOCUS; GENE AB No disease-modifying therapies are available for synucleinopathies, including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple systems atrophy (MSA). The lack of therapies has been impeded by a paucity of validated drug targets and problematic cell-based model systems. New approaches are therefore needed to identify genes and compounds that directly target the underlying cellular pathologies elicited by the pathological protein, alpha-synuclein (alpha-syn). This small, lipid-binding protein impinges on evolutionarily conserved processes such as vesicle trafficking and mitochondrial function. For decades, the genetically tractable, single-cell eukaryote, budding yeast, has been used to study nearly all aspects of cell biology. More recently, yeast has revealed key insights into the underlying cellular pathologies caused by alpha-syn. The robust cellular toxicity caused by alpha-syn expression facilitates unbiased high-throughput small-molecule screening. Critically, one must validate the discoveries made in yeast in disease-relevant neuronal models. Here, we describe two recent reports that together establish yeast-to-human discovery platforms for synucleinopathies. In this exemplar, genes and small molecules identified in yeast were validated in patient-derived neurons that present the same cellular phenotypes initially discovered in yeast. On validation, we returned to yeast, where unparalleled genetic approaches facilitated the elucidation of a small molecule's mode of action. This approach enabled the identification and neuronal validation of a previously unknown "druggable" node that interfaces with the underlying, precipitating pathologies caused by alpha-syn. Such platforms can provide sorely needed leads and fresh ideas for disease-modifying therapy for these devastating diseases. (C) 2014 International Parkinson and Movement Disorder Society C1 [Tardiff, Daniel F.; Khurana, Vikram; Chung, Chee Yeun; Lindquist, Susan] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA. [Khurana, Vikram] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Khurana, Vikram] Harvard Univ, Sch Med, Boston, MA USA. [Lindquist, Susan] MIT, Dept Biol, Howard Hughes Med Inst, Cambridge, MA USA. RP Lindquist, S (reprint author), 9 Cambridge Ctr, Cambridge, MA 02142 USA. EM lindquist_admin@wi.mit.edu FU National Research Service Award (NRSA) fellowship [F32NS061419]; Thome Memorial Foundation; JPB Foundation; Eleanor Schwartz Charitable Foundation; HHMI; American Brain Foundation; Parkinson's Disease Foundation; Harvard Neurodiscovery Center Pilot Project Program; NIH/NIA [K01 AG038546] FX S.L. is an investigator for HHMI. D. F. T. was funded by a National Research Service Award (NRSA) fellowship F32NS061419, the Thome Memorial Foundation, and research supported by the JPB Foundation (D. F. T. and S. L.), the Eleanor Schwartz Charitable Foundation, and an HHMI Collaborative Innovation Award (D. F. T., V. K., C.Y.C., S. L.). V. K. was funded by an American Brain Foundation and Parkinson's Disease Foundation Clinician-Scientist Development Award, and the Harvard Neurodiscovery Center Pilot Project Program. C.Y.C. was supported by funding from the NIH/NIA (K01 AG038546). NR 51 TC 11 Z9 11 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD SEP PY 2014 VL 29 IS 10 BP 1231 EP 1240 DI 10.1002/mds.25989 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA AP6CH UT WOS:000342164600030 PM 25131316 ER PT J AU Burdick, DJ Cholerton, B Watson, GS Siderowf, A Trojanowski, JQ Weintraub, D Ritz, B Rhodes, SL Rausch, R Factor, SA Wood-Siverio, C Quinn, JF Chung, KA Srivatsal, S Edwards, KL Montine, TJ Zabetian, CP Leverenz, JB AF Burdick, Daniel J. Cholerton, Brenna Watson, G. S. Siderowf, Andrew Trojanowski, John Q. Weintraub, Daniel Ritz, Beate Rhodes, Shannon L. Rausch, Renecca Factor, Stewart A. Wood-Siverio, Cathy Quinn, Joseph F. Chung, Kathryn A. Srivatsal, Sindhu Edwards, Karen L. Montine, Thomas J. Zabetian, Cyrus P. Leverenz, James B. TI People with Parkinson's Disease and Normal MMSE Score Have a Broad Range of Cognitive Performance SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; Parkinson's disease with dementia; cognition; assessment of cognitive disorders/dementia; mild cognitive impairment ID MINI-MENTAL-STATE; SOCIETY TASK-FORCE; DATA SET UDS; DIAGNOSTIC-CRITERIA; CLINICAL-DIAGNOSIS; DEMENTIA; IMPAIRMENT; MOCA; VALIDATION; PREDICTORS AB Cognitive impairment, including dementia, is common in Parkinson's disease (PD). The Mini-Mental State Examination (MMSE) has been recommended as a screening tool for Parkinson's disease dementia (PDD), with values below 26 indicative of possible dementia. Using a detailed neuropsychological battery, we examined the range of cognitive impairment in PD patients with an MMSE score of 26 or higher. In this multicenter, cross-sectional, observational study, we performed neuropsychological testing in a sample of 788 PD patients with MMSE scores of 26 or higher. Evaluation included tests of global cognition, executive function, language, memory, and visuospatial skills. A consensus panel reviewed results for 342 subjects and assigned a diagnosis of no cognitive impairment, mild cognitive impairment, or dementia. Sixty-seven percent of the 788 subjects performed 1.5 standard deviations below the normative mean on at least one test. On eight of the 15 tests, more than 20% of subjects scored 1.5 standard deviations or more below the normative mean. Greatest impairments were found on Hopkins Verbal Learning and Digit Symbol Coding tests. The sensitivity of the MMSE to detect dementia was 45% in a subset of participants who underwent clinical diagnostic procedures. A remarkably wide range of cognitive impairment can be found in PD patients with a relatively high score on the MMSE, including a level of cognitive impairment consistent with dementia. Given these findings, clinicians must be aware of the limitations of the MMSE in detecting cognitive impairment, including dementia, in PD. (C) 2014 International Parkinson and Movement Disorder Society C1 [Burdick, Daniel J.] Evergreen Hosp Med Ctr, Booth Gardner Parkinsons Care Ctr, Kirkland, WA USA. [Cholerton, Brenna; Watson, G. S.; Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Cholerton, Brenna; Watson, G. S.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Siderowf, Andrew] Avid Radiopharmaceut, Philadelphia, PA USA. [Trojanowski, John Q.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA. [Trojanowski, John Q.] Univ Penn, Inst Aging, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Ritz, Beate; Rhodes, Shannon L.] Univ Calif Los Angeles, Dept Epidemiol, Los Angeles, CA USA. [Ritz, Beate; Rausch, Renecca] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Factor, Stewart A.; Wood-Siverio, Cathy] Emory Univ, Dept Neurol, Atlanta, GA 30322 USA. [Quinn, Joseph F.; Chung, Kathryn A.] Parkinsons Dis Res Educ & Clin Ctr, Portland VA Med Ctr, Portland, OR USA. [Quinn, Joseph F.; Chung, Kathryn A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Srivatsal, Sindhu; Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. [Srivatsal, Sindhu; Zabetian, Cyrus P.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Edwards, Karen L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Leverenz, James B.] Cleveland Clin Fdn, Lou Ruvo Ctr Brain Hlth, Cleveland, OH 44195 USA. RP Leverenz, JB (reprint author), Cleveland Clin, 9500 Euclid Ave U10, Cleveland, OH 44195 USA. EM leverej@ccf.org RI Ritz, Beate/E-3043-2015; OI Zabetian, Cyrus/0000-0002-7739-4306 FU Department of Veterans Affairs; American Parkinson Disease Association; Consolidated Anti-Aging Foundation; National Institutes of Health [P50 NS062684, P50 NS053488, P50 NS038367, R01 NS065070, RO1 ES010544]; Northwest Collaborative Care; Jane and Lee Seidman Fund FX This study was supported by the Department of Veterans Affairs and grants from the American Parkinson Disease Association, Consolidated Anti-Aging Foundation, National Institutes of Health (P50 NS062684, P50 NS053488, P50 NS038367, R01 NS065070, RO1 ES010544), Northwest Collaborative Care, Jane and Lee Seidman Fund. NR 35 TC 12 Z9 12 U1 2 U2 24 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD SEP PY 2014 VL 29 IS 10 BP 1258 EP 1264 DI 10.1002/mds.25924 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA AP6CH UT WOS:000342164600036 PM 25073717 ER PT J AU Gusella, JF MacDonald, ME Lee, JM AF Gusella, James F. MacDonald, Marcy E. Lee, Jong-Min TI Genetic Modifiers of Huntington's Disease SO MOVEMENT DISORDERS LA English DT Review DE Huntington's disease; huntingtin; HTT; genetic association; genetic modifier ID AGE-OF-ONSET; TRINUCLEOTIDE REPEAT LENGTH; KNOCK-IN MICE; EXPANDED CAG REPEAT; VENEZUELAN KINDREDS; MODIFYING AGE; PREDICT-HD; PROGRESSION; PGC-1-ALPHA; EXPANSION AB Huntington's disease (HD) is a devastating neurodegenerative disorder that directly affects more than 1 in 10,000 persons in Western societies but, as a family disorder with a long, costly, debilitating course, it has an indirect impact on a far greater proportion of the population. Although some palliative treatments are used, no effective treatment exists for preventing clinical onset of the disorder or for delaying its inevitable progression toward premature death, approximately 15 years after diagnosis. Huntington's disease involves a movement disorder characterized by chorea, as well as a variety of psychiatric disturbances and intellectual decline, with a gradual loss of independence. A dire need exists for effective HD therapies to alleviate the suffering and costs to the individual, family, and health care system. In past decades, genetics, the study of DNA sequence variation and its consequences, provided the tools to map the HD gene to chromosome 4 and ultimately to identify its mutation as an expanded CAG trinucleotide repeat in the coding sequence of a large protein, dubbed huntingtin. Now, advances in genetic technology offer an unbiased route to the identification of genetic factors that are disease-modifying agents in human patients. Such genetic modifiers are expected to highlight processes capable of altering the course of HD and therefore to provide new, human-validated targets for traditional drug development, with the goal of developing rational treatments to delay or prevent onset of HD clinical signs. (C) 2014 International Parkinson and Movement Disorder Society C1 [Gusella, James F.] Massachusetts Gen Hosp, Mol Neurogenet Unit, Dept Neurol, Boston, MA 02114 USA. [Gusella, James F.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. RP Gusella, JF (reprint author), Massachusetts Gen Hosp, Mol Neurogenet Unit, Dept Neurol, Boston, MA 02114 USA. EM gusella@helix.mgh.harvard.edu NR 60 TC 12 Z9 12 U1 4 U2 32 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD SEP PY 2014 VL 29 IS 11 SI SI BP 1359 EP 1365 DI 10.1002/mds.26001 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA AP6CJ UT WOS:000342164800005 PM 25154728 ER PT J AU Aronin, N DiFiglia, M AF Aronin, Neil DiFiglia, Marian TI Huntingtin-Lowering Strategies in Huntington's Disease: Antisense Oligonucleotides, Small RNAs, and Gene Editing SO MOVEMENT DISORDERS LA English DT Review DE Huntington's disease; huntingtin; gene regulation; clinical trial ID CONVECTION-ENHANCED DELIVERY; CENTRAL-NERVOUS-SYSTEM; CAG REPEAT EXPANSION; MUTANT HUNTINGTIN; TRINUCLEOTIDE REPEAT; ENZYME COMPLEX; MOUSE MODEL; EXPRESSION; BRAIN; MICE AB The idea to lower mutant huntingtin is especially appealing in Huntington's disease (HD). It is autosomal dominant, so that expression of the mutant allele causes the disease. Advances in RNA and gene regulation provide foundations for the huntingtin gene (both normal and mutant alleles) and possibly the mutant allele only. There is much preclinical animal work to support the concept of gene and RNA silencing, but, to date, no clinical studies have been attempted in HD. Preventing expression of mutant huntingtin protein is at the cusp for a human trial. Antisense oligonucleotides delivered to patients with amyotrophic lateral sclerosis have been well tolerated; small RNAs administered to rodent and nonhuman primate brain knocked down huntingtin messenger RNA (mRNA); short-hairpin complementary DNA of microRNAs can be expressed in adeno-associated virus to provide long-term silencing of huntingtin mRNA and protein. We expect that these approaches will be ready for clinical studies in the near future, once safety has been validated. Our understanding of gene editing-changing the huntingtin gene itself-is rapidly progressing. Harnessing our knowledge of transcription and translation should push scientific creativity to new and exciting advances that overcome the lethality of the mutant gene in HD. (C) 2014 International Parkinson and Movement Disorder Society C1 [Aronin, Neil] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01655 USA. [Aronin, Neil] Univ Massachusetts, Sch Med, RNA Therapeut Inst, Worcester, MA 01655 USA. [DiFiglia, Marian] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA USA. RP Aronin, N (reprint author), Univ Massachusetts, Sch Med, Dept Med, 55 Lake Ave North, Worcester, MA 01655 USA. EM Neil.Aronin@umassmed.edu NR 50 TC 16 Z9 16 U1 2 U2 21 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD SEP PY 2014 VL 29 IS 11 SI SI BP 1455 EP 1461 DI 10.1002/mds.26020 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA AP6CJ UT WOS:000342164800016 PM 25164989 ER PT J AU Chahine, LM Weintraub, D Hawkins, KA Siderowf, A Eberly, S Oakes, D Seibyl, J Stern, MB Marek, K Jennings, D AF Chahine, L. M. Weintraub, D. Hawkins, K. A. Siderowf, A. Eberly, S. Oakes, D. Seibyl, J. Stern, M. B. Marek, K. Jennings, D. CA PARS Investigators TI Cognitive Impairment as a Feature of Prodromal Parkinson's Disease: Evidence from the PARS Study. SO MOVEMENT DISORDERS LA English DT Meeting Abstract CT 28th Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson Disease and Other Movement Disorders CY SEP 19, 2014 CL St Louis, MO C1 [Chahine, L. M.; Weintraub, D.; Stern, M. B.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, D.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, D.] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. [Hawkins, K. A.] Yale Univ, Dept Psychol, New Haven, CT 06520 USA. [Siderowf, A.] Avid Radiopharmaceut, Philadelphia, PA USA. [Eberly, S.; Oakes, D.] Univ Rochester, Sch Med, Dept Biostat, Rochester, NY USA. [Seibyl, J.; Marek, K.; Jennings, D.] Inst Neurodegenerat Disorders, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD SEP PY 2014 VL 29 IS 10 BP E7 EP E7 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA AP6CH UT WOS:000342164600018 ER PT J AU Smith, K Eyal, E Weintraub, D AF Smith, K. Eyal, E. Weintraub, D. CA ADAGIO Investigators TI Combined Rasagiline and Antidepressant Use in Parkinson's Disease in the ADAGIO Study: Effects on Non-motor Symptoms and Tolerability. SO MOVEMENT DISORDERS LA English DT Meeting Abstract CT 28th Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson Disease and Other Movement Disorders CY SEP 19, 2014 CL St Louis, MO C1 [Smith, K.; Weintraub, D.] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Eyal, E.] Teva Pharmaceut Ind, Petah Tiqwa, Israel. [Weintraub, D.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, D.] Philadelphia VA Med Ctr, Dept Vet Affairs, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD SEP PY 2014 VL 29 IS 10 BP E3 EP E4 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA AP6CH UT WOS:000342164600008 ER PT J AU Umeh, CC Liao, Z Dhima, K Franco, D Duong, K Boot, B Bayer, S Trisini-Lipsanopoulos, A Hyman, BT Dickerson, B Growdon, J Sudarsky, L Sperling, R Ivinson, A Scherzer, C AF Umeh, C. C. Liao, Z. Dhima, K. Franco, D. Duong, K. Boot, B. Bayer, S. Trisini-Lipsanopoulos, A. Hyman, B. T. Dickerson, B. Growdon, J. Sudarsky, L. Sperling, R. Ivinson, A. Scherzer, C. TI Metabolomic Biomarkers in Early Parkinson's Disease. SO MOVEMENT DISORDERS LA English DT Meeting Abstract CT 28th Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson Disease and Other Movement Disorders CY SEP 19, 2014 CL St Louis, MO C1 [Umeh, C. C.; Liao, Z.; Dhima, K.; Franco, D.; Duong, K.; Boot, B.; Trisini-Lipsanopoulos, A.; Sudarsky, L.; Scherzer, C.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Bayer, S.; Dickerson, B.; Growdon, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hyman, B. T.] Massachusetts Alzheimers Dis Res Ctr, Boston, MA USA. [Sperling, R.] Brigham & Womens Hosp, Ctr Alzheimers Res & Treatment, Boston, MA 02115 USA. [Ivinson, A.] Harvard NeuroDiscovery Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD SEP PY 2014 VL 29 IS 10 BP E7 EP E7 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA AP6CH UT WOS:000342164600019 ER PT J AU Glass, LRD Canoll, P Lignelli, A Ligon, AH Kazim, M AF Glass, Lora R. Dagi Canoll, Peter Lignelli, Angela Ligon, Azra H. Kazim, Michael TI Optic Nerve Glioma: Case Series With Review of Clinical, Radiologic, Molecular, and Histopathologic Characteristics SO OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article ID ANTERIOR VISUAL PATHWAY; PILOCYTIC ASTROCYTOMAS; TUMOR; BRAF; ACTIVATION; MIB-1; MRI; P53 AB Purpose: This study was designed to better understand the biologic nature of optic nerve gliomas (ONGs) and to investigate staining techniques that might improve the pathologic interpretation of surgical margins. Methods: In this retrospective case series, clinical data on patient presentation, MRI, surgical visualization, and initial pathologic interpretation were gathered. Specimens were then reexamined using analysis of p53, isocitrate dehydrogenase 1 (IDH1), MIB-1, and B-rapidly accelerated fibrosarcoma (BRAF) duplication. Results: Six patients were studied. All were diagnosed with World Health Organization grade 1 ONGs on original pathology. On reexamination, BRAF tandem duplication was found in 2 patients with neurofibromatosis Type 1 association. P53 immunoreactivity was noted in a third case. No cases had IDH1 immunoreactivity. Focal elevations of MIB-1 up to 7.5% were noted in 2 cases. Conclusions: ONGs are neoplasms with variable degrees of aggressiveness. As more is understood regarding their varied genetic underpinnings, improved pathologic classification and individualized treatment regimens may be achieved. The authors hope that this study helps guide the oculoplastic community toward a multi-institutional, prospective study of ONG genomic sequencing. C1 [Glass, Lora R. Dagi; Kazim, Michael] Columbia Univ, Dept Ophthalmol, Med Ctr, New York Presbyterian Hosp, New York, NY 10027 USA. [Canoll, Peter] Columbia Univ, Dept Neuropathol, Med Ctr, New York Presbyterian Hosp, New York, NY USA. [Lignelli, Angela] Columbia Univ, Dept Neuroradiol, Med Ctr, New York Presbyterian Hosp, New York, NY USA. [Ligon, Azra H.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Ligon, Azra H.] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02115 USA. [Ligon, Azra H.] Harvard Univ, Sch Med, Boston, MA USA. RP Glass, LRD (reprint author), Edward S Harkness Eye Inst, 635 West 165th St, New York, NY 10032 USA. EM loradglass@gmail.com FU Orbital Disease Education and Research Foundation FX Supported by Orbital Disease Education and Research Foundation. NR 22 TC 3 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0740-9303 EI 1537-2677 J9 OPHTHAL PLAST RECONS JI Ophthalmic Plast. Reconstr. Surg. PD SEP-OCT PY 2014 VL 30 IS 5 BP 372 EP 376 DI 10.1097/IOP.0000000000000106 PG 5 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA AP3BV UT WOS:000341950900016 PM 24762952 ER PT J AU Ghafouri, RH Allard, FD Migliori, ME Freitag, SK AF Ghafouri, Roya H. Allard, Felicia D. Migliori, Michael E. Freitag, Suzanne K. TI Lower Eyelid Involutional Ectropion Repair With Lateral Tarsal Strip and Internal Retractor Reattachment With Full-Thickness Eyelid Sutures SO OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article ID DETACHMENT AB Purpose: To report a novel surgical technique for lower eyelid involutional ectropion repair using a lateral tarsal strip and internal retractor reattachment procedure involving full-thickness eyelid sutures. Methods: A retrospective review was performed of patients who underwent repair of involutional ectropion via lateral tarsal strip and internal retractor reattachment with full-thickness eyelid sutures by 1 surgeon. Patients having concomitant or previous eyelid surgical procedures were excluded. Collected data included patient demographics, surgical outcomes, and length of follow up. Results: Forty-one lower eyelids of 31 patients with involutional ectropion underwent surgical repair. There were 17 men and 14 women in the age range of 69 to 92 years (mean age 82.2 +/- 5.9 years). Surgical sites included 22 right and 19 left lower eyelids. Follow up ranged from 1 to 48 months with an average of 5.9 months. Surgical success with anatomical correction of involutional ectropion was achieved in 39 of 41 eyelids (95.1%). There were no perioperative or postoperative complications. Two of 41 (4.9%) eyelids had recurrence of ectropion 7 and 18 months after the procedure. Conclusions: This procedure combining lateral tarsal strip with internal retractor reattachment involving full-thickness eyelid sutures effectively addresses horizontal eyelid laxity and tarsal instability, providing an effective technique to correct involutional ectropion of the lower eyelid. C1 [Allard, Felicia D.] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA. [Migliori, Michael E.] Brown Univ, Warren Alpert Med Sch, Div Ophthalmol, Providence, RI 02912 USA. [Freitag, Suzanne K.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA. RP Freitag, SK (reprint author), Massachusetts Eye & Ear Infirm, Ophthalm Plast Surg Serv, 243 Charles St, Boston, MA 02114 USA. EM eyelid@meei.harvard.edu NR 9 TC 3 Z9 3 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0740-9303 EI 1537-2677 J9 OPHTHAL PLAST RECONS JI Ophthalmic Plast. Reconstr. Surg. PD SEP-OCT PY 2014 VL 30 IS 5 BP 424 EP 426 DI 10.1097/IOP.0000000000000218 PG 3 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA AP3BV UT WOS:000341950900028 PM 25025386 ER PT J AU Christman, MP Kerner, JK Cheng, C Piris, A Nepo, AG Sepehr, A Kroshinsky, D AF Christman, Mitalee P. Kerner, Jennifer K. Cheng, Carol Piris, Adriano Nepo, Anne G. Sepehr, Alireza Kroshinsky, Daniela TI Rhabdomyosarcoma Arising in a Giant Congenital Melanocytic Nevus SO PEDIATRIC DERMATOLOGY LA English DT Article ID NEUROCUTANEOUS MELANOSIS AB A number of lesions have been documented to arise within congenital melanocytic nevi (CMNs). Although the most frequent malignancy arising within a CMN is melanoma, the association between rhabdomyosarcoma and CMN has rarely been documented. We present a case arising in a 4-month-old girl with a giant CMN. She presented for evaluation of a pedunculated lesion at the superior gluteal crease that had been present since birth and exhibited rapid growth. Biopsy of the lesion revealed two distinct components: an expansile proliferation of pleomorphic cells with varying degrees of cellularity and a proliferation of banal-appearing melanocytic nevic cells. The cells of the expansile proliferation displayed a wide range of morphologic features, including nests of round cells, spindle-shaped cells, and more differentiated rhabdomyoblasts within a myxoid, highly vascularized stroma. Cross-striations, a marker of skeletal muscle differentiation, were present. These tumor cells were strongly immunoreactive with desmin, myo-D1, and myogenin. Fluorescence in situ hybridization analysis with PAX3/7-FKHR probes was negative. A diagnosis of embryonal rhabdomyosarcoma in association with CMN was made. Initial excision revealed tumor at the margins, and the patient underwent reexcision with subsequent chemotherapy with vincristine, actinomycin D, and cyclophosphamide. She was disease-free at the 6-year follow-up. It has been postulated that the combination of melanocytic and rhabdomyoblastic cells within the same lesion may imply derivation from a common pluripotent stem cell or neural crest cell. Clinicians following patients with giant CMN should consider rhabdomyosarcoma in the differential diagnosis of lesions arising within the nevus. C1 [Christman, Mitalee P.; Kerner, Jennifer K.; Sepehr, Alireza] Harvard Univ, Sch Med, Boston, MA USA. [Kerner, Jennifer K.; Sepehr, Alireza] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA. [Cheng, Carol; Kroshinsky, Daniela] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. [Piris, Adriano; Nepo, Anne G.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Piris, Adriano; Nepo, Anne G.] Albany Med Ctr, Dept Pediat, Albany, NY USA. RP Kroshinsky, D (reprint author), Massachusetts Gen Hosp, 50 Staniford St,200, Boston, MA 02114 USA. EM dkroshinsky@partners.org NR 14 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0736-8046 EI 1525-1470 J9 PEDIATR DERMATOL JI Pediatr. Dermatol. PD SEP-OCT PY 2014 VL 31 IS 5 BP 584 EP 587 DI 10.1111/pde.12359 PG 4 WC Dermatology; Pediatrics SC Dermatology; Pediatrics GA AP1FE UT WOS:000341811700009 PM 24913904 ER PT J AU Malhotra, Y Yang, CS McNamara, J Antaya, RJ AF Malhotra, Yogangi Yang, Catherine S. McNamara, Joseph Antaya, Richard J. TI Congenital Kaposiform Hemangioendothelioma with Kasabach-Merritt Phenomenon Successfully Treated with Low-Dose Radiation Therapy SO PEDIATRIC DERMATOLOGY LA English DT Article ID HEMANGIOMA AB Kaposiform hemangioendothelioma (KHE) associated with Kasabach-Merritt phenomenon is a life-threatening vasculopathy. The current mainstay treatment for KHEs is corticosteroids and chemotherapy, but these medications do not work for all patients and carry significant side effects. We report a neonate with a large congenital KHE who responded extremely well to low-dose radiation therapy. C1 [Malhotra, Yogangi] Yale Univ, Div Neonatol, New Haven, CT USA. [Yang, Catherine S.] Yale Univ, Sch Med, New Haven, CT USA. [McNamara, Joseph; Antaya, Richard J.] Yale Univ, Dept Pediat, New Haven, CT 06520 USA. [Antaya, Richard J.] Yale Univ, Dept Dermatol, New Haven, CT 06520 USA. [Malhotra, Yogangi] New York Med Coll, Div Neonatol, Maria Fareri Childrens Hosp, Westchester, NY USA. [Yang, Catherine S.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA. RP Malhotra, Y (reprint author), New York Med Coll, Div Neonatol, Valhalla, NY 10595 USA. EM yogimed@gmail.com NR 7 TC 7 Z9 7 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0736-8046 EI 1525-1470 J9 PEDIATR DERMATOL JI Pediatr. Dermatol. PD SEP-OCT PY 2014 VL 31 IS 5 BP 595 EP 598 DI 10.1111/pde.12090 PG 4 WC Dermatology; Pediatrics SC Dermatology; Pediatrics GA AP1FE UT WOS:000341811700012 PM 23458157 ER PT J AU Smart, CE Annan, F Bruno, LPC Higgins, LA Acerini, CL AF Smart, Carmel E. Annan, Francesca Bruno, Luciana P. C. Higgins, Laurie A. Acerini, Carlo L. TI Nutritional management in children and adolescents with diabetes SO PEDIATRIC DIABETES LA English DT Article DE consensus; diabetes; guidelines; nutrition ID INTENSIVE INSULIN THERAPY; POSTPRANDIAL GLUCOSE EXCURSIONS; DIAGNOSED CELIAC-DISEASE; GLYCEMIC INDEX DIETS; GLUTEN-FREE DIET; EATING-DISORDERS; CARDIOVASCULAR RISK; PUMP THERAPY; CARBOHYDRATE CONTENT; COMPLICATIONS TRIAL C1 [Smart, Carmel E.] John Hunter Childrens Hosp, Dept Endocrinol, Newcastle, NSW, Australia. [Annan, Francesca] Alder Hey Childrens NHS Fdn Trust, Dept Nutr & Dietet, Liverpool, Merseyside, England. [Bruno, Luciana P. C.] Univ Fed Sao Paulo, Dept Endocrinol, Sao Paulo, Brazil. [Higgins, Laurie A.] Joslin Diabet Ctr, Pediat Adolescent & Young Adult Sect, Boston, MA 02215 USA. [Acerini, Carlo L.] Univ Cambridge, Dept Paediat, Cambridge, England. RP Smart, CE (reprint author), John Hunter Childrens Hosp, Dept Endocrinol, Lookout Rd New Lambton Hts, Newcastle, NSW, Australia. EM carmel.smart@hnehealth.nsw.gov.au OI Acerini, Carlo/0000-0003-2121-5871 NR 155 TC 14 Z9 15 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1399-543X EI 1399-5448 J9 PEDIATR DIABETES JI Pediatr. Diabetes PD SEP PY 2014 VL 15 SU 20 BP 135 EP 153 DI 10.1111/pedi.12175 PG 19 WC Endocrinology & Metabolism; Pediatrics SC Endocrinology & Metabolism; Pediatrics GA AO9YN UT WOS:000341716900011 PM 25182313 ER PT J AU Brink, S Joel, D Laffel, L Lee, WWR Olsen, B Phelan, H Hanas, R AF Brink, Stuart Joel, Dipesalema Laffel, Lori Lee, Warren Wei Rhen Olsen, Birthe Phelan, Helen Hanas, Ragnar TI Sick day management in children and adolescents with diabetes SO PEDIATRIC DIABETES LA English DT Article DE DKA prevention; hydroxybutyric acid; ketones; pediatric; sick days ID RANDOMIZED CLINICAL-TRIAL; REDUCES HOSPITAL VISITS; DOSE GLUCAGON RESCUE; KETOACIDOSIS; PREVENTION; TYPE-1; HYPOGLYCEMIA; MELLITUS; T1DM C1 [Brink, Stuart] New England Diabet & Endocrinol Ctr NEDEC, Waltham, MA 02451 USA. [Hanas, Ragnar] Univ Gothenburg, NU Hosp Grp Uddevalla, Dept Pediat, Gothenburg, Sweden. [Hanas, Ragnar] Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Gothenburg, Sweden. [Joel, Dipesalema] Princess Marina Hosp, Botswana Baylor Childrens Clin Ctr Excellence, Gaborone, Botswana. [Laffel, Lori] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. [Lee, Warren Wei Rhen] Growth & Diabet Ctr, Singapore, Singapore. [Olsen, Birthe] Glostrup Univ Hosp, Dept Pediat, Copenhagen, Denmark. [Phelan, Helen] John Hunter Childrens Hosp, Newcastle, NSW, Australia. RP Brink, S (reprint author), New England Diabet & Endocrinol Ctr NEDEC, 40 Second Ave,Suite 170, Waltham, MA 02451 USA. EM stuartbrink@gmail.com FU Medtronic; NovoNordisk; Sanofi; ESPE; Abbott Diabetes Care; NIH; Helmsley Trust; Omnipod; Lilly; Johnson and Johnson; Bayer Roche; Menarini; Boehringer Ingelheim; sanofi-aventis; DexCom; CDiC; Life for a Child; Minimed Medtronics; LifeScan; Genentech; Serono; Teva Pharmaceuticals; Eli Lilly; SelfCare; Inverness Medical; Medical Foods; Abbott-Medisense; LifeScan/Johnson and Johnson; Pharmacia; Bristol-Squibb Myers; Pfizer; Becton-Dickenson FX B. O.: advisory boards for NovoNordisk and Medtronic speaker's fees, honoraria and research grants from Medtronic, NovoNordisk, and Sanofi. D. J.: funding from ESPE. H. P. consultant for Sanofi. L. L.: funding from Abbott Diabetes Care, honoraria, grants and/or advisor or consultant for research from the NIH, Helmsley Trust, Medtronic, Omnipod, Lilly, NovoNordisk, Johnson and Johnson, Bayer Roche, Menarini, Boehringer Ingelheim, sanofi-aventis and DexCom. S. J. B.: honoraria or speaker's fees from Eli Lilly, Novo-Nordisk, CDiC, Life for a Child, Minimed Medtronics, LifeScan, Genentech, Serono, Teva Pharmaceuticals; and has received research grants from Eli Lilly, Novo-Nordisk, NIH, SelfCare, Inverness Medical, Medical Foods, Abbott-Medisense, LifeScan/Johnson and Johnson, Genentech, Pharmacia, Bristol-Squibb Myers, Pfizer, Becton-Dickenson and Serono. He is the owner of the New England Diabetes and Endocrinology Center (NEDEC) and President of New England Diabetes and Endocrinology Research Fund, Incorporated (NEDERF, Inc.). R. H.: speaker's honoraria and/or advisory board for NovoNordisk, Lilly, Sanofi, Medtronic, Roche, Menarini, Abbott and Unomedical. W. W. R. L.: speakers honoraria and/or advisory boards for Lilly, NovoNordisk, Sanofi, Medtronic, Abbott. NR 29 TC 2 Z9 2 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1399-543X EI 1399-5448 J9 PEDIATR DIABETES JI Pediatr. Diabetes PD SEP PY 2014 VL 15 SU 20 BP 193 EP 202 DI 10.1111/pedi.12193 PG 10 WC Endocrinology & Metabolism; Pediatrics SC Endocrinology & Metabolism; Pediatrics GA AO9YN UT WOS:000341716900014 PM 25182314 ER PT J AU Lopez, ND Phillips, KM AF Lopez, Natasha D. Phillips, Kristy M. TI Fluconazole Pharmacokinetics in a Morbidly Obese, Critically Ill Patient Receiving Continuous Venovenous Hemofiltration SO PHARMACOTHERAPY LA English DT Article DE fluconazole; pharmacokinetics; obesity; CVVH; hemofiltration; drug monitoring; critical care; lean body weight ID ACUTE-RENAL-FAILURE; ANTIFUNGAL AGENTS; PHARMACODYNAMICS; HEMODIAFILTRATION; CANDIDIASIS; CANDIDEMIA; ASSOCIATION; MORTALITY; THERAPY; HUMANS AB Current fluconazole dosing strategies can be described using either standardized doses (800 or 400mg) or as weight-based dosing recommendations (12 mg/kg loading dose followed by 6 mg/kg maintenance dose). The ideal method of fluconazole dosing is still unclear for certain patient populations, such as those receiving renal replacement therapy or the morbidly obese. We describe a 48-year-old man with a body mass index of 84kg/m(2) who was receiving continuous venovenous hemofiltration (CVVH) and was treated with fluconazole by using a weight-based dose determined by lean body weight, infused at a rate of 200mg/hour. Blood samples were collected at hour 0 (i.e., similar to 24hrs after the loading dose was administered) and at 3.5, 6.8, and 11.3hours after the start of the 600-mg maintenance dose, infused over 3hours. Pharmacokinetic parameters calculated were maximum serum concentration 9.64mg/L, minimum serum concentration 5.98mg/L, area under the serum concentration-time curve from 0-24hours (AUC(0-24)) 184.75mg/L center dot hour, elimination rate constant 0.0199hour(-1), elimination half-life 34.8hours, and total body clearance 3.25L/hour. Our data, when combined with previously published literature, do not support using a linear dose-to-AUC approximation to estimate drug dosing needs in the critically ill patient population receiving CVVH. In addition, our results suggest that morbidly obese patients are able to achieve pharmacodynamic goals defined as an AUC:MIC ratio higher than 25 by using a lean body weight for fluconazole dosing calculations. C1 [Lopez, Natasha D.; Phillips, Kristy M.] Massachusetts Gen Hosp, Dept Pharm, Boston, MA 02114 USA. RP Phillips, KM (reprint author), Massachusetts Gen Hosp, Med Intens Care Unit, 55 Fruit St,GRB 005, Boston, MA 02114 USA. EM kmphillips@partners.org NR 28 TC 1 Z9 2 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-0008 EI 1875-9114 J9 PHARMACOTHERAPY JI Pharmacotherapy PD SEP PY 2014 VL 34 IS 9 BP A162 EP A168 DI 10.1002/phar.1470 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA AO9YI UT WOS:000341716300001 ER PT J AU Wang, JH AF Wang, Jia-huai TI The immunology connection-my first T cell receptor structure projects SO PROTEIN & CELL LA English DT Bibliography C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Wang, JH (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM jwang@red.dfci.harvard.edu NR 0 TC 0 Z9 0 U1 1 U2 3 PU HIGHER EDUCATION PRESS PI BEIJING PA SHATANHOU ST 55, BEIJING 100009, PEOPLES R CHINA SN 1674-800X EI 1674-8018 J9 PROTEIN CELL JI Protein Cell PD SEP PY 2014 VL 5 IS 9 BP 649 EP 652 DI 10.1007/s13238-014-0091-7 PG 4 WC Cell Biology SC Cell Biology GA AP5MN UT WOS:000342123400001 PM 25087847 ER PT J AU Fang, A Matheny, NL Wilhelm, S AF Fang, Angela Matheny, Natalie L. Wilhelm, Sabine TI Body Dysmorphic Disorder SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Article DE Body dysmorphic disorder; Obsessive-compulsive spectrum; Treatment; Cognitive-behavioral therapy; Serotonin reuptake inhibitor ID OBSESSIVE-COMPULSIVE DISORDER; COGNITIVE-BEHAVIORAL THERAPY; POPULATION-BASED SURVEY; CLINICAL-FEATURES; EATING-DISORDERS; CONTROLLED-TRIAL; 200 INDIVIDUALS; SOCIAL ANXIETY; OPEN-LABEL; FOLLOW-UP AB Body dysmorphic disorder (BDD) can be a severe and often debilitating psychiatric disorder that has been largely under-recognized and under-diagnosed. Pharmacologic and nonpharmacologic treatment options are available but limited. This review aims to provide an updated overview of the psychopathology and epidemiology of BDD, with an emphasis on current pharmacologic and nonpharmacologic treatment options for BDD. C1 [Fang, Angela; Matheny, Natalie L.; Wilhelm, Sabine] Harvard Univ, Massachusetts Gen Hosp, Sch Med, OCD & Related Disorders Program,Dept Psychiat, Boston, MA 02114 USA. RP Wilhelm, S (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, OCD & Related Disorders Program,Dept Psychiat, 185 Cambridge St,2nd Floor, Boston, MA 02114 USA. EM wilhelm@psych.mgh.harvard.edu FU NIMH NIH HHS [5 R01 MH093402-03, 5R01 MH091078-03] NR 91 TC 2 Z9 2 U1 2 U2 17 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0193-953X EI 1558-3147 J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD SEP PY 2014 VL 37 IS 3 BP 287 EP + DI 10.1016/j.psc.2014.05.003 PG 15 WC Psychiatry SC Psychiatry GA AP5LT UT WOS:000342121400004 PM 25150563 ER PT J AU Browne, HA Gair, SL Scharf, JM Grice, DE AF Browne, Heidi A. Gair, Shannon L. Scharf, Jeremiah M. Grice, Dorothy E. TI Genetics of Obsessive-Compulsive Disorder and Related Disorders SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Article DE OCD; Genetics; Heritability; Twin study; Familial recurrence; GWAS; Candidate gene; Model system ID GENOME-WIDE ASSOCIATION; COPY NUMBER VARIANTS; LA-TOURETTES-SYNDROME; SPECTRUM DISORDERS; COMMON VARIANTS; ENVIRONMENTAL-INFLUENCES; SLITRK1 VAR321; RISK-FACTORS; FAMILY; TWIN AB Twin and family studies support a significant genetic contribution to obsessive-compulsive disorder (OCD) and related disorders, such as chronic tic disorders, trichotillomania, skin-picking disorder, body dysmorphic disorder, and hoarding disorder. Recently, population-based studies and novel laboratory-based methods have confirmed substantial heritability in OCD. Genome-wide association studies and candidate gene association studies have provided information on specific gene variations that may be involved in the pathobiology of OCD, though a substantial portion of the genetic risk architecture remains unknown. C1 [Browne, Heidi A.; Gair, Shannon L.; Grice, Dorothy E.] Icahn Sch Med Mt Sinai, Dept Psychiat, Div Tics OCD & Related Disorders, OCD & Related Disorders Program, New York, NY 10029 USA. [Browne, Heidi A.; Grice, Dorothy E.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA. [Scharf, Jeremiah M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Movement Disorders Unit,Dept Neurol, Boston, MA 02114 USA. [Scharf, Jeremiah M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Psychiat & Neurodev Genet Unit,Dept Psychiat, Boston, MA 02114 USA. RP Scharf, JM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Movement Disorders Unit,Dept Neurol, 185 Cambridge St,6254, Boston, MA 02114 USA. EM jscharf@partners.org; dorothy.grice@mssm.edu FU NIMH NIH HHS [R01 MH092516]; NINDS NIH HHS [K02 NS085048, U01 NS40024] NR 94 TC 5 Z9 5 U1 5 U2 40 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0193-953X EI 1558-3147 J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD SEP PY 2014 VL 37 IS 3 BP 319 EP + DI 10.1016/j.psc.2014.06.002 PG 18 WC Psychiatry SC Psychiatry GA AP5LT UT WOS:000342121400006 PM 25150565 ER PT J AU Garfin, DR Silver, RC Gil-Rivas, V Guzman, J Murphy, JM Cova, F Rincon, PP Squicciarini, AM George, M Guzman, MP AF Garfin, Dana Rose Silver, Roxane Cohen Gil-Rivas, Virginia Guzman, Javier Murphy, J. Michael Cova, Felix Paz Rincon, Paulina Maria Squicciarini, Ana George, Myriam Paz Guzman, Maria TI Children's Reactions to the 2010 Chilean Earthquake: The Role of Trauma Exposure, Family Context, and School-Based Mental Health Programming SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY LA English DT Article DE children; earthquake; natural disaster; posttraumatic stress; school intervention ID POSTTRAUMATIC-STRESS; PSYCHOLOGICAL RESPONSES; HURRICANE-ANDREW; NATURAL DISASTER; SEPTEMBER 11; INTERVENTION; SYMPTOMS; PSYCHOPATHOLOGY; GENDER; PTSD AB Theoretically derived factors (preexisting child characteristics, trauma exposure, caregiver-child relationship, and school-based mental health programming) were examined as potential correlates of distress in children residing in the region closest to the epicenter of the 2010 Chilean earthquake. One year before the earthquake, 2nd-grade students who attended 9 schools that provide government-run mental health intervention programs were assessed via parent and teacher reports for pre-intervention psychosocial difficulties. Between 3-6 months after the earthquake, a preexisting non-trauma focused, school-based intervention was delivered. Approximately 9 months post-earthquake, 117 of these children (randomly selected; mean age = 7.59), were interviewed about their experiences during the earthquake and their subsequent psychological responses. Children were exposed to multiple disaster-related traumatic events (M = 4.90; SD = 1.78); most reported posttraumatic stress (PTS) symptoms and 25.6% met criteria for the Diagnostic and Statistical Manual of Mental Disorders-defined (DSM-IV-TR; APA, 2000) probable PTSD. Female gender and exposure to violent, injurious, or death-related postdisaster traumas were correlated with PTS symptoms. Children's reports of characteristics of the home environment (conflict with their caregiver, caregiver unavailability to discuss the earthquake) were positively associated with PTS symptoms. Children's perceptions of caregiver unavailability to discuss the earthquake were associated with higher ongoing earthquake-related worry. Participation in the mental health intervention was associated with significantly lower earthquake-related worry and appeared to protect at-risk youth from elevated PTS symptomatology. Results suggest that participation in school-based mental health programs may be protective for children postdisaster and a negative family environment may be associated with increased postdisaster distress. Implications and potential applications of findings are discussed. C1 [Garfin, Dana Rose; Silver, Roxane Cohen] Univ Calif Irvine, Dept Psychol & Social Behav, Irvine, CA 92697 USA. [Gil-Rivas, Virginia] Univ N Carolina, Charlotte, NC 28223 USA. [Guzman, Javier; Maria Squicciarini, Ana] Junta Nacl Auxilio Escolar & Becas, Santiago, Chile. [Guzman, Javier] Univ Desarrollo, Metropolitana, Chile. [Murphy, J. Michael] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Cova, Felix; Paz Rincon, Paulina] Univ Concepcion, Biobio, Chile. [George, Myriam] Univ Chile, Santiago, Chile. [Paz Guzman, Maria] Fdn Amer Solidaria, Santiago, Chile. RP Silver, RC (reprint author), Univ Calif Irvine, Dept Psychol & Social Behav, 4201 Social & Behav Sci Gateway, Irvine, CA 92697 USA. EM rsilver@uci.edu RI Guzman, Javier /E-8170-2016 OI Guzman, Javier /0000-0002-8194-039X NR 62 TC 4 Z9 4 U1 4 U2 19 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1942-9681 EI 1942-969X J9 PSYCHOL TRAUMA-US JI Psychol. Trauma PD SEP PY 2014 VL 6 IS 5 BP 563 EP 573 DI 10.1037/a0036584 PG 11 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AP1SE UT WOS:000341850700014 ER PT J AU Gerstenblith, TA Stern, TA AF Gerstenblith, Ted Avi Stern, Theodore A. TI Lyme Disease: A Review of Its Epidemiology, Evaluation, and Treatment SO PSYCHOSOMATICS LA English DT Review ID ERYTHEMA CHRONICUM MIGRANS; PSYCHOLOGICAL-FACTORS; DIAGNOSIS; ARTHRITIS; TRIALS AB Background: Lyme disease, a tick-borne illness transmitted to humans, has become increasingly recognized. Objective: Given the myriad neuro vegetative and neuropsychiatric symptoms that can be associated with Lyme disease, we sought to review the epidemiology, evaluation, and treatment of the disorder. Methods: A case vignette that highlights manifestations of the condition and dilemmas associated with its treatment is presented. Conclusions: Knowledge about its symptoms, its abnormal laboratory tests, and its course can help to guide the timely and appropriate management of this spirochetal infection. C1 [Stern, Theodore A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Avery D Weisman Psychiat Consultat Serv, Boston, MA 02114 USA. RP Stern, TA (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Warren Bldg,Room 605, Boston, MA 02114 USA. EM TStern@Partners.org NR 34 TC 4 Z9 4 U1 4 U2 24 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0033-3182 J9 PSYCHOSOMATICS JI Psychosomatics PD SEP-OCT PY 2014 VL 55 IS 5 BP 421 EP 429 PG 9 WC Psychiatry; Psychology SC Psychiatry; Psychology GA AP3PD UT WOS:000341988300001 PM 25016354 ER PT J AU Heffernan, SP Stern, TA AF Heffernan, Sean P. Stern, Theodore A. TI Characteristics and Trends in Peer-Reviewed Publications in the Field of Psychosomatic Medicine SO PSYCHOSOMATICS LA English DT Article ID MEDICALLY UNEXPLAINED SYMPTOMS; DEPRESSION; DELIRIUM; CARE; CONSULTATION; HEALTH; ILL AB Background: The field of psychosomatic medicine/consultation-liaison psychiatry, now a subspecialty in psychiatry, has focused its efforts on clinical care, education, and research at the interface of psychiatry, medicine, and neurology. Objective: We sought to categorize characteristics and trends (over the past decade) in several journals intended primarily for practitioners of psychosomatic medicine. Methods: We reviewed all articles published in 3 peer-reviewed journals (i.e., Psychosomatics, General Hospital Psychiatry, and the Journal of Psychosomatic Research) in 2002 and 2012. Results: Each of the 3 journals has a different approach to publication of original research, clinical reviews, and case reports. Conclusions: The 3 journals demonstrate differing levels of international involvement, publish a different number of articles of different types (e.g., case reports, reviews, and original research), and focus on different types of medical-psychiatric problems. C1 [Heffernan, Sean P.; Stern, Theodore A.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Heffernan, SP (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 55 Fruit St, Boston, MA 02114 USA. EM spheffernan@partners.org NR 35 TC 1 Z9 1 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0033-3182 J9 PSYCHOSOMATICS JI Psychosomatics PD SEP-OCT PY 2014 VL 55 IS 5 BP 450 EP 457 PG 8 WC Psychiatry; Psychology SC Psychiatry; Psychology GA AP3PD UT WOS:000341988300004 PM 25016352 ER PT J AU Bastawrous, S Bhargava, P Behnia, F Djang, DSW Haseley, DR AF Bastawrous, Sarah Bhargava, Puneet Behnia, Fatemeh Djang, David S. W. Haseley, David R. TI Newer PET Application with an Old Tracer: Role of F-18-NaF Skeletal PET/CT in Oncologic Practice SO RADIOGRAPHICS LA English DT Article ID POSITRON-EMISSION-TOMOGRAPHY; PLANAR BONE-SCINTIGRAPHY; F-18-FLUORIDE PET; BREAST-CANCER; F-18-FDG PET/CT; FLUORIDE-ION; LUNG-CANCER; METABOLIC-ACTIVITY; PAGETS-DISEASE; CHILD-ABUSE AB The skeleton is one of the most common sites for metastatic disease, particularly from breast and prostate cancer. Bone metastases are associated with considerable morbidity, and accurate imaging of the skeleton is important in determining the appropriate therapeutic plan. Sodium fluoride labeled with fluorine 18 (sodium fluoride F 18 [F-18-NaF]) is a positron-emitting radiopharmaceutical first introduced several decades ago for skeletal imaging. F-18-NaF was approved for clinical use as a positron emission tomographic (PET) agent by the U.S. Food and Drug Administration in 1972. The early use of this agent was limited, given the difficulties of imaging its high-energy photons on the available gamma cameras. For skeletal imaging, it was eventually replaced by technetium 99m (Tc-99m)-labeled agents because of the technical limitations of F-18-NaF. During the past several years, the widespread availability and implementation of hybrid PET and computed tomographic (CT) dualmodality systems (PET/CT) have encouraged a renewed interest in F-18-NaF PET/CT for routine clinical use in bone imaging. Because current PET/CT systems offer high sensitivity and spatial resolution, the use of F-18-NaF has been reevaluated for the detection of malignant and nonmalignant osseous disease. Growing evidence suggests that F-18-NaF PET/CT provides increased sensitivity and specificity in the detection of bone metastases. Furthermore, the favorable pharmacokinetics of F-18-NaF, combined with the superior imaging characteristics of PET/CT, supports the routine clinical use of F-18-NaF PET/CT for oncologic imaging for skeletal metastases. In this article, a review of the indications, imaging appearances, and utility of F-18-NaF PET/CT in the evaluation of skeletal disease is provided, with an emphasis on oncologic imaging. (C) RSNA, 2014 C1 [Bastawrous, Sarah; Bhargava, Puneet; Behnia, Fatemeh] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA. [Bastawrous, Sarah; Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA 98108 USA. [Djang, David S. W.; Haseley, David R.] Seattle Nucl Med, Seattle, WA USA. RP Bastawrous, S (reprint author), Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA. EM ssheikh@u.washington.edu OI Bastawrous, Sarah/0000-0002-7690-3121; Bhargava, Puneet/0000-0002-3849-9666 NR 54 TC 17 Z9 17 U1 0 U2 6 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0271-5333 J9 RADIOGRAPHICS JI Radiographics PD SEP-OCT PY 2014 VL 34 IS 5 BP 1295 EP 1316 DI 10.1148/rg.345130061 PG 22 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AP2QO UT WOS:000341919000012 PM 25208282 ER PT J AU Fuentes-Orrego, JM Pinho, D Kulkarni, NM Agrawal, M Ghoshhajra, BB Sahani, DV AF Fuentes-Orrego, Jorge M. Pinho, Daniella Kulkarni, Naveen M. Agrawal, Mukta Ghoshhajra, Brian B. Sahani, Dushyant V. TI New and Evolving Concepts in CT for Abdominal Vascular Imaging SO RADIOGRAPHICS LA English DT Article ID DUAL-ENERGY CT; STATISTICAL ITERATIVE RECONSTRUCTION; MAXIMUM INTENSITY PROJECTION; IODINATED CONTRAST MATERIAL; AAPM/RSNA PHYSICS TUTORIAL; TUBE POTENTIAL SELECTION; RADIATION-DOSE REDUCTION; COMPUTED-TOMOGRAPHY; MULTIDETECTOR CT; KILOVOLTAGE SELECTION AB Computed tomographic (CT) angiography has become the standard of care, supplanting invasive angiography for comprehensive initial evaluation of acute and chronic conditions affecting the vascular system in the abdomen and elsewhere. Over the past decade, the capabilities of CT have improved substantially; simultaneously, the expectations of the referring physician and vascular surgeons have also evolved. Increasingly, CT angiography is used as an imaging biomarker for treatment selection and assessment of effectiveness. However, the growing use of CT angiography has also introduced some challenges, as potential radiation-associated and contrast media-induced risks need to be addressed. These concerns can be partly confronted by modifying scanning parameters (applying a low tube voltage) with or without using software-based solutions. Most recently, multienergy technology has endowed CT with new capabilities offering improved CT angiographic image quality and novel plaque characterization while decreasing radiation and iodine dose. In this article, we discuss current and new approaches using both conventional and multienergy CT for studying vascular disease in the abdomen. We propose various approaches to overcoming commonly encountered image quality challenges in CT angiography. In addition, we describe supplemental strategies for improving patient safety that leverage the available technology. (C) RSNA, 2014 C1 [Fuentes-Orrego, Jorge M.; Pinho, Daniella; Kulkarni, Naveen M.; Agrawal, Mukta; Ghoshhajra, Brian B.; Sahani, Dushyant V.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Abdominal Imaging & Intervent,Dept Radiol, Boston, MA 02114 USA. RP Sahani, DV (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Abdominal Imaging & Intervent,Dept Radiol, 55 Fruit St, Boston, MA 02114 USA. EM dsahani@partners.org OI Fuentes-Orrego, Jorge/0000-0002-9254-0746 FU Siemens Healthcare; Elsevier FX B.B.G.: Activities related to the present article: grants from Siemens Healthcare. Activities not related to the present article: travel support from Siemens Healthcare for unrelated lectures on cardiac imaging. Other activities: disclosed no relevant relationships. D.V.S.: Activities related to the present article: disclosed no relevant relationships. Activities not related to the present article: research agreements with GE Healthcare and Siemens Medical Solutions; royalties from Elsevier. Other activities: disclosed no relevant relationships. NR 77 TC 4 Z9 4 U1 0 U2 2 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0271-5333 J9 RADIOGRAPHICS JI Radiographics PD SEP-OCT PY 2014 VL 34 IS 5 BP 1363 EP 1384 DI 10.1148/rg.345130070 PG 22 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AP2QO UT WOS:000341919000016 PM 25208285 ER PT J AU Locatelli, SM LaVela, SL Gosch, M AF Locatelli, Sara M. LaVela, Sherri L. Gosch, Megan TI Health Care Workers' Reported Discomfort While Wearing Filtering Face-Piece Respirators SO WORKPLACE HEALTH & SAFETY LA English DT Article ID PERSONAL PROTECTIVE EQUIPMENT; FACIAL PROTECTION; PERCEPTIONS; FEATURES; IMPACT AB Filtering face-piece respirators (FFRs) are one method of protecting health care workers from airborne particles; however, research suggests adherence is poor, perhaps due to worker discomfort. Three separate focus groups were conducted at two Veterans Affairs health care facilities. Seventeen health care workers who reported using FFRs as part of their job duties were in the focus groups. Focus group transcripts were coded using qualitative descriptive coding techniques. Participants described experiences of discomfort and physical mask features they believed contributed to discomfort. Participants believed FFRs influenced patient care because some patients felt uneasy and changed health care workers' behaviors (e.g., doffing procedures, loss of concentration, rushed patient care, and avoidance of patients in isolation resulting from FFR discomfort). Assessment of comfort and tolerability should occur during fit-testing. These factors should also be taken into account by management when training employees on the proper use of FFRs, as well as in future research to improve comfort and tolerability. C1 [Locatelli, Sara M.; LaVela, Sherri L.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Innovat Complex Chron Healthcare, Dept Vet Affairs, Hines, IL 60141 USA. [LaVela, Sherri L.] Northwestern Univ, Feinberg Sch Med, Inst Publ Hlth, Ctr Healthcare Studies, Chicago, IL 60611 USA. [Gosch, Megan] Natl Ctr Occupat Hlth & Infect Control, Off Publ Hlth, Dept Vet Affairs, Gainesville, FL USA. RP Locatelli, SM (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hlth Serv Res & Dev, 5000 South 5th Ave,Mailcode 151H, Hines, IL 60141 USA. EM Sara.Locatelli@va.gov FU National Center for Occupational Health and Infection Control, Office of Public Health, Department of Veterans Affairs FX Supported by the National Center for Occupational Health and Infection Control, Office of Public Health, Department of Veterans Affairs. NR 19 TC 2 Z9 2 U1 1 U2 7 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 2165-0799 EI 2165-0969 J9 WORKPLACE HEALTH SAF JI Workplace Health Saf. PD SEP PY 2014 VL 62 IS 9 BP 362 EP 368 DI 10.3928/21650799-20140804-03 PG 7 WC Nursing SC Nursing GA AP3FE UT WOS:000341960200004 PM 25102476 ER PT J AU Lee, J Sanders, KM Cox, M AF Lee, Jennifer Sanders, Karen M. Cox, Malcolm TI Honoring Those Who Have Served: How Can Health Professionals Provide Optimal Care for Members of the Military, Veterans, and Their Families? SO ACADEMIC MEDICINE LA English DT Editorial Material AB With over one million service members separating from the military over the next several years, it seems prudent to ask whether U. S. health care professionals and systems of care are prepared to evaluate and treat the obvious and more subtle injuries ascribed to military deployment and combat. The authors suggest that several systemic interventions-adding military health history sections to electronic health records, history and physical diagnosis textbooks, and licensing exams while also ensuring that this content is adequately covered in undergraduate and graduate health professional training-will enable all health care professionals to provide service members and veterans with the high-quality care that they deserve. The authors also highlight the U.S. Department of Veterans Affairs' recent innovations in education and care delivery, which are enhancing the education of thousands of students and residents, who will be better prepared to care for veterans after receiving this training. C1 [Lee, Jennifer] Commonwealth Virginia, Hlth & Human Resources, Richmond, VA USA. [Lee, Jennifer] Vet Hlth Adm, Off Community Engagement, US Dept Vet Affairs, Washington, DC USA. [Sanders, Karen M.; Cox, Malcolm] Vet Hlth Adm, Off Acad Affiliat, US Dept Vet Affairs, Washington, DC USA. [Sanders, Karen M.] Vet Hlth Adm, Off Acad Affiliat, Dept Vet Affairs, Washington, DC USA. [Cox, Malcolm] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Sanders, KM (reprint author), VHA Off Acad Affiliat 10A2D, 810 Vermont Ave NW, Washington, DC 20420 USA. EM Karen.Sanders@va.gov NR 7 TC 6 Z9 6 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD SEP PY 2014 VL 89 IS 9 BP 1198 EP 1200 DI 10.1097/ACM.0000000000000367 PG 3 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA AO7HU UT WOS:000341524400006 PM 24979290 ER PT J AU Kahn, MJ Maurer, R Wartman, SA Sachs, BP AF Kahn, Marc J. Maurer, Ralph Wartman, Steven A. Sachs, Benjamin P. TI A Case for Change: Disruption in Academic Medicine SO ACADEMIC MEDICINE LA English DT Article ID PRIMARY-CARE; TELEHEALTH; IMPACT AB Disruptive technologies allow less expensive and more efficient processes to eventually dominate a market sector. The academic health center's tripartite mission of education, clinical care, and research is threatened by decreasing revenues and increasing expenses and is, as a result, ripe for disruption. The authors describe current disruptive technologies that threaten traditional operations at academic health centers and provide a prescription not only to survive, but also to prosper, in the face of disruptive forces. C1 [Kahn, Marc J.] Tulane Univ, Sch Med, New Orleans, LA 70112 USA. [Maurer, Ralph] Tulane Univ, Freeman Sch Business, Levy Rosenblum Inst, New Orleans, LA 70118 USA. [Wartman, Steven A.] Assoc Acad Hlth Ctr, Washington, DC USA. [Sachs, Benjamin P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol, Boston, MA USA. RP Sachs, BP (reprint author), Massachusetts Gen Hosp, Dept Obstet & Gynecol, 55 Fruit St, Boston, MA 02114 USA. EM bsachs@mgh.harvard.edu NR 21 TC 5 Z9 5 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD SEP PY 2014 VL 89 IS 9 BP 1216 EP 1219 DI 10.1097/ACM.0000000000000418 PG 4 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA AO7HU UT WOS:000341524400012 PM 25006713 ER PT J AU Kolehmainen, C Brennan, M Filut, A Isaac, C Carnes, M AF Kolehmainen, Christine Brennan, Meghan Filut, Amarette Isaac, Carol Carnes, Molly TI Afraid of Being "Witchy With a 'B'": A Qualitative Study of How Gender Influences Residents' Experiences Leading Cardiopulmonary Resuscitation SO ACADEMIC MEDICINE LA English DT Article ID INTERNAL-MEDICINE RESIDENTS; TRAUMA RESUSCITATION; STEREOTYPE THREAT; FEMALE LEADERS; WOMEN; METAANALYSIS; PERFORMANCE; BEHAVIOR; TEAMS; BACKLASH AB Purpose Ineffective leadership during cardiopulmonary resuscitation ("code") can negatively affect a patient's likelihood of survival. In most teaching hospitals, internal medicine residents lead codes. In this study, the authors explored internal medicine residents' experiences leading codes, with a particular focus on how gender influences the code leadership experience. Method The authors conducted individual, semistructured telephone or in-person interviews with 25 residents (May 2012 to February 2013) from 9 U.S. internal medicine residency programs. They audio recorded and transcribed the interviews and then thematically analyzed the transcribed text. Results Participants viewed a successful code as one with effective leadership. They agreed that the ideal code leader was an authoritative presence; spoke with a deep, loud voice; used clear, direct communication; and appeared calm. Although equally able to lead codes as their male colleagues, female participants described feeling stress from having to violate gender behavioral norms in the role of code leader. In response, some female participants adopted rituals to signal the suspension of gender norms while leading a code. Others apologized afterwards for their counternormative behavior. Conclusions Ideal code leadership embodies highly agentic, stereotypical male behaviors. Female residents employed strategies to better integrate the competing identities of code leader and female gender. In the future, residency training should acknowledge how female gender stereotypes may conflict with the behaviors required to enact code leadership and offer some strategies, such as those used by the female residents in this study, to help women integrate these dual identities. C1 [Kolehmainen, Christine; Brennan, Meghan; Carnes, Molly] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Kolehmainen, Christine; Brennan, Meghan] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Filut, Amarette] Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI USA. [Isaac, Carol] Mercer Univ, Atlanta, GA USA. [Carnes, Molly] Univ Wisconsin, Madison, WI USA. [Carnes, Molly] Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI USA. RP Kolehmainen, C (reprint author), Geriatr Res Educ & Clin Ctr GRECC 11G, 2500 Overlook Terrace, Madison, WI 53705 USA. EM ckolehmainen@wisc.edu FU Advanced Fellowship in Women's Health; William S. Middleton Memorial Veteran's Hospital; University of Wisconsin-Madison Center for Women's Health Research; National Institutes of Health [R01 GM88477, DP4 GM96822] FX This study was supported by funding from the Advanced Fellowship in Women's Health, William S. Middleton Memorial Veteran's Hospital, and University of Wisconsin-Madison Center for Women's Health Research. The funding body played no role in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript. The contents do not represent the views of the Department of Veterans Affairs or the U.S. Government. Dr. Carnes's work on increasing scientific workforce diversity is funded by the National Institutes of Health (R01 GM88477 and DP4 GM96822). GRECC manuscript #2014-03. NR 41 TC 4 Z9 4 U1 0 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD SEP PY 2014 VL 89 IS 9 BP 1276 EP 1281 DI 10.1097/ACM.0000000000000372 PG 6 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA AO7HU UT WOS:000341524400025 PM 24979289 ER PT J AU Patel, MS Arora, V Patel, MS Kinney, JM Pauly, MV Asch, DA AF Patel, Mitesh S. Arora, Vishal Patel, Mamta S. Kinney, June M. Pauly, Mark V. Asch, David A. TI The Role of MD and MBA Training in the Professional Development of a Physician: A Survey of 30 Years of Graduates From the Wharton Health Care Management Program SO ACADEMIC MEDICINE LA English DT Article ID UNITED-STATES; LEADERSHIP; OPPORTUNITIES; EDUCATION; STUDENTS AB Purpose The number of medical schools offering MD and MBA training has increased fivefold in the last two decades. The authors evaluated graduates' perceptions of the role of such training on their career and professional development. Method In 2011, the authors surveyed physician graduates from the Wharton School MBA Program in Heath Care Management at the University of Pennsylvania from 1981 to 2010. Survey responses were analyzed and evaluated using grounded theory. Results Among 247 eligible graduates, 59.9% (148/247) completed the questionnaire and 89.9% (133/148) of them provided free-text responses. Approximately 85.1% (126/148) of respondents were male and 79.7% (118/148) entered residency training; however, both rates declined slightly over time. Among respondents within their first decade after graduation, 46.2% (24/52) reported clinical practice as their primary work sector compared with 39.5% (15/38) among respondents 11 to 20 years after graduation and 19.2% (5/26) of respondents 21 to 30 years after graduation. Overall, graduates reported mostly positive attitudes and often noted the benefits of career acceleration, professional flexibility, and credibility in multidisciplinary domains. The few negative remarks were focused on the opportunity cost of time and how peers in one discipline may negatively perceive the role of the other discipline's degree. Conclusions Graduates with an MD and MBA report mostly positive attitudes towards their training, and many are pursuing leadership and primarily nonclinical roles later in their careers. These findings reveal new insights for policies affecting physician workforce. Further study is necessary to evaluate whether similar trends exist more broadly. C1 [Patel, Mitesh S.; Arora, Vishal] Univ Penn, Philadelphia, PA 19104 USA. [Patel, Mitesh S.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Patel, Mamta S.; Kinney, June M.] Univ Penn, Wharton Sch, Hlth Care Management Program, Philadelphia, PA 19104 USA. [Pauly, Mark V.; Asch, David A.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Asch, David A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Asch, David A.] Penn Med Ctr Hlth Care Innovat, Philadelphia, PA USA. RP Patel, MS (reprint author), 423 Guardian Dr,1303B Blockley Hall, Philadelphia, PA 19104 USA. EM mpatel@upenn.edu FU Department of Veterans Affairs; Robert Wood Johnson Foundation FX Dr. Patel was supported by the Department of Veterans Affairs and the Robert Wood Johnson Foundation. NR 13 TC 6 Z9 6 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD SEP PY 2014 VL 89 IS 9 BP 1282 EP 1286 DI 10.1097/ACM.0000000000000366 PG 5 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA AO7HU UT WOS:000341524400026 PM 24979286 ER PT J AU Berk, LJ Muret-Wagstaff, SL Goyal, R Joyal, JA Gordon, JA Faux, R Oriol, NE AF Berk, Louis J. Muret-Wagstaff, Sharon L. Goyal, Riya Joyal, Julie A. Gordon, James A. Faux, Russell Oriol, Nancy E. TI Inspiring careers in STEM and healthcare fields through medical simulation embedded in high school science education SO ADVANCES IN PHYSIOLOGY EDUCATION LA English DT Editorial Material DE medical simulation; science education; health care; science, technology, engineering and mathematics ID SELF-EFFICACY BELIEFS; PHYSIOLOGY COURSE; WOMEN AB The most effective ways to promote learning and inspire careers related to science, technology, engineering, and mathematics (STEM) remain elusive. To address this gap, we reviewed the literature and designed and implemented a high-fidelity, medical simulation-based Harvard Medical School MEDscience course, which was integrated into high school science classes through collaboration between medical school and K-12 faculty. The design was based largely on the literature on concepts and mechanisms of self-efficacy. A structured telephone survey was conducted with 30 program alumni from the inaugural school who were no longer in high school. Near-term effects, enduring effects, contextual considerations, and diffusion and dissemination were queried. Students reported high incoming attitudes toward STEM education and careers, and these attitudes showed before versus after gains (P < .05). Students in this modest sample over-whelmingly attributed elevated and enduring levels of impact on their interest and confidence in pursuing a science or healthcare-related career to the program. Additionally, 63% subsequently took additional science or health courses, 73% participated in a job or educational experience that was science related during high school, and 97% went on to college. Four of every five program graduates cited a health-related college major, and 83% offered their strongest recommendation of the program to others. Further study and evaluation of simulation-based experiences that capitalize on informal, naturalistic learning and promote self-efficacy are warranted. C1 [Berk, Louis J.] Univ Massachusetts, Sch Med, Worcester, MA USA. [Muret-Wagstaff, Sharon L.; Oriol, Nancy E.] Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02215 USA. [Muret-Wagstaff, Sharon L.; Oriol, Nancy E.] Harvard Univ, Sch Med, Dept Anaesthesia, Boston, MA 02115 USA. [Goyal, Riya] Hofstra Univ, Hofstra North Shore LIJ Sch Med, Hempstead, NY 11550 USA. [Joyal, Julie A.] Harvard Univ, Sch Med, HMS MEDsci, Boston, MA 02115 USA. [Gordon, James A.] Massachusetts Gen Hosp, MGH Learning Lab, Dept Emergency Med, Boston, MA 02114 USA. [Gordon, James A.] Massachusetts Gen Hosp, Div Med Simulat, Dept Emergency Med, Boston, MA 02114 USA. [Gordon, James A.; Oriol, Nancy E.] Harvard Univ, Sch Med, Gilbert Program Med Simulat, Boston, MA 02115 USA. [Faux, Russell] Davis Sq Res Associates, Somerville, NJ USA. RP Oriol, NE (reprint author), Harvard Univ, Sch Med, Tosteson Med Educ Ctr, 260 Longwood Ave, Boston, MA 02115 USA. EM nancy_oriol@hms.harvard.edu NR 25 TC 3 Z9 3 U1 4 U2 29 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1043-4046 EI 1522-1229 J9 ADV PHYSIOL EDUC JI Adv. Physiol. Educ. PD SEP 1 PY 2014 VL 38 IS 3 BP 210 EP 215 DI 10.1152/advan.00143.2013 PG 6 WC Education, Scientific Disciplines; Physiology SC Education & Educational Research; Physiology GA AO9WW UT WOS:000341711900003 PM 25179609 ER PT J AU Wiste, A Robinson, EB Milaneschi, Y Meier, S Ripke, S Clements, CC Fitzmaurice, GM Rietschel, M Penninx, BW Smoller, JW Perlis, RH AF Wiste, Anna Robinson, Elise B. Milaneschi, Yuri Meier, Sandra Ripke, Stephan Clements, Caitlin C. Fitzmaurice, Garrett M. Rietschel, Marcella Penninx, Brenda W. Smoller, Jordan W. Perlis, Roy H. TI Bipolar polygenic loading and bipolar spectrum features in major depressive disorder SO BIPOLAR DISORDERS LA English DT Article DE bipolar disorder; depression; genetics; major depressive disorder; polygenic score; STAR*D ID GENOME-WIDE ASSOCIATION; FAMILY-HISTORY METHOD; STAR-ASTERISK-D; CLINICAL-FEATURES; QUESTIONNAIRE; EPISODES; RELIABILITY; OUTPATIENTS; POPULATION; DEFINITION AB Objectives Family and genetic studies indicate overlapping liability for major depressive disorder and bipolar disorder. The purpose of the present study was to determine whether this shared genetic liability influences clinical presentation. Methods A polygenic risk score for bipolar disorder, derived from a large genome-wide association meta-analysis, was generated for each subject of European-American ancestry (n=1,274) in the Sequential Treatment Alternatives to Relieve Depression study (STAR*D) outpatient major depressive disorder cohort. A hypothesis-driven approach was used to test for association between bipolar disorder risk score and features of depression associated with bipolar disorder in the literature. Follow-up analyses were performed in two additional cohorts. Results A generalized linear mixed model including seven features hypothesized to be associated with bipolar spectrum illness was significantly associated with bipolar polygenic risk score [F=2.07, degrees of freedom (df)=7, p=0.04]. Features included early onset, suicide attempt, recurrent depression, atypical depression, subclinical mania, subclinical psychosis, and severity. Post-hoc univariate analyses demonstrated that the major contributors to this omnibus association were onset of illness at age 18years [odds ratio (OR)=1.2, p=0.003], history of suicide attempt (OR=1.21, p=0.03), and presence of at least one manic symptom (OR=1.16, p=0.02). The maximal variance in these traits explained by polygenic score ranged from 0.8% to 1.1%. However, analyses in two replication cohorts testing a five-feature model did not support this association. Conclusions Bipolar genetic loading appeared to be associated with bipolar-like presentation in major depressive disorder in the primary analysis. However, the results were at most inconclusive because of lack of replication. Replication efforts were challenged by different ascertainment and assessment strategies in the different cohorts. The methodological approach described here may prove useful in applying genetic data to clarify psychiatric nosology in future studies. C1 [Wiste, Anna; Clements, Caitlin C.; Smoller, Jordan W.; Perlis, Roy H.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Ctr Human Genet Res, Boston, MA 02114 USA. [Wiste, Anna; Clements, Caitlin C.; Perlis, Roy H.] Massachusetts Gen Hosp, Dept Psychiat, Ctr Expt Drugs & Diagnost, Boston, MA 02114 USA. [Robinson, Elise B.; Ripke, Stephan] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA. [Milaneschi, Yuri; Penninx, Brenda W.] Vrije Univ Amsterdam, Dept Psychiat, Med Ctr, Amsterdam, Netherlands. [Meier, Sandra; Rietschel, Marcella] Heidelberg Univ, Dept Genet Epidemiol Psychiat, Cent Inst Mental Hlth, Med Fac Mannheim, Mannheim, Germany. [Fitzmaurice, Garrett M.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Penninx, Brenda W.] Leiden Univ, Med Ctr, Dept Psychiat, Leiden, Netherlands. [Penninx, Brenda W.] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, NL-9713 AV Groningen, Netherlands. [Smoller, Jordan W.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Perlis, RH (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Ctr Expt Drugs & Diagnost, Simches Res Bldg 185 Cambridge St, Boston, MA 02114 USA. EM rperlis@chgr.mgh.harvard.edu OI Robinson, Elise/0000-0003-2314-2792 FU NIMH [5R25MH094612]; National Institutes of Health (NIH) [T32MH017119]; German Federal Ministry of Education and Research (BMBF); MooDS-Net [01GS08147]; European Union (ADAMS project) [HEALTH-F4-2009-242257]; European Community's Seventh Framework Programme [279227]; National Institute of Mental Health (NIMH) [MH086026]; Netherlands Scientific Organization (ZonMW Geestkracht program) [10-000-1002]; Centre for Medical Systems Biology (NWO Genomics); Neuroscience Campus Amsterdam (NCA); NESDA; NTR; Genetic Association Information Network (GAIN) of the Foundation for the US National Institutes of Health FX The authors would like to express gratitude to the Psychiatric Genomics Consortium for the availability of data for the polygenic scoring. The authors gratefully acknowledge the investigators of NESDA, the Bonn/Mannheim cohort, and the STAR*D trial as well as the patient participants in those studies. AW was supported by NIMH 5R25MH094612. AW and EBR were supported by National Institutes of Health (NIH) T32MH017119. MR was supported by the German Federal Ministry of Education and Research (BMBF) within the context of the National Genome Research Network plus (NGFNplus), and the MooDS-Net (grant 01GS08147); and was also supported by the 7th framework programme of the European Union (ADAMS project, HEALTH-F4-2009-242257) and the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 279227. RHP was supported by National Institute of Mental Health (NIMH) MH086026. Funding support for NESDA was provided by the Netherlands Scientific Organization (ZonMW Geestkracht program, 10-000-1002), Centre for Medical Systems Biology (NWO Genomics), the Neuroscience Campus Amsterdam (NCA), and the EMGO+ institute, and matching funds from participating institutes in NESDA and NTR. Genotyping was funded by the Genetic Association Information Network (GAIN) of the Foundation for the US National Institutes of Health. Genotype data were obtained from dbGaP (http://www.ncbi.nlm.nih.gov/dbgap, accession number phs000020.v1.p1). NR 38 TC 5 Z9 5 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-5647 EI 1399-5618 J9 BIPOLAR DISORD JI Bipolar Disord. PD SEP PY 2014 VL 16 IS 6 BP 608 EP 616 DI 10.1111/bdi.12201 PG 9 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AO8GU UT WOS:000341592700006 PM 24725193 ER PT J AU Lee, J Napadow, V Park, K AF Lee, Jeungchan Napadow, Vitaly Park, Kyungmo TI Pain and sensory detection threshold response to acupuncture is modulated by coping strategy and acupuncture sensation SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE LA English DT Article DE Coping strategy; Acupuncture; Acupuncture sensation; Pain; Sensory threshold ID OPIOID-INDUCED HYPERALGESIA; RANDOMIZED CONTROLLED-TRIAL; NEEDLING SENSATION; ANALGESIA; FMRI; ELECTROACUPUNCTURE; STIMULATION; VOLUNTEERS; PERCEPTION; PREDICTOR AB Background: Acupuncture has been shown to reduce pain, and acupuncture-induced sensation may be important for this analgesia. In addition, cognitive coping strategies can influence sensory perception. However, the role of coping strategy on acupuncture modulation of pain and sensory thresholds, and the association between acupuncture sensation and these modulatory effects, is currently unknown. Methods: Electroacupuncture (EA) was applied at acupoints ST36 and GB39 of 61 healthy adults. Different coping conditions were experimentally designed to form an active coping strategy group (AC group), who thought they could control EA stimulation intensity, and a passive coping strategy group (PC group), who did not think they had such control. Importantly, neither group was actually able to control EA stimulus intensity. Quantitative sensory testing was performed before and after EA, and consisted of vibration (VDT), mechanical (MDT), warm (WDT), and cold (CDT) detection thresholds, and pressure (PPT), mechanical (MPT), heat (HPT) and cold (CPT) pain thresholds. Autonomic measures (e. g. skin conductance response, SCR) were also acquired to quantify physiological response to EA under different coping conditions. Subjects also reported the intensity of any acupuncture-induced sensations. Results: Coping strategy was induced with successful blinding in 58% of AC subjects. Compared to PC, AC showed greater SCR to EA. Under AC, EA reduced PPT and CPT. In the AC group, improved pain and sensory thresholds were correlated with acupuncture sensation (VDTchange vs. MI: r=0.58, CDTchange vs. tingling: r=0.53, CPTchange vs. tingling; r=0.55, CPTchange vs. dull; r=0.55). However, in the PC group, improved sensory thresholds were negatively correlated with acupuncture sensation (CDTchange vs. intensity sensitization: r=-0.52, WDTchange vs. fullness: r=-0.57). Conclusions: Our novel approach was able to successfully induce AC and PC strategies to EA stimulation. The interaction between psychological coping strategy and acupuncture sensation intensity can differentially modulate pain and sensory detection threshold response to EA. In a clinical context, our findings suggest that instructions given to the patient can significantly affect therapeutic outcomes and the relationship between acupuncture intensity and clinical response. Specifically, acupuncture analgesia can be enhanced by matching physical stimulation intensity with psychological coping strategy to acupuncture contexts. C1 [Lee, Jeungchan; Napadow, Vitaly; Park, Kyungmo] Kyung Hee Univ, Dept Biomed Engn, Yongin 446701, Gyeonggi, South Korea. [Napadow, Vitaly] Massachusetts Gen Hosp, Dept Radiol, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Napadow, Vitaly] Logan Univ, Dept Radiol, Chesterfield, MO 63017 USA. RP Park, K (reprint author), Kyung Hee Univ, Dept Biomed Engn, Yongin 446701, Gyeonggi, South Korea. EM saenim@khu.ac.kr FU National Research Foundation - Korean Ministry of Science, ICT and Future Planning [NRF-2011-0028968]; Ministry of Health & Welfare and Seoul Metropolitan Government (Traditional Korean Medicine RD Project) [HI13C0700]; MKE (The Ministry of Knowledge Economy), under the ITRC(Information Technology Research Center) support program [NIPA-2013-(H0301-13-2001)]; NIH grants from the USA: NCCAM [P01-AT006663, R01-AT005280, R01-AT007550]; NIH grants from the USA: NIAMS [R01-AR064367] FX This study was supported by a grant from the National Research Foundation funded by the Korean Ministry of Science, ICT and Future Planning (NRF-2011-0028968), the Ministry of Health & Welfare and Seoul Metropolitan Government (Traditional Korean Medicine R&D Project, HI13C0700), and the MKE (The Ministry of Knowledge Economy), under the ITRC(Information Technology Research Center) support program supervised by the NIPA(National IT Industry Promotion Agency) (NIPA-2013-(H0301-13-2001)), Korea. VN was supported by the following NIH grants from the USA: NCCAM: P01-AT006663, R01-AT005280, R01-AT007550; NIAMS: R01-AR064367. NR 37 TC 2 Z9 2 U1 1 U2 12 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6882 J9 BMC COMPLEM ALTERN M JI BMC Complement. Altern. Med. PD SEP 1 PY 2014 VL 14 AR 324 DI 10.1186/1472-6882-14-324 PG 10 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA AO8JZ UT WOS:000341602000001 PM 25175308 ER PT J AU Albanes, D Till, C Klein, EA Goodman, PJ Mondul, AM Weinstein, SJ Taylor, PR Parnes, HL Gaziano, JM Song, XL Fleshner, NE Brown, PH Meyskens, FL Thompson, IM AF Albanes, Demetrius Till, Cathee Klein, Eric A. Goodman, Phyllis J. Mondul, Alison M. Weinstein, Stephanie J. Taylor, Philip R. Parnes, Howard L. Gaziano, J. Michael Song, Xiaoling Fleshner, Neil E. Brown, Powel H. Meyskens, Frank L., Jr. Thompson, Ian M. TI Plasma Tocopherols and Risk of Prostate Cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT) SO CANCER PREVENTION RESEARCH LA English DT Article ID SERUM ALPHA-TOCOPHEROL; GAMMA-TOCOPHEROL; BETA-CAROTENE; FOLLOW-UP; ASSOCIATION; RETINOL; COHORT; MEN; SUPPLEMENTATION; MICRONUTRIENTS AB The Selenium and Vitamin E Cancer Prevention Trial (SELECT) showed higher prostate cancer incidence in men supplemented with high-dose alpha-tocopherol. We, therefore, examined whether presupplementation plasma alpha-tocopherol or gamma-tocopherol was associated with overall or high-grade prostate cancer. A stratified case-cohort sample that included 1,746 incident prostate cancer cases diagnosed through June 2009 and a subcohort of 3,211 men was derived from the SELECT trial of 35,533 men. Plasma was collected at entry from 2001 to 2004, and median follow-up was 5.5 years (range, 0-7.9 years). Incidence of prostate cancer as a function of plasma a-tocopherol, g-tocopherol, and supplementation with alpha-tocopherol or selenomethionine was estimated by the hazard ratio (HR). Plasma gamma-tocopherol was not associated with prostate cancer. Men with higher alpha-tocopherol concentrations seemed to have risk similar to that of men with lower concentrations [overall HR for fifth (Q5) vs. first quintile (Q1), 1.21; 95 % confidence interval (CI), 0.88-1.66; P-trend = 0.24; in the trial placebo arm, Q5 HR, 0.85; 95% CI, 0.44-1.62; P-trend = 0.66]. We found a strong positive plasma alpha-tocopherol association among men receiving the trial selenomethionine supplement [Q5 HR, 2.04; 95% CI, 1.29-3.22; P-trend = 0.005]. A positive plasma a-tocopherol-prostate cancer association also seemed limited to high-grade disease (Gleason grade, 7-10; overall Q5 HR, 1.59; 95% CI, 1.13-2.24; P-trend = 0.001; among men receiving selenomethionine, Q5 HR, 2.12; 95% CI, 1.32-3.40; P-trend = 0.0002). Our findings indicate that higher plasma a-tocopherol concentrations may interact with selenomethionine supplements to increase high-grade prostate cancer risk, suggesting a biologic interaction between a-tocopherol and selenium itself or selenomethionine. (C) 2014 AACR. C1 [Albanes, Demetrius; Mondul, Alison M.; Weinstein, Stephanie J.; Taylor, Philip R.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Till, Cathee; Goodman, Phyllis J.] Fred Hutchinson Canc Res Ctr, SWOG Stat Ctr, Seattle, WA 98104 USA. [Klein, Eric A.] Cleveland Clin, Glickman Urol & Kidney Inst, Dept Urol, Cleveland, OH 44106 USA. [Parnes, Howard L.] NCI, Canc Prevent Div, Bethesda, MD 20892 USA. [Gaziano, J. Michael] VA Boston Healthcare Syst, Res & Informat Ctr, Boston, MA USA. [Song, Xiaoling] Fred Hutchinson Canc Res Ctr, Biomarker Lab, Seattle, WA 98104 USA. [Fleshner, Neil E.] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada. [Brown, Powel H.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Meyskens, Frank L., Jr.] Univ Calif Irvine, Dept Med, Orange, CA 92668 USA. [Thompson, Ian M.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA. RP Albanes, D (reprint author), NCI, Div Canc Epidemiol & Genet, NIH, 9609 Med Ctr Dr,Room 6E342, Bethesda, MD 20892 USA. EM daa@nih.gov RI Albanes, Demetrius/B-9749-2015 OI Mondul, Alison/0000-0002-8843-1416; FU National Cancer Institute [7U10CA037429-29]; Intramural Program of the U.S. Public Health Service, NIH, National Cancer Institute; National Center for Complementary and Alternative Medicine National Institutes of Health, NIH, Department of Health and Human Services FX This work was supported in part by Public Health Service Cooperative Agreement grant 7U10CA037429-29 awarded by the National Cancer Institute in cooperation with the National Center for Complementary and Alternative Medicine National Institutes of Health, NIH, Department of Health and Human Services (to C. Till, E.A. Klein, P.J. Goodman, F.L. Meyskens Jr, and I.M. Thompson), and by the Intramural Program of the U.S. Public Health Service, NIH, National Cancer Institute (to D. Albanes, A. Mondul, S.J. Weinstein, and P.R. Taylor). Study agents and packaging were provided by Perrigo Company (Allegan, MI), Sabinsa Corporation (Piscataway, NJ), Tishcon Corporation (Westbury, NY), and DSM Nutritional Products, Inc. (Parsipanny, NJ). NR 44 TC 16 Z9 17 U1 2 U2 15 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1940-6207 EI 1940-6215 J9 CANCER PREV RES JI Cancer Prev. Res. PD SEP PY 2014 VL 7 IS 9 BP 886 EP 895 DI 10.1158/1940-6207.CAPR-14-0058 PG 10 WC Oncology SC Oncology GA AP0XB UT WOS:000341788300002 PM 24961880 ER PT J AU Kalpathy-Cranner, J Gerstner, ER Emblen, KE Andronesi, OC Rosen, B AF Kalpathy-Cranner, Jayashree Gerstner, Elizabeth R. Emblen, Kyrre E. Andronesi, Ovidiu C. Rosen, Bruce TI Advanced Magnetic Resonance Imaging of the Physical Processes in Human Glioblastoma SO CANCER RESEARCH LA English DT Article ID CEREBRAL BLOOD-VOLUME; CONTRAST-ENHANCED MRI; HIGH-GRADE GLIOMAS; RESPONSE ASSESSMENT CRITERIA; FUNCTIONAL DIFFUSION MAPS; BRAIN WHITE-MATTER; RECURRENT GLIOBLASTOMA; IN-VIVO; DCE-MRI; ANTIANGIOGENIC THERAPY AB The most common malignant primary brain tumor, glioblastorna multiforme (GBM) is a devastating disease with a grim prognosis. Patient survival is typically less than two years and fewer than 10% of patients survive more than five years. Magnetic resonance imaging (MRI) can have great utility in the diagmosis, grading, and management of patients with GBM as many of the physical manifestations of the pathologic processes in GBM can be visualized and quantified using MRI. Newer MRI techniques such as dynamic contrast enhanced and dynamic susceptibility contrast MRI provide functional information about the tumor hemodynarnic status. Diffusion MRI can shed light on tumor cellularity and the disruption of white matter tracts in the proximity of tumors. MR spectroscopy can be used to study new tumor tissue markers such as IDII mutations. MRI is helping to noninvasively explore the link between the molecular basis of gliornas and the imaging characteristics of their physical processes. We, here, review several approaches to MR-based imaging and discuss the potential for these techniques to quantify the physical processes in glioblas Loma, including tumor cellularity and vascularity, metabolite expression, and pat terns of tumor growth and recurrence. We conclude with challenges and opportunities for further research in applying physical principles to better understand the biologic process in this deadly disease. (C) 2014 AACR, C1 [Kalpathy-Cranner, Jayashree; Emblen, Kyrre E.; Andronesi, Ovidiu C.; Rosen, Bruce] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Kalpathy-Cranner, Jayashree; Emblen, Kyrre E.; Andronesi, Ovidiu C.; Rosen, Bruce] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. [Kalpathy-Cranner, Jayashree; Andronesi, Ovidiu C.; Rosen, Bruce] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Kalpathy-Cranner, Jayashree; Gerstner, Elizabeth R.; Andronesi, Ovidiu C.; Rosen, Bruce] Harvard Univ, Sch Med, Boston, MA USA. [Gerstner, Elizabeth R.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Emblen, Kyrre E.] Oslo Univ Hosp, Intervent Ctr, Oslo, Norway. RP Kalpathy-Cranner, J (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, 149 13th St, Charlestown, MA 02129 USA. EM kalpathy@nmr.mgh.harvard.edu RI Emblem, Kyrre/H-6691-2012; OI Emblem, Kyrre/0000-0002-6580-9519; Kalpathy-Cramer, Jayashree/0000-0001-8906-9618 FU NIH [U01CA154602, R00LM009889]; South-Eastern Norway Regional Health Authority [2013069]; K22 Career Development Award from the National Cancer Institute of the NIH [K22CA178269-01]; NCI/NIH [U01CA154602] FX J. Kalpathy-Cramer is funded in part by the NIH grants U01CA154602 and R00LM009889, ER. Gerstner is supported in part by NIH grant U01CA154602, Emblem is funded by South-Eastern Norway Regional Health Authority Grant 2013069, O. Andronesi is funded in part by a K22 Career Development Award from the National Cancer Institute of the NIH (K22CA178269-01) and B. Rosen is funded in part by NCI/NIH grant U01CA154602. NR 172 TC 27 Z9 27 U1 2 U2 15 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD SEP 1 PY 2014 VL 74 IS 17 BP 4622 EP 4637 DI 10.1158/0008-5472.CAN-14-0383 PG 16 WC Oncology SC Oncology GA AP1MC UT WOS:000341833300007 PM 25183787 ER PT J AU Blagoev, KB Wilkerson, J Stein, WD Yang, J Bates, SE Fojo, T AF Blagoev, Krastan B. Wilkerson, Julia Stein, Wilfred D. Yang, James Bates, Susan E. Fojo, Tito TI Therapies with Diverse Mechanisms of Action Kill Cells by a Similar Exponential Process in Advanced Cancers SO CANCER RESEARCH LA English DT Article ID PHASE-II TRIAL; INDEPENDENT PROSTATE-CANCER; GROWTH-RATE CONSTANTS; INTERFERON-ALPHA; CARCINOMA; SURVIVAL; BEVACIZUMAB; SUNITINIB; THALIDOMIDE; DOCETAXEL AB Successful cancer treatments are generally defined as those that decrease tumor quantity. In many cases, this decrease occurs exponentially, with deviations from a strict exponential being attributed to a growing fraction of drug-resistant cells. Deviations from an exponential decrease in tumor quantity can also be expected if drugs have a nonuniform spatial distribution inside the tumor, for example, because of interstitial pressure inside the tumor. Here, we examine theoretically different models of cell killing and analyze data from clinical trials based on these models. We show that the best description of clinical outcomes is by first-order kinetics with exponential decrease of tumor quantity. We analyzed the total tumor quantity in a diverse group of clinical trials with various cancers during the administration of different classes of anticancer agents and in all cases observed that the models that best fit the data describe the decrease of the sensitive tumor fraction exponentially. The exponential decrease suggests that all drug-sensitive cancer cells have a single rate-limiting step on the path to cell death. If there are intermediate steps in the path to cell death, they are not rate limiting in the observational time scale utilized in clinical trials-tumor restaging at 6- to 8-week intervals. On shorter time scales, there might be intermediate steps, but the rate-limiting step is the same. Our analysis, thus, points to a common pathway to cell death for cancer cells in patients. (C) 2014 AACR. C1 [Blagoev, Krastan B.] Natl Sci Fdn, Arlington, VA 22230 USA. [Blagoev, Krastan B.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA. [Blagoev, Krastan B.] Antinula Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Wilkerson, Julia; Stein, Wilfred D.; Bates, Susan E.; Fojo, Tito] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [Stein, Wilfred D.] Hebrew Univ Jerusalem, Jerusalem, Israel. [Yang, James] NCI, Surg Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. RP Blagoev, KB (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Bldg 149,13th St, Charlestown, MA 02129 USA. EM kblagoev@nsf.gov OI Wilkerson, Julia/0000-0002-6965-0867 FU National Science Foundation FX The National Science Foundation supported the work of K.B. Blagoev. NR 21 TC 2 Z9 2 U1 0 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD SEP 1 PY 2014 VL 74 IS 17 BP 4653 EP 4662 DI 10.1158/0008-5472.CAN-14-0420 PG 10 WC Oncology SC Oncology GA AP1MC UT WOS:000341833300009 PM 25183789 ER PT J AU Tchaicha, JH Akbay, EA Altabef, A Mikse, OR Kikuchi, E Rhee, K Liao, RG Bronson, RT Sholl, LM Meyerson, M Hammerman, PS Wong, KK AF Tchaicha, Jeremy H. Akbay, Esra A. Altabef, Abigail Mikse, Oliver R. Kikuchi, Eiki Rhee, Kevin Liao, Rachel G. Bronson, Roderick T. Sholl, Lynette M. Meyerson, Matthew Hammerman, Peter S. Wong, Kwok-Kin TI Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC SO CANCER RESEARCH LA English DT Article ID SQUAMOUS-CELL CARCINOMAS; GROWTH-FACTOR RECEPTOR-3; THERAPEUTIC TARGET; BLADDER-CANCER; GENE FUSIONS; STEM-CELLS; IN-VIVO; MUTATIONS; EXPRESSION; FAMILY AB Somatic mutations in FGFR2 are present in 4% to 5% of patients diagnosed with non-small cell lung cancer (NSCLC). Amplification and mutations in FGFR genes have been identified in patients with NSCLCs, and clinical trials are testing the efficacy of anti-FGFR therapies. FGFR2 and other FGFR kinase family gene alterations have been found in both lung squamous cell carcinoma and lung adenocarcinoma, although mouse models of FGFR-driven lung cancers have not been reported. Here, we generated a genetically engineered mouse model (GEMM) of NSCLC driven by a kinase domain mutation in FGFR2. Combined with p53 ablation, primary grade 3/4 adenocarcinoma was induced in the lung epithelial compartment exhibiting locally invasive and pleiotropic tendencies largely made up of multinucleated cells. Tumors were acutely sensitive to pan-FGFR inhibition. This is the first FGFR2-driven lung cancer GEMM, which can be applied across different cancer indications in a preclinical setting. (C) 2014 AACR. C1 [Tchaicha, Jeremy H.; Akbay, Esra A.; Altabef, Abigail; Mikse, Oliver R.; Kikuchi, Eiki; Rhee, Kevin; Liao, Rachel G.; Meyerson, Matthew; Hammerman, Peter S.; Wong, Kwok-Kin] Dana Farber Canc Inst, Dept Med, Boston, MA 02215 USA. [Tchaicha, Jeremy H.; Akbay, Esra A.; Mikse, Oliver R.; Kikuchi, Eiki; Meyerson, Matthew; Hammerman, Peter S.; Wong, Kwok-Kin] Harvard Univ, Sch Med, Boston, MA USA. [Tchaicha, Jeremy H.; Akbay, Esra A.; Altabef, Abigail; Mikse, Oliver R.; Kikuchi, Eiki; Rhee, Kevin; Wong, Kwok-Kin] Ludwig Inst Canc, Cambridge, MA USA. [Liao, Rachel G.; Meyerson, Matthew; Hammerman, Peter S.] Broad Inst, Cambridge, MA USA. [Bronson, Roderick T.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Div Immunol, Boston, MA USA. [Sholl, Lynette M.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Wong, Kwok-Kin] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA USA. RP Wong, KK (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM peter_hammerman@dfci.harvard.edu; kwong1@partners.org RI Kikuchi, Eiki/M-9688-2014; OI Liao, Rachel/0000-0002-7830-1976 FU NCI [1K08CA163677, P50CA090578]; Stephen D. and Alice Cutler Investigator Fund; United against Lung Cancer; Lung Cancer Research Foundation; American Lung Association; Novartis Pharmaceuticals; NIH [CA122794, CA140594, CA163896, CA166480, CA154303, CA120964] FX P.S. Hammerman is supported by NCI grants 1K08CA163677 and the Stephen D. and Alice Cutler Investigator Fund. M. Meyerson is supported by United against Lung Cancer, the Lung Cancer Research Foundation, the American Lung Association, Novartis Pharmaceuticals, and NCI grant P50CA090578. K.-K. Wong is supported by the NIH (CA122794, CA140594, CA163896, CA166480, CA154303, and CA120964), United against Lung Cancer, and the American Lung Association. NR 38 TC 12 Z9 15 U1 0 U2 5 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD SEP 1 PY 2014 VL 74 IS 17 BP 4676 EP 4684 DI 10.1158/0008-5472.CAN-13-3218 PG 9 WC Oncology SC Oncology GA AP1MC UT WOS:000341833300012 PM 25035393 ER PT J AU Chow, KH Shin, DM Jenkins, MH Miller, EE Shih, DJ Choi, S Low, BE Philip, V Rybinski, B Bronson, RT Taylor, MD Yun, K AF Chow, Kin-Hoe Shin, Dong-Mi Jenkins, Molly H. Miller, Emily E. Shih, David J. Choi, Seungbum Low, Benjamin E. Philip, Vivek Rybinski, Brad Bronson, Roderick T. Taylor, Michael D. Yun, Kyuson TI Epigenetic States of Cells of Origin and Tumor Evolution Drive Tumor-Initiating Cell Phenotype and Tumor Heterogeneity SO CANCER RESEARCH LA English DT Article ID CANCER STEM-CELLS; MOUSE MODEL; MOLECULAR SUBGROUPS; MEDULLOBLASTOMA; MICE; PATHWAY; IDENTIFICATION; GENERATION; MUTATIONS; DISTINCT AB A central confounding factor in the development of targeted therapies is tumor cell heterogeneity, particularly in tumor-initiating cells (TIC), within clinically identical tumors. Here, we show how activation of the Sonic Hedgehog (SHH) pathway in neural stem and progenitor cells creates a foundation for tumor cell evolution to heterogeneous states that are histologically indistinguishable but molecularly distinct. In spontaneous medulloblastomas that arise in Patched (Ptch)(+/-) mice, we identified three distinct tumor subtypes. Through cell type-specific activation of the SHH pathway in vivo, we determined that different cells of origin evolved in unique ways to generate these subtypes. Moreover, TICs in each subtype had distinct molecular and cellular phenotypes. At the bulk tumor level, the three tumor subtypes could be distinguished by a 465-gene signature and by differential activation levels of the ERK and AKT pathways. Notably, TICs from different subtypes were differentially sensitive to SHH or AKT pathway inhibitors, highlighting new mechanisms of resistance to targeted therapies. In summary, our results show how evolutionary processes act on distinct cells of origin to contribute to tumoral heterogeneity, at both bulk tumor and TIC levels. (C) 2014 AACR. C1 [Chow, Kin-Hoe; Jenkins, Molly H.; Miller, Emily E.; Choi, Seungbum; Low, Benjamin E.; Philip, Vivek; Rybinski, Brad; Yun, Kyuson] Jackson Lab, Bar Harbor, ME 04609 USA. [Shin, Dong-Mi] NIAID, Immunogenet Lab, NIH, Bethesda, MD USA. [Shin, Dong-Mi] Seoul Natl Univ, Dept Food & Nutr, Seoul, South Korea. [Shih, David J.; Taylor, Michael D.] Hosp Sick Children, Div Neurosurg, Program Dev & Stem Cell Biol, Toronto, ON M5G 1X8, Canada. [Bronson, Roderick T.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Yun, K (reprint author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA. EM Kyuson.yun@jax.org RI Shih, David/H-3186-2011; OI Shih, David/0000-0002-9802-4937; Rybinski, Brad/0000-0002-3180-4496; Philip, Vivek/0000-0001-5126-707X FU National Cancer Institute Center [P30CA034196] FX This work was supported in part by the National Cancer Institute Center Support Grant P30CA034196 and a gift from Walter and Dorsey Cabot (to K. Yun). NR 31 TC 8 Z9 8 U1 1 U2 9 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD SEP 1 PY 2014 VL 74 IS 17 BP 4864 EP 4874 DI 10.1158/0008-5472.CAN-13-3293 PG 11 WC Oncology SC Oncology GA AP1MC UT WOS:000341833300029 PM 25136069 ER PT J AU Suryani, S Carol, H Chonghaile, TN Frismantas, V Sarmah, C High, L Bornhauser, B Cowley, MJ Szymanska, B Evans, K Boehm, I Tonna, E Jones, L Manesh, DM Kurmasheva, RT Billups, C Kaplan, W Letai, A Bourquin, JP Houghton, PJ Smith, MA Lock, RB AF Suryani, Santi Carol, Hernan Chonghaile, Triona Ni Frismantas, Viktoras Sarmah, Chintanu High, Laura Bornhauser, Beat Cowley, Mark J. Szymanska, Barbara Evans, Kathryn Boehm, Ingrid Tonna, Elise Jones, Luke Manesh, Donya Moradi Kurmasheva, Raushan T. Billups, Catherine Kaplan, Warren Letai, Anthony Bourquin, Jean-Pierre Houghton, Peter J. Smith, Malcolm A. Lock, Richard B. TI Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts SO CLINICAL CANCER RESEARCH LA English DT Article ID PRECLINICAL TESTING PROGRAM; GENE-EXPRESSION; ANTITUMOR-ACTIVITY; ABT-737 TARGETS; BCL-2 PROTEINS; CANCER-CELLS; MCL-1; APOPTOSIS; RESISTANCE; INHIBITOR AB Purpose: Predictive biomarkers are required to identify patients who may benefit from the use of BH3 mimetics such as ABT-263. This study investigated the efficacy of ABT-263 against a panel of patient-derived pediatric acute lymphoblastic leukemia (ALL) xenografts and utilized cell and molecular approaches to identify biomarkers that predict in vivo ABT-263 sensitivity. Experimental Design: The in vivo efficacy of ABT-263 was tested against a panel of 31 patient-derived ALL xenografts composed of MLL-, BCP-, and T-ALL subtypes. Basal gene expression profiles of ALL xenografts were analyzed and confirmed by quantitative RT-PCR, protein expression and BH3 profiling. An in vitro coculture assay with immortalized human mesenchymal cells was utilized to build a predictive model of in vivo ABT-263 sensitivity. Results: ABT-263 demonstrated impressive activity against pediatric ALL xenografts, with 19 of 31 achieving objective responses. Among BCL2 family members, in vivo ABT-263 sensitivity correlated best with low MCL1 mRNA expression levels. BH3 profiling revealed that resistance to ABT-263 correlated with mitochondrial priming by NOXA peptide, suggesting a functional role for MCL1 protein. Using an in vitro coculture assay, a predictive model of in vivo ABT-263 sensitivity was built. Testing this model against 11 xenografts predicted in vivo ABT-263 responses with high sensitivity (50%) and specificity (100%). Conclusion: These results highlight the in vivo efficacy of ABT-263 against a broad range of pediatric ALL subtypes and shows that a combination of in vitro functional assays can be used to predict its in vivo efficacy. (C) 2014 AACR. C1 [Suryani, Santi; Carol, Hernan; Sarmah, Chintanu; High, Laura; Szymanska, Barbara; Evans, Kathryn; Boehm, Ingrid; Tonna, Elise; Jones, Luke; Manesh, Donya Moradi; Lock, Richard B.] UNSW, Lowy Canc Res Ctr, Childrens Canc Inst Australia Med Res, Randwick, NSW 2031, Australia. [Chonghaile, Triona Ni; Letai, Anthony] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Frismantas, Viktoras; Bornhauser, Beat; Bourquin, Jean-Pierre] Univ Childrens Hosp, Div Pediat Oncol, Zurich, Switzerland. [Cowley, Mark J.; Kaplan, Warren] St Vincents Hosp, Garvan Inst Med Res, Peter Wills Bioinformat Ctr, Darlinghurst, NSW 2010, Australia. [Kurmasheva, Raushan T.; Houghton, Peter J.] Nationwide Childrens Hosp, Ctr Childhood Canc, Columbus, OH USA. [Billups, Catherine] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA. [Smith, Malcolm A.] NCI, Canc Therapy Evaluat Program, Bethesda, MD USA. RP Lock, RB (reprint author), UNSW, Lowy Canc Res Ctr, Childrens Canc Inst Australia Med Res, POB 81, Randwick, NSW 2031, Australia. EM rlock@ccia.unsw.edu.au RI Bornhauser, Beat/M-4437-2014; Ni Chonghaile, Triona/L-9418-2015; Lock, Richard/G-4253-2013; OI Ni Chonghaile, Triona/0000-0002-3041-4031; Cowley, Mark/0000-0002-9519-5714 FU National Cancer Institute [NOI-CM-42216, NOI-CM-91001-03]; Leukaemia Foundation of Australia; Cancer Council New South Wales; Krebsliga Zurich; Foundation Kind und Krebs; Hanne Liebermann Stiftung; Swiss National Research Foundation; Cure Cancer Australia Foundation; Cancer Institute NSW; National Health and Medical Research Council FX This research was funded by grants from the National Cancer Institute (NOI-CM-42216 and NOI-CM-91001-03); the Leukaemia Foundation of Australia the Cancer Council New South Wales; the Krebsliga Zurich to B. Bornhauser, and the Foundation Kind und Krebs, the Hanne Liebermann Stiftung, and the Swiss National Research Foundation to J.-P. Bourquin. S. Suryani is supported by Postdoctoral Fellowships from the Leukaemia Foundation of Australia and the Cure Cancer Australia Foundation, and an Early Career Fellowship from the Cancer Institute NSW. R. B. Lock is supported by a Fellowship from the National Health and Medical Research Council. NR 50 TC 22 Z9 22 U1 1 U2 5 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD SEP 1 PY 2014 VL 20 IS 17 BP 4520 EP 4531 DI 10.1158/1078-0432.CCR-14-0259 PG 12 WC Oncology SC Oncology GA AP1MV UT WOS:000341835500013 PM 25013123 ER PT J AU Shiwarski, DJ Shao, CB Bill, A Kim, J Xiao, D Bertrand, CA Seethala, RS Sano, D Myers, JN Ha, P Grandis, J Gaither, LA Puthenveedu, MA Duvvuri, U AF Shiwarski, Daniel J. Shao, Chunbo Bill, Anke Kim, Jean Xiao, Dong Bertrand, Carol A. Seethala, Raja S. Sano, Daisuke Myers, Jeffery N. Ha, Patrick Grandis, Jennifer Gaither, L. Alex Puthenveedu, Manojkumar A. Duvvuri, Umamaheswar TI To "Grow" or "Go": TMEM16A Expression as a Switch between Tumor Growth and Metastasis in SCCHN SO CLINICAL CANCER RESEARCH LA English DT Article ID EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; E-CADHERIN; CELLS; CARCINOMA; ANO1; IDENTIFICATION; CONTRIBUTES; PROGRESSION AB Purpose: Tumor metastasis is the leading cause of death in patients with cancer. However, the mechanisms that underlie metastatic progression remain unclear. We examined TMEM16A (ANO1) expression as a key factor shifting tumors between growth and metastasis. Experimental Design: We evaluated 26 pairs of primary and metastatic lymph node (LN) tissue from patients with squamous cell carcinoma of the head and neck (SCCHN) for differential expression of TMEM16A. In addition, we identified mechanisms by which TMEM16A expression influences tumor cell motility via proteomic screens of cell lines and in vivo mouse studies of metastasis. Results: Compared with primary tumors, TMEM16A expression decreases in metastatic LNs of patients with SCCHN. Stable reduction of TMEM16A expression enhances cell motility and increases metastases while decreasing tumor proliferation in an orthotopic mouse model. Evaluation of human tumor tissues suggests an epigenetic mechanism for decreasing TMEM16A expression through promoter methylation that correlated with a transition between an epithelial and a mesenchymal phenotype. These effects ofTMEM16A expression on tumor cell size and epithelial-to-mesenchymal transition (EMT) required the amino acid residue serine 970 (S970); however, mutation of S970 to alanine does not disrupt the proliferative advantages of TMEM16A overexpression. Furthermore, S970 mediates the association of TMEM16A with Radixin, an actin-scaffolding protein implicated in EMT. Conclusions: Together, our results identify TMEM16A, an eight transmembrane domain Ca2+-activated Cl- channel, as a primary driver of the "Grow" or "Go" model for cancer progression, in which TMEM16A expression acts to balance tumor proliferation and metastasis via its promoter methylation. (C) 2014 AACR. C1 [Shiwarski, Daniel J.; Kim, Jean; Xiao, Dong; Grandis, Jennifer; Duvvuri, Umamaheswar] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA. [Shiwarski, Daniel J.; Kim, Jean; Xiao, Dong; Grandis, Jennifer; Duvvuri, Umamaheswar] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15213 USA. [Shiwarski, Daniel J.; Puthenveedu, Manojkumar A.] Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA. [Shao, Chunbo; Ha, Patrick] Johns Hopkins Univ, Sch Med, Dept Otolaryngol, Baltimore, MD 21205 USA. [Bill, Anke; Gaither, L. Alex] Novartis Inst Biomed Res Inc, Dept Dev & Mol Pathways, Cambridge, MA USA. [Bertrand, Carol A.] Univ Pittsburgh, Med Ctr, Dept Cell Biol, Pittsburgh, PA 15213 USA. [Seethala, Raja S.] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15213 USA. [Sano, Daisuke] Yokohama City Univ, Sch Med, Yokohama, Kanagawa 232, Japan. [Myers, Jeffery N.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA. RP Duvvuri, U (reprint author), Univ Pittsburgh, Med Ctr, Suite 500,200 Lothrop St,W948 Biomed Sci Tower, Pittsburgh, PA 15213 USA. EM duvvuriu@upmc.edu RI Puthenveedu, Manojkumar/A-3795-2016; OI Puthenveedu, Manojkumar/0000-0002-3177-4231; Shiwarski, Daniel/0000-0001-6978-303X FU Head and Neck Cancer SPORE grant through a Career Development Award [P50-CA097190]; Department of Veterans Affairs Biomedical Laboratory Science Research and Development RD; PNC Foundation; University of Pittsburgh Competitive Medical Research Fund; Department of Otolaryngology, University of Pittsburgh School of Medicine FX This work was supported in part by the Head and Neck Cancer SPORE grant (P50-CA097190, to J. Grandis), through a Career Development Award and a Pilot Project grant from the Department of Veterans Affairs Biomedical Laboratory Science Research and Development R&D (to U. Duvvuri), the PNC Foundation, the University of Pittsburgh Competitive Medical Research Fund, and start-up funds from the Department of Otolaryngology, University of Pittsburgh School of Medicine (to U. Duvvuri). NR 27 TC 23 Z9 24 U1 1 U2 10 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD SEP 1 PY 2014 VL 20 IS 17 BP 4673 EP 4688 DI 10.1158/1078-0432.CCR-14-0363 PG 16 WC Oncology SC Oncology GA AP1MV UT WOS:000341835500026 PM 24919570 ER PT J AU Hawryluk, EB Tsao, H AF Hawryluk, Elena B. Tsao, Hensin y TI Melanoma: Clinical Features and Genomic Insights SO COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY LA English DT Article ID PRIMARY CUTANEOUS MELANOMA; BRAF INHIBITOR RESISTANCE; V600E MUTANT MELANOMA; UVEAL MELANOMA; MALIGNANT-MELANOMA; METASTATIC MELANOMA; MELANOCYTIC NEVI; MEK INHIBITION; MC1R VARIANTS; ULTRAVIOLET-RADIATION AB Recent efforts in genomic research have enabled the characterization of molecular mechanisms underlying many types of cancers, ushering novel approaches for diagnosis and therapeutics. Melanoma is a molecularly heterogeneous disease, as many genetic alterations have been identified and the clinical features can vary. Although discoveries of frequent mutations including BRAF have already made clinically significant impact on patient care, there is a growing body of literature suggesting a role for additional mutations, driver and passenger types, in disease pathophysiology. Although some mutations have been strongly associated with clinical phenotypes of melanomas (such as physical distribution or morphologic subtype), the function or implications of many of the recently identified mutations remains less clear. The phenotypic and clinical impact of genomic mutations in melanoma remains a promising opportunity for progress in the care of melanoma patients. C1 [Hawryluk, Elena B.] Harvard Univ, Sch Med, Boston Childrens Hosp, Dermatol Program, Boston, MA 02115 USA. [Hawryluk, Elena B.; Tsao, Hensin y] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. RP Tsao, H (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. EM htsao@partners.org FU Dermatology Foundation Fellowship in Pediatric Dermatology; [K24 CA149202] FX The authors gratefully acknowledge Dr. Matthew Hawryluk for his critical review and comments on this work. Funding for this effort is supported in part by K24 CA149202, the generous donors to the Massachusetts General Hospital Millennium Melanoma fund (both to H. T.), and the Dermatology Foundation Fellowship in Pediatric Dermatology (E. B. H.). NR 113 TC 0 Z9 0 U1 0 U2 2 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI COLD SPRING HARBOR PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA SN 1943-0264 J9 CSH PERSPECT BIOL JI Cold Spring Harbor Perspect. Biol. PD SEP PY 2014 VL 6 IS 9 AR a015388 DI 10.1101/cshperspect.a015388 PG 17 WC Cell Biology SC Cell Biology GA AO8BH UT WOS:000341576800012 ER PT J AU Callegari, L Zhao, X Borrero, S AF Callegari, L. Zhao, X. Borrero, S. TI MENTAL ILLNESS, SUBSTANCE USE DISORDER AND CONTRACEPTIVE ADHERENCE AMONG WOMEN VETERANS SO CONTRACEPTION LA English DT Meeting Abstract C1 [Callegari, L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 EI 1879-0518 J9 CONTRACEPTION JI Contraception PD SEP PY 2014 VL 90 IS 3 MA P129 BP 336 EP 336 DI 10.1016/j.contraception.2014.05.150 PG 1 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AP0GF UT WOS:000341738600164 ER PT J AU Taborsky, GJ Mei, Q Hackney, DJ Mundinger, TO AF Taborsky, G. J., Jr. Mei, Q. Hackney, D. J. Mundinger, T. O. TI The search for the mechanism of early sympathetic islet neuropathy in autoimmune diabetes SO DIABETES OBESITY & METABOLISM LA English DT Review DE glucagon; hypoglycaemia; neuropathy; P75 neurotrophin receptor; sympathetic; type 1 diabetes ID INSULIN-INDUCED HYPOGLYCEMIA; AUTONOMIC NERVOUS-SYSTEM; INCREASED GLUCAGON-SECRETION; P75 NEUROTROPHIN RECEPTOR; GROWTH-FACTOR; B-CELLS; NERVES; RESPONSES; PANCREAS; RELEASE AB This review outlines our search for the mechanism causing the early loss of islet sympathetic nerves in autoimmune diabetes. Since our previous work has documented the importance of autonomic stimulation of glucagon secretion during hypoglycaemia, the loss of these nerves may contribute to the known impairment of this specific glucagon response early in human type 1 diabetes. We therefore briefly review the contribution that autonomic activation, and sympathetic neural activation in particular, makes to the subsequent glucagon response to hypoglycaemia. We also detail evidence that animal models of autoimmune diabetes mimic both the early loss of islet sympathetic nerves and the impaired glucagon response seen in human type 1 diabetes. Using data from these animal models, we examine mechanisms by which this loss of islet nerves could occur. We provide evidence that it is not due to diabetic hyperglycaemia, but is related to the lymphocytic infiltration of the islet. Ablating the p75 neurotrophin receptor, which is present on sympathetic axons, prevents early sympathetic islet neuropathy (eSIN), but, interestingly, not diabetes. Thus, we appear to have separated the immune-related loss of islet sympathetic nerves from the immune-mediated destruction of islet -cells. Finally, we speculate on a way to restore the sympathetic innervation of the islet. C1 [Taborsky, G. J., Jr.] Vet Affairs Puget Sound Hlth Care Syst, Div Endocrinol Metab, Seattle, WA USA. [Taborsky, G. J., Jr.; Mei, Q.; Mundinger, T. O.] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Hackney, D. J.] Seattle Inst Biomed & Clin Res, Seattle, WA USA. RP Taborsky, GJ (reprint author), VA Puget Sound Hlth Care Syst, Res 151,1660 S Columbian Way, Seattle, WA 98108 USA. EM taborsky@u.washington.edu FU Medical Research Service of the Department of Veterans Affairs; National Institutes of Health [R01-DK-50154, P30-DK-017047] FX This work was supported by the Medical Research Service of the Department of Veterans Affairs and National Institutes of Health grants R01-DK-50154 and P30-DK-017047. The authors wish to thank Trish Banik for technical assistance and Pam Henderson for administrative assistance (both of the VA Puget Sound Health Care System). NR 48 TC 2 Z9 2 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1462-8902 EI 1463-1326 J9 DIABETES OBES METAB JI Diabetes Obes. Metab. PD SEP PY 2014 VL 16 SU 1 BP 96 EP 101 DI 10.1111/dom.12341 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AP2EY UT WOS:000341886600014 PM 25200302 ER PT J AU Gandaglia, G Trinh, QD Hu, JC Schiffmann, J Becker, A Roghmann, F Popa, I Tian, Z Perrotte, P Montorsi, F Briganti, A Karakiewicz, PI Sun, M Abdollah, F AF Gandaglia, G. Trinh, Q. -D. Hu, J. C. Schiffmann, J. Becker, A. Roghmann, F. Popa, I. Tian, Z. Perrotte, P. Montorsi, F. Briganti, A. Karakiewicz, P. I. Sun, M. Abdollah, F. TI The impact of robot-assisted radical prostatectomy on the use and extent of pelvic lymph node dissection in the "post-dissemination" period SO EJSO LA English DT Article DE Prostate cancer; Radical prostatectomy; Robotic-assisted radical prostatectomy; Pelvic lymph node dissection; Staging ID UNITED-STATES; CANCER; LYMPHADENECTOMY; YIELD; MEN; METASTASIS; OUTCOMES; THERAPY AB Introduction: Previous series during the dissemination era of minimally invasive techniques for treatment of prostate cancer (PCa) showed a declining use of pelvic lymph node dissection (PLND). The aim of our study was to re-assess the impact of robot-assisted radical prostatectomy (RARP) on the utilization rate of PLND and its extent in the post-dissemination period. Methods: Relying on the Surveillance Epidemiology and End Results (SEER) Medicare-linked database, 5804 patients with non-metastatic PCa undergoing open radical prostatectomy (ORP) or RARP between years 2008 and 2009 were identified. Uni- and multivariable logistic regression analyses tested the relationship between surgical approach (RARP vs. ORP) and: 1 the rate of PLND (pNx vs. pN0-1); and 2 - the extent of PLND (limited vs. extended). Results: Overall, 3357 (57.8%) patients underwent a PLND. The proportion of patients treated with PLND was significantly higher among ORP vs. RARP patients: 71.2 vs. 48.6%, respectively (P < 0.001). In addition, the median number of lymph nodes removed was significantly higher for patients treated with ORP vs. RARP: 5 vs. 4, respectively (P < 0.001). In multivariable analyses, ORP was associated with 2.7- and 1.3-fold higher odds of undergoing PLND and of receiving an extended PLND compared to RARP, respectively (both P < 0.001). Stratified analyses according to disease risk classifications revealed similar trends. Conclusions: In the post-dissemination era, RARP remains associated with a decreased use of PLND and suboptimum extent. Efforts should be made to improve guideline adherence in performing a PLND whenever indicated according to tumor aggressiveness, despite surgical approach. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Gandaglia, G.; Schiffmann, J.; Becker, A.; Roghmann, F.; Popa, I.; Tian, Z.; Karakiewicz, P. I.; Sun, M.; Abdollah, F.] Univ Montreal, Ctr Hlth, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ, Canada. [Gandaglia, G.; Montorsi, F.; Briganti, A.; Abdollah, F.] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Urol Res Inst, Dept Urol, Milan, Italy. [Trinh, Q. -D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Brigham & Womens Hosp,Dept Surg,Div Urol, Boston, MA 02115 USA. [Hu, J. C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Schiffmann, J.; Becker, A.] Univ Med Ctr Hamburg Eppendorf, Martini Clin, Hamburg, Germany. [Roghmann, F.] Ruhr Univ Bochum, Dept Urol, Bochum, Germany. [Perrotte, P.; Karakiewicz, P. I.] Univ Montreal, Ctr Hlth, Dept Urol, Montreal, PQ, Canada. RP Gandaglia, G (reprint author), Canc Prognost & Hlth Outcomes Unit, 264 Blvd Rene Levesque E Room 228, Montreal, PQ H2X 1P1, Canada. EM giorgio.gandaglia@gmail.com OI , Jonas/0000-0002-0654-5920 FU University of Montreal Health Centre Urology Specialists; Fonds de la Recherche en Sante du Quebec; University of Montreal Department of Surgery; University of Montreal Health Centre (CHUM) Foundation FX Pierre I Karakiewicz is partially supported by the University of Montreal Health Centre Urology Specialists, Fonds de la Recherche en Sante du Quebec, the University of Montreal Department of Surgery and the University of Montreal Health Centre (CHUM) Foundation. NR 25 TC 25 Z9 25 U1 1 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0748-7983 EI 1532-2157 J9 EJSO-EUR J SURG ONC JI EJSO PD SEP PY 2014 VL 40 IS 9 BP 1080 EP 1086 DI 10.1016/j.ejso.2013.12.016 PG 7 WC Oncology; Surgery SC Oncology; Surgery GA AP0IU UT WOS:000341745500007 PM 24411705 ER PT J AU Cronin, T Vandenberghe, LH Hantz, P Juttner, J Reimann, A Kacso, AE Huckfeldt, RM Busskamp, V Kohler, H Lagali, PS Roska, B Bennett, J AF Cronin, Therese Vandenberghe, Luk H. Hantz, Peter Juttner, Josephine Reimann, Andreas Kacso, Agota-Eniko Huckfeldt, Rachel M. Busskamp, Volker Kohler, Hubertus Lagali, Pamela S. Roska, Botond Bennett, Jean TI Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adeno-associated virus capsid and promoter SO EMBO MOLECULAR MEDICINE LA English DT Article DE adeno-associated virus; capsid library; multi-electrode array; optogenetics; promoter optimization ID LEBERS CONGENITAL AMAUROSIS; SULFATE PROTEOGLYCAN BINDING; RESTORES VISUAL RESPONSES; GENE-THERAPY; DIRECTED EVOLUTION; HEPARIN-BINDING; TYPE-2 CAPSIDS; VECTORS; EXPRESSION; MGLUR6 AB In this report, we describe the development of a modified adeno-associated virus (AAV) capsid and promoter for transduction of retinal ON-bipolar cells. The bipolar cells, which are post-synaptic to the photoreceptors, are important retinal targets for both basic and preclinical research. In particular, a therapeutic strategy under investigation for advanced forms of blindness involves using optogenetic molecules to render ON-bipolar cells light-sensitive. Currently, delivery of adequate levels of gene expression is a limiting step for this approach. The synthetic AAV capsid and promoter described here achieves high level of optogenetic transgene expression in ON-bipolar cells. This evokes high-frequency (similar to 100Hz) spiking responses in ganglion cells of previously blind, rd1, mice. Our vector is a promising vehicle for further development toward potential clinical use. C1 [Cronin, Therese; Vandenberghe, Luk H.; Huckfeldt, Rachel M.; Bennett, Jean] Univ Penn, Scheie Eye Inst, Ctr Adv Retinal & Ophthalm Therapeut, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA. [Cronin, Therese; Hantz, Peter; Juttner, Josephine; Reimann, Andreas; Busskamp, Volker; Kohler, Hubertus; Lagali, Pamela S.; Roska, Botond] Friedrich Miescher Inst Biomed Res, Basel, Switzerland. [Vandenberghe, Luk H.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst, Boston, MA USA. [Kacso, Agota-Eniko] Univ Babes Bolyai, Fac Phys, R-3400 Cluj Napoca, Romania. [Busskamp, Volker] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. [Lagali, Pamela S.] Ottawa Hosp Res Inst, Regenerat Med Program, Ottawa, ON, Canada. RP Bennett, J (reprint author), Univ Penn, Scheie Eye Inst, Ctr Adv Retinal & Ophthalm Therapeut, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA. EM therese.cronin@fmi.ch; jebennet@mail.med.upenn.edu RI Busskamp, Volker/E-6339-2015 OI Busskamp, Volker/0000-0001-7517-8944 FU Hope for Vision; Marie Heim-Vogtlin (MHV) program of the Swiss National Science Foundation; NEI/NIH [8DP1 EY023177]; Foundation Fighting Blindness; Research to prevent blindness; FM Kirby Foundation; [1R24EY019861-01A1] FX The GRM6-GFP mice used for library screening were kindly provided by Noga Vardi (Perelman School of Medicine, University of Pennsylvania). TC was funded by grants from Hope for Vision and the Marie Heim-Vogtlin (MHV) program of the Swiss National Science Foundation. Additional support was provided by NEI/NIH 8DP1 EY023177, 1R24EY019861-01A1, Foundation Fighting Blindness, Research to prevent blindness, FM Kirby Foundation. NR 57 TC 32 Z9 32 U1 1 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1757-4676 EI 1757-4684 J9 EMBO MOL MED JI EMBO Mol. Med. PD SEP PY 2014 VL 6 IS 9 BP 1175 EP 1190 DI 10.15252/emmm.201404077 PG 16 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA AO9TQ UT WOS:000341700700007 PM 25092770 ER PT J AU Lin, HW Jung, D Lee, LN Sadow, PM Rocco, JW AF Lin, Harrison W. Jung, David Lee, Linda N. Sadow, Peter M. Rocco, James W. TI Solitary myofibroma of the oropharynx causing airway obstruction in an adult SO ENT-EAR NOSE & THROAT JOURNAL LA English DT Article AB Myofibromas are benign neoplasms believed to be the most common fibrous proliferation of childhood. We present an unusual case of a 44-year-old woman who developed acute airway obstruction from a myofibroma in the oropharynx and accordingly required emergent tracheotomy tube placement. Serial laser excisions to adequately remove the entire lesion while maintaining pharyngeal structure and function were performed, and the patient was successfully decannulated. To date she has remained free of signs and symptoms of recurrence. Although rare in adults, solitary myofibromas should be considered in the differential diagnosis of any subcutaneous or submucosal head and neck lesion. Moreover, clinicians treating adult and pediatric patients with known solitary or multicentric forms of myofibroma should be aware of its potential for airway obstruction. Patients found to have a pharyngeal myofibroma should be managed with airway stabilization, surgical excision with preservation of speech and swallow function, and close postoperative monitoring for recurrence. C1 [Lin, Harrison W.] Univ Calif Irvine, Dept Otolaryngol Head & Neck Surg, Orange, CA 92868 USA. [Jung, David; Lee, Linda N.; Rocco, James W.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. [Sadow, Peter M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Rocco, James W.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. Massachusetts Eye & Ear Infirm, Boston, MA USA. RP Lin, HW (reprint author), Univ Calif Irvine, 101 City Dr South,Bldg 56,Suite 500, Orange, CA 92868 USA. EM harrisonlin@gmail.com NR 6 TC 0 Z9 0 U1 1 U2 2 PU VENDOME GROUP LLC PI NEW YORK PA 6 EAST 32 ST, 8 FLOOR, NEW YORK, NY 10016 USA SN 0145-5613 EI 1942-7522 J9 ENT-EAR NOSE THROAT JI ENT-Ear Nose Throat J. PD SEP PY 2014 VL 93 IS 9 BP 410 EP + PG 3 WC Otorhinolaryngology SC Otorhinolaryngology GA AP3GM UT WOS:000341963600008 PM 25255348 ER PT J AU Tan, TC Koutsogeorgis, ID Grapsa, J Papadopoulos, C Katsivas, A Nihoyannopoulos, P AF Tan, Timothy C. Koutsogeorgis, Ilias D. Grapsa, Julia Papadopoulos, Costas Katsivas, Apostolos Nihoyannopoulos, Petros TI Left atrium and the imaging of atrial fibrosis: catch it if you can! SO EUROPEAN JOURNAL OF CLINICAL INVESTIGATION LA English DT Review DE Atrial fibrillation; echocardiography; fibrosis; left atrium; magnetic resonance imaging; remodelling ID 2-DIMENSIONAL SPECKLE-TRACKING; CARDIOVASCULAR MAGNETIC-RESONANCE; MITRAL VALVULAR DISEASE; CATHETER ABLATION; DELAYED-ENHANCEMENT; STRAIN-RATE; INITIAL-EXPERIENCE; UPSTREAM THERAPIES; CLINICAL-EVIDENCE; EUROPEAN-SOCIETY AB Atrial fibrillation is a sustained arrhythmia commonly encountered in clinical practice. It has a high prevalence among the elderly and contributes significantly to the global socio-economic burden. Among many risk factors predisposing to atrial fibrillation is left atrial remodelling and wall fibrosis. Frequently, pathological left atrial wall remodelling and fibrosis results in low atrial compliance and elastance significantly increase the risk of developing permanent atrial fibrillation. We reviewed all literature which employs imaging and left atrial fibrosis and we present all available imaging modalities. Current imaging tools may play a role in the detection of atrial fibrosis, hence providing valuable information for risk stratification and management of patients with atrial fibrillation. C1 [Tan, Timothy C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Cardiol, Boston, MA USA. [Koutsogeorgis, Ilias D.; Papadopoulos, Costas; Katsivas, Apostolos] Red Cross Hosp, Dept Cardiol, Athens, Greece. [Grapsa, Julia; Nihoyannopoulos, Petros] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Cardiol, London, England. RP Nihoyannopoulos, P (reprint author), Imperial Coll NHS Trust, Dept Cardiol, Hammersmith Hosp, Du Cane Rd, London W12 0HS, England. EM p.nihoyannopoulos@imperial.ac.uk NR 67 TC 5 Z9 5 U1 3 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0014-2972 EI 1365-2362 J9 EUR J CLIN INVEST JI Eur. J. Clin. Invest. PD SEP PY 2014 VL 44 IS 9 BP 872 EP 881 DI 10.1111/eci.12305 PG 10 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA AO8SM UT WOS:000341624500006 PM 25066356 ER PT J AU Burge, SK Becho, J Ferrer, RL Wood, RC Talamantes, M Katerndahl, DA AF Burge, Sandra K. Becho, Johanna Ferrer, Robert L. Wood, Robert C. Talamantes, Melissa Katerndahl, David A. TI Safely Examining Complex Dynamics of Intimate Partner Violence SO FAMILIES SYSTEMS & HEALTH LA English DT Article DE spouse abuse; battered women; domestic violence; nonlinear dynamics; longitudinal studies ID DOMESTIC VIOLENCE; PRIMARY-CARE; HEALTH; RELIABILITY; WOMEN; DISORDERS; VALIDITY; STRESS; ADULT; ABUSE AB The overall goal of this study is to use complexity science to gain a deeper understanding of the nonlinear day-to-day dynamics of intimate partner violence, with implications for clinical interventions. This report describes research methods for gathering information about partner violence in real time and assesses recruitment and retention, adherence to study protocol, data validity, and participant safety. Research assistants enrolled 200 women in moderately violent intimate relationships and asked them to report about their relationships every day for 12 weeks. Daily, participants telephoned an Interactive Voice Response (IVR) system and responded to 34 survey questions. They also completed baseline and end-of-study surveys and maintained telephone contact with the study team weekly. Forty-two participants completed qualitative end-of-study interviews to describe their relationships and the impact of the study on their lives. Of 200 enrollees, 145 women provided enough data for nonlinear analyses, averaging 63.5 daily reports of 84 possible. Participants submitted 9,201 daily reports, documenting partner's verbal or physical aggression on 39.4% of days, and their own aggression on 23.1%. Two women were withdrawn from the study for safety reasons; the remainder reported that study participation posed no additional threat. Eighty women sought assistance from community resources. Violence severity did not appear to change over the 12 weeks. The research team successfully and safely recruited and retained 145 women who provided valuable data for a study of complex dynamics of intimate partner violence. C1 [Burge, Sandra K.; Becho, Johanna; Ferrer, Robert L.; Wood, Robert C.; Katerndahl, David A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA. [Talamantes, Melissa] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Burge, SK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, 7703 Floyd Curl Dr,Mail Code 7795, San Antonio, TX 78229 USA. EM burge@uthscsa.edu FU "Dynamics of Human Behavior" program, National Science Foundation [0525026] FX This study was funded with a grant from the "Dynamics of Human Behavior" program, National Science Foundation, Award 0525026. Automated data collection was provided by the University of Colorado, Department of Family Medicine Information Services group. We thank Stephanie Mitchell, Kelli Giacomini, and Wilson Pace for their invaluable assistance with IVR. We also express appreciation to Norma Cantu and Diandrea Garza for their commitment to screening and enrolling women for this study. NR 36 TC 8 Z9 8 U1 3 U2 13 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1091-7527 EI 1939-0602 J9 FAM SYST HEALTH JI Fam. Syst. Health PD SEP PY 2014 VL 32 IS 3 BP 259 EP 270 DI 10.1037/fsh0000013 PG 12 WC Health Care Sciences & Services; Family Studies; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Family Studies; Public, Environmental & Occupational Health GA AP1QF UT WOS:000341845300002 PM 24911769 ER PT J AU Hill, SJ Rolland, T Adelmant, G Xia, XF Owen, MS Dricot, A Zack, TI Sahni, N Jacob, Y Hao, T McKinney, KM Clark, AP Reyon, D Tsai, SQ Joung, JK Beroukhim, R Marto, JA Vidal, M Gaudet, S Hill, DE Livingston, DM AF Hill, Sarah J. Rolland, Thomas Adelmant, Guillaume Xia, Xianfang Owen, Matthew S. Dricot, Amelie Zack, Travis I. Sahni, Nidhi Jacob, Yves Hao, Tong McKinney, Kristine M. Clark, Allison P. Reyon, Deepak Tsai, Shengdar Q. Joung, J. Keith Beroukhim, Rameen Marto, Jarrod A. Vidal, Marc Gaudet, Suzanne Hill, David E. Livingston, David M. TI Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage SO GENES & DEVELOPMENT LA English DT Article DE BRCA1 interaction screening; DNA damage; transcription ID RNA-POLYMERASE-II; NEGATIVE BREAST-CANCER; PLATINUM-BASED CHEMOTHERAPY; PROTEIN INTERACTION NETWORK; COPY-NUMBER ALTERATION; GENOME STABILITY; HUMAN-CELLS; HOMOLOGOUS RECOMBINATION; MMS22L-NFKBIL2 COMPLEX; MMS22L-TONSL COMPLEX AB BRCA1 is a breast and ovarian tumor suppressor. Given its numerous incompletely understood functions and the possibility that more exist, we performed complementary systematic screens in search of new BRCA1 protein-interacting partners. New BRCA1 functions and/or a better understanding of existing ones were sought. Among the new interacting proteins identified, genetic interactions were detected between BRCA1 and four of the interactors: TONSL, SETX, TCEANC, and TCEA2. Genetic interactions were also detected between BRCA1 and certain interactors of TONSL, including both members of the FACT complex. From these results, a new BRCA1 function in the response to transcription-associated DNA damage was detected. Specifically, new roles for BRCA1 in the restart of transcription after UV damage and in preventing or repairing damage caused by stabilized R loops were identified. These roles are likely carried out together with some of the newly identified interactors. This new function may be important in BRCA1 tumor suppression, since the expression of several interactors, including some of the above-noted transcription proteins, is repeatedly aberrant in both breast and ovarian cancers. C1 [Hill, Sarah J.; Rolland, Thomas; Adelmant, Guillaume; Xia, Xianfang; Owen, Matthew S.; Dricot, Amelie; Zack, Travis I.; Sahni, Nidhi; Jacob, Yves; Hao, Tong; McKinney, Kristine M.; Clark, Allison P.; Beroukhim, Rameen; Marto, Jarrod A.; Vidal, Marc; Gaudet, Suzanne; Hill, David E.; Livingston, David M.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA. [Hill, Sarah J.; Rolland, Thomas; Xia, Xianfang; Owen, Matthew S.; Dricot, Amelie; Sahni, Nidhi; Jacob, Yves; Hao, Tong; McKinney, Kristine M.; Clark, Allison P.; Vidal, Marc; Gaudet, Suzanne; Hill, David E.; Livingston, David M.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. [Rolland, Thomas; Xia, Xianfang; Owen, Matthew S.; Dricot, Amelie; Sahni, Nidhi; Jacob, Yves; Hao, Tong; Vidal, Marc; Gaudet, Suzanne; Hill, David E.] Dana Farber Canc Inst, CCSB, Boston, MA 02215 USA. [Adelmant, Guillaume; Marto, Jarrod A.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Adelmant, Guillaume; Marto, Jarrod A.] Dana Farber Canc Inst, Blais Prote Ctr, Boston, MA 02215 USA. [Zack, Travis I.; Beroukhim, Rameen] Broad Inst, Cambridge, MA 02142 USA. [Jacob, Yves] Inst Pasteur, Dept Virol, Unite Genet Mol Virus ARN, F-75015 Paris, France. [Jacob, Yves] CNRS, UMR3569, F-75015 Paris, France. [Jacob, Yves] Univ Paris Diderot, Unite Genet Mol Virus ARN, F-75015 Paris, France. [Reyon, Deepak; Tsai, Shengdar Q.; Joung, J. Keith] Massachusetts Gen Hosp, Mol Pathol Unit, Ctr Computat & Integrat Biol, Charlestown, MA 02129 USA. [Reyon, Deepak; Tsai, Shengdar Q.; Joung, J. Keith] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA. [Reyon, Deepak; Tsai, Shengdar Q.; Joung, J. Keith] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Beroukhim, Rameen] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. RP Livingston, DM (reprint author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA. EM david_livingston@dfci.harvard.edu FU Department of Defense Breast Cancer Research Program Fellowship [W81XWH-08-1-0748]; National Cancer Institute (NCI) Fellowship [1F30CA167895-01]; Breast Cancer Research Foundation; Susan G. Komen Foundation for the Cure [SAC110022]; NCI SPORE grant in breast cancer research [P50CA089393]; NCI [R01 (R01CA136512), P01 (P01CA080111)]; National Institutes of Health (NIH) Director's Pioneer Award [DP1 GM105378]; Jim and Ann Orr Massachusetts General Hospital Research Scholar Award; National Institute of Neurological Disorders and Stroke [P01NS047572]; Dana-Farber Cancer Institute Strategic Research Initiative; Susan Smith Center for Women's Cancers; Honorable Tina Brozman Foundation; National Human Genome Research Institute grant [R01HG001715]; NCI grant [U54CA112962] FX We thank members of the Livingston laboratory and Dana-Farber Cancer Institute Center for Cancer Systems Biology for helpful discussions and technical advice, Myles Brown and Min Ni for helpful discussion regarding Oncomine Concepts Map analysis, Xialu Li for the gift of the pcDNA3-RNASEH1 plasmid, and Shailja Pathania for the gift of the pLX304-HA-Myc-BRCA1 plasmid. S.J.H. was supported initially by Department of Defense Breast Cancer Research Program Fellowship W81XWH-08-1-0748 and subsequently by National Cancer Institute (NCI) Fellowship 1F30CA167895-01. This work was supported by grants from the Breast Cancer Research Foundation, the Susan G. Komen Foundation for the Cure (SAC110022), an NCI SPORE grant (P50CA089393) in breast cancer research to the Dana-Farber/Harvard Cancer Center, and R01 (R01CA136512) and P01 (P01CA080111) grants from the NCI to D.M.L. D.R., S.Q.T., and J.K.J. were supported by a National Institutes of Health (NIH) Director's Pioneer Award (DP1 GM105378) and the Jim and Ann Orr Massachusetts General Hospital Research Scholar Award. J.A.M. and G.A. were supported by a National Institute of Neurological Disorders and Stroke P01 grant (P01NS047572), the Dana-Farber Cancer Institute Strategic Research Initiative, the Susan Smith Center for Women's Cancers, and The Honorable Tina Brozman Foundation. This work was also supported by National Human Genome Research Institute grant R01HG001715 awarded to M.V. and D.E.H., and NCI grant U54CA112962 subaward to M.V. S.J.H. and D.M.L. conceived the project. S.J.H., D.M.L., and D.E.H. wrote the paper with contributions to the Materials and Methods from T.R., G.A., X.X., S.G., and M.S.O. S.J.H. performed the experiments, with contributions from G.A., A.D., Y.J., and N.S. Data analysis was performed by S.J.H., with contributions from T.R., G.A., T.I.Z., M.S.O., X.X., S.G., and T.H. D.M.L., D.E.H., M.V., J.A.M., R.B., K.M.M., S.G., and J.K.J. advised on various technologies. D.R., S.Q.T., and J.K.J. designed and generously provided the TALEN plasmids. ARC. provided the BRCA1 cDNA-expressing HCC38 cell line. NR 73 TC 19 Z9 19 U1 1 U2 9 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI COLD SPRING HARBOR PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA SN 0890-9369 EI 1549-5477 J9 GENE DEV JI Genes Dev. PD SEP 1 PY 2014 VL 28 IS 17 BP 1957 EP 1975 DI 10.1101/gad.241620.114 PG 19 WC Cell Biology; Developmental Biology; Genetics & Heredity SC Cell Biology; Developmental Biology; Genetics & Heredity GA AO9KN UT WOS:000341674700010 PM 25184681 ER PT J AU Kocharyan, A Feldman, R Singleton, A Han, X Bleier, BS AF Kocharyan, Armine Feldman, Rachel Singleton, Amy Han, Xue Bleier, Benjamin S. TI P-glycoprotein inhibition promotes prednisone retention in human sinonasal polyp explants SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE chronic sinusitis; nasal polyposis; P-glycoprotein; MDR1; ATP-dependent efflux pumps; corticosteroids; steroid resistance; prednisone ID CHRONIC RHINOSINUSITIS; EXPRESSION; DEXAMETHASONE; IMMUNOMODULATOR; IDENTIFICATION; TRANSPORTERS; MODULATION; CELLS AB BackgroundP-glycoprotein (P-gp) is an efflux pump, which is part of the innate chemo-immunity defense system and is overexpressed in chronic rhinosinusitis with nasal polyps (CRSwNP). P-gp is capable of regulating corticosteroid retention and thus P-gp upregulation has been implicated in steroid resistance in several inflammatory disorders. The goal of this study is to determine whether P-gp regulates intracellular steroid retention in CRSwNP. MethodsThis was a Massachusetts Eye and Ear Infirmary Institutional Review Board (IRB)-approved study in nasal polyp explants. Polyps were exposed to 50 g/mL of prednisone for 30 minutes with or without the presence of a P-gp inhibitor (Verapamil 12.5 M or Zosuquidar 0.31 M) followed by a 40-minute washout period (n = 16 per group). Intracellular steroid retention was determined by quantifying the concentration of both intracytoplasmic and secreted steroid using an enzyme-linked immunosorbent assay (ELISA). Concentrations relative to control were compared using a Student t test. ResultsThe intracytoplasmic prednisone concentration was significantly greater relative to control following P-gp inhibition with Verapamil (155.28% 22.48%, p < 0.05) and Zosuquidar (125.81% +/- 12.41%, p < 0.05). Similarly, the amount of prednisone secreted by the explant was significantly reduced at 30 minutes following P-gp inhibition with Zosuquidar (78.64% +/- 2.98%, p < 0.05) and 40 minutes following P-gp inhibition with Verapamil (80.56% +/- 5.02%, p < 0.05). ConclusionInhibition of P-gp enhances the intracellular accumulation of prednisone in nasal polyps. This suggests that P-gp participates in regulation of glucocorticoid retention in sinonasal mucosa. These findings, coupled with the known overexpression of P-gp in CRSwNP, may point to a possible mechanism for steroid resistance in this patient population. C1 [Kocharyan, Armine; Feldman, Rachel; Bleier, Benjamin S.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA. [Singleton, Amy; Han, Xue] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA. RP Bleier, BS (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otol & Laryngol, 243 Charles St, Boston, MA 02114 USA. EM benjamin_bleier@meei.harvard.edu FU American Rhinologic Society FX Funding sources for the study: American Rhinologic Society New Investigator Grant. NR 21 TC 4 Z9 4 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD SEP PY 2014 VL 4 IS 9 BP 734 EP 738 DI 10.1002/alr.21361 PG 5 WC Otorhinolaryngology SC Otorhinolaryngology GA AP0QP UT WOS:000341767900006 PM 25145685 ER PT J AU Chhabra, N Healy, DY Freitag, SK Bleier, BS AF Chhabra, Nipun Healy, David Y. Freitag, Suzanne K. Bleier, Benjamin S. TI The nasoseptal flap for reconstruction of the medial and inferior orbit SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE endoscopic orbital surgery; nasoseptal flap; orbital reconstruction; orbital defect; vascularized tissue reconstruction ID SKULL BASE; CAVERNOUS HEMANGIOMAS; SURGERY AB BackgroundEndoscopic endonasal orbital surgery may result in large orbital defects that mandate reconstruction to minimize the risk of diplopia and enophthalmos. The purpose of this study is to determine whether the nasoseptal flap can provide adequate coverage of maximal orbital defects. MethodsThis was an anatomic cadaveric study. Morphometric measurements were completed in 5 cadaveric orbits to determine the dimensions of an orbital defect comprising the entire lamina papyracea and the orbital floor. The dimensions of a planned nasoseptal flap were then calculated and an appropriately sized flap was harvested to verify complete coverage of the defect. ResultsThe mean standard deviation (SD) medial orbital defect was a depth of 47.3 mm +/- 2.52, height of 13.67 mm +/- 2.73, and width of 13.33 mm +/- 1.03 for the orbital floor. The mean flap dimensions were a width of 55 +/- 6.16 mm, height of 48 +/- 4.47 mm, and depth of 70 +/- 3.54 mm. In all cases, the harvested flap adequately covered the orbital defect. These dimensions correlated with flap incisions subtending the mucocutaneous junction anteriorly, the inferior meatus laterally, the attachment of the middle turbinate superiorly, and the choanal arch posteriorly. ConclusionEndoscopic orbital approaches may result in large orbital defects with significant orbital fat herniation and extraocular muscle exposure. Immediate vascularized flap reconstruction of the orbit may help to limit the attendant morbidity including diplopia and enophthalmos. This study is the first to demonstrate the feasibility of the nasoseptal flap for the reconstruction of maximal orbital defects. C1 [Chhabra, Nipun; Healy, David Y.; Bleier, Benjamin S.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otolaryngol Head & Neck Surg, Boston, MA USA. [Freitag, Suzanne K.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA. RP Bleier, BS (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM benjamin_bleier@meei.harvard.edu NR 12 TC 3 Z9 3 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD SEP PY 2014 VL 4 IS 9 BP 763 EP 766 DI 10.1002/alr.21351 PG 4 WC Otorhinolaryngology SC Otorhinolaryngology GA AP0QP UT WOS:000341767900011 PM 25044694 ER PT J AU Yoshida, T Georgopoulos, K AF Yoshida, Toshimi Georgopoulos, Katia TI Ikaros fingers on lymphocyte differentiation SO INTERNATIONAL JOURNAL OF HEMATOLOGY LA English DT Article DE Ikaros; Mi-2 beta; NuRD; LMPP; T-ALL; B-ALL; Lymphocyte precursors; Epigenetic regulation ID ACUTE LYMPHOBLASTIC-LEUKEMIA; CHROMATIN REMODELER MI-2-BETA; DNA-BINDING PROTEINS; T-CELL DEVELOPMENT; TRANSCRIPTION FACTOR; HISTONE DEACETYLASE; LINEAGE COMMITMENT; BONE-MARROW; HEMATOPOIETIC PROGENITORS; MULTIPLE-MYELOMA AB The Ikaros family of DNA-binding proteins are critical regulators of lymphocyte differentiation. In multipotent, hematopoietic progenitors, Ikaros supports transcriptional priming of genes promoting lymphocyte differentiation. Ikaros targets the Nucleosome Remodeling Deacetylase (NuRD) complex to lymphoid lineage genes, thereby increasing chromatin accessibility and transcriptional priming. After lymphoid lineage specification, Ikaros expression is raised to levels characteristic of intermediate B cell and T cell precursors, which is necessary to support maturation and prevent leukemogenesis. Loss of Ikaros in T cell precursors allows the NuRD complex to repress lymphocyte genes and extends its targeting to genes that support growth and proliferation, causing their activation and triggering a cascade of events that leads to leukemogenesis. Loss of Ikaros in B cell precursors blocks differentiation and perpetuates stromal adhesion by enhancing integrin signaling. The combination of integrin and cytokine signaling in Ikaros-deficient pre-B cells promotes their survival and self-renewal. The stages of lymphocyte differentiation that are highly dependent on Ikaros are underscored by changes in Ikaros transcription, supported by a complex network of stage-specific regulatory networks that converge upon the Ikzf1 locus. It is increasingly apparent that understanding the regulatory networks that operate upstream and downstream of Ikaros is critical not only for our understanding of normal lymphopoiesis, but also in placing the right finger on the mechanisms that support hematopoietic malignancies in mouse and human. C1 [Yoshida, Toshimi; Georgopoulos, Katia] Harvard Univ, Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Sch Med, Charlestown, MA 02129 USA. RP Yoshida, T (reprint author), Harvard Univ, Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Sch Med, Bldg 149-3,13th St, Charlestown, MA 02129 USA. EM toshimi.yoshida@cbrc2.mgh.harvard.edu; katia.georgopoulos@cbrc2.mgh.harvard.edu FU NCI NIH HHS [R01 CA162092] NR 69 TC 19 Z9 19 U1 1 U2 14 PU SPRINGER JAPAN KK PI TOKYO PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN SN 0925-5710 EI 1865-3774 J9 INT J HEMATOL JI Int. J. Hematol. PD SEP PY 2014 VL 100 IS 3 BP 220 EP 229 DI 10.1007/s12185-014-1644-5 PG 10 WC Hematology SC Hematology GA AP2BT UT WOS:000341878100005 PM 25085254 ER PT J AU Martin, WJ Shim, M Paulus, HE Chaudhari, S Feng, JY Elashoff, D Hahn, TJ Ranganath, VK AF Martin, William J. Shim, Man Paulus, Harold E. Chaudhari, Sandeep Feng, JingYuan Elashoff, David Hahn, Theodore J. Ranganath, Veena K. CA RADIUS Investigators TI Older Age at Rheumatoid Arthritis Onset and Comorbidities Correlate With Less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index Response to Etanercept in the RADIUS 2 Registry SO JCR-JOURNAL OF CLINICAL RHEUMATOLOGY LA English DT Article DE rheumatoid arthritis; age; outcomes; disease activity; functional status; etanercept ID ANTIRHEUMATIC DRUG INTERVENTION; ELDERLY-PATIENTS; SERIOUS INFECTIONS; YOUNGER; THERAPY; POPULATION; BIOLOGICS; REMISSION; CRITERIA; OUTCOMES AB Background: Controversy exists in understanding the effects of age at onset and comorbidities in predicting rheumatoid arthritis (RA) response to biologic therapy. Objective: The objective of this study was to investigate the influence of age at onset and number of comorbidities on Health Assessment Questionnaire-Disability Index (HAQ-DI) and Clinical Disease Activity Index (CDAI) responses in active RA patients after 6 months of treatment with etanercept. Methods: One thousand eight hundred ninety-nine RA patients were assessed after 6 months of etanercept therapy. Patients met the following inclusion criteria: initiated etanercept, continued therapy for at least 6 months, and were not in CDAI low disease activity (LDA) at baseline (CDAI <= 10.0). Changes in HAQ-DI and CDAI scores over 6 months were analyzed across age of onset quintiles. Multivariate regression models evaluated the independent association between both age at onset and number of comorbidities with change in HAQ-DI/CDAI scores or achieving LDA, while accounting for other covariates. Results: Significant improvements in HAQ-DI and CDAI scores were observed in all age-onset groups, although HAQ-DI improvements were less in older-onset patients. Results of multiple linear regression demonstrated that younger age at onset, higher baseline HAQ-DI/CDAI score, rheumatoid factor positivity, shorter disease duration, and fewer comorbidities at baseline were independently associated with improvement in both HAQ-DI and CDAI scores. Similarly, achieving CDAI LDA after 6 or more months of etanercept was associated with younger age at onset, higher baseline CDAI, shorter disease duration, and fewer comorbidities. Conclusions: These patients with older-onset RA and more comorbidities clinically improved with etanercept, but had lower odds of achieving CDAI LDA. Age of onset and number of comorbidities may be important in determining RA tumor necrosis factor inhibitor response. C1 [Martin, William J.; Shim, Man; Paulus, Harold E.; Elashoff, David; Hahn, Theodore J.; Ranganath, Veena K.] Univ Calif Los Angeles, Los Angeles, CA 90095 USA. [Chaudhari, Sandeep] PharmaNet i3 Strateg Resourcing, Tampa, FL USA. [Feng, JingYuan] Amgen Inc, Thousand Oaks, CA 91320 USA. [Hahn, Theodore J.] VA Greater Los Angeles Geriatr Res Educ & Clin Ct, Los Angeles, CA USA. RP Ranganath, VK (reprint author), Univ Calif Los Angeles, 1000 Vet Ave,Rehab Bldg 32-59, Los Angeles, CA 90095 USA. EM vranganath@mednet.ucla.edu FU Immunex, a wholly owned subsidiary of Amgen Inc; Wyeth; ACR/REF/ASP; UCLA Older Americans Independence Center, NIA [AG028748] FX This study was sponsored by Immunex, a wholly owned subsidiary of Amgen Inc, and by Wyeth, which was acquired by Pfizer in October 2009.; V.K.R. received the ACR/REF/ASP Junior Career Development Award in Geriatric Medicine and UCLA Older Americans Independence Center, NIA AG028748. The remaining authors declare no conflict of interest. NR 42 TC 2 Z9 2 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-1608 EI 1536-7355 J9 JCR-J CLIN RHEUMATOL JI JCR-J. Clin. Rheumatol. PD SEP PY 2014 VL 20 IS 6 BP 301 EP 305 DI 10.1097/RHU.0000000000000152 PG 5 WC Rheumatology SC Rheumatology GA AO7WJ UT WOS:000341563000006 PM 25160011 ER PT J AU Uchimura-Makita, Y Nakano, Y Tokuyama, T Fujiwara, M Watanabe, Y Sairaku, A Kawazoe, H Matsumura, H Oda, N Ikanaga, H Motoda, C Kajihara, K Oda, N Verrier, RL Kihara, Y AF Uchimura-Makita, Yuko Nakano, Yukiko Tokuyama, Takehito Fujiwara, Mai Watanabe, Yoshikazu Sairaku, Akinori Kawazoe, Hiroshi Matsumura, Hiroya Oda, Nozomu Ikanaga, Hiroki Motoda, Chikaaki Kajihara, Kenta Oda, Noboru Verrier, Richard L. Kihara, Yasuki TI Time-Domain T-Wave Alternans is Strongly Associated with a History of Ventricular Fibrillation in Patients with Brugada Syndrome SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY LA English DT Article DE ambulatory monitoring; Brugada syndrome; implantable cardioverter-defibrillator; sudden death; T-wave alternans; ventricular fibrillation ID SODIUM-CHANNEL BLOCKER; I ANTIARRHYTHMIC-DRUG; ST-SEGMENT-ELEVATION; SUDDEN CARDIAC DEATH; LONG-TERM PROGNOSIS; RISK STRATIFICATION; ELECTROCARDIOGRAPHIC PATTERN; MYOCARDIAL-INFARCTION; PREDICTIVE-VALUE; HEART-FAILURE AB Time-Domain T-Wave Alternans and Brugada Syndrome. Aims: T-wave alternans (TWA) is an indicator of vulnerability to ventricular arrhythmias and is useful for predicting sudden cardiac death (SCD) in patients with various structural heart diseases. We evaluated whether high levels of time-domain TWA on ambulatory ECG (AECG) are associated with a history of ventricular fibrillation (VF) in Brugada syndrome (BrS) patients. Methods and Results: We examined the associations among VF history, family history of SCD, spontaneous type 1 electrocardiogram (ECG), late potentials, VF induction by programmed electrical stimulation, and TWA in 45 BrS patients (44 males; mean age, 45 +/- 15 years). TWA analyzed from 24-h AECG recordings using the modified moving average method was positive in 13 of 43 patients (30%). Patients with a history of VF had a significantly higher incidence of a positive TWA test (82% vs. 13%; P < 0.001) and spontaneous type 1 ECG (92% vs. 38%; P = 0.007) than those without VF history. Multivariate analysis indicated that positive TWA (OR 7.217; 95% CI 2.503-35.504; P = 0.002) and spontaneous type 1 ECG (OR 5.530; 95% CI 1.651-34.337; P = 0.020) were closely associated with VF history. Spontaneous type 1 ECG had high sensitivity (92%) but low specificity (63%). Positive TWA was a reliable marker with high sensitivity and specificity (82% and 88%, respectively). Conclusion: Elevated time-domain TWA on AECG confirms arrhythmia risk in symptomatic BrS patients without the need for provocative stimuli. C1 [Uchimura-Makita, Yuko; Nakano, Yukiko; Tokuyama, Takehito; Fujiwara, Mai; Watanabe, Yoshikazu; Sairaku, Akinori; Kawazoe, Hiroshi; Matsumura, Hiroya; Oda, Nozomu; Ikanaga, Hiroki; Motoda, Chikaaki; Kihara, Yasuki] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Cardiovasc Med, Hiroshima 7348551, Japan. [Kajihara, Kenta] Higasihiroshima Med Ctr, Div Cardiovasc Med, Hiroshima, Japan. [Oda, Noboru] Hiroshima City Asa Hosp, Div Cardiovasc Med, Hiroshima, Japan. [Verrier, Richard L.] Harvard Univ, Beth Israel Deaconess Med Ctr, Harvard Thorndike Electrophysiol Inst, Div Cardiovasc Med,Med Sch, Boston, MA 02215 USA. RP Nakano, Y (reprint author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Cardiovasc Med, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan. EM nakanoy@hiroshima-u.ac.jp FU Georgetown University; Beth Israel Deaconess Medical Center FX Dr. Verrier receives royalty income from Georgetown University and Beth Israel Deaconess Medical Center for intellectual property on T-wave alternans analysis with the modified moving average method, which was licensed to GE Healthcare and to Medtronic. Other authors: No disclosures. NR 40 TC 12 Z9 12 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1045-3873 EI 1540-8167 J9 J CARDIOVASC ELECTR JI J. Cardiovasc. Electrophysiol. PD SEP PY 2014 VL 25 IS 9 BP 1021 EP 1027 DI 10.1111/jce.12441 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AP1IE UT WOS:000341821200018 PM 24761970 ER PT J AU Sheu, J Kattapuram, SV Stankiewicz, JM Merola, JF AF Sheu, Johanna Kattapuram, Susan V. Stankiewicz, James M. Merola, Joseph F. TI Eosinophilic Fasciitis-like Disorder Developing in the Setting of Multiple Sclerosis Therapy SO JOURNAL OF DRUGS IN DERMATOLOGY LA English DT Article ID FUMARIC-ACID ESTERS; CYTOKINE SECRETION; PSORIASIS; MULTICENTER AB Importance: Dimethyl fumarate received FDA approval in March 2013 for treatment of multiple sclerosis and has had a rapid uptake in the field due in large part to a favorable safety profile. Side effects of dimethyl fumarate include flushing, gastrointestinal discomfort, and peripheral eosinophilia. We report a case of eosinophilic fasciitis-like disorder occurring in the setting of oral dimethyl fumarate therapy. Eosinophilic fasciitis is rare and may be related to the peripheral eosinophilia known to occur with this medication. Observations: We present a case of a 36-year-old male treated with oral dimethyl fumarate for 16 weeks who developed a bilateral eosinophilic fasciitis-like disorder of the thighs. Magnetic resonance imaging revealed a fluid collection in the fascial plane and histopathologic examination revealed an inflammatory infiltrate with dermal and subcutaneous edema and sclerosis consistent with eosinophilic fasciitis. We discuss studies reporting peripheral eosinophilia with fumaric acid medications as well as the literature exploring possible mechanisms. Conclusions: With the anticipated widespread use of dimethyl fumarate for multiple sclerosis patients, it is important for practitioners to recognize the symptoms of eosinophilic fasciitis and be aware of a possible association of oral dimethyl fumarate treatment with the development of an eosinophilic fasciitis-like disorder. C1 [Sheu, Johanna; Kattapuram, Susan V.; Stankiewicz, James M.; Merola, Joseph F.] Harvard Univ, Sch Med, Boston, MA USA. [Kattapuram, Susan V.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Stankiewicz, James M.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA. [Merola, Joseph F.] Brigham & Womens Hosp, Dept Med, Div Rheumatol, Dept Dermatol, Boston, MA 02115 USA. RP Merola, JF (reprint author), Brigham & Womens Hosp, Dept Med, Div Rheumatol, Dept Dermatol, 75 Francis St, Boston, MA 02115 USA. EM jfmerola@partners.org NR 15 TC 2 Z9 3 U1 0 U2 2 PU JOURNAL OF DRUGS IN DERMATOLOGY PI NEW YORK PA 377 PARK AVE SOUTH, 6TH FLOOR, NEW YORK, NY 10016 USA SN 1545-9616 J9 J DRUGS DERMATOL JI J. Drugs Dermatol. PD SEP PY 2014 VL 13 IS 9 BP 1144 EP 1147 PG 4 WC Dermatology SC Dermatology GA AP1CI UT WOS:000341803600022 PM 25226017 ER PT J AU Amawi, N Mollica, RF Lavelle, J Osman, O Nasir, L AF Amawi, Noor Mollica, Richard F. Lavelle, James Osman, Ossama Nasir, Laeth TI Overview of Research on the Mental Health Impact of Violence in the Middle East in Light of the Arab Spring SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE Mental health; Arab Spring; Middle East; trauma; annotated bibliography ID PRIMARY-CARE; REFUGEES; TRAUMA; ASSOCIATION; DEPRESSION; PREVALENCE; PSYCHIATRY; BELIEFS AB This is a baseline of published research in the trauma field by Arab researchers. It highlights groundbreaking attempts by Arab researchers to investigate the mental health impact of violence in their countries before the Arab Spring. Peer-reviewed articles (N = 157) were identified through computerized searches in PubMed, PsycINFO, Google Scholar, and Pilots Database, 1995 to 2012. A synopsis of the published research included a) country, b) screening instruments, c) sample size, d) methods, and e) results. The findings reveal that domestic violence attracted most attention after civil strife in Palestine and Lebanon. Torture survivors and victims of sexual violence received little attention. Study instruments were borrowed from Western researchers without being validated within local Arab cultures. No clinical outcome studies were found. In light of the Arab Spring, it is urgent that Arab researchers conduct studies that are evidence based and culturally valid addressing the mental health care of all traumatized citizens. C1 [Amawi, Noor; Mollica, Richard F.; Lavelle, James] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Harvard Program Refugee Trauma, Cambridge, MA 02138 USA. [Osman, Ossama; Nasir, Laeth] United Arab Emirates Univ, Al Ain, U Arab Emirates. RP Amawi, N (reprint author), 22 Putnam Ave, Cambridge, MA 02139 USA. EM nooramawi@gmail.com FU United Arab Emirates University FX This study was supported by United Arab Emirates University. NR 34 TC 3 Z9 3 U1 2 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 EI 1539-736X J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD SEP PY 2014 VL 202 IS 9 BP 625 EP 629 DI 10.1097/NMD.0000000000000174 PG 5 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AO9UN UT WOS:000341703700001 PM 25126755 ER PT J AU Miyajima, K Fujisawa, D Yoshimura, K Ito, M Nakajima, S Shirahase, J Mimura, M Miyashita, M AF Miyajima, Kaya Fujisawa, Daisuke Yoshimura, Kimio Ito, Masaya Nakajima, Satomi Shirahase, Joichiro Mimura, Masaru Miyashita, Mitsunori TI Association between Quality of End-of-Life Care and Possible Complicated Grief among Bereaved Family Members SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID ADVANCED CANCER-PATIENTS; MENTAL-HEALTH; GENERAL-POPULATION; CONTROLLED-TRIAL; GOOD DEATH; CAREGIVERS; PREVALENCE; PREPAREDNESS; DISCUSSIONS; PERSPECTIVE AB Background: Little is known about the association between quality of end-of-life care of a patient and complicated grief among bereaved family members. Objective: This study aims to examine the impact of quality of end-of-life care on complicated grief among bereaved family members in a Japanese general population sample. Methods: A mail-based cross-sectional questionnaire survey was used. A total of 641 individuals aged 40 to 79 years in the general population who lost their loved one within the period between 6 months and 10 years were enrolled. Complicated grief was assessed using the Brief Grief Questionnaire, and the bereaved family members' perceptions on quality of end-of-life care were assessed using the Care Evaluation Scale and the Good Death Inventory. Logistic regression analysis was used to identify the variables that associated with possible complicated grief. Results: Possible complicated grief was observed in 24.5% of the participants. Three components of quality of end-of-life care, namely, dissatisfaction with the explanation to the family about the patient's expected outcome, unreasonable cost of care, and family's perception that the deceased person had not achieved a sense of completion about his or her life, were significantly associated with possible complicated grief. Spousal relationship, primary caregiver, and high psychological distress also had significant association. Conclusions: Perceptions on quality of end-of-life care were significantly associated with complicated grief. Providing sufficient information to patients' family about expected outcome and enhancing patients' sense of completion about their life may prevent bereaved family members from developing complicated grief. C1 [Miyajima, Kaya; Fujisawa, Daisuke; Shirahase, Joichiro; Mimura, Masaru] Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo, Japan. [Fujisawa, Daisuke] Massachusetts Gen Hosp, Ctr Canc, Ctr Psychiat Oncol & Behav Sci, Boston, MA 02114 USA. [Yoshimura, Kimio] Keio Univ, Sch Med, Dept Hlth Policy & Management, Tokyo, Japan. [Ito, Masaya; Nakajima, Satomi] Natl Ctr Neuropsychiat & Psychiat, Natl Ctr Cognit Behav Therapy & Res, Tokyo, Japan. [Miyashita, Mitsunori] Tohoku Univ, Grad Sch Med, Dept Palliat Nursing, Sendai, Miyagi 980, Japan. RP Fujisawa, D (reprint author), Massachusetts Gen Hosp, Ctr Canc, Ctr Psychiat Oncol & Behav Sci, 55 Fruit St, Boston, MA 02114 USA. EM dai_fujisawa@yahoo.co.jp FU Ministry of Health, Labor and Welfare, Japan (MHLW) FX This study was fully supported by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare, Japan (MHLW). MHLW had no further role in the study's design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. NR 33 TC 4 Z9 4 U1 1 U2 7 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD SEP PY 2014 VL 17 IS 9 BP 1025 EP 1031 DI 10.1089/jpm.2013.0552 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA AP1RF UT WOS:000341848000012 PM 25050607 ER PT J AU Hasturk, H Kantarci, A Ghattas, M Dangaria, SJ Abdallah, R Morgan, EF Diekwisch, TGH Ashman, A Van Dyke, T AF Hasturk, Hatice Kantarci, Alpdogan Ghattas, Mazen Dangaria, Smit J. Abdallah, Rima Morgan, Elise F. Diekwisch, Thomas G. H. Ashman, Arthur Van Dyke, Thomas TI The Use of Light/Chemically Hardened Polymethylmethacrylate, Polyhydroxylethylmethacrylate, and Calcium Hydroxide Graft Material in Combination With Polyanhydride Around Implants and Extraction Sockets in Minipigs: Part II: Histologic and Micro-CT Evaluations SO JOURNAL OF PERIODONTOLOGY LA English DT Article DE Alveolar ridge augmentation; dental implants; immediate dental implant loading ID DENTAL IMPLANTS; RESORBABLE MEMBRANE; ENDOSSEOUS IMPLANTS; BONE REGENERATION; TOOTH EXTRACTION; IMMEDIATE; PLACEMENT; SURFACE; SITES; TEETH AB Background: This report is the second part of the previously published study on the impact of light/chemical hardening technology and a newly formulated composite graft material for crestal augmentation during immediate implant placement. Methods: A total of 48 implants were placed into the sockets of the mesial roots of freshly extracted mandibular premolar teeth in three minipigs. Crestal areas and intrabony spaces were randomly augmented with light-hardened graft materials including a composite graft consisting of polymethylmethacrylate, polyhydroxylethylmethacrylate, and calcium hydroxide (PPCH) plus polyanhydride (PA); PPCH graft; and PA graft, or left untreated. Distal sockets not receiving implants and the sockets of first molars (n = 60) were randomly treated with one of the graft materials or left empty. In addition, two molar sockets were treated with the original PPCH graft material. Quantitative microcomputed tomography (micro-CT) was used to assess alveolar bone structure and tissue compositions. Histologic evaluations included descriptive histology to assess the peri-implant wound healing, as well as histomorphometric measurements to determine bone-to-implant contact (BIC). Results: Both trabecular and cortical bone measurements by micro-CT did not reveal any significant differences among the groups. Sites augmented with PPCH+PA resulted in significantly greater BIC surface than PPCH alone and no-graft-treated implants (P <0.05) histologically. Stained ground sections showed complete bone formation between bone and implant surface in the PPCH+PA group, whereas sites without augmentation showed large gaps between bone and implant surfaces, indicating a slower bone apposition and less BIC surface compared to all other groups. Similar to implant sections, all materials showed positive outcome on trabecular and cortical bone formation in extraction sockets with an intact crestal cortical bone. Conclusion: Histologic evaluations supported the previous findings on implant stability and function and confirmed that PPCH+PA provides a greater BIC with a well-organized implant-bone interface and is useful in crestal augmentation during immediate implant placement. C1 [Hasturk, Hatice; Kantarci, Alpdogan; Van Dyke, Thomas] Forsyth Inst, Dept Appl Oral Sci, Ctr Periodontol, Cambridge, MA 02142 USA. [Dangaria, Smit J.] Univ Illinois, Dept Oral Biol, Coll Dent, Brodie Lab Craniofacial Genet, Chicago, IL USA. [Abdallah, Rima] Beirut Arab Univ, Beirut, Lebanon. [Morgan, Elise F.] Boston Univ, Dept Biomed Engn, Lab Orthopaed & Dev Biomech, Boston, MA 02215 USA. [Ashman, Arthur] NYU, Coll Dent, Dept Periodontol & Implant Dent, New York, NY USA. RP Hasturk, H (reprint author), Forsyth Inst, Dept Appl Oral Sci, 245 First St,Suite 1757, Cambridge, MA 02142 USA. EM hhasturk@forsyth.org RI Morgan, Elise/L-1706-2013 FU Bioplant R&D, Westport, Connecticut; U.S. Public Health Service Grant [DE019938] FX This study was supported in part by Bioplant R&D, Westport, Connecticut, and U.S. Public Health Service Grant DE019938 (TVD). The authors thank Prof. Devon A. Shipp, Department of Chemistry and Biomolecular Science, Clarkson University, Potsdam, New York; veterinary and animal care personnel: Mimi Crowley, Sharron Kirchain, Michelle Callihan, Rosa Yip, and Sergio Maura at the Boston University Medical Center, Laboratory Animal Science Center, Boston, Massachusetts; Zachary Mason, Department of Biomedical Engineering, Laboratory of Orthopaedic and Developmental Biomechanics, Boston University, Boston, Massachusetts, for his technical assistance during micro-CT imaging; and Emilie Goguet-Surmenian, Department of Periodontology, Boston University, for her assistance in histology. Implants and the implant equipment were kindly donated by Biomet 3i, Palm Beach Gardens, Florida. Specialty surgical instruments were a gift from Hu-Friedy, Chicago, Illinois. Dr. Ashman, Chief Executive Officer of Bioplant R&D, is the inventor and has issued patents on the materials tested. Drs. Hasturk, Kantarci, Ghattas, Dangaria, Abdallah, Diekwisch, and Van Dyke report no conflicts of interest related to this study. NR 42 TC 1 Z9 1 U1 0 U2 5 PU AMER ACAD PERIODONTOLOGY PI CHICAGO PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA SN 0022-3492 EI 1943-3670 J9 J PERIODONTOL JI J. Periodont. PD SEP PY 2014 VL 85 IS 9 BP 1230 EP 1239 DI 10.1902/jop.2014.120424 PG 10 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA AO8CQ UT WOS:000341580700015 PM 24502615 ER PT J AU Boehme, AK Rawal, PV Lyerly, MJ Albright, KC Shahripour, RB Palazzo, P Kapoor, N Alvi, M Houston, JT Harrigan, MR Cava, L Sisson, A Alexandrov, AW Alexandrov, AV AF Boehme, Amelia K. Rawal, Pawan V. Lyerly, Michael J. Albright, Karen C. Shahripour, Reza Bavarsad Palazzo, Paola Kapoor, Niren Alvi, Mohammad Houston, J. Thomas Harrigan, Mark R. Cava, Luis Sisson, April Alexandrov, Anne W. Alexandrov, Andrei V. TI Investigating the Utility of Previously Developed Prediction Scores in Acute Ischemic Stroke Patients in the Stroke Belt SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES LA English DT Article DE Stroke; epidemiology; stroke recovery; outcome ID TISSUE-PLASMINOGEN ACTIVATOR; TOTALED HEALTH-RISKS; EVENTS THRIVE SCORE; INTRAARTERIAL THERAPY; UNITED-STATES; THROMBOLYSIS; VALIDATION; EXPERIENCE; OUTCOMES AB Background: To assess the utility of previously developed scoring systems, we compared SEDAN, named after the components of the score (baseline blood Sugar, Early infarct signs and (hyper) Dense cerebral artery sign on admission computed tomography scan, Age, and National Institutes of Health Stroke Scale on admission), Totaled Health Risks in Vascular Events (THRIVE), Houston Intra-arterial Therapy (HIAT), and HIAT-2 scoring systems among patients receiving systemic (intravenous [IV] tissue plasminogen activator [tPA]) and endovascular (intra-arterial [IA]) treatments. Methods: We retrospectively reviewed all IV tPA and IA patients presenting to our center from 2008-2011. The scores were assessed in patients who were treated with IV tPA only, IA only, and a combination of IV tPA and IA (IV-IA). We tested the ability of THRIVE to predict discharge modified Rankin scale (mRS) 3-6, HIAT and HIAT-2 discharge mRS 4-6, and SEDAN symptomatic intracerebral hemorrhage (sICH). Results: Of the 366 patients who were included in this study, 243 had IV tPA only, 89 had IA only, and 34 had IV-IA. THRIVE was predictive of mRS 3-6 in the IV-IA (odds ratio [OR], 1.95; 95% confidence interval [CI], 1.30-2.91) and the IV group (OR, 1.71; 95% CI, 1.43-2.04), but not in the IA group. HIAT was predictive of mRS 4-6 in the IA (OR, 3.55; 95% CI, 1.65-7.25), IV (OR, 3.47; 95% CI, 2.26-5.33), and IV-IA group (OR, 6.48; 95% CI, 1.41-29.71). HIAT-2 was predictive of mRS 4-6 in the IA (OR, 1.39; 95% CI, 1.03-1.87) and IV group (OR, 1.36; 95% CI, 1.18-1.57), but not in the IV-IA group. SEDAN was not predictive of sICH in the IA or the IV-IA group, but was predictive in the IV group (OR, 1.54; 95% CI, 1.01-2.36). Conclusions: Our study demonstrated that although highly predictive of outcome in the original study design treatment groups, prediction scores may not generalize to all patient samples, highlighting the importance of validating prediction scores in diverse samples. C1 [Boehme, Amelia K.; Rawal, Pawan V.; Lyerly, Michael J.; Shahripour, Reza Bavarsad; Palazzo, Paola; Kapoor, Niren; Alvi, Mohammad; Houston, J. Thomas; Sisson, April; Alexandrov, Andrei V.] Univ Alabama Birmingham, Dept Neurol, Stroke Ctr, Birmingham, AL 35294 USA. [Boehme, Amelia K.; Albright, Karen C.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. [Lyerly, Michael J.] Birmingham Vet Affairs Med Ctr, Stroke Ctr, Birmingham, AL USA. [Harrigan, Mark R.] Univ Alabama Birmingham, Sch Med, Dept Neurosurg, Birmingham, AL USA. [Cava, Luis] Univ Colorado, Dept Neurosurg, Denver, CO 80202 USA. [Alexandrov, Anne W.] Univ Alabama Birmingham, Sch Nursing, Birmingham, AL USA. RP Boehme, AK (reprint author), 1240 Jefferson Tower,619 19th St South, Birmingham, AL 35294 USA. EM akboehme@gmail.com OI Alexandrov, Andrei V/0000-0001-8871-1023; Lyerly, Michael/0000-0003-4236-1018 FU Agency for Healthcare Research and Quality (AHRQ) [5 T32 HS013852-10]; National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH) [3 P60 MD000502-08S1]; American Heart Association (AHA) [13PRE13830003] FX The project described was supported by award numbers 5 T32 HS013852-10 from The Agency for Healthcare Research and Quality (AHRQ), 3 P60 MD000502-08S1 from The National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH) and 13PRE13830003 from the American Heart Association (AHA). The content is solely the responsibility of the authors and does not necessarily represent the official views of the AHA, AHRQ, or the NIH. NR 22 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1052-3057 EI 1532-8511 J9 J STROKE CEREBROVASC JI J. Stroke Cerebrovasc. Dis. PD SEP PY 2014 VL 23 IS 8 BP 2001 EP 2006 DI 10.1016/j.jstrokecerebrovasdis.2014.02.003 PG 6 WC Neurosciences; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA AO6TQ UT WOS:000341484900011 PM 25113079 ER PT J AU Cai, XM Razmara, A Paulus, JK Switkowski, K Fariborz, PJ Goryachev, SD D'Avolio, L Feldmann, E Thaler, DE AF Cai, Xuemei Razmara, Ali Paulus, Jessica K. Switkowski, Karen Fariborz, Pari J. Goryachev, Sergey D. D'Avolio, Leonard Feldmann, Edward Thaler, David E. TI Case Misclassification in Studies of Spinal Manipulation and Arterial Dissection SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES LA English DT Article DE Stroke; stroke prevention; risk factor; spinal manipulation ID CHIROPRACTIC MANIPULATION; UNITED-STATES; RISK-FACTORS; STROKE; CARE; COMPLICATIONS; REGISTRY; HEALTH AB Background: Spinal manipulation has been associated with cervical arterial dissection and stroke but a causal relationship has been questioned by population-based studies. Earlier studies identified cases using International Classification of Diseases Ninth Revision (ICD-9) codes specific to anatomic stroke location rather than stroke etiology. We hypothesize that case misclassification occurred in these previous studies and an underestimation of the strength of the association. We also predicted that case misclassification would differ by patient age. Methods: We identified cases in the Veterans Health Administration database using the same strategy as the prior studies. The electronic medical record was then screened for the word "dissection." The presence of atraumatic dissection was determined by medical record review by a neurologist. Results: Of 3690 patients found by ICD-9 codes over a 30-month period, 414 (11.2%) had confirmed cervical artery dissection with a positive predictive value of 10.5% (95% confidence interval [CI] 9.6%-11.5%). The positive predictive value was higher in patients less than 45 years of age vs 45 years of age or older (41% vs 9%, P < .001). We reanalyzed a previous study, which reported no association between spinal manipulation and cervical artery dissection (odds ratio [OR] 5 1.12, 95% CI.77-1.63) and recalculated an odds ratio of 2.15 (95% CI.98-4.69). For patients less than 45 years of age, the OR was 6.91 (95% CI 2.59-13.74). Conclusions: Prior studies grossly misclassified cases of cervical dissection and mistakenly dismissed a causal association with manipulation. Our study indicates that the OR for spinal manipulation exposure in cervical artery dissection is higher than previously reported. C1 [Cai, Xuemei; Razmara, Ali] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA. [Cai, Xuemei; Razmara, Ali] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Paulus, Jessica K.; Switkowski, Karen] Tufts Univ, Tufts Clin & Translat Sci Inst CTSI, Boston, MA 02111 USA. [Paulus, Jessica K.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Fariborz, Pari J.; Thaler, David E.] Tufts Med Ctr, Dept Neurol, Boston, MA 02111 USA. [Goryachev, Sergey D.; D'Avolio, Leonard] Harvard Univ, Sch Med, Div Gen & Internal Med, Boston, MA USA. [Goryachev, Sergey D.; D'Avolio, Leonard] Ariadne Labs, Boston, MA USA. [Feldmann, Edward] Tufts Univ, Sch Med, Dept Neurol, Boston, MA 02111 USA. RP Thaler, DE (reprint author), Tufts Med Ctr, Dept Neurol, 800 Washington St,Box 314, Boston, MA 02111 USA. EM dthaler@tuftsmedicalcenter.org FU National Center for Research Resources [UL1 RR025752]; National Center for Advancing Translational Sciences, NIH [UL1 TR000073] FX This project was supported by the National Center for Research Resources, grant number UL1 RR025752 and the National Center for Advancing Translational Sciences, NIH, grant number UL1 TR000073. NR 18 TC 3 Z9 3 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1052-3057 EI 1532-8511 J9 J STROKE CEREBROVASC JI J. Stroke Cerebrovasc. Dis. PD SEP PY 2014 VL 23 IS 8 BP 2031 EP 2035 DI 10.1016/j.jstrokecerebrovasdis.2014.03.007 PG 5 WC Neurosciences; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA AO6TQ UT WOS:000341484900016 PM 25085345 ER PT J AU Jacobus, J Squeglia, LM Sorg, SF Nguyen-Louie, TT Tapert, SF AF Jacobus, Joanna Squeglia, Lindsay M. Sorg, Scott F. Nguyen-Louie, Tam T. Tapert, Susan F. TI Cortical Thickness and Neurocognition in Adolescent Marijuana and Alcohol Users Following 28 Days of Monitored Abstinence SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS LA English DT Article ID SPATIAL WORKING-MEMORY; HUMAN CEREBRAL-CORTEX; SURFACE-BASED ANALYSIS; ADULT CANNABIS USERS; WHITE-MATTER; NEUROPSYCHOLOGICAL PERFORMANCE; SUBSTANCE-ABUSE; BINGE DRINKING; COMPLEX FIGURE; FMRI RESPONSE AB Objective: Adolescent marijuana use continues to increase in prevalence as harm perception declines. Better understanding of marijuana's impact on neurodevelopment is crucial. This prospective study aimed to investigate cortical thickness and neurocognitive performance before and after 28 days of monitored abstinence in adolescent marijuana and alcohol users. Method: Subjects (N = 54; >70% male) were adolescent marijuana users (ages 15-18 years) with regular alcohol use (MJ + ALC; n = 24) and non-using controls (CON; n = 30) who were compared before and after 4 weeks of sequential urine toxicology to confirm abstinence. Participants underwent magnetic resonance imaging, neuropsychological assessment, and substance use assessment at both time points. Repeated-measures analysis of covariance was used to look at the main effects of group, time, and Group x Time interactions on cortical thickness and neurocognitive functioning. Bivariate correlations estimated associations between cortical thickness, substance use severity, and cognitive performance. Results: Marijuana users showed thicker cortices than controls in the left entorhinal cortex (ps < .03) before and after monitored abstinence, after adjusting for lifetime alcohol use. More lifetime marijuana use was linked to thinner cortices in temporal and frontal regions, whereas more lifetime alcohol use and heavy episodic drinking episodes was linked to thicker cortices in all four lobes (ps < .05). Age of onset of regular marijuana use was positively related to cortical thickness (ps < .03). Conclusions: Adolescent alcohol and marijuana use may be linked to altered longer-term neurodevelopmental trajectories and compromised neural health. Cortical thickness alterations and dose-dependent associations with thickness estimates were observed both before and after monitored abstinence and suggest neural differences continue to persist 28 days after cessation of marijuana use. Neural recovery may be identified with longer follow-up periods; however, observed changes related to use severity could have implications for future psychosocial outcomes. C1 [Jacobus, Joanna; Tapert, Susan F.] VA San Diego Healthcare Syst, San Diego, CA 92161 USA. [Jacobus, Joanna; Squeglia, Lindsay M.; Nguyen-Louie, Tam T.; Tapert, Susan F.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Sorg, Scott F.] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. [Nguyen-Louie, Tam T.] Univ Calif San Diego, San Diego State Univ, Joint Doctoral Program Clin Psychol, San Diego, CA 92103 USA. RP Tapert, SF (reprint author), VA San Diego Healthcare Syst, Psychol Serv 116B, 3350 La Jolla Village Dr, San Diego, CA 92161 USA. EM stapert@ucsd.edu FU National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism [P20 DA024194, R01 DA021182, F32 DA032188, R01 AA013419, T32 AA013525, U01 AA021692] FX This study was supported by National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism Grants P20 DA024194, R01 DA021182, F32 DA032188, R01 AA013419, T32 AA013525, and U01 AA021692. NR 96 TC 14 Z9 14 U1 6 U2 20 PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PI PISCATAWAY PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA SN 1937-1888 EI 1938-4114 J9 J STUD ALCOHOL DRUGS JI J. Stud. Alcohol Drugs PD SEP PY 2014 VL 75 IS 5 BP 729 EP 743 PG 15 WC Substance Abuse; Psychology SC Substance Abuse; Psychology GA AO8PA UT WOS:000341615500001 PM 25208190 ER PT J AU Svendsen, MC Akingba, AG Sinha, AK Chattin, B Turner, A Brass, M Bhatt, DL Kassab, GS AF Svendsen, Mark C. Akingba, A. George Sinha, Anjan K. Chattin, Brooke Turner, Amelia Brass, Margaret Bhatt, Deepak L. Kassab, Ghassan S. TI Conductance sizing balloon for measurement of peripheral artery minimal stent area SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID INTRAVASCULAR ULTRASOUND ASSESSMENT; BIORESORBABLE VASCULAR SCAFFOLD; ABSORB COHORT B; LUMEN AREA; IMPEDANCE CATHETER; HEART-ASSOCIATION; VALIDATION; EXPANSION; RESTENOSIS; DIAMETERS AB Background: Because stent underdeployment occurs frequently, accurate minimal stent area (MSA) measurement during postdilatation is necessary. This study investigated the accuracy and repeatability for MSA determination using a novel conductance balloon (CB) catheter for peripheral vessels. Methods: The CB catheter is a standard balloon catheter that measures electrical conductance (ratio of current/voltage drop) in real-time during inflation, which directly relates to the balloon cross-sectional area through Ohm's law. CB measurements were made in 4- to 10-mm phantoms on the bench, ex vivo in stents fully deployed in diseased human peripheral arteries, and in vivo in stents fully deployed in peripheral vessels in six swine. CB measurement accuracy and repeatability were calculated and compared with the known dimension (bench phantoms) or with intravascular ultrasound (IVUS) measurement after stent deployment (ex vivo and in vivo). Results: CB measurements were highly accurate (error: 1.8% bench, 5% ex vivo, and 5% in vivo) and repeatable (error: 0.9% bench, 1.8% ex vivo, and 1.3% in vivo), with virtually no bias (average difference in measurements: -0.05 mm bench CB vs known phantom diameters, L0.06 mm ex vivo CB vs IVUS, and -0.11 mm in vivo CB vs IVUS). Conclusions: The CB sizing capability can be integrated within a standard balloon catheter (two-in-one function) to provide accurate, real-time assessment of MSA to ensure full stent apposition rather than the use of pressure as a surrogate for size. C1 [Svendsen, Mark C.; Chattin, Brooke; Turner, Amelia; Brass, Margaret; Kassab, Ghassan S.] Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA. [Akingba, A. George; Kassab, Ghassan S.] Indiana Univ Purdue Univ, Dept Surg, Indianapolis, IN 46202 USA. [Sinha, Anjan K.] Indiana Univ Purdue Univ, Dept Cardiol, Indianapolis, IN 46202 USA. [Bhatt, Deepak L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02115 USA. [Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA USA. [Kassab, Ghassan S.] Indiana Univ Purdue Univ, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA. RP Kassab, GS (reprint author), Indiana Univ Purdue Univ, Dept Biomed Engn, 635 Barnhill Dr, Indianapolis, IN 46202 USA. EM gkassab@iupui.edu RI Akingba, A. George/D-8164-2016 FU 3DT Holdings, LLC (Indianapolis, Ind) FX 3DT Holdings, LLC (Indianapolis, Ind) provided funding for the manufacture of the balloons and for the bench and vessel testing. NR 29 TC 1 Z9 1 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD SEP PY 2014 VL 60 IS 3 BP 759 EP 766 DI 10.1016/j.jvs.2013.06.095 PG 8 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA AO8UE UT WOS:000341629700035 PM 23992994 ER PT J AU Durham, CA Aranson, NJ Ergul, EA Wang, LJ Patel, VI Cambria, RP Conrad, MF AF Durham, Christopher A. Aranson, Nathan J. Ergul, Emel A. Wang, Linda J. Patel, Virendra I. Cambria, Richard P. Conrad, Mark F. TI Aneurysmal Degeneration of Medically-Managed Acute Type B Aortic Dissections SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Joint Annual Meeting of the New-England-Society-for-Vascular-Surgery (NESVS) and the Eastern-Vascular-Society (EVS) CY SEP 11-14, 2014 CL Boston, MA SP New England Soc Vasc Surg, Eastern Vasc Soc C1 [Durham, Christopher A.; Aranson, Nathan J.; Ergul, Emel A.; Wang, Linda J.; Patel, Virendra I.; Cambria, Richard P.; Conrad, Mark F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. OI Aranson, Nathan/0000-0001-8833-4643 NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD SEP PY 2014 VL 60 IS 3 BP 815 EP 815 PG 1 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA AO8UE UT WOS:000341629700062 ER PT J AU Saraidaridis, JT Ergul, E Patel, VI Stone, DH Cambria, RP Conrad, MF AF Saraidaridis, Julia T. Ergul, Emel Patel, Virendra I. Stone, David H. Cambria, Richard P. Conrad, Mark F. TI Current Outcomes of Lower Extremity Bypass in High-Risk Patients SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Joint Annual Meeting of the New-England-Society-for-Vascular-Surgery (NESVS) and the Eastern-Vascular-Society (EVS) CY SEP 11-14, 2014 CL Boston, MA SP New England Soc Vasc Surg, Eastern Vasc Soc C1 [Saraidaridis, Julia T.; Ergul, Emel; Patel, Virendra I.; Cambria, Richard P.; Conrad, Mark F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Stone, David H.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD SEP PY 2014 VL 60 IS 3 BP 816 EP 817 PG 2 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA AO8UE UT WOS:000341629700066 ER PT J AU Mohebali, J Patel, VI Hannon, KM Romero, JM Jaff, MR Cambria, RP LaMuraglia, GM AF Mohebali, Jahan Patel, Virendra I. Hannon, Kathleen M. Romero, Javier M. Jaff, Michael R. Cambria, Richard P. LaMuraglia, Glenn M. TI Acoustic Shadowing Significantly Impairs Accurate Characterization of Stenosis in Carotid Duplex Examinations SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Joint Annual Meeting of the New-England-Society-for-Vascular-Surgery (NESVS) and the Eastern-Vascular-Society (EVS) CY SEP 11-14, 2014 CL Boston, MA SP New England Soc Vasc Surg, Eastern Vasc Soc C1 [Mohebali, Jahan; Patel, Virendra I.; Hannon, Kathleen M.; Romero, Javier M.; Jaff, Michael R.; Cambria, Richard P.; LaMuraglia, Glenn M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD SEP PY 2014 VL 60 IS 3 BP 822 EP 822 PG 1 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA AO8UE UT WOS:000341629700079 ER PT J AU Lancaster, RT Mohebali, J Twerdahl, E Ergul, E Kwolek, CJ Conrad, MF Cambria, RP Patel, VI AF Lancaster, Robert T. Mohebali, Jahan Twerdahl, Eric Ergul, Emel Kwolek, Christopher J. Conrad, Mark F. Cambria, Richard P. Patel, Virendra I. TI Risk Stratified Analysis of Open Versus Fenestrated Repair of Complex Abdominal Aortic Aneurysms SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Joint Annual Meeting of the New-England-Society-for-Vascular-Surgery (NESVS) and the Eastern-Vascular-Society (EVS) CY SEP 11-14, 2014 CL Boston, MA SP New England Soc Vasc Surg, Eastern Vasc Soc C1 [Lancaster, Robert T.; Mohebali, Jahan; Twerdahl, Eric; Ergul, Emel; Kwolek, Christopher J.; Conrad, Mark F.; Cambria, Richard P.; Patel, Virendra I.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD SEP PY 2014 VL 60 IS 3 BP 823 EP 824 PG 2 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA AO8UE UT WOS:000341629700083 ER PT J AU Brinster, CJ Cambria, MR Ergul, EA Conrad, MF Cambria, RP AF Brinster, Clayton J. Cambria, Matthew R. Ergul, Emel A. Conrad, Mark F. Cambria, Richard P. TI Long Term Follow Up After EVAR: A Contemporary Series SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Joint Annual Meeting of the New-England-Society-for-Vascular-Surgery (NESVS) and the Eastern-Vascular-Society (EVS) CY SEP 11-14, 2014 CL Boston, MA SP New England Soc Vasc Surg, Eastern Vasc Soc C1 [Brinster, Clayton J.; Cambria, Matthew R.; Ergul, Emel A.; Conrad, Mark F.; Cambria, Richard P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD SEP PY 2014 VL 60 IS 3 BP 829 EP 829 PG 1 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA AO8UE UT WOS:000341629700097 ER PT J AU Farber, A Imrey, P Kaufman, J Huber, T Kraiss, L Vita, J Kusek, J Bercelli, S Fenves, A Young, C Vazquez, M Larive, B Li, L Radeva, M Beck, G Feldman, H AF Farber, Alik Imrey, Peter Kaufman, James Huber, Thomas Kraiss, Larry Vita, Joseph Kusek, John Bercelli, Scott Fenves, Andrew Young, Carlton Vazquez, Miguel Larive, Brett Li, Liang Radeva, Milena Beck, Gerald Feldman, Harold CA HFM Study Grp TI Surgeon's Intraoperative Assessments During Autogenous Arteriovenous Fistula Creation Strongly Correlate With Early Fistula Thrombosis SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Joint Annual Meeting of the New-England-Society-for-Vascular-Surgery (NESVS) and the Eastern-Vascular-Society (EVS) CY SEP 11-14, 2014 CL Boston, MA SP New England Soc Vasc Surg, Eastern Vasc Soc C1 [Farber, Alik; Vita, Joseph] Boston Med Ctr, Boston, MA USA. [Imrey, Peter; Larive, Brett; Li, Liang; Radeva, Milena; Beck, Gerald] Cleveland Clin Fdn, Cleveland, OH USA. [Kaufman, James] VA Boston Healthcare Syst, Boston, MA USA. [Huber, Thomas; Bercelli, Scott] Univ Florida, Coll Med, Gainesville, FL USA. [Kraiss, Larry] Univ Utah, Salt Lake City, UT USA. [Kusek, John] NIDDK, Bethesda, MD 20892 USA. [Fenves, Andrew] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Young, Carlton] Univ Alabama Birmingham, Birmingham, AL USA. [Vazquez, Miguel] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Feldman, Harold] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD SEP PY 2014 VL 60 IS 3 BP 832 EP 832 PG 1 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA AO8UE UT WOS:000341629700103 ER PT J AU Vimaleswaran, KS Cavadino, A Berry, DJ Jorde, R Dieffenbach, AK Lu, C Alves, AC Heerspink, HJL Tikkanen, E Eriksson, J Wong, A Mangino, M Jablonski, KA Nolte, IM Houston, DK Ahluwalia, TS van der Most, PJ Pasko, D Zgaga, L Thiering, E Vitart, V Fraser, RM Huffman, JE de Boer, RA Schottker, B Saum, KU McCarthy, MI Dupuis, J Herzig, KH Sebert, S Pouta, A Laitinen, J Kleber, ME Navis, G Lorentzon, M Jameson, K Arden, N Cooper, JA Acharya, J Hardy, R Raitakari, O Ripatti, S Billings, LK Lahti, J Osmond, C Penninx, BW Rejnmark, L Lohman, KK Paternoster, L Stolk, RP Hernandez, DG Byberg, L Hagstrom, E Melhus, H Ingelsson, E Mellstrom, D Ljunggren, O Tzoulaki, I McLachlan, S Theodoratou, E Tiesler, CMT Jula, A Navarro, P Wright, AF Polasek, O Hayward, C Wilson, JF Rudan, I Salomaa, V Heinrich, J Campbell, H Price, JF Karlsson, M Lind, L Michaesson, K Bandinelli, S Frayling, TM Hartman, CA Sorensen, TIA Kritchevsky, SB Flo, BLLJGEJC Eriksson, JG Florez, JC Spector, TD Lehtimaki, T Kuh, D Humphries, SE Cooper, C Ohlsson, C Marz, W de Borst, MH Kumari, M Kivimaki, M Wang, TJ Power, C Brenner, H Grimnes, G van der Harst, P Snieder, H Hingorani, AD Pilz, S Whittaker, JC Jarvelin, MR Hypponen, E AF Vimaleswaran, Karani S. Cavadino, Alana Berry, Diane J. Jorde, Rolf Dieffenbach, Aida Karina Lu, Chen Alves, Alexessander Couto Heerspink, Hiddo J. Lambers Tikkanen, Emmi Eriksson, Joel Wong, Andrew Mangino, Massimo Jablonski, Kathleen A. Nolte, Ilja M. Houston, Denise K. Ahluwalia, Tarunveer Singh van der Most, Peter J. Pasko, Dorota Zgaga, Lina Thiering, Elisabeth Vitart, Veronique Fraser, Ross M. Huffman, Jennifer E. de Boer, Rudolf A. Schoettker, Ben Saum, Kai-Uwe McCarthy, Mark I. Dupuis, Josee Herzig, Karl-Heinz Sebert, Sylvain Pouta, Anneli Laitinen, Jaana Kleber, Marcus E. Navis, Gerjan Lorentzon, Mattias Jameson, Karen Arden, Nigel Cooper, Jackie A. Acharya, Jayshree Hardy, Rebecca Raitakari, Olli Ripatti, Samuli Billings, Liana K. Lahti, Jari Osmond, Clive Penninx, Brenda W. Rejnmark, Lars Lohman, Kurt K. Paternoster, Lavinia Stolk, Ronald P. Hernandez, Dena G. Byberg, Liisa Hagstrom, Emil Melhus, Hakan Ingelsson, Erik Mellstroem, Dan Ljunggren, Osten Tzoulaki, Ioanna McLachlan, Stela Theodoratou, Evropi Tiesler, Carla M. T. Jula, Antti Navarro, Pau Wright, Alan F. Polasek, Ozren Hayward, Caroline Wilson, James F. Rudan, Igor Salomaa, Veikko Heinrich, Joachim Campbell, Harry Price, Jacqueline F. Karlsson, Magnus Lind, Lars Michaesson, Karl Bandinelli, Stefania Frayling, Timothy M. Hartman, Catharina A. Sorensen, Thorkild I. A. Kritchevsky, Stephen B. Langdahl, Bente Lomholt Eriksson, Johan G. Florez, Jose C. Spector, Tim D. Lehtimaki, Terho Kuh, Diana Humphries, Steve E. Cooper, Cyrus Ohlsson, Claes Maerz, Winfried de Borst, Martin H. Kumari, Meena Kivimaki, Mika Wang, Thomas J. Power, Chris Brenner, Hermann Grimnes, Guri van der Harst, Pim Snieder, Harold Hingorani, Aroon D. Pilz, Stefan Whittaker, John C. Jarvelin, Marjo-Riitta Hypponen, Elina CA LifeLines Cohort Study Investigato ICBP CHARGE Consortium Global Blood Pressure Genetics Gl TI Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study SO LANCET DIABETES & ENDOCRINOLOGY LA English DT Article ID GENOME-WIDE ASSOCIATION; RENIN-ANGIOTENSIN SYSTEM; D SUPPLEMENTATION; GENETIC-VARIANTS; TRIAL; METAANALYSIS; OUTCOMES; DISEASE; HEALTH; KIDNEY AB Background Low plasma 25-hydroxyvitamin D (25[OH]D) concentration is associated with high arterial blood pressure and hypertension risk, but whether this association is causal is unknown. We used a mendelian randomisation approach to test whether 25(OH)D concentration is causally associated with blood pressure and hypertension risk. Methods In this mendelian randomisation study, we generated an allele score (25[OH]D synthesis score) based on variants of genes that affect 25(OH)D synthesis or substrate availability (CYP2R1 and DHCR7), which we used as a proxy for 25(OH)D concentration. We meta-analysed data for up to 108 173 individuals from 35 studies in the D-CarDia collaboration to investigate associations between the allele score and blood pressure measurements. We complemented these analyses with previously published summary statistics from the International Consortium on Blood Pressure (ICBP), the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium, and the Global Blood Pressure Genetics (Global BPGen) consortium. Findings In phenotypic analyses (up to n=49 363), increased 25(OH) D concentration was associated with decreased systolic blood pressure (beta per 10% increase, -0.12 mm Hg, 95% CI -0.20.to -0.04; p=0.003) and reduced odds of hypertension (odds ratio [OR] 0.98, 95% CI 0.97-0.99; p=0.0003), but not with decreased diastolic blood pressure (beta per 10% increase, -0.02 mm Hg, -0.08 to 0.03; p=0.37). In meta-analyses in which we combined data from D-CarDia and the ICBP (n=146 581, after exclusion of overlapping studies), each 25(OH)D-increasing allele of the synthesis score was associated with a change of -0.10 mm Hg in systolic blood pressure (-0.21 to -0.0001; p=0.0498) and a change of -0.08 mm Hg in diastolic blood pressure (-0.15 to -0.02; p=0.01). When D-CarDia and consortia data for hypertension were meta-analysed together (n=142 255), the synthesis score was associated with a reduced odds of hypertension (OR per allele, 0.98, 0.96-0.99; p=0.001). In instrumental variable analysis, each 10% increase in genetically instrumented 25(OH) D concentration was associated with a change of -0.29 mm Hg in diastolic blood pressure (-0.52 to -0.07; p=0.01), a change of -0.37 mm Hg in systolic blood pressure (-0.73 to 0.003; p=0.052), and an 8 1% decreased odds of hypertension (OR 0.92, 0.87-0.97; p=0.002). Interpretation Increased plasma concentrations of 25(OH)D might reduce the risk of hypertension. This finding warrants further investigation in an independent, similarly powered study. C1 [Vimaleswaran, Karani S.; Cavadino, Alana; Berry, Diane J.; Power, Chris; Hypponen, Elina] UCL Inst Child Hlth, London, England. [Vimaleswaran, Karani S.] Univ Reading, Sch Chem Food & Pharm, Dept Food & Nutr Sci, Hugh Sinclair Unit Human Nutr, Reading, Berks, England. [Jorde, Rolf; Grimnes, Guri] Univ Tromso, Dept Clin Med, Tromso Endocrine Res Grp, Tromso, Norway. [Dieffenbach, Aida Karina; Schoettker, Ben; Saum, Kai-Uwe; Brenner, Hermann] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany. [Lu, Chen; Dupuis, Josee] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Alves, Alexessander Couto; Jarvelin, Marjo-Riitta] Univ London Imperial Coll Sci Technol & Med, Fac Med, Sch Publ Hlth, Dept Epidemiol & Biostat, London, England. [Tzoulaki, Ioanna] Univ London Imperial Coll Sci Technol & Med, Fac Med, Sch Publ Hlth, London, England. [Jarvelin, Marjo-Riitta] Univ London Imperial Coll Sci Technol & Med, MRC, PHE Ctr Environm & Hlth, London, England. [Heerspink, Hiddo J. Lambers] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharmacol, Groningen, Netherlands. [Nolte, Ilja M.; van der Most, Peter J.; Stolk, Ronald P.; Snieder, Harold] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands. [Hartman, Catharina A.] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, Groningen, Netherlands. [Navis, Gerjan; van der Harst, Pim] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands. [Navis, Gerjan; de Borst, Martin H.] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Div Nephrol, Groningen, Netherlands. [Tikkanen, Emmi] Inst Mol Med Finland, Tukholmankatu, Finland. [Eriksson, Joel; Lorentzon, Mattias; Mellstroem, Dan; Ohlsson, Claes] Sahlgrens Univ Hosp, Ctr Bone & Arthrit Res, Inst Med, Gothenburg, Sweden. [Wong, Andrew; Hardy, Rebecca; Kuh, Diana] UCL, MRC, Unit Lifelong Hlth & Ageing, London, England. [Cooper, Jackie A.; Acharya, Jayshree; Humphries, Steve E.] UCL, Inst Cardiovasc Sci, BHF Labs, London, England. [Hingorani, Aroon D.] UCL, Genet Epidemiol Grp, London, England. [Kumari, Meena; Kivimaki, Mika] UCL, Dept Epidemiol & Publ Hlth, London, England. [Mangino, Massimo; Spector, Tim D.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England. [Jablonski, Kathleen A.] George Washington Univ, Sch Publ Hlth, Biostat Ctr, Dept Epidemiol & Biostat, Rockville, MD USA. [Houston, Denise K.; Kritchevsky, Stephen B.] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC USA. [Lohman, Kurt K.] Wake Forest Sch Med, Dept Biostat Sci, Div Publ Hlth Sci, Winston Salem, NC USA. [Ahluwalia, Tarunveer Singh; Sorensen, Thorkild I. A.] Univ Copenhagen, Fac Hlth & Med Sci, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark. [Ahluwalia, Tarunveer Singh] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen Prospect Studies Asthma Childhood, Copenhagen, Denmark. [Sorensen, Thorkild I. A.] Bispebjerg & Frederiksberg Hosp, Inst Prevent Med, Copenhagen, Denmark. [Ahluwalia, Tarunveer Singh] Gentofte Univ Hosp, Danish Pediat Asthma Ctr, Copenhagen, Denmark. [Pasko, Dorota; Frayling, Timothy M.] Univ Exeter, Sch Med, Exeter, Devon, England. [Zgaga, Lina; Fraser, Ross M.; McLachlan, Stela; Theodoratou, Evropi; Wilson, James F.; Rudan, Igor; Campbell, Harry; Price, Jacqueline F.] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland. [Vitart, Veronique; Huffman, Jennifer E.; Navarro, Pau; Wright, Alan F.; Hayward, Caroline] Univ Edinburgh, Inst Genet & Mol Med, MRC, Human Genet Unit, Edinburgh, Midlothian, Scotland. [Zgaga, Lina] Trinity Coll Dublin, Dept Publ Hlth & Primary Care, Dublin, Ireland. [Thiering, Elisabeth; Tiesler, Carla M. T.; Heinrich, Joachim] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Neuherberg, Germany. [Thiering, Elisabeth] Univ Munich, Dr von Hauner Childrens Hosp, Div Metab Dis & Nutr Med, Munich, Germany. [Tiesler, Carla M. T.] Univ Munich, Dr von Hauner Childrens Hosp, Inst Med Informat Biometry & Epidemiol, Munich, Germany. [McCarthy, Mark I.] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England. [McCarthy, Mark I.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England. [Arden, Nigel; Cooper, Jackie A.] Univ Oxford, NIHR Oxford Musculoskeletal Biomed Res Unit, Oxford, England. [McCarthy, Mark I.] Oxford NIHR Biomed Res Ctr, Oxford, England. [Dupuis, Josee] NHLBI, Framingham Heart Study, Framingham, MA USA. [Herzig, Karl-Heinz] Univ Oulu, Inst Biomed, Oulu, Finland. [Herzig, Karl-Heinz; Sebert, Sylvain; Jarvelin, Marjo-Riitta] Univ Oulu, Bioctr, Oulu, Finland. [Alves, Alexessander Couto; Sebert, Sylvain; Jarvelin, Marjo-Riitta] Univ Oulu, Inst Hlth Sci, Oulu, Finland. [Herzig, Karl-Heinz] Oulu Univ Hosp, Med Res Ctr Oulu, Oulu, Finland. [Pouta, Anneli] Oulu Univ Hosp, Dept Clin Sci, Oulu, Finland. [Jarvelin, Marjo-Riitta] Oulu Univ Hosp, Unit Primary Care, Oulu, Finland. [Pouta, Anneli; Jarvelin, Marjo-Riitta] Natl Inst Hlth & Welf, Oulu, Finland. [Laitinen, Jaana] Finnish Inst Occupat Hlth, Helsinki, Finland. [Kleber, Marcus E.; Maerz, Winfried] Heidelberg Univ, Mannheim Med Fac, Med Clin Nephrol Hypertensiol Rheumatol Endocrino, Mannheim, Germany. [Jameson, Karen; Arden, Nigel; Cooper, Jackie A.; Osmond, Clive] Univ Southampton, MRC, Lifecourse Epidemiol Unit, Southampton, Hants, England. [Raitakari, Olli] Univ Turku, Res Ctr Appl & Prevent Cardiovasc Med, Turku, Finland. [Raitakari, Olli] Turku Univ Hosp, Dept Clin Physiol & Nucl Med, FIN-20520 Turku, Finland. [Tikkanen, Emmi; Ripatti, Samuli] Univ Helsinki, Inst Mol Med Finland, Helsinki, Finland. [Tikkanen, Emmi; Ripatti, Samuli] Univ Helsinki, Hjelt Inst, Helsinki, Finland. [Lahti, Jari] Univ Helsinki, Inst Behav Sci, Helsinki, Finland. [Eriksson, Johan G.] Univ Helsinki, Dept Gen Practice & Primary Hlth Care, Helsinki, Finland. [Penninx, Brenda W.] Vrije Univ Amsterdam, Med Ctr, EMGO Inst, Dept Psychiat, Amsterdam, Netherlands. [Billings, Liana K.; Florez, Jose C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Billings, Liana K.; Florez, Jose C.] Massachusetts Gen Hosp, Diabet Res Ctr, Diabet Unit, Boston, MA 02114 USA. [Billings, Liana K.; Florez, Jose C.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA. [Billings, Liana K.; Florez, Jose C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Billings, Liana K.] NorthShore Univ Hlth Syst, Evanston, IL USA. [Rejnmark, Lars; Langdahl, Bente Lomholt] Aarhus Univ Hosp, Dept Endocrinol & Internal Med, DK-8000 Aarhus, Denmark. [Paternoster, Lavinia] Univ Bristol, Sch Social & Community Med, MRC, Integrat Epidemiol Unit, Bristol, Avon, England. [Hernandez, Dena G.] NIA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA. [Byberg, Liisa; Michaesson, Karl] Uppsala Univ, Dept Surg Sci, Uppsala, Sweden. [Hagstrom, Emil; Melhus, Hakan; Ingelsson, Erik; Ljunggren, Osten; Lind, Lars] Uppsala Univ, Uppsala Clin Res Ctr, Dept Med Sci, Uppsala, Sweden. [Ingelsson, Erik] Uppsala Univ, Mol Epidemiol & Sci Life Lab, Uppsala, Sweden. [Jula, Antti] Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Turku, Finland. [Polasek, Ozren] Univ Split, Sch Med, Croatian Ctr Global Hlth, Split, Croatia. [Salomaa, Veikko; Eriksson, Johan G.] Natl Inst Hlth & Welf, Helsinki, Finland. [Karlsson, Magnus] Lund Univ, Skane Univ Hosp, Dept Clin Sci & Orthopaed Surg, Clin & Mol Osteoporosis Res Unit, Malmo, Sweden. [Bandinelli, Stefania] Azienda Sanitaria Firenze, Geriatr Unit, Florence, Italy. [Eriksson, Johan G.] Vasa Cent Hosp, Vaasa, Finland. [Eriksson, Johan G.] Folkhalsan Res Ctr, Helsinki, Finland. [Eriksson, Johan G.] Univ Helsinki, Cent Hosp, Unit Gen Practice, Helsinki, Finland. [Lehtimaki, Terho] Univ Tampere, Dept Clin Chem, Fimlab Labs, Tampere, Finland. [Lehtimaki, Terho] Univ Tampere, Sch Med, Tampere, Finland. [Maerz, Winfried] Synlab Acad, Mannheim, Germany. [Wang, Thomas J.] Vanderbilt Univ, Div Cardiovasc Med, Nashville, TN 37235 USA. [Maerz, Winfried; Pilz, Stefan] Med Univ Graz, Dept Internal Med, Div Endocrinol, Graz, Austria. [Maerz, Winfried; Pilz, Stefan] Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, Graz, Austria. [Whittaker, John C.] GlaxoSmithKline, Quantitat Sci, Stevenage, Herts, England. [Hypponen, Elina] Univ S Australia, Sch Populat Hlth, Sansom Inst Hlth Res, Adelaide, SA 5001, Australia. [Hypponen, Elina] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia. RP Hypponen, E (reprint author), Univ S Australia, Sch Populat Hlth, GPO Box 2471, Adelaide, SA 5001, Australia. EM elina.hypponen@unisa.edu.au RI Polasek, Ozren/B-6002-2011; Rudan, Igor/I-1467-2012; mangino, massimo/F-5134-2011; Wong, Andrew/M-8899-2016; Lambers Heerspink, Hiddo/K-3358-2014; Hypponen, Elina/B-2596-2014; Theodoratou, Evropi/C-3430-2014; Lu, Chen/D-8514-2015; Ripatti, Samuli/H-9446-2014; Wilson, James F/A-5704-2009; Brenner, Hermann/B-4627-2017; OI Lahti, Jari/0000-0002-4310-5297; Kleber, Marcus/0000-0003-0663-7275; Schottker, Ben/0000-0002-1217-4521; Thiering, Elisabeth/0000-0002-5429-9584; Fraser, Ross/0000-0003-0488-2592; Paternoster, Lavinia/0000-0003-2514-0889; Zgaga, Lina/0000-0003-4089-9703; Humphries, Stephen E/0000-0002-8221-6547; Kumari, Meena/0000-0001-9716-1035; Jarvelin, Marjo-Riitta/0000-0002-2149-0630; Navarro, Pau/0000-0001-5576-8584; Polasek, Ozren/0000-0002-5765-1862; Rudan, Igor/0000-0001-6993-6884; mangino, massimo/0000-0002-2167-7470; Wong, Andrew/0000-0003-2079-4779; Lambers Heerspink, Hiddo/0000-0002-3126-3730; Hypponen, Elina/0000-0003-3670-9399; Theodoratou, Evropi/0000-0001-5887-9132; Ripatti, Samuli/0000-0002-0504-1202; Wilson, James F/0000-0001-5751-9178; Brenner, Hermann/0000-0002-6129-1572; Alves, Alex/0000-0001-8519-7356; Karani, Vimal/0000-0002-8485-8930 FU British Heart Foundation; UK Medical Research Council; Academy of Finland FX British Heart Foundation, UK Medical Research Council, and Academy of Finland. NR 33 TC 78 Z9 79 U1 3 U2 25 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2213-8587 J9 LANCET DIABETES ENDO JI Lancet Diabetes Endocrinol. PD SEP PY 2014 VL 2 IS 9 BP 719 EP 729 DI 10.1016/S2213-8587(14)70113-5 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AP1AY UT WOS:000341800000014 PM 24974252 ER PT J AU Reynolds, C Roderick, JE LaBelle, JL Bird, G Mathieu, R Bodaar, K Colon, D Pyati, U Stevenson, KE Qi, J Harris, M Silverman, LB Sallan, SE Bradner, JE Neuberg, DS Look, AT Walensky, LD Kelliher, MA Gutierrez, A AF Reynolds, C. Roderick, J. E. LaBelle, J. L. Bird, G. Mathieu, R. Bodaar, K. Colon, D. Pyati, U. Stevenson, K. E. Qi, J. Harris, M. Silverman, L. B. Sallan, S. E. Bradner, J. E. Neuberg, D. S. Look, A. T. Walensky, L. D. Kelliher, M. A. Gutierrez, A. TI Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia SO LEUKEMIA LA English DT Article ID C-MYC; BCL-2 FAMILY; GENE-EXPRESSION; APOPTOSIS; NOTCH1; RESISTANCE; INHIBITION; ZEBRAFISH; IDENTIFICATION; TARGET AB Treatment resistance in T-cell acute lymphoblastic leukemia (T-ALL) is associated with phosphatase and tensin homolog (PTEN) deletions and resultant phosphatidylinositol 3'-kinase (PI3K)-AKT pathway activation, as well as MYC overexpression, and these pathways repress mitochondrial apoptosis in established T-lymphoblasts through poorly defined mechanisms. Normal T-cell progenitors are hypersensitive to mitochondrial apoptosis, a phenotype that is dependent on the expression of proapoptotic BIM. In a conditional zebrafish model, MYC downregulation induced BIM expression in T-lymphoblasts, an effect that was blunted by expression of constitutively active AKT. In human T-ALL cell lines and treatment-resistant patient samples, treatment with MYC or PI3K-AKT pathway inhibitors each induced BIM upregulation and apoptosis, indicating that BIM is repressed downstream of MYC and PI3K-AKT in high-risk T-ALL. Restoring BIM function in human T-ALL cells using a stapled peptide mimetic of the BIM BH3 domain had therapeutic activity, indicating that BIM repression is required for T-ALL viability. In the zebrafish model, where MYC downregulation induces T-ALL regression via mitochondrial apoptosis, T-ALL persisted despite MYC downregulation in 10% of bim wild-type zebrafish, 18% of bim heterozygotes and in 33% of bim homozygous mutants (P = 0.017). We conclude that downregulation of BIM represents a key survival signal downstream of oncogenic MYC and PI3K-AKT signaling in treatment-resistant T-ALL. C1 [Reynolds, C.; LaBelle, J. L.; Mathieu, R.; Bodaar, K.; Silverman, L. B.; Sallan, S. E.; Look, A. T.; Walensky, L. D.; Gutierrez, A.] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. [Roderick, J. E.; Kelliher, M. A.] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA USA. [LaBelle, J. L.; Bird, G.; Colon, D.; Pyati, U.; Silverman, L. B.; Sallan, S. E.; Look, A. T.; Walensky, L. D.; Gutierrez, A.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [LaBelle, J. L.] Univ Chicago, Pritzker Sch Med, Dept Pediat, Chicago, IL 60637 USA. [Stevenson, K. E.; Neuberg, D. S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Qi, J.; Bradner, J. E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Harris, M.] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Pathol, Boston, MA 02115 USA. RP Gutierrez, A (reprint author), Harvard Univ, Sch Med, Boston Childrens Hosp, Div Hematol Oncol, 300 Longwood Ave,Karp 8, Boston, MA 02115 USA. EM alejandro.gutierrez@childrens.harvard.edu FU National Institutes of Health/National Cancer Institute [CA167124]; William Lawrence Blanche Hughes Foundation FX This work was supported by the National Institutes of Health/National Cancer Institute Grant CA167124 and by a grant from the William Lawrence Blanche Hughes Foundation. AG is a Research Fellow of the Gabrielle's Angel Foundation for Cancer Research. We thank Domenico Accili for the FOXO-D256 Delta construct, and Lin He for the MSCV-19a-20-19b construct, both of which were obtained from Addgene. We also thank Dean Felsher for the murine T-ALL cell line 4188. NR 49 TC 15 Z9 16 U1 3 U2 12 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 EI 1476-5551 J9 LEUKEMIA JI Leukemia PD SEP PY 2014 VL 28 IS 9 BP 1819 EP 1827 DI 10.1038/leu.2014.78 PG 9 WC Oncology; Hematology SC Oncology; Hematology GA AP0VG UT WOS:000341783000008 PM 24552990 ER PT J AU Eda, H Santo, L Cirstea, DD Yee, AJ Scullen, TA Nemani, N Mishima, Y Waterman, PR Arastu-Kapur, S Evans, E Singh, J Kirk, CJ Westlin, WF Raje, NS AF Eda, H. Santo, L. Cirstea, D. D. Yee, A. J. Scullen, T. A. Nemani, N. Mishima, Y. Waterman, P. R. Arastu-Kapur, S. Evans, E. Singh, J. Kirk, C. J. Westlin, W. F. Raje, N. S. TI A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity SO LEUKEMIA LA English DT Article ID SINGLE-AGENT CARFILZOMIB; B-CELL DEVELOPMENT; X-LINKED AGAMMAGLOBULINEMIA; C-SRC; PROTEIN-KINASE; MARROW MICROENVIRONMENT; PRECLINICAL ACTIVITY; RESORBING ACTIVITY; STIMULATING FACTOR; P42/P44 MAPK AB Bruton's tyrosine kinase (Btk) modulates B-cell development and activation and has an important role in antibody production. Interestingly, Btk may also affect human osteoclast (OC) function; however, the mechanism was unknown. Here we studied a potent and specific Btk inhibitor, CC-292, in multiple myeloma (MM). In this report, we demonstrate that, although CC-292 increased OC differentiation, it inhibited OC function via inhibition of c-Src, Pyk2 and cortactin, all involved in OC-sealing zone formation. As CC-292 did not show potent in vitro anti-MM activity, we next evaluated it in combination with the proteasome inhibitor, carfilzomib. We first studied the effect of carfilzomib on OC. Carfilzomib did not have an impact on OC-sealing zone formation but significantly inhibited OC differentiation. CC-292 combined with carfilzomib inhibited both sealing zone formation and OC differentiation, resulting in more profound inhibition of OC function than carfilzomib alone. Moreover, the combination treatment in an in vivo MM mouse model inhibited tumor burden compared with CC-292 alone; it also increased bone volume compared with carfilzomib alone. These results suggest that CC-292 combined with carfilzomib augments the inhibitory effects against OC within the bone microenvironment and has promising therapeutic potential for the treatment of MM and related bone disease. C1 [Eda, H.; Santo, L.; Cirstea, D. D.; Yee, A. J.; Scullen, T. A.; Nemani, N.; Mishima, Y.; Raje, N. S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02114 USA. [Waterman, P. R.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Arastu-Kapur, S.; Kirk, C. J.] Onyx Pharmaceut Inc, San Francisco, CA USA. [Evans, E.; Singh, J.; Westlin, W. F.] Celgene Avil Res, Bedford, MA USA. RP Raje, NS (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med Oncol,Ctr Canc, POB 216,55 Fruit St, Boston, MA 02114 USA. EM nraje@partners.org FU Onyx Pharmaceuticals Inc (South San Francisco, CA, USA); Proteasome Research and Integrative Science for Multiple Myeloma-Onyx Novel Therapies Program (PRISM-NTP); Leukemia & Lymphoma Society clinical scholar Award FX This work was supported by Onyx Pharmaceuticals Inc (South San Francisco, CA, USA) and the Proteasome Research and Integrative Science for Multiple Myeloma-Onyx Novel Therapies Program (PRISM-NTP). NS Raje is a recipient of the Leukemia & Lymphoma Society clinical scholar Award. NR 57 TC 12 Z9 12 U1 0 U2 8 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 EI 1476-5551 J9 LEUKEMIA JI Leukemia PD SEP PY 2014 VL 28 IS 9 BP 1892 EP 1901 DI 10.1038/leu.2014.69 PG 10 WC Oncology; Hematology SC Oncology; Hematology GA AP0VG UT WOS:000341783000016 PM 24518207 ER PT J AU Narayana, S Wong, CJ AF Narayana, Sirisha Wong, Christopher J. TI Office-Based Screening of Common Psychiatric Conditions SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article DE Screening; Depression; Anxiety; Cost-effectiveness; Outcomes ID PATIENT HEALTH QUESTIONNAIRE; PRIMARY-CARE PATIENTS; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; COMORBIDITY SURVEY REPLICATION; GENERALIZED ANXIETY DISORDER; CASE-FINDING INSTRUMENTS; UTAH RATING-SCALE; DSM-IV DISORDERS; MAJOR DEPRESSION AB Depression and anxiety disorders are common conditions with significant morbidity. Many screening tools of varying length have been well validated for these conditions in the office-based setting. Novel instruments, including Internet-based and computerized adaptive testing, may be promising tools in the future. The best evidence for cost-effectiveness currently is for screening of major depression linked with the collaborative care model for treatment. Data are not conclusive regarding comparative cost-effectiveness of screening for multiple conditions at once or for other conditions. This article reviews screening tools for depression and anxiety disorders in the ambulatory setting. C1 [Narayana, Sirisha] Univ Washington, VA Puget Sound Hlth Care Syst, Dept Med, Div Gen Internal Med, Seattle, WA 98108 USA. [Wong, Christopher J.] Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA 98105 USA. RP Wong, CJ (reprint author), Univ Washington, Dept Med, Div Gen Internal Med, 4245 Roosevelt Way Northeast,Box 354760, Seattle, WA 98105 USA. EM cjwong@uw.edu NR 77 TC 4 Z9 4 U1 2 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0025-7125 EI 1557-9859 J9 MED CLIN N AM JI Med. Clin. N. Am. PD SEP PY 2014 VL 98 IS 5 BP 959 EP + DI 10.1016/j.mcna.2014.06.002 PG 23 WC Medicine, General & Internal SC General & Internal Medicine GA AO8OO UT WOS:000341614300005 PM 25134868 ER PT J AU Schwartz, JC Podell, ER Han, SSW Berry, JD Eggan, KC Cech, TR AF Schwartz, Jacob C. Podell, Elaine R. Han, Steve S. W. Berry, James D. Eggan, Kevin C. Cech, Thomas R. TI FUS is sequestered in nuclear aggregates in ALS patient fibroblasts SO MOLECULAR BIOLOGY OF THE CELL LA English DT Article ID RNA-POLYMERASE-II; AMYOTROPHIC-LATERAL-SCLEROSIS; BINDING PROTEIN TLS; NEURON DISEASES ALS; SPLICING FACTOR TLS; GENE-TRANSCRIPTION; DENDRITIC SPINES; STRESS GRANULES; SR PROTEINS; WILD-TYPE AB Mutations in the RNA-binding protein FUS have been shown to cause the neurodegenerative disease amyotrophic lateral sclerosis (ALS). We investigate whether mutant FUS protein in ALS patient-derived fibroblasts affects normal FUS functions in the nucleus. We investigated fibroblasts from two ALS patients possessing different FUS mutations and a normal control. Fibroblasts from these patients have their nuclear FUS protein trapped in SDS-resistant aggregates. Genome-wide analysis reveals an inappropriate accumulation of Ser-2 phosphorylation on RNA polymerase II (RNA Pol II) near the transcription start sites of 625 genes for ALS patient cells and after small interfering RNA (siRNA) knockdown of FUS in normal fibroblasts. Furthermore, both the presence of mutant FUS protein and siRNA knockdown of wild-type FUS correlate with altered distribution of RNA Pol II within fibroblast nuclei. A loss of FUS function in orchestrating Ser-2 phosphorylation of the CTD of RNA Pol II is detectable in ALS patient-derived fibroblasts expressing mutant FUS protein, even when the FUS protein remains largely nuclear. A likely explanation for this loss of function is the aggregation of FUS protein in nuclei. Thus our results suggest a specific mechanism by which mutant FUS can have biological consequences other than by the formation of cytoplasmic aggregates. C1 [Schwartz, Jacob C.; Podell, Elaine R.; Cech, Thomas R.] Univ Colorado, Dept Chem & Biochem, Howard Hughes Med Inst, Boulder, CO 80309 USA. [Schwartz, Jacob C.; Podell, Elaine R.; Cech, Thomas R.] Univ Colorado, BioFrontiers Inst, Boulder, CO 80309 USA. [Han, Steve S. W.; Berry, James D.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Han, Steve S. W.; Eggan, Kevin C.] Harvard Univ, Harvard Stem Cell Inst, Howard Hughes Med Inst, Cambridge, MA 02138 USA. [Han, Steve S. W.; Eggan, Kevin C.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. RP Cech, TR (reprint author), Univ Colorado, Dept Chem & Biochem, Howard Hughes Med Inst, Boulder, CO 80309 USA. EM thomas.cech@colorado.edu RI Schwartz, Jacob/J-6477-2012 FU National Institute of General Medical Sciences National Research Service Award Fellowship [1F32GM095311-01]; National Institute of Neurological Disorders and Stroke [1K99NS082376-01A1]; American Academy of Neurology/ALS Association; Harvard Catalyst KL2 Medical Research Investigator Training Program FX We thank M. Cudkowicz and the Neurological Clinical Research Institute at Massachusetts General Hospital. We also thank R. Brown (University of Massachusetts Medical School, Worcester, MA) for the coordination of patient recruitment. J.C.S. was supported by National Institute of General Medical Sciences National Research Service Award Fellowship 1F32GM095311-01 and National Institute of Neurological Disorders and Stroke 1K99NS082376-01A1. S.S.W.H. was supported by a Clinician Development Award from the American Academy of Neurology/ALS Association and the Harvard Catalyst KL2 Medical Research Investigator Training Program. T.R.C. is an investigator and K.C.E. is an Early Career Scientist of the Howard Hughes Medical Institute. NR 51 TC 20 Z9 20 U1 0 U2 7 PU AMER SOC CELL BIOLOGY PI BETHESDA PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA SN 1059-1524 EI 1939-4586 J9 MOL BIOL CELL JI Mol. Biol. Cell PD SEP 1 PY 2014 VL 25 IS 17 BP 2571 EP 2578 DI 10.1091/mbc.E14-05-1007 PG 8 WC Cell Biology SC Cell Biology GA AO8WW UT WOS:000341637300004 PM 25009283 ER PT J AU Zhang, YX Sicinska, E Czaplinski, JT Remillard, SP Moss, S Wang, YC Brain, C Loo, A Snyder, EL Demetri, GD Kim, S Kung, AL Wagner, AJ AF Zhang, Yi-Xiang Sicinska, Ewa Czaplinski, Jeffrey T. Remillard, Stephen P. Moss, Samuel Wang, Yuchuan Brain, Christopher Loo, Alice Snyder, Eric L. Demetri, George D. Kim, Sunkyu Kung, Andrew L. Wagner, Andrew J. TI Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo SO MOLECULAR CANCER THERAPEUTICS LA English DT Article ID DEDIFFERENTIATED LIPOSARCOMA; CYCLIN-D; ADIPOCYTIC DIFFERENTIATION; THERAPEUTIC RESPONSE; DEPENDENT KINASES; TUMOR-SUPPRESSOR; PHASE-II; CANCER; MDM2; P53 AB Well-differentiated/dedifferentiated liposarcomas (WD/DDLPS) are among the most common subtypes of soft tissue sarcomas. Conventional systemic chemotherapy has limited efficacy and novel therapeutic strategies are needed to achieve better outcomes for patients. The cyclin-dependent kinase 4 (CDK4) gene is highly amplified in more than 95% of WD/DDLPS. In this study, we explored the role of CDK4 and the effects of NVP-LEE011 (LEE011), a novel selective inhibitor of CDK4/CDK6, on a panel of human liposarcoma cell lines and primary tumor xenografts. We found that both CDK4 knockdown by siRNA and inhibition by LEE011 diminished retinoblastoma (RB) phosphorylation and dramatically decreased liposarcoma cell growth. Cell-cycle analysis demonstrated arrest at G(0)-G(1). siRNA-mediated knockdown of RB rescued the inhibitory effects of LEE011, demonstrating that LEE011 decreased proliferation through RB. Oral administration of LEE011 to mice bearing human liposarcoma xenografts resulted in approximately 50% reduction in tumor F-18-fluorodeoxyglucose uptake with decreased tumor biomarkers, including RB phosphorylation and bromodeoxyuridine incorporation in vivo. Continued treatment inhibited tumor growth or induced regression without detrimental effects on mouse weight. After prolonged continuous dosing, reestablishment of RB phosphorylation and cell-cycle progression was noted. These findings validate the critical role of CDK4 in maintaining liposarcoma proliferation through its ability to inactivate RB function, and suggest its potential function in the regulation of survival and metabolism of liposarcoma, supporting the rationale for clinical development of LEE011 for the treatment of WD/DDLPS. (C) 2014 AACR. C1 [Zhang, Yi-Xiang; Sicinska, Ewa; Czaplinski, Jeffrey T.; Remillard, Stephen P.; Moss, Samuel; Demetri, George D.; Wagner, Andrew J.] Harvard Univ, Sch Med, Dana Farber Harvard, Ludwig Ctr, Boston, MA USA. [Zhang, Yi-Xiang; Remillard, Stephen P.; Demetri, George D.; Wagner, Andrew J.] Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol, Dept Med Oncol, Boston, MA 02215 USA. [Sicinska, Ewa; Czaplinski, Jeffrey T.; Moss, Samuel] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Dept Med Oncol, Boston, MA 02215 USA. [Wang, Yuchuan] Johns Hopkins Sch Med, Dept Radiol, Baltimore, MD USA. [Brain, Christopher; Loo, Alice; Kim, Sunkyu] Novartis Inst Biomed Res, Cambridge, MA USA. [Snyder, Eric L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Snyder, Eric L.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA. [Snyder, Eric L.] Columbia Univ, Med Ctr, Dept Pediat, New York, NY USA. RP Wagner, AJ (reprint author), Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol, 450 Brookline Ave, Boston, MA 02215 USA. EM Andrew_Wagner@dfci.harvard.edu OI Wang, Yuchuan/0000-0001-5111-6562; Kung, Andrew/0000-0002-9091-488X FU Virginia and D.K. Ludwig Fund for Cancer Research; Peter and Paula Fasseas Fund for Liposarcoma Research; Liposarcoma Research Fund FX This work was supported by Virginia and D.K. Ludwig Fund for Cancer Research (to G.D. Demetri), the Peter and Paula Fasseas Fund for Liposarcoma Research (to A.J. Wagner), and the Liposarcoma Research Fund (to A.J. Wagner). NR 37 TC 23 Z9 23 U1 0 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 EI 1538-8514 J9 MOL CANCER THER JI Mol. Cancer Ther. PD SEP PY 2014 VL 13 IS 9 BP 2184 EP 2193 DI 10.1158/1535-7163.MCT-14-0387 PG 10 WC Oncology SC Oncology GA AO9FH UT WOS:000341660800005 PM 25028469 ER PT J AU Mine, N Yamamoto, S Kufe, DW Von Hoff, DD Kawabe, T AF Mine, Naoki Yamamoto, Sayaka Kufe, Donald W. Von Hoff, Daniel D. Kawabe, Takumi TI Activation of Nrf2 Pathways Correlates with Resistance of NSCLC Cell Lines to CBP501 In Vitro SO MOLECULAR CANCER THERAPEUTICS LA English DT Article ID ANTIOXIDANT RESPONSE ELEMENT; CUL3-BASED E3 LIGASE; LUNG-CANCER; TRANSCRIPTIONAL REGULATION; KEAP1-NRF2 PATHWAY; G(2) CHECKPOINT; GENE; PROTEIN; ADAPTER; DETOXIFICATION AB CBP501 is an anticancer drug candidate that was investigated in two randomized phase II clinical trials for patients with nonsquamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). CBP501 has been shown to have two mechanisms of action, namely calmodulin modulation and G(2) checkpoint abrogation. Here, we searched for a biomarker to predict sensitivity to CBP501. Twenty-eight NSCLC cell lines were classified into two subgroups, CBP501-sensitive and -insensitive, by quantitatively analyzing the cis-diamminedichloro-platinum (II) (CDDP)-enhancing activity of CBP501 through treatments with short-term (1 hour) coexposure to CDDP and CBP501 or to either alone. Microarray analysis was performed on these cell lines to identify gene expression patterns that correlated with CBP501 sensitivity. We found that multiple nuclear factor erythroid-2-related factor 2 (Nrf2) target genes showed high expression in CBP501-insensitive cell lines. Western blot and immunocytochemical analysis for Nrf2 in NSCLC cell lines also indicated higher protein level in CBP501-insensitive cell lines. Moreover, CBP501 sensitivity is modulated by silencing or sulforaphane-induced overexpression of Nrf2. These results indicate that Nrf2 transcription factor is a potential candidate as a biomarker for resistance to CBP501. This study might help to identify those subpopulations of patients who would respond well to the CBP501 and CDDP combination treatment of NSCLC. (C) 2014 AACR. C1 [Mine, Naoki; Yamamoto, Sayaka; Kawabe, Takumi] CanBas Co Ltd, Numazu, Shizuoka 4100801, Japan. [Kufe, Donald W.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Von Hoff, Daniel D.] Translat Genom Res Inst TGen, Phoenix, AZ USA. RP Kawabe, T (reprint author), CanBas Co Ltd, 2-2-1 Otemachi, Numazu, Shizuoka 4100801, Japan. EM takumi@canbas.co.jp NR 40 TC 2 Z9 2 U1 1 U2 8 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 EI 1538-8514 J9 MOL CANCER THER JI Mol. Cancer Ther. PD SEP PY 2014 VL 13 IS 9 BP 2215 EP 2225 DI 10.1158/1535-7163.MCT-13-0808 PG 11 WC Oncology SC Oncology GA AO9FH UT WOS:000341660800008 PM 25053821 ER PT J AU Carruthers, RL Rotstein, DL Healy, BC Chitnis, T Weiner, HL Buckle, GJ AF Carruthers, Robert L. Rotstein, Dalia L. Healy, Brian C. Chitnis, Tanuja Weiner, Howard L. Buckle, Guy J. TI An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy SO MULTIPLE SCLEROSIS JOURNAL LA English DT Article DE Natalizumab; fingolimod; JCV serology; observational data ID PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMITTING MULTIPLE-SCLEROSIS; PLACEBO-CONTROLLED TRIAL; CEREBROSPINAL-FLUID; DIAGNOSTIC-CRITERIA; DNA-SEQUENCES; VIRUS-DNA; GUIDELINES; SAMPLES; COHORT AB Background: The lack of prospective trial data comparing certain multiple sclerosis (MS) therapies could be addressed with observational research. Objective: The objective of this paper is to investigate outcomes of natalizumab versus fingolimod treatment in an MS cohort using a novel method of patient selection. Methods: We reviewed entries from our clinic's database for all relapsing-remitting MS patients started on fingolimod and natalizumab where JCV serology was used to determine treatment. We analyzed each group for time to first relapse and in a second analysis, time to first relapse or gadolinium-enhancing lesion. Results: Sixty-nine patients on natalizumab and 36 on fingolimod met our inclusion criteria and had adequate follow-up for analysis. The baseline clinical characteristics at the time of treatment switch were similar. With a mean follow-up of 1.5 years for both treatment groups, there was a trend favoring natalizumab in time to first relapse, although this was not statistically significant (2.20 (0.87, 5.55) p = 0.095). There was a significant difference in the secondary outcome, time to relapse or gadolinium-enhancing lesion (2.31 (1.03, 5.17) p = 0.041), favoring natalizumab. Adjusted analyses favored natalizumab for both outcomes (p < 0.05). Conclusion: This work employed an observational study design where treatment allocation by JCV serology allowed for treatment groups with well-balanced characteristics. C1 [Carruthers, Robert L.; Rotstein, Dalia L.; Healy, Brian C.; Chitnis, Tanuja; Weiner, Howard L.; Buckle, Guy J.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Carruthers, Robert L.; Rotstein, Dalia L.; Healy, Brian C.; Chitnis, Tanuja; Weiner, Howard L.; Buckle, Guy J.] Brigham & Womens Hosp, Partners Multiple Sclerosis Ctr, Brookline, MA 02446 USA. [Healy, Brian C.] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA. RP Buckle, GJ (reprint author), Brigham & Womens Hosp, 1 Brookline Pl,Suite 225, Brookline, MA 02446 USA. EM gbuckle@partners.org FU National Multiple Sclerosis Fellowship; Multiple Sclerosis Society of Canada FX RC received a clinical fellowship training grant from the National Multiple Sclerosis Fellowship. DR received a post-doctoral fellowship from the Multiple Sclerosis Society of Canada. NR 33 TC 6 Z9 6 U1 0 U2 4 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 EI 1477-0970 J9 MULT SCLER J JI Mult. Scler. J. PD SEP PY 2014 VL 20 IS 10 BP 1381 EP 1390 DI 10.1177/1352458514535282 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AP1FG UT WOS:000341811900017 PM 24852928 ER PT J AU Samocha, KE Robinson, EB Sanders, SJ Stevens, C Sabo, A McGrath, LM Kosmicki, JA Rehnstrom, K Mallick, S Kirby, A Wall, DP MacArthur, DG Gabriel, SB DePristo, M Purcell, SM Palotie, A Boerwinkle, E Buxbaum, JD Cook, EH Gibbs, RA Schellenberg, GD Sutcliffe, JS Devlin, B Roeder, K Neale, BM Daly, MJ AF Samocha, Kaitlin E. Robinson, Elise B. Sanders, Stephan J. Stevens, Christine Sabo, Aniko McGrath, Lauren M. Kosmicki, Jack A. Rehnstrom, Karola Mallick, Swapan Kirby, Andrew Wall, Dennis P. MacArthur, Daniel G. Gabriel, Stacey B. DePristo, Mark Purcell, Shaun M. Palotie, Aarno Boerwinkle, Eric Buxbaum, Joseph D. Cook, Edwin H., Jr. Gibbs, Richard A. Schellenberg, Gerard D. Sutcliffe, James S. Devlin, Bernie Roeder, Kathryn Neale, Benjamin M. Daly, Mark J. TI A framework for the interpretation of de novo mutation in human disease SO NATURE GENETICS LA English DT Article ID AUTISM SPECTRUM DISORDERS; DNA-SEQUENCING DATA; INTELLECTUAL DISABILITY; GENOME; PATTERNS; GENES; RATES AB Spontaneously arising (de novo) mutations have an important role in medical genetics. For diseases with extensive locus heterogeneity, such as autism spectrum disorders (ASDs), the signal from de novo mutations is distributed across many genes, making it difficult to distinguish disease-relevant mutations from background variation. Here we provide a statistical framework for the analysis of excesses in de novo mutation per gene and gene set by calibrating a model of de novo mutation. We applied this framework to de novo mutations collected from 1,078 ASD family trios, and, whereas we affirmed a significant role for loss-of-function mutations, we found no excess of de novo loss-of-function mutations in cases with IQ above 100, suggesting that the role of de novo mutations in ASDs might reside in fundamental neurodevelopmental processes. We also used our model to identify similar to 1,000 genes that are significantly lacking in functional coding variation in non-ASD samples and are enriched for de novo loss-of-function mutations identified in ASD cases. C1 [Samocha, Kaitlin E.; Robinson, Elise B.; Kosmicki, Jack A.; Kirby, Andrew; MacArthur, Daniel G.; Purcell, Shaun M.; Neale, Benjamin M.; Daly, Mark J.] Massachusetts Gen Hosp, Dept Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA. [Samocha, Kaitlin E.; Robinson, Elise B.; Kosmicki, Jack A.; Kirby, Andrew; MacArthur, Daniel G.; Purcell, Shaun M.; Neale, Benjamin M.; Daly, Mark J.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Samocha, Kaitlin E.; Robinson, Elise B.; Stevens, Christine; Kirby, Andrew; MacArthur, Daniel G.; Gabriel, Stacey B.; Purcell, Shaun M.; Neale, Benjamin M.; Daly, Mark J.] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA USA. [Samocha, Kaitlin E.; Robinson, Elise B.; Stevens, Christine; Neale, Benjamin M.; Daly, Mark J.] Broad Inst Harvard & MIT, Stanley Ctr Psychiat Res, Cambridge, MA USA. [Samocha, Kaitlin E.] Harvard Univ, Sch Med, Program Genet & Gen Biol & Biomed Sci, Boston, MA USA. [Sanders, Stephan J.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Sanders, Stephan J.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA. [Sabo, Aniko; Boerwinkle, Eric; Gibbs, Richard A.] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA. [McGrath, Lauren M.; Purcell, Shaun M.; Palotie, Aarno] Massachusetts Gen Hosp, Dept Psychiat, Psychiatr & Neurodev Genet Unit, Boston, MA 02114 USA. [McGrath, Lauren M.; Purcell, Shaun M.; Palotie, Aarno] Harvard Univ, Sch Med, Boston, MA USA. [Kosmicki, Jack A.; Wall, Dennis P.] Harvard Univ, Sch Med, Ctr Biomed Informat, Boston, MA USA. [Kosmicki, Jack A.; Wall, Dennis P.] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA. [Rehnstrom, Karola; Palotie, Aarno] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland. [Rehnstrom, Karola; Palotie, Aarno] Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Cambridge, England. [Mallick, Swapan] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. [DePristo, Mark] Synapdx, Lexington, MA USA. [Purcell, Shaun M.; Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Purcell, Shaun M.; Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. [Purcell, Shaun M.; Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. [Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, Houston, TX 77030 USA. [Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Seaver Autism Ctr Res & Treatment, New York, NY 10029 USA. [Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA. [Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, New York, NY 10029 USA. [Cook, Edwin H., Jr.] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA. [Schellenberg, Gerard D.] Univ Penn, Perelman Sch Med, Pathol & Lab Med, Philadelphia, PA USA. [Sutcliffe, James S.] Vanderbilt Univ, Ctr Mol Neurosci, Nashville, TN 37235 USA. [Devlin, Bernie] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Roeder, Kathryn] Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA. [Roeder, Kathryn] Carnegie Mellon Univ, Lane Ctr Computat Biol, Pittsburgh, PA 15213 USA. RP Daly, MJ (reprint author), Massachusetts Gen Hosp, Dept Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA. EM mjdaly@atgu.mgh.harvard.edu RI Sutcliffe, James/C-1348-2012; OI Sutcliffe, James/0000-0001-5200-6007; Robinson, Elise/0000-0003-2314-2792; Buxbaum, Joseph/0000-0001-8898-8313; Sanders, Stephan/0000-0001-9112-5148 FU Autism Genetic Resource Exchange (AGRE) Consortium, a program of Autism Speaks [1U24MH081810]; Autism Speaks; Simons Foundation; Autism Consortium; US National Institutes of Health (NIH) [R01MH089208, R01MH089025, R01MH089004, R01MH089175, R01MH089482, P50HD055751, R01MH057881, R01MH061009]; Lung GO Sequencing Project [HL-102923]; Women's Health Initiative (WHI) Sequencing Project [HL-102924]; Broad GO Sequencing Project [HL-102925]; Seattle GO Sequencing Project [HL-102926]; Heart GO Sequencing Project [HL-103010]; [U54HG003273]; [U54HG003067] FX All data from published studies are available in the respective publications. All newly generated data and computational tools used in this paper will be available online as downloadable material. We have also constructed a website to query genes that provides information on constraint and the de novo mutations found in the specified gene across published studies of de novo mutation. We would like to thank E. Daly and M. Chess for their contributions to data analysis and the construction of the website, respectively. We acknowledge the following resources and families who contributed to them: the National Institute of Mental Health (NIMH) repository (U24MH068457); the Autism Genetic Resource Exchange (AGRE) Consortium, a program of Autism Speaks (1U24MH081810 to C.M. Lajonchere); The Autism Simplex Collection (TASC) (grant from Autism Speaks); the Simons Foundation Autism Research Initiative (SFARI) Simplex Collection (grant from the Simons Foundation); and The Autism Consortium (grant from the Autism Consortium). This work was directly supported by US National Institutes of Health (NIH) grants R01MH089208 (M.J.D.), R01MH089025 (J.D.B.), R01MH089004 (G.D.S.), R01MH089175 (R.A.G.) and R01MH089482 (J.S.S.) and was supported in part by US NIH grants P50HD055751 (E.H.C.), R01MH057881 (B.D.) and R01MH061009 (J.S.S.). We acknowledge partial support from grants U54HG003273 (R.A.G.) and U54HG003067 (E. Lander). We thank T. Lehner (NIMH), A. Felsenfeld (National Human Genome Research Institute) and P. Bender (NIMH) for their support and contribution to the project. E.B., J.D.B., B.D., M.J.D., R.A.G., K. Roeder, A.S., G.D.S. and J.S.S. are lead investigators in the ARRA Autism Sequencing Collaboration (AASC). We would also like to thank the NHLBI GO Exome Sequencing Project (ESP) and its ongoing studies that produced and provided exome variant calls on the web: the Lung GO Sequencing Project (HL-102923), the Women's Health Initiative (WHI) Sequencing Project (HL-102924), the Broad GO Sequencing Project (HL-102925), the Seattle GO Sequencing Project (HL-102926) and the Heart GO Sequencing Project (HL-103010). NR 25 TC 149 Z9 149 U1 3 U2 31 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 EI 1546-1718 J9 NAT GENET JI Nature Genet. PD SEP PY 2014 VL 46 IS 9 BP 944 EP + DI 10.1038/ng.3050 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA AO8CE UT WOS:000341579400007 PM 25086666 ER PT J AU Lorenzo, FR Huff, C Myllymaki, M Olenchock, B Swierczek, S Tashi, T Gordeuk, V Wuren, T Ri-Li, G McClain, DA Khan, TM Koul, PA Guchhait, P Salama, ME Xing, JC Semenza, GL Liberzon, E Wilson, A Simonson, TS Jorde, LB Kaelin, WG Koivunen, P Prchal, JT AF Lorenzo, Felipe R. Huff, Chad Myllymaki, Mikko Olenchock, Benjamin Swierczek, Sabina Tashi, Tsewang Gordeuk, Victor Wuren, Tana Ri-Li, Ge McClain, Donald A. Khan, Tahsin M. Koul, Parvaiz A. Guchhait, Prasenjit Salama, Mohamed E. Xing, Jinchuan Semenza, Gregg L. Liberzon, Ella Wilson, Andrew Simonson, Tatum S. Jorde, Lynn B. Kaelin, William G., Jr. Koivunen, Peppi Prchal, Josef T. TI A genetic mechanism for Tibetan high-altitude adaptation SO NATURE GENETICS LA English DT Article ID HYPOXIA-INDUCIBLE FACTOR; HYDROXYLASE DOMAIN PROTEIN-2; OXYGEN SENSING PATHWAY; FACTOR-I; PROLYL 4-HYDROXYLASES; ERYTHROCYTOSIS; IDENTIFICATION; POLYCYTHEMIA; HOMEOSTASIS; MUTATION AB Tibetans do not exhibit increased hemoglobin concentration at high altitude. We describe a high-frequency missense mutation in the EGLN1 gene, which encodes prolyl hydroxylase 2 (PHD2), that contributes to this adaptive response. We show that a variant in EGLN1, c.[12C>G; 380G>C], contributes functionally to the Tibetan high-altitude phenotype. PHD2 triggers the degradation of hypoxia-inducible factors (HIFs), which mediate many physiological responses to hypoxia, including erythropoiesis. The PHD2 p.[Asp4Glu; Cys127Ser] variant exhibits a lower Km value for oxygen, suggesting that it promotes increased HIF degradation under hypoxic conditions. Whereas hypoxia stimulates the proliferation of wild-type erythroid progenitors, the proliferation of progenitors with the c.[12C>G; 380G>C] mutation in EGLN1 is significantly impaired under hypoxic culture conditions. We show that the c.[12C>G; 380G>C] mutation originated similar to 8,000 years ago on the same haplotype previously associated with adaptation to high altitude. The c.[12C>G; 380G>C] mutation abrogates hypoxia-induced and HIF-mediated augmentation of erythropoiesis, which provides a molecular mechanism for the observed protection of Tibetans from polycythemia at high altitude. C1 [Lorenzo, Felipe R.; Swierczek, Sabina; Tashi, Tsewang; McClain, Donald A.; Prchal, Josef T.] Univ Utah, Sch Med, Dept Med, Salt Lake City, UT 84112 USA. [Lorenzo, Felipe R.; Swierczek, Sabina; Tashi, Tsewang; McClain, Donald A.; Prchal, Josef T.] Geoger E Wahlin Vet Adm Med Ctr, Salt Lake City, UT USA. [Huff, Chad; Xing, Jinchuan; Simonson, Tatum S.; Jorde, Lynn B.; Prchal, Josef T.] Univ Utah, Sch Med, Eccles Inst Human Genet, Salt Lake City, UT USA. [Huff, Chad] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA. [Myllymaki, Mikko; Koivunen, Peppi] Univ Oulu, Fac Biochem & Mol Med, Oulu Ctr Cell Matrix Res, Bioctr Oulu, Oulu, Finland. [Olenchock, Benjamin] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Cardiovasc Med, Boston, MA USA. [Gordeuk, Victor] Univ Illinois, Sickle Cell Ctr, Chicago, IL USA. [Wuren, Tana; Ri-Li, Ge] Qinghai Univ, Res Ctr High Altitude Med, Xining, Peoples R China. [Khan, Tahsin M.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Koul, Parvaiz A.] Sherikashmir Inst Med Sci, Srinagar, Jammu & Kashmir, India. [Guchhait, Prasenjit] Reg Ctr Biotechnol, Gurgaon, India. [Salama, Mohamed E.] Univ Utah, Dept Pathol, Salt Lake City, UT USA. [Salama, Mohamed E.] ARUP Labs, Salt Lake City, UT USA. [Xing, Jinchuan] Rutgers State Univ, Dept Genet, Piscataway, NJ USA. [Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Vascr Program, Baltimore, MD USA. [Liberzon, Ella; Kaelin, William G., Jr.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Liberzon, Ella] Howard Hughes Med Inst, Chevy Chase, MD USA. [Wilson, Andrew] Univ Utah, Sch Med, Dept Family & Prevent Med, Salt Lake City, UT 84112 USA. [Simonson, Tatum S.] Univ Calif San Diego, Sch Med, Div Physiol, La Jolla, CA 92093 USA. RP Prchal, JT (reprint author), Univ Utah, Sch Med, Dept Med, Salt Lake City, UT 84112 USA. EM josef.prchal@hsc.utah.edu OI Koul, Parvaiz/0000-0002-1700-9285; Wilson, Andrew/0000-0003-3679-9232 FU Academy of Finland [120156, 140765, 218129]; S. Juselius Foundation; Finnish Cultural Foundation; Finnish Cancer Organizations; US National Institutes of Health (NIH) [HL119355-01, P01CA108671, HL098062]; National Human Genome Research Institute [HG005846]; National Basic Research Program of China [2012CB518200]; Program of International Science and Technology Cooperation of China [2011DFA32720]; University of Utah; Johns Hopkins Institute for Cell Engineering FX P.K. is supported by Academy of Finland grants 120156, 140765 and 218129, the S. Juselius Foundation, the Finnish Cultural Foundation and the Finnish Cancer Organizations. B.O. is supported by US National Institutes of Health (NIH) Mentored Career Development Award HL119355-01. J.X. is supported by the National Human Genome Research Institute (HG005846). G.R.-L. is supported by the National Basic Research Program of China (grant 2012CB518200) and by the Program of International Science and Technology Cooperation of China (grant 2011DFA32720). S.S. is supported by US NIH grant P01CA108671. T.S.S. is supported by the US NIH T32 Postdoctoral Fellowship HL098062. L.B.J. is supported by the University of Utah Seed Grant Program for studies of hypoxic adaptation. G.L.S. is supported by the Johns Hopkins Institute for Cell Engineering. J.T.P. is supported by US NIH grant P01CA108671, a Veterans Affairs Merit Review Award and the University of Utah Seed Grant Program for studies of hypoxic adaptation. NR 42 TC 58 Z9 64 U1 4 U2 68 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 EI 1546-1718 J9 NAT GENET JI Nature Genet. PD SEP PY 2014 VL 46 IS 9 BP 951 EP + DI 10.1038/ng.3067 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA AO8CE UT WOS:000341579400008 PM 25129147 ER PT J AU Wolpin, BM Rizzato, C Kraft, P Kooperberg, C Petersen, GM Wang, ZM Arslan, AA Beane-Freeman, L Bracci, PM Buring, J Canzian, F Duell, EJ Gallinger, S Giles, GG Goodman, GE Goodman, PJ Jacobs, EJ Kamineni, A Klein, AP Kolonel, LN Kulke, MH Li, DH Malats, N Olson, SH Risch, HA Sesso, HD Visvanathan, K White, E Zheng, W Abnet, CC Albanes, D Andreotti, G Austin, MA Barfield, R Basso, D Berndt, SI Boutron-Ruault, MC Brotzman, M Buchler, MW Bueno-de-Mesquita, HB Bugert, P Burdette, L Campa, D Caporaso, NE Capurso, G Chung, C Cotterchio, M Costello, E Elena, J Funel, N Gaziano, JM Giese, NA Giovannucci, EL Gorman, MJ Gross, M Haiman, CA Hassan, M Helzlsouer, KJ Henderson, BE Holly, EA Hu, N Hunter, DJ Innocenti, F Jenab, M Kaaks, R Key, TJ Khaw, KT Klein, EA Kogevinas, M Krogh, V Kupcinskas, J Kurtz, RC LaCroix, A Landi, MT Landi, S Le Marchand, L Mambrini, A Mannisto, S Milne, RL Nakamura, Y Oberg, AL Owzar, K Patel, AV Peeters, PHM Peters, U Pezzilli, R Piepoli, A Porta, M Real, FX Riboli, E Rothman, N Scarpa, A Shu, XO Silverman, DT Soucek, P Sund, M Talar-Wojnarowska, R Taylor, PR Theodoropoulos, GE Thornquist, M Tjonneland, A Tobias, GS Trichopoulos, D Vodicka, P Wactawski-Wende, J Wentzensen, N Wu, C Yu, H Yu, K Zeleniuch-Jacquotte, A Hoover, R Hartge, P Fuchs, C Chanock, SJ Stolzenberg-Solomon, RS Amundadottir, LT AF Wolpin, Brian M. Rizzato, Cosmeri Kraft, Peter Kooperberg, Charles Petersen, Gloria M. Wang, Zhaoming Arslan, Alan A. Beane-Freeman, Laura Bracci, Paige M. Buring, Julie Canzian, Federico Duell, Eric J. Gallinger, Steven Giles, Graham G. Goodman, Gary E. Goodman, Phyllis J. Jacobs, Eric J. Kamineni, Aruna Klein, Alison P. Kolonel, Laurence N. Kulke, Matthew H. Li, Donghui Malats, Nuria Olson, Sara H. Risch, Harvey A. Sesso, Howard D. Visvanathan, Kala White, Emily Zheng, Wei Abnet, Christian C. Albanes, Demetrius Andreotti, Gabriella Austin, Melissa A. Barfield, Richard Basso, Daniela Berndt, Sonja I. Boutron-Ruault, Marie-Christine Brotzman, Michelle Buechler, Markus W. Bueno-de-Mesquita, H. Bas Bugert, Peter Burdette, Laurie Campa, Daniele Caporaso, Neil E. Capurso, Gabriele Chung, Charles Cotterchio, Michelle Costello, Eithne Elena, Joanne Funel, Niccola Gaziano, J. Michael Giese, Nathalia A. Goggins, Michael Gorman, Megan J. Gross, Myron Haiman, Christopher A. Hassan, Manal Helzlsouer, Kathy J. Henderson, Brian E. Holly, Elizabeth A. Hu, Nan Hunter, David J. Innocenti, Federico Jenab, Mazda Kaaks, Rudolf Key, Timothy J. Khaw, Kay-Tee Klein, Eric A. Kogevinas, Manolis Krogh, Vittorio Kupcinskas, Juozas Kurtz, Robert C. LaCroix, Andrea Landi, Maria T. Landi, Stefano Le Marchand, Loic Mambrini, Andrea Mannisto, Satu Milne, Roger L. Nakamura, Yusuke Oberg, Ann L. Owzar, Kouros Patel, Alpa V. Peeters, Petra H. M. Peters, Ulrike Pezzilli, Raffaele Piepoli, Ada Porta, Miquel Real, Francisco X. Riboli, Elio Rothman, Nathaniel Scarpa, Aldo Shu, Xiao-Ou Silverman, Debra T. Soucek, Pavel Sund, Malin Talar-Wojnarowska, Renata Taylor, Philip R. Theodoropoulos, George E. Thornquist, Mark Tjonneland, Anne Tobias, Geoffrey S. Trichopoulos, Dimitrios Vodicka, Pavel Wactawski-Wende, Jean Wentzensen, Nicolas Wu, Chen Yu, Herbert Yu, Kai Zeleniuch-Jacquotte, Anne Hoover, Robert Hartge, Patricia Fuchs, Charles Chanock, Stephen J. Stolzenberg-Solomon, Rachael S. Amundadottir, Laufey T. TI Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer SO NATURE GENETICS LA English DT Article ID RECOMBINATION HOTSPOTS; BLADDER-CANCER; RISK LOCI; LINKAGE DISEQUILIBRIUM; GENETIC SUSCEPTIBILITY; OVARIAN-CANCER; VARIANTS; METAANALYSIS; IMPUTATION; DISEASE AB We performed a multistage genome-wide association study including 7,683 individuals with pancreatic cancer and 14,397 controls of European descent. Four new loci reached genome-wide significance: rs6971499 at 7q32.3 (LINC-PINT, per-allele odds ratio (OR) = 0.79, 95% confidence interval (CI) 0.74-0.84, P = 3.0 x 10(-12)), rs7190458 at 16q23.1 (BCAR1/CTRB1/CTRB2, OR = 1.46, 95% CI 1.30-1.65, P = 1.1 x 10(-10)), rs9581943 at 13q12.2 (PDX1, OR = 1.15, 95% CI 1.10-1.20, P = 2.4 x 10(-9)) and rs16986825 at 22q12.1 (ZNRF3, OR = 1.18, 95% CI 1.12-1.25, P = 1.2 x 10(-8)). We identified an independent signal in exon 2 of TERT at the established region 5p15.33 (rs2736098, OR = 0.80, 95% CI 0.76-0.85, P = 9.8 x 10(-14)). We also identified a locus at 8q24.21 (rs1561927, P = 1.3 x 10(-7)) that approached genome-wide significance located 455 kb telomeric of PVT1. Our study identified multiple new susceptibility alleles for pancreatic cancer that are worthy of follow-up studies. C1 NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Wolpin, Brian M.; Gorman, Megan J.; Fuchs, Charles] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Wolpin, Brian M.; Hunter, David J.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Rizzato, Cosmeri; Canzian, Federico] German Canc Res Ctr, Genom Epidemiol Grp, Heidelberg, Germany. [Kraft, Peter; Sesso, Howard D.; Trichopoulos, Dimitrios; Wu, Chen] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Kraft, Peter; Barfield, Richard] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Kooperberg, Charles; Goodman, Gary E.; LaCroix, Andrea; Thornquist, Mark] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA. [Petersen, Gloria M.] Mayo Clin, Dept Hlth Sci Res, Div Epidemiol, Rochester, MN USA. [Wang, Zhaoming; Beane-Freeman, Laura; Abnet, Christian C.; Albanes, Demetrius; Andreotti, Gabriella; Berndt, Sonja I.; Caporaso, Neil E.; Chung, Charles; Hu, Nan; Landi, Maria T.; Rothman, Nathaniel; Silverman, Debra T.; Taylor, Philip R.; Tobias, Geoffrey S.; Wentzensen, Nicolas; Yu, Kai; Hoover, Robert; Hartge, Patricia; Chanock, Stephen J.; Stolzenberg-Solomon, Rachael S.; Amundadottir, Laufey T.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Wang, Zhaoming; Burdette, Laurie; Chung, Charles; Chanock, Stephen J.] Leidos Biomed Res Inc, Div Canc Epidemiol & Genet, Frederick Natl Lab Canc Res, Canc Genom Res Lab,Natl Canc Inst, Frederick, MD USA. [Arslan, Alan A.] NYU, Sch Med, Dept Obstet & Gynecol, New York, NY USA. [Arslan, Alan A.; Zeleniuch-Jacquotte, Anne] NYU, Sch Med, Dept Environm Med, New York, NY USA. [Arslan, Alan A.; Zeleniuch-Jacquotte, Anne] NYU, New York, NY USA. [Bracci, Paige M.; Holly, Elizabeth A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Buring, Julie; Sesso, Howard D.; Gaziano, J. Michael] Harvard Univ, Sch Med, Boston, MA USA. [Buring, Julie; Sesso, Howard D.; Gaziano, J. Michael] Brigham & Womens Hosp, Dept Med, Div Aging, Boston, MA 02115 USA. [Duell, Eric J.] Bellvitge Biomed Res Inst IDIBELL, Catalan Inst Oncol ICO, Canc Epidemiol Res Program, Unit Nutr Environm & Canc, Barcelona, Spain. [Gallinger, Steven] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada. [Giles, Graham G.; Milne, Roger L.] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia. [Giles, Graham G.; Milne, Roger L.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Ctr Biostat & Epidemiol, Melbourne, Vic, Australia. [Goodman, Phyllis J.] Fred Hutchinson Canc Res Ctr, Southwest Oncol Grp Stat Ctr, Seattle, WA 98104 USA. [Jacobs, Eric J.; Patel, Alpa V.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA. [Kamineni, Aruna] Grp Hlth Res Inst, Seattle, WA USA. [Klein, Alison P.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA. [Klein, Alison P.] Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Kolonel, Laurence N.] Canc Res Ctr Hawaii, Honolulu, HI USA. [Li, Donghui; Hassan, Manal] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA. [Malats, Nuria] CNIO Spanish Natl Canc Res Ctr, Genet & Mol Epidemiol Grp, Madrid, Spain. [Olson, Sara H.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA. [Risch, Harvey A.] Yale Univ, Sch Publ Hlth, Dept Chron Dis Epidemiol, New Haven, CT USA. [Visvanathan, Kala] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [White, Emily] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [White, Emily; Austin, Melissa A.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Zheng, Wei; Shu, Xiao-Ou] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA. [Zheng, Wei; Shu, Xiao-Ou] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Basso, Daniela] Univ Hosp Padova, Dept Lab Med, Padua, Italy. [Boutron-Ruault, Marie-Christine] INSERM, Ctr Res Epidemiol & Populat Hlth CESP, Nutr Hormones & Womens Hlth Team, Villejuif, France. [Boutron-Ruault, Marie-Christine] Univ Paris 11, UMRS 1018, Villejuif, France. [Boutron-Ruault, Marie-Christine] IGR, Villejuif, France. [Brotzman, Michelle] Westat Corp, Rockville, MD USA. [Buechler, Markus W.; Giese, Nathalia A.] Univ Heidelberg Hosp, Dept Gen Surg, Heidelberg, Germany. [Bueno-de-Mesquita, H. Bas] Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands. [Bueno-de-Mesquita, H. Bas] Univ Med Ctr Utrecht, Dept Gastroenterol & Hepatol, Utrecht, Netherlands. [Bueno-de-Mesquita, H. Bas; Peeters, Petra H. M.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands. [Bugert, Peter] Heidelberg Univ, Med Fac Mannheim, Inst Transfus Med & Immunol, German Red Cross Blood Serv Baden Wurttemberg Hes, Mannheim, Germany. [Campa, Daniele; Kaaks, Rudolf] DKFZ, Div Canc Epidemiol, Heidelberg, Germany. [Capurso, Gabriele] Univ Roma La Sapienza, Digest & Liver Dis Unit, I-00185 Rome, Italy. [Cotterchio, Michelle] Univ Toronto, Canc Care Ontario, Toronto, ON M5S 1A1, Canada. [Cotterchio, Michelle] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada. [Costello, Eithne] Univ Liverpool, Liverpool Pancreas Biomed Res Unit, Natl Inst Hlth, Liverpool L69 3BX, Merseyside, England. [Elena, Joanne] NCI, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA. [Funel, Niccola] Univ Hosp Pisa, Unit Expt Surg Pathol, Dept Surg, Pisa, Italy. [Gaziano, J. Michael] Vet Affairs Boston Healthcare Syst, Geriatr Res Educ & Clin Ctr, Res & Informat Ctr, Massachusetts Vet Epidemiol, Boston, MA USA. [Fuchs, Charles] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA. [Fuchs, Charles] Harvard Univ, Sch Med, Boston, MA USA. [Fuchs, Charles] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Goggins, Michael] Sidney Kimmel Canc Ctr, Dept Pathol, Baltimore, MD USA. [Goggins, Michael] Johns Hopkins Univ, Baltimore, MD USA. [Goggins, Michael] Sidney Kimmel Canc Ctr, Dept Med, Baltimore, MD USA. [Goggins, Michael] Sidney Kimmel Canc Ctr, Dept Oncol, Baltimore, MD USA. [Gross, Myron] Univ Minnesota, Lab Med & Pathol, Minneapolis, MN USA. [Haiman, Christopher A.; Henderson, Brian E.] Univ So Calif, Los Angeles, CA USA. [Helzlsouer, Kathy J.] Mercy Med Ctr, Prevent & Res Ctr, Baltimore, MD USA. [Hunter, David J.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Hunter, David J.] Harvard Univ, Sch Med, Boston, MA USA. [Innocenti, Federico] Univ N Carolina, Eshelman Sch Pharm, Ctr Pharmacogen & Individualized Therapy, Lineberger Comprehens Canc Ctr,Sch Med, Chapel Hill, NC USA. [Jenab, Mazda] Int Agcy Res Canc, Lyon, France. [Key, Timothy J.] Canc Epidemiol Unit, Oxford, England. [Khaw, Kay-Tee] Univ Cambridge, Sch Clin Med, Cambridge, England. [Klein, Eric A.] Cleveland Clin, Glickman Urol & Kidney Inst, Cleveland, OH 44106 USA. [Kogevinas, Manolis] CIBER Epidemiol & Salud Publ CIBERESP, Ctr Recerca Epidemiol Ambiental CREAL, Barcelona, Spain. [Kogevinas, Manolis; Porta, Miquel] Hosp del Mar, Inst Med Res IMIM, Barcelona, Spain. [Kogevinas, Manolis] Natl Sch Publ Hlth, Dept Nutr, Athens, Greece. [Krogh, Vittorio] Fdn IRCCS Ist Nazl Tumori, Epidemiol & Prevent Unit, Milan, Italy. [Kupcinskas, Juozas] Lithuanian Univ Hlth Sci, Dept Gastroenterol, Kaunas, Lithuania. [Kurtz, Robert C.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA. [Landi, Stefano] Univ Pisa, Dept Biol, Pisa, Italy. [Le Marchand, Loic; Yu, Herbert] Univ Hawaii, Ctr Canc, Canc Epidemiol Program, Honolulu, HI 96822 USA. [Mambrini, Andrea] ASL1 Massa Carrara, Oncol Dept, Massa Carrara, Italy. [Mannisto, Satu] Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Helsinki, Finland. [Nakamura, Yusuke] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Tokyo, Japan. [Oberg, Ann L.] Mayo Clin, Dept Hlth Sci Res, Div Biomed Stat & Informat, Alliance Stat & Data Ctr, Rochester, MN USA. [Owzar, Kouros] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Alliance Stat & Data Ctr, Durham, NC USA. [Peeters, Petra H. M.; Riboli, Elio] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostat, London, England. [Peters, Ulrike] Fred Hutchinson Canc Res Ctr, Dept Epidemiol, Seattle, WA 98104 USA. [Pezzilli, Raffaele] SantOrsola Malpighi Hosp, Dept Digest Dis & Internal Med, Pancreas Unit, Bologna, Italy. [Piepoli, Ada] Opera Padre Pio Pietrelcina, Inst Sci, Dept Gastroenterol, San Giovanni Rotondo, Italy. [Piepoli, Ada] Opera Padre Pio Pietrelcina, Reg Gen Hosp Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy. [Porta, Miquel] Univ Autonoma Barcelona, Sch Med, Dept Epidemiol, E-08193 Barcelona, Spain. [Porta, Miquel] CIBERESP, Madrid, Spain. [Real, Francisco X.] CNIO Spanish Natl Canc Res Ctr, Epithelial Carcinogenesis Grp, Madrid, Spain. [Real, Francisco X.] Univ Pompeu Fabra, Dept Ciencies & Salut, Barcelona, Spain. [Scarpa, Aldo] Univ & Hosp Trust Verona, ARC NET Ctr Appl Res Canc, Verona, Italy. [Soucek, Pavel] Natl Inst Publ Hlth, Ctr Toxicol & Safety, Toxicogenom Unit, Prague, Czech Republic. [Sund, Malin] Umea Univ, Dept Surg & Perioperat Sci, Umea, Sweden. [Talar-Wojnarowska, Renata] Med Univ Lodz, Dept Digest Tract Dis, Lodz, Poland. [Theodoropoulos, George E.] Hippocrat Univ Hosp, Propaideut Surg Dept 1, Athens, Greece. [Tjonneland, Anne] Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark. [Trichopoulos, Dimitrios] Acad Athens, Bur Epidemiol Res, Athens, Greece. [Trichopoulos, Dimitrios] Hellenic Hlth Fdn, Athens, Greece. [Vodicka, Pavel] Acad Sci Czech Republic, Inst Expt Med, Dept Mol Biol Canc, Prague, Czech Republic. [Wactawski-Wende, Jean] SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA. RP Stolzenberg-Solomon, RS (reprint author), NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. EM rachael.solomon@nih.gov; amundadottirl@mail.nih.gov RI Piepoli, Ada/K-9299-2016; Amundadottir, Laufey/L-7656-2016; Tobias, Geoffrey/M-4135-2016; scarpa, aldo/K-6832-2016; Talar-Wojnarowska, Renata/T-1009-2016; Kogevinas, Manolis/C-3918-2017; Gallinger, Steven/E-4575-2013; Porta, Miquel/B-5787-2008; Albanes, Demetrius/B-9749-2015; Beane Freeman, Laura/C-4468-2015; Real Arribas, Francisco/H-5275-2015; Basso, Daniela/J-7855-2016; Campa, Daniele/K-1617-2016; Krogh, Vittorio/K-2628-2016; Abnet, Christian/C-4111-2015; Boutron-Ruault, Marie-Christine/H-3936-2014; Malats, Nuria/H-7041-2015; OI Piepoli, Ada/0000-0001-7487-8754; Amundadottir, Laufey/0000-0003-1859-8971; Tobias, Geoffrey/0000-0002-2878-8253; scarpa, aldo/0000-0003-1678-739X; Duell, Eric J/0000-0001-5256-0163; Soucek, Pavel/0000-0002-4294-6799; Funel, Niccola/0000-0002-5028-2363; Porta, Miquel/0000-0003-1684-7428; Beane Freeman, Laura/0000-0003-1294-4124; Real Arribas, Francisco/0000-0001-9501-498X; Basso, Daniela/0000-0001-8745-6171; Campa, Daniele/0000-0003-3220-9944; Krogh, Vittorio/0000-0003-0122-8624; Abnet, Christian/0000-0002-3008-7843; Malats, Nuria/0000-0003-2538-3784; Giles, Graham/0000-0003-4946-9099; Landi, Stefano/0000-0001-8364-6357; Zeleniuch-Jacquotte, Anne/0000-0001-9350-1303 FU National Cancer Institute (NCI), US National Institutes of Health (NIH) [HHSN261200800001E]; NIH/NCI [K07 CA140790]; American Society of Clinical Oncology Conquer Cancer Foundation; Howard Hughes Medical Institute; Lustgarten Foundation FX This project was funded in whole or in part with federal funds from the National Cancer Institute (NCI), US National Institutes of Health (NIH) under contract number HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the US Department of Health and Human Services, and mention of trade names, commercial products or organizations does not imply endorsement by the US government. Major support for PanScan III sample identification and processing was provided by the Lustgarten Foundation for Pancreatic Cancer Research. Additional support was received from NIH/NCI K07 CA140790, the American Society of Clinical Oncology Conquer Cancer Foundation, the Howard Hughes Medical Institute, the Lustgarten Foundation, the Robert T. and Judith B. Hale Fund for Pancreatic Cancer Research and Promises for Purple to B.M.W. A full list of acknowledgments for each participating study is provided in the Supplementary Note. NR 75 TC 52 Z9 54 U1 5 U2 33 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 EI 1546-1718 J9 NAT GENET JI Nature Genet. PD SEP PY 2014 VL 46 IS 9 BP 994 EP + DI 10.1038/ng.3052 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA AO8CE UT WOS:000341579400014 PM 25086665 ER PT J AU Mormino, EC AF Mormino, Elizabeth C. TI The Relevance of Beta-Amyloid on Markers of Alzheimer's Disease in Clinically Normal Individuals and Factors That Influence These Associations SO NEUROPSYCHOLOGY REVIEW LA English DT Review DE Aging; Preclinical Alzheimer's disease; Beta-amyloid; Amyloid PET imaging; Resilience ID NORMAL OLDER-ADULTS; MILD COGNITIVE IMPAIRMENT; APOLIPOPROTEIN-E GENOTYPE; BRAINS DEFAULT NETWORK; PITTSBURGH COMPOUND-B; A-BETA; LIFE-SPAN; IN-VIVO; FUNCTIONAL CONNECTIVITY; MEMORY PERFORMANCE AB Aberrant accumulation of beta-amyloid (A beta) is thought to be an early event in a biological cascade that eventually leads to Alzheimer's disease (AD). Along these lines, many clinically normal (CN) older individuals have evidence of beta-amyloid (A beta) accumulation, which may be indicative of preclinical AD. However, relationships between A beta and "downstream" AD markers are often inconsistent across studies. These inconsistencies may be due to the presence of other age-related processes that also influence AD markers, as well as additional risk factors that interact with A beta to influence downstream changes. For instance, it is possible that the effect of A beta is modified by neurodegeneration, genetics, sex-differences and cognitive reserve. Thus, a multivariate approach to determining risk of AD within CN participants may be more appropriate than reliance on A beta status alone. An understanding of how additional risk factors interact with A beta to influence an individual's trajectory towards AD is essential for characterizing preclinical AD and has implications for prevention trials. C1 [Mormino, Elizabeth C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA. [Mormino, Elizabeth C.] Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. RP Mormino, EC (reprint author), Martinos Ctr Biomed Imaging, 149 13th St, Charlestown, MA 02129 USA. EM bmormino@nmr.mgh.harvard.edu FU NIH [F32-AG044054, P01-AG036694] FX E. Mormino has received funding from NIH grant F32-AG044054 and P01-AG036694. NR 142 TC 12 Z9 12 U1 1 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1040-7308 EI 1573-6660 J9 NEUROPSYCHOL REV JI Neuropsychol. Rev. PD SEP PY 2014 VL 24 IS 3 SI SI BP 300 EP 312 DI 10.1007/s11065-014-9267-4 PG 13 WC Psychology, Clinical; Neurosciences SC Psychology; Neurosciences & Neurology GA AO8UD UT WOS:000341629600004 PM 25108368 ER PT J AU Deschler, DG Richmon, JD Khariwala, SS Ferris, RL Wang, MB AF Deschler, Daniel G. Richmon, Jeremy D. Khariwala, Samir S. Ferris, Robert L. Wang, Marilene B. TI The "New" Head and Neck Cancer Patient-Young, Nonsmoker, Nondrinker, and HPV Positive: Evaluation SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Review DE oropharyngeal cancer; human papillomavirus (HPV); unknown primary; management neck mass ID SQUAMOUS-CELL-CARCINOMA; LYMPH-NODE METASTASES; UNKNOWN PRIMARY; OROPHARYNGEAL CANCER; HUMAN-PAPILLOMAVIRUS; ROBOTIC SURGERY; MANAGEMENT; TONSILLECTOMY; TUMORS AB Objective The near epidemic rise of the incidence of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinomas (OPSCC) presents the practitioner with a new head and neck cancer patient, vastly different from those with the traditional risk factors who formed the basis of most practitioners' training experience. Accordingly, a thorough and disease-specific evaluation process is necessitated. This article will review the evaluation of the HPV-related cancer patient, including a review of the HPV-positive oropharyngeal cancer epidemic from the surgeon's perspective, evaluation of the primary lesion, evaluation of the neck mass, and role of imaging, to provide a framework for addressing the challenging questions patients may ask. Data Sources Available peer-reviewed literature and practice guidelines. Review Methods Assessment of selected specific topics by authors solicited from the Head and Neck Surgery and Oncology Committee of the American Academy of OtolaryngologyHead and Neck Surgery Foundation and the American Head and Neck Society. Conclusions and Implications for Practice The dramatic rise in OPSSC related to HPV is characterized by a new cancer patient who is younger and lacks traditional risk factors. Today's caregiver must be prepared to appropriately evaluate, counsel, and treat these patients with HPV-positive disease with the expectation that traditional treatment algorithms will evolve to maintain or improve current excellent cure rates while lessening treatment related side effects. C1 [Deschler, Daniel G.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otolaryngol Head & Neck Surg, Boston, MA USA. [Richmon, Jeremy D.] Johns Hopkins Med Ctr, Dept Otolaryngol Head & Neck Surg, Baltimore, MD USA. [Khariwala, Samir S.] Univ Minnesota, Dept Otolaryngol Head & Neck Surg, Minneapolis, MN USA. [Ferris, Robert L.] Univ Pittsburgh, Med Ctr, Dept Otolaryngol Head & Neck Surg, Pittsburgh, PA USA. [Wang, Marilene B.] Univ Calif Los Angeles, Dept Otolaryngol Head & Neck Surg, Los Angeles, CA USA. RP Deschler, DG (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, 243 Charles St, Boston, MA 02420 USA. EM daniel_deschler@meei.harvard.edu FU NIDCR NIH HHS [K23 DE023572] NR 26 TC 21 Z9 22 U1 1 U2 10 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 EI 1097-6817 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD SEP PY 2014 VL 151 IS 3 BP 375 EP 380 DI 10.1177/0194599814538605 PG 6 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA AP0MU UT WOS:000341757000003 PM 24925311 ER PT J AU Sethi, RKV Kozin, ED Lam, AC Emerick, KS Deschler, DG AF Sethi, Rosh K. V. Kozin, Elliott D. Lam, Allen C. Emerick, Kevin S. Deschler, Daniel G. TI Primary Tracheoesophageal Puncture with Supraclavicular Artery Island Flap after Total Laryngectomy or Laryngopharyngectomy SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE supraclavicular artery island flap; tracheoesophageal puncture; voice prosthesis; voice restoration; total laryngectomy ID RECONSTRUCTION AB The supraclavicular artery island flap (SCAIF) is increasingly employed for laryngectomy reconstruction with excellent success. Although tracheoesophageal puncture (TEP) with intraoperative prosthesis placement is also positively reported, this is not described in patients following SCAIF. We review our experience with primary TEP with prosthesis placement and voice outcomes in patients after SCAIF reconstruction. Seven patients underwent SCAIF with primary TEP after laryngectomy from 2011 to 2013. Five underwent total laryngectomy (TL) and 2 underwent TL with partial pharyngectomy. All patients had 16 French Indwelling Blom-Singer prostheses placed intraoperatively without complications. Six patients achieved tracheoesophageal voice (median time = 1.5 months). Two patients required cricopharyngeal segment Botox injections. One patient remained aphonic. One patient developed prosthesis leakage addressed with prosthesis replacement. Our preliminary data demonstrate that similar to free tissue transfer reconstruction, primary TEP with intraoperative placement of the voice prosthesis at the time of SCAIF reconstruction is safe and effective. C1 [Sethi, Rosh K. V.; Kozin, Elliott D.; Lam, Allen C.; Emerick, Kevin S.; Deschler, Daniel G.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA. [Kozin, Elliott D.; Lam, Allen C.; Emerick, Kevin S.; Deschler, Daniel G.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA. RP Deschler, DG (reprint author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, 243 Charles St, Boston, MA 02114 USA. EM Daniel_Deschler@meei.harvard.edu RI Kozin, Elliott/J-1225-2014 OI Kozin, Elliott/0000-0002-0305-0682 FU NIDCD NIH HHS [T32 DC000020] NR 12 TC 3 Z9 3 U1 0 U2 3 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 EI 1097-6817 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD SEP PY 2014 VL 151 IS 3 BP 421 EP 423 DI 10.1177/0194599814539443 PG 3 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA AP0MU UT WOS:000341757000009 PM 24925312 ER PT J AU Lin, Y Luo, J Zhu, WE Srivastava, M Schaue, D Elashoff, DA Dubinett, SM Sharma, S Wu, B St John, MA AF Lin, Yuan Luo, Jie Zhu, Weichao Eric Srivastava, Minu Schaue, Dorthe Elashoff, David A. Dubinett, Steven M. Sharma, Sherven Wu, Benjamin St John, Maie A. TI A Cytokine-Delivering Polymer Is Effective in Reducing Tumor Burden in a Head and Neck Squamous Cell Carcinoma Murine Model SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE head and neck cancer; squamous cell carcinoma; polymer; novel therapeutics ID LYMPHOID-TISSUE CHEMOKINE; CC-CHEMOKINE; RECEPTOR CCR7; GENE-THERAPY; MOUSE MODEL; CANCER; RADIOTHERAPY; CCL21; ACTIVATION; MECHANISMS AB Objective This study aimed to evaluate the therapeutic efficacy of a novel polymer platform delivering cisplatin and cytokines in the treatment of head and neck squamous cell carcinoma (HNSCC). Study Design In vivo study. Setting Academic research laboratory. Subjects and Methods Mice were randomized to receive implantation of (1) no polymer, (2) plain polymer, (3) plain polymer with local cisplatin injection, or (4) cisplatin polymer. The 2 groups of mice implanted with cisplatin polymer or no polymer were further randomized to receive (1) 4 Grays external beam radiation for 4 days or (2) no radiation. For cytokine studies, mice were grouped into (1) no polymer, (2) plain polymer, (3) plain polymer with intratumoral injection of recombinant CCL21 twice a week, (4) polymer containing parental dendritic cells, or (5) polymer containing dendritic cells secreting CCL21 (DC-CCL21). Results The cisplatin-secreting polymer effectively reduced tumors in the mice by more than 16-fold (P < .01). We also observed a statistically significant lower tumor weight among mice treated with cisplatin polymer and concomitant radiation compared to control groups. The DC-CCL21 polymer reduced SCCVII/SF tumors in the C3H/HeJ mice by more than 41% (P < .01). Conclusion Herein, we demonstrate the efficacy of a novel polymer platform in delivering cisplatin and cytokines. We also demonstrate that we can effectively grow dendritic cells in the polymer that can actively secrete CCL21 for a minimum of 5 days. This polymer may represent a new therapeutic modality for patients with HNSCC. Once this polymer platform is optimized, we will plan to pursue prospective trials in patients with HNSCC. C1 [Lin, Yuan; Luo, Jie; St John, Maie A.] Univ Calif Los Angeles, Dept Head & Neck Surg, Los Angeles, CA 90095 USA. [Lin, Yuan; Luo, Jie; St John, Maie A.] Univ Calif Los Angeles, UCLA Head & Neck Canc Program, Los Angeles, CA 90095 USA. [Lin, Yuan; Luo, Jie; Srivastava, Minu; Dubinett, Steven M.; Sharma, Sherven] Univ Calif Los Angeles, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA. [Zhu, Weichao Eric; Wu, Benjamin] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA 90095 USA. [Srivastava, Minu; Dubinett, Steven M.; Sharma, Sherven] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Schaue, Dorthe] Univ Calif Los Angeles, Dept Radiat Oncol, Los Angeles, CA 90095 USA. [Elashoff, David A.; Dubinett, Steven M.; St John, Maie A.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. [Elashoff, David A.] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90095 USA. [Wu, Benjamin] Univ Calif Los Angeles, Div Adv Prosthodont Biomat & Hosp Dent, Los Angeles, CA 90095 USA. [Wu, Benjamin] Univ Calif Los Angeles, Dept Mat Sci & Engn, Los Angeles, CA 90095 USA. [Wu, Benjamin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Orthoped Surg, Los Angeles, CA 90095 USA. RP St John, MA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, 37-131 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM mstjohn@mednet.ucla.edu FU American Academy of Otolaryngology-American Head & Neck Society Surgeon Scientist Career Development Award; Tobacco-Related Disease Research Program of the University of California; STOP Cancer Foundation; Jonsson Cancer Center; NIDCR K23 FX Funding source: This study was supported by the American Academy of Otolaryngology-American Head & Neck Society Surgeon Scientist Career Development Award (M.A.S.J.), the Tobacco-Related Disease Research Program of the University of California (M.A.S.J.), the STOP Cancer Foundation (M.A.S.J.), The Jonsson Cancer Center, and NIDCR K23 (M.A.S.J.). NR 35 TC 2 Z9 2 U1 1 U2 6 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 EI 1097-6817 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD SEP PY 2014 VL 151 IS 3 BP 447 EP 453 DI 10.1177/0194599814533775 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA AP0MU UT WOS:000341757000014 PM 24825873 ER PT J AU Bortsov, AV Platts-Mills, TF Peak, DA Jones, JS Swor, RA Domeier, RM Lee, DC Rathlev, NK Hendry, PL Fillingim, RB McLean, SA AF Bortsov, Andrey V. Platts-Mills, Timothy F. Peak, David A. Jones, Jeffrey S. Swor, Robert A. Domeier, Robert M. Lee, David C. Rathlev, Niels K. Hendry, Phyllis L. Fillingim, Roger B. McLean, Samuel A. TI Effect of pain location and duration on life function in the year after motor vehicle collision SO PAIN LA English DT Article DE Motor vehicle collision; Musculoskeletal pain; Pain interference; Whiplash ID WHIPLASH-ASSOCIATED DISORDERS; QUALITY-OF-LIFE; CHRONIC MUSCULOSKELETAL PAIN; REAR-END COLLISION; GENERAL-POPULATION; WIDESPREAD PAIN; OLDER-ADULTS; BACK-PAIN; NECK PAIN; DEPRESSIVE SYMPTOMS AB Persistent musculoskeletal pain is common after motor vehicle collision (MVC) and often results in substantial disability. The objective of this study was to identify distributions of post-MVC pain that most interfere with specific life functions and that have the greatest interference with aggregate life function. Study data were obtained from a prospective longitudinal multicenter emergency department-based cohort of 948 European Americans experiencing MVC. Overall pain (0-10 numeric rating scale [NRS]), pain in each of 20 body regions (0-10 NRS), and pain interference (Brief Pain Inventory, 0-10 NRS) were assessed 6 weeks, 6 months, and 1 year after MVC. After adjustment for overall pain intensity, an axial distribution of pain caused the greatest interference with most specific life functions (R-2 = 0.15-0.28, association P values of <.001) and with overall function. Axial pain explained more than twice as much variance in pain interference as other pain distributions. However, not all patients with axial pain had neck pain. Moderate or severe low back pain was as common as neck pain at week 6 (prevalence 37% for each) and overlapped with neck pain in only 23% of patients. Further, pain across all body regions accounted for nearly twice as much of the variance in pain interference as neck pain alone (60% vs 34%). These findings suggest that studies of post-MVC pain should not focus on neck pain alone. (C) 2014 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved. C1 [Bortsov, Andrey V.; Platts-Mills, Timothy F.; McLean, Samuel A.] Univ N Carolina, Dept Anesthesiol, Chapel Hill, NC 27599 USA. [Platts-Mills, Timothy F.; McLean, Samuel A.] Univ N Carolina, Dept Emergency Med, Chapel Hill, NC 27599 USA. [Peak, David A.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Jones, Jeffrey S.] Spectrum Hlth Hosp, Dept Emergency Med, Grand Rapids, MI USA. [Swor, Robert A.] William Beaumont Hosp, Dept Emergency Med, Royal Oak, MI 48072 USA. [Domeier, Robert M.] St Joseph Mercy Hosp, Dept Emergency Med, Ann Arbor, MI 48104 USA. [Lee, David C.] N Shore Univ Hosp, Dept Emergency Med, Manhasset, NY USA. [Rathlev, Niels K.] Baystate Med Ctr, Dept Emergency Med, Springfield, MA USA. [Hendry, Phyllis L.] Univ Florida, Coll Med, Dept Emergency Med, Jacksonville, FL USA. [Hendry, Phyllis L.] Shands Jacksonville, Jacksonville, FL USA. [Fillingim, Roger B.] Univ Florida, Coll Dent, Dept Community Dent & Behav Sci, Gainesville, FL USA. RP McLean, SA (reprint author), Univ N Carolina, Med Sch Wing C CB 7010, Chapel Hill, NC 27599 USA. EM smclean@aims.unc.edu OI McLean, Samuel/0000-0001-9482-3582 FU National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health [R01AR056328]; National Institute on Aging of the National Institutes of Health [K23AG038548] FX Supported in part by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (award R01AR056328; McLean) and the National Institute on Aging of the National Institutes of Health (award K23AG038548; Platts-Mills). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes NR 59 TC 4 Z9 4 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0304-3959 EI 1872-6623 J9 PAIN JI Pain PD SEP PY 2014 VL 155 IS 9 BP 1836 EP 1845 DI 10.1016/j.pain.2014.06.013 PG 10 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA AP1ZZ UT WOS:000341873000020 PM 24972071 ER EF